Drug,Patent/ appln.No.,Assignee,Condition(s) Treated,Drug Type,Family,Priority Date,File Date,Publication/Granted/Re-Issued Date,Expiry Date,Status,Patent Type,Description,Before/After FDA Approval,Orange / Purple Book,Google Patents URL
Biktarvy,US6153751A,Emory University,HIV,Small Molecule,1,2/1/1990,6/22/1999,11/28/2000,2/1/2010,Expired,Method of Production / Process,The patent claims cover a method of preparing intermediates and the synthesis of the compound emtricitabine. ,Before,No,https://patents.google.com/patent/US6153751A/en?oq=US6153751A
Biktarvy,US7402588B2,Emory University,HIV,Small Molecule,6,2/1/1990,3/28/2006,7/22/2008,2/1/2010,Expired,Method of Treatment,"Thapplication claimed a method for treating HIV infection in humans comprising administering an effective amount of emtricitabine, related prodrugs and simple analogs of and pharmaceutical compositions.",Before,No,https://patents.google.com/patent/US7402588B2/en?oq=US7402588B2
Biktarvy,US20050004148A1,Emory University,HIV,Small Molecule,1,2/1/1990,11/3/2003,1/6/2005,,Abandoned,Main Compound,"The application claimed the compound emtricitabine, the racemate, both enantiomeric forms, and N- and O-substituted derivatives as well as pharmaceutical compositions and use to treat HIV. ",Before,No,https://patents.google.com/patent/US20050004148A1/en?oq=US20050004148A1
Biktarvy,US5204466A,Emory University,HIV,Small Molecule,1,2/1/1990,2/1/1990,4/20/1993,4/20/2010,Expired,Method of Production / Process,The patent claims cover a process for preparing intermediates  and the synthesis of the compound emtricitabine. ,Before,No,https://patents.google.com/patent/US5204466A/en?oq=US5204466A
Biktarvy,US5210085A,Emory University,HIV,Small Molecule,1,2/1/1990,2/22/1991,5/11/1993,5/11/2010,Expired,Method of Treatment,"The patent claims cover a method for treating a human having an HIV infection comprising administering to the human an effective HIV-treatment amount of the compound emtricitabine, its phosphate forms (mono/di/tri),or N-alkylated analogs.",Before,No,https://patents.google.com/patent/US5210085A/en?oq=US5210085A
Biktarvy,US20060234982A1,Gilead Sciences,HIV,Small Molecule,3,1/14/2003,1/13/2004,10/19/2006,,Abandoned,Method of Treatment,The application claimed a method for the treatment or prevention of the symptoms or effects of an HIV infection in an infected animal which comprises administering to said animal a therapeutically effective amount of a combination comprising  emtricitabine and tenofovir alafenamide (GS-7340).  ,Before,No,https://patents.google.com/patent/US20060234982A1/en?oq=US20060234982A1
Biktarvy,US20040224916A1,Gilead Sciences,HIV,Small Molecule,3,1/14/2003,1/13/2004,11/11/2004,,Abandoned,Method of Treatment,"The application claimed a method for the treatment or prevention of the symptoms or effects of an HIV infection in an infected animal which comprises administering to said animal a therapeutically effective amount of a combination comprising  emtricitabine and tenofovir alafenamide (GS-7340), as well as other HIV drugs. ",Before,No,https://patents.google.com/patent/US20040224916A1/en?oq=US20040224916A1
Biktarvy,US20060246130A1,Gilead Sciences,HIV,Small Molecule,3,1/14/2003,1/13/2004,11/2/2006,,Abandoned,Method of Treatment,"The application claimed a method comprising administering a therapeutically effective amount of a composition comprising compositions of tenofovir disoproxil fumarate and emtricitabine, as well as a third HIV drug.",Before,No,https://patents.google.com/patent/US20060246130A1/en?oq=US20060246130A1
Biktarvy,US20140213556A1,Gilead Sciences,HIV,Small Molecule,3,1/14/2003,3/27/2014,7/31/2014,,Abandoned,Method of Treatment,The application claimed a method for the treatment or prevention of the symptoms or effects of an HIV infection in an infected animal which comprises administering to said animal a therapeutically effective amount of a composition comprising tenofovir disoproxil fumarate and emtricitabine.,Before,No,https://patents.google.com/patent/US20140213556A1/en?oq=US20140213556A1
Biktarvy,US20170232019A1,Gilead Sciences,HIV,Small Molecule,3,1/14/2003,5/4/2017,8/17/2017,,Abandoned,Method of Treatment,The application claimed a method for the treatment or prevention of the symptoms or effects of an HIV infection in an infected animal which comprises administering to said animal a therapeutically effective amount of a composition comprising tenofovir disoproxil fumarate and emtricitabine.  ,Before,No,https://patents.google.com/patent/US20170232019A1/en?oq=US20170232019A1
Biktarvy,US20170273994A1,Gilead Sciences,HIV,Small Molecule,3,1/14/2003,6/14/2017,9/28/2017,,Abandoned,Method of Treatment,The application claimed a method for the prevention of the symptoms or effects of an HIV infection in an animal which comprises administering to said animal a fixed-dose combination comprising 300 mg of tenofovir disoproxil fumarate and 200 mg of emtricitabine. ,Before,No,https://patents.google.com/patent/US20170273994A1/en?oq=US20170273994A1
Biktarvy,US20020119443A1,Gilead Sciences,HIV,Small Molecule,4,7/21/2000,7/20/2001,8/29/2002,,Abandoned,Method of Production / Process,The application claimed a screening method for identifying a methoxyphosphonate nucleotide analogue prodrug (such as analogs of tenofovir alafenamide fumarate) conferring enhanced activity in a target tissue.  ,Before,No,https://patents.google.com/patent/US20020119443A1/en?oq=US20020119443A1
Biktarvy,US20040018150A1,Gilead Sciences,HIV,Small Molecule,4,7/21/2000,7/20/2001,1/29/2004,,Abandoned,Method of Production / Process,The application claimed a screening method for identifying a methoxyphosphonate nucleotide analogue prodrug (such as analogs of tenofovir alafenamide fumarate) conferring enhanced activity in a target tissue. ,Before,No,https://patents.google.com/patent/US20040018150A1/en?oq=US20040018150A1
Biktarvy,US20030219727A1,Gilead Sciences,HIV,Small Molecule,4,7/21/2000,1/28/2003,11/27/2003,,Abandoned,Method of Production / Process,The application claimed a screening method for identifying a methoxyphosphonate nucleotide analogue prodrug (such as analogs of tenofovir alafenamide fumarate) conferring enhanced activity in a target tissue. ,Before,No,https://patents.google.com/patent/US20030219727A1/en?oq=US20030219727A1
Biktarvy,US20060024659A1,Gilead Sciences,HIV,Small Molecule,4,7/21/2000,2/24/2004,2/2/2006,,Abandoned,Method of Production / Process,The application claimed a screening method for identifying a methoxyphosphonate nucleotide analogue prodrug (such as analogs of tenofovir alafenamide fumarate) conferring enhanced activity in a target tissue. ,Before,No,https://patents.google.com/patent/US20060024659A1/en?oq=US20060024659A1
Biktarvy,US20050159392A1,Gilead Sciences,HIV,Small Molecule,4,7/21/2000,1/6/2005,7/21/2005,,Abandoned,Method of Treatment,"The application claimed a method of inhibiting replication of an HIV virion, comprising contacting a cell comprising an HIV virion with a nucleotide analog including close analogs and metabolites of tenofovir alafenamide fumarate.",Before,No,https://patents.google.com/patent/US20050159392A1/en?oq=US20050159392A1
Biktarvy,US20050124584A1,Gilead Sciences,HIV,Small Molecule,4,7/21/2000,1/6/2005,6/9/2005,,Abandoned,Formulation / Combination,The application claimed a pharmaceutical composition comprising a pharmaceutically acceptable excipient and at least 80% by weight the single diastereomer that is tenofovir alafenamide fumarate. ,Before,No,https://patents.google.com/patent/US20050124584A1/en?oq=US20050124584A1
Biktarvy,US20050124585A1,Gilead Sciences,HIV,Small Molecule,4,7/21/2000,1/6/2005,6/9/2005,,Abandoned,Derivative,The application claimed a ucleotide phosphoramidate analog of tenofovir wherein only the amino acid ester group and the phosphonate ester group are variable.,Before,No,https://patents.google.com/patent/US20050124585A1/en?oq=US20050124585A1
Biktarvy,US20050215527A1,Emory University,HIV,Small Molecule,6,2/1/1990,5/9/2005,9/29/2005,,Abandoned,Method of Treatment,"The application claimed a method for treating HIV infection in humans comprising administering an effective amount of emtricitabine,  its derivatives, or salts in a gelatin capsule for oral delivery. ",Before,No,https://patents.google.com/patent/US20050215527A1/en?oq=US20050215527A1
Biktarvy,US20090048190A1,Emory University,HIV,Small Molecule,6,2/1/1990,5/2/2008,2/19/2009,,Abandoned,Formulation / Combination,"The application claimed a pharmaceutical composition comprising an effective amount to treat HIV infection in humans of emtricitabine or or a physiologically acceptable salt thereof, in combination with a second antiviral compound, in a pharmaceutically acceptable carrier.",Before,No,https://patents.google.com/patent/US20090048190A1/en?oq=US20090048190A1
Biktarvy,US20170056424A1,Gilead Sciences,HIV,Small Molecule,8,1/15/2014,10/5/2016,3/2/2017,,Abandoned,Method of Treatment,"The application claimed a method for treating or preventing a viral infection in a human, comprising administering to the human a crystal form, Form I, of tenofovir  (PMPA). ",Before,No,https://patents.google.com/patent/US20170056424A1/en?oq=US20170056424A1
Biktarvy,US5539116A,Emory University,HIV,Small Molecule,1,2/1/1990,2/10/1993,7/23/1996,7/23/2013,Expired,Enantiomer / Stereoisomer,The patent claims cover an enantiomeric form of the compound emtricitabine. ,Before,No,https://patents.google.com/patent/US5539116A/en?oq=US5539116A
Biktarvy,US20210053988A1,Gilead Sciences,HIV,Small Molecule,9,12/21/2012,5/6/2020,2/25/2021,,Pending,Derivative,The application claimed analogs of bictegravir. ,After,No,https://patents.google.com/patent/US20210053988A1/en?oq=US20210053988A1
Biktarvy,US20170197985A1,Gilead Sciences,HIV,Small Molecule,10,6/20/2014,6/19/2015,7/13/2017,,Abandoned,Salt Form,"The application claimed  the sodium salt of bictegravir, crystalline forms and combinations with 1-3 other drugs, pharmaceutical compositions, and the combination with  tenofovir alafenamide hemifumarate and emtricitabine. Compound Patent, and crystal Forms. ",Before,No,https://patents.google.com/patent/US20170197985A1/en?oq=US20170197985A1
Biktarvy,US20170000807A1,Gilead Sciences,HIV,Small Molecule,12,6/30/2015,6/29/2016,1/5/2017,,Abandoned,Formulation / Combination,The application claimed a solid oral dosage form comprising tenofovir alafenamide or a pharmaceutically acceptable salt thereof and emtricitabine or a pharmaceutically acceptable salt thereof,Before,No,https://patents.google.com/patent/US20170000807A1/en?oq=US20170000807A1
Biktarvy,US20180177734A1,Gilead Sciences,HIV,Small Molecule,12,6/30/2015,6/29/2016,6/28/2018,,Abandoned,Formulation / Combination,The application claimed a solid oral dosage form comprising tenofovir alafenamide or a pharmaceutically acceptable salt thereof and emtricitabine or a pharmaceutically acceptable salt thereof.,Before,No,https://patents.google.com/patent/US20180177734A1/en?oq=US20180177734A1
Biktarvy,US20210052502A1,Gilead Sciences,HIV,Small Molecule,13,11/9/2015,8/6/2020,2/25/2021,,Abandoned,Method of Production / Process,The application claimed a method of producing a multilayer tablet comprising the compound bictegravir and tenofovir alafenamideseparately to form a bilayer tablet ,After,No,https://patents.google.com/patent/US20210052502A1/en?oq=US20210052502A1
Biktarvy,US20190233448A1,Gilead Sciences,HIV,Small Molecule,14,1/31/2017,3/21/2019,8/1/2019,,Pending,Salt Form,"The application claims tenofovir alafenamide hemipamoate, its crystalline Form 2, pharmaceutical  compositions and a method for treating a virus.  ",After,No,https://patents.google.com/patent/US20190233448A1/en?oq=US20190233448A1
Biktarvy,US20170027967A1,Gilead Sciences,HIV,Small Molecule,17,6/30/2015,6/28/2016,2/2/2017,,Abandoned,Formulation / Combination,"The application claimed a solid oral dosage form comprising rilpivirine or a pharmaceutically acceptable salt thereof, tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof. ",Before,No,https://patents.google.com/patent/US20170027967A1/en?oq=US20170027967A1
Biktarvy,US5814639A,Emory University,HIV,Small Molecule,1,2/1/1990,2/16/1993,9/29/1998,9/29/2015,Expired,Main Compound,The patent claims cover the basic compound emtricitabine,Before,No,https://patents.google.com/patent/US5814639A/en?oq=US5814639A
Biktarvy,US20150368264A1,Gilead Sciences,HIV,Small Molecule,20,6/20/2014,6/16/2015,12/24/2015,,Abandoned,Method of Production / Process,The application claimed  processes and intermediate compounds for synthesizing bictegravir.,Before,No,https://patents.google.com/patent/US20150368264A1/en?oq=US20150368264A1
Biktarvy,US20180085387A1,Gilead Sciences,HIV,Small Molecule,21,9/27/2016,9/26/2017,3/29/2018,,Abandoned,Formulation / Combination,"The application claimed a solid oral dosage form comprising bictegravir, darunavir, cobicistat, and an unnamed phosphoramidate prodrug of a dehydroadenosine for treating HIV. ",Before,No,https://patents.google.com/patent/US20180085387A1/en?oq=US20180085387A1
Biktarvy,US20210393631A1,Gilead Sciences,HIV,Small Molecule,23,9/19/2018,9/18/2019,12/23/2021,,Pending,Method of Treatment,"The application claims a method of preventing an HIV infection in a subject, comprising administering to the subject bictegravir, or a pharmaceutically acceptable salt thereof. including with up to 3 additional compounds.",After,No,https://patents.google.com/patent/US20210393631A1/en?oq=US20210393631A1
Biktarvy,US20180153887A1,Gilead Sciences,HIV,Small Molecule,26,7/12/2013,6/9/2017,6/7/2018,,Abandoned,Derivative,"The application claimed analogs of bictegravir, pharmaceutical compositions and methods of treatment.",Before,No,https://patents.google.com/patent/US20180153887A1/en?oq=US20180153887A1
Biktarvy,US20190046526A1,Gilead Sciences,HIV,Small Molecule,26,7/12/2013,1/10/2018,2/14/2019,,Abandoned,Derivative,"The application claimed  analogs of bictegravir, pharmaceutical compositions and methods of treatment.",Before,No,https://patents.google.com/patent/US20190046526A1/en?oq=US20190046526A1
Biktarvy,US5914400A,Emory University,HIV,Small Molecule,1,2/1/1990,6/7/1995,6/22/1999,6/22/2016,Expired,Method of Production / Process,"The patent claims cover a process for preparing emtricitabine, including intermediates. ",Before,No,https://patents.google.com/patent/US5914400A/en?oq=US5914400A
Biktarvy,US5914331A,Emory University,HIV,Small Molecule,6,2/1/1990,6/7/1995,6/22/1999,7/2/2017,Expired,Derivative,The patent claims cover prodrug derivatives and phosphorylated metabolites of emtricitabine. ,Before,No,https://patents.google.com/patent/US5914331A/en?oq=US5914331A
Biktarvy,US6114343A,Emory University,HIV,Small Molecule,1,2/1/1990,6/7/1995,9/5/2000,9/5/2017,Expired,Formulation / Combination,"The patent claims cover a pharmaceutical composition comprising emtricitabine as a single enantiomer and in mono-, di-, tri-phosphate forms ",Before,No,https://patents.google.com/patent/US6114343A/en?oq=US6114343A
Biktarvy,US6642245B1,Emory University,HIV,Small Molecule,6,2/1/1990,6/7/1995,11/4/2003,4/11/2020,Expired,Method of Treatment,"The patent claims cover a method for treating HIV infection in humans comprising administering an effective amount of emtricitabineor its physiologically acceptable salt, optionally in a pharmaceutically acceptable carrier.",Before,No,https://patents.google.com/patent/US6642245B1/en?oq=US6642245B1
Biktarvy,US7803788B2,Gilead Sciences,HIV,Small Molecule,4,7/21/2000,4/28/2008,9/28/2010,2/2/2022,Expired,Method of Treatment,The patent claims cover a method for antiviral therapy by administering a therapeutically effective amount of a diastereomerically enriched form of the prodrug tenofovir alafenamide fumarate  and a number of phosphoramidate analogs. ,Before,Yes,https://patents.google.com/patent/US7803788B2/en?oq=US7803788B2
Biktarvy,US6703396,Emory University,HIV,Small Molecule,7,2/1/1990,3/13/1995,3/9/2004,10/12/2022,Expired,Enantiomer / Stereoisomer,"The patent claims cover The (-)-enantiomer of emtricitabine and acyl- or alkyl-derivatives thereof. Also claims mono/di/tri phosphate forms (metabolites), and pharmaceutical compositions including for iv administration. ",Before,No,https://patents.google.com/patent/US6703396B1/en?oq=US6703396
Biktarvy,US8592397B2,Gilead Sciences,HIV,Small Molecule,3,1/14/2003,8/20/2008,11/26/2013,1/13/2024,Active,Formulation / Combination,The patent claims cover a chemically stable fixed dose combination pharmaceutical dosage form comprising 300 mg tenofovir disoproxil fumarate and 200 mg emtricitabine.,Before,No,https://patents.google.com/patent/US8592397B2/en?oq=US8592397B2
Biktarvy,US8716264B2,Gilead Sciences,HIV,Small Molecule,3,1/14/2003,9/4/2008,5/6/2014,1/13/2024,Active,Formulation / Combination,The patent claims cover a chemically stable fixed-dose combination comprising 300 mg of tenofovir disoproxil fumarate and 200 mg of emtricitabine wherein the combination exhibits less than 10% degradation of the tenofovir disoproxil fumarate and emtricitabine after six months at 40° C./75% relative humidity when packaged and stored with silica gel desiccant at 40° C./70% relative humidity. ,Before,No,https://patents.google.com/patent/US8716264B2/en?oq=US8716264B2
Biktarvy,US9744181B2,Gilead Sciences,HIV,Small Molecule,3,1/14/2003,10/24/2014,8/29/2017,1/13/2024,Active,Formulation / Combination,"The patent claims cover a fixed-dose combination comprising 300 mg of tenofovir disoproxil fumarate and 200 mg of emtricitabine wherein the combination exhibits equal to or less than 5% degradation of the tenofovir disoproxil fumarate and emtricitabine after six months at 40° C./75% relative humidity when packaged and stored with silica gel desiccant, and wherein the fixed-dose combination is a tablet. ",Before,No,https://patents.google.com/patent/US9744181B2/en?oq=US9744181B2
Biktarvy,US9457036B2,Gilead Sciences,HIV,Small Molecule,3,1/14/2003,10/24/2014,10/4/2016,3/12/2024,Active,Formulation / Combination,The patent claims cover a fixed dose combination containing 300 mg of ftenofovir disoproxil fumarate and and 200 mg of emtricitabine.,Before,No,https://patents.google.com/patent/US9457036B2/en?oq=US9457036B2
Biktarvy,US7390791B2,Gilead Sciences,HIV,Small Molecule,4,7/21/2000,3/11/2004,6/24/2008,4/17/2025,Active,Derivative,The patent claims cover the diastereomerically enriched form of the prodrug tenofovir alafenamide fumarate  and a number of phosphoramidate analogs. ,Before,Yes,https://patents.google.com/patent/US7390791B2/en?oq=US7390791B2
Biktarvy,US8754065B2,Gilead Sciences,HIV,Small Molecule,5,8/16/2011,8/15/2012,6/17/2014,8/15/2032,Active,Salt Form,"The patent claims cover tenofovir alafenamide hemifumarate,  a crystalline form, compositions and methods of treating an HIV infection. ",Before,Yes,https://patents.google.com/patent/US8754065B2/en?oq=US8754065B2
Biktarvy,US9296769B2,Gilead Sciences,HIV,Small Molecule,5,8/16/2011,3/5/2014,3/29/2016,8/15/2032,Active,Formulation / Combination,"The patent claims cover a composition comprising tenofovir alafenamide hemifumarate, wherein the composition comprises less than about 5% by weight of tenofovir alafenamide monofumarate. ",Before,Yes,https://patents.google.com/patent/US9296769B2/en?oq=US9296769B2
Biktarvy,US8664386B2,Gilead Sciences,HIV,Small Molecule,25,10/7/2011,10/3/2012,3/4/2014,10/3/2032,Active,Method of Production / Process,The patent claims cover a process for the method of selective crystallization of tenofovir alafenamide fumarate. ,Before,No,https://patents.google.com/patent/US8664386B2/en?oq=US8664386B2
Biktarvy,US9029534B2,Gilead Sciences,HIV,Small Molecule,25,10/7/2011,1/14/2014,5/12/2015,10/3/2032,Active,Method of Production / Process,"The patent claims cover a diastereoselective process for making tenofovir alafenamide fumarate.

",Before,No,https://patents.google.com/patent/US9029534B2/en?oq=US9029534B2
Biktarvy,US9346841B2,Gilead Sciences,HIV,Small Molecule,25,10/7/2011,4/8/2015,5/24/2016,10/3/2032,Active,Method of Production / Process,"The patent claims cover a diastereoselective process for making tenofovir alafenamide fumarate
",Before,No,https://patents.google.com/patent/US9346841B2/en?oq=US9346841B2
Biktarvy,US9676804B2,Gilead Sciences,HIV,Small Molecule,25,10/7/2011,4/21/2016,6/13/2017,10/3/2032,Active,Method of Production / Process,The patent claims cover a process  of preparing the mono-phenoxy ester of tenofovir (PMPA),Before,No,https://patents.google.com/patent/US9676804B2/en?oq=US9676804B2
Biktarvy,US9216996B2,Gilead Sciences,HIV,Small Molecule,9,12/21/2012,12/19/2013,12/22/2015,12/19/2033,Active,Main Compound,"The patent claims cover the base compound bictegravir, its stereoisomers and pharmaceutical compositions.",Before,Yes,https://patents.google.com/patent/US9216996B2/en?oq=US9216996B2
Biktarvy,US9732092B2,Gilead Sciences,HIV,Small Molecule,9,12/21/2012,11/11/2016,8/15/2017,12/19/2033,Active,Main Compound,The patent claims cover the base compound bictegravir and a large number of related analogs. ,Before,Yes,https://patents.google.com/patent/US9732092B2/en?oq=US9732092B2
Biktarvy,US10035809B2,Gilead Sciences,HIV,Small Molecule,9,12/21/2012,5/18/2017,7/31/2018,12/19/2033,Active,Derivative,The patent claims cover analogs of bictegravir. ,Before,No,https://patents.google.com/patent/US10035809B2/en?oq=US10035809B2
Biktarvy,US10689399B2,Gilead Sciences,HIV,Small Molecule,9,12/21/2012,6/25/2018,6/23/2020,12/19/2033,Active,Derivative,The patent claims cover analogs of the compound bictegravir.,After,No,https://patents.google.com/patent/US10689399B2/en?oq=US10689399B2
Biktarvy,US9663528B2,Gilead Sciences,HIV,Small Molecule,9,12/21/2012,7/31/2015,5/30/2017,2/19/2034,Active,Enantiomer / Stereoisomer,The patent claims cover stereoisomers of the compound bictegravir and a pharamceutical composition. ,Before,No,https://patents.google.com/patent/US9663528B2/en?oq=US9663528B2
Biktarvy,US9421214B2,Gilead Sciences,HIV,Small Molecule,26,7/12/2013,7/11/2014,8/23/2016,7/11/2034,Active,Derivative,The patent claims cover analogs of bictegravir to treat HIV. ,Before,No,https://patents.google.com/patent/US9421214B2/en?oq=US9421214B2
Biktarvy,US9700554B2,Gilead Sciences,HIV,Small Molecule,26,7/12/2013,7/12/2016,7/11/2017,7/11/2034,Active,Method of Treatment,The patent claims cover a method  of treating an HIV infection in a human having or at risk of having an HIV infection by administering to the human a therapeutically effective amount of certain analogs of bictegravir.,Before,No,https://patents.google.com/patent/US9700554B2/en?oq=US9700554B2
Biktarvy,US10668064B2,Gilead Sciences,HIV,Small Molecule,26,7/12/2013,8/2/2018,6/2/2020,7/11/2034,Active,Derivative,The patent claims cover analogs of bictegravir and pharmaceutical compositions,After,No,https://patents.google.com/patent/US10668064B2/en?oq=US10668064B2
Biktarvy,US9487546B2,Gilead Sciences,HIV,Small Molecule,8,1/15/2014,1/9/2015,11/8/2016,1/9/2035,Active,Crystalline,The patent claims cover a crystal form of the compound tenofovir (PMPA).  ,Before,No,https://patents.google.com/patent/US9487546B2/en?oq=US9487546B2
Biktarvy,US10519168B2,Gilead Sciences,HIV,Small Molecule,20,6/20/2014,6/30/2017,12/31/2019,6/16/2035,Active,Method of Production / Process,The patent claims cover a process for intermediate steps for preparing bictegravir.,Before,No,https://patents.google.com/patent/US10519168B2/en?oq=US10519168B2
Biktarvy,US10975096B2,Gilead Sciences,HIV,Small Molecule,20,6/20/2014,11/18/2019,4/13/2021,6/16/2035,Active,Method of Production / Process,The patent claims covers a process for making  intermediate compounds for synthesizing bictegravir.,After,No,https://patents.google.com/patent/US10975096B2/en?oq=US10975096B2
Biktarvy,US9708342B2,Gilead Sciences,HIV,Small Molecule,10,6/20/2014,6/19/2015,7/18/2017,6/19/2035,Active,Salt Form,"The patent claims cover the sodium salt of bictegravir, crystalline Forms 1 and 2, hydrates, anhydrous forms and combinations with 1-3 other drugs, pharmaceutical compositions, and the combination with  tenofovir alafenamide hemifumarate and emtricitabine.",Before,Yes,https://patents.google.com/patent/US9708342B2/en?oq=US9708342B2
Biktarvy,US10385067B2,Gilead Sciences,HIV,Small Molecule,10,6/20/2014,6/15/2017,8/20/2019,6/19/2035,Active,Method of Treatment,"The patent claims cover a method for treating an HIV infection in a human in need thereof, comprising administering to the human a therapeutically effective amount of a compound the crystal Form I of bictegravir and in combination with tenofovir alafenamide hemifumarate and emtricitabine to treat HIV.",Before,Yes,https://patents.google.com/patent/US10385067B2/en?oq=US10385067B2
Biktarvy,US9682084B2,Gilead Sciences,HIV,Small Molecule,19,6/20/2014,6/19/2015,6/20/2017,6/19/2035,Active,Crystalline,"The patent claims cover a crystalline form 1 of bictegravir and combinations with other HIV drugs including tenofovir disoproxil fumarate, tenofovir alafenamide, tenofovir alafenamide hemifumarate and emtricitabine.",Before,No,https://patents.google.com/patent/US9682084B2/en?oq=US9682084B2
Biktarvy,US10098886B2,Gilead Sciences,HIV,Small Molecule,19,6/20/2014,5/5/2017,10/16/2018,6/19/2035,Active,Method of Treatment,"The patent claims cover method for treating an HIV infection in a human in need thereof, comprising administering to the human a therapeutically effective amount of a crystalline Form 1 of bictegravir and in combination with tenofovir alafenamide fumarate and emtricitabine.",Before,No,https://patents.google.com/patent/US10098886B2/en?oq=US10098886B2
Biktarvy,US11202780,Gilead Sciences,HIV,Small Molecule,19,6/20/2014,1/10/2020,12/21/2021,6/19/2035,Active,Crystalline,The patent claims covers crystalline Form III of bictegravir,After,No,https://patents.google.com/patent/US11202780B2/en?oq=US11202780
Biktarvy,US9777028B2,Gilead Sciences,HIV,Small Molecule,11,6/17/2015,6/13/2016,10/3/2017,6/13/2036,Active,Crystalline,"The patent claims cover a solvate of tenofovir alafenamide sesquifumarate, wherein the solvate comprises a solvent selected from the group consisting of isopropanol, methyl ethyl ketone, tetrahydrofuran and acetone.",Before,No,https://patents.google.com/patent/US9777028B2/en?oq=US9777028B2
Biktarvy,US10155781B2,Gilead Sciences,HIV,Small Molecule,11,6/17/2015,9/5/2017,12/18/2018,6/13/2036,Active,Crystalline,"The patent claims cover  crystalline forms of tenofovir alafenamide saccharin, tenofovir alafenamide mucate, tenofovir alafenamide ethanesulfate, tenofovir alafenamide benzensulfonate, tenofovir alafenamide methanesulfonate and tenofovir alafenamide sulfate",Before,No,https://patents.google.com/patent/US10155781B2/en?oq=US10155781B2
Biktarvy,US10548846,Gilead Sciences,HIV,Small Molecule,13,11/9/2015,11/8/2016,2/4/2020,11/8/2036,Active,Formulation / Combination,"The patent claims cover a multilayer tablet comprising 50 mg of the compound bictegravir, 25 mg tenofovir alafenamide, and 200 mg of emtricitabine.",Before,Yes,https://patents.google.com/patent/US10548846B2/en?oq=US10548846
Biktarvy,US10287307B2,Gilead Sciences,HIV,Small Molecule,14,1/31/2017,1/29/2018,5/14/2019,1/29/2038,Active,Crystalline,The patent claims cover a crystalline tenofovir alafenamide sebacate Form I and its method of use by subcutaneous injection in a long-acting depot formulation. ,Before,No,https://patents.google.com/patent/US10287307B2/en?oq=US10287307B2
Biktarvy,US11253524B2,Gilead Sciences,HIV,Small Molecule,22,1/19/2018,1/18/2019,2/22/2022,1/18/2039,Active,Derivative,The patent claims cover metabolite analogs of bictegravir.,After,No,https://patents.google.com/patent/US11253524B2/en?oq=US11253524B2
Eliquis,"US 2004038980A1
",Bristol-Myers Squibb,Stroke/ Embolism,Small Molecule,1,12/23/1998,8/15/2003,2/26/2004,,Abandoned,Main Compound,"The patent application claimed a broad set of compounds including encompassing  the active ingredient apixaban, which is used in the product Eliquis, as well as pharmaceutical compositions and salt forms, and methods of treating thromboembolic disorders.",Before,No,https://patents.google.com/patent/US20040038980A1/en?oq=US+2004038980A1
Eliquis,"US 20050261287 A1
",Bristol-Myers Squibb,Stroke/ Embolism,Small Molecule,2,9/21/2001,6/16/2005,11/24/2005,,Abandoned,Main Compound,"The patent applications claimed a broad set of compounds including encompassing  the active ingredient apixaban, which is used in the product Eliquis, as well as pharmaceutical compositions and salt forms, and methods of treating thromboembolic disorders.",Before,No,https://patents.google.com/patent/US20050261287A1/en?oq=US+20050261287+A1
Eliquis,US 20070191306 A1,Bristol-Myers Squibb,Stroke/ Embolism,Small Molecule,5,8/17/2005,8/15/2006,8/16/2007,,Abandoned,Formulation / Combination,The patent application claimed oral and injectable formulations comprising apixaban and beta-cyclodextrin ,Before,No,https://patents.google.com/patent/US20070191306A1/en?oq=US+20070191306+A1
Eliquis,"US20070027186 A1
",Bristol-Myers Squibb,Stroke/ Embolism,Small Molecule,3,12/10/2001,9/7/2006,2/1/2007,,Abandoned,Method of Production / Process,The patent application claimed intermediate compounds for making apixaban (Eliquis),Before,No,https://patents.google.com/patent/US20070027186A1/en?oq=US20070027186+A1
Eliquis,"US 20070203178 A1
",Bristol-Myers Squibb,Stroke/ Embolism,Small Molecule,4,9/28/2004,2/23/2007,8/30/2007,,Abandoned,Crystalline,The patent application claimed crystalline solvates of apixaban (Eliquis). ,Before,No,https://patents.google.com/patent/US20070203178A1/en?oq=US+20070203178+A1
Eliquis,US 20080026447 A1,Bristol-Myers Squibb,Stroke/ Embolism,Small Molecule,7,4/20/2006,4/19/2007,1/31/2008,,Abandoned,Method of Treatment,The patent application claimed a method and kit for determining the concentration of a factor VIIa inhibitor in a plasma sample. ,Before,No,https://patents.google.com/patent/US20080026447A1/en?oq=US+20080026447+A1
Eliquis,US 20070259913 A1,Bristol-Myers Squibb,Stroke/ Embolism,Small Molecule,6,5/4/2006,5/4/2007,11/8/2007,,Abandoned,Method of Treatment,The patent application claimed method of prophylaxis of thrombotic and thromboembolic events in a cancer patient  by administering apixaban (Eliquis) or a polymorph or pharmaceutically acceptable solvate form ,Before,No,https://patents.google.com/patent/US20070259913A1/en?oq=US+20070259913+A1
Eliquis,"US 20090291913 A1
",Bristol-Myers Squibb,Stroke/ Embolism,Small Molecule,5,8/17/2005,8/4/2009,11/26/2009,,Abandoned,Formulation / Combination,"The patent application claimed a formulation, including an injectable form, containing apixaban (Eliquis) and a form of cyclodextrin. ",Before,No,https://patents.google.com/patent/US20090291913A1/en?oq=US+20090291913+A1
Eliquis,US 20120087978 A1,Pfizer,Stroke/ Embolism,Small Molecule,8,6/16/2009,6/15/2010,4/12/2012,,Abandoned,Formulation / Combination,The application claimed a dosage form for controlled release comprising apixaban (Eliquis) and a solubility enhancing agent.,Before,No,https://patents.google.com/patent/US20120087978A1/en?oq=US+20120087978+A1
Eliquis,"US 20140113892 A1
",Bristol-Myers Squibb,Stroke/ Embolism,Small Molecule,2,9/21/2001,5/10/2013,4/24/2014,,Abandoned,Derivative,The patent application claimed lactum containing compounds as Factor Xa inhibitors from a slightly different Markush group to apixaban (Eliquis).,After,No,https://patents.google.com/patent/US20140113892A1/en?oq=US+20140113892+A1
Eliquis,"US 20140030330 A1
",Pfizer,Stroke/ Embolism,Small Molecule,8,6/16/2009,7/2/2013,1/30/2014,,Abandoned,Formulation / Combination,The patent application claimed a solubility improved dosage form comprising apixaban (Eliquis) ,After,No,https://patents.google.com/patent/US20140030330A1/en?oq=US+20140030330+A1
Eliquis,US20150343034A1,Pfizer,Stroke/ Embolism,Small Molecule,14,1/31/2013,1/23/2014,12/3/2015,,Abandoned,Method of Treatment,The patent application claimed an antidote for reducing or preventing excessive bleeding upon treatment with Factor Xa inhibitors including apixaban.,After,No,https://patents.google.com/patent/US20150343034A1/en?oq=US20150343034A1
Eliquis,"US 20140335178 A1
",Pfizer,Stroke/ Embolism,Small Molecule,8,6/16/2009,5/19/2014,11/13/2014,,Abandoned,Formulation / Combination,The application claimed a dosage form for controlled release comprising apixaban (Eliquis) and a solubility enhancing agent.,After,No,https://patents.google.com/patent/US20140335178A1/en?oq=US+20140335178+A1
Eliquis,"US 20150210691 A1
",Bristol-Myers Squibb,Stroke/ Embolism,Small Molecule,2,9/21/2001,4/8/2015,7/30/2015,,Abandoned,Main Compound,The patent application claimed a Markush group of compounds similar to apixaban (Eliquis),After,No,https://patents.google.com/patent/US20150210691A1/en?oq=US+20150210691+A1
Eliquis,"US 20160243101 A1 
",Bristol-Myers Squibb,Stroke/ Embolism,Small Molecule,9,2/25/2010,3/31/2016,8/25/2016,,Abandoned,Formulation / Combination,The application claimed a solid pharmaceutical composition comprising crystalline forms of apixaban (Eliquis) with particle size D90equal to or less than 89 microns.,After,No,https://patents.google.com/patent/US20160243101A1/en?oq=US+20160243101+A1+
Eliquis,"US 20170202824 A1
",Bristol-Myers Squibb,Stroke/ Embolism,Small Molecule,9,2/25/2010,3/30/2017,7/20/2017,,Abandoned,Formulation / Combination,The patent applicatuion claimed a solid pharmaceutical composition comprising crystalline apixaban (Eliquis) and a dissolution specification. ,After,No,https://patents.google.com/patent/US20170202824A1/en?oq=US+20170202824+A1
Eliquis,US 20170202825 A1,Bristol-Myers Squibb,Stroke/ Embolism,Small Molecule,9,2/25/2010,3/30/2017,7/20/2017,,Abandoned,Formulation / Combination,The patent application claimed a tablet/capsule comprising 2.5mg to 5mg of apixaban (Eliquis) and a pharmceutically acceptab;e diluent or carrier obtained by a blending and granulation process.,After,No,https://patents.google.com/patent/US20170202825A1/en?oq=US+20170202825+A1
Eliquis,US20210145817A1,Bristol-Myers Squibb,Stroke/ Embolism,Small Molecule,12,4/16/2018,4/15/2019,5/20/2021,,Pending,Formulation / Combination,The patent application claimed a treated core comprising apixaban (Eliquis) and a carrier on the core substrate.,After,No,https://patents.google.com/patent/US20210145817A1/en?oq=US20210145817A1
Eliquis,US20210000930A1,Pfizer,Stroke/ Embolism,Small Molecule,14,1/31/2013,3/16/2020,1/7/2021,,Abandoned,Method of Treatment,"The application claimed a method for reversing the anticoagulen effect of a direct Factor Xa inhibitor, including apixaban (Eliquis). ",After,No,https://patents.google.com/patent/US20210000930A1/en?oq=US20210000930A1
Eliquis,US20200375968A1,Bristol-Myers Squibb,Stroke/ Embolism,Small Molecule,9,2/25/2010,5/14/2020,12/3/2020,,Abandoned,Formulation / Combination,"The application claimed a tablet and an immediate release tablet comprising up to about 5mg of apixaban (Eliquis), a pharmaceutically acceptable diluent and carrier and an optional coating.",After,No,https://patents.google.com/patent/US20200375968A1/en?oq=US20200375968A1
Eliquis,US6413980B1,Bristol-Myers Squibb,Stroke/ Embolism,Small Molecule,1,12/23/1998,12/22/1999,7/2/2002,12/22/2019,Expired,Main Compound,"The patent claims cover a broad set of compounds including encompassing  the active ingredient apixaban, which is used in the product Eliquis, as well as pharmaceutical compositions and salt forms, and methods of treating thromboembolic disorders.",Before,No,https://patents.google.com/patent/US6413980B1/en?oq=US6413980B1
Eliquis,"US6673810B2
",Bristol-Myers Squibb,Stroke/ Embolism,Small Molecule,1,12/23/1998,7/3/2001,1/6/2004,12/22/2019,Expired,Main Compound,"The patent claims cover  a broad set of compounds including the active ingredient apixaban, which is used in the produt Eliquis, as well as pharmaceutical compositions and salt forms, and methods of treating thromboembolic disorders.",Before,No,https://patents.google.com/patent/US6673810B2/en?oq=US6673810B2
Eliquis,US6858616B2,Bristol-Myers Squibb,Stroke/ Embolism,Small Molecule,1,12/23/1998,4/26/2002,2/22/2005,4/25/2020,Expired,Derivative," The patent claims cover a broad set of compounds similar to the active ingredient apixiban (Eliquis) as well as pharmaceutical compositions and salt forms, and methods of treating thromboembolic disorders.",Before,No,https://patents.google.com/patent/US6858616B2/en?oq=US6858616B2
Eliquis,US 7371761 B2,Bristol-Myers Squibb,Stroke/ Embolism,Small Molecule,2,9/21/2001,1/16/2007,5/13/2008,9/17/2022,Active,Main Compound,"The patent claims cover a broad set of compounds including specifically the active ingredient apixaban (Eliquis), as well as pharmaceutical compositions and salt forms, and methods of treating thromboembolic disorders.",Before,No,https://patents.google.com/patent/US7371761B2/en?oq=US+7371761+B2
Eliquis,US 7531535 B2,Bristol-Myers Squibb,Stroke/ Embolism,Small Molecule,2,9/21/2001,12/13/2007,5/12/2009,9/17/2022,Active,Derivative," The patent claims cover various analogs of apixiban (Eliquis) as well as pharmaceutical compositions and salt forms, and methods of treating thromboembolic disorders. This patent potentially blocks off competitors researching similar compounds to apixiban",Before,No,https://patents.google.com/patent/US7531535B2/en?oq=US7531535
Eliquis,US 7691846 B2,Bristol-Myers Squibb,Stroke/ Embolism,Small Molecule,2,9/21/2001,3/10/2009,4/6/2010,9/17/2022,Active,Derivative,"The patent claims cover compounds with a slightly different Markush group to that covering apixaban (Eliquis) as well as pharmaceutical compositions and salt forms, and methods of treating thromboembolic disorders. ",Before,No,https://patents.google.com/patent/US7691846B2/en?oq=US+7691846+B2
Eliquis,US 7960411 B2,Bristol-Myers Squibb,Stroke/ Embolism,Small Molecule,2,9/21/2001,1/22/2010,6/14/2011,9/17/2022,Active,Derivative,"The patent claims cover compounds with a slightly different Markush group to that covering apixaban (Eliquis) as well as pharmaceutical compositions and salt forms, and methods of treating thromboembolic disorders. This patent blocks off competitors researching similar compounds to apixiban.",Before,No,https://patents.google.com/patent/US7960411B2/en?oq=US+7960411+B2
Eliquis,US 8188120 B2,Bristol-Myers Squibb,Stroke/ Embolism,Small Molecule,2,9/21/2001,5/5/2011,5/29/2012,9/17/2022,Active,Derivative,"The patent claims cover compounds with a slightly different Markush group to that covering apixaban (Eliquis) as well as pharmaceutical compositions and salt forms, and methods of treating thromboembolic disorders. ",Before,No,https://patents.google.com/patent/US8188120B2/en?oq=US+8188120+B2
Eliquis,US 8470854 B2,Bristol-Myers Squibb,Stroke/ Embolism,Small Molecule,2,9/21/2001,4/12/2012,6/25/2013,9/17/2022,Active,Derivative,"The patent claims cover compounds with a slightly different Markush group to that covering apixaban (Eliquis) as well as pharmaceutical compositions and salt forms, and methods of treating thromboembolic disorders. This patent blocks off competitors researching similar compounds to apixiban.",Before,No,https://patents.google.com/patent/US8470854B2/en?oq=US+8470854+B2
Eliquis,"US9975891B2
",Bristol-Myers Squibb,Stroke/ Embolism,Small Molecule,2,9/21/2001,11/7/2016,5/22/2018,9/17/2022,Active,Derivative,"The patent claims cover compounds with a slightly different Markush group to that covering apixaban (Eliquis) as well as pharmaceutical compositions and salt forms, and methods of treating thromboembolic disorders. ",After,No,https://patents.google.com/patent/US9975891B2/en?oq=US9975891B2
Eliquis,US6989391 B2 ,Bristol-Myers Squibb,Stroke/ Embolism,Small Molecule,2,9/21/2001,5/20/2004,1/24/2006,10/28/2022,Active,Derivative,"The patent claims cover  compounds similar in structure to apixiban (Eliquis) as well as pharmaceutical compositions and salt forms, and methods of treating thromboembolic disorders. ",Before,No,https://patents.google.com/patent/US6989391B2/en?oq=US6989391+B2+
Eliquis,US 6919451 B2,Bristol-Myers Squibb,Stroke/ Embolism,Small Molecule,3,12/10/2001,12/3/2002,7/19/2005,12/3/2022,Active,Method of Production / Process,"The patent claims cover a process for synthesising the active ingredient apixaban (Eliquis), in particular its heterocyclic core. ",Before,No,https://patents.google.com/patent/US6919451B2/en?oq=US+6919451+B2
Eliquis,US7153960  B2,Bristol-Myers Squibb,Stroke/ Embolism,Small Molecule,3,12/10/2001,6/8/2005,12/26/2006,12/3/2022,Active,Method of Production / Process,The patent claims cover the process for preparing intermediates for synthesising the active ingredient apixaban (Eliquis).,Before,No,https://patents.google.com/patent/US7153960B2/en?oq=US7153960++B2
Eliquis,"US6995172 B2

",Bristol-Myers Squibb,Stroke/ Embolism,Small Molecule,2,9/21/2001,10/21/2004,2/7/2006,12/23/2022,Active,Main Compound,"The patent claims cover the active ingredient apixaban, a pharmaceutical composition and methods for treating a thromboembolic disorder. ",Before,No,https://patents.google.com/patent/US6995172B2/en?oq=US6995172+B2
Eliquis,"US7005435 B2
",Bristol-Myers Squibb,Stroke/ Embolism,Small Molecule,2,9/21/2001,10/20/2004,2/28/2006,1/29/2023,Active,Derivative,"The patent claims cover a similar compound to apixaban (Eliquis), pharmaceutical compositions and method for treating a thromboembolic disorder.  ",Before,No,https://patents.google.com/patent/US7005435B2/en?oq=US7005435+B2
Eliquis,US 7338963 B2,Bristol-Myers Squibb,Stroke/ Embolism,Small Molecule,2,9/21/2001,8/5/2005,3/4/2008,4/8/2023,Active,Main Compound,"The patent claims cover the active ingredient apixaban, pharmaceutical compositions and methods for treating a thromboembolic disorde",Before,No,https://patents.google.com/patent/US7338963B2/en?oq=US+7338963+B2
Eliquis,US7396932 ,Bristol-Myers Squibb,Stroke/ Embolism,Small Molecule,4,9/28/2004,9/26/2005,7/8/2008,10/10/2026,Active,Method of Production / Process,The patent claims cover a process for obtaining compounds similar to apixaban (Eliquis).,Before,No,https://patents.google.com/patent/US7396932B2/en?oq=US7396932+
Eliquis,"US6967208 B2
",Bristol-Myers Squibb,Stroke/ Embolism,Small Molecule,2,9/21/2001,9/17/2002,11/22/2005,11/21/2026,Active,Main Compound,"The patent claims cover the active ingredient apixaban, pharmaceutical compositions and methods for treating a thromboembolic disorder. ",Before,Yes,https://patents.google.com/patent/US6967208B2/en?oq=US6967208+B2
Eliquis,US 9326945 B2,Bristol-Myers Squibb,Stroke/ Embolism,Small Molecule,9,2/25/2010,2/24/2011,5/3/2016,2/24/2031,Active,Formulation / Combination,The patent claims cover a formulation of apixaban containing crystalline material with d90 of less than 89 microns; an at least 77% dissolves within 30 minutes in phosphate buffer. ,Before,Yes,https://patents.google.com/patent/US9326945B2/en?oq=US+9326945+B2
Eliquis,US 9452134 B2,Bristol-Myers Squibb,Stroke/ Embolism,Small Molecule,10,9/26/2012,9/26/2013,9/27/2016,9/26/2033,Active,Formulation / Combination,"The patent claims cover a liquid formulation suitable for administration orally or through a nasogastric tube comprising apixaban and a suitable vehicle, such as water and two solubilisers.",After,No,https://patents.google.com/patent/US9452134B2/en?oq=US+9452134+B2
Eliquis,"US10016362B2
",Bristol-Myers Squibb,Stroke/ Embolism,Small Molecule,10,9/26/2012,5/24/2016,7/10/2018,9/26/2033,Active,Formulation / Combination,"The patent claims cover a liquid formulation suitable for administration orally or through a nasogastric tube comprising apixaban and a suitable vehicle, such as water and two solubilisers.",After,No,https://patents.google.com/patent/US10016362B2/en?oq=US10016362B2
Eliquis,US10588950,Pfizer,Stroke/ Embolism,Small Molecule,14,1/31/2013,1/17/2018,3/17/2020,1/23/2034,Active,Method of Treatment,The patent claims cover a method for reversing the anticoagulent effect of a direct Factor Xa inhibitor including apixaban (Eliquis).,After,No,https://patents.google.com/patent/US10588950B2/en?oq=US10588950
Eliquis,"US 20170202826 A1
",Bristol-Myers Squibb / Pfizer,Stroke/ Embolism,Small Molecule,8,6/16/2009,3/30/2017,7/20/2017,,Pending,Formulation / Combination,"The patent application claimed  a formulation  comprising a solid amorphous dispersion of apixaban (Eliquis) and a polymer, wherein the solid amorphous dispersion is spray-dried. ",After,No,https://patents.google.com/patent/US20170202826A1/en?oq=US+20170202826+A1
Enbrel,US5395760,Immunex,Arthritis,Biologic,1,9/5/1989,5/10/1990,3/7/1995,3/7/2012,Expired,Product,The patent claims cover a isolated DNA sequence consisting of a DNA sequence encoding only the amino acid sequence selected from the group consisting of amino acids 1-235 of FIG. 2A and amino acids 1-233 of and the DNA sequence that encodes for a soluble TNF-R,Before,No,https://patents.google.com/patent/US5395760A/en?oq=US5395760
Enbrel,US5610279,Hoffman La Roche,Arthritis,Biologic,2,9/12/1989,7/21/1993,3/11/1997,3/11/2014,Expired,Product,"The patent claims cover a recombinant protein encoded by a polynucleotide which comprises two DNA subsequences, wherein the first subsequence encodes a soluble fragment of the insoluble TNF receptor protein, wherein said insoluble TNF receptor protein has a apparent molecular weight of about 55 kilodaltons as determined on a non-reducing SDS-polyacrylamide gel, and the second subsequence encodes all of the domains of the constant region of a human immunoglobulin heavy chain other than the first domain of said constant region.",Before,No,https://patents.google.com/patent/US5610279A/en?oq=US5610279
Enbrel,US5708142,Genentech,Arthritis,Biologic,6,5/27/1994,5/27/1994,1/13/1998,1/13/2015,Expired,Product,The patent claims an isolated TRAF selected from the group consisting of TRAF1 having the amino acid sequence depicted in SEQ. ID. NO:2 and TRAF2 having the amino acid sequence depicted in SEQ. ID. NO:4,Before,No,https://patents.google.com/patent/US5708142A/en?oq=US5708142
Enbrel,US5670319 ,Genentech,Arthritis,Biologic,6,5/27/1994,10/28/1994,9/23/1997,9/23/2014,Expired,Biomarker,"The patent claims cover an assay for identifying a factor capable of specific binding to the intracellular domain of a native TNF-R2, comprising(a) expressing nucleic acid molecules encoding a polypeptide comprising a fusion of an intracellular domain sequence from within amino acids 346-384 to amino acids 423-424 of native human TNF-R2 to the DNA-binding domain of a transcriptional activator, and a fusion of a candidate polypeptide factor to the activation domain of a transcriptional activator, in a single host cell carrying a reporter gene; and (b) monitoring the binding of said candidate factor to said intracellular domain sequence of TNF-R2 by detecting a signal of the molecule encoded by said reporter gene.2. Assay for identifying agents that bind to TNF",Before,No,https://patents.google.com/patent/US5670319A/en?oq=US5670319+
Enbrel,US5712155 ,Immunex,Arthritis,Biologic,1,9/5/1989,11/29/1994,1/27/1998,9/14/2015,Expired,Product,"The patent claims cover an isolated DNA sequence selected from the group consisting of: (a) a DNA sequence that encodes a polypeptide having the amino acid sequence selected from the group consisting of amino acids 1 to X of FIG. 2A and amino acids 1 to 233, wherein X is an amino acid from 163 to 235; and
(b) a DNA sequence capable of hybridization to the complement of the DNA sequence of (a) under moderately stringent conditions (50° C., 2× SSC) and which encodes a polypeptide that is capable of binding to TNF and which is at least 88% identical to a polypeptide encoded by the DNA of (a).",Before,No,https://patents.google.com/patent/US5712155A/en?oq=US5712155
Enbrel,US5605690 ,Immunex,Arthritis,Biologic,1,9/5/1989,2/8/1995,2/25/1997,2/25/2014,Expired,Method of Treatment,"The patent claims cover a method for lowering the levels of active TNF-α in a mammal in need thereof which comprises administering to said mammal a TNF-lowering amount of a TNF antagonist selected from the group consisting of: (a) a TNF receptor comprising the sequence of amino acids 3-163 of SEQ ID NO:1; and
(b) a chimeric antibody comprising a TNF receptor according to (a) fused to the constant domain of an immunoglobulin molecule.",Before,No,https://patents.google.com/patent/US5605690A/en?oq=US5605690+
Enbrel,US6541610 ,Immunex,Arthritis,Biologic,1,9/5/1989,3/20/1995,4/1/2003,4/1/2020,Expired,Product,"The patent claims cover an isolated DNA molecule that encodes a fusion protein comprising two tumor necrosis factor receptor (TNFR) polypeptides and one interleukin-1 receptor (IL-1R) polypeptide, wherein said fusion protein is of a formula selected from: TNFR-linker-TNFR-linker-IL-1R; and IL-1R-linker-TNFR-linker-TNFR,
wherein each linker is a peptide linker; and wherein each TNFR represents a soluble TNFR.2. An isolated DNA molecule that encodes a fusion protein; or a vector, or the fusion protein",Before,No,https://patents.google.com/patent/US6541610B1/en?oq=US6541610
Enbrel,US5808029 ,Hoffman La Roche,Arthritis,Biologic,2,9/12/1989,5/19/1995,9/15/1998,9/15/2015,Expired,Product,The patent claims a polynucleotide with a defined sequence.,Before,No,https://patents.google.com/patent/US5808029A/en?oq=US5808029
Enbrel,US8063182,Hoffman La Roche,Arthritis,Biologic,2,9/12/1989,5/19/1995,11/22/2011,11/22/2028,Active,Product,"The patent claims cover a human tumor necrosis factor (TNF)-binding soluble fragment of an insoluble human TNF receptor, wherein the insoluble human TNF receptor (i) specifically binds human TNF, (ii) has an apparent molecular weight of about 75 kilodaltons on a non-reducing SDS-polyacrylamide gel, and (iii) comprises the amino acid sequence LPAQVAFXPYAPEPGSTC (SEQ ID NO: 10); and
(b) all of the domains of the constant region of a human immunoglobulin IgG heavy chain other than the first domain of said constant region;wherein said protein specifically binds human TNF. This is the primary patent covering etanercept .",Before,No,https://patents.google.com/patent/US8063182B1/en?oq=US8063182
Enbrel,US8163522,Hoffman La Roche,Arthritis,Biologic,2,9/12/1989,5/19/1995,4/24/2012,4/24/2029,Active,Method of Production/Process,"The patent claims cover a  method comprising the steps of: (a) culturing a host cell comprising a polynucleotide, wherein the polynucleotide encodes a protein consisting of: (i) the extracellular region of an insoluble human TNF receptor, wherein the insoluble human TNF receptor has an apparent molecular weight of about 75 kilodaltons as determined on a non-reducing SDS polyacrylamide gel and comprises the amino acid sequence LPAQVAFXPYAPEPGSTC (SEQ ID NO: 10), and (ii) all of the domains of the constant region of a human IgG immunoglobulin heavy chain other than the first domain of said constant region, and (b) purifying an expression product of the polynucleotide from the cell mass or the culture medium.",Before,No,https://patents.google.com/patent/US8163522B1/en?oq=US8163522
Enbrel,US5741667 ,Genentech,Arthritis,Biologic,6,5/27/1994,5/22/1995,4/21/1998,4/21/2015,Expired,Product,"The patent claims cover an isolated nucleic acid molecule comprising a nucleotide sequence encoding a native mammalian TRAF1 or TRAF2 protein or a TRAF protein, comprising at least amino acids 180 to 409 of SEQ. ID. NO: 2, or at least amino acids 272 to 501 of SEQ. ID. NO: 4.",Before,No,https://patents.google.com/patent/US5741667A/en?oq=US5741667+
Enbrel,US5945397 ,Immunex,Arthritis,Biologic,1,9/5/1989,5/16/1996,8/31/1999,9/5/2009,Expired,Formulation,"The patent claims cover a  composition consisting essentially of a protein comprising a sequence of amino acids selected from the group consisting of amino acids 1-163 of SEQ ID NO:2 and amino acids 1-233 of SEQ ID NO:4, wherein said protein is capable of binding TNF.",Before,No,https://patents.google.com/patent/US5945397A/en?oq=US5945397
Enbrel,US5869612 ,Genentech,Arthritis,Biologic,6,5/27/1994,11/5/1996,2/9/1999,5/27/2014,Expired,Product,The patent claims cover an isolated tumor necrosis factor receptor associated factor (TRAF) comprising an amino acid sequence selected from the group consisting of: (1) the N-terminal RING finger domain of TRAF2 of SEQ. ID. NO: 4; (2) amino acids 180 to 409 of TRAF1 of SEQ. ID. NO: 2; (3) amino acids 272 to 501 of TRAF2 of SEQ. ID. NO: 4; (4) amino acids 2-181 of TRAF1 of SEQ. ID. NO: 2; and (5) amino acids 1-162 of TRAF2 of SEQ. ID. NO: 4.,Before,No,https://patents.google.com/patent/US5869612A/en?oq=US5869612
Enbrel,US6500922 ,Genentech,Arthritis,Biologic,6,5/27/1994,1/7/1997,12/31/2002,5/27/2014,Expired,Product,"The patent claims cover an isolated human tumor necrosis factor receptor associated factor (TRAF) prepared by (a) screening a human recombinant cDNA library prepared from tissue expressing human TNF-R2 at a detectable level with one or more labeled oligonucleotide probe(s) having about 30 to 50 bases derived from the nucleotide sequence encoding marine TRAF1 (SEQ. ID. NO:1) or murine TRAF2 (SEQ. ID. NO:3), wherein said probe(s) are designed based on TRAF1 or TRAF2 regions which have the least codon redundance, under stringent conditions comprising overnight incubation at 42° C. in a solution comprising 20% formamide, 5×SSC, 50 mM sodium phosphate (pH7.6), 5×Denhardt's solution, 10% dextran sulfate, and 20 g/ml denature, sheared salmon sperm DNA;
(b) inserting the DNA hybridizing to said probe(s) into a replicable expression vector; (c) transforming a recombinant host cell with said expression vector; (d) culturing the transformed host cell; and (e) recovering said human TRAF.",Before,No,https://patents.google.com/patent/US6500922B1/en?oq=US6500922
Enbrel,US6027915,Immunex,Arthritis,Biologic,8,1/11/1996,1/13/1997,2/22/2000,1/11/2016,Expired,Method of Production/Process,"The patent claims cover an isolated expression augmenting sequence element (EASE), selected from the group consisting of DNAs comprising nucleotides 1 through 14507, nucleotides 5980 through 14507, nucleotides 8671 through 14507, nucleotides 8671 through 10515, nucleotides 9277 through 10515, nucleotides 8672 through 12273, nucleotides 10100 through 14293 of SEQ ID NO:1, fragments of the foregoing DNAs that have expression augmenting activity and that are at least 603 bp in length, DNAs complementary to the foregoing DNAs, DNAs that are at least about 80% identical in nucleotide sequence to the foregoing DNAs and that have expression augmenting activity, and combinations of the foregoing DNAs that have expression augmenting activity.",Before,No,https://patents.google.com/patent/US6027915A/en?oq=US6027915
Enbrel,USRE36755 ,Immunex,Arthritis,Biologic,1,9/5/1989,8/31/1998,6/27/2000,10/23/2012,Expired,Product,The patent claims cover an isolated DNA sequence or an expression vector that allow for production of a peptide that binds to TNF,Before,No,https://patents.google.com/patent/USRE36755E/en?oq=USRE36755
Enbrel,US6201105 ,Immunex,Arthritis,Biologic,1,9/5/1989,1/20/1999,3/13/2001,9/5/2009,Expired,Product,The patent claims cover are combinant protein comprising amino acids 1-163 and wherein said recombinant protein binds TNF.,After,No  ,https://patents.google.com/patent/US6201105B1/en?oq=US6201105
Enbrel,US6306820,Amgen,Arthritis,Biologic,9,12/6/1996,6/4/1999,10/23/2001,12/8/2017,Expired,Formulation,"The patent claims cover a pharmaceutical composition comprising a TNF binding protein and a Fas antigen and a method for treating septic shock which comprises administering to a patient in need thereof therapeutically effective amounts of a TNF binding protein which is administered prior to, concurrently with or after administration of a Fas antigen.",After,No,https://patents.google.com/patent/US6306820B1/en?oq=US6306820
Enbrel,US6312951 ,Immunex,Arthritis,Biologic,8,1/11/1996,11/5/1999,11/6/2001,1/11/2016,Expired,Method of Production/Process,"The patent claims cover an  isolated expression augmenting sequence element (EASE), selected from the group consisting of DNAs comprising nucleotides 46 through 14507, nucleotides 5980 through 14507, nucleotides 8671 through 14507, nucleotides 8671 through 10515, nucleotides 9277 through 10515, nucleotides 8672 through 12273, nucleotides 10100 through 14293 of SEQ ID NO: 1, fragments of the foregoing DNAs that have expression augmenting activity, DNAs complementary to the foregoing DNAs, DNAs that are at least about 80% identical in nucleotide sequence to the foregoing DNAs and that have expression augmenting activity, and combinations of the foregoing DNAs that have expression augmenting activity..",After,No,https://patents.google.com/patent/US6312951B1/en?oq=US6312951
Enbrel,US6309841 ,Immunex,Arthritis,Biologic,8,1/11/1996,9/12/2000,10/30/2001,1/11/2016,Expired,Product,"The patent claims cover a polynucleotide selected from the group consisting of DNA comprising nucleotides 11303-12192 of SEQ ID NO:1, nucleotides 11538-12165 of SEQ ID NO:1, fragments of the foregoing DNA that have expression augmenting activity, DNA complementary to the foregoing DNA, and combinations of the foregoing DNA that have expression augmenting activity.",After,No,https://patents.google.com/patent/US6309841B1/en?oq=US6309841
Enbrel,US6808902 ,Amgen,Arthritis,Biologic,5,11/12/1999,11/9/2000,10/26/2004,11/9/2020,Expired,Process,"The patent claims cover a process for preparing a pharmacologically active compound, which comprises:(a) preparing in E. Coli a pharmacologically active compound comprising IL-1ra, wherein said IL-1ra is fused to an Fc domain (b) refolding the pharmacologically active compound with a copper (II) halide in a concentration of at least about 10 mM; and
(c) isolating the treated fusion molecule.",After,No,https://patents.google.com/patent/US6808902B1/en?oq=US6808902
Enbrel,US6572852 ,Immunex,Arthritis,Biologic,1,9/5/1989,1/12/2001,6/3/2003,9/5/2009,Expired,Method of Treatment,"The patent claims cover a method of suppressing a TNF-dependent inflammatory response in a mammal comprising administering an effective amount of recombinant tumor necrosis factor receptor (TNFR) to a mammal afflicted with said inflammatory response, wherein said recombinant TNFR comprises amino acids 1-163 of SEQ ID NO:2.",After,No,https://patents.google.com/patent/US6572852B2/en?oq=US6572852
Enbrel,US2001021380 ,Immunex,Arthritis,Biologic,7,4/19/1999,2/7/2001,9/13/2001,,Abandoned,Method of Treatment,The application claimed a method of treating a human patient having tropical spastic paraparesis/HTLV-1 associated myelopathy comprising administering to said patient a therapeutically effective amount of a TNFα inhibitor.,After,No,https://patents.google.com/patent/US20010021380A1/en?oq=US2001021380+
Enbrel,US2002119924,Amgen,Arthritis,Biologic,9,12/6/1996,7/17/2001,8/29/2002,,Abandoned,Method of Treatment,"The application claimed a method for treating an acute or chronic inflammatory disease which comprises administering to a patient in need thereof therapeutically effective amounts of a TNF binding protein and at least one additional anti-inflammatory drug, wherein said TNF binding protein and additional anti-inflammatory drug are administered separately or in combination. ",After,No,https://patents.google.com/patent/US20020119924A1/en?oq=US2002119924
Enbrel,US6596514 ,Immunex,Arthritis,Biologic,8,1/11/1996,10/9/2001,7/22/2003,7/11/2016,Expired,Product,"The patent claims cover an isolated polynucleotide, comprising a nucleic acid molecule selected from the group consisting of nucleotides 11538-11692 of SEQ ID NO:1, nucleotides 11538-11760 of SEQ ID NO:1, nucleotides 11673-12165 of SEQ ID NO:1, nucleotides 11813-12165 of SEQ ID NO:1, nucleotides 11899-12165 of SEQ ID NO:1, fragments of the foregoing DNA that have expression augmenting activity, DNA complementary to the foregoing DNA, and combinations of the foregoing DNA that have expression augmenting activity. ",After,No,https://patents.google.com/patent/US6596514B2/en?oq=US6596514
Enbrel,US2003082736 ,Immunex,Arthritis,Biologic,1,9/5/1989,9/24/2002,5/1/2003,,Abandoned,Product,The application claimed a fusion protein comprising a human tumor necrosis factor receptor (TNF-R) and a human interleukin-1 receptor (IL-1R).2. ,After,No,https://patents.google.com/patent/US20030082736A1/en?oq=US2003082736
Enbrel,US7244836 ,Genentech,Arthritis,Biologic,6,5/27/1994,10/30/2002,7/17/2007,11/22/2014,Expired,Product,The patent claims cover an isolated nucleic acid molecule comprising a nucleotide sequence that can hybridize under stringent conditions to the coding sequence of SEQ ID NO:1 or the complement thereof.,After,No,https://patents.google.com/patent/US7244836B2/en?oq=US7244836
Enbrel,US2003148955 ,Immunex,Arthritis,Biologic,7,4/19/1999,12/9/2002,8/7/2003,,Abandoned,Method of Treatment,"The application claimed a method of preventing or reducing resistance to imatinib in a chronic myelogenous leukemia patient comprising administering TNFR:Fc to a chronic myelogenous leukemia patient, wherein said patient is treated concurrently with imatinib.",After,No,https://patents.google.com/patent/US20030148955A1/en?oq=US2003148955
Enbrel,US2003180287 ,Immunex,Arthritis,Biologic,3,2/27/2002,2/27/2003,9/25/2003,,Abandoned,Formulation,"The application claimed a  pharmaceutical composition that is a stable aqueous formulation comprising an Fc domain containing polypeptide and an aggregation inhibitor, wherein the aggregation inhibitor is L-arginine.",After,No,https://patents.google.com/patent/US20030180287A1/en?oq=US2003180287
Enbrel,US7057022 ,Immunex,Arthritis,Biologic,1,9/5/1989,4/23/2003,6/6/2006,9/5/2009,Expired,Product,"The patent claims cover a purified antibody that specifically binds TNF-R, wherein said TNF-R is a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:2.",After,No,https://patents.google.com/patent/US7057022B2/en?oq=US7057022
Enbrel,US2004047863,Amgen,Arthritis,Biologic,9,12/6/1996,7/16/2003,3/11/2004,,Abandoned,Method of Treatment,"The application claimed a  method for treating an acute or chronic inflammatory disease which comprises administering to a patient in need thereof therapeutically effective amounts of a TNF binding protein and at least one additional anti-inflammatory drug, wherein said TNF binding protein and additional anti-inflammatory drug are administered separately or in combination.",After,No,https://patents.google.com/patent/US20040047863A1/en?oq=US2004047863
Enbrel,US2004048799,Amgen,Arthritis,Biologic,9,12/6/1996,7/16/2003,3/11/2004,,Abandoned,Method of Treatment,"The application claimed a method for treating an acute or chronic inflammatory disease which comprises administering to a patient in need thereof therapeutically effective amounts of a TNF binding protein and at least one additional anti-inflammatory drug, wherein said TNF binding protein and additional anti-inflammatory drug are administered separately or in combination.",After,No,https://patents.google.com/patent/US20040048799A1/en?oq=US2004048799
Enbrel,US2004220103 ,Immunex,Arthritis,Biologic,7,4/19/1999,5/25/2004,11/4/2004,,Abandoned,Method of Treatment,"The application claimed a method for treating a human patient suffering from a hereditary condition comprising administering to the patient a therapeutically effective amount of a TNFα inhibitor, wherein the hereditary condition is selected from the group consisting of Gaucher's disease, Huntington's disease, linear IgA disease, and muscular dystrophy.",After,No,https://patents.google.com/patent/US20040220103A1/en?oq=US2004220103
Enbrel,US7276477 ,Amgen,Arthritis,Biologic,4,8/1/2003,7/29/2004,10/2/2007,11/18/2024,Active,Crystal Form,The patent claims cover a crystal of etanercept in the form of a needle or a rod.,After,No,https://patents.google.com/patent/US7276477B2/en?oq=US7276477
Enbrel,US7723490 ,Amgen,Arthritis,Biologic,5,11/12/1999,8/24/2004,5/25/2010,3/26/2021,Expired,Process,"The patent claims cover a process for preparing a pharmacologically active compound, which comprises: (a) preparing an active compound which is a fusion molecule comprising a pharmacologically active domain and an Fc domain; (b) incubating the active compound with copper (II) chloride (CuCl2) at a concentration from about 10 mM to 50 mM; and (c) subsequently isolating the active compound",After,No,https://patents.google.com/patent/US7723490B2/en?oq=US7723490
Enbrel,US2007264257 ,Wyeth,Arthritis,Biologic,10,10/8/2004,10/11/2005,11/15/2007,,Abandoned,Method of Treatment,The application claimed a  method for treating an autoimmune disease in a subject comprising: administering to the subject a therapeutically effective amount of: (a) a B cell depleting agent; and (b) at least one anti-cytokine agent.,After,No,https://patents.google.com/patent/US20070264257A1/en?oq=US2007264257
Enbrel,US7459528 ,Immunex,Arthritis,Biologic,1,9/5/1989,10/28/2005,12/2/2008,9/5/2009,Expired,Product,"The patent claims cover an isolated glycoprotein that is capable of binding TNF, wherein said glycoprotein comprises amino acids 1-163 of SEQ ID NO:2 and is not isolated from human urine.",After,No,https://patents.google.com/patent/US7459528B2/en?oq=US7459528
Enbrel,US2006275868 ,Immunex,Arthritis,Biologic,1,9/5/1989,6/13/2006,12/7/2006,,Abandoned,Product,"The application claimed a fusion protein of the formula: TNF-R-peptide linker-IL-1R and a method for treating a condition mediated by tumor necrosis factor and by interleukin-1, comprising administering a therapeutically effective amount of a pharmaceutical composition.",After,No,https://patents.google.com/patent/US20060275868A1/en?oq=US2006275868
Enbrel,US8008453B2,Amgen,Arthritis,Biologic,42,8/12/2005,8/10/2006,8/30/2011,5/28/2030,Active,Formulation,The patent claims cover a  composition of many derivative types of etanercept.,After,No,https://patents.google.com/patent/US8008453B2/en?oq=US8008453B2
Enbrel,US7648702 ,Immunex,Arthritis,Biologic,3,2/27/2002,4/6/2007,1/19/2010,2/27/2023,Active,Formulation,"The patent claims cover a pharmaceutical composition that is a stable aqueous formulation comprising a polypeptide that is an extracellular ligand-binding portion of a human p75 tumor necrosis factor receptor fused to the Fe region of a human IgG1 and an aggregation inhibitor, wherein the aggregation inhibitor is L-arginine at a concentration of from about 10 mM to about 200 mM.
 ",After,No,https://patents.google.com/patent/US7648702B2/en?oq=US7648702
Enbrel,US7754858 ,Genentech,Arthritis,Biologic,6,5/27/1994,6/7/2007,7/13/2010,5/27/2014,Expired,Product,The patent claims cover an antibody capable of specific binding to a native tumor necrosis factor receptor associated factor (TRAF) polypeptide consisting of an amino acid sequence selected from the group consisting of: (a) amino acid residues 180 to 409 of TRAF1 of SEQ. ID. NO: 2; and(b) amino acid residues 2-181 of TRAF1 of SEQ. ID. NO: 2.,After,No,https://patents.google.com/patent/US7754858B2/en?oq=US7754858
Enbrel,US2009270592 ,Immunex,Arthritis,Biologic,1,9/5/1989,10/24/2007,10/29/2009,,Abandoned,Method of Production/Process,"The application claimed a purified preparation of a protein,wherein the protein comprises amino acids 1-163 of SEQ ID NO:2,wherein the protein has been purified by a method comprising the following steps:(a) concentrating a supernatant from a mammalian cell culture which contains the protein; (b) purifying the protein in the concentrated supernatant by subjecting it to affinity chromatography and/or ion exchange chromatography.",After,No,https://patents.google.com/patent/US20090270592A1/en?oq=US2009270592
Enbrel,US2008213282,Amgen,Arthritis,Biologic,11,12/21/2006,12/19/2007,9/4/2008,,Abandoned,Formulation,"The application claimed a formulation comprising a glutamic acid or aspartic acid buffer having a pH from about 4.0 to about 6.0, proline at a concentration of about 2% to about 10%, and an antibody or antigen-binding fragment and a method of treating a condition caused by increased expression of nerve growth factor or increased sensitivity to nerve growth factor in a patient, comprising administering to a patient a pharmaceutically effective amount of a formulation comprising a glutamic acid buffer or aspartic acid buffer having a pH from about 4.0 to about 6.0, proline at a concentration of about 2% to about 10%, and an effective amount of an antibody or antigen-binding fragment to nerve-growth factor.",After,No,https://patents.google.com/patent/US20080213282A1/en?oq=US2008213282
Enbrel,US7915225 ,Immunex,Arthritis,Biologic,7,4/19/1999,2/27/2009,3/29/2011,8/13/2019,Expired,Method of Treatment," The patent claims cover a method for treating a patient having psoriasis comprising administering to the patient a therapeutically effective dose of TNFR:Fc, wherein the patient attains at least fifty percent improvement in PASI score.
",After,No,https://patents.google.com/patent/US7915225B2/en?oq=US7915225
Enbrel,US8119604B2 ,Immunex,Arthritis,Biologic,3,2/27/2002,12/7/2009,2/21/2012,2/27/2023,Active,Method of Treatment,"The patent claims cover amethod of treating a mammal suffering from rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and/or psoriasis, the method comprising administering to the mammal a therapeutically effective amount of a pharmaceutical composition that is a stable aqueous formulation comprising a polypeptide that is an extracellular ligand-binding portion of a human p75 tumor necrosis factor receptor fused to the Fc region of a human IgG1 and an aggregation inhibitor, wherein the aggregation inhibitor in the pharmaceutical composition is L-arginine at a concentration of from about 10 mM to about 200 mM.
 ",After,No,https://patents.google.com/patent/US8119604B2/en?oq=US8119604
Enbrel,US2010267936 ,Amgen,Arthritis,Biologic,5,11/12/1999,4/27/2010,10/21/2010,,Abandoned,Process,"The application claimed a process for preparing a pharmacologically active compound, which comprises: (a) preparing a fusion molecule comprising an Fc domain and a pharmacologically active compound; (b) treating the fusion molecule with guanidine HCl at a concentration of at least about 4 M; (c) increasing the pH to about 8.5; and (d) isolating the treated fusion molecule.",After,No,https://patents.google.com/patent/US20100267936A1/en?oq=US2010267936
Enbrel,US2012142605,Amgen,Arthritis,Biologic,13,5/5/2009,5/5/2010,6/7/2012,,Abandoned,Method of Treatment,"The application claimed a method for treating a patient having psoriasis, comprising: (a) selecting a patient who has (i) a PASI score of at least about 10 and at least about 10% of his/her body surface area (BSA) affected by psoriasis and/or (ii) a sPGA score of >2; (b) administering etanercept to the patient at a dose of about 50 milligrams twice per week for a first time period of about 12 weeks and then administering etanercept to the patient at a dose of about 50 milligrams once per week for an additional time period of about 12 weeks; (c) administering (i) an upper midstrength, potent, or superpotent topical preparation containing a glucocorticoid in any one of Classes 1-3 to the patient once during the first and/or the additional time period of (b), wherein the topical preparation is administered at least once per week for a continuous time period of not more than four weeks or (ii) the topical preparation of (c)(i) intermittently during the first and/or additional time period of (b), wherein the topical preparation is administered on an as-needed basis for one or more continuous time periods of not more than four weeks each, wherein each continuous time period in which the topical preparation is administered is separated by an intervening continuous time period in which the topical preparation is not administered, which is at least as long as the preceding continuous time period during which the topical preparation was administered; and(d) assessing the PASI and/or the sPGA score of the patient at the end of the first time period of (b); wherein the treatment is therapeutically effective.of Treatment 2. Also includes use of PASI diagnostic survey tool",After,No,https://patents.google.com/patent/US20120142605A1/en?oq=US2012142605
Enbrel,US2011027273 ,Wyeth,Arthritis,Biologic,10,10/8/2004,6/23/2010,2/3/2011,,Abandoned,Method of Treatment,The application claimed a method for treating an autoimmune disease in a subject comprising: administering to the subject a therapeutically effective amount of: (a) a B cell depleting agent; and (b) at least one anti-cytokine agent such (etanercept).,After,No,https://patents.google.com/patent/US20110027273A1/en?oq=US2011027273
Enbrel,US8119605 ,Immunex,Arthritis,Biologic,7,4/19/1999,2/4/2011,2/21/2012,8/13/2019,Expired,Method of Treatment,The patent claims cover a method for treating a patient having ordinary psoriasis comprising administering to the patient a therapeutically effective dose of TNFR:Fc. ,After,No,https://patents.google.com/patent/US8119605B2/en?oq=US8119605
Enbrel,US9114175B2,Amgen,Arthritis,Biologic,42,8/12/2005,6/28/2011,8/25/2015,8/10/2036,Active,Formulation,The patent claims cover a  composition of many derivative types of etanercept.,After,No,https://patents.google.com/patent/US9114175B2/en?oq=US9114175B2
Enbrel,US8410060 ,Immunex,Arthritis,Biologic,7,4/19/1999,2/6/2012,4/2/2013,8/13/2019,Expired,Method of Treatment,The patent claims cover a method for treating a patient having psoriatic arthritis comprising administering to the patient a therapeutically effective dose of TNFR:Fc.,After,No,https://patents.google.com/patent/US8410060B2/en?oq=US8410060
Enbrel,US8828947 ,Immunex,Arthritis,Biologic,3,2/27/2002,2/21/2012,9/9/2014,2/27/2023,Active,Formulation,"The patent claims cover akit comprising a composition comprising a polypeptide (etanercept) that is an extracellular ligand-binding portion of a human p75 tumor necrosis factor receptor fused to the Fc region of a human IgG1 and from about 10 mM to about 200 mM L-arginine, and instructions for use of said composition.
",After,No,https://patents.google.com/patent/US8828947B2/en?oq=US8828947
Enbrel,US10092706B2,Amgen,Arthritis,Biologic,15,4/20/2011,4/20/2012,10/9/2018,12/5/2033,Active,Device,"The patent claims cover a a single-use cassette for use with an autoinjector, the cassette comprising: a housing; an inner sleeve disposed in the housing and movable between first and second positions, a syringe disposed in the inner sleeve; a lock cap for securing the syringe in the inner sleeve, the lock cap including an elastomeric bumper, the lock cap affixed to a distal end of the inner sleeve with the elastomeric bumper contacting a distal end of the syringe, wherein the distal end of the inner sleeve comprises at least one receptacle and the lock cap comprises at least one arm member for inserting into the receptacle; and a shield remover extending through an opening in a proximal end of the housing for removing a needle shield from the syringe, wherein the shield remover comprises an elongated body having a proximal end and a distal end, the distal end comprising at least one flexible tongue that expands outwardly when the shield remover is removed from the cassette to prevent the shield remover from being reinserted into the cassette and wherein the cassette comprises the therapeutic product etanercept.",After,No,https://patents.google.com/patent/US10092706B2/en?oq=US10092706B2
Enbrel,US8722631 ,Immunex,Arthritis,Biologic,7,4/19/1999,2/21/2013,5/13/2014,8/13/2019,Expired,Method of Treatment,"The patent claims cover a method of treatment comprising administering a dose of TNFR:Fc to a patient having psoriatic arthritis and/or plaque psoriasis, wherein the dose is administered one time or two times per week, and wherein the dose administered is 25-50 mg or 50-100 mg, andwherein the dose is administered by subcutaneous injection. Treatment 2. psoriatic arthritis or plaque prosiasis",After,No,https://patents.google.com/patent/US8722631B2/en?oq=US8722631
Enbrel,US10481164B2,Amgen,Arthritis,Biologic,43,3/26/2012,3/26/2013,11/19/2019,9/29/2036,Active,Method of Production/Process,The patent claims cover a method for controlling levels of biological impurities in an elution pool from a cation exchange chromatography resin. The patent describes the method can be used in relation to etanercept.,After,No,https://patents.google.com/patent/US10481164B2/en?oq=US10481164B2
Enbrel,US9822388B2,Amgen,Arthritis,Biologic,77,3/14/2013,3/10/2014,11/21/2017,3/10/2034,Active,Method of Production/Process,The patent claims cover a method for modulating one or more high mannose glycan species on a recombinant protein during mammalian cell culture. The patent describes  the claimed invention can be used in relation to etanercept.,After,No,https://patents.google.com/patent/US9822388B2/en?oq=US9822388B2
Enbrel,US2016024144A1,Amgen,Arthritis,Biologic,16,3/14/2013,3/11/2014,1/28/2016,,Abandoned,Method of Production/Process,"The application claimed a method for purifying a recombinant protein (such as etanercept) from a sample containing the recombinant protein and a second protein that binds to the protein, comprising subjecting the sample to a tentacle anion exchange matrix chromatography medium under conditions whereby the recombinant protein binds to the tentacle anion exchange matrix chromatography medium, followed by eluting the recombinant protein bound to the chromatography medium in an eluant, whereby at least 85% of the recombinant protein is recovered in the eluant and at least 75% of the second protein is removed from the eluant.",After,No,https://patents.google.com/patent/US20160024144A1/en?oq=US2016024144A1
Enbrel,US10492990B2,Amgen,Arthritis,Biologic,17,3/15/2013,3/14/2014,12/3/2019,8/30/2036,Active,Device,"The patent claims cover a  cassette for an injector, the cassette comprising: a housing;a cassette identification arrangement (cassette ID) defining a code containing information about the cassette, the code being detectable and decipherable by the injector, the cassette ID disposed on the housing, embedded within the housing, provided on or in a separate structure contained within the housing, or any combination thereof; a sleeve movably disposed within the housing, the sleeve for directly or indirectly holding a drug container; and a locking arrangement for interlocking the sleeve with the housing, the locking arrangement comprising a spring-biased member associated with one of the housing and the sleeve and biased toward the other one of the housing and the sleeve when the locking arrangement is in a locked position, and a fixed member associated with the other one of the housing and the sleeve for interlocking with the spring-biased member; wherein the spring-biased member comprises at least one locking foot and the fixed member comprises at least one slot, the at least one locking foot engaging the at least one slot when the locking arrangement is in the locked position, to interlock the sleeve with the housing wherein the cassette comprises the drug container filled with etanercept. ",After,No,https://patents.google.com/patent/US10492990B2/en?oq=US10492990B2
Enbrel,US10092703B2,Amgen,Arthritis,Biologic,45,3/15/2013,3/14/2014,10/9/2018,7/1/2035,Active,Device,"The patent claims cover a cassette for an injector, the cassette comprising: a housing; and a body member having a fluid chamber for containing a drug and an injection needle in fluid communication with the fluid chamber, the body member moveable in the housing between a proximal position and a distal position; a locking arrangement for interlocking the body member with the housing, the locking arrangement comprising a spring-biased member associated with one of the housing and the body member, and a fixed member associated with the other one of the housing and the body member for interlocking with the spring-biased member;
wherein the locking arrangement further comprises a cam for unlocking the spring-biased and fixed members; wherein the cam is actuated by the injector during a needle-insertion cycle of the injector and wherein the cassette comprises a therapeutic product selected from one of epoetin alfa, darbepoetin alfa, etanercept, TNF-receptor/Fc fusion protein, peqylated filgastrim, peqylated G-CSF, peqylated hu-met-G-CSF, filgrastim, G-CSF, hu-met-G-CSF, romiplostim, panitumumab, cinacalcet, denosamab, AMG 162, an antibody to IL-17 Receptor A, an antagonist of angiopoietin-2, a TNF blocker, and a TNF inhibitor.",After,No,https://patents.google.com/patent/US10092703B2/en?oq=US10092703B2
Enbrel,US2014212420 ,Immunex,Arthritis,Biologic,7,4/19/1999,3/25/2014,7/31/2014,,Abandoned,Method of Treatment,The application claimed a method for treating a patient having psoriasis comprising administering to the patient a therapeutically effective dose of TNFR:Fc.,After,No,https://patents.google.com/patent/US20140212420A1/en?oq=US2014212420
Enbrel,US9481901B2,Amgen,Arthritis,Biologic,75,5/30/2013,5/29/2014,11/1/2016,5/29/2034,Active,Method of Production/Process,The patent claims cover a method for increasing a high mannose glycoform content of a recombinant protein during a cell culture process. The patent describes the invention can be applied to etanercept. ,After,No,https://patents.google.com/patent/US9481901B2/en?oq=US9481901B2
Enbrel,US9518111 ,Immunex,Arthritis,Biologic,3,2/27/2002,9/5/2014,12/13/2016,2/27/2023,Active,Formulation," The patent claims cover a pharmaceutical composition comprising a polypeptide (etanercept) that is an extracellular ligand-binding portion of a human p75 tumor necrosis factor receptor fused to the Fc region of a human IgG1 and from about 10 mM to about 200 mM L-arginine.
",After,No,https://patents.google.com/patent/US9518111B2/en?oq=US9518111
Enbrel,US10994112B2,Amgen,Arthritis,Biologic,26,2/5/2014,2/3/2015,5/4/2021,12/31/2035,Active,Device,"The patent claims cover a drug delivery device comprising: a base having a first region and a second region adjacent to the first region; a drug delivery assembly carried by the first region of the base for facilitating the delivery of a medicament to a patient during use of the drug delivery device, the drug delivery assembly including a plurality of needles disposed on the base;
an antenna disposed in the first region of the base and at least partially between at least two of the plurality of needles; and
an electromagnetic field generator carried by the base and in selective electrical communication with the antenna for selectively radiating an electromagnetic field from the antenna at least in a direction directly away from the base and into a tissue of the patient during use of the drug delivery device, thereby facilitating transfer of the medicament to the patient.The patent describes the invention can be used with etanercept. 
",After,No,https://patents.google.com/patent/US10994112B2/en?oq=US10994112B2
Enbrel,US2015315271,Amgen,Arthritis,Biologic,11,12/21/2006,5/5/2015,11/5/2015,,Abandoned,Formulation,"The application claimed a  formulation comprising a glutamic acid or aspartic acid buffer having a pH from about 4.0 to about 6.0, proline at a concentration of about 2% to about 10%, and an antibody or antigen-binding fragment.",After,No,https://patents.google.com/patent/US20150315271A1/en?oq=US2015315271
Enbrel,US10188740B2,Amgen,Arthritis,Biologic,42,8/12/2005,7/10/2015,1/29/2019,11/6/2027,Active,Derivative,The patent claims cover functionalized or conjugated derivatives of the antibody etanercept.,After,No,https://patents.google.com/patent/US10188740B2/en?oq=US10188740B2
Enbrel,US10695506B2,Amgen,Arthritis,Biologic,68,10/14/2014,10/14/2015,6/30/2020,5/2/2036,Active,Device,"The patent claims cover a drug injection device comprising: a housing; a container disposed within the housing, the container having a needle and a plunger and being adapted to store a product for administration to a patient at an injection site, the plunger adapted to expel the product through the needle, wherein a portion of the needle extends out of the housing; a needle guard coupled to the housing adjacent to the needle of the container, the needle guard movable relative to the housing between (a) a fully extended position wherein the needle guard extends from the housing and beyond the portion of the needle extending out of the housing, (b) an intermediate position wherein the needle guard extends from the housing approximately the same distance that the needle extends out of the housing, and (c) a fully retracted position wherein a substantial portion of the needle extending out of the housing is exposed beyond the needle guard; and at least one indicia disposed on the needle guard exposed distal to the housing at least in the fully extended position, the at least one indicia providing a visual indication of the position of the needle relative to the injection site based on a position of the needle guard relative to the housing. The patent describes the invention can be used with etanercept. ",After,No,https://patents.google.com/patent/US10695506B2/en?oq=US10695506B2
Enbrel,US20170333559A1,Amgen,Arthritis,Biologic,44,10/23/2014,10/22/2015,11/23/2017,,Pending,Formulation,"The application claims a method for reducing the viscosity of a liquid pharmaceutical formulation comprising a therapeutic protein at a concentration of at least 70 mg/ml, comprising the step of combining the therapeutic protein with a viscosity-reducing concentration of an excipient selected from the group consisting of the n-acetyl arginine, n-acetyl lysine, n-acetyl histidine, n-acetyl proline and mixtures thereof. The patent describes the invention can be applied to etanercept. ",After,No,https://patents.google.com/patent/US20170333559A1/en?oq=US20170333559A1
Enbrel,US11275090B2,Amgen,Arthritis,Biologic,30,11/19/2014,11/19/2015,3/15/2022,7/2/2037,Active,Method of Production/Process,"The patent claims cover a  method of determining sialic acid moiety on a recombinant glycoprotein (etanercept), the method comprising digesting the recombinant glycoprotein with a sialidase to liberate sialic acid, loading the sialidase-digested recombinant glycoprotein onto a hydrophilic interaction chromatography (HILIC) column, eluting the liberated sialic acid with acetonitrile as mobile phase A and either 20% formic acid or 1% formic acid as mobile phase B, and quantitating the sialic acid using condensation nucleation light scattering detection.",After,No,https://patents.google.com/patent/US11275090B2/en?oq=US11275090B2
Enbrel,US11357916B2,Amgen,Arthritis,Biologic,58,12/19/2014,12/10/2015,6/14/2022,12/10/2035,Active,Device,The patent claims cover an on-body drug delivery device.The patent describes the invention can be used with etanercept. ,After,No,https://patents.google.com/patent/US11357916B2/en?oq=US11357916B2
Enbrel,US10799630B2,Amgen,Arthritis,Biologic,70,12/19/2014,12/18/2015,10/13/2020,6/29/2036,Active,Device,"The patent claims cover a drug delivery device comprising:a reservoir including a bore having a first end and a second end, and a plunger assembly including a plunger moveable within the bore between the first end and the second end;a cannula having an operational state wherein the cannula is connected in fluid communication with the reservoir;a drive coupled to the plunger assembly to move the plunger between the first end and the second end;a lock configured to selectively limit movement of the plunger between the first end and the second end;a housing, wherein the reservoir, the drive, and the lock are disposed at least partially within the housing;a proximity sensor operably coupled to move relative to the housing, the proximity sensor comprising at least a portion of a lever having a first end pivotably attached within the housing and a second end, the proximity sensor having a first sensor state wherein the second end of the lever extends outside of the housing and a second sensor state wherein the second end of the lever is retracted toward the housing relative to the first sensor state, the lock limiting movement of the plunger assembly when the proximity sensor is in the first sensor state; anda biasing member configured to exert a biasing force on the first end of the lever at a distance away from a pivot for the lever to bias the proximity sensor toward the first sensor state. The patent describes the invention can be used with etanercept. ",After,No,https://patents.google.com/patent/US10799630B2/en?oq=US10799630B2
Enbrel,US20160175527A1,Amgen,Arthritis,Biologic,70,12/19/2014,2/10/2016,6/23/2016,,Abandoned,Device,"The application claimed an on-body injector comprising: a reservoir including a bore having a first end and a second end, and a plunger assembly including a plunger moveable within the bore between the first and second ends; a volume of a drug product disposed in the reservoir, the drug product comprising a monoclonal antibody (IgG) that binds human Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9);a cannula having an operational state wherein the cannula is connected in fluid communication with the reservoir; a drive coupled to the plunger assembly to move the plunger between the first and second ends for moving the drug product out of the reservoir and through the cannula; a housing, wherein the reservoir, the cannula, and the drive are disposed at least partially within the housing; and a proximity sensor operably coupled to move relative to the housing, the proximity sensor having a first sensor state wherein the proximity sensor extends from the housing and a second sensor state wherein the proximity sensor is retracted toward the housing relative to the first sensor state.1 relates to injection of PCSK9 antibody. The patent describes the invention can be used with etanercept. ",After,No,https://patents.google.com/patent/US20160175527A1/en?oq=US20160175527A1
Enbrel,US10765801B2,Amgen,Arthritis,Biologic,70,12/19/2014,2/19/2016,9/8/2020,2/15/2037,Active,Device,The patent claims cover an on-body injector. The patent describes the invention can be used with etanercept. ,After,No,https://patents.google.com/patent/US10765801B2/en?oq=US10765801B2
Enbrel,US20180193562A1,Amgen,Arthritis,Biologic,35,2/27/2015,2/27/2016,7/12/2018,,Pending,Device,"The application claims drug delivery device comprising:a casing having an opening, the casing containing a drug storage container including a dose delivery member such that at least an insertion portion of the dose delivery member is configured to extend through the opening in the casing; a needle guard disposed adjacent to the opening and movable relative to the casing between an extended position and a retracted position, the insertion portion of the dose delivery member being surrounded by the needle guard in the extended position and the insertion portion of the dose delivery member being at least partially exposed when the needle guard is in the retracted position;an interference arrangement for providing a selected threshold of resistance to movement of the needle guard from the extended position to the retracted position during insertion of the dose delivery member into body tissue at an injection site, the interference arrangement having a first member associated with a surface of the casing, and a second member extending from the needle guard, the first and second members engaging one another to retain the needle guard in the extended position, one of the first and second members moving if the selected threshold of resistance is exceeded to allow the members to slide past one another and to allow the needle guard to move into the retracted position when the device is pressed toward the injection site during insertion of the dose delivery member. The patent describes the invention can be used with etanercept. ",After,No,https://patents.google.com/patent/US20180193562A1/en?oq=US20180193562A1
Enbrel,US2017096471 ,Immunex,Arthritis,Biologic,7,4/19/1999,9/8/2016,4/6/2017,,Abandoned,Method of Treatment,The application claimed a method for treating a patient having psoriasis comprising administering to the patient a therapeutically effective dose of TNFR:Fc.,After,No,https://patents.google.com/patent/US20170096471A1/en?oq=US2017096471
Enbrel, US 10184143 B2,Amgen,Arthritis,Biologic,75,5/30/2013,10/4/2016,1/22/2019,7/12/2034,Active,Method of Production/Process,"The patent claims cover a serum-free perfusion media containing mannose, wherein the mannose to total hexose ratio in the serum-free perfusion media is greater than 0 but less than 1.0. The patent describes the invention can be applied to etanercept. ",After,No,https://patents.google.com/patent/US10184143B2/en?oq=+US+10184143+B2
Enbrel,US2017051039 ,Immunex,Arthritis,Biologic,3,2/27/2002,11/2/2016,2/23/2017,,Abandoned,Formulation,"The patent claims cover apharmaceutical composition that is a stable aqueous formulation comprising an Fc domain containing polypeptide and an aggregation inhibitor, wherein the aggregation inhibitor is L-arginine.
",After,No,https://patents.google.com/patent/US20170051039A1/en?oq=US2017051039+
Enbrel,US11351308B2,Amgen,Arthritis,Biologic,41,12/9/2015,12/9/2016,6/7/2022,3/23/2039,Active,Device,The patent claims cover a drug delivery device wherein the drug comprises one of: (a) a granulocyte colony-stimulating factor (G-CSF); (b) a monoclonal antibody (IgG) that binds human Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9); (c) a product that relates to calcitonin gene-related peptide (CGRP); (d) a product that targets or modulates sclerostin; (e) an etanercept; (f) a TNF-receptor/Fc fusion protein; (g) a TNF blocker; or (h) bispecific T cell engager antibodies such as blinatumomab.,After,No,https://patents.google.com/patent/US11351308B2/en?oq=US11351308B2
Enbrel,US20190192766A1,Amgen,Arthritis,Biologic,29,4/29/2016,3/1/2017,6/27/2019,,Pending,Device,The application claims a drug delivery device.  The patent describes the invention can be used with etanercept. ,After,No,https://patents.google.com/patent/US20190192766A1/en?oq=US20190192766A1
Enbrel,US11200298B2,Amgen,Arthritis,Biologic,71,3/15/2016,3/14/2017,12/14/2021,2/19/2038,Active,Device,"The patent claims cover a non-transitory computer-readable medium storing thereon instructions that, when executed on one or more processors, implement a method for determining predicted failure rates of drug injection devices. The patent describes the invention can be used with etanercept. ",After,No,https://patents.google.com/patent/US11200298B2/en?oq=US11200298B2
Enbrel,US20190151544A1,Amgen,Arthritis,Biologic,28,5/2/2016,4/24/2017,5/23/2019,,Pending,Device,The application claims an on-body injector system.  The patent describes  the invention can be used with etanercept. ,After,No,https://patents.google.com/patent/US20190151544A1/en?oq=US20190151544A1
Enbrel,US20200338269A1,Amgen,Arthritis,Biologic,56,6/3/2016,5/8/2017,10/29/2020,,Pending,Device,The application claims a testing apparatus for simulating and measuring characteristics of one or more impacts experienced during operation of a drug delivery device. The patent describes the invention can be used with etanercept. ,After,No,https://patents.google.com/patent/US20200338269A1/en?oq=US20200338269A1
Enbrel, US11285266B2,Amgen,Arthritis,Biologic,50,7/1/2016,5/15/2017,3/29/2022,9/26/2038,Active,Device,The patent claims cover a drug delivery device. The patent describes the invention can be used with etanercept. ,After,No,https://patents.google.com/patent/US11285266B2/en?oq=+US11285266B2
Enbrel,US11238150B2,Amgen,Arthritis,Biologic,37,5/16/2016,5/16/2017,2/1/2022,12/5/2038,Active,Device,The patent claims cover a medical device with limited computational capability. The patent describes the invention can be used with etanercept. ,After,No,https://patents.google.com/patent/US11238150B2/en?oq=US11238150B2
Enbrel,US2018002733A1,Amgen,Arthritis,Biologic,77,3/14/2013,7/17/2017,1/4/2018,,Abandoned,Method of Production/Process,"The application claimed a method for modulating mannose 5 on a recombinant protein during a mammalian cell culture process comprising limiting the amount of glucose in the cell culture medium, wherein the concentration of the glucose is from about 0 to 6 g/L, and supplementing the cell culture medium with galactose or sucrose, wherein the concentration of galactose is from 6-13 g/L or the concentration of sucrose is from about 16-24 g/L. The patent describes the claimed invention can be used in relation to etanercept.",After,No,https://patents.google.com/patent/US20180002733A1/en?oq=US2018002733A1
Enbrel,US10709845B2,Amgen,Arthritis,Biologic,53,7/21/2016,7/17/2017,7/14/2020,7/23/2038,Active,Device,The patent claims cover a rotatable drive mechanism for a drug delivery device. The patent describes the invention can be used with etanercept. ,After,No,https://patents.google.com/patent/US10709845B2/en?oq=US10709845B2
Enbrel,US20190328965A1,Amgen,Arthritis,Biologic,18,8/17/2016,7/20/2017,10/31/2019,,Pending,Device,"The application claims drug delivery device  wherein the drug comprises one of: (a) a granulocyte colony-stimulating factor (G-CSF);
(b) a monoclonal antibody (IgG) that binds human Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9); (c) a product that relates to calcitonin gene-related peptide (CGRP); (d) a product that targets or modulates sclerostin; (e) an etanercept; (f) a TNF-receptor/Fc fusion protein;(g) a TNF blocker; or (h) bispecific T cell engager antibodies such as blinatumomab.",After,No,https://patents.google.com/patent/US20190328965A1/en?oq=US20190328965A1
Enbrel,US10786629B2,Amgen,Arthritis,Biologic,17,3/15/2013,10/13/2017,9/29/2020,3/14/2034,Active,Device,"The patent claims cover a cassette for an injector, the cassette comprising a therapeutic product selected from the group consisting of epoetin alfa, darbepoetin alfa, etanercept, pegylated filgastrim, filgrastim, romiplostim, panitumumab, cinacalcet, and denosamab. ",After,No,https://patents.google.com/patent/US10786629B2/en?oq=US10786629B2
Enbrel,US11020537B2,Amgen,Arthritis,Biologic,17,3/15/2015,10/13/2017,6/1/2021,3/14/2034,Active,Device,"The patent claims cover a cassette for an injector, the cassette comprising a therapeutic product selected from the group consisting of epoetin alfa, darbepoetin alfa, etanercept, pegylated filgastrim, filgrastim, romiplostim, panitumumab, cinacalcet, and denosamab. ",After,No,https://patents.google.com/patent/US11020537B2/en?oq=US11020537B2
Enbrel,US2018110856,Amgen,Arthritis,Biologic,12,10/21/2016,10/19/2017,4/26/2018,,Abandoned,Formulation,"The application claimed a pharmaceutical composition comprising between 75 mM and 150 mM NaCl, between 5 mM and 100 mM arginine, between 0.5% and 2% (w/v) sucrose, and between 40 mg/mL and 100 mg/mL etanercept, wherein the pharmaceutical composition comprises less than 2.0 mM total additional buffering agent, and the pH of the composition is between 6.1 and 6.5.",After,No,https://patents.google.com/patent/US20180110856A1/en?oq=US2018110856
Enbrel,US20200261643A1,Amgen,Arthritis,Biologic,31,10/25/2016,10/25/2017,8/20/2020,,Pending,Device,"The application claims a wearable drug delivery device, comprising: an injector including a reservoir, a needle or cannula, and a drive mechanism for urging drug product out of the reservoir, through the needle or cannula and to a patient; and
an adhesive applicator attached to the injector and including a perimeter portion that encircles at least a portion of a perimeter of the injector, the injector including a sidewall with at least one side gripping feature and the adhesive applicator including at least one feature such as a slit or a tab for facilitating deformation to conform to the contours of a patient's skin. The patent describes the invention can be used with etanercept. ",After,No,https://patents.google.com/patent/US20200261643A1/en?oq=US20200261643A1
Enbrel, US20190358411A1,Amgen,Arthritis,Biologic,85,1/17/2017,1/16/2018,11/28/2019,,Abandoned,Device,The application claimed an injection device for drug delivery. The patent describes the invention can be used with etanercept. ,After,No,https://patents.google.com/patent/US20190358411A1/en?oq=+US20190358411A1
Enbrel,US20190381238A1,Amgen,Arthritis,Biologic,87,3/6/2017,3/6/2018,12/19/2019,,Pending,Device,The application claims a wearable drug delivery device. The patent describes the invention can be used with etanercept. ,After,No,https://patents.google.com/patent/US20190381238A1/en?oq=US20190381238A1
Enbrel,US20200131518 A1,Amgen,Arthritis,Biologic,23,3/14/2017,3/14/2018,4/30/2020,,Pending,Method of Production/Process,"The application claims a method of modulating the levels of total afucosylated (TAF) glycoforms of a recombinant glycosylated protein (etanercept) produced by glycosylation-competent cells in a cell culture, comprising (i) maintaining the cell culture at an initial set point pH for an initial cell culture period and (ii) ceasing to maintain the cell culture at the initial set point pH after the initial cell culture period, wherein the initial pH is selected from a pH that is greater than about 6.50 and less than 7.5, and wherein the initial cell culture period is about 4 days to about 6 days.",After,No,https://patents.google.com/patent/US20200131518A1/en?oq=US20200131518+A1
Enbrel,US20190298924A1,Amgen,Arthritis,Biologic,51,4/3/2018,4/3/2018,10/3/2019,,Pending,Device,The application claims a system for delayed delivery of a drug. The patent describes the invention can be used with etanercept. ,After,No,https://patents.google.com/patent/US20190298924A1/en?oq=US20190298924A1
Enbrel,US10307483B2,Amgen,Arthritis,Biologic,12,10/21/2016,4/20/2018,6/4/2019,10/19/2037,Active,Formulation,"The patent claims cover a pharmaceutical composition comprising between 75 mM and 150 mM NaCl, between 5 mM and 100 mM arginine, between 0.5% and 2% (w/v) sucrose, and between 40 mg/mL and 100 mg/mL etanercept, wherein the pharmaceutical composition comprises less than 2.0 mM total additional buffering agent, and the pH of the composition is between 6.1 and 6.5.",After,No,https://patents.google.com/patent/US10307483B2/en?oq=US10307483B2
Enbrel,US10835685B2,Amgen,Arthritis,Biologic,54,5/30/2018,5/30/2018,11/17/2020,9/21/2038,Active,Device,The patent claims cover a plunger rod drive mechanism for a drug delivery device. The patent describes the invention can be used with etanercept. ,After,No,https://patents.google.com/patent/US10835685B2/en?oq=US10835685B2
Enbrel,US11083840B2,Amgen,Arthritis,Biologic,55,6/1/2018,6/1/2018,8/10/2021,12/19/2038,Active,Device,The patent claims cover a modular fluid path assembly for a drug delivery device. The patent describes the invention can be used with etanercept. ,After,No,https://patents.google.com/patent/US11083840B2/en?oq=US11083840B2
Enbrel,US20200206429A1,Amgen,Arthritis,Biologic,88,6/22/2017,6/12/2018,7/2/2020,,Pending,Device, The application claims a drug delivery device. The patent describes the invention can be used with etanercept. ,After,No,https://patents.google.com/patent/US20200206429A1/en?oq=US20200206429A1
Enbrel,US11103636B2,Amgen,Arthritis,Biologic,40,8/22/2017,6/22/2018,8/31/2021,12/1/2038,Pending,Device,The application claims a wearable drug delivery device. The patent describes the invention can be used with etanercept. ,After,No,https://patents.google.com/patent/US11103636B2/en?oq=US11103636B2
Enbrel,US10918805B2,Amgen,Arthritis,Biologic,15,4/20/2011,7/3/2018,7/4/2019,11/3/2032,Active,Device,"The patent claims cover a single-use cassette for use with an autoinjector, the cassette comprising: a housing;an inner sleeve disposed in the housing and movable between first and second positions along a longitudinal axis, the inner sleeve comprising one or more side walls defining an interior, and at least one receptacle having a rearward opening, the at least one receptacle separate from and disposed adjacent to the interior; a syringe disposed in the interior of the inner sleeve; and lock cap for securing the syringe in the inner sleeve, the lock cap including an elastomeric bumper, the lock cap affixed to a distal end of the inner sleeve with the elastomeric bumper contacting a distal end of the syringe, wherein the lock cap comprises at least one arm member extending generally parallel to the longitudinal axis for inserting into the at least one receptacle wherein the cassette comprises the therapeutic agent etanercept.",After,No,https://patents.google.com/patent/US10918805B2/en?oq=US10918805B2
Enbrel, US20210361529A1,Amgen,Arthritis,Biologic,65,7/21/2017,7/11/2018,11/25/2021,,Pending,Device,The application claims a drug delivery device. The patent describes the invention can be used with etanercept. ,After,No,https://patents.google.com/patent/US20210361529A1/en?oq=+US20210361529A1
Enbrel,US20210154410A1,Amgen,Arthritis,Biologic,66,7/25/2017,7/11/2018,5/27/2021,,Pending,Device,The application claims a drug delivery device. The patent describes the invention can be used with etanercept. ,After,No,https://patents.google.com/patent/US20210154410A1/en?oq=US20210154410A1
Enbrel,US20210330880A1,Amgen,Arthritis,Biologic,67,7/25/2017,7/11/2018,10/28/2021,,Pending,Device,The application claims a drug delivery device. The patent describes the invention can be used with etanercept. ,After,No,https://patents.google.com/patent/US20210330880A1/en?oq=US20210330880A1
Enbrel,US10421987B2,Amgen,Arthritis,Biologic,75,5/30/2013,7/18/2018,9/24/2019,5/29/2034,Active,Method of Production/Process,The patent claims cover a method for increasing a high mannose glycoform content of a recombinant protein during a mammalian cell culture process. The patent describes the invention can be applied to etanercept. ,After,No,https://patents.google.com/patent/US10421987B2/en?oq=US10421987B2
Enbrel,US11192919B2,Amgen,Arthritis,Biologic,16,3/14/2013,7/23/2018,12/7/2021,11/13/2035,Active,Method of Production/Process,"The patent claims cover a method for purifying a recombinant protein ( such as etanercept) from a sample containing the recombinant protein and a second protein that binds to the protein, comprising subjecting the sample to a tentacle anion exchange matrix chromatography medium under conditions whereby the recombinant protein binds to the tentacle anion exchange matrix chromatography medium, followed by eluting the recombinant protein bound to the chromatography medium in an eluant, whereby at least 85% of the recombinant protein is recovered in the eluant and at least 75% of the second protein is removed from the eluant, wherein the recombinant protein contains a CH2/CH3 region of an antibody, and the second protein is Protein A or Protein G.2. ",After,No,https://patents.google.com/patent/US11192919B2/en?oq=US11192919B2
Enbrel,US11077246B2,Amgen,Arthritis,Biologic,69,8/18/2017,7/31/2018,8/3/2021,5/14/2039,Active,Device,The application claims a wearable drug delivery device. The patent describes the invention can be used with etanercept.,After,No,https://patents.google.com/patent/US11077246B2/en?oq=US11077246B2
Enbrel,US20200164155A1,Amgen,Arthritis,Biologic,72,8/9/2017,8/7/2018,5/28/2020,,Pending,Device,The application claims a wearable drug delivery device. The patent describes the invention can be used with etanercept. ,After,No,https://patents.google.com/patent/US20200164155A1/en?oq=US20200164155A1
Enbrel,US20200289745A1,Amgen,Arthritis,Biologic,49,10/9/2019,3/19/2020,9/17/2020,,Pending,Device,The application claims a drug delivery device.  The patent describes the invention can be used with etanercept. ,After,No,https://patents.google.com/patent/US20200289745A1/en?oq=US20200289745A1
Enbrel,US20200297927A1,Amgen,Arthritis,Biologic,27,10/4/2017,9/26/2018,9/24/2020,,Pending,Device,The application claims a drug delivery device. The patent describes the invention can be used with etanercept. ,After,No,https://patents.google.com/patent/US20200297927A1/en?oq=US20200297927A1
Enbrel,US2019022217A1,Amgen,Arthritis,Biologic,12,10/21/2016,9/27/2018,1/24/2019,,Pending,Formulation,"The application claims a method of making a pharmaceutical composition of etanercept that does not comprise an additional buffering agent and has a pH from 6.1 to 6.5, comprising exchanging an etanercept formulation comprising an additional buffering agent against a solution without any additional buffering agent, wherein the resulting pharmaceutical composition comprises between 40 mg/mL and 100 mg/mL etanercept, and wherein the etanercept formulation comprising an additional buffering agent and the solution without any additional buffering agent each has a pH from 6.1 to 6.5.",After,No,https://patents.google.com/patent/US20190022217A1/en?oq=US2019022217A1
Enbrel, US20200254172A1,Amgen,Arthritis,Biologic,46,10/6/2017,10/1/2018,8/13/2020,,Pending,Device,"The application claims a drug delivery device. The patent describes the invention can be used with etanercept. 

",After,No,https://patents.google.com/patent/US20200254172A1/en?oq=+US20200254172A1
Enbrel,US20190247579 A1,Amgen,Arthritis,Biologic,57,10/6/2017,10/4/2018,8/15/2019,,Pending,Method of Production/Process,The application claims a esting assembly for a drug delivery device. The patent describes the invention can be used with etanercept. ,After,No,https://patents.google.com/patent/US20190247579A1/en?oq=US20190247579+A1
Enbrel,US20190135471A1,Amgen,Arthritis,Biologic,48,11/3/2017,11/2/2018,5/9/2019,,Pending,Device,"The application claims a drug delivery sterilization system. The patent describes the invention can be used with etanercept. 
",After,No,https://patents.google.com/patent/US20190135471A1/en?oq=US20190135471A1
Enbrel,US20200323958A1,Amgen,Arthritis,Biologic,14,11/13/2017,11/5/2018,10/15/2020,,Pending,Method of Production/Process,The application claims a method of producing etanercept from recombinant CHO cells comprising running an N-1 perfusion bioreactor at a temperature of between 37° C. to 38° C. before running an N production bioreactor.,After,No,https://patents.google.com/patent/US20200323958A1/en?oq=US20200323958A1
Enbrel, US20200338271A1,Amgen,Arthritis,Biologic,47,11/6/2017,11/6/2018,10/29/2020,,Pending,Method of Production/Process,The application claims a  fill-finish assembly . The patent describes the invention can be used with etanercept. ,After,No,https://patents.google.com/patent/US20200338271A1/en?oq=+US20200338271A1
Enbrel,US11071826B2,Amgen,Arthritis,Biologic,22,11/16/2017,11/13/2018,7/27/2021,11/2/2039,Active,Device,"The patent claims cover a drug delivery device  comprising a drug disposed in the cassette, the drug comprising etanercept.",After,No,https://patents.google.com/patent/US11071826B2/en?oq=US11071826B2
Enbrel,US11213626B2,Amgen,Arthritis,Biologic,21,11/16/2017,11/13/2018,1/4/2022,12/31/2039,Active,Device,"The patent claims cover a drug delivery device comprising a drug in the reservoir, wherein the drug comprises etanercept.",After,No,https://patents.google.com/patent/US11213626B2/en?oq=US11213626B2
Enbrel,US11266744B2,Amgen,Arthritis,Biologic,42,8/12/2005,11/30/2018,3/8/2022,5/8/2027,Active,Derivative,The patent claims cover  a DNA molecule that encodes for derivatives of the antibody etanercept.,After,No,https://patents.google.com/patent/US11266744B2/en?oq=US11266744B2
Enbrel,US2019144523A1       ,Immunex,Arthritis,Biologic,3,2/27/2002,1/11/2019,5/16/2019,,Abandoned,Formulation,"The application claimed a pharmaceutical composition that is a stable aqueous formulation comprising an Fc domain containing polypeptide and an aggregation inhibitor, wherein the aggregation inhibitor is L-arginine.",After,No,https://patents.google.com/patent/US20190144523A1/en?oq=US2019144523A1
Enbrel,US20210060259A1,Amgen,Arthritis,Biologic,24,1/17/2018,1/17/2019,3/4/2021,,Pending,Device,The application claims a delivery assembly for a drug delivery device. The patent describes the invention can be used with etanercept. ,After,No,https://patents.google.com/patent/US20210060259A1/en?oq=US20210060259A1
Enbrel,US20210010946A1,Amgen,Arthritis,Biologic,25,3/30/2018,2/12/2019,1/14/2021,,Pending,Method of Production/Process,The application claims an inspection system for a drug container for the identification of foreign matter. The patent describes the invention can be used with etanercept. ,After,No,https://patents.google.com/patent/US20210010946A1/en?oq=US20210010946A1
Enbrel,US20190275241A1,Amgen,Arthritis,Biologic,52,3/9/2018,3/8/2019,9/12/2019,,Pending,Device,The application claims a drug delivery device. The patent describes the invention can be used with etanercept. ,After,No,https://patents.google.com/patent/US20190275241A1/en?oq=US20190275241A1
Enbrel,US20210079065A1,Amgen,Arthritis,Biologic,81,3/26/2018,3/26/2019,3/18/2021,,Pending,Method of Production/Process,"The application claims a method of producing an antibody composition, wherein the level of total afucosylated (TAF) glycans in the antibody composition is less than about 10%, the method comprising maintaining glycosylation-competent cells in a cell culture medium comprising fucose, wherein fucose is present in the culture medium at a concentration of about 0.17 g/L to about 1.0 g/L. The patent describes the invention can be used with etanercept. ",After,No,https://patents.google.com/patent/US20210079065A1/en?oq=US20210079065A1
Enbrel,US20210163531A1,Amgen,Arthritis,Biologic,20,4/12/2018,3/28/2019,6/3/2021,,Pending,Method of Production/Process,"The application claims a method for preparing a composition comprising a protein, wherein the protein is any one of the following proteins: etanercept, aflibercept, adalimumab, epoetin alfa, darbepoetin alfa, filgrastim, pegfilgrastim, bevacizumab, cetuximab, infliximab, rituximab, eculizumab, trastuzumab, evolocumab, denosumab, romosozumab, erenumab, blinatumomab, and a BiTE antibody construct.",After,No,https://patents.google.com/patent/US20210163531A1/en?oq=US20210163531A1
Enbrel,US20210093554A1,Amgen,Arthritis,Biologic,19,4/24/2018,4/2/2019,4/1/2021,,Pending,Method of Production/Process,The application claims a method of making an injectable pharmaceutical composition comprising etanercept.,After,No,https://patents.google.com/patent/US20210093554A1/en?oq=US20210093554A1
Enbrel,US11104714B2,Immunex,Arthritis,Biologic,3,2/27/2002,4/26/2019,8/31/2021,2/27/2023,Active,Formulation,"The patent claims cover amethod of treating rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis in a subject in need thereof, the method comprising administering to the subject a weekly single subcutaneous dose of about 10-80 mg of etanercept,
wherein the etanercept is administered in a pharmaceutical composition comprising about 50 mg/ml etanercept, an excipient, and a buffer; wherein the excipient is lysine and the buffer is sodium citrate; wherein the pharmaceutical composition does not comprise arginine; and wherein the composition has not been lyophilized.
 ",After,No,https://patents.google.com/patent/US11104714B2/en?oq=US11104714B2
Enbrel,US20210260279A1,Amgen,Arthritis,Biologic,34,7/24/2018,7/11/2019,8/26/2021,,Pending,Device,The application claims a drug delivery device. The patent describes the invention can be used with etanercept. ,After,No,https://patents.google.com/patent/US20210260279A1/en?oq=US20210260279A1
Enbrel,US20210228797A1,Amgen,Arthritis,Biologic,36,7/31/2018,7/12/2019,7/29/2021,,Pending,Device,The application claims a fluid path assembly for a drug delivery device. patent describes the invention can be used with etanercept. ,After,No,https://patents.google.com/patent/US20210228797A1/en?oq=US20210228797A1
Enbrel,US20210228815A1,Amgen,Arthritis,Biologic,33,7/24/2018,7/22/2019,7/29/2021,,Pending,Device,The application claims a drug delivery device.  The patent describes the invention can be used with etanercept. ,After,No,https://patents.google.com/patent/US20210228815A1/en?oq=US20210228815A1
Enbrel,US20210128844A1,Amgen,Arthritis,Biologic,76,7/24/2018,7/23/2019,5/6/2021,,Pending,Device,The application claims a drug delivery device. The patent describes the invention can be used with etanercept. ,After,No,https://patents.google.com/patent/US20210128844A1/en?oq=US20210128844A1
Enbrel,US20210369982A1,Amgen,Arthritis,Biologic,32,7/24/2018,7/23/2019,12/2/2021,,Pending,Device,"The application claims  apparatus, comprising:a body including:a handle in which a syringe assembly is configured to be disposed;
a base having a bottom face configured to be disposed adjacent a user; andan absorbent material coupled with the bottom face, the absorbent material structured to hold a fluid to be released onto the user prior to or during an injection procedure. 
The patent describes the invention can be used with etanercept. 

",After,No,https://patents.google.com/patent/US20210369982A1/en?oq=US20210369982A1
Enbrel, US20210236636A1,Amgen,Arthritis,Biologic,79,7/31/2018,7/30/2019,8/5/2021,,Pending,Formulation,The application claims a pharmaceutical composition comprisingva masked antigen binding protein. The patent describes the invention can be used with etanercept. ,After,No,https://patents.google.com/patent/US20210236636A1/en?oq=+US20210236636A1
Enbrel,US10894972B2,Amgen,Arthritis,Biologic,75,5/30/2013,8/9/2019,1/19/2021,5/29/2034,Active,Method of Production/Process,"The patent claims cover a cell culture media containing mannose, wherein the mannose to total hexose ratio in the cell culture media is greater than 0 but less than 1.0. The patent describes the invention can be applied to etanercept. ",After,No,https://patents.google.com/patent/US10894972B2/en?oq=US10894972B2
Enbrel, US20210228811A1,Amgen,Arthritis,Biologic,60,9/28/2018,9/17/2019,7/29/2021,,Pending,Device,The application claims a drug delivery device. The patent describes the invention can be used with etanercept. ,After,No,https://patents.google.com/patent/US20210228811A1/en?oq=+US20210228811A1
Enbrel,US20200018771A1,Amgen,Arthritis,Biologic,43,3/26/2012,9/23/2019,1/16/2020,,Pending,Method of Production/Process,The application claims a method for determining a stop collection point during ion exchange chromatography. The patent describes  the invention can be used in relation to etanercept.,After,No,https://patents.google.com/patent/US20200018771A1/en?oq=US20200018771A1
Enbrel,US20200101229A1,Amgen,Arthritis,Biologic,62,10/2/2018,10/2/2019,4/2/2020,,Pending,Device,The application claims a system for injecting a drug. The patent describes the invention can be used with etanercept. ,After,No,https://patents.google.com/patent/US20200101229A1/en?oq=US20200101229A1
Enbrel,US20210338936A1,Amgen,Arthritis,Biologic,38,10/5/2018,10/4/2019,11/4/2021,,Pending,Device,The application claims a drug delivery device. The patent describes the invention can be used with etanercept. ,After,No,https://patents.google.com/patent/US20210338936A1/en?oq=US20210338936A1
Enbrel,US20200114082A1,Amgen,Arthritis,Biologic,64,10/15/2018,10/15/2019,4/16/2020,,Pending,Device,The application claims a drug delivery device. The patent describes the invention can be used with etanercept. ,After,No,https://patents.google.com/patent/US20200114082A1/en?oq=US20200114082A1
Enbrel,US20210346596A1,Amgen,Arthritis,Biologic,39,10/15/2018,10/15/2019,11/11/2021,,Pending,Method of Production/Process,The application claims method of assembling a drug delivery device. The patent describes the invention can be used with etanercept. ,After,No,https://patents.google.com/patent/US20210346596A1/en?oq=US20210346596A1
Enbrel,US11319568B2,Amgen,Arthritis,Biologic,77,3/14/2013,10/16/2019,3/19/2020,7/8/2034,Active,Method of Production/Process,The patent claims cover a method for modulating mannose 5 on a recombinant protein during a mammalian cell culture process. The patent describes  the claimed invention can be used in relation to etanercept.,After,No,https://patents.google.com/patent/US11319568B2/en?oq=US11319568B2
Enbrel,US20200190137A1,Amgen,Arthritis,Biologic,89,12/18/2018,12/10/2019,6/18/2020,,Pending,Method of Production/Process,"The application claims a method for purifying a tumor necrosis factor receptor (TNFR):Fc fusion protein, wherein the TNFR:Fc fusion protein is etanercept.
",After,No,https://patents.google.com/patent/US20200190137A1/en?oq=US20200190137A1
Enbrel,US20200197626A1,Amgen,Arthritis,Biologic,15,4/20/2011,3/5/2020,6/25/2020,,Pending,Device,"The application claims an apparatus for injection of a therapeutic product, the apparatus comprising: a cassette which conceals a syringe containing the therapeutic product; and an autoinjector comprising: a needle insertion and product extrusion drive arrangement; and a door, movable between an open position, which allows insertion therein of the cassette, and a closed position, which allows alignment between the cassette and the needle insertion and product extrusion drive arrangement. The patent describes that the apparatus can be used with the TNF blocker or inhibitor etanercept.",After,No,https://patents.google.com/patent/US20200197626A1/en?oq=US20200197626A1
Enbrel,US20200206412A1,Amgen,Arthritis,Biologic,48,11/3/2017,3/9/2020,7/2/2020,,Abandoned,Device,"The application claimed a system comprising: a drug container assembly including a container and a seal member, the container having an opening and the seal member at least partially covering the opening in the container; an energy source configured to emit rays of energy towards a sterilization or disinfection region; a barrier disposed adjacent to the sterilization or disinfection region and having an opening; and wherein at least a portion of the drug container assembly is positioned adjacent to the opening in the barrier such that at least a portion of the seal member is disposed in the sterilization or disinfection region. The patent describes the invention can be used with etanercept. ",After,No,https://patents.google.com/patent/US20200206412A1/en?oq=US20200206412A1
Enbrel,US20200390982A1,Amgen,Arthritis,Biologic,68,10/14/2014,5/12/2020,12/17/2020,,Pending,Device,"The application claims a drug injection device comprising: a housing for holding a container, the container storing a drug therein, the housing including at least one window that allows viewing of the drug in the container; and a drug test surface disposed immediately adjacent to at least a portion of the at least one window in the housing, such that the drug in the container can be compared against the drug test surface to determine at least one of a clarity or a color of the drug by viewing the drug against the drug test surface through the at least one window of the housing. The patent describes the invention can be used with etanercept. ",After,No,https://patents.google.com/patent/US20200390982A1/en?oq=US20200390982A1
Enbrel,US20200390977A1,Amgen,Arthritis,Biologic,53,7/21/2016,6/11/2020,12/17/2020,,Pending,Device,The application claims a drug delivery device. The patent describes the invention can be used with etanercept. ,After,No,https://patents.google.com/patent/US20200390977A1/en?oq=US20200390977A1
Enbrel,US20200353160A1,Amgen,Arthritis,Biologic,70,12/19/2014,7/29/2020,11/12/2020,,Pending,Device,"The application claims an on-body injector   comprising:a reservoir filled or configured to be filled with a drug;a plunger moveable relative to the reservoir;a cannula having an operational state wherein the cannula is connected in fluid communication with the reservoir;a drive operably coupled to the plunger to move the plunger to move the drug out of the reservoir and through the cannula;a housing, wherein the reservoir, the cannula, and the drive each is disposed at least partially within the housing;
a proximity sensor having a first sensor state when the proximity sensor is not in contact with skin of a patient and a second sensor state when the proximity sensor is in contact with the skin of the patient; anda lock operably coupled to the proximity sensor, the lock having a first position resisting movement of the plunger relative to the reservoir when the proximity sensor is in the first sensor state and the lock having a second position permitting movement of the plunger relative to the reservoir when the proximity sensor is in the second sensor state. The patent describes the invention can be used with etanercept. ",After,No,https://patents.google.com/patent/US20200353160A1/en?oq=US20200353160A1
Enbrel,US20210069405A1,Amgen,Arthritis,Biologic,48,11/3/2017,11/17/2020,3/11/2021,,Pending,Device,"The application claims an on-body injector system.  The patent describes the invention can be used with etanercept. 
",After,No,https://patents.google.com/patent/US20210069405A1/en?oq=US20210069405A1
Enbrel,US20210069416A1,Amgen,Arthritis,Biologic,35,2/27/2015,11/18/2020,3/11/2021,,Pending,Device,"The application claims a drug delivery device comprising: a housing having an opening; a drug storage container including a body portion having a proximal end and a distal end and a delivery member positioned at the distal end of the body portion, the delivery member having an insertion end configured to extend at least partially through the opening during drug delivery; a plunger moveable in a distal direction with respect to the drug storage container to expel a drug from the drug storage container through the delivery member; a drive positioned at least partially within the housing and storing energy for moving the plunger in the distal direction;a guard positioned adjacent to the opening and movable relative to the housing between an extended position and a retracted position; a guard biasing member configured to urge the guard in the distal direction, wherein at least a portion of the guard biasing member is distal to the proximal end of the body portion of the drug storage container; and an arrangement configured to resist relative movement between the guard and the housing until a threshold of resistance is exceeded by a user applied force, wherein the arrangement includes a first member positioned within the housing and a second member coupled with the guard. The patent describes the invention can be used with etanercept. ",After,No,https://patents.google.com/patent/US20210069416A1/en?oq=US20210069416A1
Enbrel,US20210128842A1,Amgen,Arthritis,Biologic,15,4/20/2011,1/13/2021,5/6/2021,,Pending,Device,"The application claims a cassette for an injector, the cassette comprising: a housing; and a cassette identification (cassette ID) defining a code denoting information about the cassette, the code being detectable and decipherable by the injector. The patent describes that the cassette can be used with the TNF blocker or inhibitor etanercept.",After,No,https://patents.google.com/patent/US20210128842A1/en?oq=US20210128842A1
Enbrel,US20210393888A1,Amgen,Arthritis,Biologic,17,3/15/2013,4/27/2021,12/23/2021,,Pending,Device,"The application claims a  cassette for an injector, the cassette comprising: a housing; and a cassette identification arrangement (cassette ID) defining a code containing information about the cassette, the code being detectable and decipherable by the injector, the cassette ID disposed on the housing, embedded within the housing, or provided on or in a separate structure contained within the housing. The patent describes in various embodiments the therapeutic agent can be etanercept.",After,No,https://patents.google.com/patent/US20210393888A1/en?oq=US20210393888A1
Enbrel,US20220008652A1,Amgen,Arthritis,Biologic,69,8/18/2017,6/28/2021,1/13/2022,,Pending,Device,The application claims a wearable drug delivery device. The patent describes the invention can be used with etanercept. ,After,No,https://patents.google.com/patent/US20220008652A1/en?oq=US20220008652A1
Enbrel,US20220047808A1,Amgen,Arthritis,Biologic,55,6/1/2018,6/28/2021,2/17/2022,,Pending,Device,The patent claims cover a modular fluid path assembly for a drug delivery device. The patent describes the invention can be used with etanercept. ,After,No,https://patents.google.com/patent/US20220047808A1/en?oq=US20220047808A1
Enbrel,US20220025016A1,Immunex,Arthritis,Biologic,3,2/27/2002,8/3/2021,1/27/2022,,Pending,Formulation,"The application claims a method comprising (a) forming an aqueous pharmaceutical composition comprising etanercept, an excipient and a buffer, and (b) storing the aqueous pharmaceutical composition as a liquid for three months at 2-8° C., wherein the excipient is lysine, the buffer is sodium citrate, and wherein the aqueous pharmaceutical composition does not comprise arginine.",After,No,https://patents.google.com/patent/US20220025016A1/en?oq=US20220025016A1
Enbrel,US11293930B2,Amgen,Arthritis,Biologic,43,3/26/2012,10/7/2021,4/5/2022,3/26/2033,Active,Method of Production/Process,"The patent claims cover a  method for purifying a recombinant protein comprising: loading a mixture containing a recombinant protein and biological impurities on to a cation exchange chromatography resin; eluting by a salt gradient the recombinant protein from the cation exchange chromatography resin; measuring the intensity of light scattered by the eluate with a laser light scattering detector to obtain a light scattering (LS) signal; measuring the absorbance of the eluate with an ultraviolet (UV) absorbance detector to obtain an absorbance signal; calculating a ratio of the LS signal to the absorbance signal for each elution fraction to obtain a LS/UV fraction ratio; monitoring in real time during the elution of the recombinant protein the LS/UV fraction ratio over time for each elution fraction, wherein an increase in the LS/UV fraction ratio over time indicates an increase in the levels of biological impurities in the elution pool; terminating the elution when an increase in the LS/UV fraction ratio over time is detected; and
recovering the recombinant protein from the eluate. The patent describes  the invention can be used in relation to etanercept.",After,No,https://patents.google.com/patent/US11293930B2/en?oq=US11293930B2
Eylea, US10828345B2,Regeneron,Macular Degeneration,Biologic,5,1/13/2011,10/12/2018,11/10/2020,1/11/2032,Active,Method of Treatment,"The patent claims cover a method for treating an angiogenic eye disorder in a patient, said method comprising sequentially administering to the patient a single initial dose of a VEGF antagonist, followed by one or more secondary doses of the VEGF antagonist, followed by one or more tertiary doses of the VEGF antagonist; wherein each secondary dose is administered 4 weeks after the immediately preceding dose; and wherein each tertiary dose is administered 12 weeks after the immediately preceding dose. ",After,Yes,https://patents.google.com/patent/US10828345B2/en?oq=+US10828345B2
Eylea, US20210121524A1,Regeneron,Macular Degeneration,Biologic,5,1/13/2011,12/4/2020,4/29/2021,,Pending,Method of Treatment,"The application claims a method of treating an angiogenic eye disorder in a patient in need thereof comprising sequentially administering to the patient by intravitreal injection a single initial dose of 2 mg of aflibercept, followed by one or more secondary doses of 2 mg of aflibercept, followed by one or more tertiary doses of 2 mg of aflibercept;wherein each secondary dose is administered approximately 4 weeks following the immediately preceding dose; and wherein each tertiary dose is administered approximately 8 weeks following the immediately preceding dose; wherein the patient achieves a gain in visual acuity within 52 weeks following the initial dose.",After,No,https://patents.google.com/patent/US20210121524A1/en?oq=+US20210121524A1
Eylea, US20210205410A1,Regeneron,Macular Degeneration,Biologic,17,11/30/2017,1/13/2021,7/8/2021,,Pending,Method of Treatment,"The application claims a method for treating moderately severe to severe nonproliferative diabetic retinopathy without center-involved diabetic macular edema in a patient in need thereof comprising administering, to an eye of the patient, 5 doses about once a month followed by one or more secondary doses about every 8 weeks; of about 2 mg of VEGF antagonist (aflibercept (Eylea) tthat is a VEGF receptor-based chimeric fusion protein.",After,No,https://patents.google.com/patent/US20210205410A1/en?oq=US20210205410A1
Eylea,US 20210340220 A1,Regeneron,Macular Degeneration,Biologic,6,6/16/2006,6/15/2021,11/4/2021,,Pending,Formulation / Combination,"The patent application claimed vial containing a liquid formulation comprising: a glycosylated vascular endothelial growth factor (VEGF) antagonist fusion protein, comprising amino acids 27-457 of SEQ ID NO: 4 and glycosylated at asparagine residues corresponding to asparagine residues 62, 94, 149, 222 and 308 of SEQ ID NO: 4, polysorbate 20, sucrose, and a phosphate buffer at a pH of between 5.8 and 7.0 formulated as a mixture of mono and dibasic sodium phosphate in the absence of acid/base titration; wherein said VEGF antagonist fusion protein is substantially resistant to degradation and aggregation; and wherein said liquid formulation has a turbidity of 0.01 or lower at OD405. ",After,No,https://patents.google.com/patent/US20210340220A1/en?oq=US+20210340220+A1
Eylea,US10130681B2,Regeneron,Macular Degeneration,Biologic,5,1/13/2011,3/28/2017,11/20/2018,1/11/2032,Active,Method of Treatment,"The patent claims cover a method for treating an angiogenic eye disorder in a patient, said method comprising sequentially administering to the patient a single initial dose of a VEGF antagonist, followed by one or more secondary doses of the VEGF antagonist, followed by one or more tertiary doses of the VEGF antagonist; wherein each secondary dose is administered 2 to 4 weeks after the immediately preceding dose; and wherein each tertiary dose is administered at least 8 weeks after the immediately preceding dose.",After,Yes,https://patents.google.com/patent/US10130681B2/en?oq=US10130681B2
Eylea,US10392430B2,Regeneron,Macular Degeneration,Biologic,2,6/8/1999,6/16/2017,8/27/2019,5/23/2020,Expired,Method of Production / Process,The patent claims cover method for making a nucleic acid molecule encoding a chimeric vascular endothelial growth factor (VEGF) binding fusion protein with improved pharmacokinetic properties.,After,No ,https://patents.google.com/patent/US10392430B2/en?oq=US10392430B2
Eylea,US10400025B2,Regeneron,Macular Degeneration,Biologic,6,6/16/2006,1/24/2018,9/3/2019,6/14/2027,Active,Formulation / Combination,"The patent claims cover a formulation suitable for intravitreal administration comprising: (a) 1 mg/mL to 100 mg/mL of a vascular endothelial growth factor (VEGF) antagonist; (b) an organic co-solvent; (c) 5 mM to 40 mM of a phosphate buffer; and (d) 1.0% to 10% of a stabilizing agent selected from the group consisting of sucrose, sorbitol, glycerol, trehalose, and mannitol; wherein the VEGF antagonist is a fusion protein comprising an immunoglobulin-like (Ig) domain 2 of a first VEGF receptor and Ig domain 3 of a second VEGF receptor, and a multimerizing component.",After,No,https://patents.google.com/patent/US10400025B2/en?oq=US10400025B2
Eylea,US10406226B2,Regeneron,Macular Degeneration,Biologic,8,3/25/2005,8/31/2017,9/10/2019,3/22/2026,Active,Method of Production / Process,The patent claims cover a  method of manufacturing a vascular endothelial growth factor (VEGF)  antagonist fusion protein.,After,Yes,https://patents.google.com/patent/US10406226B2/en?oq=US10406226B2
Eylea,US10415055B2,Regeneron,Macular Degeneration,Biologic,23,6/4/2007,3/9/2018,9/17/2019,6/4/2028,Active,Product,"The patent claims cover an isolated cell comprising at least one exogenous nucleic acid integrated within, or adjacent to the 5′ or 3′ end of, an expression-enhancing expression and stability region (EESYR) sequence in the genome, wherein the EESYR sequence is at least 90% identical to SEQ ID NO: 6 and enhances expression of an exogenous gene integrated within, or adjacent to the 5′ or 3′ end of, the EESYR sequence by at least 1.5 fold over random integration of the exogenous gene",After,Yes,https://patents.google.com/patent/US10415055B2/en?oq=US10415055B2
Eylea,US10464992B2,Regeneron,Macular Degeneration,Biologic,6,6/16/2006,10/12/2018,5/11/2019,6/14/2027,Active,Formulation / Combination,"The patent claims cover a formulation comprising a vial including a vascular endothelial growth factor (VEGF) antagonist, an organic co-solvent,
a buffer, and a stabilizing agent",After,Yes,https://patents.google.com/patent/US10464992B2/en?oq=US10464992B2
Eylea,US10669594B2,Regeneron,Macular Degeneration,Biologic,26,3/27/2015,3/25/2016,6/2/2020,2/12/2037,Active,Method of Production / Process,The patent claims cover a method of detecting the presence or absence of a biological contaminant.,After,Yes,https://patents.google.com/patent/US10669594B2/en?oq=US10669594B2
Eylea,US10857205B2,Regeneron,Macular Degeneration,Biologic,5,1/13/2011,8/6/2018,12/8/2020,1/11/2032,Active,Method of Treatment,The patent claims cover a method for treating macular edema following retinal vein occlusion in a human subject comprising administering 2 mg aflibercept to the subject by intravitreal injection once every 4 weeks.,After,Yes,https://patents.google.com/patent/US10857205B2/en?oq=US10857205B2
Eylea,US10857231B2,Regeneron,Macular Degeneration,Biologic,8,3/25/2005,8/8/2019,12/8/2020,3/22/2026,Active,Formulation / Combination,"The patent claims cover a liquid formulation comprising  10-50 mg/ml of a vascular endothelial growth factor (VEGF) antagonist fusion protein comprising amino acids 27-457 of SEQ ID NO: 4, buffer comprising histidine,an organic co-solvent comprising polysorbate, and a stabilizing agent comprising a sugar, an amino acid or both, wherein said VEGF antagonist fusion protein exhibits less than about 3% degradation after 15 months of storage at 5° C and a method for manufacturing.",After,Yes,https://patents.google.com/patent/US10857231B2/en?oq=US10857231B2
Eylea,US10888601B2,Regeneron,Macular Degeneration,Biologic,5,1/13/2011,4/29/2019,1/12/2021,1/11/2032,Active,Method of Treatment,"The patent claims cover a method for treating age related macular degeneration in a patient in need thereof, comprising intravitreally administering, to said patient, an effective amount of aflibercept which is 2 mg approximately every 4 weeks for the first 3 months, followed by 2 mg approximately once every 8 weeks or once every 2 months.",After,Yes,https://patents.google.com/patent/US10888601B2/en?oq=US10888601B2
Eylea,US10905786B2,Regeneron,Macular Degeneration,Biologic,28,3/27/2017,12/4/2019,2/2/2021,3/6/2038,Active,Method of Production / Process,"The patent claims cover a sterilization method comprising: creating a turbulent flow within a chamber; and while maintaining the turbulent flow, performing a sterilization pulse comprising: maintaining a sterilization pressure within the chamber for at least 5 minutes; introducing vaporized hydrogen peroxide (VHP) into the chamber; allowing the VHP to circulate within the chamber for at least 5 minutes, wherein allowing the VHP to circulate within the chamber includes removing the VHP from a lower interior of the chamber and re-introducing the VHP into an upper interior of the chamber; and introducing dry gas into the chamber, wherein the dry gas has a dew point of −10° C. or lower wherein, during the sterilization pulse, a condensation layer forms on a primary packaging component.",After,Yes,https://patents.google.com/patent/US10905786B2/en?oq=US10905786B2
Eylea,US10918754B2,Regeneron,Macular Degeneration,Biologic,28,3/27/2017,3/6/2018,2/16/2021,3/6/2038,Active,Method of Production / Process,"The patent claims cover a sterilization method including creating a turbulent flow within a chamber;while maintaining the turbulent flow, performing a sterilization pulse comprising:maintaining a sterilization pressure within the chamber of about 400 millibars to about 800 millibars for at least 5 minutes; introducing vaporized hydrogen peroxide (VHP) into the chamber; allowing the VHP to circulate within the chamber for at least 5 minutes; and
introducing a first gas into the chamber;",After,Yes,https://patents.google.com/patent/US10918754B2/en?oq=US10918754B2
Eylea,US10927342B2,Regeneron,Macular Degeneration,Biologic,29,8/4/2015,1/14/2020,2/23/2021,08-03-2036,Active,Method of Production / Process,"The patent claims cover a method for cultivating a eukaryotic cell expressing aflibercept (Eylea), comprising: (a) providing a base cell culture medium supplemented with about 0.1 mM to about 10 mM L-taurine; (b) propagating or maintaining the eukaryotic cell in said base cell culture medium to form a cell culture; and (c) producing aflibercept from the cell culture; wherein supplementing the base cell culture medium with L-taurine increases the titer of aflibercept by at least 3% when compared to the titer of aflibercept from cells propagated or maintained in a cell culture medium containing less than 0.1 mM L-taurine.",After,Yes,https://patents.google.com/patent/US10927342B2/en?oq=US10927342B2
Eylea,US10973879B2,Regeneron,Macular Degeneration,Biologic,17,11/30/2017,11/29/2018,4/13/2021,5/17/2039,Active,Method of Treatment,"The patent claims cover a method for treating diabetic retinopathy in a patient in need of such treatment, said method comprising administering, to an eye of the patient, (i) an initial dose; (ii) a 2nd dose one month after the initial dose; (iii) a 3rd dose one month after 2nd dose; (iv) a 4th dose 8 weeks after the 3rd dose; and then (v) one or more doses every 16 weeks starting after the 4th dose; of about 2 mg of VEGF antagonist (aflibercept (Eylea) that is a VEGF receptor-based chimeric molecule. ",After,Yes,https://patents.google.com/patent/US10973879B2/en?oq=US10973879B2
Eylea,US11053280B2,Regeneron,Macular Degeneration,Biologic,30,12/6/2019,8/18/2020,7/6/2021,8/18/2040,Active,Method of Production / Process,"The patent claims cover a method of producing aflibercept, comprising: (a) producing a clarified harvest of cells cultured in a chemically defined medium (CDM); (b) binding aflibercept from said clarified harvest to a Protein A resin, wherein said aflibercept includes variants that have at least one oxidized amino acid residue selected from the group consisting of methionine, tryptophan, histidine, phenylalanine, tyrosine and a combination thereof; (c) eluting said aflibercept of step (b) forming an affinity eluate, wherein said eluate has a first color; (d) subjecting said eluate comprising aflibercept to an anion exchange chromatography (AEX) column; and (e) collecting a flowthrough fraction, wherein said flowthrough fraction has a second color, and wherein said first color of said affinity eluate is a more intense yellow brown color than said second color of said flowthrough fraction when said affinity eluate and flowthrough fraction protein concentrations are normalized.",After,Yes,https://patents.google.com/patent/US11053280B2/en?oq=US11053280B2
Eylea,US11066458B2,Regeneron,Macular Degeneration,Biologic,6,6/16/2006,9/25/2019,1/16/2020,7/26/2027,Active,Formulation / Combination,"The patent claims cover a glass vial comprising an ophthalmic formulation suitable for intravitreal administration comprising: a vascular endothelial growth factor (VEGF) antagonist fusion protein, an organic co-solvent, a buffer, and a stabilizing agent.",After,Yes,https://patents.google.com/patent/US11066458B2/en?oq=US11066458B2
Eylea,US11071780B2,Regeneron,Macular Degeneration,Biologic,14,11/25/2014,12/28/2018,7/27/2021,3/21/2036,Active,Method of Treatment,"The patent claims cover a method for treating a vascular eye disease or disorder, in a human subject in need thereof, comprising intravitreally administering 2 mg aflibercept and 6 mg nesvacumab in a pharmaceutical composition comprising (i) 40 mg/ml of aflibercept;
(ii) 120 mg/ml of nesvacumab; (iii) a sodium phosphate buffer at pH of 6.2±0.3; (iv) polysorbate 20; (v) sodium chloride; and
(vi) sucrose, to the subject",After,No,https://patents.google.com/patent/US11071780B2/en?oq=US11071780B2
Eylea,US11084865B2,Regeneron,Macular Degeneration,Biologic,6,6/16/2006,1/10/2020,8/10/2021,6/14/2027,Active,Formulation / Combination,"The patent claims cover a vial comprising an ophthalmic formulation suitable for intravitreal administration that comprises: a vascular endothelial growth factor (VEGF) antagonist, an organic co-solvent, a buffer, and a stabilizing agent.",After,Yes,https://patents.google.com/patent/US11084865B2/en?oq=US11084865B2
Eylea,US11098112B2,Regeneron,Macular Degeneration,Biologic,30,12/6/2019,8/18/2020,8/24/2021,8/18/2040,Active,Method of Production / Process,"The patent claims cover a ethod of producing aflibercept (Eylea), comprising: (a) producing a clarified harvest of cells cultured in a chemically defined medium (CDM); (b) binding aflibercept from said clarified harvest using an affinity chromatography column comprising a polypeptide capable of binding to or interacting with said aflibercept, wherein said polypeptide is an antibody, a fusion protein, a ScFv or a fragment thereof and wherein said polypeptide comprises an isolated amino acid sequence selected from a SEQ ID NO.: 72, SEQ ID NO.: 73, SEQ ID NO.: 74, SEQ ID NO.: 75, SEQ ID NO.: 76, SEQ ID NO.: 77, SEQ ID NO.: 78, SEQ ID NO.: 79 and SEQ ID NO.: 80; (c) eluting said aflibercept of step (b) forming an affinity eluate; optionally, (d) subjecting said eluted aflibercept of (c) to a second chromatography capture step; and (e) collecting a flowthrough fraction, wherein said flowthrough fraction has aflibercept.",After,No,https://patents.google.com/patent/US11098112B2/en?oq=US11098112B2
Eylea,US11098311B2,Regeneron,Macular Degeneration,Biologic,30,12/6/2019,8/18/2020,8/24/2021,8/18/2040,Active,Product,"The patent claims cover an isolated, synthetic, or recombinant polypeptide having IdeS protease activity comprising the amino acid sequence selected from the group consisting of SEQ ID NO.: 2, SEQ ID NO.: 3, SEQ ID NO.: 4, SEQ ID NO.: 5, SEQ ID NO.: 6, SEQ ID NO.: 7, SEQ ID NO.: 8, SEQ ID NO.: 9, SEQ ID NO.: 10, SEQ ID NO.: 11, SEQ ID NO.: 12, SEQ ID NO.: 13, SEQ ID NO.: 14, SEQ ID NO.: 15 and SEQ ID NO.: 16.",After,No,https://patents.google.com/patent/US11098311B2/en?oq=US11098311B2
Eylea,US11103552B2,Regeneron,Macular Degeneration,Biologic,16,5/10/2018,5/10/2019,8/31/2021,5/15/2039,Active,Formulation / Combination,"The patent claims cover an aqueous pharmaceutical formulation comprising: a VEGF receptor fusion protein (aflibercept (Eylea) comprising two polypeptides that each comprises an immunoglobin-like (Ig) domain 2 of VEGFR1, an Ig domain 3 of VEGFR2, and a multimerizing component at a concentration of at least about 100 mg/ml; about 5% sucrose; L-arginine; a histidine-based buffer; and about 0.03% surfactant; wherein the formulation has a pH of about 5.0 to about 6.8.",After,No,https://patents.google.com/patent/US11103552B2/en?oq=US11103552B2
Eylea,US11104715B2,Regeneron,Macular Degeneration,Biologic,30,12/6/2019,8/18/2020,8/31/2021,8/18/2040,Active,Method of Production / Process,The patent claims cover a method of producing aflibercept harvested from a host cell cultured in a chemically defined medium (CDM).,After,Yes,https://patents.google.com/patent/US11104715B2/en?oq=US11104715B2
Eylea,US11160918B2,Regeneron,Macular Degeneration,Biologic,31,7/29/2019,7/29/2020,11/2/2021,7/29/2040,Active,Packaging,The patent claims cover packaging for a sterile syringe.,After,Yes,https://patents.google.com/patent/US11160918B2/en?oq=US11160918B2
Eylea,US11174283B2,Regeneron,Macular Degeneration,Biologic,30,12/6/2019,3/18/2021,11/16/2021,8/18/2040,Active,Method of Production / Process,"The patent claims cover a method of producing aflibercept, comprising producing a clarified harvest of cells cultured in a chemically defined medium (CDM).",After,Yes,https://patents.google.com/patent/US11174283B2/en?oq=US11174283B2
Eylea,US11180540B2,Regeneron,Macular Degeneration,Biologic,30,12/6/2019,8/18/2020,11/23/2021,8/18/2040,Active,Method of Production / Process,"The patent claims cover a method of producing aflibercept (Eylea) MiniTrap from a clarified harvest of a cell cultured in a chemically defined medium (CDM) and expressing aflibercept, comprising: (a) binding aflibercept from said clarified harvest to a first capture chromatography; (b) eluting said aflibercept of step (a) and subjecting said aflibercept to enzymatic cleavage to remove its Fc domain thereby forming MiniTrap; (c) subjecting (b) to a second capture chromatography, wherein said second capture chromatography step is subjected to one or more washes, and wherein a first flowthrough fraction comprises MiniTrap and has a first color, wherein said first color has a b* value ranging from 1.5 to 15.0 when protein concentration is normalized to 5.0 g/L; (d) subjecting said first flowthrough fraction of step (c) to anion exchange chromatography (AEX); and (e) washing said AEX column of step (d), wherein said MiniTrap is collected in a second flowthrough fraction and has a second color, wherein said second color has a b* value ranging from 0.5 to 15.0 when protein concentration is normalized to 5.0 g/L and wherein said first color is a more intense yellow brown color than said second color.",After,No,https://patents.google.com/patent/US11180540B2/en?oq=US11180540B2
Eylea,US11186625B2,Regeneron,Macular Degeneration,Biologic,30,12/6/2019,8/18/2020,11/30/2021,8/18/2040,Active,Formulation / Combination,"The patent claims cover a  composition comprising oxo-aflibercept, wherein one or more amino acid residues of aflibercept is oxidized and wherein said one or more amino acid residues is histidine and/or tryptophan.",After,Yes,https://patents.google.com/patent/US11186625B2/en?oq=US11186625B2
Eylea,US11253572B2,Regeneron,Macular Degeneration,Biologic,5,1/13/2011,6/21/2021,2/22/2022,1/11/2032,Active,Method of Treatment,"The patent claims cover a method of treating an angiogenic eye disorder in a patient in need thereof comprising sequentially administering to the patient by intravitreal injection a single initial dose of 2 mg of aflibercept, followed by one or more secondary doses of 2 mg of aflibercept, followed by one or more tertiary doses of 2 mg of aflibercept;wherein each secondary dose is administered approximately 4 weeks following the immediately preceding dose; and wherein each tertiary dose is administered approximately 8 weeks following the immediately preceding dose; wherein the patient achieves a gain in visual acuity within 52 weeks following the initial dose",After,Yes,https://patents.google.com/patent/US11253572B2/en?oq=US11253572B2
Eylea,US11268109B2,Regeneron,Macular Degeneration,Biologic,24,10/23/2014,2/12/2021,6/10/2021,10/21/2035,Active,Product,"The patent claims cover a cell comprising an exogenous nucleic acid integrated within a locus of the genome of the cell, wherein the locus comprises a nucleotide sequence that has a sequence identity of at least 98% to SEQ ID NO: 1 or SEQ ID NO: 4, and wherein the exogenous nucleic acid comprises a first selectable marker under control of a promoter, wherein the cell is a Chinese hamster ovary (CHO) cell.",After,No,https://patents.google.com/patent/US11268109B2/en?oq=US11268109B2
Eylea,US11286290B2,Regeneron,Macular Degeneration,Biologic,30,12/6/2019,3/24/2021,3/29/2022,8/18/2040,Active,Method of Production / Process,"The patent claims cover a method of purifying a VEGF MiniTrap, comprising: a) producing a clarified harvest of cells cultured in a chemically defined medium (CDM); b) binding aflibercept (Eylea) from said clarified harvest using an affinity chromatography column comprising a polypeptide capable of binding to or interacting with said aflibercept, wherein said polypeptide is an antibody, a fusion protein, a ScFv or a fragment thereof and wherein said polypeptide comprises an isolated amino acid sequence selected from a SEQ ID NO.: 72, SEQ ID NO.: 73, SEQ ID NO.: 74, SEQ ID NO.: 75, SEQ ID NO.: 76, SEQ ID NO.: 77, SEQ ID NO.: 78, SEQ ID NO.: 79 and SEQ ID NO.: 80; c) eluting said aflibercept of step (b) and subjecting said aflibercept to enzymatic cleavage to remove its Fc domain thereby forming a sample having a VEGF MiniTrap; optionally, d) subjecting said sample to a second chromatography capture step; ande) collecting a flowthrough fraction, wherein said flowthrough fraction has said VEGF MiniTrap.",After,No,https://patents.google.com/patent/US11286290B2/en?oq=US11286290B2
Eylea,US11306135B2,Regeneron,Macular Degeneration,Biologic,30,12/6/2019,8/30/2021,4/19/2022,8/18/2040,Active,Formulation / Combination,"The patent claims cover a composition comprising oxo-aflibercept, wherein one or more amino acid residues of aflibercept is oxidized and wherein said one or more amino acid residues is histidine.
",After,Yes,https://patents.google.com/patent/US11306135B2/en?oq=US11306135B2
Eylea,US11312936B2,Regeneron,Macular Degeneration,Biologic,29,8/4/2015,8/3/2016,4/26/2022,08-03-2036,Active,Method of Production / Process,"The patent claims cover a method for culturing recombinant eukaryotic cells for improved production of a recombinant protein of interest, comprising the steps of: (a) propagating or maintaining the cells in a defined cell culture medium during a growth phase, and (b) supplementing the defined cell culture medium with about 0.09 mM to about 0.9 mM ornithine and about 0.1 mM to about 10 mM L-taurine, and expressing the recombinant protein of interest during production phase, wherein the addition of L-taurine increases the titer of the recombinant protein of interest by at least 3% when compared to cells expressing the recombinant protein of interest in a cell culture medium containing less than 0.1 mM L-taurine.",After,No,https://patents.google.com/patent/US11312936B2/en?oq=US11312936B2
Eylea,US2004266686 ,Regeneron,Macular Degeneration,Biologic,1,6/8/1999,4/16/2004,12/30/2004,,Abandoned,Method of Treatment,"The patent application claimed a method of treating inflammatory skin disease, comprising administering a vascular endothelial growth factor antagonist.",Before,No,https://patents.google.com/patent/US20040266686A1/en?oq=US2004266686+
Eylea,US2005281831 ,Genentech,Macular Degeneration,Biologic,10,5/7/1996,1/26/2005,12/22/2005,,Abandoned,Method of Treatment,The patent application claimed a method of inhibiting vascularization and angiogenesis comprising administering a chimeric vascular endothelial growth factor (VEGF) receptor protein that has immunoglobulion like domains from two or more different VEGF receptor molecules. . ,Before,No,https://patents.google.com/patent/US20050281831A1/en?oq=US2005281831+
Eylea,US2007128695 ,Genentech,Macular Degeneration,Biologic,10,5/7/1996,9/30/2006,6/7/2007,,Abandoned,Product,The patent application claimed a chimeric vascular endothelial growth factor (VEGF) receptor protein capable of binding to VEGF wherein said chimeric VEGF receptor comprises immunoglobulin like domains. ,Before,No ,https://patents.google.com/patent/US20070128695A1/en?oq=US2007128695
Eylea,US2009234103 ,Genentech,Macular Degeneration,Biologic,10,5/7/1996,4/17/2008,9/17/2009,,Abandoned,Product,The patent application claimed a vascular endothelial growth factor (VEGF) receptor/immunoglobulin chimera consisting essentially of Ig-like domains 2 and 3 of one or more VEGF-receptor molecule(s). ,Before,No ,https://patents.google.com/patent/US20090234103A1/en?oq=US2009234103+
Eylea,US2011028698 ,Regeneron,Macular Degeneration,Biologic,2,6/8/1999,9/17/2010,2/3/2011,,Abandoned,Product,The patent application claimed amino acid sequences of Ig-like extracellular domains. ,Before,No,https://patents.google.com/patent/US20110028698A1/en?oq=US2011028698+
Eylea,US2011300578 ,Genentech,Macular Degeneration,Biologic,10,5/7/1996,4/28/2011,12/8/2011,,Abandoned,Product,"The patent application claimed nucleic acid molecule encoding a protein comprising a heterologous polypeptide fused to a first Ig-like domain and a second Ig-like domain, a method of producing a protein capable of binding VEGF and a vector comprising a nucleic acid molecule, including the vector is an expression vector. ",Before,No ,https://patents.google.com/patent/US20110300578A1/en?oq=US2011300578+
Eylea,US2011301338 ,Genentech,Macular Degeneration,Biologic,10,5/7/1996,4/28/2011,12/8/2011,,Abandoned,Product,The patent application claimed protein comprising a heterologous polypeptide fused to a first Ig-like domain and a second Ig-like domain.,Before,No,https://patents.google.com/patent/US20110301338A1/en?oq=US2011301338+
Eylea,US2011301339 ,Genentech,Macular Degeneration,Biologic,10,5/7/1996,4/28/2011,12/8/2011,,Abandoned,Product,The patent application claimed a method of binding a vascular endothelial growth factor (VEGF).,Before,No,https://patents.google.com/patent/US20110301339A1/en?oq=US2011301339+
Eylea,US2013084635 ,Regeneron,Macular Degeneration,Biologic,2,6/8/1999,11/21/2012,4/4/2013,,Abandoned,Method of Production / Process,The patent application claimed cell culture compositions to produce the vascular endothelial growth factor (VEGF) protein.,After,No,https://patents.google.com/patent/US20130084635A1/en?oq=US2013084635+
Eylea,US2016144025 ,Regeneron,Macular Degeneration,Biologic,14,11/25/2014,11/17/2015,5/26/2016,,Abandoned,Method of Treatment,"The application claimed a method for treating a vascular eye disease, the method comprising sequentially administering one or more doses of a pharmaceutical composition comprising therapeutically active amount of an anti-Ang-2 inhibitor and a VEGF antagonist (aflibercept) to a subject in need thereof. ",After,No,https://patents.google.com/patent/US20160144025A1/en?oq=US2016144025+
Eylea,US2017073407 ,Regeneron,Macular Degeneration,Biologic,8,3/25/2005,11/3/2016,3/16/2017,,Abandoned,Product,"The patent application claimed polynucleotide encoding a VEGF antagonist fusion protein, wherein said VEGF antagonist fusion protein comprises an immunoglobulin-like (Ig) domain 2 of a first VEGF receptor, an Ig domain 3 of a second VEGF receptor, and a multimerizing component",After,No,https://patents.google.com/patent/US20170073407A1/en?oq=US2017073407+
Eylea,US2017080086 ,Regeneron,Macular Degeneration,Biologic,14,11/25/2014,12/6/2016,3/23/2017,,Abandoned,Formulation / Combination,The application claimed a stable liquid formulation comprising: (i) a vascular endothelial growth factor (VEGF) antagonist; (ii) an antibody that binds specifically to human angiopoietin-2 (hAng-2); (iii) a buffer at pH of 6.2±0.3; (iv) a non-ionic detergent; (v) a tonicity agent; and (vi) a stabilizer; wherein the VEGF antagonist is a VEGF receptor-based chimeric molecule (“VEGF Trap”) including aflibercept.,After,No,https://patents.google.com/patent/US20170080086A1/en?oq=US2017080086+
Eylea,US20180030480A1,Regeneron,Macular Degeneration,Biologic,24,10/23/2014,10/13/2017,2/1/2018,,Abandoned,Product,"The application claimed a vehicle for modifying a CHO cell genome, comprising a vector that comprises: a. a 5′ homology arm homologous to a sequence present in the nucleotide sequence of SEQ ID NO: 1 or SEQ ID NO: 4, b. an exogenous nucleic acid, and c. a 3′ homology arm homologous to a sequence present in the nucleotide sequence of SEQ ID NO: 1 or SEQ ID NO: 4.",After,No,https://patents.google.com/patent/US20180030480A1/en?oq=US20180030480A1
Eylea,US20180289623A1,Regeneron,Macular Degeneration,Biologic,11,10/16/2015,10/14/2016,10/11/2018,,Pending,Formulation / Combination,"The application claims a general biphasic pharmaceutical formulation comprising: at least 25 mg/mL of polyethylene glycol (PEG) at least 100 mg/mL of a protein; a soluble phase comprising less than 50% of said protein; and an insoluble phase comprising said protein excluded from said soluble phase by said PEG; wherein said protein is stable for at least 30 days at physiological temperature, and said soluble phase has access through a semi-permeable membrane to an environment with a lower concentration of said protein. The patent describes how the formulation can be used with aflibercept (Eylea)",After,No,https://patents.google.com/patent/US20180289623A1/en?oq=US20180289623A1
Eylea,US20190010531,Regeneron,Macular Degeneration,Biologic,19,7/6/2017,7/3/2018,1/10/2019,,Abandoned,Method of Production / Process,"The application claimed a method comprising culturing a population of cells expressing a recombinant heterologous glycoprotein in cell culture media comprising soy hydrolysate to produce the recombinant heterologous glycoprotein (including etanercept, rilonacept, and aflibercept (Eylea), and wherein the soy hydrolysate comprises ≤0.067% (w/w) ornithine or putrescine",After,No,https://patents.google.com/patent/US20190010531A1/en?oq=US20190010531
Eylea,US20190056350A1,Regeneron,Macular Degeneration,Biologic,18,8/18/2017,8/17/2018,2/21/2019,,Pending,Method of Production / Process,"The application claims a method for analyzing charge variants of vascular endothelial growth factor VEGF-Trap comprising: loading a protein sample onto a separation capillary comprising a mixture of at least a carrier ampholyte, methylcellulose, and a stabilizing additive; applying a first voltage for a first predetermined period of time such that the carrier ampholyte forms a pH gradient within the capillary; applying a second voltage for a second predetermined period of time to focus the migration of charge variants of the protein within the capillary such that the overall charge of the variants is neutral; and detecting and quantifying charge variants of the protein",After,No,https://patents.google.com/patent/US20190056350A1/en?oq=US20190056350A1
Eylea,US20190360027,Regeneron,Macular Degeneration,Biologic,15,5/25/2018,5/25/2018,11/28/2019,,Pending,Method of Diagnosis,The  application claims a method for treating a macular degeneration patient with a vascular endothelial growth factor (VEGF) inhibitor (aflibercept (Eylea) comprising the steps of determining whether the patient has one or more genetic variants associated with visual acuity and/or anatomic outcome,After,No,https://patents.google.com/patent/US20190360027A1/en?oq=US20190360027
Eylea,US20200002732A1,Regeneron,Macular Degeneration,Biologic,24,10/23/2014,9/19/2019,1/2/2020,,Pending,Product,"The application claims a cell comprising an exogenous nucleic acid sequence integrated at a specific site within a locus, wherein the locus comprises a nucleotide sequence that is at least 90% identical to SEQ ID NO:1 or SEQ ID NO: 4.",After,No,https://patents.google.com/patent/US20200002732A1/en?oq=US20200002732A1
Eylea,US20200131554,Regeneron,Macular Degeneration,Biologic,19,7/6/2017,1/14/2020,4/30/2020,,Abandoned,Method of Production / Process,"The application claimed a method of producing aflibercept, comprising culturing a population of cells expressing aflibercept in a cell culture medium comprising soy hydrolysate, wherein the soy hydrolysate comprises ≤0.067% (w/w) ornithine or putrescine, thereby producing aflibercept.",After,No,https://patents.google.com/patent/US20200131554A1/en?oq=US20200131554
Eylea,US20200248278A1,Regeneron,Macular Degeneration,Biologic,26,3/27/2015,4/22/2020,8/6/2020,,Pending,Method of Production / Process,"The application claims a positive amplification control (PAC) plasmid comprising: a unique artificial plasmid-specific sequence (UAPS),
a target amplification polynucleotide (TAP) sequence, wherein said TAP comprises all or part of a parvovirus NS-1 sequence, and
a nucleic acid extraction control (NEC) nucleotide sequence, wherein said NEC comprises an M13 bacteriophage nucleotide sequence.",After,No,https://patents.google.com/patent/US20200248278A1/en?oq=US20200248278A1
Eylea,US20210023173A1,Regeneron,Macular Degeneration,Biologic,5,1/13/2011,10/16/2020,1/28/2021,,Pending,Method of Treatment,"The application claims method of treating macular edema following retinal vein occlusion in a patient in need thereof comprising administering 2 mg aflibercept to the patient by intravitreal injection approximately once every 4 weeks, wherein the patient achieves a gain in visual acuity following treatment.",After,No,https://patents.google.com/patent/US20210023173A1/en?oq=US20210023173A1
Eylea,US20210077624A1,Regeneron,Macular Degeneration,Biologic,8,3/25/2005,11/17/2020,3/18/2021,,Pending,Method of Production / Process,"The application claims a mammalian cell comprising a polynucleotide that encodes a fusion protein, wherein said fusion protein comprises an immunoglobulin-like (Ig) domain 2 of a first VEGF receptor, an Ig domain 3 of a second VEGF receptor, and a multimerizing component; wherein said fusion protein does not comprise a signal peptide and does not comprise a C-terminal lysine; and wherein said fusion protein binds vascular endothelial growth factor (VEGF).",After,No,https://docs.google.com/spreadsheets/d/1NYybCy0iI4wqA2JxbUwRIZpMZvi68tRIQ3Uer3eCW0s/edit?pli=1#gid=322905020
Eylea,US20210085753A1,Regeneron,Macular Degeneration,Biologic,5,1/13/2011,12/4/2020,3/25/2021,,Pending,Method of Treatment,"The application claims a method of treating an angiogenic eye disorder in a patient in need thereof comprising sequentially administering to the patient a single initial dose of 2 mg of aflibercept, followed by two secondary doses of 2 mg of aflibercept followed by one or more tertiary doses of 2 mg of aflibercept; wherein each secondary dose is administered to the patient by intravitreal injection approximately 4 weeks following the immediately preceding dose; and wherein each tertiary dose is administered on an as needed/pro re nata (PRN) basis, based on visual and/or anatomic outcomes as assessed by a physician or other qualified medical professional; wherein the patient achieves a gain in visual acuity within 52 weeks following the initial dose.",After,No,https://patents.google.com/patent/US20210085753A1/en?oq=US20210085753A1
Eylea,US20210252105A1,Regeneron,Macular Degeneration,Biologic,8,3/25/2005,5/5/2021,8/19/2021,,Pending,Formulation / Combination,"The patent application claims a formulation comprising: 10-50 mg/ml of a vascular endothelial growth factor (VEGF) antagonist fusion protein comprising amino acids 27-457 of SEQ ID NO: 4, a buffer comprising histidine, a stabilizing agent comprising a sugar, an amino acid or both,
wherein said VEGF antagonist fusion protein exhibits less than 3% degradation after 15 months of storage at 5° C",After,No,https://patents.google.com/patent/US20210252105A1/en?oq=US20210252105A1
Eylea,US20210252147A1,Regeneron,Macular Degeneration,Biologic,8,3/25/2005,5/4/2021,8/19/2021,,Pending,Formulation / Combination,"The application claims a vial comprising a formulation comprising: 10-50 mg/ml of a vascular endothelial growth factor (VEGF) antagonist fusion protein comprising amino acids 27-457 of SEQ ID NO: 4, a buffer comprising histidine, an organic co-solvent comprising polysorbate, and a stabilizing agent comprising a sugar, an amino acid or both.",After,No,https://patents.google.com/patent/US20210252147A1/en?oq=US20210252147A1
Eylea,US20210308216A1,Regeneron,Macular Degeneration,Biologic,5,1/13/2011,6/17/2021,10/7/2021,,Pending,Method of Treatment,"The application claims method for treating an angiogenic eye disorder in a patient in need thereof, said method comprising administering by intravitreal injection one or more maintenance doses of 2 mg of a VEGF antagonist comprising amino acids 27-457 of SEQ ID NO:2 at least about 8 weeks after the immediately preceding dose; wherein said patient has previously received by intravitreal injection an initial dose of 2 mg of the VEGF antagonist followed by one or more secondary doses of 2 mg of the VEGF antagonist; wherein each secondary dose was administered about 2 to 4 weeks after the immediately preceding dose; and wherein the patient achieves a gain in visual acuity at 24 weeks following the initial dose compared to baseline. ",After,No,https://patents.google.com/patent/US20210308216A1/en?oq=US20210308216A1
Eylea,US20210340605A1,Regeneron,Macular Degeneration,Biologic,15,5/25/2018,5/20/2021,11/4/2021,,Pending,Method of Treatment,"The application claims a method for treating a macular degeneration patient with aflibercept (Eylea), comprising the steps of: administering to the patient an initial treatment comprising intravitreal injection of about 2 mg of aflibercept about every 8 weeks; evaluating the patient for intraretinal fluid following the initial treatment with aflibercept; and if intraretinal fluid is present in the patient, then administering to the patient by intravitreal injection about 2 mg of aflibercept at a dosage frequency of about every 4 to 7 weeks; or if intraretinal fluid is not present in the patient, then administering to the patient by intravitreal injection about 2 mg of aflibercept at a dosage frequency of about every 9 to 12 weeks; wherein the patient has one or more genetic variants of human vascular endothelial growth factor (VEGF) selected from the group consisting of rs2056688, rs5962084, rs5962087, rs5915722, and rs596209.",After,No,https://patents.google.com/patent/US20210340605A1/en?oq=US20210340605A1
Eylea,US20210353714A1,Regeneron,Macular Degeneration,Biologic,16,5/10/2018,7/23/2021,11/18/2021,,Pending,Method of Treatment,"The application claims a method for treating an angiogenic eye disorder in a human patient in need thereof comprising administering an intravitreal injection of at least about 8 mg of a VEGF receptor fusion protein (aflibercept (Eylea) comprising two polypeptides that comprise an immunoglobulin-like (Ig) domain 2 of VEGFR1, an Ig domain 3 of a VEGFR2, and a multimerizing component, to the eye of the patient.",After,No,https://patents.google.com/patent/US20210353714A1/en?oq=US20210353714A1
Eylea,US20210388407A1,Regeneron,Macular Degeneration,Biologic,19,7/6/2017,8/23/2021,12/16/2021,,Pending,Method of Production / Process,The application claims a method comprising: culturing a population of cells expressing a recombinant heterologous glycoprotein in cell culture media comprising soy hydrolysate to produce the recombinant heterologous glycoprotein (including aflibercept (Eylea)  and wherein the soy hydrolysate comprises ≤0.067% (w/w) ornithine or putrescine.,After,No,https://patents.google.com/patent/US20210388407A1/en?oq=US20210388407A1
Eylea,US20210388408A1,Regeneron,Macular Degeneration,Biologic,19,7/6/2017,8/23/2021,12/16/2021,,Pending,Method of Production / Process,The application claims  method for making aflibercept (Eylea) comprising: method comprising: a. enzymatically digesting soy extract in a residue-free reaction vessel to manufacture a soy hydrolysate; b. measuring the amount of ornithine or putrescine in the soy hydrolysate; and c. selecting soy hydrolysate with ≤0.067% (w/w) ornithine or putrescine for use in a cell culture media.,After,No,https://patents.google.com/patent/US20210388408A1/en?oq=US20210388408A1
Eylea,US20210393530A1,Regeneron,Macular Degeneration,Biologic,8,3/25/2005,5/7/2021,12/23/2021,,Pending,Formulation / Combination,"The application claims a pre-filled syringe comprising a formulation comprising: 10-50 mg/ml of a vascular endothelial growth factor (VEGF) antagonist fusion protein comprising amino acids 27-457 of SEQ ID NO: 4, a pH of 6.0-6.5, an organic co-solvent, a stabilizing agent comprising a sugar, an amino acid, or both, and wherein said VEGF antagonist fusion protein exhibits less than 3% degradation after 15 months of storage at 5° C. ",After,No,https://patents.google.com/patent/US20210393530A1/en?oq=US20210393530A1
Eylea,US20210393778A1,Regeneron,Macular Degeneration,Biologic,8,3/25/2005,5/6/2021,12/23/2021,,Pending,Formulation / Combination,"The application claims a vial comprising a formulation comprising: 10-50 mg/ml of a vascular endothelial growth factor (VEGF) antagonist fusion protein comprising amino acids 27-457 of SEQ ID NO: 4, a buffer comprising histidine, a stabilizing agent comprising a sugar, an amino acid or both,
wherein there is no detectable degradation of said VEGF antagonist fusion protein after 6 months of storage at 2-8° C.",After,No ,https://patents.google.com/patent/US20210393778A1/en?oq=US20210393778A1
Eylea,US20220009997A1,Regeneron,Macular Degeneration,Biologic,30,12/6/2019,7/16/2021,1/13/2022,,Pending,Product,"The application claims a polypeptide (aflibercept (Eylea) having an isolated amino acid sequence comprising at least 70% sequence identity over a full length of said isolated amino acid sequence as set forth in the group consisting of SEQ ID NO.: 2, SEQ ID NO.: 3, SEQ ID NO.: 4, SEQ ID NO.: 5, SEQ ID NO.: 6, SEQ ID NO.: 7, SEQ ID NO.: 8, SEQ ID NO.: 9, SEQ ID NO.: 10, SEQ ID NO.: 11, SEQ ID NO.: 12, SEQ ID NO.: 13, SEQ ID NO.: 14, SEQ ID NO.: 15 and SEQ ID NO.: 16, wherein said polypeptide excludes IdeS as set forth in SEQ ID NO.: 1.",After,No,https://patents.google.com/patent/US20220009997A1/en?oq=US20220009997A1
Eylea,US20220023529A1,Regeneron,Macular Degeneration,Biologic,31,7/29/2019,10/6/2021,1/27/2022,,Pending,Packaging,The patent claims cover a method of removing packaging for a sterile syringe.,After,No,https://patents.google.com/patent/US20220023529A1/en?oq=US20220023529A1
Eylea,US20220033471A1,Regeneron,Macular Degeneration,Biologic,30,12/6/2019,7/22/2021,2/3/2022,,Pending,Product,"The application claims  a polypeptide (aflibercept (Eylea) having an isolated amino acid sequence comprising at least 70% sequence identity over a full length of said isolated amino acid sequence as set forth in the group consisting of SEQ ID NO.: 2, SEQ ID NO.: 3, SEQ ID NO.: 4, SEQ ID NO.: 5, SEQ ID NO.: 6, SEQ ID NO.: 7, SEQ ID NO.: 8, SEQ ID NO.: 9, SEQ ID NO.: 10, SEQ ID NO.: 11, SEQ ID NO.: 12, SEQ ID NO.: 13, SEQ ID NO.: 14, SEQ ID NO.: 15 and SEQ ID NO.: 16, wherein said polypeptide excludes IdeS as set forth in SEQ ID NO.: 1.",After,No,https://patents.google.com/patent/US20220033471A1/en?oq=US20220033471A1
Eylea,US20220033472A1,Regeneron,Macular Degeneration,Biologic,30,12/6/2019,10/1/2021,2/3/2022,,Pending,Method of Production / Process,"The application claims a method of producing aflibercept (Eylea) MiniTrap, comprising producing aflibercept using cells cultured in a chemically defined medium (CDM).
",After,No,https://patents.google.com/patent/US20220033472A1/en?oq=US20220033472A1
Eylea,US20220048975A1,Regeneron,Macular Degeneration,Biologic,30,12/6/2019,10/13/2021,2/17/2022,,Pending,Method of Production / Process,"The application claims  method of producing aflibercept, comprising culturing aflibercept using clarified harvest of cells in a chemically defined medium (CDM).",After,No,https://patents.google.com/patent/US20220048975A1/en?oq=US20220048975A1
Eylea,US20220098280A1,Regeneron,Macular Degeneration,Biologic,30,12/6/2019,8/26/2021,3/31/2022,,Pending,Formulation / Combination,"The application claims a composition comprising oxo-aflibercept, wherein one or more amino acid residues of aflibercept is oxidized and wherein said one or more amino acid residues is histidine.",After,No,https://patents.google.com/patent/US20220098280A1/en?oq=US20220098280A1
Eylea,US20220127331A1,Regeneron,Macular Degeneration,Biologic,30,12/6/2019,12/21/2021,4/28/2022,,Pending,Method of Production / Process,The application claims a method of producing aflibercept harvested from a host cell cultured in a chemically defined medium (CDM).,After,No,https://patents.google.com/patent/US20220127331A1/en?oq=US20220127331A1
Eylea,US20220162289A1,Regeneron,Macular Degeneration,Biologic,30,12/6/2019,2/8/2022,5/26/2022,,Pending,Method of Production / Process,"The application claims a method for preparing a prefilled syringe comprising the step of loading a syringe with aflibercept (Eylea), wherein the process of producing aflibercept comprises the steps of: (a) binding aflibercept produced in a chemically defined media (CDM) having at least one oxidized amino acid residue selected from group consisting of tryptophan, histidine, and a combination thereof to a first capture chromatography; (b) eluting said aflibercept of step (a) forming an affinity eluate, wherein said eluate has a first color; (c) subjecting said affinity eluate to an ion exchange chromatography column; and (d) collecting a flowthrough fraction, wherein said flowthrough fraction has a second color, and wherein said first color is a more intense yellow-brown color than said second color when said affinity eluate and said flowthrough fraction protein concentrations are normalized to 5.0 g/L.",After,No,https://patents.google.com/patent/US20220162289A1/en?oq=US20220162289A1
Eylea,US5952199,Genentech,Macular Degeneration,Biologic,10,5/7/1996,6/13/1997,9/14/1999,5/7/2016,Expired,Product,The patent claims cover a chimeric vascular endothelial growth factor (VEGF )receptor protein that is capable of binding to VEGF and exerts an inhibitory effect . ,Before,No,https://patents.google.com/patent/US5952199A/en?oq=US5952199
Eylea,US6100071 ,Genentech,Macular Degeneration,Biologic,10,5/7/1996,5/7/1996,8/8/2000,5/7/2016,Expired,Product,"The patent claims cover proteins with 3 tyrosine kinase regions capable of binding to and inhibiting vascular endothelial growth factor VEGF,  nucleic acid sequences to produce the protein, expression vectors, host cells, process of production and pharmaceutical compositions. ",Before,No,https://patents.google.com/patent/US6100071A/en?oq=US6100071+
Eylea,US6383486 ,Genentech,Macular Degeneration,Biologic,10,5/7/1996,7/1/1999,5/7/2002,5/7/2016,Expired,Method of Treatment,The patent claims cover a method of treatment by inhibiting vascularization with a therapeutically effective amount of a composition comprising a chimeric vascular endothelial growth factor (VEGF ) receptor protein.,Before,No,https://patents.google.com/patent/US6383486B1/en?oq=US6383486+
Eylea,US6833349,Regeneron,Macular Degeneration,Biologic,1,6/8/1999,1/31/2001,12/21/2004,8/8/2020,Expired,Method of Treatment,The patent claims cover a method of treating psoriasis in a mammal comprising administering a vascular endothelial growth factor (VEGF) antagonist to the mammal wherein the VEGF antagonist is a fusion protein.,Before,No,https://patents.google.com/patent/US6833349B2/en?oq=US6833349
Eylea,US6897294 ,Genentech,Macular Degeneration,Biologic,10,5/7/1996,3/20/2002,5/24/2005,5/24/2016,Expired,Product,The patent claims cover a chimeric vascular endothelial growth factor (VEGF) receptor protein comprising immunoglobulin like domains from two or more different VGEF receptor molecules. ,Before,No,https://patents.google.com/patent/US6897294B2/en?oq=US6897294+
Eylea,US7070959 ,Regeneron,Macular Degeneration,Biologic,2,6/8/1999,5/23/2000,7/4/2006,6/16/2023,Active,Product,"The patent claims cover an isolated nucleic acid molecule encoding a fusion protein capable of binding vascular endothelial growth factor (VEGF) and a multimerizing component, as well as an expression vector and host-vector system. ",Before,Yes,https://patents.google.com/patent/US7070959B1/en?oq=US7070959
Eylea,US7087411,Regeneron,Macular Degeneration,Biologic,2,6/8/1999,6/30/2003,8/8/2006,3/7/2021,Expired,Product,The patent claims cover an isolated nucleic acid molecule encoding a fusion polypeptide capable of binding vascular endothelial growth factor (VEGF). ,Before,No,https://patents.google.com/patent/US7087411B2/en?oq=US7087411
Eylea,US7279159 ,Regeneron,Macular Degeneration,Biologic,3,6/30/2003,6/29/2004,10/9/2007,11/11/2024,Active,Product,"The patent claims cover  a defined fusion polypeptide with or without spacer units between, a multimerizing component and their action as dimers to inhibit vascular endothelial growth factor (VEGF).",Before,No,https://patents.google.com/patent/US7279159B2/en?oq=US7279159
Eylea,US7300653B2,Regeneron,Macular Degeneration,Biologic,21,5/28/2003,4/23/2004,11/27/2007,10/19/2025,Active,Method of Treatment,"The patent claims cover a  method of improving transplant survival in a subject, comprising administering to the subject prior to or following corneal transplantation a first agent capable of blocking, inhibiting, or ameliorating vascular endothelial growth factor (VEGF). ",Before,No,https://patents.google.com/patent/US7300653B2/en?oq=US7300653B2
Eylea,US7300654,Regeneron,Macular Degeneration,Biologic,22,5/28/2003,1/19/2005,11/27/2007,4/17/2025,Active,Method of Treatment,"The patent claims cover a method of improving transplant survival in a high risk keratoplasty subject, comprising administering to the subject prior to or following corneal transplantation, a first agent capable of blocking, inhibiting, or ameliorating vascular endothelial growth factor (VEGF)-mediated activity, such that transplant survival is improved.",Before,No,https://patents.google.com/patent/US7300654B2/en?oq=US7300654
Eylea,US7303746 ,Regeneron,Macular Degeneration,Biologic,2,6/8/1999,11/12/2004,12/4/2007,7/22/2021,Expired,Method of Treatment,"The patent claim covers a method of treating retinal neovascularization, comprising administering a fusion polypeptide capable of binding vascular endothelial growth factor (VEGF).",Before,No,https://patents.google.com/patent/US7303746B2/en?oq=US7303746+
Eylea,US7303747 ,Regeneron,Macular Degeneration,Biologic,2,6/8/1999,9/1/2005,12/4/2007,1/17/2021,Expired,Method of Treatment,"The patent claims cover a therapeutic method for treating or ameliorating an eye disorder, comprising administering a fusion polypeptide comprising the amino acid sequence of SEQ ID NO:6 and an effective amount of a vascular endothelial growth factor (VEGF) inhibitor of an initial dose of at least approximately 25-4000 micrograms VEGF inhibitor protein per eye",Before,No,https://patents.google.com/patent/US7303747B2/en?oq=US7303747+
Eylea,US7303748 ,Regeneron,Macular Degeneration,Biologic,4,2/2/2005,2/2/2006,12/4/2007,5/7/2026,Active,Method of Treatment,"The patent claims cover a method of treating an eye injury, comprising locally administering an effective amount of an agent capable of blocking or inhibiting vascular endothelial growth factor (VEGF) and the eye injury is corneal or conjunctival injury caused by a penetrating object, a foreign body, or a chemical or burn injury.",Before,No,https://patents.google.com/patent/US7303748B2/en?oq=US7303748+
Eylea,US7306799 ,Regeneron,Macular Degeneration,Biologic,2,6/8/1999,3/25/2005,12/11/2007,5/23/2020,Expired,Method of Treatment,"The patent claims cover therapeutic method for treating or ameliorating an eye disorder, comprising administering a fusion polypeptide capable of binding vascular endothelial growth factor (VEGF) to a patient.",Before,No,https://patents.google.com/patent/US7306799B2/en?oq=US7306799+
Eylea,US7374757 ,Regeneron,Macular Degeneration,Biologic,2,6/8/1999,12/17/2004,5/20/2008,5/23/2021,Expired,Product,"The patent claims cover a fusion protein consisting of a vascular endothelial growth factor (VEGF) receptor component having immunoglobulin-like (Ig) domains and a multimerizing component, wherein the fusion protein binds VEGF.  ",Before,No,https://patents.google.com/patent/US7374757B2/en?oq=US7374757+
Eylea,US7374758 ,Regeneron,Macular Degeneration,Biologic,2,6/8/1999,12/17/2004,5/20/2008,5/23/2021,Expired,Method of Treatment,The patent claims cover a method of inhibiting vascular endothelial growth factor (VEGF) by administering  a pharmaceutical composition comprising  a a VEGF antagonist and a pharmaceutically acceptable carrier.  ,Before,No,https://patents.google.com/patent/US7374758B2/en?oq=US7374758+
Eylea,US7396664 ,Regeneron,Macular Degeneration,Biologic,2,6/8/1999,8/16/2005,7/8/2008,3/16/2021,Expired,Product,"The patent claims cover a recombinant  nucleic acid molecule encoding a fusion polypeptide, a vector comprising the nucleic acid molecule and a method of producing a VEGF fusion polypeptide.",Before,No,https://patents.google.com/patent/US7396664B2/en?oq=US7396664+
Eylea,US7399612 ,Regeneron,Macular Degeneration,Biologic,3,6/30/2003,2/2/2006,7/15/2008,11/6/2023,Active,Product,"The patent claims cover an isolated nucleic acid molecule encoding a fusion protein, intermediates and a method of producing a VEGF-binding fusion protein comprising a vector.",Before,No,https://patents.google.com/patent/US7399612B2/en?oq=US7399612+
Eylea,US7521049 ,Regeneron,Macular Degeneration,Biologic,2,6/8/1999,11/30/2007,4/21/2009,5/23/2020,Expired,Method of Treatment,The patent claims cover a method of treating or ameliorating an eye disorders comprising administering a fusion polypeptide capable of binding vascular endothelial growth factor (VEGF) and a multimerizing component.,Before,No,https://patents.google.com/patent/US7521049B2/en?oq=US7521049+
Eylea,US7524499 ,Regeneron,Macular Degeneration,Biologic,2,6/8/1999,4/14/2008,4/28/2009,7/29/2020,Expired,Product,The patent claims cover a fusion protein consisting of a vascular endothelial growth factor (VEGF) receptor component having immunoglobulin-like (Ig) domains and a multimerizing component.,Before,No,https://patents.google.com/patent/US7524499B2/en?oq=US7524499+
Eylea,US7531173B2,Regeneron,Macular Degeneration,Biologic,4,2/2/2005,11/30/2007,5/12/2009,2/2/2026,Active,Product,This seems to be a duplicate of the immediately-preceding entry in the Landscape,Before,No,https://patents.google.com/patent/US7531173B2/en?oq=US7531173B2
Eylea,US7608261 ,Regeneron,Macular Degeneration,Biologic,6,6/16/2006,6/14/2007,10/27/2009,7/31/2027,Active,Formulation / Combination,"The patent claims cover a ophthalmic formulation of a vascular endothelial growth factor (VEGF) antagonist, comprising:  a) 1-100 mg/ml of a VEGF antagonist comprising the amino acid sequence of SEQ ID NO:4; b) 0.01-5% of one or more organic co-solvent(s) which is one or more of polysorbate, polyethylene glycol (PEG), and propylene glycol; c) 30-150 mM of a tonicity agent selected from sodium chloride or potassium chloride; and,
d) 5-40 mM of sodium phosphate buffer",Before,No,https://patents.google.com/patent/US7608261B2/en?oq=US7608261+
Eylea,US7635474 ,Regeneron,Macular Degeneration,Biologic,3,6/30/2003,6/9/2008,12/22/2009,6/30/2023,Active,Product,"The patent claims cover an article of manufacturing comprising packaging material and a pharmaceutical agent contained within the packaging material, wherein the pharmaceutical agent comprises at least one vascular endothelial growth factor (VEGF)-binding fusion protein and the VEGF-binding fusion protein consists of R1, R2, and a multimerizing component.",Before,No,https://patents.google.com/patent/US7635474B2/en?oq=US7635474+
Eylea,US7704500 ,Regeneron,Macular Degeneration,Biologic,2,6/8/1999,4/14/2008,4/27/2010,5/23/2020,Expired,Method of Treatment,"The patent claims cover a method of  attenuating or reducing formation of ascites that are ovarian cancer associated in a mammal, comprising administering to the mammal an effective amount of a fusion protein vascular endothelial growth factor (VEGF) antagonist. ",Before,No,https://patents.google.com/patent/US7704500B2/en?oq=US7704500+
Eylea,US7771721 ,Genentech,Macular Degeneration,Biologic,10,5/7/1996,4/17/2008,8/10/2010,5/7/2016,Expired,Method of Treatment,The patent claims cover a method of vascularization or angiogenesis using  a chimeric vascular endothelial growth factor (VEGF ) receptor protein. ,Before,No,https://patents.google.com/patent/US7771721B2/en?oq=US7771721+
Eylea,US7771997B2,Regeneron,Macular Degeneration,Biologic,23,6/4/2007,6/4/2008,8/10/2010,7/2/2028,Active,Product,"The patent claims cover an  isolated cell comprising an expression-enhancing sequence selected from SEQ ID NO:1-6, and at least one recombinase recognition site located immediately adjacent to SEQ ID NO:1-6.",Before,No,https://patents.google.com/patent/US7771997B2/en?oq=US7771997B2
Eylea,US7807164,Regeneron,Macular Degeneration,Biologic,6,6/16/2006,9/16/2009,10/5/2010,6/14/2027,Active,Method of Production / Process,"The patent claims cover method of making a lyophilized formulation, comprising: lyophilizing a VEGF antagonist formulation, wherein the VEGF antagonist formulation comprises (a) 5-50 mg/ml of the VEGF antagonist of SEQ ID NO:4; (b) 5-25 mM of sodium phosphate buffer, pH about 5.8-7.0;
(c) 0.01-0.15% of an organic co-solvent, selected from the group consisting of polysorbate, polyethylene glycol (PEG), propylene glycol, and a combination thereof; and, (d) 1-10% of a stabilizing agent selected from the group consisting of sucrose, sorbitol, glycerol, trehalose, and mannitol. patent.",Before,No,https://patents.google.com/patent/US7807164B2/en?oq=US7807164
Eylea,US7964377 ,Regeneron,Macular Degeneration,Biologic,2,6/8/1999,12/15/2008,6/21/2011,9/16/2020,Expired,Product,The patent claims cover an isolated nucleic acid molecule encoding a fusion protein capable of binding vascular endothelial growth factor (VEGF) and a multimerizing component.,Before,No,https://patents.google.com/patent/US7964377B2/en?oq=US7964377
Eylea,US7972598 ,Regeneron,Macular Degeneration,Biologic,3,6/30/2003,11/23/2009,7/5/2011,6/30/2023,Active,Product,The patent claim covers a vascular endothelial growth factor (VEGF)-binding fusion protein wherein the VEGF protein has 2 Ig domains and a multimerizing component.,Before,No,https://patents.google.com/patent/US7972598B2/en?oq=US7972598+
Eylea,US8029791 ,Regeneron,Macular Degeneration,Biologic,2,6/8/1999,4/14/2008,10/4/2011,9/27/2021,Expired,Product,"The patent claims cover a dimeric vascular endothelial growth factor (VEGF) antagonist, comprising two fusion protein and a composition comprising a VEGF antagonist and a carrier, wherein the VEGF antagonist comprises two fusion proteins.",Before,No,https://patents.google.com/patent/US8029791B2/en?oq=US8029791+
Eylea,US8084234 ,Regeneron,Macular Degeneration,Biologic,2,6/8/1999,3/1/2010,12/27/2011,5/23/2020,Expired,Product,The patent claims cover an isolated nucleic acid molecule encoding a fusion protein capable of binding vascular endothelial growth factor (VEGF) and an expression vector comprising a nucleic acid molecule encoding a fusion protein capable of binding vascular endothelial growth factor (VEGF).,Before,No,https://patents.google.com/patent/US8084234B2/en?oq=US8084234+
Eylea,US8092803 ,Regeneron,Macular Degeneration,Biologic,6,6/16/2006,7/9/2010,1/10/2012,6/21/2027,Active,Formulation / Combination,"The patent claims cover stable liquid ophthalmic formulation of a vascular endothelial growth factor (VEGF) antagonist, comprising: (a) between 50 mg/ml to about 10 mg/ml of a VEGF antagonist comprising amino acids 27-475 of SEQ ID NO:4; (b) about 0.03% to about 0.1% polysorbate; (c) about 5-40 mM of sodium phosphate buffer, pH of about 5.8 to about 7.0; and (d) either: (i) about 5% sucrose and about 40 to about 50 mM NaCl, or
(ii) about 135 mM NaCl, wherein at least 99% of the VEGF antagonist is present in native conformation following storage at 5° C. for 2 months as measured by size exclusion chromatography. ",Before,No,https://patents.google.com/patent/US8092803B2/en?oq=US8092803+
Eylea,US8110546 ,Regeneron,Macular Degeneration,Biologic,8,3/25/2005,7/13/2010,2/7/2012,3/22/2026,Active,Formulation / Combination,"The patent claims cover a  stable liquid formulation of a vascular endothelial growth factor (VEGF) inhibitor comprising 10-100 mg/ml of a fusion protein comprising amino acids 27-457 of SEQ ID NO: 4, and a multimerizing component; 5 mM phosphate and 5 mM citrate, at a pH of about 6.0-6.5; about 20% sucrose; about 50-100 mM NaCl; and about 0.1% polysorbate 20; wherein at least 92% of the fusion protein antagonist is present in native conformation as measured by SE-HPLC following storage at 5° C. for 12 months",Before,No,https://patents.google.com/patent/US8110546B2/en?oq=US8110546+
Eylea,US8268313 ,Genentech,Macular Degeneration,Biologic,10,5/7/1996,4/28/2011,9/18/2012,5/7/2016,Expired,Product,The patent claims cover a method of binding vascular endothelial growth factor (VEGF ) with a protein containing certain specified peptide sequences.,Before,No,https://patents.google.com/patent/US8268313B2/en?oq=US8268313+
Eylea,US8268591 ,Genentech,Macular Degeneration,Biologic,10,5/7/1996,4/28/2011,9/18/2012,5/7/2016,Expired,Product,"The patent claims cover a nucleic acid molecule encoding a protein capable of binding to vascular endothelial growth factor (VEGF), vectors, host cells and methods of purifying the protein. ",Before,No,https://patents.google.com/patent/US8268591B2/en?oq=US8268591+
Eylea,US8273353 ,Genentech,Macular Degeneration,Biologic,10,5/7/1996,4/28/2011,9/25/2012,5/7/2016,Expired,Product,The patent claims cover a protein consisting of a heterologous polypeptide fused to nucleic acid sequences that are capable of binding vascular endothelial growth factor (VEGF).,Before,No,https://patents.google.com/patent/US8273353B2/en?oq=US8273353+
Eylea,US8343737 ,Regeneron,Macular Degeneration,Biologic,2,6/8/1999,5/13/2011,1/1/2013,5/23/2020,Expired,Method of Production / Process,"The patent claims cover a cell culture composition comprising cells suspended in culture medium, wherein the cells contain an expression vector comprising a nucleic acid molecule that encodes the amino acid sequence.",Before,No,https://patents.google.com/patent/US8343737B2/en?oq=US8343737+
Eylea,US8389239B2,Regeneron,Macular Degeneration,Biologic,23,6/4/2007,6/4/2010,3/5/2013,11/24/2028,Active,Product,"The patent claims cover an  isolated cell comprising an expression-enhancing sequence comprising SEQ ID NO:5, a gene of interest (GOI) operably linked to the expression-enhancing sequence, and at least one recombinase recognition site immediately adjacent to the GOI.",Before,No,https://patents.google.com/patent/US8389239B2/en?oq=US8389239B2
Eylea,US8404638 ,Regeneron,Macular Degeneration,Biologic,8,3/25/2005,1/4/2012,3/26/2013,3/22/2026,Active,Formulation / Combination,"The patent claims cover a non-liquid formulation of a vascular endothelial growth factor (VEGF) antagonist made according to the steps of: (a) combining in a liquid solution the following excipients: (i) about 50 mg/mL of a VEGF antagonist, which is a dimer consisting of two identical polypeptides consisting of amino acids 27-457 of SEQ ID NO:4; (ii) about 10 mM histidine, pH about 6.3-6.5; (iii) about 1.5% polyethylene glycol (PEG) 3350; (iv) about 5% sucrose; and (v) about 1.5% glycine; and (b) lyophilizing the combination of step (a), wherein, following storage of the lyophilized combination obtained after step (b) at 5° C. for about 6 months, at least 98% of the VEGF antagonist is present in native conformation as measured by size exclusion chromatography upon reconstitution.",After,No,https://patents.google.com/patent/US8404638B2/en?oq=US8404638+
Eylea,US8481046 ,Regeneron,Macular Degeneration,Biologic,6,6/16/2006,12/19/2011,7/9/2013,6/14/2027,Active,Method of Production / Process,"The patent claims cover a method of producing a lyophilized formulation of a VEGF antagonist, comprising the step of subjecting to lyophilization a prelyophilization formulation, which comprises: (a) 5-50 mg/ml of a vascular endothelial growth factor (VEGF) antagonist, comprising amino acids 27-457 of SEQ ID NO:4; (b) 5-25 mM of sodium phosphate buffer, pH about 5.8-7.0; (c) 0.01-0.15% of an organic co-solvent, selected from the group consisting of polysorbate, polyethylene glycol (PEG), propylene glycol, and a combination thereof; and, (d) 1-10% of a stabilizing agent selected from the group consisting of sucrose, sorbitol, glycerol, trehalose, and mannitol, to generate a lyophilized formulation.",After,No,https://patents.google.com/patent/US8481046B2/en?oq=US8481046+
Eylea,US8647842 ,Regeneron,Macular Degeneration,Biologic,2,6/8/1999,4/5/2012,2/11/2014,5/23/2020,Expired,Method of Production / Process,The patent claims cover a method for producing a fusion protein capable of binding vascular endothelial growth factor (VEGF) comprising a process of growing recombinant cells and isolating the fusion protein.,After,No,https://patents.google.com/patent/US8647842B2/en?oq=US8647842
Eylea,US8710004 ,Regeneron,Macular Degeneration,Biologic,8,3/25/2005,3/23/2012,4/29/2014,4/25/2026,Active,Formulation / Combination,"The patent claims cover a stable liquid formulation of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist, comprising 10-100 mg/ml of a fusion protein comprising amino acids 27-457 of SEQ ID NO: 4; 5 mM phosphate and 5 mM citrate, at a pH of about 6.0-6.5; about 20% sucrose; about 50-100 mM NaCl; and about 0.1% polysorbate 20. ",After,No,https://patents.google.com/patent/US8710004B2/en?oq=US8710004+
Eylea,US8802107 ,Regeneron,Macular Degeneration,Biologic,6,6/16/2006,6/11/2013,8/12/2014,6/14/2027,Active,Method of Production / Process,"The patent claims cover a method of producing a lyophilized formulation of a VEGF antagonist, comprising a step of subjecting to lyophilization a pre-lyophilized formulation, which comprises: (a) 5-50 mg/ml of a vascular endothelial growth factor (VEGF) antagonist, comprising the amino acids 27-457 of SEQ ID NO:4; (b) 5-25 mM of sodium phosphate buffer, pH about 5.8-7.0; (c) 0.01-0.15% of an organic co-solvent, selected from the group consisting of polysorbate, polythylene glycol (PEG) propylene glycol, and a combination thereof; and (d) 1-10% of a stabilizing agent selected from the group consisting of sucrose, sorbitol, glycerol, trehalose, and mannitol, to generate a lyophilized formulation.",After,No,https://patents.google.com/patent/US8802107B2/en?oq=US8802107+
Eylea,US8921316 ,Regeneron,Macular Degeneration,Biologic,8,3/25/2005,6/4/2013,12/30/2014,3/22/2026,Active,Formulation / Combination,"The patent claims cover a stable liquid formulation comprising 100 mg/mL of a VEGF antagonist, which is a dimer comprising two identical poly-peptides comprising amino acids 27-457 of SEQ ID NO:4, 20 mM histidine, 3% polyethylene glycol (PEG) 3350 w/v, 5% sucrose w/v, and 1.5% glycine w/v, at pH 6.3-6.5.",After,No,https://patents.google.com/patent/US8921316B2/en?oq=US8921316+
Eylea,US9139644 ,Regeneron,Macular Degeneration,Biologic,2,6/8/1999,12/18/2013,9/22/2015,5/23/2020,Expired,Product,"The patent claims cover a chimeric polypeptide capable of antagonizing vascular endothelial growth factor (VEGF) activity with a modified extracellular binding domain that exhibits ""improved pharmacokinetic properties.",After,No,https://patents.google.com/patent/US9139644B2/en?oq=US9139644+
Eylea,US9222106,Regeneron,Macular Degeneration,Biologic,23,6/4/2007,1/29/2013,12/29/2015,3/23/2029,Active,Product,"The patent claims cover an  isolated cell comprising an expression-enhancing sequence selected from the group consisting of SEQ ID NOs:1-4, a gene of interest (GOI) operably linked to the expression-enhancing sequence, and at least one recombinase recognition site immediately adjacent to the GOI an d a method of making the protein of interest.",After,No,https://patents.google.com/patent/US9222106B2/en?oq=US9222106
Eylea,US9254338B2,Regeneron,Macular Degeneration,Biologic,5,1/13/2011,7/12/2013,2/9/2016,5/22/2032,Active,Method of Treatment,"The patent claims cover a method for treating an angiogenic eye disorder in a patient, said method comprising sequentially administering to the patient a single initial dose of a VEGF antagonist, followed by one or more secondary doses of the VEGF antagonist, followed by one or more tertiary doses of the VEGF antagonist; wherein each secondary dose is administered 2 to 4 weeks after the immediately preceding dose; and wherein each tertiary dose is administered at least 8 weeks after the immediately preceding dose.",After,Yes,https://patents.google.com/patent/US9254338B2/en?oq=US9254338B2
Eylea,US9273113 ,Genentech,Macular Degeneration,Biologic,10,5/7/1996,8/13/2012,3/1/2016,5/7/2016,Expired,Method of Treatment,The patent claims cover a method of treating as condition associated with undesired vascularization by administering a chimeric vascular endothelial growth factor (VEGF) receptor protein. ,After,No,https://patents.google.com/patent/US9273113B2/en?oq=US9273113+
Eylea,US9340594 ,Regeneron,Macular Degeneration,Biologic,6,6/16/2006,7/14/2014,5/17/2016,6/14/2027,Active,Formulation / Combination,The patent claims cover a pre-filled syringe suitable for intravitreal administration comprising a 1 mL luer glass syringe fitted with a plunger and a stable ophthalmic formulation of a vascular endothelial growth factor (VEGF) trap.,After,No,https://patents.google.com/patent/US9340594B2/en?oq=US9340594+
Eylea,US9416167 ,Regeneron,Macular Degeneration,Biologic,8,3/25/2005,11/21/2014,8/16/2016,3/22/2026,Active,Formulation / Combination,"The patent claims cover a stable pharmaceutical formulation comprising: (a) 50-100 mg/mL of a vascular endothelial growth factor (VEGF) antagonist fusion protein dimer consisting of two identical fusion polypeptides consisting essentially of (i) the immunoglobulin-like domain 2 of the human Flt1 VEGF receptor, (ii) the immunoglobulin-like domain 3 of the human Flk1 or the human Flt4 VEGF receptor, and (iii) an immunoglobulin Fc domain; (b) 5-50 mM histidine; (c) 0.1-3.0% polyethylene glycol (PEG) 3350; (d) 0.24-3.0% glycine; and (e) 0.5-6.0% sucrose, pH 6.3-6.5.",After,No,https://patents.google.com/patent/US9416167B2/en?oq=US9416167+
Eylea,US9511140 ,Regeneron,Macular Degeneration,Biologic,8,3/25/2005,3/8/2016,12/6/2016,3/22/2026,Active,Formulation / Combination,"The patent claims cover a stable liquid formulation of a vascular endothelial growth factor (VEGF)-specific antagonist, comprising: 10-100 mg/ml of a fusion protein comprising a receptor component, which comprises an immunoglobulin-like (Ig) domain 2 of a first VEGF receptor and an Ig domain 3 of a second VEGF receptor, and a multimerizing component; 1-10 mM phosphate buffer; 1-10 mM citrate buffer; 25-150 mM NaCl; and 5-30% sucrose, at a pH of about 6-6.5.",After,No,https://patents.google.com/patent/US9511140B2/en?oq=US9511140+
Eylea,US9562238B2,Regeneron,Macular Degeneration,Biologic,23,6/4/2007,12/14/2015,2/7/2017,6/4/2028,Active,Method of Production / Process,"The patent claims cover a method of making a recombinant cell comprising introducing at least one exogenous sequence into an expression-enhancing expression and stability region (EESYR) sequence, or 5′ or 3′ of an EESYR sequence, wherein the EESYR sequence is selected from the group consisting of SEQ ID NO:1-6.",After,No,https://patents.google.com/patent/US9562238B2/en?oq=US9562238B2
Eylea,US9580489 ,Regeneron,Macular Degeneration,Biologic,6,6/16/2006,5/11/2016,2/28/2017,6/14/2027,Active,Formulation / Combination,"The patent claims cover formulation comprising:(a) 1-100 mg/mL of a VEGF-specific fusion protein antagonist;(b) 5-40 mM of a buffer;
(c) 0.01-5% of an organic co-solvent; and (d) a stabilizer or 30-150 mM of a tonicity agent, wherein the VEGF-specific fusion protein antagonist represents at least 90% of the total weight of protein in the composition.",After,No,https://patents.google.com/patent/US9580489B2/en?oq=US9580489
Eylea,US9636400 ,Regeneron,Macular Degeneration,Biologic,8,3/25/2005,5/10/2016,5/2/2017,3/22/2026,Active,Formulation / Combination,"The patent claims cover a formulation comprising: 5-200 mg/mL of a VEGF-specific fusion protein antagonist; 1-50 mM of a buffer; 25-150 mM or 0.5-30% of a stabilizer and 0.0005-5% of a polysorbate, wherein VEGF-specific fusion protein antagonist represents at least 90% of the total weight of protein in the formulation.",After,No,https://patents.google.com/patent/US9636400B2/en?oq=US9636400+
Eylea,US9669069B2,Regeneron,Macular Degeneration,Biologic,5,1/13/2011,12/17/2015,6/6/2017,1/11/2032,Active,Method of Treatment,"The patent claims cover a  method for treating an angiogenic eye disorder in a patient,comprising sequentially administering to the patient a single initial dose of a VEGF antagonist, followed by one or more secondary doses of the VEGF antagonist, followed by one or more tertiary doses of the VEGF antagonist; wherein each secondary dose is administered 2 to 4 weeks after the immediately preceding dose; and wherein each tertiary dose is administered on an as-needed/pro re nata (PRN) basis.",After,Yes,https://patents.google.com/patent/US9669069B2/en?oq=US9669069B2
Eylea,US9708386 ,Regeneron,Macular Degeneration,Biologic,2,6/8/1999,8/11/2015,7/18/2017,5/23/2020,Expired,Product,"The patent claims cover a chimeric polypeptide capable of antagonizing vascular endothelial growth factor (VEGF) activity with a modified extracellular binding domain that exhibits ""improved pharmacokinetic properties.",After,No,https://patents.google.com/patent/US9708386B2/en?oq=US9708386+
Eylea,US9816110B2,Regeneron,Macular Degeneration,Biologic,24,10/23/2014,10/21/2015,11/14/2017,10/21/2035,Active,Product,"The patent claims cover an isolated cell comprising an exogenous nucleic acid integrated within a locus of the genome of the cell, wherein the locus comprises a nucleotide sequence selected from SEQ ID NO:1 or SEQ ID NO: 4.",After,Yes,https://patents.google.com/patent/US9816110B2/en?oq=US9816110B2
Eylea,US9914763 ,Regeneron,Macular Degeneration,Biologic,6,6/16/2006,4/11/2016,3/13/2018,7/8/2027,Active,Formulation / Combination,"The patent claims cover a prefilled glass syringe suitable for intravitreal administration containing a stable ophthalmic formulation, comprising:
a vascular endothelial growth factor (VEGF) antagonist, an organic co-solvent, a buffer, and a stabilizing agent. ",After,No,https://patents.google.com/patent/US9914763B2/en?oq=US9914763+
Eylea,US9932605B2,Regeneron,Macular Degeneration,Biologic,23,6/4/2007,12/20/2016,4/3/2018,6/4/2028,Active,Product,"The patent claims cover an isolated cell comprising at least one exogenous nucleic acid integrated within, or 5′ or 3′ to, an expression-enhancing expression and stability region (EESYR) sequence, wherein the EESYR sequence is selected from the group consisting of SEQ ID NOS: 1-5.",After,No,https://patents.google.com/patent/US9932605B2/en?oq=US9932605B2
Humira,US6416757 ,Peptide Technology / Peptech/ Arana Therapeutics,Arthritis,Biologic,1,8/7/1989,7/30/1999,7/9/2002,8/7/2010,Expired,Product,"The patent claims cover an antibody or fragment that binds to 4 specified amino acid sequences of TNFa, preventing TNFa binding to the receptor.",Before,No,https://patents.google.com/patent/US6416757B1/en?oq=US6416757+
Humira,US6448380,Peptide Technology / Peptech/ Arana Therapeutics,Arthritis,Biologic,1,8/7/1989,12/13/2000,9/10/2002,8/7/2010,Expired,Product," The patent claims cover an antibody or fragment that binds to TNFa in 4  specified regions, preventing TNFa binding to the receptor. ",Before,No,https://patents.google.com/patent/US6448380B2/en?oq=US6448380
Humira,US6451983,Peptide Technology / Peptech/ Arana Therapeutics,Arthritis,Biologic,1,8/7/1989,12/13/2000,9/17/2002,8/7/2010,Expired,Product,"The patent claims cover an antibody or fragment that binds to TNFa in 4 specified"" regions, preventing TNFa binding to the receptor.",Before,No,https://patents.google.com/patent/US6451983B2/en?oq=US6451983
Humira,US6498237 ,Peptide Technology / Peptech/ Arana Therapeutics,Arthritis,Biologic,1,8/7/1989,12/13/2000,12/24/2002,8/7/2010,Expired,Product,"The patent claims cover an antibody or fragment that binds to TNFa in 3 specified regions, preventing TNFa binding to the receptor. ",Before,No,https://patents.google.com/patent/US6498237B2/en?oq=US6498237+
Humira,US6593458,Peptide Technology / Peptech/ Arana Therapeutics,Arthritis,Biologic,1,8/7/1989,12/13/2000,7/15/2003,8/7/2010,Expired,Product, The patent claims cover any antibody or fragment thereof that binds to a single 20-AA sequence of TNFa.,Before,No,https://patents.google.com/patent/US6593458B1/en?oq=US6593458
Humira,US7517963,Peptide Technology / Peptech/ Arana Therapeutics,Arthritis,Biologic,1,8/7/1989,1/5/2006,4/14/2009,8/7/2010,Expired,Product,"The patent claims cover an isolated antibody or fragment thereof that specifically binds to mature human TNF-α, wherein the antibody or fragment thereof competitively inhibits MAb 53 (ECACC Accession No. 90012433) for specific binding to mature human TNF-α and, wherein when the antibody or fragment thereof binds mature human TNF-α, the induction of tumor fibrin deposition is unaffected, and the induction of endothelial procoagulant activity, cytotoxicity, tumor regression and tumor receptor binding to TNF-α are inhibited. ",After,No,https://patents.google.com/patent/US7517963B2/en?oq=US7517963
Humira,US7544782,Peptide Technology / Peptech/ Arana Therapeutics,Arthritis,Biologic,1,8/7/1989,2/23/2006,6/9/2009,8/7/2010,Expired,Product,"The patent claims cover an isolated antibody or fragment thereof that specifically binds to mature human TNF-α, wherein the antibody or fragment thereof competitively inhibits MAb 54 (ECACC Accession No. 89083103) for specific binding to mature human TNF-α and, wherein when the antibody or fragment thereof binds mature human TNF-α, the induction of endothelial procoagulant, induction of tumor fibrin deposition, cytotoxicity, tumor regression and tumor receptor binding activities are inhibited.",After,No,https://patents.google.com/patent/US7544782B2/en?oq=US7544782
Humira,US7528237,Peptide Technology / Peptech/ Arana Therapeutics,Arthritis,Biologic,1,8/7/1989,4/19/2007,5/5/2009,8/7/2010,Expired,Product,"The patent claims cover an antibody isolated antibody or fragment thereof that specifically binds to mature human TNF-α, wherein when the antibody or fragment thereof binds mature human TNF-α, the induction of endothelial procoagulant activity is inhibited, tumor receptor binding isunaffected; andwherein the antibody or fragment thereof competitively inhibits sheep anti-sera raised against a TNF-α peptide for specific binding to mature human TNF-α,wherein the TNF-α peptide is a peptide consisting of residues Val1-Arg2-Ser3-Ser4-Ser5-Arg6-Thr7-Pro8-Ser9-Asp10-Lys11-Pro12-Val13-Ala14-His15-Val16-Val17-Ala18 (peptide 301) of mature human TNF. ",After,No,https://patents.google.com/patent/US7528237B2/en?oq=US7528237
Humira,US7553641,Peptide Technology / Peptech/ Arana Therapeutics,Arthritis,Biologic,1,8/7/1989,6/7/2007,6/30/2009,8/7/2010,Expired,Method of Production / Process,"The patent claims cover a cell line producing an antibody or fragment thereof, wherein the antibody or fragment thereof specifically binds to mature human TNF-α.",After,No,https://patents.google.com/patent/US7553641B2/en?oq=US7553641
Humira,US7605233 ,Peptide Technology / Peptech/ Arana Therapeutics,Arthritis,Biologic,1,8/7/1989,6/11/2007,10/20/2009,8/7/2010,Expired,Product,"The patent claims cover an  isolated antibody or fragment thereof that specifically binds to mature human TNF-α, wherein the antibody or fragment thereof competitively inhibits MAb 42 (ECACC Accession No. 89080304) for specific binding to mature human TNF-α and, wherein when the antibody or fragment thereof binds mature human TNF-α, the induction of endothelial procoagulant activity is inhibited, and the cytotoxicity, tumor regression and tumor receptor binding to TNF-α are not effected.",After,No,https://patents.google.com/patent/US7605233B2/en?oq=US7605233+
Humira,US5959087,Peptide Technology / Peptech/ Arana Therapeutics,Arthritis,Biologic,1,8/7/1989,3/17/1997,9/28/1999,2/18/2012,Expired,Product,"The patent claims cover an  antibody which specially binds to human TNF-α, the antibody being characterized in that when it binds to TNF-α, the following biological activities of the TNF-α are inhibited: a) tumor regression; b) induction of endothelial procoagulant; c) induction of tumor fibrin deposition; d) cytotoxicity; and
c) receptor binding the antibody being selected from the group consisting of MAb 1 (ECACC 89080301), MAb 54 (ECACC 89083103) and MAb 47 (ECACC 89121402).",Before,No,https://patents.google.com/patent/US5959087A/en?oq=US5959087
Humira,US5644034,Peptide Technology / Peptech/ Arana Therapeutics,Arthritis,Biologic,1,8/7/1989,11/23/1994,7/1/1997,7/1/2014,Expired,Product,"The patent claims cover an antibody which specifically binds to human TNF-α, the antibody being characterized in that when it binds to TNF-α, the induction of endothelial procoagulant activity of the TNF-α is inhibited; the induction of tumour fibrin deposition and tumour regression activities of the TNF-α are enhanced; and the cytotoxicity and receptor binding activities of the TNF-α are unaffected.",Before,No,https://patents.google.com/patent/US5644034A/en?oq=US5644034
Humira,US6258562 ,BASF / Abbott / AbbVie,Arthritis,Biologic,2,2/9/1996,2/10/1997,7/10/2001,2/9/2016,Expired,Method of Production / Process,"The patent claims cover nucleic acid molecules that encode for the Light Chain and Heavy Chain antibody regions. Also claims expression vectors, host cells, and expression of antibody.",Before,No,https://patents.google.com/patent/US6258562B1/en?oq=US6258562+
Humira,US6509015,BASF / Abbott / AbbVie,Arthritis,Biologic,2,2/9/1996,3/31/2000,1/21/2003,2/9/2016,Expired,Method of Treatment,"The patent claims cover a method for inhibiting human TNFα activity comprising contacting human TNFα with an antibody such that human TNFα activity is inhibited, wherein the antibody is an isolated human antibody, or an antigen-binding portion thereof, that dissociates from human TNFα with a Kd of 1×10−8 M or less and a Koff rate constant of 1×10−3 s−1 or less, both determined by surface plasmon resonance, and neutralizes human TNFα cytotoxicity in a standard in vitro L929 assay with an IC50 of 1×10−7 M or less.",Before,No,https://patents.google.com/patent/US6509015B1/en?oq=US6509015
Humira,US7588761,BASF / Abbott / AbbVie,Arthritis,Biologic,2,2/9/1996,9/21/2005,9/15/2009,2/9/2016,Expired,Formulation / Combination,"The patent claims cover a  composition comprising a biodegradable, biocompatible polymer and a human antibody, or an antigen-binding portion thereof, that dissociates from human TNFα with a Kd of 1×10−8 M or less and a Koff rate constant of 1×10−3s−1 or less, both determined by surface plasmon resonance, and neutralizes human TNFα cytotoxicity in a standard in vitro L929 assay with an IC50 of 1×10−7 M or less, wherein the biodegradable, biocompatible polymer provides controlled release.",After,No,https://patents.google.com/patent/US7588761B2/en?oq=US7588761
Humira,US7541031,BASF / Abbott / AbbVie,Arthritis,Biologic,2,2/9/1996,4/17/2007,6/2/2009,2/9/2016,Expired,Method of Treatment,"The patent claims cover a method for treating a subject suffering from rheumatoid arthritis, comprising administering to the subject both an antibody and methotrexate, such that the rheumatoid arthritis is treated, wherein the antibody is an isolated human antibody, or an antigen-binding portion thereof, that dissociates from human TNFα with a Kd of 1×10−8 M or less and a Koff rate constant of 1×10−3 s−1 or less, both determined by surface plasmon resonance, neutralizes human TNFα cytotoxicity in a standard in vitro L929 assay with an IC50 of 1×10−7 M or less, and neutralizes TNFα-induced cellular activation in a standard in vitro assay for TNRα-induced ELAM-1 expression on human umbilical vein endothelial cells (HUVEC).",After,No,https://patents.google.com/patent/US7541031B2/en?oq=US7541031
Humira,US8206714,BASF / Abbott / AbbVie,Arthritis,Biologic,2,2/9/1996,2/11/2009,6/26/2012,2/9/2016,Expired,Method of Treatment,"The patent claims cover a method for inhibiting human TNFα activity in a human subject suffering from rheumatoid arthritis comprising administering to the human subject an interleukin-17 inhibitor and an isolated human anti-TNFα antibody, or an antigen binding portion thereof, such that human TNFα activity in the human subject is inhibited, wherein the anti-TNFα antibody, or antigen binding portion thereof, dissociates from human TNFα with a Kd of 1×10−8 M or less and a Koff rate constant of 1×10−3 s−1 or less, both determined by surface plasmon resonance, and neutralizes human TNFα cytotoxicity in a standard in vitro L929 assay with an IC50 of 1×10−7 M or less.",After,No,https://patents.google.com/patent/US8206714B2/en?oq=US8206714
Humira,US8197813,BASF / Abbott / AbbVie,Arthritis,Biologic,2,2/9/1996,3/10/2009,6/12/2012,2/9/2016,Expired,Product,"The patent claims cover an isolated human antibody, or an antigen-binding portion thereof, that dissociates from human TNFα (hTNFα) with a Kd of 1×10−8 M or less and a Koff rate constant of 1×10−3 s−1 or less, both determined by surface plasmon resonance, and inhibits human TNFα-induced expression of ELAM-1 on human umbilical vein endothelial cells.",After,No,https://patents.google.com/patent/US8197813B2/en?oq=US8197813
Humira,US8372400,BASF / Abbott / AbbVie,Arthritis,Biologic,2,2/9/1996,10/13/2009,2/12/2013,2/9/2016,Expired,Method of Treatment,"The patent claims cover a  method for treating rheumatoid arthritis in a human subject comprising administering to the human subject both a recombinant, isolated human anti-TNFα antibody, or an antigen-binding portion thereof, and a non-steroidal anti-inflammatory drug (NSAID), such that rheumatoid arthritis is treated, wherein the antibody, or antigen-binding portion thereof, dissociates from human TNFα with a Kd of 1×10−8 M or less and a Koff rate constant of 1×10−3 s−1 or less, both determined by surface plasmon resonance, and neutralizes human TNFα cytotoxicity in a standard in vitro L929 assay with an IC50 of 1×10−7 M or less.",After,No,https://patents.google.com/patent/US8372400B2/en?oq=US8372400
Humira,US8414894 ,BASF / Abbott / AbbVie,Arthritis,Biologic,2,2/9/1996,12/30/2011,4/9/2013,2/9/2016,Expired,Product,"The patent claims cover a method for inhibiting human TNFα activity in vitro comprising contacting human TNFα with an isolated antibody such that human TNFα activity is inhibited, wherein the antibody is an isolated human antibody, or an antigen-binding portion thereof, that dissociates from human TNFα with a Kd of 1×10−8 M or less and a Koff rate constant of 1×10−3 s−1 or less, both determined by surface plasmon resonance, and neutralizes human TNFα cytotoxicity in a standard in vitro L929 assay with an IC50 of 1×10−7 M or less.",After,No,https://patents.google.com/patent/US8414894B2/en?oq=US8414894+
Humira,US8372401,BASF / Abbott / AbbVie,Arthritis,Biologic,2,2/9/1996,5/8/2012,2/12/2013,2/9/2016,Expired,Product,"The patent claims cover an  isolated human anti-TNFa antibody, or an antigen-binding portion thereof, comprising a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 1 and a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 2, wherein the antibody, or antigen-binding portion thereof, comprises an IgG1 heavy chain constant region and a kappa light chain constant region.",After,No,https://patents.google.com/patent/US8372401B2/en?oq=US8372401
Humira,US8753633,BASF / Abbott / AbbVie,Arthritis,Biologic,2,2/9/1996,6/15/2012,6/17/2014,2/9/2016,Expired,Product,"The patent claims cover a method of treating a human subject having an inflammatory bowel disease, said method comprising administering an isolated human anti-TNFα antibody, or an antigen-binding portion thereof, to the subject, wherein the antibody, or antigen-binding portion thereof, comprises a light chain variable region (LCVR) comprising a complementarity determining region 3 (CDR3) domain comprising the amino acid sequence as set forth in SEQ ID NO: 3, or modified from SEQ ID NO: 3 by a single alanine substitution at position 1, 4, 5, 7 or 8, a CDR2 domain comprising the amino acid sequence as set forth in SEQ ID NO: 5, and a CDR1 domain comprising the amino acid sequence as set forth in SEQ ID NO: 7,a heavy chain variable region (HCVR) comprising a CDR3 domain comprising the amino acid sequence as set forth in SEQ ID NO: 4, or modified from SEQ ID NO: 4 by a single alanine substitution at position 2, 3, 4, 5, 6, 8, 9, 10 or 11, a CDR2 domain comprising the amino acid sequence as set forth in SEQ ID NO: 6, and a CDR1 domain comprising the amino acid sequence as set forth in SEQ ID NO: 8, andan IgG1 or an IgG4 heavy chain constant region.",After,No,https://patents.google.com/patent/US8753633B2/en?oq=US8753633
Humira,US6090382,BASF / Abbott / AbbVie,Arthritis,Biologic,2,2/9/1996,2/9/1996,7/18/2000,12/31/2016,Expired,Product,"The patent claims cover a TNFa binding antibody by its pharmacokinetic parameters of Kd, Koff, and IC50. ",Before,No,https://patents.google.com/patent/US6090382A/en?oq=US6090382
Humira,US7223394 ,BASF / Abbott / AbbVie,Arthritis,Biologic,2,2/9/1996,3/7/2001,5/29/2007,3/16/2019,Expired,Method of Treatment,"The patent claims cover a method for treating a subject suffering from rheumatoid arthritis, comprising administering to the subject both an antibody and methotrexate, such that the rheumatoid arthritis is treated, wherein the antibody is an isolated human antibody, or an antigen-binding portion thereof, tat dissociates from human TNFα with a Kd of 1×10−8 M or less and a Koff rate constant of 1×10−3 s−1 or less, both determined by surface plasmon resonance, and neutralizes human TNFα cytotoxicity in a standard in vitro L929 assay with an IC50 of 1×10−7 M or less.",Before,No,https://patents.google.com/patent/US7223394B2/en?oq=US7223394+
Humira,US8911737,Abbott / AbbVie,Arthritis,Biologic,3,6/8/2001,4/18/2014,12/16/2014,6/5/2022,Expired,Method of Treatment,"The patent claims cover a method for treating Crohn's disease in a human subject, comprising administering subcutaneously to a human subject having Crohn's disease a total body dose of 40 mg of a human anti-TNFα antibody once every 13-15 days for a time period sufficient to treat Crohn's disease, wherein the anti-TNFα antibody comprises an IgG1 heavy chain constant region; a variable light (“VL”) chain region comprising a CDR1 having the amino acid sequence of SEQ ID NO:7, a CDR2 having the amino acid sequence of SEQ ID NO:5, and a CDR3 having the amino acid sequence of SEQ ID NO:3; and a variable heavy (“VH”) chain region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 8, a CDR2 having the amino acid sequence of SEQ ID NO:6 and a CDR3 having the amino acid sequence of SEQ ID NO:4.",After,Yes,https://patents.google.com/patent/US8911737B2/en?oq=US8911737
Humira,US8974790,Abbott / AbbVie,Arthritis,Biologic,3,6/8/2001,5/30/2014,3/10/2015,6/5/2022,Expired,Method of Treatment,"The patent claims cover a method for treating ulcerative colitis in a human subject, comprising administering subcutaneously to a human subject having ulcerative colitis a total body dose of 40 mg of a human anti-TNFα antibody once every 13-15 days for a time period sufficient to treat the ulcerative colitis, wherein the anti-TNFα antibody comprises an IgG1 heavy chain constant region; a variable light (“VL”) chain region comprising a CDR1 having the amino acid sequence of SEQ ID NO:7, a CDR2 having the amino acid sequence of SEQ ID NO:5, and a CDR3 having the amino acid sequence of SEQ ID NO:3; and a variable heavy (“VH”) chain region comprising a CDR1 having the amino acid sequence of SEQ ID NO:8, a CDR2 having the amino acid sequence of SEQ ID NO:6and a CDR3 having the amino acid sequence of SEQ ID NO:4.",After,Yes,https://patents.google.com/patent/US8974790B2/en?oq=US8974790
Humira,US9073987,Abbott / AbbVie,Arthritis,Biologic,3,6/8/2001,5/30/2014,7/7/2015,6/5/2022,Expired,Method of Treatment,"The patent claims cover a method of reducing signs and symptoms in a patient with moderately to severely active rheumatoid arthritis, comprising:administering to said patient a total body dose of 40 mg of a human anti-TNFα antibody,
wherein the dose is administered subcutaneously from a 40 mg dosage unit form once every 13-15 days, and
wherein the anti-TNFα antibody comprises an IgG1 heavy chain constant region; a variable light (“VL”) chain region comprising a CDR1 having the amino acid sequence of SEQ ID NO:7, a CDR2 having the amino acid sequence of SEQ ID NO:5, and a CDR3 having the amino acid sequence of SEQ ID NO:3; and a variable heavy (“VH”) chain region comprising a CDR1 having the amino acid sequence of SEQ ID NO:8, a CDR2 having the amino acid sequence of SEQ ID NO:6 and a CDR3 having the amino acid sequence of SEQ ID NO:4.",After,No,https://patents.google.com/patent/US9073987B2/en?oq=US9073987
Humira,US8992926,Abbott / AbbVie,Arthritis,Biologic,3,6/8/2001,9/26/2014,3/31/2015,6/5/2022,Expired,Method of Treatment,"The patent claims cover a method for treating rheumatoid spondylitis in a human subject, comprising administering subcutaneously to a human subject having rheumatoid spondylitis a total body dose of 40 mg of a human anti-TNFα antibody once every 13-15 days for a time period sufficient to treat the rheumatoid spondylitis, wherein the anti-TNFα antibody comprises an IgG1 heavy chain constant region; a variable light (“VL”) chain region comprising a CDR1 having the amino acid sequence of SEQ ID NO:7, a CDR2 having the amino acid sequence of SEQ ID NO:5, and a CDR3 having the amino acid sequence of SEQ ID NO:3; and a variable heavy (“VH”) chain region comprising a CDR1 having the amino acid sequence of SEQ ID NO:8, a CDR2 having the amino acid sequence of SEQ ID NO:6 and a CDR3 having the amino acid sequence of SEQ ID NO:4.",After,Yes,https://patents.google.com/patent/US8992926B2/en?oq=US8992926
Humira,US9017680,Abbott / AbbVie,Arthritis,Biologic,3,6/8/2001,11/14/2014,4/28/2015,6/5/2022,Expired,Method of Treatment,"The patent claims cover a method of reducing signs and symptoms in a patient with moderately to severely active rheumatoid arthritis, comprising: administering to said patient, in combination with methotrexate, a human anti-TNFα antibody,wherein the human anti-TNFα antibody is administered subcutaneously in a total body dose of 40 mg once every 13-15 days, andwherein the anti-TNFα antibody comprises an IgG1 heavy chain constant region; a variable light (“VL”) chain region comprising a CDR1 having the amino acid sequence of SEQ ID NO:7, a CDR2 having the amino acid sequence of SEQ ID NO:5, and a CDR3 having the amino acid sequence of SEQ ID NO:3; and a variable heavy (“VH”) chain region comprising a CDR1 having the amino acid sequence of SEQ ID NO:8, a CDR2 having the amino acid sequence of SEQ ID NO:6 and a CDR3 having the amino acid sequence of SEQ ID NO:4.",After,No,https://patents.google.com/patent/US9017680B2/en?oq=US9017680
Humira,US9546212,Abbott / AbbVie,Arthritis,Biologic,3,6/8/2001,6/10/2016,1/17/2017,6/5/2022,Expired,Method of Treatment,"The patent claims cover a method for treating rheumatoid arthritis in a human subject, comprising administering subcutaneously to a human subject having rheumatoid arthritis a total body dose of 40 mg of a human anti-TNFα antibody once every 13-15 days for a time period sufficient to treat the rheumatoid arthritis, wherein the anti-TNFα antibody comprises: an IgG1 heavy chain constant region; a variable light (“VL”) chain region comprising a CDR1 having the amino acid sequence of SEQ ID NO:7, a CDR2 having the amino acid sequence of SEQ ID NO:5, and a CDR3 having the amino acid sequence of SEQ ID NO:3; and a variable heavy (“VH”) chain region comprising a CDR1 having the amino acid sequence of SEQ ID NO:8, a CDR2 having the amino acid sequence of SEQ ID NO:6 and a CDR3 having the amino acid sequence of SEQ ID NO:4, wherein the human subject achieves an ACR20.",After,Yes,https://patents.google.com/patent/US9546212B2/en?oq=US9546212
Humira,US8932591,Abbott / AbbVie,Arthritis,Biologic,7,8/16/2002,5/15/2012,1/13/2015,8/16/2022,Active,Formulation / Combination,"The patent claims cover a  liquid aqueous pharmaceutical formulation having a pH of about 4.5 to about 6, comprising an isolated human IgG1 anti-human Tumor Necrosis Factor alpha (hTNFα) antibody, or an antigen-binding portion thereof, at a concentration of 35-115 mg/ml, a polyol, a surfactant, and a buffer system comprising citrate and phosphate, wherein the antibody, or antigen-binding portion thereof, comprises a light chain variable region comprising a CDR1 domain comprising the amino acid sequence set forth in SEQ ID NO:7; a CDR2 domain comprising the amino acid sequence set forth in SEQ ID NO:5; and a CDR3 domain comprising the amino acid sequence set forth in SEQ ID NO:3; and a heavy chain variable region comprising a CDR1 domain comprising the amino acid sequence set forth in SEQ ID NO:8; a CDR2 domain comprising the amino acid sequence set forth in SEQ ID NO:6; and a CDR3 domain comprising the amino acid sequence set forth in SEQ ID NO:4.",After,No,https://patents.google.com/patent/US8932591B2/en?oq=US8932591
Humira,US8795670 ,Abbott / AbbVie,Arthritis,Biologic,7,8/16/2002,11/27/2013,8/5/2014,8/16/2022,Active,Formulation / Combination,"The patent claims cover a stable liquid aqueous pharmaceutical formulation comprising (a) a human IgG1 anti-human Tumor Necrosis Factor alpha (TNFα) antibody, or an antigen-binding portion thereof, at a concentration of 45 to 105 mg/ml, (b) a polyol, (c) a polysorbate at a concentration of 0.1 to 10 mg/ml, and (d) a buffer system comprising histidine and having a pH of 4.5 to 7.0,wherein the antibody comprises the light chain variable region and the heavy chain variable region of D2E7.",After,No,https://patents.google.com/patent/US8795670B2/en?oq=US8795670+
Humira,US8802100,Abbott / AbbVie,Arthritis,Biologic,7,8/16/2002,11/27/2013,8/12/2014,8/16/2022,Active,Formulation / Combination,"The patent claims cover a stable liquid aqueous pharmaceutical formulation comprising (a) a human IgG1 anti-human Tumor Necrosis Factor alpha (TNFα) antibody, or an antigen-binding portion thereof, at a concentration of 45 to 150 mg/ml, (b) a polyol, (c) a polysorbate at a concentration of 0.1 to 10 mg/ml, and(d) a buffer system having a pH of 4.5 to 7.0, wherein the antibody comprises the light chain variable region and the heavy chain variable region of D2E7.",After,No,https://patents.google.com/patent/US8802100B2/en?oq=US8802100
Humira,US8802101,Abbott / AbbVie,Arthritis,Biologic,7,8/16/2002,11/27/2013,8/12/2014,8/16/2022,Active,Formulation / Combination,"The patent claims cover a stable liquid aqueous pharmaceutical formulation comprising (a) a human IgG1 anti-human Tumor Necrosis Factor alpha (TNFα) antibody, or an antigen-binding portion thereof, at a concentration of 45 to 105 mg/ml, (b) a polyol, (c) a polysorbate at a concentration of 0.1 to 10 mg/ml, and (d) a buffer system comprising acetate and having a pH of 4.5 to 7.0, wherein the antibody comprises the light chain variable region and the heavy chain variable region of D2E7.",After,No,https://patents.google.com/patent/US8802101B2/en?oq=US8802101
Humira,US8802102,Abbott / AbbVie,Arthritis,Biologic,7,8/16/2002,1/3/2014,8/12/2014,8/16/2022,Active,Formulation / Combination,"The patent claims cover a  stable liquid aqueous pharmaceutical formulation comprising (a) a human IgG1 anti-human Tumor Necrosis Factor alpha (TNFα) antibody, or an antigen-binding portion thereof, at a concentration of 45 to 105 mg/ml, (b) a polyol, (c) a polysorbate at a concentration of 0.1 to 10 mg/ml, and (d) a buffer system comprising succinate and having a pH of 4.5 to 7.0, wherein the antibody comprises the light chain variable region and the heavy chain variable region of D2E7.",After,No,https://patents.google.com/patent/US8802102B2/en?oq=US8802102
Humira,US8940305,Abbott / AbbVie,Arthritis,Biologic,7,8/16/2002,7/2/2014,1/27/2015,8/16/2022,Active,Formulation / Combination,"The patent claims cover a stable liquid aqueous pharmaceutical formulation comprising (a) a human IgG1 anti-human Tumor Necrosis Factor alpha (TNFα) antibody, or an antigen-binding portion thereof, at a concentration of 20 to 150 mg/ml, (b) a polyol, (c) a surfactant, and (d) a buffer system comprising gluconate and having a pH of 4.0 to 8.0,
wherein the antibody comprises the light chain variable region and the heavy chain variable region of D2E7.",After,No,https://patents.google.com/patent/US8940305B2/en?oq=US8940305
Humira,US8911741,Abbott / AbbVie,Arthritis,Biologic,7,8/16/2002,7/2/2014,12/16/2014,8/16/2022,Active,Formulation / Combination,"The patent claims cover a stable liquid aqueous pharmaceutical formulation comprising (a) a human IgG1 anti-human Tumor Necrosis Factor alpha (TNFα) antibody, or an antigen-binding portion thereof, at a concentration of 20 to 150 mg/ml, (b) a polyol, (c) a polysorbate, and (d) a buffer system comprising phosphate and having a pH of 4.0 to 8.0,
wherein the antibody comprises the light chain variable region and the heavy chain variable region of D2E7.",After,No,https://patents.google.com/patent/US8911741B2/en?oq=US8911741
Humira,US8916157,Abbott / AbbVie,Arthritis,Biologic,7,8/16/2002,8/6/2014,12/23/2014,8/16/2022,Active,Formulation / Combination,"The patent claims cover a stable liquid aqueous pharmaceutical formulation comprising (a) a human IgG1 anti-human Tumor Necrosis Factor alpha (TNFα) antibody, or an antigen-binding portion thereof, at a concentration of 20 to 150 mg/ml, (b) a tonicity agent, (c) a surfactant, and (d) a buffer system having a pH of 4.0 to 8.0, wherein the antibody comprises the light chain variable region and the heavy chain variable region of D2E7.",After,No,https://patents.google.com/patent/US8916157B2/en?oq=US8916157
Humira,US8916158,Abbott / AbbVie,Arthritis,Biologic,7,8/16/2002,8/6/2014,12/23/2014,8/16/2022,Active,Formulation / Combination,"The patent claims cover a stable liquid aqueous pharmaceutical formulation comprising (a) a human IgG1 anti-human Tumor Necrosis Factor alpha (TNFα) antibody, or an antigen-binding portion thereof, at a concentration of 20 to 150 mg/ml, (b) a polyol, (c) a surfactant, and (d) a buffer system having a pH of 4 to 8, wherein the antibody comprises the light chain variable region and the heavy chain variable region of D2E7.",After,No,https://patents.google.com/patent/US8916158B2/en?oq=US8916158
Humira,US9114166,Abbott / AbbVie,Arthritis,Biologic,7,8/16/2002,12/2/2014,8/25/2015,8/16/2022,Active,Formulation / Combination,"The patent claims cover a stable liquid aqueous pharmaceutical formulation comprising: a human anti-human Tumor Necrosis Factor alpha (TNFα) IgG1 antibody at a concentration of 50 mg/ml, wherein the antibody comprises the light chain variable region and the heavy chain variable region of D2E7, and a buffer system;
wherein the formulation is isotonic, suitable for single-use subcutaneous injection, and has a pH of 4.0 to 8.0.",After,No,https://patents.google.com/patent/US9114166B2/en?oq=US9114166
Humira,US9220781,Abbott / AbbVie,Arthritis,Biologic,7,8/16/2002,7/14/2015,12/29/2015,8/16/2022,Active,Formulation / Combination,"The patent claims cover a stable liquid aqueous pharmaceutical formulation comprising (a) a human IgG1 anti-human Tumor Necrosis Factor alpha (TNFα) antibody at a concentration of 50 mg/ml, (b) a polyol, (c) a polysorbate, and
(d) a buffer system comprising an organic acid and having a pH of 4 to 8, wherein the antibody is D2E7, and wherein the formulation is suitable for subcutaneous injection.

",After,No,https://patents.google.com/patent/US9220781B2/en?oq=US9220781
Humira,US9272041,Abbott / AbbVie,Arthritis,Biologic,7,8/16/2002,8/14/2015,3/1/2016,8/16/2022,Active,Formulation / Combination,"The patent claims cover a stable liquid aqueous pharmaceutical formulation comprising (a) a human IgG1 anti-human Tumor Necrosis Factor alpha (TNFα) antibody at a concentration of 50 mg/ml, (b) a polyol, (c) a polysorbate, and
(d) a buffer system comprising acetate and having a pH of 4 to 8, wherein the antibody is D2E7, and wherein the formulation is suitable for subcutaneous injection.",After,No,https://patents.google.com/patent/US9272041B2/en?oq=US9272041
Humira,US9272042 ,Abbott / AbbVie,Arthritis,Biologic,7,8/16/2002,8/14/2015,3/1/2016,8/16/2022,Active,Formulation / Combination,"The patent claims cover a stable liquid aqueous pharmaceutical formulation comprising (a) a human IgG1 anti-human Tumor Necrosis Factor alpha (TNFα) antibody at a concentration of 50 mg/ml, (b) a polyol, (c) a polysorbate, and
(d) a buffer system comprising phosphate and having a pH of 4 to 8, wherein the antibody is D2E7, and
wherein the formulation is suitable for subcutaneous injection.",After,No,https://patents.google.com/patent/US9272042B2/en?oq=US9272042+
Humira,US9289497,Abbott / AbbVie,Arthritis,Biologic,7,8/16/2002,8/14/2015,3/22/2016,8/16/2022,Active,Formulation / Combination,"The patent claims cover a  stable liquid aqueous pharmaceutical formulation comprising(a) a human IgG1 anti-human Tumor Necrosis Factor alpha (TNFα) antibody at a concentration of 50 mg/ml,(b) a polyol,(c) a polysorbate, and
(d) a buffer system comprising gluconate and having a pH of 4 to 8,wherein the antibody is D2E7, and wherein the formulation is suitable for subcutaneous injection",After,No,https://patents.google.com/patent/US9289497B2/en?oq=US9289497
Humira,US9295725,Abbott / AbbVie,Arthritis,Biologic,7,8/16/2002,8/14/2015,3/29/2016,8/16/2022,Active,Formulation / Combination,"The patent claims cover a stable liquid aqueous pharmaceutical formulation comprising(a) a human IgG1 anti-human Tumor Necrosis Factor alpha (TNFα) antibody at a concentration of 50 mg/ml,(b) a polyol,(c) a polysorbate, and(d) a buffer system comprising succinate and having a pH of 4 to 8,wherein the antibody is D2E7, and wherein the formulation is suitable for subcutaneous injection.",After,No,https://patents.google.com/patent/US9295725B2/en?oq=US9295725
Humira,US9327032,Abbott / AbbVie,Arthritis,Biologic,7,8/16/2002,8/14/2015,5/3/2016,8/16/2022,Active,Formulation / Combination,"The patent claims cover a stable liquid aqueous pharmaceutical formulation comprising (a) a human IgG1 anti-human Tumor Necrosis Factor alpha (TNFα) antibody at a concentration of 50 mg/ml, (b) a polyol, (c) a polysorbate, and
(d) a buffer system comprising histidine and having a pH of 4 to 8, wherein the antibody is D2E7, and wherein the formulation is suitable for subcutaneous injection.",After,No,https://patents.google.com/patent/US9327032B2/en?oq=US9327032
Humira,US9302011,Abbott / AbbVie,Arthritis,Biologic,7,8/16/2002,10/15/2015,4/5/2016,8/16/2022,Active,Formulation / Combination,"The patent claims cover a stable liquid aqueous pharmaceutical formulation comprising (a) 50 mg/ml of a human IgG1 anti-human Tumor Necrosis Factor alpha (TNFα) antibody, wherein the antibody comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:1 and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 2; (b) a polyol; (c) a polysorbate; and (d) a buffer system comprising an organic acid;
wherein the formulation has a pH of 4 to 8, and wherein the formulation is suitable for subcutaneous injection.",After,No,https://patents.google.com/patent/US9302011B2/en?oq=US9302011
Humira,US9950066,Abbott / AbbVie,Arthritis,Biologic,7,8/16/2002,4/11/2016,4/24/2018,8/16/2022,Active,Formulation / Combination,"The patent claims cover a stable liquid aqueous pharmaceutical formulation comprising (a) a human IgG1 anti-human Tumor Necrosis Factor alpha (TNFα) antibody at a concentration of 50 mg/ml, (b) a polyol, (c) a polysorbate, and
(d) a buffer system comprising citrate and phosphate and having a pH of 4 to 8, wherein the antibody is D2E7, and
wherein the formulation is suitable for subcutaneous injection.",After,No,https://patents.google.com/patent/US9950066B2/en?oq=US9950066
Humira,US9732152,Abbott / AbbVie,Arthritis,Biologic,7,8/16/2002,1/27/2017,8/15/2017,8/16/2022,Active,Formulation / Combination,"The patent claims cover a stable liquid aqueous pharmaceutical formulation comprising(a) a human IgG1 anti-human Tumor Necrosis Factor alpha (TNFα) antibody at a concentration of 45-105 mg/ml,(b) a polyol,(c) a polysorbate, and
(d) a buffer system comprising histidine and having a pH of 4 to 8,wherein the antibody is D2E7, and wherein the formulation is suitable for subcutaneous injection.",After,No,https://patents.google.com/patent/US9732152B2/en?oq=US9732152
Humira,US9738714 ,Abbott / AbbVie,Arthritis,Biologic,7,8/16/2002,1/27/2017,8/22/2017,8/16/2022,Active,Formulation / Combination,"The patent claims cover a stable liquid aqueous pharmaceutical formulation comprising (a) a human IgG1 anti-human Tumor Necrosis Factor alpha (TNFα) antibody at a concentration of 45-105 mg/ml, (b) a polyol, (c) a polysorbate, and
(d) a buffer system comprising succinate and having a pH of 4 to 8, wherein the antibody is D2E7, and
wherein the formulation is suitable for subcutaneous injection.",After,No,https://patents.google.com/patent/US9738714B2/en?oq=US9738714
Humira,US9750808,Abbott / AbbVie,Arthritis,Biologic,7,8/16/2002,1/27/2017,9/5/2017,8/16/2022,Active,Formulation / Combination,"The patent claims cover a stable liquid aqueous pharmaceutical formulation comprising: a human anti-human Tumor Necrosis Factor alpha (TNFα) IgG1 antibody at a concentration of 45 to 105 mg/ml, wherein the antibody is D2E7, and a buffer system; wherein the formulation is isotonic, suitable for single-use subcutaneous injection, and has a pH of 4 to 8.",After,No,https://patents.google.com/patent/US9750808B2/en?oq=US9750808
Humira,US8906373,Abbott / AbbVie,Arthritis,Biologic,5,7/19/2002,4/30/2014,12/9/2014,7/18/2023,Active,Method of Treatment,"The patent claims cover a method of treatment of psoriasis in a patient with moderate to severe active psoriatic arthritis (PsA), comprising subcutaneously administering to said patient 40 mg adalimumab every other week, wherein said patient has ≧3 swollen and ≧3 tender joints prior to the treatment and has failed NSAID therapy, and wherein said patient achieves a 90% reduction of the Psoriasis Area and Severity Index Score (PASI 90) at week 24 of the treatment.",After,Yes,https://patents.google.com/patent/US8906373B2/en?oq=US8906373
Humira,US9067992 ,Abbott / AbbVie,Arthritis,Biologic,5,5/16/2005,12/8/2014,6/30/2015,7/18/2023,Active,Method of Treatment,"The patent claims cover a  method of treatment of moderate to severe active psoriatic arthritis in adult patients, wherein each said patient has ≧3 swollen and ≧3 tender joints prior to the treatment and has failed NSAID therapy, comprising subcutaneously administering to each said patient 40 mg of adalimumab every other week, wherein 23% of said patients achieve 70% reduction in American College of Rheumatology (ACR) score at week 24 of the treatment.",After,Yes,https://patents.google.com/patent/US9067992B2/en?oq=US9067992+
Humira,US9085620,Abbott / AbbVie,Arthritis,Biologic,5,7/19/2002,4/8/2015,7/21/2015,7/18/2023,Active,Method of Treatment,"The patent claims cover a method of administering adalimumab for treatment of psoriatic arthritis, comprising filling adalimumab into vessels and subcutaneously administering 40 mg of said adalimumab to a patient having psoriatic arthritis every other week.",After,Yes,https://patents.google.com/patent/US9085620B1/en?oq=US9085620
Humira,US9090689 ,Abbott / AbbVie,Arthritis,Biologic,5,7/19/2002,4/8/2015,7/28/2015,7/18/2023,Active,Method of Treatment,"The patent claims cover a  method of administering adalimumab for treatment of moderate to severe chronic plaque psoriasis, comprising filling adalimumab into vessels and subcutaneously administering 40 mg of said adalimumab to a patient having moderate to severe chronic plaque psoriasis every other week.",After,Yes,https://patents.google.com/patent/US9090689B1/en?oq=US9090689+
Humira,US8846046,Abbott / AbbVie,Arthritis,Biologic,5,10/24/2002,10/24/2003,9/30/2014,10/24/2023,Active,Method of Treatment,"The patent claims cover a method for treating arthritis comprising administering by injection to a subject an isolated fully human anti-TNFα antibody at a weekly dose of 0.1 mg/kg such that the arthritis is treated as demonstrable by mean arthritic score, wherein the anti-TNFα antibody is D2E7.",After,No,https://patents.google.com/patent/US8846046B2/en?oq=US8846046
Humira,US9085618 ,AbbVie,Arthritis,Biologic,11,10/18/2013,11/12/2013,7/21/2015,11/12/2023,Active,Method of Production / Process,"The patent claims cover a low acidic species composition comprising adalimumab, wherein the composition comprises less than 10% total acidic species of adalimumab and wherein less than 75% of the lysine variant species of the composition have zero C-terminal lysines (Lys 0), and wherein the acidic species of adalimumab are quantified based on the relative area percent of peaks that elute earlier than the main peak in a WCX-10 HPLC chromatogram of adalimumab wherein the WCX-10 HPLC chromatogram is generated using a first mobile phase of 10mM Sodium Phosphate dibasic (pH 7.5) and a second mobile phase of 10mM Sodium Phosphate dibasic, 500 mM Sodium Chloride (pH 5.5) and wherein the WCX-10 HPLC chromatogram is generated using detection at 280 nm.",After,Yes,https://patents.google.com/patent/US9085618B2/en?oq=US9085618+
Humira,US9266949 ,AbbVie,Arthritis,Biologic,11,10/18/2013,12/18/2014,2/23/2016,11/12/2023,Active,Method of Production / Process,The patent claims cover a method for producing a composition comprising an immunoglobulin comprising the 6 CDR domains of adalimumab.,After,Yes,https://patents.google.com/patent/US9266949B2/en?oq=US9266949+
Humira,US9315574,AbbVie,Arthritis,Biologic,11,10/18/2013,12/29/2014,4/19/2016,11/12/2023,Active,Method of Production / Process,The patent claims cover a method for producing a composition comprising an immunoglobulin comprising the 6 CDR domains of adalimumab.,After,Yes,https://patents.google.com/patent/US9315574B2/en?oq=US9315574
Humira,US9200069,AbbVie,Arthritis,Biologic,11,10/18/2013,2/4/2015,12/1/2015,11/12/2023,Active,Method of Production / Process,"The patent claims cover a method of making a pharmaceutical composition, comprising mixing (a) 25-100 mg of a low acidic species composition comprising adalimumab, wherein the low acidic species composition comprises less than 10% total acidic species of adalimumab, wherein the acidic species of adalimumab have a net negative charge relative to the adalimumab main species and the acidic species comprise species selected from the group consisting of charge variants, structure variants, fragmentation variants and any combinations thereof; wherein the acidic species of adalimumab do not include process-related impurities selected from the group consisting of host cell proteins, host cell nucleic acids, chromatographic materials and media components, and wherein said low acidic species adalimumab composition demonstrates increased cartilage penetration as compared to a non-low acidic species composition of adalimumab; and
(b) a pharmaceutically acceptable carrier, thereby making a pharmaceutical composition.",After,No,https://patents.google.com/patent/US9200069B2/en?oq=US9200069
Humira,US9200070,AbbVie,Arthritis,Biologic,11,10/18/2013,5/15/2015,12/1/2015,11/12/2023,Active,Formulation / Combination,"The patent claims cover a low acidic species adalimumab pharmaceutical composition suitable for administration to a human subject comprising40 mg of adalimumab wherein the low acidic species adalimumab pharmaceutical composition comprises less than 10% total acidic species of adalimumab, wherein the acidic species of adalimumab have a net negative charge relative to the adalimumab main species and the acidic species comprise species selected from the group consisting of charge variants, structure variants, fragmentation variants and any combinations thereof; wherein the acidic species of adalimumab do not include process-related impurities selected from the group consisting of host cell proteins, host cell nucleic acids, chromatographic materials and media components; and wherein said low acidic species adalimumab pharmaceutical composition demonstrates increased cartilage penetration as compared to a non-low acidic species composition of adalimumab; and a pharmaceutically acceptable carrier.",After,No,https://patents.google.com/patent/US9200070B2/en?oq=US9200070
Humira,US9522953,AbbVie,Arthritis,Biologic,11,10/18/2013,1/28/2016,12/20/2016,11/12/2023,Active,Device,"The patent claims cover a pre-filled syringe comprising a low acidic species composition comprising adalimumab, wherein the composition comprises less than 10% total acidic species of adalimumab, wherein the acidic species of adalimumab have a net negative charge relative to the adalimumab main species and the acidic species comprise species selected from the group consisting of charge variants, structure variants, fragmentation variants and any combinations thereof,
wherein the acidic species of adalimumab do not include process-related impurities selected from the group consisting of host cell proteins, host cell nucleic acids, chromatographic materials and media components, and wherein the % acidic species is determined using WCX-10 HPLC wherein the WCX-10 HPLC chromatogram is generated using a first mobile phase of 10 mM Sodium Phosphate dibasic (pH 7.5) and a second mobile phase of 10 mM Sodium Phosphate dibasic, 500 mM Sodium Chloride (pH 5.5) and wherein the WCX-10 HPLC chromatogram is generated using detection at 280 nm.",After,Yes,https://patents.google.com/patent/US9522953B2/en?oq=US9522953
Humira,US8889135 ,Abbott / AbbVie,Arthritis,Biologic,3,6/8/2001,6/5/2002,11/18/2014,1/4/2025,Active,Method of Treatment,"The patent claims cover a method for treating rheumatoid arthritis in a human subject, comprising administering subcutaneously to a human subject having rheumatoid arthritis a total body dose of 40 mg of a human anti-TNFα antibody once every 13 -15 days for a time period sufficient to treat the rheumatoid arthritis, wherein the anti-TNFα antibody comprises an IgG1 heavy chain constant region; a variable light (“VL”) chain region comprising a CDR1 having the amino acid sequence of SEQ ID NO:7, a CDR2 having the amino acid sequence of SEQ ID NO:5, and a CDR3 having the amino acid sequence of SEQ ID NO:3; and a variable heavy (“VH”) chain region comprising a CDR1 having the amino acid sequence of SEQ ID NO:8, a CDR2 having the amino acid sequence of SEQ ID NO:6 and a CDR3 having the amino acid sequence of SEQ ID NO:4.",Before,No,https://patents.google.com/patent/US8889135B2/en?oq=US8889135+
Humira,US8961973,Abbott / AbbVie,Arthritis,Biologic,5,4/9/2004,3/28/2014,2/24/2015,4/11/2025,Active,Method of Treatment,"The patent claims cover a multiple-variable dose method for inducing clinical remission of Crohn's disease in a subject in need thereof, comprising subcutaneously administering to the subject: a first dose of 160 mg of a recombinant human anti-TNFα antibody administered to the subject within a day; and a second dose of 80 mg of the antibody administered to the subject within a day, wherein the second dose is administered two weeks following administration of the first dose; wherein the antibody comprises:a heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:8; a CDR2 comprising the amino acid sequence of SEQ ID NO:6; and a CDR3 comprising the amino acid sequence of SEQ ID NO:4; anda light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:7; a CDR2 comprising the amino acid sequence of SEQ ID NO:5; and a CDR3 comprising the amino acid sequence of SEQ ID NO:3.",After,Yes,https://patents.google.com/patent/US8961973B2/en?oq=US8961973
Humira,US8961974 ,Abbott / AbbVie,Arthritis,Biologic,5,4/9/2004,3/28/2014,2/24/2015,4/11/2025,Active,Method of Treatment,"The patent claims cover a multiple-variable dose method for treating ulcerative colitis in a subject in need thereof, comprising subcutaneously administering to the subject: a first dose of 160 mg of a recombinant human anti-TNFα antibody administered to the subject within a day; and a second dose of 80 mg of the antibody administered to the subject within a day, wherein the second dose is administered two weeks following administration of the first dose;
wherein the antibody comprises: a heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:8; a CDR2 comprising the amino acid sequence of SEQ ID NO:6; and a CDR3 comprising the amino acid sequence of SEQ ID NO:4; and a light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:7; a CDR2 comprising the amino acid sequence of SEQ ID NO:5; and a CDR3 comprising the amino acid sequence of SEQ ID NO:3.",After,Yes,https://patents.google.com/patent/US8961974B2/en?oq=US8961974+
Humira,US8986693,Abbott / AbbVie,Arthritis,Biologic,5,4/9/2004,10/9/2014,3/24/2015,4/11/2025,Active,Method of Treatment,"The patent claims cover a method for treating moderate to severe chronic plaque psoriasis, comprising subcutaneously administering to an adult patient having moderate to severe chronic plaque psoriasis a first dose of 80 mg of adalimumab, followed by 40 mg of adalimumab every other week starting one week after said first dosing, wherein the patient achieves at least Psoriasis Area and Severity Index (PASI) 90 response at week 12 of the treatment.",After,Yes,https://patents.google.com/patent/US8986693B1/en?oq=US8986693
Humira,US9187559,Abbott / AbbVie,Arthritis,Biologic,5,4/9/2004,2/20/2015,11/17/2015,4/11/2025,Active,Method of Treatment,"The patent claims cover a multiple-variable dose method for treating idiopathic inflammatory bowel disease in a human subject in need thereof, comprising subcutaneously administering to the human subject: a first dose of 160 mg of adalimumab administered to the human subject within a day; and a second dose of 80 mg of adalimumab administered to the human subject within a day, wherein the second dose is administered two weeks following administration of the first dose.",After,Yes,https://patents.google.com/patent/US9187559B2/en?oq=US9187559
Humira,US9499615 ,Abbott / AbbVie,Arthritis,Biologic,5,4/9/2004,7/20/2015,11/22/2016,4/11/2025,Active,Method of Treatment,"The patent claims cover a multiple-variable dose method for treating idiopathic inflammatory bowel disease in a subject in need thereof, comprising subcutaneously administering to the subject: a 160 mg dose of a recombinant human anti-TNFα antibody administered to the subject within a day; and a 40 mg dose of the antibody administered to the subject within a day, wherein the 40 mg dose is administered two weeks following administration of the 160 mg dose;
wherein the antibody comprises: a heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:8; a CDR2 comprising the amino acid sequence of SEQ ID NO:6; and a CDR3 comprising the amino acid sequence of SEQ ID NO:4; and a light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:7; a CDR2 comprising the amino acid sequence of SEQ ID NO:5; and a CDR3 comprising the amino acid sequence of SEQ ID NO:3.",After,No,https://patents.google.com/patent/US9499615B2/en?oq=US9499615+
Humira,US9512216,Abbott / AbbVie,Arthritis,Biologic,5,4/9/2004,6/3/2016,12/6/2016,4/11/2025,Active,Method of Treatment,"The patent claims cover a method for treating moderate to severe chronic plaque psoriasis, comprising subcutaneously administering to an adult patient having moderate to severe chronic plaque psoriasis an initial dose of 80 mg of adalimumab, followed by 40 mg of adalimumab every other week starting one week after said first dosing, wherein the patient achieves at least Psoriasis Area and Severity Index (PASI) 75 response at week 12 of the treatment.",After,Yes,https://patents.google.com/patent/US9512216B2/en?oq=US9512216
Humira,US8808700,Abbott / AbbVie,Arthritis,Biologic,5,5/16/2005,3/28/2014,8/19/2014,5/16/2026,Active,Method of Treatment,"The patent claims cover a method for treating erosive polyarthritis, comprising administering a human anti-TNFα antibody to a human subject having erosive polyarthritis associated with psoriatic arthritis, ankylosing spondylitis or juvenile rheumatoid arthritis, wherein a modified Total Sharp Score (mTSS) of the subject is maintained or decreased following said treating as compared to baseline prior to said treating, and wherein the human anti-TNFα antibody (adalimumab) comprises: (1) a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 1 and (2) a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 2.",After,Yes,https://patents.google.com/patent/US8808700B1/en?oq=US8808700
Humira,US8216583,Abbott / AbbVie,Arthritis,Biologic,7,8/16/2002,8/15/2003,7/10/2012,10/8/2026,Active,Formulation / Combination,"The patent claims cover a stable liquid aqueous pharmaceutical formulation comprising a human anti-Tumor Necrosis Factor alpha (TNFα) antibody, or antigen-binding fragment thereof, at a concentration of between about 20 and about 150 mg/ml, a polyol, a surfactant, and a buffer system comprising citrate and phosphate, wherein said formulation has a pH of about 4 to about 8, and wherein the antibody, or antigen-binding portion thereof, comprises a light chain variable region comprising a complementary determining region (CDR) 1 domain comprising the amino acid sequence set forth in SEQ ID NO:7; a CDR2 domain comprising the amino acid sequence set forth in SEQ ID NO:5; and a CDR3 domain comprising the amino acid sequence set forth in SEQ ID NO: 3, or modified from SEQ ID NO: 3 by a single alanine substitution at position 1, 4, 5, 7, or 8, or by one to five conservative amino acid substitutions at positions 1, 3, 4, 6, 7, 8, and/or 9; and
comprises a heavy chain variable region comprising a CDR 1 domain comprising the amino acid sequence set forth in SEQ ID NO:8; a CDR2 domain comprising the amino acid sequence set forth in SEQ ID NO:6; and a CDR3 domain comprising the amino acid sequence set forth in SEQ ID NO: 4, or modified from SEQ ID NO: 4 by a single alanine substitution at position 2, 3, 4, 5, 6, 8, 9, 10, or 11, or by one to five conservative amino acid substitutions at positions 2, 3, 4, 5, 6, 8, 9, 10, 11, and/or 12.",After,No,https://patents.google.com/patent/US8216583B2/en?oq=US8216583
Humira,US9061005,Abbott / AbbVie,Arthritis,Biologic,5,4/9/2004,3/28/2012,6/23/2015,11/22/2026,Active,Method of Treatment,"The patent claims cover a multiple-variable dose method for treating idiopathic inflammatory bowel disease in a subject in need thereof, comprising subcutaneously administering to the subject: a first dose of 160 mg of a recombinant human anti-TNFα antibody administered to the subject within a day; and a second dose of 80 mg of the antibody administered to the subject within a day, wherein the second dose is administered two weeks following administration of the first dose;
wherein the antibody comprises:a heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:8; a CDR2 comprising the amino acid sequence of SEQ ID NO:6; and a CDR3 comprising the amino acid sequence of SEQ ID NO:4; and a light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:7; a CDR2 comprising the amino acid sequence of SEQ ID NO:5; and a CDR3 comprising the amino acid sequence of SEQ ID NO:3.",After,Yes,https://patents.google.com/patent/US9061005B2/en?oq=US9061005
Humira,US8231876,AbbVie,Arthritis,Biologic,8,4/5/2006,9/15/2010,7/31/2012,4/4/2027,Active,Method of Production / Process,The patent claims cover a host cell protein (HCP)-reduced antibody preparation and a pharmaceutical composition.,After,Yes,https://patents.google.com/patent/US8231876B2/en?oq=US8231876
Humira,US8883156,AbbVie,Arthritis,Biologic,8,4/5/2006,6/26/2013,11/11/2014,4/4/2027,Active,Method of Treatment,"The patent claims cover a method of treating a disorder in which TNFα activity is detrimental in a subject, the method comprising administering a composition comprising a therapeutically effective amount of adalimumab to the subject.",After,Yes,https://patents.google.com/patent/US8883156B2/en?oq=US8883156
Humira,US8916153,AbbVie,Arthritis,Biologic,8,4/5/2006,6/26/2013,12/23/2014,4/4/2027,Active,Formulation / Combination,"The patent claims cover a pharmaceutical composition comprising adalimumab and a pharmaceutically acceptable carrier, wherein the adalimumab is produced in a Chinese Hamster Ovary (CHO) cell expression system; and wherein the composition is characterized in that when the composition is assayed in a cathepsin L kinetic assay, a level of cathepsin L activity from 0.4 to less than 1.84 RFU/s/mg of adalimumab is observed.",After,Yes,https://patents.google.com/patent/US8916153B2/en?oq=US8916153
Humira,US8895009,AbbVie,Arthritis,Biologic,8,4/5/2006,8/1/2013,11/25/2014,4/4/2027,Active,Formulation / Combination,"The patent claims cover a liquid composition comprising adalimumab, wherein the adalimumab is expressed in a Chinese Hamster Ovary (CHO) cell expression system; and wherein the composition is characterized in that when the composition is assayed in a cathepsin L kinetic assay, a level of cathepsin L activity from 0.4 to less than 1.84 RFU/s/mg of adalimumab is observed.",After,Yes,https://patents.google.com/patent/US8895009B2/en?oq=US8895009
Humira,US8906372,AbbVie,Arthritis,Biologic,8,4/5/2006,8/2/2013,12/9/2014,4/4/2027,Active,Method of Treatment,"The patent claims cover a method of treating a disorder in which TNFα activity is detrimental in a subject, the method comprising administering a composition comprising a therapeutically effective amount of adalimumab to the subject.",After,Yes,https://patents.google.com/patent/US8906372B2/en?oq=US8906372
Humira,US9096666,AbbVie,Arthritis,Biologic,8,4/5/2006,11/21/2014,8/4/2015,4/4/2027,Active,Formulation / Combination,"The patent claims cover a liquid composition comprising adalimumab, wherein the adalimumab is expressed in a Chinese Hamster Ovary (CHO) cell expression system; and the composition is characterized in that when the composition is assayed in a cathepsin L kinetic assay, a level of cathepsin L activity less than 1.84 RFU/s/mg of adalimumab is observed.",After,Yes,https://patents.google.com/patent/US9096666B2/en?oq=US9096666
Humira,US9102723 ,AbbVie,Arthritis,Biologic,8,4/5/2006,11/21/2014,8/11/2015,4/4/2027,Active,Method of Production / Process,"The patent claims cover a method for preparing an adalimumab formulation, comprising the step of mixing a liquid composition comprising adalimumab with a pharmaceutically acceptable carrier, wherein the adalimumab is expressed in a Chinese Hamster Ovary (CHO) cell expression system, and the composition is characterized in that when the composition is assayed in a cathepsin L kinetic assay, a level of cathepsin L activity of less than 1.84 RFU/s/mg of adalimumab is observed.",After,Yes,https://patents.google.com/patent/US9102723B2/en?oq=US9102723+
Humira,US9273132,AbbVie,Arthritis,Biologic,8,4/5/2006,7/10/2015,3/1/2016,4/4/2027,Active,Method of Treatment,"The patent claims cover a A method of treating a disorder in which TNFα activity is detrimental in a subject, the method comprising administering a liquid pharmaceutical composition comprising a therapeutically effective amount of adalimumab and a pharmaceutically acceptable carrier to the subject such that the disorder is treated.",After,Yes,https://patents.google.com/patent/US9273132B2/en?oq=US9273132
Humira,US9328165,AbbVie,Arthritis,Biologic,8,4/5/2006,8/31/2015,5/3/2016,4/4/2027,Active,Formulation / Combination,"The patent claims cover a iquid pharmaceutical composition comprising adalimumab and one or more of sorbitol, a sugar, glycerol, or a preservative,wherein the adalimumab is expressed in a Chinese Hamster Ovary (CHO) cell expression system; and the composition is characterized in that when the composition is assayed in a cathepsin L kinetic assay, a level of cathepsin L activity no greater than 1.3 RFU/s/mg of adalimumab is observed, wherein the cathepsin L kinetic assay comprises:i.) diluting the composition in a polystyrene container in a solution containing 25 mM NaOAc, 5 mM DTT and 1 mM EDTA at pH 5.5,ii.) adding dextran sulfate to a concentration of 0.035 μg/mL and incubating at 37° C. for six hours,
iii.) adding Z-leucine-arginine covalently bound at its C-terminus to a fluorescent 7-amino-4-methyl coumarin (Z-leucine-arginine-AMC), wherein the diluting, adding, and incubating steps are sufficient to permit the measurement of cathepsin L hydrolysis of the Z-leucine-arginine-AMC within a linear range, and iv.) measuring Z-leucine-arginine-AMC hydrolysis in the linear range in RFU/s/mg of adalimumab.",After,Yes,https://patents.google.com/patent/US9328165B2/en?oq=US9328165
Humira,US9913902,AbbVie,Arthritis,Biologic,8,4/5/2006,9/28/2017,3/13/2018,4/4/2027,Active,Formulation / Combination,"The patent claims cover a liquid pharmaceutical composition comprising 50 mg/ml of adalimumab and a pharmaceutically acceptable carrier, wherein the adalimumab is expressed in a Chinese hamster ovary (CHO) cell expression system; and the composition is characterized in that when the composition is assayed in a cathepsin L kinetic assay, a level of cathepsin L activity less than 1.3 RFU/s/mg of adalimumab is observed, wherein the cathepsin L kinetic assay comprises:
i. diluting the composition 600-fold in a polystyrene container in a solution containing 25 mM NaOAc, 5 mM DTT and 1 mM EDTA at pH 5.5,ii. adding dextran sulfate to a concentration of 0.035 μg/mL and incubating at 37° C. for six hours,
iii. adding Z-leucine-arginine covalently bound at its C-terminus to a fluorescent 7-amino-4-methyl coumarin (Z-leucine-arginine-AMC), wherein the diluting, adding, and incubating steps are sufficient to permit the measurement of cathepsin L hydrolysis of the Z-leucine-arginine-AMC within a linear range, and iv. measuring Z-leucine-arginine-AMC hydrolysis in the linear range in RFU/s/mg of adalimumab.",After,Yes,https://patents.google.com/patent/US9913902B2/en?oq=US9913902
Humira,US9399061,Abbott / AbbVie,Arthritis,Biologic,5,4/10/2006,4/10/2007,7/26/2016,4/10/2027,Active,Method of Treatment,"The patent claims cover a method for treating an adult patient having moderate to severe active rheumatoid arthritis (RA), wherein the patient is nonresponsive to treatment with etanercept and infliximab, the method comprising administering 40 mg of adalimumab to the patient every other week to thereby treat the moderate to severe active RA.",After,No,https://patents.google.com/patent/US9399061B2/en?oq=US9399061
Humira,US9605064 ,Abbott / AbbVie,Arthritis,Biologic,5,4/10/2006,8/18/2010,3/28/2017,5/14/2027,Active,Method of Treatment,"The patent claims cover a method for treating psoriasis in a subject who has failed to respond to or has lost responsiveness to etanercept and infliximab, the method comprising administering 80 mg of adalimumab subcutaneously to the subject, and administering 40 mg of adalimumab subcutaneously to the subject every other week starting one week following administration of the 80 mg of adalimumab to the subject.",After,No,https://patents.google.com/patent/US9605064B2/en?oq=US9605064+
Humira,US8926975,Abbott / AbbVie,Arthritis,Biologic,5,6/8/2006,6/17/2014,1/6/2015,6/8/2027,Active,Method of Treatment,"The patent claims cover a method of treating active ankylosing spondylitis (AS) in a subject having total spinal ankylosis comprising selecting a subject having active AS and total spinal ankylosis, and subcutaneously administering 40 mg of an isolated human anti-TNFα antibody to the subject once every other week, wherein the human anti-TNFα antibody comprises a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 1, and comprises a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 2, wherein the human anti-TNFα antibody is adalimumab.",After,Yes,https://patents.google.com/patent/US8926975B2/en?oq=US8926975
Humira,US9486584,Abbott / AbbVie,Arthritis,Biologic,5,6/30/2006,11/6/2015,11/8/2016,6/29/2027,Active,Method of Treatment,"The patent claims cover a method for treating a disorder in which TNFα activity is detrimental in a subject, the method comprising:using adalimumab to treat the disorder by subcutaneous injection, the adalimumab contained in an automatic injection device with a housing having an open first end and a second end; biasing a syringe actuation component in the housing with a first biasing mechanism for first moving a syringe disposed in the housing towards the first end of the housing such that a hollow needle in fluid communication with a syringe barrel holding the adalimumab projects from the first end and for subsequently applying pressure to a bung sealing the syringe barrel to force the adalimumab through the hollow needle;\wherein the syringe actuation component comprises a pressurizer, at a first end of the syringe actuation component, for selectively applying pressure to the bung, a rod comprising a compressible portion projecting from the rod along at least a portion of a length of the rod, the compressible portion having a first expanded position prior to entering the barrel portion of the syringe and a second compressed position for initiating movement of the bung and a flange between a second end of the syringe actuation component and the compressible portion; and
wherein the first biasing mechanism is disposed between the flange of the syringe actuation component and the second end of the housing.",After,No,https://patents.google.com/patent/US9486584B2/en?oq=US9486584
Humira,US9572938,Abbott / AbbVie,Arthritis,Biologic,5,6/30/2006,10/6/2011,2/21/2017,7/11/2027,Active,Device,The patent claims cover a needleless automatic injection training device for training a recipient on administration of a substance. The patent describes the invention can be applied to adalimumab.,After,No,https://patents.google.com/patent/US9572938B2/en?oq=US9572938
Humira,US8715664,Abbott / AbbVie,Arthritis,Biologic,5,5/16/2005,5/16/2006,5/6/2014,7/24/2027,Active,Method of Treatment,"The patent claims cover a method for inhibiting radiographic disease progression in a human subject having erosive polyarthritis associated with a disorder in which TNFα activity is detrimental, comprising administering to the subject having erosive polyarthritis an isolated human anti-TNFα antibody (adalimumab) or antigen-binding portion thereof, such that radiographic disease progression is inhibited in the subject, wherein a Total Sharp Score (TSS) of the subject is either maintained or decreased following administration of the human anti-TNFα antibody, or antigen-binding portion thereof, wherein the human anti-TNFα antibody, or an antigen-binding portion thereof, dissociates from human TNFα with a Kd of 1×10−8 M or less and a Koff rate constant of 1×10−3 s−1 or less, both determined by surface plasmon resonance, and neutralizes human TNFα cytotoxicity in a standard in vitro L929 assay with an IC50 of 1×10−7 M or less.",After,Yes,https://patents.google.com/patent/US8715664B2/en?oq=US8715664
Humira,US7919264,Abbott,Arthritis,Biologic,24,11/1/2005,10/31/2006,4/5/2011,8/7/2027,Active,Method of Treatment,"The patent claims cover a method for determining the efficacy of a human anti-TNFα antibody, or an antigen-binding portion thereof, for treating a subject having ankylosing spondylitis (AS), said method comprising determining a level of a collagen degradation biomarker and a synovitis biomarker in a sample(s) obtained from the subject following administration of the human anti-TNFα antibody, or an antigen-binding portion thereof; and comparing the level of the collagen degradation biomarker and the synovitis biomarker in the sample(s) obtained from the subject with a known standard level of the collagen degradation biomarker and the synovitis biomarker associated with AS, wherein a lower level of the collagen degradation biomarker and the synovitis biomarker in the sample(s) from the subject relative to the known standard level of the collagen degradation biomarker and the synovitis biomarker indicates that the human anti-TNFα antibody, or an antigen-binding portion thereof, is efficacious for the treatment of AS in the subject.",After,No,https://patents.google.com/patent/US7919264B2/en?oq=US7919264
Humira,US8663945,AbbVie,Arthritis,Biologic,9,9/13/2006,11/30/2011,3/4/2014,9/13/2027,Active,Method of Production / Process,"The patent claims cover a method of producing an anti-TNFα antibody (adalimumab) in a mammalian cell culture, said method comprising: a) culturing Chinese Hamster Ovary (CHO) cells comprising a nucleic acid encoding the antibody, or a fragment thereof, in a cell culture growth medium to form the mammalian cell culture; and b) culturing the CHO cells in a cell culture production medium, wherein glucose is added to the mammalian cell culture to maintain a glucose concentration of at least 2 g/L, such that the anti-TNFα antibody is produced, wherein the anti-TNFα antibody comprises a light chain variable region (LCVR) having a CDR3 domain comprising the amino acid sequence of SEQ ID NO:3, a CDR2 domain comprising the amino acid sequence of SEQ ID NO:5, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO: 7, and comprises a heavy chain variable region (HCVR) having a CDR3 domain comprising the amino acid sequence of SEQ ID NO:4, a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 6, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO:8.",After,Yes,https://patents.google.com/patent/US8663945B2/en?oq=US8663945
Humira,US9234032,AbbVie,Arthritis,Biologic,9,9/13/2006,1/16/2014,1/12/2016,9/13/2027,Active,Method of Production / Process,"The patent claims cover a fed-batch method for producing adalimumab in mammalian cells in culture, wherein said mammalian cells express said adalimumab, the method comprising:culturing the mammalian cells in a cell culture production medium in large scale at a first temperature; and then reducing the temperature under which the mammalian cells are cultured to a second lower temperature during adalimumab production, wherein said adalimumab is produced at a titer of at least 1.3 g/L in said cell culture and said adalimumab is further purified by a process including Protein A affinity chromatography.",After,Yes,https://patents.google.com/patent/US9234032B2/en?oq=US9234032
Humira,US8906646 ,AbbVie,Arthritis,Biologic,9,9/13/2006,3/26/2014,12/9/2014,9/13/2027,Active,Method of Production / Process,"The patent claims cover a fed-batch method of producing adalimumab, comprising expressing adalimumab in Chinese Hamster Ovary (CHO) cells in a cell culture production medium in large -scale, wherein said CHO cells comprise an expression vector encoding adalimumab, wherein glucose concentration in said medium is monitored, and the glucose concentration in said medium drops to a level between 1 and 5 g/L, and glucose is added to said medium to maintain the glucose concentration in said medium at least 1-5g/L, and wherein adalimumab is further affinity purified using a Protein A resin.",After,Yes,https://patents.google.com/patent/US8906646B2/en?oq=US8906646+
Humira,US8911964 ,AbbVie,Arthritis,Biologic,9,9/13/2006,3/26/2014,12/16/2014,9/13/2027,Active,Method of Production / Process,"The patent claims cover a ed-batch production method of making adalimumab, comprising culturing Chinese Hamster Ovary (CHO) cells comprising a nucleic acid encoding adalimumab in a cell culture production medium in large-scale, wherein glucose concentration in said medium is monitored, the glucose concentration in said medium decreases to below 2 g/L, and glucose is added to said medium when the glucose concentration in said medium decreases to below 2 g/L, or the glucose concentration in said medium is monitored and glucose is added to said medium to maintain the glucose concentration in said medium at a concentration of at least 2 g/L but no greater than 7 g/L, such that adalimumab is produced at a titer of at least 2 g/L in said cell culture production medium.",After,Yes,https://patents.google.com/patent/US8911964B2/en?oq=US8911964+
Humira,US9073988,AbbVie,Arthritis,Biologic,9,9/13/2006,12/8/2014,7/7/2015,9/13/2027,Active,Method of Production / Process,"The patent claims cover a fed batch method for making adalimumab, said method comprising culturing mammalian cells comprising a nucleic acid encoding said adalimumab in a cell culture production medium in large scale, wherein the pH of the cell culture production medium is adjusted according to a pH linear ramp comprising beginning at a starting pH and ending at a final pH that is less than the starting pH, such that said adalimumab is produced, and wherein said produced anti-TNFα antibody is further affinity purified using a Protein A resin.",After,No,https://patents.google.com/patent/US9073988B2/en?oq=US9073988
Humira,US9090867 ,AbbVie,Arthritis,Biologic,9,9/13/2006,12/15/2014,7/28/2015,9/13/2027,Active,Method of Production / Process,"The patent claims cover a fed-batch method for making adalimumab, said method comprising culturing mammalian cells comprising a nucleic acid encoding said adalimumab in a cell culture production medium in large scale, wherein the pH of the cell culture production medium is adjusted such that the culturing begins at a starting pH and ends at a final pH that is less than the starting pH, such that said adalimumab is produced at a titer of at least 2 g/L in said cell culture production medium.",After,Yes,https://patents.google.com/patent/US9090867B2/en?oq=US9090867+
Humira,US9284371,AbbVie,Arthritis,Biologic,9,9/13/2006,10/22/2015,3/15/2016,9/13/2027,Active,Method of Production / Process,"The patent claims cover a method of producing adalimumab, comprising culturing in large-scale mammalian cells that express adalimumab in a cell culture production medium, wherein the pH of the cell culture production medium is adjusted from a first pH to a second pH during said culturing, the second pH being lower than the first pH, and the cell culture production medium is not removed but is supplemented with glucose or one or more other nutrients at least once during adalimumab production; and wherein adalimumab produced by the mammalian cells is purified from the cell culture production medium using a process including Protein A affinity purification.",After,Yes,https://patents.google.com/patent/US9284371B2/en?oq=US9284371
Humira,US10119118B2,AbbVie,Arthritis,Biologic,9,9/13/2006,6/20/2016,11/6/2018,9/13/2027,Active,Method of Production / Process,"The patent claims cover a serum-free cell culture medium comprising Part A, Part B, and Part C, wherein a) Part A consists essentially of a modified basal medium, wherein the modified basal medium is JRH 67411; b) Part B consists essentially of an inorganic iron source; and c) Part C comprises a recombinant growth factor; a buffer; and osmolarity regulator; an energy source; and at least two different non-animal hydrolysates.",After,No,https://patents.google.com/patent/US10119118B2/en?oq=US10119118B2
Humira,US8889136,Abbott / AbbVie,Arthritis,Biologic,5,4/9/2004,4/11/2005,11/18/2014,10/9/2027,Active,Method of Treatment,"The patent claims cover a  multiple-variable dose method for inducing clinical remission of Crohn's disease in a subject in need thereof, comprising subcutaneously administering to the subject: a first dose of 160 mg of a recombinant human anti-TNFα antibody administered as a set of four injections of 40 mg of the antibody administered to the subject within a day; and a second dose of 80 mg of the antibody administered as a set of two injections of 40 mg of the antibody administered to the subject within a day, wherein the second dose is administered two weeks following administration of the first dose;
wherein the antibody comprises: a heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:8; a CDR2 comprising the amino acid sequence of SEQ ID NO:6; and a CDR3 comprising the amino acid sequence of SEQ ID NO:4; anda light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:7; a CDR2 comprising the amino acid sequence of SEQ ID NO:5; and a CDR3 comprising the amino acid sequence of SEQ ID NO:3.",After,Yes,https://patents.google.com/patent/US8889136B2/en?oq=US8889136
Humira,US8436149B2,Abbott / AbbVie,Arthritis,Biologic,38,10/27/2006,9/2/2011,5/7/2013,10/25/2027,Active,Crystalline,"The patent claims cover a crystal of an IgG human anti-hTNFalpha antibody comprising two heavy chains each with a molecular weight of about 50 kDa and comprising a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 1, and a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 2, wherein said crystal has a needle morphology with a length of about 2-500 μm and an l/d ratio of about 3 to 30, wherein the antibody is adalimumab (D2E7).",After,No,https://patents.google.com/patent/US8436149B2/en?oq=US8436149B2
Humira,US8772458B2,Abbott / AbbVie,Arthritis,Biologic,38,10/27/2006,2/22/2013,7/8/2014,10/25/2027,Active,Method of Treatment,"The patent claims cover a method for treating a TNFalpha-related disorder in a subject in need thereof, said method comprising the step of administering to the subject an effective amount of anti-hTNFalpha antibody crystals, wherein the antibody is adalimumab.",After,No,https://patents.google.com/patent/US8772458B2/en?oq=US8772458B2
Humira,US9086418B2,AbbVie,Arthritis,Biologic,24,11/1/2005,2/25/2011,7/21/2015,11/27/2027,Active,Method of Treatment,"The patent claims cover a method for treating a subject having active ankylosing spondylitis (AS), said method comprising
(a) identifying a subject having active AS; (b) administering 40 mg of adalimumab to the subject; (c) determining a post-treatment level of type II collagen C-telopeptide (CTX-II) in a urine sample(s) obtained from the subject following administration of adalimumab to the subject, wherein the post-treatment level of CTX-II is determined using an antibody that specifically binds to CTX-II in an immunoassay; and (d) administering at least one additional dose of 40 mg of adalimumab to the subject provided that the post-treatment level of CTX-II in the sample(s) obtained from the subject is lower than a known standard level of CTX-II, thereby treating the subject having active AS.",After,No,https://patents.google.com/patent/US9086418B2/en?oq=US9086418B2
Humira,US11083792,AbbVie,Arthritis,Biologic,8,4/5/2006,11/8/2018,8/10/2021,2/14/2028,Active,Formulation / Combination,"The patent claims cover a liquid pharmaceutical composition comprising adalimumab and a pharmaceutically acceptable carrier, wherein the adalimumab is expressed in a Chinese hamster ovary (CHO) cell expression system; and the composition is characterized in that when the composition is assayed in a cathepsin L kinetic assay, a level of fluorescent activity no greater than 0.0144 RFU/sec is observed.",After,Yes,https://patents.google.com/patent/US11083792B2/en?oq=US11083792
Humira,US7863426,AbbVie,Arthritis,Biologic,8,4/5/2006,4/4/2007,1/4/2011,3/13/2028,Active,Method of Production / Process,The patent claims cover a method for producing a host cell protein (HCP)-reduced antibody preparation from a mixture comprising an antibody (adalimumab) and at least one HCP.,After,No,https://patents.google.com/patent/US7863426B2/en?oq=US7863426
Humira,US8410259B2,AbbVie,Arthritis,Biologic,36,3/30/2007,4/29/2011,4/2/2013,4/13/2028,Active,Method of Production / Process,"The patent claims cover a yeast host cell comprising a recombinant vector, wherein the recombinant vector comprises a recombinant expression vector element (rEVE) polynucleotide molecule comprising a nucleotide sequence.",After,No,https://patents.google.com/patent/US8410259B2/en?oq=US8410259B2
Humira,US8092998,Abbott / AbbVie,Arthritis,Biologic,32,5/31/2007,5/30/2008,1/10/2012,6/4/2028,Active,Method of Diagnosis,"The patent claims cover a method for predicting responsiveness to a TNFα inhibitor in a subject having an autoimmune disorder, wherein the anti-TNFα antibody, or antigen-binding portion thereof, is adalimumab",After,No,https://patents.google.com/patent/US8092998B2/en?oq=US8092998
Humira,US9284370 ,Abbott / AbbVie,Arthritis,Biologic,6,6/11/2007,4/6/2015,3/15/2016,6/10/2028,Active,Method of Treatment,"The patent claims cover a method for treating polyarticular juvenile idiopathic arthritis in a subject comprising subcutaneously administering adalimumab to the subject every other week, wherein 20 mg of adalimumab is administered to the subject every other week if the subject weighs at least 15 kg and less than 30 kg, or wherein 40 mg of adalimumab is administered to the subject every other week if the subject weighs more than or equal to 30 kg.",After,Yes,https://patents.google.com/patent/US9284370B1/en?oq=US9284370+
Humira,US9669093 ,Abbott / AbbVie,Arthritis,Biologic,6,6/11/2007,2/12/2016,6/6/2017,6/10/2028,Active,Method of Treatment,"The patent claims cover a method for treating polyarticular juvenile idiopathic arthritis in a subject comprising weighing the subject and subcutaneously administering adalimumab to the subject every other week, wherein 20 mg of adalimumab is administered to the subject every other week if the subject weighs at least 15 kg and less than 30 kg, or wherein 40 mg of adalimumab is administered to the subject every other week if the subject weighs more than or equal to 30 kg.",After,Yes,https://patents.google.com/patent/US9669093B2/en?oq=US9669093+
Humira,US8883146B2,AbbVie,Arthritis,Biologic,39,11/30/2007,2/22/2013,11/11/2014,11/28/2028,Active,Formulation / Combination,"The patent claims cover an aqueous formulation comprising an antibody, or antigen-binding fragment thereof, at a concentration of at least 50 mg/ml, a non-ionizable excipient, a buffer, and water, wherein the formulation has a conductivity of less than about 2.5 mS/cm, and the antibody, or antigen-binding fragment thereof, has a molecular weight (Mw) greater than about 47 kDa.",After,No,https://patents.google.com/patent/US8883146B2/en?oq=US8883146B2
Humira,US9085619B2,AbbVie,Arthritis,Biologic,39,11/30/2007,10/3/2014,7/21/2015,11/28/2028,Active,Formulation / Combination,"The patent claims cover an aqueous pharmaceutical formulation consisting essentially of: (a) an anti-tumor necrosis factor alpha antibody comprising a light chain variable region (LCVR) having a CDR3 domain comprising the amino acid sequence of SEQ ID NO:3, a CDR2 domain comprising the amino acid sequence of SEQ ID NO:5, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO: 7, and a heavy chain variable region (HCVR) having a CDR3 domain comprising the amino acid sequence of SEQ ID NO:4, a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 6, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO:8, wherein the concentration of the antibody is 50 to 200 mg/ml; and
(b) water.",After,Yes,https://patents.google.com/patent/US9085619B2/en?oq=US9085619B2
Humira,US11167030B2,AbbVie,Arthritis,Biologic,39,11/30/2007,12/29/2020,11/9/2021,11/28/2028,Active,Formulation / Combination,"The patent claims cover an aqueous pharmaceutical formulation comprising: (a) an anti-tumor necrosis factor alpha antibody comprising a light chain variable region (LCVR) having a CDR3 domain comprising the amino acid sequence of SEQ ID NO:3, a CDR2 domain comprising the amino acid sequence of SEQ ID NO:5, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO: 7, and a heavy chain variable region (HCVR) having a CDR3 domain comprising the amino acid sequence of SEQ ID NO:4, a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 6, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO:8, wherein the concentration of the antibody is 50 to 200 mg/ml;",After,Yes,https://patents.google.com/patent/US11167030B2/en?oq=US11167030B2
Humira,US11191834B2,AbbVie,Arthritis,Biologic,39,11/30/2007,12/29/2020,12/7/2021,11/28/2028,Active,Formulation / Combination,"The patent claims cover a aqueous pharmaceutical formulation comprising: (a) an anti-tumor necrosis factor alpha antibody comprising a light chain variable region (LCVR) having a CDR3 domain comprising the amino acid sequence of SEQ ID NO:3, a CDR2 domain comprising the amino acid sequence of SEQ ID NO:5, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO: 7, and a heavy chain variable region (HCVR) having a CDR3 domain comprising the amino acid sequence of SEQ ID NO:4, a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 6, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO:8, wherein the concentration of the antibody is 50 to 200 mg/ml;
(b) a surfactant; (c) a polyol; and (d) water; wherein the formulation does not comprise a buffering system, and wherein the pH of the formulation is from 4 to 8.",After,Yes,https://patents.google.com/patent/US11191834B2/en?oq=US11191834B2
Humira,US9279015,Abbott / AbbVie,Arthritis,Biologic,5,4/10/2006,2/4/2008,3/8/2016,5/31/2029,Active,Method of Treatment,"The patent claims cover a method of treating a subject having early axial spondyloarthritis (SpA), comprising administering to the subject an isolated human anti-TNFα antibody, or an antigen-binding portion thereof, to the subject, such that early axial spondyloarthritis is treated.",After,No,https://patents.google.com/patent/US9279015B2/en?oq=US9279015
Humira,US7935808B2,Abbott / AbbVie,Arthritis,Biologic,36,3/30/2007,3/28/2008,5/3/2011,8/7/2029,Active,Method of Production / Process,"The patent claims cover a isolated recombinant expression vector element (rEVE) polynucleotide molecule comprising a nucleotide base sequence selected from the group consisting of the nucleotide base sequence of SEQ ID NO:1, the nucleotide base sequence of SEQ ID NO:2, a sequence complementary to any foregoing sequence, an expression-enhancing portion of any foregoing sequence, and combinations thereof.",After,No,https://patents.google.com/patent/US7935808B2/en?oq=US7935808B2
Humira,US9018361 ,Abbott / AbbVie,Arthritis,Biologic,14,10/20/2008,3/26/2014,4/28/2015,10/20/2029,Active,Method of Production / Process,The patent claims cover a process for purifying adalimumab from a fermentation harvest of a Chinese Hamster Ovary (CHO) cell culture expressing said adalimumab.,After,No,https://patents.google.com/patent/US9018361B2/en?oq=US9018361+
Humira,US8420081B2,AbbVie,Arthritis,Biologic,37,11/30/2007,11/28/2008,4/16/2013,1/13/2030,Active,Formulation / Combination,"The patent claims cover an aqueous formulation comprising an antibody, or antigen-binding fragment thereof, at a concentration of at least about 20 mg/mL and water, wherein the formulation has a conductivity of less than about 2.5 mS/cm and the antibody, or antigen-binding fragment thereof, has a molecular weight (Mw) greater than about 47 kDa.
",After,Yes,https://patents.google.com/patent/US8420081B2/en?oq=US8420081B2
Humira,US8034906B2,Abbott / AbbVie,Arthritis,Biologic,38,10/27/2006,10/25/2007,10/11/2011,2/8/2030,Active,Crystalline,"The patent claims cover a crystal of an intact D2E7 (adalimumab) antibody, wherein said crystal has a needle morphology with a length of about 2-500 μm and an l/d ratio of about 3 to 30.",After,No,https://patents.google.com/patent/US8034906B2/en?oq=US8034906B2
Humira,US8093045,AbbVie,Arthritis,Biologic,9,9/13/2006,9/13/2007,1/10/2012,6/30/2030,Active,Method of Production / Process,"The patent claims cover a fed batch method of producing an anti-TNFα antibody, or a fragment thereof, comprising
a) culturing Chinese Hamster Ovary (CHO) cells comprising a nucleic acid encoding the anti-TNFα antibody, or fragment thereof, in a cell culture comprising a cell culture production medium; and b) feeding the CHO cells by adding a hydrolysate enrichment solution and a basal enrichment solution to the cell culture during a time period, wherein the basal enrichment solution comprises a plant-based hydrolysate and 75-300 g/L of a yeast-based hydrolysate such that the anti-TNFα antibody, or fragment thereof, is produced, wherein the fully human anti-TNFα antibody, or fragment thereof, is adalimumab, or a fragment thereof.",After,No,https://patents.google.com/patent/US8093045B2/en?oq=US8093045
Humira,US9561328,Abbott / AbbVie,Arthritis,Biologic,34,4/29/2009,12/17/2013,2/7/2017,10/17/2030,Active,Device,The patent claims cover a syringe plunger/ automatic injection device  of a polymeric material. The patent describes the device can be applied to adalimumab.,After,No,https://patents.google.com/patent/US9561328B2/en?oq=US9561328
Humira,US8895709 ,Abbott / AbbVie,Arthritis,Biologic,14,10/20/2008,10/20/2009,11/25/2014,12/18/2030,Active,Method of Production / Process,"The patent claims cover a method for producing a host cell-protein (HCP) reduced anti-IL-12 antibody, or antigen binding portion thereof, preparation from a sample mixture comprising an anti-IL-12 antibody, or antigen binding portion thereof, and at least one HCP.",After,No,https://patents.google.com/patent/US8895709B2/en?oq=US8895709+
Humira,US8999337,Abbott / AbbVie,Arthritis,Biologic,6,6/11/2007,6/10/2008,4/7/2015,2/6/2031,Active,Method of Treatment,"The patent claims cover a method for treating juvenile idiopathic arthritis (JIA) in a subject comprising administering an isolated human anti-TNFα antibody, or an antigen-binding portion thereof, to the subject, wherein 20 mg of the anti-TNFα antibody, or antigen-binding portion thereof, is administered to the subject if the subject weighs less than 30 kg, or wherein 40 mg of the anti-TNFα antibody, or antigen-binding portion thereof, is administered to the subject if the subject weighs more than or equal to 30 kg, wherein the human anti-TNFα antibody is adalimumab or golimumab, or the antigen-binding portion thereof is a portion of adalimumab or golimumab.",After,Yes,https://patents.google.com/patent/US8999337B2/en?oq=US8999337
Humira,US8679061 ,Abbott / AbbVie,Arthritis,Biologic,5,6/30/2006,3/5/2008,3/25/2014,2/23/2031,Active,Device,The patent claims cover a automatic injection device wherein the TNF inhibitor comprises adalimumab.,After,No,https://patents.google.com/patent/US8679061B2/en?oq=US8679061+
Humira,US9624295,Abbott / AbbVie,Arthritis,Biologic,5,4/10/2006,4/10/2007,4/18/2017,3/31/2031,Active,Method of Treatment,"The patent claims cover a method of treating a subject having oligoarthritis with a tender joint count (TJC)<5 or a swollen joint count (SJC)<5, in association with psoriatic arthritis, the method comprising administering to the subject about 40 mg of adalimumab once subcutaneously every other week.",After,Yes,https://patents.google.com/patent/US9624295B2/en?oq=US9624295
Humira,US8747854B2,AbbVie,Arthritis,Biologic,25,6/3/2010,6/3/2011,6/10/2014,6/3/2031,Active,Method of Treatment,The patent claims cover a method for treating a subject having moderate to severe hidradenitis suppurativa (HS) with adalimumab.,After,No,https://patents.google.com/patent/US8747854B2/en?oq=US8747854B2
Humira,US9334320B2,AbbVie,Arthritis,Biologic,25,6/3/2010,5/28/2014,5/10/2016,7/15/2031,Active,Method of Treatment,The patent claims cover a method for treating a subject having moderate to severe hidradenitis suppurativa (HS) with adalimumab.,After,No,https://patents.google.com/patent/US9334320B2/en?oq=US9334320B2
Humira,US8758301B2,AbbVie,Arthritis,Biologic,28,12/15/2009,12/15/2010,6/24/2014,12/18/2031,Active,Device,"The patent claims cover an  automatic injection device having a proximal end configured to deliver a dose of a therapeutic agent and a distal end configured to be controllable by a user wherein the therapeutic agent is a human TNFα antibody, or antigen-binding portion thereof, is adalimumab or golimumab.",After,No,https://patents.google.com/patent/US8758301B2/en?oq=US8758301B2
Humira,US9265887,AbbVie,Arthritis,Biologic,29,1/24/2011,1/24/2012,2/23/2016,1/24/2032,Active,Device,The patent claims cover an automatic injection device wherein the TNF inhibitor is adalimumab.,After,No,https://patents.google.com/patent/US9265887B2/en?oq=US9265887
Humira,US8708968,AbbVie,Arthritis,Biologic,,1/24/2011,1/24/2012,4/29/2014,1/24/2032,Active,Device,The patent claims cover a apparatus for removing a needle shield from a syringe.,After,Yes,https://patents.google.com/patent/US8708968B2/en?oq=US8708968
Humira,US9062106,AbbVie,Arthritis,Biologic,13,4/27/2011,4/26/2012,6/23/2015,4/26/2032,Active,Method of Production / Process,"The patent claims cover a method for increasing the galactosylation level of a recombinantly expressed adalimumab, comprising supplementing a media used in the expression of the recombinantly expressed adalimumab with a sufficient amount of a manganese supplement to achieve a manganese concentration in the media of 0.2-100 μM and a sufficient amount of a galactose supplement to achieve a galactose concentration in the media of 1-100 mM, thereby increasing the galactosylation level of the recombinantly expressed adalimumab, wherein the galactosylation level of a recombinantly expressed adalimumab is increased as compared to the galactosylation level of adalimumab recombinantly expressed in media which is not supplemented with said manganese supplement and said galactose supplement.",After,Yes,https://patents.google.com/patent/US9062106B2/en?oq=US9062106
Humira,US9090688 ,AbbVie,Arthritis,Biologic,13,4/27/2011,9/22/2014,7/28/2015,4/26/2032,Active,Method of Production / Process,"The patent claims cover a process for producing an antibody comprising the heavy and light chain variable domains of adalimumab, the process comprising culturing a mammalian cell which produces said antibody in a cell culture media that comprises a concentration of manganese of 0.2-100 μM and a concentration of galactose of 1-100 mM, wherein said concentration of manganese and galactose is sufficient to increase the galactosylation level of said antibody as compared to the galactosylation level of an antibody comprising the heavy and light chain variable domains of adalimumab produced in a cell culture media that does not comprise said concentration of manganese and galactose, thereby producing said antibody.",After,Yes,https://patents.google.com/patent/US9090688B2/en?oq=US9090688+
Humira,US9255143,AbbVie,Arthritis,Biologic,13,4/27/2011,2/11/2015,2/9/2016,4/26/2032,Active,Formulation / Combination,"The patent claims cover a composition comprising adalimumab, wherein more than 25% of the total N-linked oligosaccharides present on said adalimumab are of a galactose-containing fucosylated biantennary oligosaccharide form (sum of NA1F+NA2F).",After,No,https://patents.google.com/patent/US9255143B2/en?oq=US9255143
Humira,US9365645,AbbVie,Arthritis,Biologic,13,4/27/2011,2/3/2016,6/14/2016,4/26/2032,Active,Formulation / Combination,"The patent claims cover a composition comprising an antibody comprising the heavy and light chain variable domains of adalimumab, wherein less than 70% of the total N-linked oligosaccharides present on said antibody are of an agalactosyl fucosylated biantennary oligosaccharide form (sum NGA2F+NGA2F-GlcNAc).",After,No,https://patents.google.com/patent/US9365645B1/en?oq=US9365645
Humira,US9505834 ,AbbVie,Arthritis,Biologic,13,4/27/2011,3/31/2016,11/29/2016,4/26/2032,Active,Method of Production / Process,"The patent claims cover a method for increasing the galactosylation level of a recombinantly expressed antibody comprising the heavy and light chain variable domains of adalimumab, comprising supplementing a chemically defined (CD) cell culture media used in the expression of the antibody with a manganese supplement, thereby increasing the galactosylation level of the antibody, wherein the galactosylation level of the antibody is increased as compared to the galactosylation level of the antibody recombinantly expressed in the chemically defined cell culture media which is not supplemented with the manganese supplement.",After,Yes,https://patents.google.com/patent/US9505834B2/en?oq=US9505834+
Humira,US9878102,AbbVie,Arthritis,Biologic,29,1/24/2011,2/18/2016,1/30/2018,5/22/2032,Active,Device,The patent claims cover an injection device.The patent describes the invention can be applied to adalimumab.,After,No,https://patents.google.com/patent/US9878102B2/en?oq=US9878102
Humira,US8636704B2,Abbott / AbbVie,Arthritis,Biologic,34,4/29/2009,4/29/2010,1/28/2014,6/28/2032,Active,Device,The patent claims cover a syringe plunger formed of a polymeric material. The patent describes the device can be applied to adalimumab.,After,No,https://patents.google.com/patent/US8636704B2/en?oq=US8636704B2
Humira,US9408973B2,AbbVie,Arthritis,Biologic,26,9/22/2011,9/21/2012,8/9/2016,9/2/2032,Active,Device,"The patent claims cover an  automatic injection device, wherein the liquid therapeutic agent comprises adalimumab.",After,No,https://patents.google.com/patent/US9408973B2/en?oq=US9408973B2
Humira,US8992476B2,AbbVie,Arthritis,Biologic,26,9/22/2011,9/21/2012,3/31/2015,10/24/2032,Active,Device,"The patent claims cover an automatic injection device, wherein the liquid therapeutic agent comprises adalimumab.",After,No,https://patents.google.com/patent/US8992476B2/en?oq=US8992476B2
Humira,US9956353,AbbVie,Arthritis,Biologic,30,3/29/2011,3/29/2012,5/1/2018,11/22/2032,Active,Device,"The patent claims cover a shroud deployment assembly for use in an automatic injection device wherein the human TNFα antibody, or antigen-binding portion thereof, is adalimumab or golimumab.",After,No,https://patents.google.com/patent/US9956353B2/en?oq=US9956353
Humira,US9206390,AbbVie,Arthritis,Biologic,10,9/2/2012,3/14/2013,12/8/2015,3/14/2033,Active,Method of Production / Process,"The patent claims cover a method for controlling the oligosaccharide distribution of a recombinantly-expressed immunoglobulin, wherein the immunoglobulin is an anti-TNFα antibody and the anti-TNFα antibody is adalimumab.",After,No,https://patents.google.com/patent/US9206390B2/en?oq=US9206390
Humira,US9181572,AbbVie,Arthritis,Biologic,12,4/20/2012,3/14/2013,11/10/2015,3/14/2033,Active,Method of Production / Process,"The patent claims cover a method for producing a composition comprising adalimumab, comprising culturing a cell producing adalimumab in a cell culture media comprising an amount of one or more basic amino acids sufficient to produce a composition comprising adalimumab in which less than 62% of the lysine variant species of adalimumab have zero C-terminal lysines (Lys 0).",After,Yes,https://patents.google.com/patent/US9181572B2/en?oq=US9181572
Humira,US9249182B2,AbbVie,Arthritis,Biologic,21,5/24/2012,3/14/2013,2/2/2016,3/14/2033,Active,Method of Production / Process,"The patent claims cover a method for producing a preparation comprising a protein of interest and a reduced amount of at least one impurity, wherein wherein the protein of interest is an immunoglobulin and the immunoglobulin comprises the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2 and CDRL3 of adalimumab.",After,No,https://patents.google.com/patent/US9249182B2/en?oq=US9249182B2
Humira,US9505833 ,AbbVie,Arthritis,Biologic,12,4/20/2012,11/12/2013,11/29/2016,3/14/2033,Active,Method of Production / Process,"The patent claims cover a composition comprising adalimumab and methylglyoxal (MGO)-modified forms of adalimumab, wherein said composition was expressed in Chinese Hamster Ovary (CHO) cells cultured in chemically defined media (CDM), wherein said MGO-modified forms of adalimumab comprise a MGO-modified arginine amino acid at one or more of positions 30 (R30) of SEQ ID NO. 1, 93 (R93) of SEQ ID NO. 1, 108 (R108) of SEQ ID NO. 1, 16 (R16) of SEQ ID NO. 2, 259 (R259) of SEQ ID NO. 2, 359 (R359) of SEQ ID NO. 2, and 420 (R420) of SEQ ID NO. 2, and wherein said composition was purified by ion exchange chromatography such that said MGO-modified forms of adalimumab in said composition comprise less than about 1% of the total amount of adalimumab and MGO-modified forms of adalimumab.",After,No,https://patents.google.com/patent/US9505833B2/en?oq=US9505833+
Humira,US9512214,AbbVie,Arthritis,Biologic,10,9/2/2012,2/28/2014,12/6/2016,3/14/2033,Active,Method of Production / Process,"The patent claims cover a method for controlling the oligosaccharide distribution of a recombinantly-expressed immunoglobulin comprising a heavy chain variable region comprising the sequence of SEQ ID NO: 2 and a light chain variable region comprising the sequence of SEQ ID NO: 7, wherein the immunoglobulin is adalimumab.",After,No,https://patents.google.com/patent/US9512214B2/en?oq=US9512214
Humira,US9193787,AbbVie,Arthritis,Biologic,12,4/20/2012,10/23/2014,11/24/2015,3/14/2033,Active,Method of Production / Process,"The patent claims cover a method for purifying a composition comprising adalimumab, the method comprising: (a) contacting a cation exchange adsorbent with a composition comprising adalimumab and adalimumab comprising one or more methylglyoxal (MGO)-modified arginine amino acids at position 30 (R30) of SEQ ID NO. 1, position 93 (R93) of SEQ ID NO. 1, position 108 (R108) of SEQ ID NO. 1, position 16 (R16) of SEQ ID NO. 2, position 259 (R259) of SEQ ID NO. 2, position 359 (R359) of SEQ ID NO. 2, or position 420 (R420) of SEQ ID NO. 2; (b) removing adalimumab comprising one or more methylglyoxal (MGO)-modified arginine amino acids from the cation exchange adsorbent; and(c) subsequently eluting the adalimumab from the cation exchange adsorbent using an elution buffer.",After,No,https://patents.google.com/patent/US9193787B2/en?oq=US9193787
Humira,US9346879,AbbVie,Arthritis,Biologic,12,4/20/2012,12/29/2014,5/24/2016,3/14/2033,Active,Method of Production / Process,"The patent claims cover a method for producing a composition comprising adalimumab, the method comprising:
contacting a first sample comprising adalimumab comprising more than 10% total acidic species of adalimumab to a first chromatography media in the presence of a loading buffer, wherein the first chromatography media is selected from the group consisting of an ion exchange chromatography media, an affinity chromatography media and a hydrophobic interaction chromatography (HIC) media, and collecting a first chromatography sample, wherein the first chromatography sample comprises a composition of adalimumab comprising less than 10% total acidic species of adalimumab, wherein the acidic species of adalimumab correspond to the peaks that elute earlier than the main peak in a WCX-10 HPLC chromatogram of adalimumab, wherein the WCX-10 HPLC chromatogram is generated using a first mobile phase of 10 mM Sodium Phosphate dibasic (pH 7.5) and a second mobile phase of 10 mM Sodium Phosphate dibasic, 500 mM Sodium Chloride (pH 5.5), and wherein the WCX-10 HPLC chromatogram is generated using detection at 280 nm.",After,Yes,https://patents.google.com/patent/US9346879B2/en?oq=US9346879
Humira,US9234033,AbbVie,Arthritis,Biologic,10,9/2/2012,2/26/2015,1/12/2016,3/14/2033,Active,Method of Production / Process,"The patent claims cover a process for producing a recombinantly-expressed immunoglobulin comprising a heavy chain variable region comprising the sequence of SEQ ID NO: 2 and a light chain variable region comprising the sequence of SEQ ID NO: 7, wherein the immunoglobulin is adalimumab.",After,No,https://patents.google.com/patent/US9234033B2/en?oq=US9234033
Humira,US9290568,AbbVie,Arthritis,Biologic,10,9/2/2012,2/26/2015,3/22/2016,3/14/2033,Active,Method of Production / Process,"The patent claims cover a process for producing a recombinantly-expressed immunoglobulin comprising a heavy chain variable region comprising the sequence of SEQ ID NO: 2 and a light chain variable region comprising the sequence of SEQ ID NO: 7, comprising culturing a mammalian cell which recombinantly expresses the immunoglobulin during a production stage in a cell culture media comprising at least 0.4 g/L of asparagine, thereby producing the recombinantly-expressed immunoglobulin, wherein the immunoglobulin is adalimumab.",After,Yes,https://patents.google.com/patent/US9290568B2/en?oq=US9290568
Humira,US9708399,AbbVie,Arthritis,Biologic,12,3/14/2013,6/8/2015,7/18/2017,3/14/2033,Active,Method of Production / Process,"The patent claims cover a method for producing a low acidic species human anti-TNFα antibody composition comprising a human anti-TNFα antibody, or antigen-binding portion thereof, wherein the human anti-TNFα antibody, or antigen-binding portion thereof, comprises a light chain variable region (LCVR) having a CDR1 domain, a CDR2 domain, and a CDR3 domain of adalimumab; and a heavy chain variable region (HCVR) having a CDR1 domain, a CDR2 domain, and a CDR3 domain of adalimumab.",After,No,https://patents.google.com/patent/US9708399B2/en?oq=US9708399
Humira,US9359434,AbbVie,Arthritis,Biologic,12,4/20/2012,9/2/2015,6/7/2016,3/14/2033,Active,Method of Production / Process,"The patent claims cover a  method for producing a composition comprising adalimumab, the method comprising culturing a mammalian cell producing adalimumab in cell culture media comprising 2 g/L to 11 g/L of each of one or more basic amino acids, to produce a composition comprising adalimumab, wherein the composition comprises less than 20% total acidic species of adalimumab, wherein the acidic species of adalimumab correspond to the peaks that elute earlier than the main peak in a WCX-10 HPLC chromatogram of adalimumab, and wherein the WCX-10 HPLC chromatogram is generated using a first mobile phase of 10 mM Sodium Phosphate dibasic (pH 7.5) and a second mobile phase of 10 mM Sodium Phosphate dibasic, 500 mM Sodium Chloride (pH 5.5), and wherein the WCX-10 HPLC chromatogram is generated using detection at 280 nm.",After,Yes,https://patents.google.com/patent/US9359434B2/en?oq=US9359434
Humira,US9708400,AbbVie,Arthritis,Biologic,12,4/20/2012,10/27/2015,7/18/2017,3/14/2033,Active,Method of Production / Process,"The patent claims cover a composition comprising a human anti-TNFα antibody comprising the heavy and light chain variable domains of adalimumab, wherein less than 62% of the lysine variant species in said composition have zero C-terminal lysines (Lys 0).",After,No,https://patents.google.com/patent/US9708400B2/en?oq=US9708400
Humira,US9683033 ,AbbVie,Arthritis,Biologic,12,4/20/2012,1/28/2016,6/20/2017,3/14/2033,Active,Method of Production / Process,"The patent claims cover a composition comprising adalimumab, wherein the composition comprises less than 10% total acidic species of adalimumab, wherein the acidic species of adalimumab are product-related impurities and do not include process-related impurities comprising host cells and lysed host cells, and wherein the acidic species of adalimumab correspond to the peaks that elute earlier than the main peak in a WCX-10 HPLC chromatogram of adalimumab as shown in FIG. 141.",After,Yes,https://patents.google.com/patent/US9683033B2/en?oq=US9683033+
Humira,US10857302B2,AbbVie,Arthritis,Biologic,26,9/22/2011,5/25/2018,12/8/2020,4/5/2033,Active,Device,The patent claims cover a syringe carrier for use within an automatic injection device. The patent describes the device can be applied to adalimumab.,After,No,https://patents.google.com/patent/US10857302B2/en?oq=US10857302B2
Humira,US9067990,AbbVie,Arthritis,Biologic,12,3/14/2013,3/14/2013,6/30/2015,4/21/2033,Active,Method of Production / Process,"The patent claims cover a method for producing an antibody composition comprising a reduced amount of acidic species of the antibody, wherein the antibody comprises the heavy and light chains of adalimumab.",After,No,https://patents.google.com/patent/US9067990B2/en?oq=US9067990
Humira,US9150645,AbbVie,Arthritis,Biologic,12,4/20/2012,3/14/2013,10/6/2015,5/13/2033,Active,Method of Production / Process,"The patent claims cover a method for producing a composition comprising adalimumab, the method comprising culturing a mammalian cell producing adalimumab in cell culture media comprising 2 g/L to 11 g/L of each of one or more basic amino acids selected from the group consisting of arginine, lysine, ornithine and histidine, and combinations thereof, to produce a composition comprising adalimumab, wherein the composition comprises less than 20% total acidic species of adalimumab, wherein the acidic species of adalimumab do not include process-related impurities selected from the group consisting of host cells and lysed host cells and wherein the acidic species of adalimumab correspond to the peaks that elute earlier than the main peak in a WCX-10 HPLC chromatogram of adalimumab, and wherein the WCX-10 HPLC chromatogram is generated using a first mobile phase of 10 mM Sodium Phosphate dibasic (pH 7.5) and a second mobile phase of 10 mM Sodium Phosphate dibasic, 500 mM Sodium Chloride (pH 5.5), and wherein the WCX-10 HPLC chromatogram is generated using detection at 280 nm.",After,Yes,https://patents.google.com/patent/US9150645B2/en?oq=US9150645
Humira,US9981087,AbbVie,Arthritis,Biologic,26,9/22/2011,3/30/2015,5/29/2018,6/12/2033,Active,Device,"The patent claims cover an automatic injection device.The patent describes the device can be applied to adalimumab.
",After,No,https://patents.google.com/patent/US9981087B2/en?oq=US9981087
Humira,US9957318,AbbVie,Arthritis,Biologic,12,4/20/2012,5/9/2016,5/1/2018,7/22/2033,Active,Method of Production / Process,"The patent claims cover a method of making a pharmaceutical composition, comprising mixing (a) a composition comprising adalimumab, wherein the composition comprises less than 10% total acidic species of adalimumab, wherein the acidic species of adalimumab correspond to the peaks that elute earlier than the main peak in a WCX-10 HPLC chromatogram of adalimumab, wherein the WCX-10 HPLC chromatogram is generated using a first mobile phase of 10 mM Sodium Phosphate dibasic (pH 7.5) and a second mobile phase of 10 mM Sodium Phosphate dibasic, 500 mM Sodium Chloride (pH 5.5), and wherein the WCX-10 HPLC chromatogram is generated using detection at 280 nm; and
(b) a pharmaceutically acceptable carrier, thereby making a pharmaceutical composition.",After,Yes,https://patents.google.com/patent/US9957318B2/en?oq=US9957318
Humira,US9334319,AbbVie,Arthritis,Biologic,12,4/20/2012,3/14/2013,5/10/2016,10/12/2033,Active,Formulation / Combination,"The patent claims cover a composition comprising adalimumab, wherein the composition comprises less than 10% total acidic species of adalimumab, wherein the acidic species of adalimumab correspond to the peaks that elute earlier than the main peak in a WCX-10 HPLC chromatogram of adalimumab, wherein the WCX-10 HPLC chromatogram is generated using a first mobile phase of 10 mM Sodium Phosphate dibasic (pH 7.5) and a second mobile phase of 10 mM Sodium Phosphate dibasic, 500 mM Sodium Chloride (pH 5.5), and wherein the WCX-10 HPLC chromatogram is generated using detection at 280 nm.",After,Yes,https://patents.google.com/patent/US9334319B2/en?oq=US9334319
Humira,US8946395B1,AbbVie,Arthritis,Biologic,20,10/18/2013,11/12/2013,2/3/2015,11/12/2033,Active,Method of Production / Process,"The patent claims cover a method for producing a preparation comprising adalimumab and having a reduced level of at least one impurity, said method comprising:(a) contacting a sample comprising adalimumab and at least one impurity, to a HIC media, in the presence of a load buffer such that (i) a portion of the adalimumab in the sample binds to the HIC media at a Kp of greater than 20 and (ii) a substantial portion of the at least one impurity binds to the HIC media;
(b) collecting a flow through fraction comprising the adalimumab unbound to the HIC media; (c) washing the HIC media with a wash buffer such that a substantial portion of the adalimumab bound to the HIC media is released from the media, wherein the salt concentration and/or the pH of the wash buffer are within 20% of the salt concentration and/or pH of the load buffer; and(d) collecting a wash fraction comprising the adalimumab released from the HIC media, wherein each of the flow through and wash fractions comprise adalimumab and have a reduced level of the at least one impurity.",After,No,https://patents.google.com/patent/US8946395B1/en?oq=US8946395B1
Humira,US9181337B2,AbbVie,Arthritis,Biologic,33,10/18/2013,11/12/2013,11/10/2015,11/12/2033,Active,Method of Production / Process,"The patent claims cover a composition comprising a human anti-TNFα antibody, wherein less than 65% of the lysine variant species in said composition have zero C-terminal lysines (Lys 0),wherein the lysine variant species include the main peak and peaks that elute at a relative residence time later than the main peak, as detected using weak cation-exchange chromatography, andwherein the human anti-TNFα antibody comprises a light chain variable region (LCVR) having a CDR1 domain comprising the amino acid sequence of SEQ ID NO:7, a CDR2 domain comprising the amino acid sequence of SEQ ID NO:5, and a CDR3 domain comprising the amino acid sequence of SEQ ID NO:3; and a heavy chain variable region (HCVR) having a CDR1 domain comprising the amino acid sequence of SEQ ID NO:8, a CDR2 domain comprising the amino acid sequence of SEQ ID NO:6, and a CDR3 domain comprising the amino acid sequence of SEQ ID NO:4, wherein said human anti-TNFαantibody is adalimumab.",After,Yes,https://patents.google.com/patent/US9181337B2/en?oq=US9181337B2
Humira,US9017687,AbbVie,Arthritis,Biologic,12,10/18/2013,11/13/2013,4/28/2015,11/12/2033,Active,Method of Production / Process,The patent claims cover a method for producing a low acidic species adalimumab composition. ,After,No,https://patents.google.com/patent/US9017687B1/en?oq=US9017687
Humira,US9688752,AbbVie,Arthritis,Biologic,12,10/18/2013,3/2/2015,6/7/2017,11/12/2033,Active,Method of Production / Process,"The patent claims cover a method for producing a low acidic species composition comprising an anti-TNFα antibody, or antigen-binding portion thereof, wherein the anti-TNFα antibody, or antigen-binding portion thereof, comprises a light chain variable region (LCVR) having a CDR1 domain comprising the amino acid sequence of SEQ ID NO: 7, a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 5, and a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 3; and a heavy chain variable region (HCVR) having a CDR1 domain comprising the amino acid sequence of SEQ ID NO: 8, a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 6, and a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 4, wherein the anti-TNFα antibody, or antigen-binding portion thereof, is adalimumab, or an antigen-binding portion thereof.",After,No,https://patents.google.com/patent/US9688752B2/en?oq=US9688752
Humira,US9499616B2,AbbVie,Arthritis,Biologic,33,10/18/2013,10/27/2015,11/22/2016,11/12/2033,Active,Method of Production / Process,"The patent claims cover a method for producing a composition comprising a human anti-TNFα antibody, comprising
culturing a cell producing the antibody in a cell culture media comprising an amount of one or more basic amino acids sufficient to produce a composition comprising the antibody in which less than 65% of the lysine variant species of the antibody have zero C-terminal lysines (Lys 0), wherein the lysine variant species include the main peak and peaks that elute at a relative residence time later than the main peak, as detected using weak cation-exchange chromatography, and
wherein the antibody comprises a light chain variable region (LCVR) having a CDR1 domain comprising the amino acid sequence of SEQ ID NO:7, a CDR2 domain comprising the amino acid sequence of SEQ ID NO:5, and a CDR3 domain comprising the amino acid sequence of SEQ ID NO:3; and a heavy chain variable region (HCVR) having a CDR1 domain comprising the amino acid sequence of SEQ ID NO:8, a CDR2 domain comprising the amino acid sequence of SEQ ID NO:6, and a CDR3 domain comprising the amino acid sequence of SEQ ID NO:4, whereinthe antibody is adalimumab.",After,Yes,https://patents.google.com/patent/US9499616B2/en?oq=US9499616B2
Humira,US9499614B2,AbbVie,Arthritis,Biologic,22,3/14/2013,3/13/2014,11/22/2016,3/13/2034,Active,Method of Production / Process,"The patent claims cover a method of producing a composition comprising an immunoglobulin with an increased level of mannosylated N-glycans and/or a decreased level of fucosylated N-glycans, wherein the immunoglobulin comprises a light chain variable region of SEQ ID NO:1 and a heavy chain variable region of SEQ ID NO:2, said method comprising: culturing a mammalian host cell expressing said immunoglobulin in cell culture media supplemented with 5 mM-100 mM sucrose, thereby producing said composition comprising said immunoglobulin with an increased level of mannosylated N-glycans and/or a decreased level of fucosylated N-glycans as compared to a control, wherein said control is a composition comprising the immunoglobulin produced by culturing the mammalian host cell expressing said immunoglobulin in cell culture media which is not supplemented with sucrose, wherein the immunoglobulin is adalimumab, or an antigen binding fragment thereof.
",After,Yes,https://patents.google.com/patent/US9499614B2/en?oq=US9499614B2
Humira,US9943649B2,AbbVie,Arthritis,Biologic,27,9/22/2011,3/20/2014,4/17/2018,7/1/2034,Active,Device,"The patent claims cover an automatic injection device comprising a liquid therapeutic agent in the reservoir, the liquid therapeutic agent comprising adalimumab.",After,No,https://patents.google.com/patent/US9943649B2/en?oq=US9943649B2
Humira,US2003206898 ,Abbott,Arthritis,Biologic,4,4/26/2002,4/26/2002,11/6/2003,,Abandoned,Method of Treatment,"The application claimed a method for treating a disorder in a human subject which disease is treatable with a TNFα antibody or antigen binding fragment thereof, comprising administering a composition to the human subject in need thereof, on a biweekly dosing regimen such that the disorder is treated, said composition comprising an anti-TNFα antibody or an antigen binding portion thereof and administering one or more other drug(s).",Before,No,https://patents.google.com/patent/US20030206898A1/en?oq=US2003206898+
Humira,US2004033228,Abbott / AbbVie,Arthritis,Biologic,7,8/16/2002,8/16/2002,2/19/2004,,Abandoned,Formulation / Combination,"The application claimed a pharmaceutical formulation selected frrom the group consisting of: (a) A liquid aqueous pharmaceutical formulation comprising a therapeutically effective amount of an antibody in a buffered solution, said formulation having a pH between about 4 and 8 and having a shelf life of at least 18 months. (b) An aqueous pharmaceutical formulation comprising a therapeutically effective amount of an antibody in a buffered solution, said formulation having a pH between about 4 and 8 and having a shelf life of at least 18 months in the liquid state.
(c) A liquid aqueous pharmaceutical formulation comprising a therapeutically effective amount of an antibody in a buffered solution, said formulation having a pH between about 4 and 8 which maintains stability following at least 3 freeze/thaw cycles of the formulation. (d) A liquid aqueous pharmaceutical formulation comprising a therapeutically effective amount of an antibody in a buffered solution, said formulation having a pH between 4 and 8 and having enhanced stability of at least 12 months at a temperature of 2-8° C.",Before,No,https://patents.google.com/patent/US20040033228A1/en?oq=US2004033228
Humira,US2003162948,Peptide Technology / Peptech/ Arana Therapeutics,Arthritis,Biologic,1,8/7/1989,10/3/2002,8/28/2003,,Abandoned,Product,"The application claimed  a ligand capable of binding to human TNF, the ligand being characterised in that when it binds to TNF the in vivo tumour regression activity of the TNF is enhanced. ",Before,No,https://patents.google.com/patent/US20030162948A1/en?oq=US2003162948
Humira,US2003139580,Peptide Technology / Peptech/ Arana Therapeutics,Arthritis,Biologic,1,2/18/1992,10/3/2002,7/24/2003,,Abandoned,Product,"The application claimed a ligand capable of binding to human TNF, the ligand being characterised in that when it binds to TNF the in vivo tumour regression activity of the TNF is enhanced.",Before,No,https://patents.google.com/patent/US20030139580A1/en?oq=US2003139580
Humira,US2004214993,Peptide Technology / Peptech/ Arana Therapeutics,Arthritis,Biologic,1,2/18/1992,10/3/2002,10/28/2004,,Abandoned,Product,"The application claimed an isolated antibody or fragment thereof that specifically binds to mature human TNF-α,
wherein the antibody or fragment thereof competitively inhibits MAb 53 (accession No. 90012433) for specific binding to mature human TNF-α and, wherein when the antibody or fragment thereof binds mature human TNF-α, the induction of tumor fibrin deposition is unaffected, and the induction of endothelial procoagulant activity, cytotoxicity, tumor regression and tumor receptor binding are inhibited.",Before,No,https://patents.google.com/patent/US20040214993A2/en?oq=US2004214993
Humira,US2003219438 ,BASF / Abbott / AbbVie,Arthritis,Biologic,2,2/9/1996,11/22/2002,11/27/2003,,Abandoned,Product,"The application claimed an isolated human antibody, or an antigen-binding portion thereof, that dissociates from human TNFα with a Kd of 1×10−8 M or less and a Koff rate constant of 1×10−3 s−1 or less, both determined by surface plasmon resonance, and neutralizes human TNFα cytotoxicity in a standard in vitro L929 assay with an IC50 of 1×10−7 M or less.",Before,No,https://patents.google.com/patent/US20030219438A1/en?oq=US2003219438+
Humira,US2003232970,Peptide Technology / Peptech/ Arana Therapeutics,Arthritis,Biologic,1,8/7/1989,12/16/2002,12/18/2003,,Abandoned,Product,"The application claimed a ligand capable of binding to human TNF, the ligand being characterised in that when it binds to TNF the in vivo tumour regression activity of the TNF is enhanced.",Before,No,https://patents.google.com/patent/US20030232970A1/en?oq=US2003232970
Humira,US2003135029,Peptide Technology / Peptech/ Arana Therapeutics,Arthritis,Biologic,1,2/18/1992,12/16/2002,7/17/2003,,Abandoned,Product,"The application claimed a ligand capable of binding to human TNF, the ligand being characterised in that when it binds to TNF the in vivo tumour regression activity of the TNF is enhanced.",Before,No,https://patents.google.com/patent/US20030135029A1/en?oq=US2003135029
Humira,US2003199678,Peptide Technology / Peptech/ Arana Therapeutics,Arthritis,Biologic,1,2/18/1992,12/16/2002,10/23/2003,,Abandoned,Product,"The application claimed a  ligand capable of binding to human TNF, the ligand being characterised in that when it binds to TNF the in vivo tumour regression activity of the TNF is enhanced.",Before,No,https://patents.google.com/patent/US20030199678A1/en?oq=US2003199678
Humira,US2004002588 ,Peptide Technology / Peptech/ Arana Therapeutics,Arthritis,Biologic,1,8/7/1989,12/20/2002,1/1/2004,,Abandoned,Product,"The application claimed a ligand capable of binding to human TNF, the ligand being characterised in that when it binds to TNF the in vivo tumour regression activity of the TNF is enhanced.",Before,No,https://patents.google.com/patent/US20040002588A1/en?oq=US2004002588
Humira,US2003170204,Peptide Technology / Peptech/ Arana Therapeutics,Arthritis,Biologic,1,2/18/1992,12/20/2002,9/11/2003,,Abandoned,Product,"The application claimed a  ligand capable of binding to human TNF, the ligand being characterised in that when it binds to TNF the in vivo tumour regression activity of the TNF is enhanced.",Before,No,https://patents.google.com/patent/US20030170204A1/en?oq=US2003170204
Humira,US2003208049,Peptide Technology / Peptech/ Arana Therapeutics,Arthritis,Biologic,1,2/18/1992,12/20/2002,11/6/2003,,Abandoned,Product,"The application claimed a ligand capable of binding to human TNF, the ligand being characterised in that when it binds to TNF the in vivo tumour regression activity of the TNF is enhanced.",Before,No,https://patents.google.com/patent/US20030208049A1/en?oq=US2003208049
Humira,US2003166874,Peptide Technology / Peptech/ Arana Therapeutics,Arthritis,Biologic,1,8/7/1989,1/14/2003,9/4/2003,,Abandoned,Product,"The application claimed a ligand capable of binding to human TNF, the ligand being characterised in that when it binds to TNF the in vivo tumour regression activity of the TNF is enhanced.",After,No,https://patents.google.com/patent/US20030166874A1/en?oq=US2003166874
Humira,US2003171553,Peptide Technology / Peptech/ Arana Therapeutics,Arthritis,Biologic,1,8/7/1989,1/14/2003,9/11/2003,,Abandoned,Product,"The application claimed a ligand capable of binding to human TNF, the ligand being characterised in that when it binds to TNF the in vivo tumour regression activity of the TNF is enhanced.
",After,No,https://patents.google.com/patent/US20030171553A1/en?oq=US2003171553
Humira,US2003208047,Peptide Technology / Peptech/ Arana Therapeutics,Arthritis,Biologic,1,8/7/1989,1/14/2003,11/6/2003,,Abandoned,Product,"The application claimed a ligand capable of binding to human TNF, the ligand being characterised in that when it binds to TNF the in vivo tumour regression activity of the TNF is enhanced.",After,No,https://patents.google.com/patent/US20030208047A1/en?oq=US2003208047
Humira,US2003216552,Peptide Technology / Peptech/ Arana Therapeutics,Arthritis,Biologic,1,8/7/1989,1/14/2003,11/20/2003,,Abandoned,Product,"The application claimed a ligand capable of binding to human TNF, the ligand being characterised in that when it binds to TNF the in vivo tumour regression activity of the TNF is enhanced.",After,No,https://patents.google.com/patent/US20030216552A1/en?oq=US2003216552
Humira,US2004002589,Peptide Technology / Peptech/ Arana Therapeutics,Arthritis,Biologic,1,8/7/1989,1/14/2003,1/1/2004,,Abandoned,Product,"The application claimed a ligand capable of binding to human TNF, the ligand being characterised in that when it binds to TNF the in vivo tumour regression activity of the TNF is enhanced.",After,No,https://patents.google.com/patent/US20040002589A1/en?oq=US2004002589
Humira,US2003171554,Peptide Technology / Peptech/ Arana Therapeutics,Arthritis,Biologic,1,8/7/1989,1/15/2003,9/11/2003,,Abandoned,Product,"The application claimed a ligand capable of binding to human TNF, the ligand being characterised in that when it binds to TNF the in vivo tumour regression activity of the TNF is enhanced.",After,No,https://patents.google.com/patent/US20030171554A1/en?oq=US2003171554
Humira,US2003171555 ,Peptide Technology / Peptech/ Arana Therapeutics,Arthritis,Biologic,1,8/7/1989,1/15/2003,9/11/2003,,Abandoned,Product,"The application claimed a  ligand capable of binding to human TNF, the ligand being characterised in that when it binds to TNF the in vivo tumour regression activity of the TNF is enhanced.",After,No,https://patents.google.com/patent/US20030171555A1/en?oq=US2003171555+
Humira,US2004002590 ,Peptide Technology / Peptech/ Arana Therapeutics,Arthritis,Biologic,1,8/7/1989,1/15/2003,1/1/2004,,Abandoned,Product,"The application claimed a ligand capable of binding to human TNF, the ligand being characterised in that when it binds to TNF the in vivo tumour regression activity of the TNF is enhanced.
",After,No,https://patents.google.com/patent/US20040002590A1/en?oq=US2004002590+
Humira,US2004092721,Peptide Technology / Peptech/ Arana Therapeutics,Arthritis,Biologic,1,8/7/1989,1/15/2003,5/13/2004,,Abandoned,Product,"The application claimed a ligand capable of binding to human TNF, the ligand being characterised in that when it binds to TNF the in vivo tumour regression activity of the TNF is enhanced.
",After,No,https://patents.google.com/patent/US20040092721A1/en?oq=US2004092721
Humira,US2003225254 ,Peptide Technology / Peptech/ Arana Therapeutics,Arthritis,Biologic,1,8/7/1989,2/7/2003,12/4/2003,,Abandoned,Product,"The application claimed a  ligand capable of binding to human TNF, the ligand being characterised in that when it binds to TNF the in vivo tumour regression activity of the TNF is enhanced.",After,No,https://patents.google.com/patent/US20030225254A1/en?oq=US2003225254+
Humira,US2003232971,Peptide Technology / Peptech/ Arana Therapeutics,Arthritis,Biologic,1,8/7/1989,6/2/2003,12/18/2003,,Abandoned,Product,"The application claimed a  ligand capable of binding to human TNF, the ligand being characterised in that when it binds to TNF the in vivo tumour regression activity of the TNF is enhanced.",After,No,https://patents.google.com/patent/US20030232971A1/en?oq=US2003232971
Humira,US2004126372,Abbott / AbbVie,Arthritis,Biologic,5,7/19/2002,7/18/2003,7/1/2004,,Abandoned,Method of Treatment,"The application claimed a method of treating a TNFα-related disorder in a subject, wherein the TNFα-related disorder is selected from the group consisting of a spondyloarthropathy, a pulmonary disorder, a coronary disorder, a metabolic disorder, anemia, pain, a hepatic disorder, a skin disorder, a nail disorder, or vasculitis, comprising administering to the subject a therapeutically effective amount of a neutralizing, high affinity TNFα antibody, such that said TNFα-related disorder is treated.",After,No,https://patents.google.com/patent/US20040126372A1/en?oq=US2004126372
Humira,US2004126373,Abbott / AbbVie,Arthritis,Biologic,5,7/19/2002,7/18/2003,7/1/2004,,Abandoned,Method of Treatment,"The application claimed a method of treating or preventing a coronary disorder in a subject comprising administering a therapeutically effective amount of a TNFα antibody, or an antigen-binding fragment thereof, to the subject, wherein the antibody dissociates from human TNFα with a Kd of 1×10−8 M or less and a Koff rate constant of 1×10−3 s−1 or less, both determined by surface plasmon resonance, and neutralizes human TNFα cytotoxicity in a standard in vitro L929 assay with an IC50 of 1×10−7 M or less, such that the coronary disorder is treated or prevented.",After,No,https://patents.google.com/patent/US20040126373A1/en?oq=US2004126373
Humira,US2004131614,Abbott / AbbVie,Arthritis,Biologic,5,7/19/2002,7/18/2003,7/8/2004,,Abandoned,Method of Treatment,"The application claimed a method of treating idiopathic interstitial lung disease or a chronic obstructive airway disorder in a subject comprising administering to the subject a therapeutically effective amount of a neutralizing, high affinity TNFα antibody, such that said disorder is treated.",After,No,https://patents.google.com/patent/US20040131614A1/en?oq=US2004131614
Humira,US2004136989,Abbott / AbbVie,Arthritis,Biologic,5,7/19/2002,7/18/2003,7/15/2004,,Abandoned,Method of Treatment,"The application claimed a method of treating a subject suffering from vasculitis comprising administering a therapeutically effective amount of a TNFα antibody, or an antigen-binding fragment thereof, to the subject, wherein the antibody dissociates from human TNFα with a Kd of 1×10−8 M or less and a Koffrate constant of 1×10−3 s−1 or less, both determined by surface plasmon resonance, and neutralizes human TNFα cytotoxicity in a standard in vitro L929 assay with an IC50 of 1×10−7 M or less, such that the vasculitis is treated.",After,No,https://patents.google.com/patent/US20040136989A1/en?oq=US2004136989
Humira,US2004136990,Abbott / AbbVie,Arthritis,Biologic,5,7/19/2002,7/18/2003,7/15/2004,,Abandoned,Method of Treatment,"The application claimed a method of treating pain in a subject comprising administering to the subject a therapeutically effective amount of a neutralizing, high affinity TNFα antibody, such that said pain is treated.",After,No,https://patents.google.com/patent/US20040136990A1/en?oq=US2004136990
Humira,US2004136991,Abbott / AbbVie,Arthritis,Biologic,5,7/19/2002,7/18/2003,7/15/2004,,Abandoned,Method of Treatment,"The application claimed a method of treating a subject suffering from anemia comprising administering a therapeutically effective amount of a TNFα antibody, or an antigen-binding fragment thereof, to the subject, wherein the antibody dissociates from human TNFα with a Kd of 1×10−8 M or less and a Koff rate constant of 1×10−3 s−1 or less, both determined by surface plasmon resonance, and neutralizes human TNFα cytotoxicity in a standard in vitro L929 assay with an IC50 of 1×10−7 M or less, such that the anemia is treated.",After,No,https://patents.google.com/patent/US20040136991A1/en?oq=US2004136991
Humira,US2004151722,Abbott / AbbVie,Arthritis,Biologic,5,7/19/2002,7/18/2003,8/5/2004,,Abandoned,Method of Treatment,"The application claimed a method of treating a subject suffering from a metabolic disorder comprising administering a therapeutically effective amount of a TNFα antibody, or an antigen-binding fragment thereof, to the subject, wherein the antibody dissociates from human TNFα with a Kd of 1×10−8 M or less and a Koff rate constant of 1×10−3 s−1 or less, both determined by surface plasmon resonance, and neutralizes human TNFα cytotoxicity in a standard in vitro L929 assay with an IC50 of 1×10−7 M or less, such that the metabolic disorder is treated.",After,No,https://patents.google.com/patent/US20040151722A1/en?oq=US2004151722
Humira,US2004219142,Abbott / AbbVie,Arthritis,Biologic,5,7/19/2002,7/18/2003,11/4/2004,,Abandoned,Method of Treatment,"The application claimed a method of treating a skin or nail disorder in a subject comprising administering to the subject a therapeutically effective amount of a neutralizing, high affinity TNFα antibody, such that said skin disorder or nail disorder is treated.",After,No,https://patents.google.com/patent/US20040219142A1/en?oq=US2004219142
Humira,US2007202104,Abbott / AbbVie,Arthritis,Biologic,5,7/19/2002,7/18/2003,8/30/2007,,Abandoned,Method of Treatment,"The application claimed a method of treating a subject suffering from a spondyloarthropathy comprising administering a therapeutically effective amount of a human antibody, or an antigen-binding fragment thereof, to the subject, wherein the antibody dissociates from human TNFα with a Kd of 1×10−8 M or less and a Koff rate constant of 1×10−3 s−1 or less, both determined by surface plasmon resonance, and neutralizes human TNFα cytotoxicity in a standard in vitro L929 assay with an IC50 of 1×10−7 M or less, such that the spondyloarthropathy is treated.",After,No,https://patents.google.com/patent/US20070202104A1/en?oq=US2007202104
Humira,US2013243786 ,Abbott / AbbVie,Arthritis,Biologic,5,7/19/2002,7/18/2003,9/19/2013,,Abandoned,Method of Treatment,"The application claimed a method of reducing the number of joints having active arthritis in a subject having juvenile rheumatoid arthritis disease (JRA), comprising biweekly, subcutaneous administration to the subject of a dosage comprising 10-150 mg of an isolated human anti-TNFα antibody, or an antigen-binding portion thereof, that dissociates from human TNFα with a Kd of 1×10−8 M or less and a Koff rate constant of 1×10−3 s−1 or less, both determined by surface plasmon resonance, and neutralizes human TNFα cytotoxicity in a standard in vitro L929 assay with an IC50 of 1×10−7 M or less, such that the number of joints having active arthritis is reduced in the subject.",After,No,https://patents.google.com/patent/US20130243786A1/en?oq=US2013243786+
Humira,US2004126376,Peptide Technology / Peptech/ Arana Therapeutics,Arthritis,Biologic,1,8/7/1989,11/5/2003,7/1/2004,,Abandoned,Product,"The application claimed a ligand capable of binding to human TNF, the ligand being characterised in that when it binds to TNF the in vivo tumour regression activity of the TNF is enhanced.",After,No,https://patents.google.com/patent/US20040126376A1/en?oq=US2004126376
Humira,US2006140951,Peptide Technology / Peptech/ Arana Therapeutics,Arthritis,Biologic,1,8/7/1989,2/22/2006,6/29/2006,,Abandoned,Product,The application claimed ann antibody or fragment that binds to TNFa and prevents AA's 77-94 from binding to the receptor; and compositions thereof. ,After,No,https://patents.google.com/patent/US20060140951A1/en?oq=US2006140951
Humira,US2006140952 ,Peptide Technology / Peptech/ Arana Therapeutics,Arthritis,Biologic,1,8/7/1989,2/22/2006,6/29/2006,,Abandoned,Product,"The application claimed an antibody or fragment that  prevents AA's 22-40 of TNFa from binding to the receptor, and compositions thereof.",After,No,https://patents.google.com/patent/US20060140952A1/en?oq=US2006140952+
Humira,US2007065426,Peptide Technology / Peptech/ Arana Therapeutics,Arthritis,Biologic,1,8/7/1989,2/28/2006,3/22/2007,,Abandoned,Product,The application claimed an  antibody or fragment that binds to 3 specified AA regions/sequences of TNFa,After,No,https://patents.google.com/patent/US20070065426A1/en?oq=US2007065426
Humira,US2006159677,Peptide Technology / Peptech/ Arana Therapeutics,Arthritis,Biologic,1,8/7/1989,3/7/2006,7/20/2006,,Abandoned,Product,The application claimed an  antibody or fragment that prevents  AA's 54-66 from binding to TNFa; and compositions thereof. ,After,No,https://patents.google.com/patent/US20060159677A1/en?oq=US2006159677
Humira,US2006204499,Peptide Technology / Peptech/ Arana Therapeutics,Arthritis,Biologic,1,8/7/1989,5/8/2006,9/14/2006,,Abandoned,Product,The application claimed an antibody or fragment that prevents AA's 22-40; 49-97; 110-127; and 136-153 from binding to TNFa.,After,No,https://patents.google.com/patent/US20060204499A1/en?oq=US2006204499
Humira,US2006233802,Peptide Technology / Peptech/ Arana Therapeutics,Arthritis,Biologic,1,8/7/1989,6/6/2006,10/19/2006,,Abandoned,Product,The application claimed an antibody or fragment that prevents 18 topographic regions of TNFa frombinding to the receptor. ,After,No,https://patents.google.com/patent/US20060233802A1/en?oq=US2006233802
Humira,US2008045949,Abbott,Arthritis,Biologic,16,6/17/2005,6/19/2006,2/21/2008,,Abandoned,Method of Treatment,"The application claimed a method of treating a degenerative intervertebral disc disorder comprising implanting a disc stabilization device into a subject suffering from the disorder and administering at least one therapeutic agent which promotes healing of the disc to the subject such that treatment of the disorder occurs, wherein the agent is selected from the group consisting of a) an agent which inhibits pro-inflammatory cytokines; b) an anti-enzymatic agent which inhibits degradation of the extracellular matrix of the disc; c) an agent which inhibits angiogenesis in the disc; and
d) a growth factor which promotes extracellular matrix production.",After,No,https://patents.google.com/patent/US20080045949A1/en?oq=US2008045949
Humira,US2007065912,Abbott,Arthritis,Biologic,15,7/21/2005,7/21/2006,3/22/2007,,Abandoned,Method of Production / Process,"The application claimed an expression vector for generating one or more recombinant protein products comprising a sORF insert; said sORF insert comprising a first nucleic acid sequence encoding a first polypeptide, a first intervening nucleic acid sequence encoding a first protein cleavage site, and a second nucleic acid sequence encoding a second polypeptide; wherein said intervening nucleic acid sequence encoding said first protein cleavage site is operably positioned between said first nucleic acid sequence and said second nucleic acid sequence; and wherein said expression vector is capable of expressing a sORF polypeptide cleavable at said first protein cleavage site.",After,No,https://patents.google.com/patent/US20070065912A1/en?oq=US2007065912
Humira,US2008131374,Abbott / AbbVie,Arthritis,Biologic,5,4/19/2006,5/4/2007,6/5/2008,,Abandoned,Method of Treatment,"The application claimed a method of determining the efficacy of a human TNFα antibody (adalimumab) or antigen-binding portion thereof, for treating rheumatoid arthritis (RA).",After,No,https://patents.google.com/patent/US20080131374A1/en?oq=US2008131374
Humira,US2009317399,Abbott / AbbVie,Arthritis,Biologic,5,4/10/2006,5/18/2007,12/24/2009,,Abandoned,Method of Treatment,"The application claimed a method of treating early Crohn's disease in a subject comprising administering to the subject a human TNFα antibody, or antigen-binding fragment thereof, such that early Crohn's disease is treated.",After,No,https://patents.google.com/patent/US20090317399A1/en?oq=US2009317399
Humira,US2008311043,Abbott / AbbVie,Arthritis,Biologic,5,6/8/2006,6/8/2007,12/18/2008,,Abandoned,Method of Treatment,"The application claimed a method of determining the efficacy of a TNFα inhibitor for treating psoriatic arthritis in a subject comprising:determining an ACR response of a patient population having psoriatic arthritis who was administered the TNFα inhibitor,wherein an ACR response selected from the group consisting of an ACR20 response in at least about 39% of the patient population, an ACR50 response in at least about 25% of the patient population, and an ACR70 response in at least about 14% of the patient population, indicates that the TNFα inhibitor is an effective TNFα inhibitor for the treatment of psoriatic arthritis.",After,No,https://patents.google.com/patent/US20080311043A1/en?oq=US2008311043
Humira,US2010021451,Abbott / AbbVie,Arthritis,Biologic,5,6/8/2006,6/8/2007,1/28/2010,,Abandoned,Method of Treatment,"The application claimed a method of decreasing pain and fatigue in a subject having AS comprising administering a human TNFα antibody, or antigen-binding portion thereof, to the subject such that pain and fatigue are decreased.",After,No,https://patents.google.com/patent/US20100021451A1/en?oq=US2010021451
Humira,US2008118496,Abbott / AbbVie,Arthritis,Biologic,5,4/10/2006,6/11/2007,5/22/2008,,Abandoned,Method of Treatment,"The application claimed a method of preventing a flare-up associated with juvenile rheumatoid arthritis (JRA) in a subject comprising administering a TNFα antibody, or antigen-binding portion thereof, to a subject, such that a flare up is prevented.",After,No,https://patents.google.com/patent/US20080118496A1/en?oq=US2008118496
Humira,US2009304682,Abbott / AbbVie,Arthritis,Biologic,5,4/9/2004,1/7/2008,12/10/2009,,Abandoned,Method of Treatment,The application claimed a method of treating Crohn's disease in a subject comprising administering to the subject a TNFα inhibitor (adalimumab) that a mean serum TNFα inhibitor trough level of about 12 μg/mL is achieved. ,After,No,https://patents.google.com/patent/US20090304682A1/en?oq=US2009304682
Humira,US2008193466,Abbott / AbbVie,Arthritis,Biologic,5,7/19/2002,4/14/2008,8/14/2008,,Abandoned,Method of Treatment,"The application claimed a method of treating a subject suffering from anemia comprising administering a therapeutically effective amount of a human antibody, or an antigen-binding fragment thereof, to the subject, wherein the antibody dissociates from human TNFα with a Kd of 1×10−8 M or less and a Koff rate constant of 1×10−3 s−1 or less, both determined by surface plasmon resonance, and neutralizes human TNFα cytotoxicity in a standard in vitro L929 assay with an IC50 of 1×10−7 M or less, such that the anemia is treated.",After,No,https://patents.google.com/patent/US20080193466A1/en?oq=US2008193466
Humira,US2010003243,Abbott / AbbVie,Arthritis,Biologic,5,6/1/2007,1/12/2009,1/7/2010,,Abandoned,Method of Diagnosis,"The application claimed a method of determining the efficacy of a human TNFα antibody, or antigen-binding fragment thereof, for achieving a clinical response in Crohn's disease in a subject, wherein the human TNFα antibody, or an antigen-binding portion thereof, is adalimumab.",After,No,https://patents.google.com/patent/US20100003243A1/en?oq=US2010003243
Humira,US2009280065,Abbott / AbbVie,Arthritis,Biologic,5,4/10/2006,3/11/2009,11/12/2009,,Abandoned,Method of Treatment,"The application claimed a method of improving a DLQI score of a subject having psoriasis from a large/extremely large score to a no or small impact score comprising administering a human TNFα antibody, or antigen-binding portion thereof, to the subject, such that the DLQI score improves from the large/extremely large score to the no or small impact score.",After,No,https://patents.google.com/patent/US20090280065A1/en?oq=US2009280065
Humira,US2010125130,Peptide Technology / Peptech/ Arana Therapeutics,Arthritis,Biologic,1,8/7/1989,9/10/2009,5/20/2010,,Abandoned,Product,"The application claimed an  isolated antibody or fragment thereof that specifically binds to mature human TNF-α, wherein the antibody or fragment thereof competitively inhibits MAb 1 (ECACC Accession No. 89080301) for specific binding to mature human TNF-α and, wherein when the antibody or fragment thereof binds mature human TNF-α, the induction of endothelial procoagulant activity, cytotoxicity, tumor regression and tumor receptor binding to TNF-α and induction of tumor fibrin deposition are inhibited.",After,No,https://patents.google.com/patent/US20100125130A1/en?oq=US2010125130
Humira,US2011034368,Abbott,Arthritis,Biologic,15,7/21/2005,6/24/2010,2/10/2011,,Abandoned,Method of Production / Process,"The application claimed an  expression vector for generating one or more recombinant protein products comprising a sORF insert; said sORF insert comprising a first nucleic acid sequence encoding a first polypeptide, a first intervening nucleic acid sequence encoding a first protein cleavage site, and a second nucleic acid sequence encoding a second polypeptide; wherein said intervening nucleic acid sequence encoding said first protein cleavage site is operably positioned between said first nucleic acid sequence and said second nucleic acid sequence; and wherein said expression vector is capable of expressing a sORF polypeptide cleavable at said first protein cleavage site.",After,No,https://patents.google.com/patent/US20110034368A1/en?oq=US2011034368
Humira,US2012171123,Abbott / AbbVie,Arthritis,Biologic,5,4/19/2006,10/25/2011,7/5/2012,,Abandoned,Method of Treatment,"The application claimed a method of determining the efficacy of a human TNFα antibody, or antigen-binding portion thereof, for treating rheumatoid arthritis (RA).",After,No,https://patents.google.com/patent/US20120171123A1/en?oq=US2012171123
Humira,US20120039900A1,Abbott / AbbVie,Arthritis,Biologic,32,5/31/2007,10/27/2011,2/16/2012,,Abandoned,Method of Diagnosis,"The application claimed a method for predicting responsiveness to a TNFα inhibitor in a subject having an autoimmune disorder, the method comprising: (i) assaying the subject for expression of one or more biomarkers predictive of responsiveness to a TNFα inhibitor in an autoimmune disorder, and (ii) predicting responsiveness of the subject to the TNFα inhibitor based on expression of the one or more biomarkers in the subject, wherein the one or more biomarkers is encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 1-10, 12-28, 30-43, 45-61, 63, 64, 66-73, and 75-82,",After,No,https://patents.google.com/patent/US20120039900A1/en?oq=US20120039900A1
Humira,US2012177596,Abbott / AbbVie,Arthritis,Biologic,3,6/8/2001,11/3/2011,7/12/2012,,Abandoned,Method of Treatment,"The application claimed a method for treating an intestinal disorder in a human subject, comprising subcutaneously administering a total body dose of 20-80 mg of an isolated human anti-TNFα antibody, or an antigen-binding fragment thereof, to the human subject, on a biweekly dosing regimen such that the intestinal disorder is treated.",After,No,https://patents.google.com/patent/US20120177596A1/en?oq=US2012177596
Humira,US2012282262,Abbott / AbbVie,Arthritis,Biologic,5,6/1/2007,1/9/2012,11/8/2012,,Abandoned,Method of Diagnosis,"The application claimed a method of determining the efficacy of a TNFα inhibitor for achieving a clinical response in Crohn's disease or maintaining remission of Crohn's disease in a subject, wherein the human TNFα antibody, or an antigen-binding portion thereof, is adalimumab.",After,No,https://patents.google.com/patent/US20120282262A1/en?oq=US2012282262
Humira,US2013004507,Abbott / AbbVie,Arthritis,Biologic,3,6/8/2001,6/22/2012,1/3/2013,,Abandoned,Method of Treatment,"The application claimed a method for treating a disorder in a human subject in which the disease is treatable with a TNFα antibody, comprising administering a composition to the human subject in need thereof, on a biweekly dosing regimen such that the disorder is treated, said composition containing an anti-TNFα antibody or an antigen binding portion thereof.",After,No,https://patents.google.com/patent/US20130004507A1/en?oq=US2013004507
Humira,US2013028903,AbbVie,Arthritis,Biologic,8,4/5/2006,6/25/2012,1/31/2013,,Abandoned,Formulation / Combination,"The application claimed a pharmaceutical composition comprising an isolated human anti-TNFα antibody which is adalimumab, or an antigen-binding portion thereof, wherein the composition contains a level of HCP no greater than about 70 ng of HCP per mg of antibody as measured by an HCP ELISA and a cathepsin L activity of no greater than about 3.0 RFU/s/mg antibody.",After,No,https://patents.google.com/patent/US20130028903A1/en?oq=US2013028903
Humira,US2013115224 ,BASF / Abbott / AbbVie,Arthritis,Biologic,2,2/9/1996,1/8/2013,5/9/2013,,Abandoned,Product,"The application claimed an isolated human antibody, or antigen-binding portion thereof, comprising a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 1 and a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 2.",After,No,https://patents.google.com/patent/US20130115224A1/en?oq=US2013115224+
Humira,US2013122018 ,BASF / Abbott / AbbVie,Arthritis,Biologic,2,2/9/1996,1/10/2013,5/16/2013,,Abandoned,Product,"The application claimed an  isolated human antibody, or an antigen-binding portion thereof, which dissociates from human TNFα with a Kd of 1×10−8 M or less and a Koff rate constant of 1×10−3 s−1 or less, both determined by surface plasmon resonance, and neutralizes TNFα-induced cellular activation in a standard in vitro assay for TNFα-induced ELAM-1 expression on human umbilical vein endothelial cells (HUVEC).",After,No,https://patents.google.com/patent/US20130122018A1/en?oq=US2013122018+
Humira,US2013243789,Abbott,Arthritis,Biologic,15,7/21/2005,1/11/2013,9/19/2013,,Abandoned,Method of Production / Process,"The application claimed an expression vector for generating one or more recombinant protein products comprising a sORF insert; said sORF insert comprising a first nucleic acid sequence encoding a first polypeptide, a first intervening nucleic acid sequence encoding a first protein cleavage site, and a second nucleic acid sequence encoding a second polypeptide; wherein said intervening nucleic acid sequence encoding said first protein cleavage site is operably positioned between said first nucleic acid sequence and said second nucleic acid sequence; and wherein said expression vector is capable of expressing a sORF polypeptide cleavable at said first protein cleavage site.",After,No,https://patents.google.com/patent/US20130243789A1/en?oq=US2013243789
Humira,US9443445B2,AbbVie,Arthritis,Biologic,31,3/2/2012,3/1/2013,9/13/2016,7/23/2033,Expired,Device,"The patent claims cover an automatic injection training device to simulate an automatic injection, wherein the TNFα inhibitor is adalimumab.",After,No,https://patents.google.com/patent/US9443445B2/en?oq=US9443445B2
Humira,US2013243763,Abbott / AbbVie,Arthritis,Biologic,5,7/19/2002,5/28/2013,9/19/2013,,Abandoned,Method of Treatment,"The application claimed a method for treating hidradenitis suppurativa (HS) in a subject, the method comprising subcutaneously administering to the subject an isolated human anti-TNFα antibody, or an antigen binding portion thereof, such that HS is treated.",After,No,https://patents.google.com/patent/US20130243763A1/en?oq=US2013243763
Humira,US2013330356,BASF / Abbott / AbbVie,Arthritis,Biologic,2,2/9/1996,8/12/2013,12/12/2013,,Abandoned,Product,"The application claimed an isolated human antibody, or antigen-binding portion thereof, comprising a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 1 and a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 2.",After,No,https://patents.google.com/patent/US20130330356A1/en?oq=US2013330356
Humira,US2013330357,BASF / Abbott / AbbVie,Arthritis,Biologic,2,2/9/1996,8/12/2013,12/12/2013,,Abandoned,Product,"The application claimed an isolated human antibody, or antigen-binding portion thereof, comprising a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 1 and a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 2.",After,No,https://patents.google.com/patent/US20130330357A1/en?oq=US2013330357
Humira,US2014248215,Abbott / AbbVie,Arthritis,Biologic,5,6/8/2006,8/26/2013,9/4/2014,,Abandoned,Method of Treatment,"The application claimed a method of determining the efficacy of a TNFα inhibitor for treating psoriatic arthritis in a subject comprising: determining an ACR20 response of a patient population having psoriatic arthritis who was administered the TNFα inhibitor, wherein an ACR20 response in at least about 39% of the patient population indicates that the TNFα inhibitor is an effective TNFα inhibitor for the treatment of psoriatic arthritis",After,No,https://patents.google.com/patent/US20140248215A1/en?oq=US2014248215
Humira,US2014134674,AbbVie,Arthritis,Biologic,9,9/13/2006,1/16/2014,5/15/2014,,Abandoned,Method of Production / Process,"The application claimed a method of producing an antibody in a mammalian cell culture such that the titer of the antibody is at least 100 mg/L, said method comprising a) culturing mammalian cells comprising a nucleic acid encoding the antibody in a cell culture production medium;b) adding sodium butyrate, N-acetylcysteine, or a combination thereof, to the cell culture medium, wherein the sodium butyrate is added to a final concentration of about 0.1 mM to 10 mM and the N-acetylcysteine is added to a final concentration of about 1 mM to 80 mM, such that the antibody is produced at a titer of at least 100 mg/L.",After,No,https://patents.google.com/patent/US20140134674A1/en?oq=US2014134674
Humira,US2015037772 ,Abbott / AbbVie,Arthritis,Biologic,5,6/30/2006,1/31/2014,2/5/2015,,Abandoned,Device,"The application claimed a training device for training a recipient on administration of a substance, the system comprising:
a circular outer housing; an activation button operatively coupled to the housing; and an audible mechanism to convey audible information to a user concerning operation of the training automatic injector. The patent describes the invention can be applied to adalimumab.",After,No,https://patents.google.com/patent/US20150037772A1/en?oq=US2015037772+
Humira,US2014186368,Abbott / AbbVie,Arthritis,Biologic,3,6/8/2001,2/7/2014,7/3/2014,,Abandoned,Method of Treatment,"The application claimed a method for treating a disorder in a human subject in which the disease is treatable with a TNFα antibody, comprising administering a composition to the human subject in need thereof, on a biweekly dosing regimen such that the disorder is treated, said composition containing an anti-TNFα antibody or an antigen binding portion thereof.",After,No,https://patents.google.com/patent/US20140186368A1/en?oq=US2014186368
Humira,US2014200332,Abbott / AbbVie,Arthritis,Biologic,5,10/24/2002,2/19/2014,7/17/2014,,Abandoned,Method of Treatment,"The application claimed a  human anti-TNFα antibody which is either D2E7, or a human anti-TNFα antibody with equivalent properties to D2E7 which dissociates from human TNFα with a Kd of 1×10−8 M or less and a keg rate constant of 1×10−3 s−1 or less, both determined by surface plasmon resonance, and neutralizes human TNFα cytotoxicity in a standard in vitro L929 assay with an IC50 of 1×10−7 M or less, for use in the treatment or alleviation of arthritis, wherein the anti-TNFα antibody is to be administered in a low dose of 0.01-0.11 mg/kg, such that the arthritis is treated or alleviated.",After,No,https://patents.google.com/patent/US20140200332A1/en?oq=US2014200332
Humira,US2014212430,Abbott / AbbVie,Arthritis,Biologic,5,4/9/2004,3/28/2014,7/31/2014,,Abandoned,Kit,The application claimed a  kit for the treatment of a disorder in which TNFα activity is detrimental comprising: a) at least one container comprising an induction dose of a TNFα inhibitor; b) at least one container comprising a treatment dose of a TNFα inhibitor; and c) instructions for administration of the induction dose of the TNFα inhibitor within an induction phase and the treatment dose of the TNFα inhibitor within a treatment phase.,After,No,https://patents.google.com/patent/US20140212430A1/en?oq=US2014212430
Humira,US2014248275,Abbott / AbbVie,Arthritis,Biologic,5,4/9/2004,3/28/2014,9/4/2014,,Abandoned,Method of Treatment,"The application claimed a multiple-variable dose method of inducing remission of Crohn's disease or reducing psoriatic plaques, comprising:administering to a subject in need thereof at least one induction dose of D2E7 such that a threshold level of TNFα inhibitor is achieved within an induction phase; and subsequently administering to the subject at least one treatment dose of D2E7 within a treatment phase, such that treatment occurs.",After,No,https://patents.google.com/patent/US20140248275A1/en?oq=US2014248275
Humira,US2014248276,Abbott / AbbVie,Arthritis,Biologic,5,4/9/2004,3/28/2014,9/4/2014,,Abandoned,Kit,"The application claimed a kit for treating psoriasis in a subject in need thereof, comprising:(a) two containers each comprising a 40 mg dose of an anti-TNFα antibody (adalimumab), wherein said two containers are used for administering a first dose of the antibody, and wherein the two 40 mg doses are administered within a day;(b) one additional container comprising a 40 mg dose of an anti-TNFα antibody, wherein said container is used for administering a second dose of the antibody; and(c) instructions for administration, wherein said instructions describe that the second dose of the antibody is subcutaneously administered one week following subcutaneous administration of the first dose of the antibody;wherein the antibody comprises a heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:8; a CDR2 comprising the amino acid sequence of SEQ ID NO:6; and a CDR3 comprising the amino acid sequence of SEQ ID NO:4; and a light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:7; a CDR2 comprising the amino acid sequence of SEQ ID NO:5; and a CDR3 comprising the amino acid sequence of SEQ ID NO:3.",After,No,https://patents.google.com/patent/US20140248276A1/en?oq=US2014248276
Humira,US20140358117A1,AbbVie,Arthritis,Biologic,28,12/15/2009,4/23/2014,12/14/2014,,Abandoned,Device,"The application claimed a firing button for use in an automatic injection device, wherein the automatic injection device comprises human TNFα antibody, or antigen-binding portion thereof, is adalimumab or golimumab.",After,No,https://patents.google.com/patent/US20140358117A1/en?oq=US20140358117A1
Humira,US10300200 B2,AbbVie,Arthritis,Biologic,19,3/1/2017,2/27/2018,5/28/2019,2/27/2038,Active,Device,"The patent claims cover a firing mechanism assembly comprising:a firing body and an activation button moveable relative to the firing body between an initial position and an actuated position, the activation button configured to deploy a plunger when moved to the actuated position, the firing mechanism assembly further including a piercing element extending from at least one of the firing body and the activation button; and a near-field communication (NFC) assembly comprising a film disposed proximate the piercing element and configured to be pierced by the piercing element upon movement of the activation button to the actuated position, and an NFC circuit configured to indicate a film status including at least an unpierced film status before the film is pierced and a pierced film status after the film is pierced.The patent describes the device can be applied to adalimumab.",After,No,https://patents.google.com/patent/US10300200B2/en?oq=US10300200+B2
Humira,US2014286939 ,Abbott / AbbVie,Arthritis,Biologic,5,7/19/2002,5/2/2014,9/25/2014,,Abandoned,Method of Treatment,"The application claimed a method of treating lupus in a subject comprising administering to the subject a therapeutically effective amount of a neutralizing, high affinity TNFα antibody, such that lupus is treated.",After,No,https://patents.google.com/patent/US20140286939A1/en?oq=US2014286939+
Humira,US2014286940 ,Abbott / AbbVie,Arthritis,Biologic,5,7/19/2002,5/2/2014,9/25/2014,,Abandoned,Method of Treatment,"The application claimed a method of treating Sjogren's syndrome in a subject comprising administering to the subject a therapeutically effective amount of a neutralizing, high affinity TNFα antibody, such that Sjogren's syndrome is treated.",After,No,https://patents.google.com/patent/US20140286940A1/en?oq=US2014286940+
Humira,US2014286941,Abbott / AbbVie,Arthritis,Biologic,5,7/19/2002,5/2/2014,9/25/2014,,Abandoned,Method of Treatment,"The application claimed a method of treating uveitis in a subject comprising administering to the subject a therapeutically effective amount of a neutralizing, high affinity TNFα antibody, such that uveitis is treated.",After,No,https://patents.google.com/patent/US20140286941A1/en?oq=US2014286941
Humira,US2015125905 ,AbbVie,Arthritis,Biologic,9,9/13/2006,6/3/2014,5/7/2015,,Abandoned,Method of Production / Process,The application claimed a fed batch method of producing an anti-TNFα antibody.,After,No,https://patents.google.com/patent/US20150125905A1/en?oq=US2015125905+
Humira,US20150183863A1,AbbVie,Arthritis,Biologic,38,10/27/2006,6/19/2014,7/2/2015,,Abandoned,Method of Production / Process,"The application claimed a batch crystallization method for crystallizing an anti-hTNFalpha antibody, comprising the steps of:
(a) providing an aqueous solution of said antibody in admixture with an inorganic phosphate salt as crystallization agent; and (b) incubating said aqueous crystallization mixture until crystals of said antibody are formed.",After,No,https://patents.google.com/patent/US20150183863A1/en?oq=US20150183863A1
Humira,US2015050216,Abbott / AbbVie,Arthritis,Biologic,5,7/19/2002,7/8/2014,2/19/2015,,Abandoned,Method of Treatment,"The application claimed a method of improving a DLQI score of a subject having psoriasis from a large/extremely large score to a no or small impact score comprising administering a human TNFα antibody, or antigen-binding portion thereof, to the subject, such that the DLQI score improves from the large/extremely large score to the no or small impact score.",After,No,https://patents.google.com/patent/US20150050216A1/en?oq=US2015050216
Humira,US2015056212 ,Abbott / AbbVie,Arthritis,Biologic,5,4/10/2006,10/28/2014,2/26/2015,,Abandoned,Method of Treatment,"The application claimed a method for maintaining clinical remission of rheumatoid arthritis in a subject, the method comprising administering to a subject who is in clinical remission from rheumatoid arthritis an antibody, or an antigen-binding portion thereof, that binds to human Tumor Necrosis Factor alpha (TNFα) in an amount effective to maintain clinical remission of rheumatoid arthritis in the subject, wherein the antibody, or antigen-binding portion thereof, comprises a light chain variable region (LCVR) having a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 3, a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 5, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO: 7; and comprises a heavy chain variable region (HCVR) comprising a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 4, a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 6, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO: 8.",After,No,https://patents.google.com/patent/US20150056212A1/en?oq=US2015056212+
Humira,US2015064194,Abbott / AbbVie,Arthritis,Biologic,5,4/10/2006,10/28/2014,3/5/2015,,Abandoned,Method of Treatment,"The application claimed a method for enhancing immunization with a vaccine and treating rheumatoid arthritis (RA) in a subject having RA, the method comprising administering to the subject a vaccine comprising an antigen and administering to the subject an antibody (adalimumab) or an antigen-binding portion thereof, that binds to human Tumor Necrosis Factor alpha (TNFα) in an amount sufficient to enhance immunization with the vaccine and treat the RA in the subject, wherein the anti-TNFα antibody, or an antigen-binding portion thereof, comprises a light chain variable region (LCVR) having a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 3, a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 5, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO: 7; and comprises a heavy chain variable region (HCVR) comprising a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 4, a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 6, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO: 8.",After,No,https://patents.google.com/patent/US20150064194A1/en?oq=US2015064194
Humira,US2015064195 ,Abbott / AbbVie,Arthritis,Biologic,5,4/10/2006,10/28/2014,3/5/2015,,Abandoned,Method of Treatment,"The application claimed a method for treating a subject having late onset rheumatoid arthritis (LORA), the method comprising administering to the subject an effective amount of an antibody, or an antigen-binding portion thereof, that binds to human Tumor Necrosis Factor alpha (TNFα) to thereby treat the LORA, wherein the antibody, or antigen-binding portion thereof, comprises a light chain variable region (LCVR) having a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 3, a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 5, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO: 7; and comprises a heavy chain variable region (HCVR) comprising a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 4, a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 6, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO: 8.",After,No,https://patents.google.com/patent/US20150064195A1/en?oq=US2015064195+
Humira,US2015071945,Abbott / AbbVie,Arthritis,Biologic,3,6/8/2001,11/14/2014,3/12/2015,,Abandoned,Formulation / Combination,"The application claimed a syringe pre-filled with a composition comprising 40 mg of a human anti-TNFα antibody and a pharmaceutically acceptable carrier, excipient or diluent, wherein the anti-TNFα antibody comprises an IgG1 heavy chain constant region; a variable light (“VL”) chain region comprising a CDR1 having the amino acid sequence of SEQ ID NO:7, a CDR2 having the amino acid sequence of SEQ ID NO:5, and a CDR3 having the amino acid sequence of SEQ ID NO:3; and a variable heavy (“VH”) chain region comprising a CDR1 having the amino acid sequence of SEQ ID NO:8, a CDR2 having the amino acid sequence of SEQ ID NO:6 and a CDR3 having the amino acid sequence of SEQ ID NO:4.",After,No,https://patents.google.com/patent/US20150071945A1/en?oq=US2015071945
Humira,US2015079101 ,Abbott / AbbVie,Arthritis,Biologic,3,6/8/2001,11/14/2014,3/12/2015,,Abandoned,Formulation / Combination,"The application claimed a syringe pre-filled with a composition comprising 40 mg of a human anti-TNFα antibody and a pharmaceutically acceptable carrier, excipient or diluent, wherein the anti-TNFα antibody comprises an IgG1 heavy chain constant region; a variable light (“VL”) chain region comprising a CDR1 having the amino acid sequence of SEQ ID NO:7, a CDR2 having the amino acid sequence of SEQ ID NO:5, and a CDR3 having the amino acid sequence of SEQ ID NO:3; and a variable heavy (“VH”) chain region comprising a CDR1 having the amino acid sequence of SEQ ID NO:8, a CDR2 having the amino acid sequence of SEQ ID NO:6 and a CDR3 having the amino acid sequence of SEQ ID NO:4.",After,No,https://patents.google.com/patent/US20150079101A1/en?oq=US2015079101+
Humira,US2015080557,AbbVie,Arthritis,Biologic,12,3/12/2013,12/3/2014,3/19/2015,,Abandoned,Method of Production / Process,"The application claimed a composition comprising a binding protein capable of binding TNF-alpha, said binding protein comprising a methylglyoxal (MGO)-susceptible amino acid, wherein said composition is prepared by substantially removing molecules of said binding protein that comprise at least one MGO-modified amino acid. The patent describes the invention can be applied to adalimumab.",After,No,https://patents.google.com/patent/US20150080557A1/en?oq=US2015080557
Humira,US20150299249A1,AbbVie,Arthritis,Biologic,20,10/18/2013,12/11/2014,10/22/2015,,Abandoned,Method of Production / Process,"The application claimed a method for producing a preparation comprising a protein of interest and having a reduced level of at least one impurity, wherein the protein of interest is adalimumab.",After,No,https://patents.google.com/patent/US20150299249A1/en?oq=US20150299249A1
Humira,US2015165023,Abbott / AbbVie,Arthritis,Biologic,3,6/8/2001,2/27/2015,6/18/2015,,Abandoned,Method of Treatment,"The application claimed a method for treating rheumatoid arthritis in a human patient with moderately to severely active rheumatoid arthritis, comprising: administering to said patient, in combination with methotrexate, a human anti-TNFα antibody comprising an IgG1 heavy chain constant region; a variable light (“VL”) chain region comprising a CDR1 having the amino acid sequence of SEQ ID NO:7, a CDR2 having the amino acid sequence of SEQ ID NO:5, and a CDR3 having the amino acid sequence of SEQ ID NO:3; and a variable heavy (“VH”) chain region comprising a CDR1 having the amino acid sequence of SEQ ID NO:8, a CDR2 having the amino acid sequence of SEQ ID NO:6 and a CDR3 having the amino acid sequence of SEQ ID NO:4, wherein the human anti-TNFα antibody is administered subcutaneously in a total body dose of 40 mg once every 13-15 days, and wherein the human anti-TNFα antibody is administered to said patient for a time period that would be sufficient for more than 49% of the moderate to severe rheumatoid arthritis population in North America to achieve an ACR20 response if so treated.",After,No,https://patents.google.com/patent/US20150165023A1/en?oq=US2015165023
Humira,US2015175691,Abbott / AbbVie,Arthritis,Biologic,3,6/8/2001,2/27/2015,6/25/2015,,Abandoned,Method of Treatment,"The application claimed a method for treating TNFα-mediated inflammation of the joints in a human subject, comprising:
administering subcutaneously to a human subject having TNFα-mediated inflammation of the joints a total body dose of 40 mg of a human anti-TNFα antibody once every 13-15 days for a time period sufficient to treat the TNFα-mediated inflammation of the joints, wherein the anti-TNFα antibody comprises an IgG1 heavy chain constant region; a variable light (“VL”) chain region comprising a CDR1 having the amino acid sequence of SEQ ID NO:7, a CDR2 having the amino acid sequence of SEQ ID NO:5, and a CDR3 having the amino acid sequence of SEQ ID NO:3; and a variable heavy (“VH”) chain region comprising a CDR1 having the amino acid sequence of SEQ ID NO:8, a CDR2 having the amino acid sequence of SEQ ID NO:6 and a CDR3 having the amino acid sequence of SEQ ID NO:4.",After,No,https://patents.google.com/patent/US20150175691A1/en?oq=US2015175691
Humira,US2015210735,Abbott / AbbVie,Arthritis,Biologic,14,10/20/2008,4/13/2015,7/30/2015,,Abandoned,Method of Production / Process,"The application claimed a pharmaceutical grade preparation comprising adalimumab, wherein the adalimumab is purified from a fermentation harvest of cultured cells expressing adalimumab.
",After,No,https://patents.google.com/patent/US20150210735A1/en?oq=US2015210735
Humira,US2016083452 ,Abbott / AbbVie,Arthritis,Biologic,14,10/20/2008,4/27/2015,3/24/2016,,Abandoned,Method of Production / Process,"The application claimed a method for producing a host cell-protein (HCP) reduced antibody preparation from a sample mixture comprising an antibody and at least one HCP. 
",After,No,https://patents.google.com/patent/US20160083452A1/en?oq=US2016083452+
Humira,US2015246968,Abbott / AbbVie,Arthritis,Biologic,3,6/8/2001,5/18/2015,9/3/2015,,Abandoned,Method of Treatment,"The application claimed a  method for treating rheumatoid arthritis in a human subject, comprising administering subcutaneously to a human subject having rheumatoid arthritis a total body dose of 40 mg of a human anti-TNFα antibody once every 14 days for a time period sufficient to treat the rheumatoid arthritis, wherein the anti-TNFα antibody comprises an IgG1 heavy chain constant region; a variable light (“VL”) chain region comprising a CDR1 having the amino acid sequence of SEQ ID NO:7, a CDR2 having the amino acid sequence of SEQ ID NO:5, and a CDR3 having the amino acid sequence of SEQ ID NO:3; and a variable heavy (“VH”) chain region comprising a CDR1 having the amino acid sequence of SEQ ID NO:8, a CDR2 having the amino acid sequence of SEQ ID NO:6 and a CDR3 having the amino acid sequence of SEQ ID NO:4.",After,No,https://patents.google.com/patent/US20150246968A1/en?oq=US2015246968
Humira,US2017044249,Abbott / AbbVie,Arthritis,Biologic,5,4/9/2004,6/19/2015,2/16/2017,,Abandoned,Method of Treatment,"The application claimed a multiple-variable dose method for treating a disorder in which TNFα activity is detrimental, comprising: administering to a subject in need thereof at least one induction dose of a TNFα inhibitor (adalimumab) such that a threshold level of TNFα inhibitor is achieved within an induction phase; and subsequently administering to the subject at least one treatment dose of the TNFα inhibitor within a treatment phase, such that treatment occurs.",After,No,https://patents.google.com/patent/US20170044249A1/en?oq=US2017044249
Humira,US20150361170A1,AbbVie,Arthritis,Biologic,39,11/30/2007,7/10/2015,12/17/2015,,Abandoned,Formulation / Combination,"The application claimed an aqueous formulation comprising a protein and water, wherein the antibody, or antigen-binding fragment thereof, is selected from the group consisting of adalimumab, alemtuzumab, CEA-Scan Arcitumomab (fab fragment), cetuximab, trastuzumab, imciromab pentetate), capromab pendetide, infliximab), abciximab, rituximab, basiliximab, palivizumab, nofetumomab, omalizumab, daclizumab, ibritumomab tiuxetan, muromonab-CD3, edrecolomab, gemtuzumab ozogamicin), golimumab, certolizumab pegol, eculizumab, ustekinumab, panitumumab, tositumomab and I131 tositumomab, and bevacizumab.",After,No,https://patents.google.com/patent/US20150361170A1/en?oq=US20150361170A1
Humira,US2016376360 ,Abbott / AbbVie,Arthritis,Biologic,5,4/9/2004,7/27/2015,12/29/2016,,Abandoned,Method of Treatment,"The application claimed a method for treating moderate to severe chronic plaque psoriasis, comprising subcutaneously administering to an adult patient having moderate to severe chronic plaque psoriasis an initial dose of 80 mg of adalimumab, followed by 40 mg of adalimumab every other week starting one week after said first dosing, wherein the patient achieves at least Psoriasis Area and Severity Index (PASI) 75 response at week 12 of the treatment.",After,No,https://patents.google.com/patent/US20160376360A9/en?oq=US2016376360+
Humira,US2016200809,Abbott / AbbVie,Arthritis,Biologic,5,4/10/2006,8/17/2015,7/14/2016,,Abandoned,Method of Treatment,"The application claimed a method for maintaining clinical remission of psoriasis in a subject, the method comprising administering adalimumab to a subject who is in clinical remission from psoriasis in an amount effective to maintain clinical remission of the psoriasis in the subject. The application also covered a method of treating psoriasis in a subject, wherein the Dermatology Life Quality Index (DLQI) score in the subject is reduced from a score of 11-30 to a score of 0-5, and wherein said DLQI score reduction is maintained by subcutaneously administering the anti-TNFα antibody in a maintenance dose of 40 mg every other week to the subject consecutively for 26 weeks, 32 weeks, 36 weeks, 42 weeks, 48 weeks, 52 weeks or 56 weeks, further wherein the anti-TNFα antibody is adalimumab.",After,No,https://patents.google.com/patent/US20160200809A1/en?oq=US2016200809
Humira,US2015361169,AbbVie,Arthritis,Biologic,8,4/5/2006,8/31/2015,12/17/2015,,Abandoned,Formulation / Combination,"The application claimed a iquid pharmaceutical composition comprising:a) adalimumab;b) a polyol selected from the group consisting of sucrose, trehalose, and sorbitol;c) a surfactant; and d) a buffer system having a pH of 4 to 8, wherein the adalimumab is expressed in a Chinese Hamster Ovary (CHO) cell expression system; and the composition is characterized in that when the composition is assayed in a cathepsin L kinetic assay, a level of cathepsin L activity less than 1.3 RFU/s/mg of adalimumab is observed",After,No,https://patents.google.com/patent/US20150361169A1/en?oq=US2015361169
Humira,US2015368335 ,Abbott / AbbVie,Arthritis,Biologic,5,7/19/2002,9/3/2015,12/24/2015,,Abandoned,Method of Treatment,"The application claimed a method of treating a TNFα-related disorder in a subject, wherein the TNFα-related disorder is selected from the group consisting of a spondyloarthropathy, a pulmonary disorder, a coronary disorder, a metabolic disorder, anemia, pain, a hepatic disorder, a skin disorder, a nail disorder, or vasculitis, comprising administering to the subject a therapeutically effective amount of a neutralizing, high affinity TNFα antibody, such that said TNFα-related disorder is treated.
",After,No,https://patents.google.com/patent/US20150368335A1/en?oq=US2015368335+
Humira,US2016280776,Abbott / AbbVie,Arthritis,Biologic,5,4/10/2006,11/9/2015,9/29/2016,,Abandoned,Method of Treatment,"The application claimed a method of preventing a flare-up associated with juvenile rheumatoid arthritis (JRA) in a subject comprising administering a TNFα antibody, or antigen-binding portion thereof, to a subject, such that a flare up is prevented.",After,No,https://patents.google.com/patent/US20160280776A1/en?oq=US2016280776
Humira,US2016297879,Abbott / AbbVie,Arthritis,Biologic,5,6/8/2006,11/18/2015,10/13/2016,,Abandoned,Method of Treatment,"The application claimed a method of determining the efficacy of a TNFα inhibitor for treating psoriatic arthritis in a subject comprising:determining an ACR20 response of a patient population having psoriatic arthritis who was administered the TNFα inhibitor,wherein an ACR20 response in at least about 39% of the patient population indicates that the TNFα inhibitor is an effective TNFα inhibitor for the treatment of psoriatic arthritis.",After,No,https://patents.google.com/patent/US20160297879A1/en?oq=US2016297879
Humira,US2016138064,AbbVie,Arthritis,Biologic,10,9/2/2012,12/3/2015,5/19/2016,,Abandoned,Method of Production / Process,"The application claimed a process for producing a recombinantly-expressed immunoglobulin, comprising culturing a mammalian cell which recombinantly expresses the immunoglobulin during a production stage in a cell culture media comprising asparagine, thereby producing the recombinantly-expressed immunoglobulin, wherein the immunoglobulin is adalimumab.",After,No,https://patents.google.com/patent/US20160138064A1/en?oq=US2016138064
Humira,US20160115193A1,AbbVie,Arthritis,Biologic,21,5/24/2012,12/22/2015,4/28/2016,,Abandoned,Method of Production / Process,The application claimed a method for producing a preparation comprising a process-related impurity-reduced and/or product-related substance-reduced composition comprising a protein of interest from a sample mixture comprising a protein of interest and at least one process-related impurity and/or product-related substance. The patent describes the invention can be applied to adalimumab.,After,No,https://patents.google.com/patent/US20160115193A1/en?oq=US20160115193A1
Humira,US2016251424,Abbott / AbbVie,Arthritis,Biologic,5,4/10/2006,3/7/2016,9/1/2016,,Abandoned,Method of Treatment,"The application claimed a method of treating early axial spondylarthritis in a subject comprising administering a human TNFα antibody (adalimumab) or antigen-binding portion thereof, to the subject, such that early axial spondylarthritis is treated.",After,No,https://patents.google.com/patent/US20160251424A1/en?oq=US2016251424
Humira,US2016186130,AbbVie,Arthritis,Biologic,9,9/13/2006,3/14/2016,6/30/2016,,Abandoned,Method of Production / Process,"The application claimed a serum-free cell culture medium comprising Part A, Part B, and Part C, wherein
a) Part A consists essentially of a modified basal medium which excludes the following components: sodium bicarbonate, a buffer, mono-basic sodium phosphate, di-basic sodium phosphate, an osmolarity regulator, a surfactant, and monosaccharide glucose; b) Part B consists essentially of an inorganic iron source; and c) Part C comprises a recombinant growth factor; a buffer; an osmolarity regulator; an energy source; and at least two different non-animal hydrolysates.",After,No,https://patents.google.com/patent/US20160186130A1/en?oq=US2016186130
Humira,US20160222101A1,AbbVie,Arthritis,Biologic,39,11/30/2007,4/11/2016,8/4/2016,,Abandoned,Method of Production / Process,"The application claimed a method of preparing an aqueous formulation comprising a protein and water, the method comprising: a) providing the protein in a first solution; and b) subjecting the first solution to diafiltration using water as a diafiltration medium until at least a five fold volume exchange with the water has been achieved to thereby prepare the aqueous formulation.",After,No,https://patents.google.com/patent/US20160222101A1/en?oq=US20160222101A1
Humira,US20170101465A1,AbbVie,Arthritis,Biologic,25,6/3/2010,5/6/2016,4/13/2017,,Abandoned,Method of Treatment,"The application claimed method for treating a subject having hidradenitis suppurativa (HS), the method comprising administering an isolated human anti-TNFα antibody, or an antigen binding portion thereof, to the subject according to a multiple variable dose regimen, such that HS is treated, wherein the multiple variable dose regimen comprises administering a first loading dose, administering a second loading dose which is less than the first loading dose, and administering a treatment dose which is less than the second loading dose, wherein the treatment dose is administered to the subject weekly, wherein the anti-TNFα antibody, or antigen binding portion thereof, is adalimumab, or an antigen binding portion thereof.",After,No,https://patents.google.com/patent/US20170101465A1/en?oq=US20170101465A1
Humira,US2017136122,AbbVie,Arthritis,Biologic,8,4/5/2006,6/7/2016,5/18/2017,,Abandoned,Method of Treatment,"The application claimed a method of treating a disorder in which TNFα activity is detrimental in a subject, the method comprising administering a liquid pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of adalimumab to the subject such that the disorder is treated.",After,No,https://patents.google.com/patent/US20170136122A1/en?oq=US2017136122
Humira,US2017157249,Abbott / AbbVie,Arthritis,Biologic,5,4/10/2006,7/21/2016,6/8/2017,,Abandoned,Method of Treatment,"The application claimed a method of preventing Pneumococcal disease and treating rheumatoid arthritis (RA) in a subject comprising administering a pneumococcal vaccine and a human TNFα antibody (adalimumab) or antigen-binding portion thereof, to the subject, such that Pneumococcal disease is prevented and rheumatoid arthritis is treated.
",After,No,https://patents.google.com/patent/US20170157249A1/en?oq=US2017157249
Humira,US2017022271,Abbott / AbbVie,Arthritis,Biologic,5,4/9/2004,10/7/2016,1/26/2017,,Abandoned,Method of Treatment,"The application claimed a multiple-variable dose method for treating a disorder in which TNFα activity is detrimental, comprising:administering to a subject in need thereof at least one induction dose of a TNFα inhibitor such that a threshold level of TNFα inhibitor is achieved within an induction phase; and subsequently administering to the subject at least one treatment dose of the TNFα inhibitor within a treatment phase, such that treatment occurs.",After,No,https://patents.google.com/patent/US20170022271A1/en?oq=US2017022271
Humira,US2017029495,AbbVie,Arthritis,Biologic,12,4/20/2012,10/18/2016,2/2/2017,,Abandoned,Method of Production / Process,"The application claimed a composition comprising a binding protein capable of binding TNF-alpha, wherein said binding protein comprises at least one methylglyoxal (MGO)-susceptible amino acid, and wherein at least a portion of said binding protein comprises one or more MGO-modified amino acids.",After,No,https://patents.google.com/patent/US20170029495A1/en?oq=US2017029495
Humira,US20170137860A1,AbbVie,Arthritis,Biologic,22,3/14/2013,11/4/2016,5/18/2017,,Abandoned,Method of Production / Process,"The application claimed a method of producing a composition comprising a protein with a modulated glycosylation profile, wherein the antibody is an anti-TNFα antibod and  the anti-TNFα antibody is adalimumab, or antigen binding fragment thereof.
",After,No,https://patents.google.com/patent/US20170137860A1/en?oq=US20170137860A1
Humira,US2017051052,AbbVie,Arthritis,Biologic,13,4/27/2011,11/8/2016,2/23/2017,,Abandoned,Method of Production / Process,The application claimed a method for controlling the galactosylation profile of a recombinantly-expressed protein comprising supplementing a production media used in the recombinant expression of said protein with a manganese supplement and/or a galactose supplement.,After,No,https://patents.google.com/patent/US20170051052A1/en?oq=US2017051052
Humira,US20170121403A1,AbbVie,Arthritis,Biologic,33,10/18/2013,11/16/2016,5/4/2017,,Abandoned,Method of Treatment,"The application claimed a method for treating a subject having a disorder in which TNFα activity is detrimental, the method comprising administering a therapeutically effective amount of a composition comprising a human anti-TNFα antibody, wherein less than 65% of the lysine variant species in said composition have zero C-terminal lysines (Lys 0), wherein said human anti-TNFα antibody is adalimumab.",After,No,https://patents.google.com/patent/US20170121403A1/en?oq=US20170121403A1
Humira,US2017158758,AbbVie,Arthritis,Biologic,11,10/18/2013,11/22/2016,6/8/2017,,Abandoned,Formulation / Combination,"The application claimed a ow acidic species adalimumab pharmaceutical composition suitable for administration to a human subject comprising 40 mg of adalimumab wherein the low acidic species adalimumab pharmaceutical composition comprises less than 10% total acidic species of adalimumab, wherein the acidic species of adalimumab have a net negative charge relative to the adalimumab main species and the acidic species comprise species selected from the group consisting of charge variants, structure variants, fragmentation variants and any combinations thereof; wherein the acidic species of adalimumab do not include process-related impurities selected from the group consisting of host cell proteins, host cell nucleic acids, chromatographic materials and media components; and wherein said low acidic species adalimumab pharmaceutical composition demonstrates reduced cell infiltration, reduced synovial proliferation, reduced proteoglycan loss, reduced cartilage destruction, and/or reduced bone erosion compared to a non-low acidic species composition of adalimumab; and a pharmaceutically acceptable carrier.",After,No,https://patents.google.com/patent/US20170158758A1/en?oq=US2017158758
Humira,US2017198034,AbbVie,Arthritis,Biologic,10,9/2/2012,12/2/2016,7/13/2017,,Abandoned,Method of Production / Process,"The application claimed a method for controlling the oligosaccharide distribution of a recombinantly-expressed immunoglobulin comprising a heavy chain variable region comprising the sequence of SEQ ID NO: 2 and a light chain variable region comprising the sequence of SEQ ID NO: 7, wherein the immunoglobulin is adalimumab.",After,No,https://patents.google.com/patent/US20170198034A1/en?oq=US2017198034
Humira,US2017137496,AbbVie,Arthritis,Biologic,10,9/2/2012,1/27/2017,5/18/2017,,Abandoned,Method of Production / Process,"The application claimed a process for producing a recombinantly-expressed immunoglobulin, comprising culturing a mammalian cell which recombinantly expresses the immunoglobulin during a production stage in a cell culture media comprising asparagine, thereby producing the recombinantly-expressed immunoglobulin, wherein the immunoglobulin is adalimumab.",After,No,https://patents.google.com/patent/US20170137496A1/en?oq=US2017137496
Humira,US20170143828A1,AbbVie,Arthritis,Biologic,39,11/30/2007,2/2/2017,5/25/2017,,Abandoned,Formulation / Combination,"The application claimed a aqueous formulation comprising an antibody, or antigen-binding fragment thereof, and water, wherein the formulation has a conductivity of less than about 2.5 mS/cm and the antibody, or antigen-binding fragment thereof, has a molecular weight (Mw) greater than about 47 kDa.",After,No,https://patents.google.com/patent/US20170143828A1/en?oq=US20170143828A1
Humira,US2017158760,Abbott / AbbVie,Arthritis,Biologic,14,10/20/2008,2/3/2017,6/8/2017,,Abandoned,Method of Production / Process,"The application claimed a method for making a pharmaceutical grade preparation comprising adalimumab, wherein the adalimumab is purified from a fermentation harvest of cultured Chinese hamster ovary (CHO) cells expressing adalimumab
",After,No,https://patents.google.com/patent/US20170158760A1/en?oq=US2017158760
Humira,US2017203041,Abbott / AbbVie,Arthritis,Biologic,5,6/30/2006,2/16/2017,7/20/2017,,Abandoned,Device,The application claimed an  automatic injection device for providing an injection of a substance into a user. The patent describes the invention can be applied to adalimumab.,After,No,https://patents.google.com/patent/US20170203041A1/en?oq=US2017203041
Humira,US2018044414,Abbott / AbbVie,Arthritis,Biologic,5,4/10/2006,3/27/2017,2/15/2018,,Abandoned,Method of Treatment,"The application claimed a method for treating a skin disorder associated with detrimental TNFα activity in a subject who has failed to respond to or has lost responsiveness to a biologic therapy, comprising administering to the subject who has failed to respond to or has lost responsiveness to the biologic therapy, a human TNFα antibody, or an antigen-binding portion thereof, such that the skin disorder is treated.
",After,No,https://patents.google.com/patent/US20180044414A1/en?oq=US2018044414
Humira,US2017210795,Abbott / AbbVie,Arthritis,Biologic,5,4/10/2006,4/13/2017,7/27/2017,,Abandoned,Method of Treatment,"The application claimed a method of treating PsA in a subject having a subtherapeutic response to treatment with a TNFα inhibitor comprising administering the TNFα inhibitor to the subject on a weekly dosing regimen, such that PsA is treated.",After,No,https://patents.google.com/patent/US20170210795A1/en?oq=US2017210795
Humira,US20190154560A1,AbbVie,Arthritis,Biologic,18,5/16/2016,5/15/2017,5/23/2019,,Abandoned,Method of Production / Process,"The application claimed a method for inspecting particles in a liquid beneficial agent contained within a container, the liquid beneficial agent comprising photoluminescent particles. The patent describes the invention can be applied to adalimumab.",After,No,https://patents.google.com/patent/US20190154560A1/en?oq=US20190154560A1
Humira,US2017355761,AbbVie,Arthritis,Biologic,12,4/20/2012,5/22/2017,12/14/2017,,Abandoned,Method of Production / Process,"The application claimed a composition comprising adalimumab, wherein the composition comprises less than 10% total acidic species of adalimumab, wherein the acidic species of adalimumab do not include process-related impurities selected from the group consisting of host cells and lysed host cells, and wherein the acidic species of adalimumab correspond to the peaks that elute earlier than the main peak in a WCX-10 HPLC chromatogram of adalimumab.",After,No,https://patents.google.com/patent/US20170355761A1/en?oq=US2017355761
Humira,US2018110854,Abbott / AbbVie,Arthritis,Biologic,6,6/11/2007,6/5/2017,4/26/2018,,Abandoned,Method of Treatment,"The application claimed a method for treating juvenile idiopathic arthritis (JIA) in a subject comprising administering a TNFα inhibitor to the subject, wherein the TNFα inhibitor is administered to the subject according to a fixed dosing regimen.",After,No,https://patents.google.com/patent/US20180110854A1/en?oq=US2018110854
Humira,US2017349654,AbbVie,Arthritis,Biologic,12,10/18/2013,6/9/2017,12/7/2017,,Abandoned,Method of Production / Process,"The application claimed a method for producing a low acidic species composition comprising an antibody, or antigen-binding portion thereof, wherein the anti-TNFα antibody, or antigen-binding portion thereof, is adalimumab, or an antigen binding-portion thereof.",After,No,https://patents.google.com/patent/US20170349654A1/en?oq=US2017349654
Humira,US2017349655,AbbVie,Arthritis,Biologic,12,4/20/2012,6/19/2017,12/7/2017,,Abandoned,Method of Production / Process,"The application claimed a composition comprising a human anti-TNFα antibody comprising the heavy and light chain variable domains of adalimumab, wherein less than 62% of the lysine variant species in said composition have zero C-terminal lysines (Lys 0).",After,No,https://patents.google.com/patent/US20170349655A1/en?oq=US2017349655
Humira,US2017342145,AbbVie,Arthritis,Biologic,12,3/14/2013,6/21/2017,11/30/2017,,Abandoned,Method of Production / Process,"The application claimed a method for reducing process-related impurities and/or product-related substances in a preparative scale sample of a protein of interest comprising at least one process-related impurities and/or product-related substance.  The patent describes the invention can be applied to adalimumab.
",After,No,https://patents.google.com/patent/US20170342145A1/en?oq=US2017342145
Humira,US20180099094A1,AbbVie,Arthritis,Biologic,17,10/12/2016,10/12/2017,4/12/2018,,Abandoned,Device,The application claimed a automatic injection device having a distal end configured to deliver a medicament held in a container therein and a proximal end configured to be controllable by a user. The patent describes the device can be applied to adalimumab.,After,No,https://patents.google.com/patent/US20180099094A1/en?oq=US20180099094A1
Humira,US20180222938A1,AbbVie,Arthritis,Biologic,20,10/18/2013,1/8/2018,8/9/2018,,Abandoned,Method of Production / Process,"The application claimed a method for producing a preparation comprising a protein of interest and having a reduced level of at least one impurity, wherein the protein of interest is adalimumab.",After,No,https://patents.google.com/patent/US20180222938A1/en?oq=US20180222938A1
Humira,US20180147358A1,AbbVie,Arthritis,Biologic,29,1/24/2011,1/26/2018,5/31/2018,,Pending,Device,The application claims an injection device. The patent describes the invention can be applied to adalimumab.,After,No,https://patents.google.com/patent/US20180147358A1/en?oq=US20180147358A1
Humira,US2019040124A1,Abbott / AbbVie,Arthritis,Biologic,5,4/10/2006,2/28/2018,2/7/2019,,Abandoned,Method of Treatment,"The application claimed a method of treating early axial spondylarthritis in a subject comprising administering a human TNFα antibody, or antigen-binding portion thereof, to the subject, such that early axial spondylarthritis is treated.",After,No,https://patents.google.com/patent/US20190040124A1/en?oq=US2019040124A1
Humira,US20180272076A1,AbbVie,Arthritis,Biologic,30,3/29/2011,3/5/2018,9/27/2018,,Abandoned,Device,"The application claimed a syringe carrier assembly for use in an automatic injection device.  The patent describes the invention can be applied to adalimumab.
",After,No,https://patents.google.com/patent/US20180272076A1/en?oq=US20180272076A1
Humira,US2019055308A1,Abbott / AbbVie,Arthritis,Biologic,5,4/9/2004,3/8/2018,2/21/2019,,Abandoned,Method of Treatment,"The application claimed a multiple-variable dose method for treating a disorder in which TNFα activity is detrimental, comprising: administering to a subject in need thereof at least one induction dose of a TNFα inhibitor (adalimumab)  that a threshold level of TNFα inhibitor is achieved within an induction phase; and subsequently administering to the subject at least one treatment dose of the TNFα inhibitor within a treatment phase, such that treatment occurs.",After,No,https://patents.google.com/patent/US20190055308A1/en?oq=US2019055308A1
Humira,US2019054171A1,Abbott / AbbVie,Arthritis,Biologic,7,8/16/2002,3/12/2018,2/21/2019,,Abandoned,Formulation / Combination,"The application claimed a pharmaceutical formulation selected from the group consisting of: (a) a liquid aqueous pharmaceutical formulation comprising a therapeutically effective amount of an antibody in a buffered solution, said formulation having a pH between about 4 and 8 and having a shelf life of at least 18 months; (b) an aqueous pharmaceutical formulation comprising a therapeutically effective amount of an antibody in a buffered solution, said formulation having a pH between about 4 and 8 and having a shelf life of at least 18 months in the liquid state;
(c) a liquid aqueous pharmaceutical formulation comprising a therapeutically effective amount of an antibody in a buffered solution, said formulation having a pH between about 4 and 8 which maintains stability following at least 3 freeze/thaw cycles of the formulation; and (d) a liquid aqueous pharmaceutical formulation comprising a therapeutically effective amount of an antibody in a buffered solution, said formulation having a pH between 4 and 8 and having enhanced stability of at least 12 months at a temperature of 2-8° C.",After,No,https://patents.google.com/patent/US20190054171A1/en?oq=US2019054171A1
Humira,US2019062418A1,Abbott / AbbVie,Arthritis,Biologic,5,5/16/2005,3/14/2018,2/28/2019,,Abandoned,Method of Treatment,"The application claimed a method for testing the efficacy of a TNFα antibody, or antigen-binding portion thereof, for decreasing radiographic progression of joint disease associated with erosive polyarthritis comprising determining the efficacy of the TNFα antibody, or antigen-binding portion thereof, using a modified Total Sharp Score (mTSS) of a patient population having joint disease associated with erosive polyarthritis and a mTSS of the patient population following administration of the TNFα antibody (adalimumab) or antigen-binding portion thereof, wherein no change or a decrease in the mTSS indicates that the TNFα antibody, or antigen-binding portion thereof, is efficacious for decreasing radiographic progression of joint disease associated with erosive polyarthritis.",After,No,https://patents.google.com/patent/US20190062418A1/en?oq=US2019062418A1
Humira,US2019062419A1,AbbVie,Arthritis,Biologic,12,4/20/2012,4/12/2018,2/28/2019,,Abandoned,Method of Production / Process,"The application claimed a method of making a pharmaceutical composition, comprising mixing (a) a composition comprising adalimumab, wherein the composition comprises less than 10% total acidic species of adalimumab, wherein the acidic species of adalimumab correspond to the peaks that elute earlier than the main peak in a WCX-10 HPLC chromatogram of adalimumab, wherein the WCX-10 HPLC chromatogram is generated using a first mobile phase of 10 mM Sodium Phosphate dibasic (pH 7.5) and a second mobile phase of 10 mM Sodium Phosphate dibasic, 500 mM Sodium Chloride (pH 5.5), and wherein the WCX-10 HPLC chromatogram is generated using detection at 280 nm; and
(b) a pharmaceutically acceptable carrier, thereby making a pharmaceutical composition.",After,No,https://patents.google.com/patent/US20190062419A1/en?oq=US2019062419A1
Humira,US20180228980A1,AbbVie,Arthritis,Biologic,27,9/22/2011,4/13/2018,8/16/2018,,Abandoned,Device,"The application claimed an automatic injection device comprising a liquid therapeutic agent in the reservoir, the liquid therapeutic agent comprising adalimumab.
",After,No,https://patents.google.com/patent/US20180228980A1/en?oq=US20180228980A1
Humira,US20190185897A1,AbbVie,Arthritis,Biologic,22,3/14/2013,7/23/2018,6/20/2019,,Abandoned,Method of Production / Process,"The application claimed a method of producing a composition comprising a protein with a modulated glycosylation profile, wherein the protein is an antibody or antigen-binding portion thereof and the protein is adalimumab.",After,No,https://patents.google.com/patent/US20190185897A1/en?oq=US20190185897A1
Humira,US2018339046A1,Abbott / AbbVie,Arthritis,Biologic,7,8/16/2002,8/7/2018,11/29/2018,,Abandoned,Formulation / Combination,"The application claimed a stable liquid aqueous pharmaceutical formulation comprising (a) a human IgG1 anti-human Tumor Necrosis Factor alpha (TNFα) antibody at a concentration of 50 mg/ml, (b) 12 mg/ml mannitol, (c) 1 mg/ml polysorbate 80, and (d) a buffer system comprising citrate and having a pH of 5.0 to 5.2, wherein the antibody is D2E7, and wherein the formulation is suitable for subcutaneous injection.",After,No,https://patents.google.com/patent/US20180339046A1/en?oq=US2018339046A1
Humira,US2019225934A1,AbbVie,Arthritis,Biologic,9,9/13/2006,8/30/2018,7/25/2019,,Abandoned,Method of Production / Process,"The application claimed a serum-free cell culture medium comprising Part A, Part B, and Part C, wherein a) Part A consists essentially of a modified basal medium which excludes the following components: sodium bicarbonate, a buffer, mono-basic sodium phosphate, di-basic sodium phosphate, an osmolarity regulator, a surfactant, and monosaccharide glucose;
b) Part B consists essentially of an inorganic iron source; andc) Part C comprises a recombinant growth factor; a buffer; an osmolarity regulator; an energy source; and at least two different non-animal hydrolysates.",After,No,https://patents.google.com/patent/US20190225934A1/en?oq=US2019225934A1
Humira,US20190358322A1,AbbVie,Arthritis,Biologic,39,11/30/2007,12/20/2018,11/28/2019,,Abandoned,Formulation / Combination,"The application claimed an aqueous formulation comprising an antibody, or antigen-binding fragment thereof, and water, wherein the formulation has a conductivity of less than about 2.5 mS/cm and the antibody, or antigen-binding fragment thereof, has a molecular weight (Mw) greater than about 47 kDa",After,No,https://patents.google.com/patent/US20190358322A1/en?oq=US20190358322A1
Humira,US2020017580A1,Abbott / AbbVie,Arthritis,Biologic,5,4/9/2004,2/25/2019,1/16/2020,,Abandoned,Method of Treatment,"The application claimed a  multiple-variable dose method for treating a disorder in which TNFα activity is detrimental, comprising: administering to a subject in need thereof at least one induction dose of a TNFα inhibitor (adalimumab) such that a threshold level of TNFα inhibitor is achieved within an induction phase; and subsequently administering to the subject at least one treatment dose of the TNFα inhibitor within a treatment phase, such that treatment occurs.",After,No,https://patents.google.com/patent/US20200017580A1/en?oq=US2020017580A1
Humira,US20210347874A1,Abbott / AbbVie,Arthritis,Biologic,5,4/9/2004,12/17/2020,11/11/2021,,Pending,Method of Treatment,"The application claims a multiple-variable dose method for treating a disorder in which TNFα activity is detrimental, comprising: administering to a subject in need thereof at least one induction dose of a TNFα inhibitor such that a threshold level of TNFα inhibitor is achieved within an induction phase; and subsequently administering to the subject at least one treatment dose of the TNFα inhibitor within a treatment phase, such that treatment occurs.",After,No,https://patents.google.com/patent/US20210347874A1/en?oq=US20210347874A1
Humira,US20210347875A1,Abbott / AbbVie,Arthritis,Biologic,5,4/9/2004,12/17/2020,11/11/2021,,Pending,Method of Treatment,"The application claims a multiple-variable dose method for treating a disorder in which TNFα activity is detrimental, comprising: administering to a subject in need thereof at least one induction dose of a TNFα inhibitor (adalimumab) such that a threshold level of TNFα inhibitor is achieved within an induction phase; and subsequently administering to the subject at least one treatment dose of the TNFα inhibitor within a treatment phase, such that treatment occurs.",After,No,https://patents.google.com/patent/US20210347875A1/en?oq=US20210347875A1
Humira,US20210113694,Abbott / AbbVie,Arthritis,Biologic,7,8/16/2002,12/18/2020,4/22/2021,,Abandoned,Formulation / Combination,"The application claimed a  stable liquid aqueous pharmaceutical formulation comprising (a) a human IgG1 anti-human Tumor Necrosis Factor alpha (TNFα) antibody, at a concentration of 45 to 105 mg/ml, (b) a polyol that is a sugar or sugar alcohol, (c) a polysorbate, which is polysorbate 20 or polysorbate 80, at a concentration of 0.1 to 10 mg/ml, and
(d) a buffer system comprising acetate and having a pH of 4.5 to 7.0,
wherein the antibody is D2E7.",After,No,https://patents.google.com/patent/US20210113694A1/en?oq=US20210113694
Humira,US20210260186A1,AbbVie,Arthritis,Biologic,8,4/5/2006,2/9/2021,8/26/2021,,Pending,Method of Treatment,"The application claimed a method of treating a disorder in which TNFα activity is detrimental comprising administering to a human subject in need thereof a liquid pharmaceutical composition comprising adalimumab and a pharmaceutically acceptable carrier, wherein the adalimumab is expressed in a Chinese hamster ovary (CHO) cell expression system; and the composition is characterized in that when the composition is assayed in a cathepsin L kinetic assay, a level of fluorescent activity no greater than 0.0144 RFU/sec is observed.
",After,No,https://patents.google.com/patent/US20210260186A1/en?oq=US20210260186A1
Imbruvica,US 7741330B1,Pharmacyclics LLC,Cancer,Small Molecule,32,10/12/2009,10/16/2009,6/22/2010,10/16/2029,Active,Derivative,The patent claims cover a markush group consisting of various analogs of ibrutinib (Imbruvica).,Before,No,https://patents.google.com/patent/US7741330B1/en?oq=US+7741330B1
Imbruvica,US 9012463B2,Pharmacyclics LLC,Cancer,Small Molecule,32,10/12/2009,10/12/2010,4/21/2015,6/25/2031,Active,Derivative,The patent claims cover structurally  similar analogs to ibrutinib (Imbruvica). ,Before,No,https://patents.google.com/patent/US9012463B2/en?oq=US+9012463B2
Imbruvica,US10004745 ,Pharmacyclics LLC,Cancer,Small Molecule,3,6/3/2010,3/10/2016,6/26/2018,6/3/2031,Active,Method of Treatment,"The patent claims cover a method for treating follicular lymphoma in an individual who has failed at least one prior therapy for follicular lymphoma, comprising: administering to the individual once per day about 560 mg of an oral dose of ibrutinib.",After,No,https://patents.google.com/patent/US10004745B2/en?oq=US10004745+
Imbruvica,US10004746 ,Pharmacyclics LLC,Cancer,Small Molecule,3,6/3/2010,7/26/2017,6/26/2018,6/3/2031,Active,Method of Treatment,The patent claims cover a  method for treating chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in an individual who has failed at least one prior therapy for chronic lymphocytic leukemia or small lymphocytic lymphoma comprising administering to the individual once per day about 420 mg of an oral dose of crystalline Form A of ibrutinib.,After,Yes,https://patents.google.com/patent/US10004746B2/en?oq=US10004746+
Imbruvica,US10010507 ,Pharmacyclics LLC,Cancer,Small Molecule,28,3/3/2015,3/1/2018,7/3/2018,3/3/2036,Active,Formulation / Combination,"The patent claims cover a solid tablet formulation comprising ibrutinib and one or more pharmaceutically acceptable excipients, wherein the ibrutinib is in micronized form; and
wherein ibrutinib is in an amount of about 140 mg, about 280 mg, about 420 mg, or about 560 mg in the tablet.",After,No,https://patents.google.com/patent/US10010507B1/en?oq=US10010507+
Imbruvica,US10016434 ,Pharmacyclics LLC,Cancer,Small Molecule,15,8/12/2013,7/18/2017,7/10/2018,8/12/2034,Active,Method of Treatment,"The patent claims cover a  method for treating HER2 amplified cancer in an individual in need thereof, wherein the cancer is selected from the group consisting of colon, lung, and pancreatic cancers, and the method comprises administering to the individual in need thereof a composition comprising ibrutinib or a pharmaceutically acceptable salt thereof.",After,No,https://patents.google.com/patent/US10016434B2/en?oq=US10016434+
Imbruvica,US10016435 ,Pharmacyclics LLC,Cancer,Small Molecule,3,6/3/2010,9/26/2017,7/10/2018,6/3/2031,Active,Method of Treatment,"The patent claims cover  for treating Waldenström's macroglobulinemia in an individual in need thereof, wherein the individual is treatment-nave for Waldenström's macroglobulinemia, comprising administering to the individual once per day about 420 mg of an oral dose of ibrutinib.",After,Yes,https://patents.google.com/patent/US10016435B2/en?oq=US10016435+
Imbruvica,US10065968 ,Pharmacyclics LLC,Cancer,Small Molecule,6,6/4/2012,2/21/2018,9/4/2018,6/3/2033,Active,Crystalline,The patent claims cover a  Form 2 crystalline form of anhydrous ibrutinib,After,No,https://patents.google.com/patent/US10065968B2/en?oq=US10065968+
Imbruvica,US10106548 ,Pharmacyclics LLC,Cancer,Small Molecule,6,6/4/2012,2/20/2018,10/23/2018,6/3/2033,Active,Crystalline,The patent claims cover a anhydrous crystalline form of ibrutinib. ,After,Yes,https://patents.google.com/patent/US10106548B2/en?oq=US10106548+
Imbruvica,US10125140 ,Pharmacyclics LLC,Cancer,Small Molecule,6,6/4/2012,7/16/2018,11/13/2018,6/3/2033,Active,Crystalline,"The patent claims cover six  crystalline forms of ibrutinib, of which many are anhydrous.",After,Yes,https://patents.google.com/patent/US10125140B1/en?oq=US10125140+
Imbruvica,US10213386B2,Pharmacyclics LLC,Cancer,Small Molecule,28,3/3/2015,5/3/2018,2/26/2019,3/3/2036,Active,Formulation / Combination,"The patent claims cover a solid tablet formulation comprising a. ibrutinib, and b. one or more pharmaceutically acceptable excipients,wherein the ibrutinib is present in an amount of at least about 50% w/w, and wherein oral administration of one or more tablet(s) of the solid tablet formulation in an amount sufficient to deliver 560 mg of ibrutinib to a population of healthy human adults in a fasted state results in a mean AUC0-∞ of about 465 ng*h/ml+/−248 ng*h/ml.
",After,No,https://patents.google.com/patent/US10213386B2/en?oq=US10213386B2
Imbruvica,US10226466,Pharmacyclics LLC,Cancer,Small Molecule,19,12/3/2014,12/8/2017,3/12/2019,12/2/2035,Active,Method of Treatment,"The patent claims cover a method of treating fibrosis, wherein the fibrosis is not associated with graft versus host disease (GVHD), comprising administering to a patient having fibrosis, wherein the fibrosis is not associated with GVHD, a therapeutically effective amount of ibrutinib. ",After,No,https://patents.google.com/patent/US10226466B2/en?oq=US10226466
Imbruvica,US10266540B2,Pharmacyclics LLC,Cancer,Small Molecule,6,6/4/2012,7/13/2018,4/23/2019,6/3/2033,Active,Crystalline,The patent claims cover overlapping anhydrous crystalline forms of ibrutinib.,After,No,https://patents.google.com/patent/US10266540B2/en?oq=US10266540B2
Imbruvica,US10294231,"Pharmacyclics LLC


",Cancer,Small Molecule,36,6/4/2012,8/23/2018,5/21/2019,6/3/2033,Active,Formulation / Combination,"The patent claims cover a pharmaceutical formulation for oral administration comprising:
(a) about 40 mg to about 200 mg of ibrutinib, (b) about 40 wt % to about 50 wt % of one or more diluents; (c) about 3 wt % to about 10 wt % of one or more disintegrating agents;
(d) about 2 wt % to about 7 wt % of one or more surfactants; and (e) one or more lubricants.",After,Yes,https://patents.google.com/patent/US10294231B2/en?oq=US10294231
Imbruvica,US10294232B2,"Pharmacyclics LLC


",Cancer,Small Molecule,36,6/4/2012,8/23/2018,5/21/2019,6/3/2033,Active,Formulation / Combination,"The patent claims cover a pharmaceutical formulation for oral administration comprising: a)about 40 mg to about 200 mg of ibrutinib, (b) about 40 wt % to about 50 wt % of one or more diluents;(c) one or more disintegrating agents; and (d) about 0.2 wt % to about 1.0 wt % of one or more lubricants.",After,Yes,https://patents.google.com/patent/US10294232B2/en?oq=US10294232B2
Imbruvica,US10463668B2,Pharmacyclics LLC,Cancer,Small Molecule,13,10/25/2013,5/3/2017,11/5/2019,10/24/2034,Active,Method of Treatment,"The patent claims cover a method of treating refractory chronic graft versus host disease (GVHD) comprising orally administering 420 mg of ibrutinib once per day to an adult human patient having chronic GVHD refractory to systemic therapy, wherein the adult human patient achieves a complete response (CR), wherein the CR is a complete resolution of symptoms attributable to chronic GVHD.",After,Yes,https://patents.google.com/patent/US10463668B2/en?oq=US10463668B2
Imbruvica,US10478439B2,Pharmacyclics LLC,Cancer,Small Molecule,3,6/3/2010,4/27/2018,11/19/2022,3/6/2031,Active,Method of Treatment,"The patent claims cover a method of inhibiting proliferation and survival of activated B-cells in a human subject suffering from a B-cell proliferative disorder, comprising: orally administering to the human subject suffering from a B-cell proliferative disorder a therapeutically effective amount of  ibrutinib.",After,Yes,https://patents.google.com/patent/US10478439B2/en?oq=US10478439B2
Imbruvica,US10653696B2,Pharmacyclics LLC,Cancer,Small Molecule,3,6/3/2010,8/8/2019,5/19/2020,3/6/2031,Active,Method of Treatment,"The patent claims cover amethod for treating mantle cell lymphoma in an individual who has already received at least one prior therapy for mantle cell lymphoma comprising orally administering to the individual a dose of 560 mg of ibrutinib on a continuous once-daily regimen until progression of the mantle cell lymphoma or unacceptable toxicity;  and
lymphocytosis is not considered progression of the mantle cell lymphoma, wherein the individual achieves a complete response.",After,Yes,https://patents.google.com/patent/US10653696B2/en?oq=US10653696B2
Imbruvica,US10695350B2,Pharmacyclics LLC,Cancer,Small Molecule,13,10/25/2013,9/25/2019,6/30/2020,10/24/2034,Active,Method of Treatment,"The patent claims cover a method for achieving a complete resolution of symptoms of chronic graft versus host disease (GVHD) in an adult patient having chronic GVHD refractory to systemic therapy comprising orally administering 420 mg of ibrutinib once per day to the adult patient having chronic GVHD refractory to systemic therapy, thereby achieving complete resolution of the symptoms of refractory chronic GVHD in the adult patient, and discontinuing administering ibrutinib when the adult patient no longer requires therapy for the chronic GVHD.",After,Yes,https://patents.google.com/patent/US10695350B2/en?oq=US10695350B2
Imbruvica,US10751342B2,Pharmacyclics LLC,Cancer,Small Molecule,3,6/3/2010,1/21/2020,8/25/2020,3/6/2031,Active,Method of Treatment,"The patent claims cover amethod for treating relapsed or refractory CLL or SLL in an individual comprising orally administering to the individual a dose of 420 mg of ibrutinib on a continuous once-daily regimen until progression of the CLL or SLL or unacceptable toxicity; and lymphocytosis is not considered progression of the CLL or SLL, wherein the individual achieves a complete response.",After,Yes,https://patents.google.com/patent/US10751342B2/en?oq=US10751342B2
Imbruvica,US10752634B2,Pharmacyclics LLC,Cancer,Small Molecule,6,6/4/2012,4/1/2020,8/25/2020,3/6/2033,Active,Formulation / Combination,"The patent claims cover a pharmaceutical formulation for oral administration comprising:
(a) about 140 mg  of ibrutinib , (b) one or more diluents; (c) one or more surfactants; and
(d) one or more lubricants.",After,No,https://patents.google.com/patent/US10752634B2/en?oq=US10752634B2
Imbruvica,US10828259,"Pharmacyclics LLC


",Cancer,Small Molecule,28,3/3/2015,4/10/2020,11/10/2020,3/3/2036,Active,Formulation / Combination,"The patent claims cover asolid tablet formulation comprising ibrutinib and pharmaceutically acceptable excipients, wherein the ibrutinib and wherein the solid tablet formulation comprises about 60% w/w to about 75% w/w of the ibrutinib, and the excipients comprise:
one or more diluents selected from group consisting of: lactose, sucrose, dextrose, dextrates, maltodextrin, mannitol, xylitol, sorbitol, cyclodextrins, calcium phosphate, calcium sulfate, starches, modified starches, cellulose, microcrystalline cellulose, microcellulose, and talc; one or more disintegrating agents selected from the group consisting of: natural starch, a pregelatinized starch, a sodium starch, methylcrystalline cellulose, methylcellulose, croscarmellose, croscarmellose sodium, crosslinked sodium carboxymethylcellulose, cross-linked carboxymethylcellulose, cross-linked croscarmellose, cross-linked starch, cross-linked polymer, cross-linked polyvinylpyrrolidone, sodium alginate, a clay, and a gum; one or more binders selected from the group consisting of: hydroxypropyl cellulose, and polyvinylpyrrolidone; colloidal silicon dioxide; and magnesium stearate.",After,No,https://patents.google.com/patent/US10828259B2/en?oq=US10828259
Imbruvica,US10954567B2,Pharmacyclics LLC,Cancer,Small Molecule,7,7/24/2012,7/23/2013,2/23/2021,7/24/2033,Active,Method of Treatment,"The patent claims cover a method for treating a hematological cancer with ibrutinib in a subject in need thereof, the method comprising: testing a sample containing a nucleic acid molecule encoding a BTK polypeptide from the subject to determine whether the encoded BTK polypeptide has a modification at amino acid position 481 of the amino acid sequence set forth in SEQ ID NO: 1;detecting the absence of the modification in the sample from the subject; and administering ibrutinib to the subject at a daily dosage of 420 mg/day or 560 mg/day.",Before,No,https://patents.google.com/patent/US10954567B2/en?oq=US10954567B2
Imbruvica,US10961251B1,Pharmacyclics LLC,Cancer,Small Molecule,6,6/4/2012,11/18/2020,3/30/2021,3/6/2033,Active,Formulation / Combination,"The patent claims cover a pharmaceutical composition comprising
a crystalline form of ibrutinib and a pharmaceutically acceptable excipient, wherein said crystalline form of ibrutinib is produced by a process, comprising combining a solvent solution comprising alcohol with a crystalline ibrutinib having 2-theta peaks at 7.0±0.1°, 14.0±0.1°, 15.7±0.1°, and 18.2±0.1°; and a pharmaceutically acceptable excipient.2. Composition of a specific crystalline form of ibrutinib produced  by an alcohol solution and said crystalline form",After,Yes,https://patents.google.com/patent/US10961251B1/en?oq=US10961251B1
Imbruvica,US2010022561 ,Pharmacyclics LLC,Cancer,Small Molecule,1,9/22/2006,7/7/2009,1/28/2010,,Abandoned,Method of Treatment,"The application claimed a method for treating an inflammatory disease comprising administering to a subject in need thereof a composition containing a therapeutically effective amount of a compound  that forms a covalent bond with a cysteine residue of a Bruton's tyrosine kinase (Btk), a Bruton's tyrosine kinase (Btk) homolog, or a Bruton's tyrosine kinase (Btk) cysteine homolog.",Before,No,https://patents.google.com/patent/US20100022561A1/en?oq=US2010022561+
Imbruvica,US2010324050 ,Pharmacyclics LLC,Cancer,Small Molecule,1,9/22/2006,3/19/2010,12/23/2010,,Abandoned,Derivative,The application claimed a markush group covering various compounds similar in structure to ibrutinib (Imbruvica).,Before,No,https://patents.google.com/patent/US20100324050A1/en?oq=US2010324050+
Imbruvica,US2011224235 ,Pharmacyclics LLC,Cancer,Small Molecule,2,7/16/2008,7/16/2009,9/15/2011,,Abandoned,Method of Treatment,The application claimed a  method for treating a disorder characterized by the presence or development of one or more solid tumors comprising administering to an individual in need thereof a composition containing a therapeutically effective amount of a compound that forms a covalent bond with a cysteine sidechain of a Bruton's tyrosine kinase (Btk) or a Bruton's tyrosine kinase homolog. T,Before,No,https://patents.google.com/patent/US20110224235A1/en?oq=US2011224235
Imbruvica,US2011281322 ,Pharmacyclics LLC,Cancer,Small Molecule,1,9/22/2006,6/16/2011,11/17/2011,,Abandoned,Method of Treatment,"The application claimed an inhibited tyrosine kinase comprising an inhibitor irreversibly and covalently bound to a cysteine residue of a Bruton's tyrosine kinase cysteine homolog selected from BMX, TEC, TXK, ITK, ErbB2, ErbB4, JAK3, and BLK.",Before,No,https://patents.google.com/patent/US20110281322A1/en?oq=US2011281322+
Imbruvica,US2012065201 ,Pharmacyclics LLC,Cancer,Small Molecule,1,3/28/2007,9/14/2011,3/15/2012,,Abandoned,Main Compound,"The application claimed  a large Markush group including ibrutinib (Imbruvica), and the stereochemistry at the single chiral center of imbruvica",Before,No,https://patents.google.com/patent/US20120065201A1/en?oq=US2012065201+
Imbruvica,US2012071497 ,Pharmacyclics LLC,Cancer,Small Molecule,3,6/3/2010,6/3/2011,3/22/2012,,Abandoned,Method of Treatment,"The application claimed a method for treating diffuse large B-cell lymphoma, activated B cell-like subtype (ABC-DLBCL), in an individual in need thereof, comprising: administering to the individual a therapeutically effective amount of an inhibitor, covering  various compounds including ibrutinib (Imbruvica), of Bruton's tyrosine kinase. ",Before,No,https://patents.google.com/patent/US20120071497A1/en?oq=US2012071497
Imbruvica,US2012087915 ,Pharmacyclics LLC,Cancer,Small Molecule,3,6/3/2010,6/3/2011,4/12/2012,,Pending,Method of Treatment,"The application claims a method for treating a hematological malignancy in an individual in need thereof, comprising: administering to the individual an amount of a Btk inhibitor,  overing  various compounds including ibrutinib (Imbruvica), to mobilize a plurality of cells from the malignancy; and analyzing the mobilized plurality of cells.",Before,No,https://patents.google.com/patent/US20120087915A1/en?oq=US2012087915+
Imbruvica,US2012100138 ,Pharmacyclics LLC,Cancer,Small Molecule,3,6/3/2010,12/29/2011,4/26/2012,,Abandoned,Method of Treatment,"The application claimed a method for treating a B-cell lymphoproliferative disorder (BCLD) in an individual comprising administering to the individual in need thereof an inhibitor of Bruton's tyrosine kinase (Btk),  including ibrutinib (Imbruvica) wherein the BCLD is an acute leukemia, Hairy cell leukemia (HCL), myeloid or myelogenous leukemia, or myeloma.",Before,No,https://patents.google.com/patent/US20120100138A1/en?oq=US2012100138+
Imbruvica,US2012101113 ,Pharmacyclics LLC,Cancer,Small Molecule,1,3/28/2007,12/29/2011,4/26/2012,,Abandoned,Main Compound,The application claimed a broad markush group covering numerous compounds including  ibrutinib (Imbruvica).,Before,No,https://patents.google.com/patent/US20120101113A1/en?oq=US2012101113+
Imbruvica,US2012101114 ,Pharmacyclics LLC,Cancer,Small Molecule,1,3/28/2007,12/29/2011,4/26/2012,,Abandoned,Method of Treatment,"The application claimed a method for treating a cancer in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of a Btk inhibitor, including  ibrutinib (Imbruvica), at least once a day.",Before,No,https://patents.google.com/patent/US20120101114A1/en?oq=US2012101114+
Imbruvica,US2012165328 ,Pharmacyclics LLC,Cancer,Small Molecule,1,3/28/2007,2/24/2012,6/28/2012,,Abandoned,Method of Treatment,"The application claimed an inhibited tyrosine kinase comprising an irreversible BLK inhibitor having a covalent bond to a cysteine residue of a B lymphocyte kinase (BLK).
",Before,No,https://patents.google.com/patent/US20120165328A1/en?oq=US2012165328+
Imbruvica,US2012184013 ,Pharmacyclics LLC,Cancer,Small Molecule,1,3/28/2007,3/1/2012,7/19/2012,,Abandoned,Method of Treatment,The application claimed an inhibited tyrosine kinase comprising an irreversible BMX inhibitor having a covalent bond to a cysteine residue of a BMX non-receptor tyrosine kinase (BMX).,Before,No,https://patents.google.com/patent/US20120184013A1/en?oq=US2012184013+
Imbruvica,US2012184567 ,Pharmacyclics LLC,Cancer,Small Molecule,1,3/28/2007,3/26/2012,7/19/2012,,Abandoned,Derivative,The application claimed a large number of compounds covering a kinase inhibitor.,Before,No,https://patents.google.com/patent/US20120184567A1/en?oq=US2012184567+
Imbruvica,US2012202264 ,Pharmacyclics LLC,Cancer,Small Molecule,1,3/28/2007,4/4/2012,8/9/2012,,Abandoned,Method of Treatment,The application claimed an inhibited tyrosine kinase comprising an irreversible ITK inhibitor having a covalent bond to a cysteine residue of an IL2-inducible T-cell kinase (ITK).,Before,No,https://patents.google.com/patent/US20120202264A1/en?oq=US2012202264+
Imbruvica,US2012296089 ,Pharmacyclics LLC,Cancer,Small Molecule,1,3/28/2007,7/6/2012,11/22/2012,,Abandoned,Derivative,The application claimed derivative compounds of ibrutinib (Imbruvica).,Before,No,https://patents.google.com/patent/US20120296089A1/en?oq=US2012296089+
Imbruvica,US2012329130 ,Pharmacyclics LLC,Cancer,Small Molecule,1,3/28/2007,9/7/2012,12/27/2012,,Abandoned,Method of Treatment,The application claimed an inhibited tyrosine kinase comprising an irreversible Tec kinase inhibitor having a covalent bond to a cysteine residue of a Tec kinase.,Before,No,https://patents.google.com/patent/US20120329130A1/en?oq=US2012329130+
Imbruvica,US20130178483,Pharmacyclics LLC,Cancer,Small Molecule,4,6/28/2011,6/28/2012,7/11/2013,,Abandoned,Method of Treatment,"The application claimed a method of inhibiting bone or cartilage resorption in an individual, said method comprising: administering to the individual a composition comprising a therapeutically effective amount of a compound that is an irreversible inhibitor of a Bruton's tyrosine kinase (BTK), including ibrutinib (Imbruvica).",Before,No,https://patents.google.com/patent/US20130178483A1/en?oq=US20130178483
Imbruvica,US2013018060 ,Pharmacyclics LLC,Cancer,Small Molecule,1,3/28/2007,9/12/2012,1/17/2013,,Abandoned,Derivative,The application claimed derivative compounds of ibrutinib (Imbruvica).,Before,No,https://patents.google.com/patent/US20130018060A1/en?oq=US2013018060+
Imbruvica,US2013202611 ,Pharmacyclics LLC,Cancer,Small Molecule,3,6/3/2010,1/8/2013,8/8/2013,,Abandoned,Method of Treatment,"The application claimed a method for treating relapsed or refractory lymphoma in an individual with comprising administering to the individual in need thereof an irreversible inhibitor of Bruton's tyrosine kinase (Btk), including ibrutinib (Imbruvica).",Before,No,https://patents.google.com/patent/US20130202611A1/en?oq=US2013202611+
Imbruvica,US2013273030 ,Pharmacyclics LLC,Cancer,Small Molecule,3,6/3/2010,1/22/2013,10/17/2013,,Abandoned,Method of Treatment,"The application claimed a method for treating relapsed or refractory lymphoma in an individual comprising administering to the individual in need thereof an irreversible inhibitor of Bruton's tyrosine kinase (Btk), namely ibrutinib (Imbruvica) with an anti-CD20 antibody such as rituximab or ofatumumab.",Before,No,https://patents.google.com/patent/US20130273030A1/en?oq=US2013273030+
Imbruvica,US2013310402 ,Pharmacyclics LLC,Cancer,Small Molecule,3,6/3/2010,4/24/2013,11/21/2013,,Abandoned,Method of Treatment,"The application claimed a method for treating relapsed or refractory non-Hodgkin's lymphoma in an individual in need thereof, comprising: administering to the individual a therapeutically-effective amount, 300mg-1000mg/day of ibrutinib (Imbruvica).",Before,No,https://patents.google.com/patent/US20130310402A1/en?oq=US2013310402+
Imbruvica,US2014057907 ,Pharmacyclics LLC,Cancer,Small Molecule,1,12/27/2007,10/31/2013,2/27/2014,,Abandoned,Method of Treatment,The application claimed a method for treating mastocytosis in an individual comprising administering to the individual ibrutinib (Imbruvica) ,Before,No,https://patents.google.com/patent/US20140057907A1/en?oq=US2014057907+
Imbruvica,US2014080844A1,Pharmacyclics LLC,Cancer,Small Molecule,32,10/12/2009,11/20/2013,3/20/2014,,Abandoned,Derivative,The application claimed derivative compounds of ibrutinib (Imbruvica).,After,No,https://patents.google.com/patent/US20140080844A1/en?oq=US2014080844A1
Imbruvica,US2014163027 ,Pharmacyclics LLC,Cancer,Small Molecule,1,3/28/2007,2/12/2014,6/12/2014,,Abandoned,Derivative,The application claimed derivative compounds of ibrutinib (Imbruvica).,After,No,https://patents.google.com/patent/US20140163027A1/en?oq=US2014163027+
Imbruvica,US2014303191 ,Pharmacyclics LLC,Cancer,Small Molecule,5,10/19/2011,10/19/2012,10/9/2014,,Abandoned,Method of Treatment,"The application claimed a  method for treating a hematological malignancy in an individual in need thereof with ibruitnib (Imbruvica), comprising administering to the individual an anti-cancer treatment, wherein the individual is identified as having an increased mobilization of a plurality of cells from the malignancy following administration of an irreversible Btk inhibitor to the individual. ",Before,No,https://patents.google.com/patent/US20140303191A1/en?oq=US2014303191+
Imbruvica,US2014336203 ,Pharmacyclics LLC,Cancer,Small Molecule,6,6/4/2012,7/23/2014,11/13/2014,,Abandoned,Formulation / Combination,"The application claimed a pharmaceutical formulation for oral administration comprising:
(a) about 40 mgs to about 200 mgs  of ibrutinib; (b) about 40 wt % to about 50 wt % of a diluent; (c) about 3 wt % to about 10 wt % of a disintegrating agent; (d) about 2 wt % to about 7 wt % of a surfactant; and (e) about 0.2 wt % to about 1.0 wt % of a lubricant.2. standard solid formulation technique; tied to crystalline Form A in later claims",After,No,https://patents.google.com/patent/US20140336203A1/en?oq=US2014336203+
Imbruvica,US2014371241 ,Pharmacyclics LLC,Cancer,Small Molecule,8,11/2/2012,3/5/2014,12/18/2014,,Abandoned,Method of Treatment,"The application claimed a method for treating a patient having a relapsed or refractory chronic lymphocytic leukemia, comprising administering to the patient ibrutinib (Imbruvica) and a Bcl-2 inhibitor.",After,No,https://patents.google.com/patent/US20140371241A1/en?oq=US2014371241+
Imbruvica,US20150118222,Pharmacyclics LLC,Cancer,Small Molecule,14,10/25/2013,10/24/2014,4/30/2015,,Abandoned,Method of Treatment,"The application claimed a method for treating a cancer comprising administering to a subject in need thereof a combination comprising ibrutinib and an immune checkpoint inhibitor.  Cancers covered include large B-cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), B cell prolymphocytic leukemia (B-PLL), non-CLL/SLL lymphoma, mantle cell lymphoma, multiple myeloma, Waldenström's macroglobulinemia, bladder cancer, breast cancer, colon cancer, gastroenterological cancer, kidney cancer, lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, proximal or distal bile duct cancer, melanoma, or a combination thereof.",After,No,https://patents.google.com/patent/US20150118222A1/en?oq=US20150118222
Imbruvica,US20150141438,Pharmacyclics LLC,Cancer,Small Molecule,12,11/15/2013,11/14/2014,5/21/2015,,Abandoned,Method of Treatment,The application claimed a method for preventing or delaying the onset of type 1 diabetes in an individual in need thereof comprising administering to the individual in need thereof a composition comprising a therapeutically-effective amount of ibrutinib.,After,No,https://patents.google.com/patent/US20150141438A1/en?oq=US20150141438
Imbruvica,US20150157634,Pharmacyclics LLC,Cancer,Small Molecule,11,12/2/2013,12/2/2014,6/11/2015,,Abandoned,Method of Treatment,"The application claimed a method of treating alloantibody driven chronic graft versus host disease (cGVHD) in a patient, comprising administering to a patient in need thereof a therapeutically effective amount of ibrutinib. ",After,No,https://patents.google.com/patent/US20150157634A1/en?oq=US20150157634
Imbruvica,US20150238490,Pharmacyclics LLC,Cancer,Small Molecule,10,2/21/2014,2/20/2015,8/27/2015,,Abandoned,Method of Treatment,"The application claimed a method for determining whether a patient diagnosed with diffuse large B cell lymphoma (DLBCL) is likely to respond to therapy with ibrutinib comprising:
a) determining a pre-administration expression level of CCL3 and/or CCL4 in a sample from the patient; b) administering a dose of ibrutinib; c) detecting a post-administration expression level of CCL3 and/or CCL4 in a sample from the patient following administration of ibrutinib to the patient; and d) characterizing the patient as likely to respond to therapy with ibrutinib if the post-administration expression level of CCL3 and/or CCL4 decreased compared to the pre-administration level of CCL3 and/or CCL4.of Treatment - METHOD OF DIAGNOSIS for predicting response",After,No,https://patents.google.com/patent/US20150238490A1/en?oq=US20150238490
Imbruvica,US2015031710 ,Pharmacyclics LLC,Cancer,Small Molecule,3,6/3/2010,2/24/2014,1/29/2015,,Abandoned,Formulation / Combination,The application claimed a pharmaceutical composition comprising about 140 mg of ibrutinib and a pharmaceutically acceptable excipient. ,After,No,https://patents.google.com/patent/US20150031710A1/en?oq=US2015031710+
Imbruvica,US2015152115 ,Pharmacyclics LLC,Cancer,Small Molecule,1,12/27/2007,2/3/2015,6/4/2015,,Abandoned,Main Compound,The patent claims cover a Markush group of ibrutinib and derivative compounds.,After,No,https://patents.google.com/patent/US20150152115A1/en?oq=US2015152115+
Imbruvica,US2015265618 ,Pharmacyclics LLC,Cancer,Small Molecule,1,3/28/2007,1/26/2015,9/24/2015,,Abandoned,Derivative,The application claimed derivative compounds of ibrutinib (Imbruvica).,After,No,https://patents.google.com/patent/US20150265618A1/en?oq=US2015265618+
Imbruvica,US2015306103 ,Pharmacyclics LLC,Cancer,Small Molecule,1,9/22/2006,2/3/2015,10/29/2015,,Abandoned,Method of Treatment,"The application claimed a method for treating a B-cell proliferative disorder in a subject in need thereof comprising administering to the subject two or more agents, wherein the first agent is from a Markush group of ibrutinib and the second agent cytarabin, and optionally additional agent(s)",After,No,https://patents.google.com/patent/US20150306103A1/en?oq=US2015306103+
Imbruvica,US2015307500 ,Pharmacyclics LLC,Cancer,Small Molecule,1,12/27/2007,5/4/2015,10/29/2015,,Abandoned,Derivative,The application claimed derivative compounds of ibrutinib (Imbruvica).,After,No,https://patents.google.com/patent/US20150307500A1/en?oq=US2015307500+
Imbruvica,US20160008366,Pharmacyclics LLC,Cancer,Small Molecule,25,7/14/2014,7/13/2015,1/14/2016,,Abandoned,Method of Treatment,"The application claimed a method for treating a CNS malignancy comprising administering to an individual in need thereof a composition containing a therapeutically effective amount of a Btk inhibitor from a broad Markush group, including ibrutinib.",After,No,https://patents.google.com/patent/US20160008366A1/en?oq=US20160008366
Imbruvica,US20160022683,Pharmacyclics LLC,Cancer,Small Molecule,18,3/14/2013,3/12/2014,1/28/2016,,Abandoned,Formulation / Combination,The application claimed a pharmaceutical composition comprising: a. a therapeutically-effective amount of Ibrutinib; b. a CYP3A4 inhibitor; and c. a pharmaceutically-acceptable excipient.,After,No,https://patents.google.com/patent/US20160022683A1/en?oq=US20160022683
Imbruvica,US20160022684,Pharmacyclics LLC,Cancer,Small Molecule,24,7/25/2014,7/23/2015,1/28/2016,,Abandoned,Method of Treatment,"The application claimed method of treating a B-cell malignancy in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination comprising ibrutinib and a BET inhibitor.",After,No,https://patents.google.com/patent/US20160022684A1/en?oq=US20160022684
Imbruvica,US20160032404,Pharmacyclics LLC,Cancer,Small Molecule,23,8/1/2014,7/31/2015,2/4/2016,,Abandoned,Method of Diagnosis,The application claimed a method for selecting an individual having diffuse large B cell lymphoma (DLBCL) for treatment with ibrutinib.,After,No,https://patents.google.com/patent/US20160032404A1/en?oq=US20160032404
Imbruvica,US20160287592,Pharmacyclics LLC & Janssen,Cancer,Small Molecule,17,4/8/2013,4/8/2014,10/6/2016,,Abandoned,Method of Treatment,"The application claimed a method for treating a B-cell proliferative disorder comprising administering to a subject in need thereof a therapeutically effective amount of a combination comprising: a. Ibrutinib; and b. an anticancer agent, wherein the anticancer agent inhibits Bcl-2; Janus kinase 2 (JAK2); Anaplastic lymphoma kinase (ALK); or heat shock protein 90 (Hsp90), wherein the combination provides a synergistic therapeutic effect compared to administration of ibrutinib or the anticancer agent alone.",After,No,https://patents.google.com/patent/US20160287592A1/en?oq=US20160287592
Imbruvica,US2016243033 ,Pharmacyclics LLC,Cancer,Small Molecule,3,6/3/2010,9/16/2015,8/25/2016,,Abandoned,Method of Treatment,"The application claimed a method for treating diffuse large B-cell lymphoma, activated B cell-like subtype (ABC-DLBCL), in an individual in need thereof, comprising: administering to the individual a therapeutically effective amount of ibrutinib.  ",After,No,https://patents.google.com/patent/US20160243033A1/en?oq=US2016243033+
Imbruvica,US2017007611 ,Pharmacyclics LLC,Cancer,Small Molecule,1,9/22/2006,2/12/2016,1/12/2017,,Abandoned,Formulation / Combination,The application claimed a composition comprising rituximab and compounds of the ibrutinib Markush Group as well methods of treating cancer.,After,No,https://patents.google.com/patent/US20170007611A1/en?oq=US2017007611+
Imbruvica,US20170209462,Pharmacyclics LLC,Cancer,Small Molecule,31,8/31/2015,8/31/2016,7/27/2017,,Abandoned,Formulation / Combination,The application claimed a combination comprising: a) ibrutinib; b) an immunomodulatory agent; and c) dexamethasone,After,No,https://patents.google.com/patent/US20170209462A1/en?oq=US20170209462
Imbruvica,US20170266186A1,Pharmacyclics LLC,Cancer,Small Molecule,5,10/19/2011,12/29/2016,9/21/2017,,Abandoned,Method of Treatment,"The application claimed a method for treating a hematological malignancy in an individual in need thereof, comprising administering to the individual a first amount of ibrutinib or a pharmaceutically acceptable salt thereof, and a second amount of GA101 or a pharmaceutically acceptable salt thereof, wherein the first amount and the second amount, together, are therapeutically effective.",After,No,https://patents.google.com/patent/US20170266186A1/en?oq=US20170266186A1
Imbruvica,US20170354655,Pharmacyclics LLC,Cancer,Small Molecule,20,11/17/2014,11/17/2015,12/14/2017,,Abandoned,Method of Treatment,"The application claimed amethod of treating a B-cell malignancy in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination comprising a BTK inhibitor such as ibrutinib in combination with a TLR9 inhibitor",After,No,https://patents.google.com/patent/US20170354655A1/en?oq=US20170354655
Imbruvica,US20170360796,"Pharmacyclics LLC, Ohio State Innovation Foundation",Cancer,Small Molecule,30,12/23/2014,12/22/2015,12/21/2017,,Abandoned,Method of Treatment,"The application claimed a combination dosing regimen for the treatment of a hematologic malignancy in a subject in need thereof comprising a first phase and a second phase, wherein the first phase is an administration of a BTK inhibitor (ibrutinib) as a single-agent treatment for a first extended period of time, and the second phase is an administration of a combination of the BTK inhibitor and an anti-CD20 therapeutic agent for a second extended period of time Treatment 2. treating hematologic malignancies with BTK inhibitor in ""Phase 1"" followed by treatment with BTK inhibitor + CD20 antibody in ""Phase 2""",After,No,https://patents.google.com/patent/US20170360796A1/en?oq=US20170360796
Imbruvica,US2017079981 ,Pharmacyclics LLC,Cancer,Small Molecule,22,8/7/2014,12/6/2016,3/23/2017,,Abandoned,Formulation / Combination,The application claimed a solid dispersion pharmaceutical composition comprising solid dispersed ibrutinib.,After,No,https://patents.google.com/patent/US20170079981A1/en?oq=US2017079981+
Imbruvica,US2017246169 ,Pharmacyclics LLC,Cancer,Small Molecule,2,7/16/2008,10/13/2016,8/31/2017,,Abandoned,Method of Treatment,"The application claimed a method for treating a solid tumor in a subject comprising administering to the subject ibrutinib or a pharmaceutically acceptable salt thereof, wherein the solid tumor is selected from colon cancer, breast cancer, and non-small cell lung cancer.",After,No,https://patents.google.com/patent/US20170246169A1/en?oq=US2017246169+
Imbruvica,US2017258729 ,Pharmacyclics LLC,Cancer,Small Molecule,28,3/3/2015,3/23/2017,9/14/2017,,Abandoned,Method of Treatment,"The application claimedmethod of treating cancer or graft versus host disease in a patient in need of such treatment, comprising administering to the patient a therapeutically effective amount of a high-load solid tablet formulation comprising ibrutinib and one or more pharmaceutically acceptable excipientsand wherein the high-load solid tablet formulation comprises at least 50% w/w of ibrutinib, and the excipients comprise,
one or more diluents selected from the group consisting of lactose, sucrose, dextrose, dextrates, maltodextrin, mannitol, xylitol, sorbitol, cyclodextrins, calcium phosphate, calcium sulfate, starches, modified starches, cellulose, microcrystalline cellulose, microcellulose, and talc;one or more disintegrating agents selected from the group consisting of natural starch, a pregelatinized starch, a sodium starch, methylcrystalline cellulose, methylcellulose, croscarmellose, croscarmellose sodium, cross-linked sodium carboxymethylcellulose, cross-linked carboxymethylcellulose, cross-linked croscarmellose, cross-linked starch, cross-linked polymer, cross-linked polyvinylpyrrolidone, sodium alginate, a clay, and a gum;one or more binders selected from the group consisting of hydroxypropyl cellulose and polyvinylpyrrolidone;sodium lauryl sulfate; colloidal silicon dioxide; and magnesium stearate.
 ",After,No,https://patents.google.com/patent/US20170258729A1/en?oq=US2017258729+
Imbruvica,US2017305919 ,Pharmacyclics LLC,Cancer,Small Molecule,6,6/4/2012,7/10/2017,10/26/2017,,Abandoned,Formulation / Combination,The application claimed a pharmaceutical formulation for oral administration comprising one or more pharmaceutically acceptable excipients and crystalline Form A ibrutinib.,After,No,https://patents.google.com/patent/US20170305919A1/en?oq=US2017305919+
Imbruvica,US2017362246 ,Pharmacyclics LLC,Cancer,Small Molecule,1,3/28/2007,8/31/2017,12/21/2017,,Abandoned,Derivative,The application claimed derivative compounds of ibrutinib (Imbruvica).,After,No,https://patents.google.com/patent/US20170362246A1/en?oq=US2017362246+
Imbruvica,US20180009814,Janssen Pharmaceutica NVPharmacyclics LLC,Cancer,Small Molecule,29,1/14/2015,1/14/2016,1/11/2018,,Abandoned,Method of Production / Process,The application claimed a  route of synthesis for making ibrutinib.,After,No,https://patents.google.com/patent/US20180009814A1/en?oq=US20180009814
Imbruvica,US20180072738,Pharmacyclics LLC,Cancer,Small Molecule,27,3/27/2015,3/25/2016,3/15/2018,,Abandoned,Crystalline,The application claimed solvated forms of ibrutinib,After,No,https://patents.google.com/patent/US20180072738A1/en?oq=US20180072738
Imbruvica,US20180072739,Pharmacyclics LLC,Cancer,Small Molecule,26,3/27/2015,3/25/2016,3/15/2018,,Abandoned,Crystalline,The application claimed cocrystal forms of ibrutinib.,After,No,https://patents.google.com/patent/US20180072739A1/en?oq=US20180072739
Imbruvica,US20180078558,Pharmacyclics LLC,Cancer,Small Molecule,11,12/2/2013,12/1/2017,3/22/2018,,Abandoned,Method of Treatment,"The application claimed  a method of treating alloantibody driven chronic graft versus host disease (cGVHD) in a patient, comprising administering to a patient in need thereof a therapeutically effective amount of a compound from a Markush group containing ibrutinib. ",After,No,https://patents.google.com/patent/US20180078558A1/en?oq=US20180078558
Imbruvica,US2018028537 ,Pharmacyclics LLC,Cancer,Small Molecule,22,8/7/2014,3/17/2017,2/1/2018,,Pending,Formulation / Combination,The application claims a solid dispersion pharmaceutical composition comprising solid dispersed ibrutinib.,After,No,https://patents.google.com/patent/US20180028537A1/en?oq=US2018028537+
Imbruvica,US2018071293 ,Pharmacyclics LLC,Cancer,Small Molecule,8,11/2/2012,7/14/2017,3/15/2018,,Abandoned,Method of Treatment,"The application claimed a  method of treating a myeloma or lymphoma in a subject in need thereof comprising co-administering: a. a first amount of ibrutinib; and b. a second amount of bortezomib, wherein, together, the first amount of ibrutinib and the second amount of bortezomib are therapeutically effective. ",After,No,https://patents.google.com/patent/US20180071293A1/en?oq=US2018071293+
Imbruvica,US2018071295 ,Pharmacyclics LLC & Janssen,Cancer,Small Molecule,21,8/8/2014,7/21/2017,3/15/2018,,Abandoned,Method of Treatment,"The application claimed amethod of treating a B-cell malignancy in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination comprising a BTK inhibitor and an anticancer agent, wherein the anticancer agent inhibits MALT1, MCL-1, or IDH1.",After,No,https://patents.google.com/patent/US20180071295A1/en?oq=US2018071295+
Imbruvica,US2018085372 ,Pharmacyclics LLC,Cancer,Small Molecule,1,9/22/2006,5/8/2017,3/29/2018,,Abandoned,Derivative,"The application claimed derivative compounds of ibrutinib (Imbruvica).

",After,No,https://patents.google.com/patent/US20180085372A1/en?oq=US2018085372+
Imbruvica,US2018155352 ,Pharmacyclics LLC,Cancer,Small Molecule,6,6/4/2012,2/2/2018,6/7/2018,,Abandoned,Crystalline,The application claimed a  2. anhydrous/unsolvated crystalline form of Ibrutinib.,After,No,https://patents.google.com/patent/US20180155352A1/en?oq=US2018155352+
Imbruvica,US2018170940 ,Pharmacyclics LLC,Cancer,Small Molecule,6,6/4/2012,2/2/2018,6/21/2018,,Abandoned,Crystalline,The application claimed  crystalline Form A ibrutinib.,After,No,https://patents.google.com/patent/US20180170940A1/en?oq=US2018170940+
Imbruvica,US2018193345 ,Pharmacyclics LLC,Cancer,Small Molecule,2,7/16/2008,10/23/2017,7/12/2018,,Abandoned,Method of Treatment,The application claimed a method for treating sarcoma in a subject comprising administering to the subject a therapeutically effective amount of ibrutinib.,After,No,https://patents.google.com/patent/US20180193345A1/en?oq=US2018193345+
Imbruvica,US2018280395 ,Pharmacyclics LLC,Cancer,Small Molecule,3,6/3/2010,5/2/2018,10/4/2018,,Abandoned,Formulation / Combination,The application claimed a solid pharmaceutical formulation of ibrutinib where 420 mg daily dose achieves a target AUC.,After,No,https://patents.google.com/patent/US20180280395A1/en?oq=US2018280395+
Imbruvica,US2018311153 ,Pharmacyclics LLC,Cancer,Small Molecule,3,6/3/2010,12/1/2017,11/1/2018,,Abandoned,Method of Treatment,"The application claimed a method for treating diffuse large B-cell lymphoma, activated B cell-like subtype (ABC-DLBCL), in an individual in need thereof, comprising: administering to the individual a therapeutically effective amount of an inhibitor of Bruton's tyrosine kinase.",After,No,https://patents.google.com/patent/US20180311153A1/en?oq=US2018311153+
Imbruvica,US2018319805 ,Pharmacyclics LLC,Cancer,Small Molecule,6,6/4/2012,7/16/2018,11/8/2018,,Abandoned,Crystalline,"The patent claims cover six  crystalline forms of ibrutinib, of which many are anhydrous.",After,No,https://patents.google.com/patent/US20180319805A1/en?oq=US2018319805+
Imbruvica,US2018362534,Pharmacyclics LLC,Cancer,Small Molecule,6,6/4/2012,8/23/2018,12/20/2018,,Abandoned,Crystalline,The application claimed crystalline anhydrous forms of ibrutinib ,After,No,https://patents.google.com/patent/US20180362534A1/en?oq=US2018362534
Imbruvica,US2019015340,"Pharmacyclics LLC


",Cancer,Small Molecule,28,3/3/2015,9/11/2018,1/17/2019,,Abandoned,Formulation / Combination,The application claimed ahigh-load solid tablet formulation comprising ibrutinib and one or more pharmaceutically acceptable excipients and wherein the high-load solid tablet formulation comprises at least 50% w/w of ibrutinib.,After,No,https://patents.google.com/patent/US20190015340A1/en?oq=US2019015340
Imbruvica,US20190367518A1,Janssen Pharmaceutica NVPharmacyclics LLC,Cancer,Small Molecule,29,1/14/2015,12/18/2018,12/05/2019,,Abandoned,Method of Production / Process,The application claimed a process for the preparation of  ibrutinib,After,No,https://patents.google.com/patent/US20190367518A1/en?oq=US20190367518A1
Imbruvica,US20190367519A1,Pharmacyclics LLC,Cancer,Small Molecule,27,3/27/2015,12/18/2018,12/5/2019,,Abandoned,Crystalline,The application claimed a solvates of acetophenone or benzyl acetate of ibrutinib.,After,No,https://patents.google.com/patent/US20190367519A1/en?oq=US20190367519A1
Imbruvica,US20190381174,Janssen Pharmaceutica NVPharmacyclics LLC,Cancer,Small Molecule,41,6/15/2018,6/14/2019,12/19/2019,,Pending,Formulation / Combination,"The application claims a stable pharmaceutical formulation comprising: (i) ibrutinib, or a pharmaceutically acceptable salt/solvate thereofand a suspending agent, optionally in the presence of a pharmaceutically acceptable carrier (e.g., aqueous carrier); and (ii) one or more preservatives, wherein at least one preservative is benzyl alcohol; and, optionally, one or more other pharmaceutically acceptable excipients.
",After,No,https://patents.google.com/patent/US20190381174A1/en?oq=US20190381174
Imbruvica,US2019117579,"Pharmacyclics LLC


",Cancer,Small Molecule,28,3/3/2015,12/20/2018,4/25/2019,,Abandoned,Formulation / Combination,"The application claimed a  high-load solid tablet formulation comprising ibrutinib and one or more pharmaceutically acceptable excipients, and wherein the high-load solid tablet formulation comprises at least 50% w/w of ibrutinib.
",After,No,https://patents.google.com/patent/US20190117579A1/en?oq=US2019117579
Imbruvica,US2019167687,"Pharmacyclics LLC


",Cancer,Small Molecule,15,8/12/2013,7/6/2018,6/6/2019,,Abandoned,Method of Treatment,"The application claimed a method for treating HER2 amplified breast cancer in an individual in need thereof comprising administering to an individual in need thereof a composition  comprising ibrutinib and with an additional therapeutic agent selected from temsirolimus; paclitaxel; ASLAN001 (also, ARRY-543); vorinostat; doxorubicin; cyclophosphamide; cisplatin; docetaxel; dasatinib; trastuzumab and docetaxel; pertuzumab and docetaxel; doxorubicin, cyclophosphamide and paclitaxal; and doxorubicin, cyclophosphamide and 5-FU.",After,No,https://patents.google.com/patent/US20190167687A1/en?oq=US2019167687
Imbruvica,US2019203297 ,"Pharmacyclics LLC


",Cancer,Small Molecule,9,3/20/2014,12/18/2017,7/4/2019,,Abandoned,Method of Diagnosis,The application claimed a method of assessing whether a subject having a hematologic cancer is less responsive or likely to become less responsive to therapy with a BTK inhibitor such as ibrutinib. ,After,No,https://patents.google.com/patent/US20190203297A1/en?oq=US2019203297+
Imbruvica,US2019248798,Pharmacyclics LLC,Cancer,Small Molecule,6,6/4/2012,4/24/2019,8/15/2019,,Abandoned,Formulation / Combination,"The application claimed a pharmaceutical formulation for oral administration comprising:
(a) about 140 mg of ibrutinib, (b) about 40 wt % to about 50 wt % of one or more diluents; and (c) about 0.2 wt % to about 1.0 wt % of one or more lubricants.",After,No,https://patents.google.com/patent/US20190248798A1/en?oq=US2019248798
Imbruvica,US2019248799,Pharmacyclics LLC,Cancer,Small Molecule,6,6/4/2012,4/24/2019,8/15/2019,,Abandoned,Formulation / Combination,"The application claimed a pharmaceutical formulation for oral administration comprising:
(a) about 40 mg to about 200 mg of ibrutinib; (b) about 40 wt % to about 50 wt % of one or more diluents; and (c) about 0.2 wt % to about 1.0 wt % of one or more lubricants.",After,No,https://patents.google.com/patent/US20190248799A1/en?oq=US2019248799
Imbruvica,US2019282578,"Pharmacyclics LLC


",Cancer,Small Molecule,22,8/7/2014,10/19/2018,9/19/2019,,Abandoned,Formulation / Combination,"The application claimed  a  solid dispersion pharmaceutical composition comprising solid dispersed ibrutinib, wherein the solid dispersed ibrutinib is a spray-dried ibrutinib composition.",After,No,https://patents.google.com/patent/US20190282578A1/en?oq=US2019282578
Imbruvica,US20200031829A1,Pharmacyclics LLC,Cancer,Small Molecule,26,3/27/2015,3/1/2019,1/30/2020,,Abandoned,Crystalline,The application claimed  cocrystal forms of ibrutinib and any of 9 coformers.,After,No,https://patents.google.com/patent/US20200031829A1/en?oq=US20200031829A1
Imbruvica,US20200108072A1,Pharmacyclics LLC,Cancer,Small Molecule,1,9/22/2006,5/20/2019,4/9/2020,,Abandoned,Derivative,The application claimed derivative compounds of ibrutinib (Imbruvica).,After,No,https://patents.google.com/patent/US20200108072A1/en?oq=US20200108072A1
Imbruvica,US20200148691A1,Pharmacyclics LLC,Cancer,Small Molecule,6,6/4/2012,1/15/2020,5/14/2020,,Abandoned,Formulation / Combination,"The application claimed a pharmaceutical formulation for oral administration comprising:
(a) about 140 mg of ibrutinib; (b) about 20 wt % to about 70 wt % of one or more diluents; (c) about 2 wt % to about 7 wt % of one or more surfactants; and
(d) one or more lubricants.",After,No,https://patents.google.com/patent/US20200148691A1/en?oq=US20200148691A1
Imbruvica,US20200171034,Janssen Pharmaceutica NVPharmacyclics LLC,Cancer,Small Molecule,40,11/30/2018,11/26/2019,6/4/2020,,Pending,Method of Treatment,"The application claims a method of treating follicular lymphoma (FL) in a subject, the method comprising:
administering to the subject a therapeutically effective amount of ibrutinib to thereby treat the FL, wherein the subject does not have one or more mutations as defined in Table 2 in one or more genes selected from AHNAK, ARID1A, ATP6AP1, BCL9L, CLTC, CNOT1, EP400, KDM2B, MYBBPA, NACA, NBPF1, NBPF10, NCOA4, NEDD4L, PRDM16, SOCS1, and TBL1XR1.
",After,No,https://patents.google.com/patent/US20200171034A1/en?oq=US20200171034
Imbruvica,US20200231595A1,Pharmacyclics LLC,Cancer,Small Molecule,6,6/4/2012,3/19/2020,7/23/2020,,Abandoned,Crystalline,The application claimed a crystalline Form A of ibrutinib.,After,No,https://patents.google.com/patent/US20200231595A1/en?oq=US20200231595A1
Imbruvica,US20200262925,Janssen Pharmaceutica NVPharmacyclics LLC,Cancer,Small Molecule,39,2/15/2019,2/14/2020,8/20/2020,,Pending,Method of Treatment,"The application claims a method of treating a B-cell malignancy in a subject, the method comprising:
administering to the subject a therapeutically effective amount of a combination of ibrutinib and an anti-PD-1 antibody to thereby treat the B-cell malignancy, wherein: a) the B-cell malignancy is DLBCL and the subject has one or more mutations in genes selected from KLHL14, RNF213, CSMD3, BCL2, NBPF1, LRP1B, or a combination thereof, wherein the one or more mutations are listed in Table 4 or 6; b) the B-cell malignancy is GCB-DLBCL and the subject has one or more mutations in genes selected from RNF213, NBPF1, or a combination thereof, wherein the one or more mutations are listed in Table 16;
c) the B-cell malignancy is FL and the subject has one or more mutations in genes selected from BCL2, CREBBP, KMT2D, MUC17, CITTA, FES, NCOA2, TPR, or a combination thereof, wherein the one or more mutations are listed in Table 8 or 10; or d) the B-cell malignancy is RT and the subject has one or more mutations in genes selected from IRF2BP2, NBPF1, KLHL6, SETX, SF3B1, or a combination thereof, wherein the one or more mutations are listed in Table 12 or 14.",After,No,https://patents.google.com/patent/US20200262925A1/en?oq=US20200262925
Imbruvica,US20200276199A1,Pharmacyclics LLC,Cancer,Small Molecule,2,7/16/2008,2/28/2019,9/3/2020,,Abandoned,Method of Treatment,"The application claimed a method for treating HER2 amplified breast cancer in an individual in need thereof comprising administering to an individual in need thereof a composition comprising a therapeutically-effective amount of ibrutinib and an additional therapeutic agent selected from trastuzumab, paclitaxel, doxorubicin, cyclophosphamide, and cisplatin. ",After,No,https://patents.google.com/patent/US20200276199A1/en?oq=US20200276199A1
Imbruvica,US20200289515A1,Pharmacyclics LLC,Cancer,Small Molecule,2,7/16/2008,3/21/2019,9/17/2020,,Abandoned,Method of Treatment,The application claimed a method for treating a solid tumor in a subject comprising administering to the subject ibrutinib.,After,No,https://patents.google.com/patent/US20200289515A1/en?oq=US20200289515A1
Imbruvica,US20200347063A1,Pharmacyclics LLC,Cancer,Small Molecule,27,3/27/2015,11/27/2019,11/5/2020,,Abandoned,Crystalline,The application claimed solvates of ibrutinib,After,No,https://patents.google.com/patent/US20200347063A1/en?oq=US20200347063A1
Imbruvica,US20200347064A1,Janssen Pharmaceutica NVPharmacyclics LLC,Cancer,Small Molecule,29,1/14/2015,12/4/2019,11/5/2020,,Abandoned,Method of Production / Process,The application claimed a pocess for preparing ibruitinib ,After,No,https://patents.google.com/patent/US20200347064A1/en?oq=US20200347064A1
Imbruvica,US20200368235A1,Pharmacyclics LLC & Janssen,Cancer,Small Molecule,17,4/8/2013,8/1/2019,11/26/2020,,Abandoned,Method of Treatment,"The application claimed a method for treating a B-cell proliferative disorder comprising administering to a subject in need thereof a therapeutically effective amount of a combination comprising: a. ibrutinib; and b. an anticancer agent, wherein the anticancer agent inhibits Bcl-2; Janus kinase 2 (JAK2); Anaplastic lymphoma kinase (ALK); or heat shock protein 90 (Hsp90), wherein the combination provides a synergistic therapeutic effect compared to administration of ibrutinib or the anticancer agent alone.",After,No,https://patents.google.com/patent/US20200368235A1/en?oq=US20200368235A1
Imbruvica,US20200397895A1,Pharmacyclics LLC,Cancer,Small Molecule,14,10/25/2013,1/24/2020,12/24/2020,,Pending,Method of Treatment,"The application claims a  method for treating a cancer comprising administering to a subject in need thereof a combination comprising ibrutinib and an immune checkpoint inhibitor.  (e.g., Keytruda, Opdivo)",After,No,https://patents.google.com/patent/US20200397895A1/en?oq=US20200397895A1
Imbruvica,US20210032258A1,Pharmacyclics LLC,Cancer,Small Molecule,6,6/4/2012,10/8/2020,2/4/2021,,Abandoned,Formulation / Combination,"The application claimed a pharmaceutical formulation for oral administration comprising: about 70 mg of ibrutinib, (b) one or more diluents; (c) one or more surfactants; and
(d) one or more lubricants. ",After,No,https://patents.google.com/patent/US20210032258A1/en?oq=US20210032258A1
Imbruvica,US20210121463A1,Pharmacyclics LLC,Cancer,Small Molecule,13,10/25/2013,6/12/2020,4/29/2021,,Abandoned,Method of Treatment,The application claimed the of a compound from a Markush group of ibrutinib )for preventing the occurrence of graft versus host disease (GVHD) or reducing the severity of GVHD occurrence in a patient requiring cell transplantation.,After,No,https://patents.google.com/patent/US20210121463A1/en?oq=US20210121463A1
Imbruvica,US20210145835A1,"Pharmacyclics LLC


",Cancer,Small Molecule,15,8/12/2013,6/29/2020,5/20/2021,,Pending,Method of Treatment,"The application claims a method for treating HER2 amplified breast cancer in an individual in need thereof comprising administering to an individual in need thereof a composition comprising ibrutinib and in combination with an anti-HER2 therapeutic agent, a pan-ErbB inhibitor, or an anti-VEGF therapeutic agent.",After,No,US20210145835A1
Imbruvica,US20210169885A1,Pharmacyclics LLC,Cancer,Small Molecule,3,6/3/2010,7/10/2020,6/10/2021,,Pending,Method of Treatment,"The application claims a method for treating a hematological malignancy in an individual in need thereof, comprising: a. administering to the individual an amount of an irreversible Btk inhibitor sufficient to mobilize a plurality of cells from the malignancy; and analyzing the mobilized plurality of cells.",After,No,https://patents.google.com/patent/US20210169885A1/en?oq=US20210169885A1
Imbruvica,US20210177854A1,Pharmacyclics LLC,Cancer,Small Molecule,11,12/2/2013,7/29/2020,6/17/2021,,Pending,Method of Treatment,"The application claimed a  method of treating alloantibody driven chronic graft versus host disease (cGVHD) in a patient, comprising administering to a patient in need thereof a therapeutically effective amount of a compound ffrom the ibrutinib Markush Group",After,No,https://patents.google.com/patent/US20210177854A1/en?oq=US20210177854A1
Imbruvica,US20210361657A1,Pharmacyclics LLC,Cancer,Small Molecule,5,10/19/2011,12/16/2020,11/25/2021,,Pending,Method of Treatment,"The application claims a method for treating a hematological malignancy in an individual in need thereof, comprising administering to the individual an anti-cancer treatment, wherein the individual is identified as having an increased mobilization of a plurality of cells from the malignancy following administration of an irreversible Btk inhibitor (ibrutinib) to the individual.",After,No,https://patents.google.com/patent/US20210361657A1/en?oq=US20210361657A1
Imbruvica,US20220008424A1,Pharmacyclics LLC,Cancer,Small Molecule,1,9/22/2006,2/19/2021,1/13/2022,,Pending,Method of Production / Process,The application claims  an intermediate compound for ibrutinib and a method of treating anautoimmune disease with a BTK inhibitor,After,No,https://patents.google.com/patent/US20220008424A1/en?oq=US20220008424A1
Imbruvica,US20220098200A1,Janssen Pharmaceutica NVPharmacyclics LLC,Cancer,Small Molecule,29,1/14/2015,2/17/2021,3/31/2022,,Pending,Method of Production / Process,The application claims a process for the preparation of ibrutinib.,After,No,https://patents.google.com/patent/US20220098200A1/en?oq=US20220098200A1
Imbruvica,US20220106317A1,Pharmacyclics LLC,Cancer,Small Molecule,27,3/27/2015,5/1/2021,4/7/2022,,Pending,Crystalline,The application claims crystalline solvates of ibrutinib. ,After,No,https://patents.google.com/patent/US20220106317A1/en?oq=US20220106317A1
Imbruvica,US20220112196A1,Pharmacyclics LLC,Cancer,Small Molecule,6,6/4/2012,5/24/2021,4/14/2022,,Pending,Formulation / Combination,"The application claims a pharmaceutical formulation for oral administration comprising:
(a) about 70 mg of ibrutinib, (b) one or more diluents; (c) one or more surfactants; and (d) one or more lubricants.",After,No,https://patents.google.com/patent/US20220112196A1/en?oq=US20220112196A1
Imbruvica,US7514444,Pharmacyclics LLC,Cancer,Small Molecule,1,9/22/2006,12/28/2006,4/7/2009,12/28/2026,Active,Main Compound,The patent claims cover the compound ibrutinib (Imbruivca) and a pharmaceutical composition. ,Before,Yes,https://patents.google.com/patent/US7514444B2/en?oq=US7514444
Imbruvica,US7718662,Pharmacyclics LLC,Cancer,Small Molecule,32,10/12/2009,10/16/2009,5/18/2010,10/16/2029,Active,Derivative,The patent claims cover covers close analogs of ibrutnib (Imbruviva) that are expected to be irreverisble inhibitors of Bruton's tyrosine kinase (BTK). ,Before,No,https://patents.google.com/patent/US7718662B1/en?oq=US7718662
Imbruvica,US7732454 ,Pharmacyclics LLC,Cancer,Small Molecule,1,9/22/2006,3/28/2007,6/8/2010,4/19/2027,Active,Derivative, The patent claims cover a group of derivative compounds of ibrutinib (Imbruvica) and a pharmaceutical compositon. ,Before,No,https://patents.google.com/patent/US7732454B2/en?oq=US7732454+
Imbruvica,US7825118 ,Pharmacyclics LLC,Cancer,Small Molecule,1,9/22/2006,12/26/2007,11/2/2010,1/28/2028,Active,Derivative,The patent claims cover a group of derivative compounds ibrutinib (Imbruvica) and a pharmaceutical composition.,Before,No,https://patents.google.com/patent/US7825118B2/en?oq=US7825118+
Imbruvica,US7960396 ,Pharmacyclics LLC,Cancer,Small Molecule,1,9/22/2006,8/31/2010,6/14/2011,12/28/2026,Active,Derivative,The patent claims cover a markush group covering various compounds similar in structure to ibrutinib (Imbruvica).,Before,No,https://patents.google.com/patent/US7960396B2/en?oq=US7960396+
Imbruvica,US8008309 ,Pharmacyclics LLC,Cancer,Small Molecule,1,9/22/2006,7/7/2009,8/30/2011,11/13/2027,Active,Main Compound,The patent claims cover the compound ibrutinib (Imbruvica) and derivative compounds.,Before,Yes,https://patents.google.com/patent/US8008309B2/en?oq=US8008309+
Imbruvica,US8088781 ,Pharmacyclics LLC,Cancer,Small Molecule,1,9/22/2006,1/20/2009,1/3/2012,12/2/2027,Active,Method of Treatment,The patent claims cover an inhibited tyrosine kinase comprising an irreversible BTK inhibitor having a covalent bond to a cysteine residue of a Bruton's tyrosine kinase (Btk).,Before,No,https://patents.google.com/patent/US8088781B2/en?oq=US8088781+
Imbruvica,US8158786 ,Pharmacyclics LLC,Cancer,Small Molecule,1,9/22/2006,6/15/2011,4/17/2012,12/28/2026,Active,Method of Production / Process,The patent claims cover a process for synthesizing the compound ibrutinib (Imbruvica). ,Before,No,https://patents.google.com/patent/US8158786B2/en?oq=US8158786+
Imbruvica,US8232280 ,Pharmacyclics LLC,Cancer,Small Molecule,1,9/22/2006,1/21/2011,7/31/2012,12/28/2026,Active,Derivative,The patent claims cover derivative compounds of ibrutinib (Imbruvica).,Before,No,https://patents.google.com/patent/US8232280B2/en?oq=US8232280+
Imbruvica,US8236812 ,Pharmacyclics LLC,Cancer,Small Molecule,1,9/22/2006,9/21/2010,8/7/2012,12/28/2026,Active,Derivative,The patent claims cover a markush group covering various compounds similar in structure to ibrutinib (Imbruvica).,Before,No,https://patents.google.com/patent/US8236812B2/en?oq=US8236812+
Imbruvica,US8399470 ,Pharmacyclics LLC,Cancer,Small Molecule,1,9/22/2006,1/30/2012,3/19/2013,12/28/2026,Active,Main Compound,"The patent claims cover a large number of compounds, including ibrutinib (Imbruvica). ",Before,No,https://patents.google.com/patent/US8399470B2/en?oq=US8399470+
Imbruvica,US8476284 ,Pharmacyclics LLC,Cancer,Small Molecule,1,9/22/2006,12/16/2011,7/2/2013,12/28/2026,Active,Method of Treatment,The patent claims cover a method for treating a lymphoma in a subject comprising administering to a subject in need thereof a therapeutically effective amount of various compounds including ibrutinib (Imbruvica).,Before,Yes,https://patents.google.com/patent/US8476284B2/en?oq=US8476284+
Imbruvica,US8497277 ,Pharmacyclics LLC,Cancer,Small Molecule,1,9/22/2006,12/6/2011,7/30/2013,12/28/2026,Active,Method of Treatment,"The patent claims cover a method for treating a B-cell proliferative disorder comprising administering to a subject in need thereof a therapeutically effective amount of an irreversible covalent Btk inhibitor, including ibrutinib (Imbruvica).",Before,Yes,https://patents.google.com/patent/US8497277B2/en?oq=US8497277+
Imbruvica,US8501751 ,Pharmacyclics LLC,Cancer,Small Molecule,1,9/22/2006,7/7/2009,8/6/2013,12/28/2026,Active,Method of Treatment,"The patent claims cover a  method for treating an arthritis comprising administering to a subject in need thereof a therapeutically effective amount of a compound, which  includes ibrutinib (Imbruvica) and numerous related compounds.",Before,No,https://patents.google.com/patent/US8501751B2/en?oq=US8501751+
Imbruvica,US8552010 ,Pharmacyclics LLC,Cancer,Small Molecule,1,9/22/2006,6/18/2012,10/8/2013,12/28/2026,Active,Method of Treatment,The patent claims cover a method of treating a myeloma in a subject comprising administering to a subject in need thereof an irreversible inhibitor of Bruton's tyrosine kinase (Btk) such as ibrutinib (Imbruvica).. ,Before,No,https://patents.google.com/patent/US8552010B2/en?oq=US8552010+
Imbruvica,US8563563 ,Pharmacyclics LLC,Cancer,Small Molecule,1,9/22/2006,1/30/2012,10/22/2013,4/26/2027,Active,Method of Treatment,"The patent claims cover method for treating a B-cell proliferative disorder in a subject in need thereof comprising administering to the subject two or more agents, wherein the first agent is an irreversible inhibitor of Bruton's tyrosine kinase (Btk), ibrutinib (Imbruvica) and the second agent is an anti-cancer drug.",Before,Yes,https://patents.google.com/patent/US8563563B2/en?oq=US8563563+
Imbruvica,US8658653 ,Pharmacyclics LLC,Cancer,Small Molecule,1,9/22/2006,1/30/2012,10/22/2013,3/21/2027,Active,Method of Treatment,"The patent claims cover a method for treating a B-cell proliferative disorder in a subject in need thereof comprising administering to the subject two or more agents, wherein the first agent is an irreversible inhibitor of Bruton's tyrosine kinase (Btk), ibrutinib (Imbruvica) and the second agent is an anti-cancer drug.",Before,No,https://patents.google.com/patent/US8563563B2/en?oq=US8563563+
Imbruvica,US8691546 ,Pharmacyclics LLC,Cancer,Small Molecule,1,9/22/2006,5/15/2012,4/8/2014,12/28/2026,Active,Method of Treatment,The patent claims cover an  inhibited tyrosine kinase comprising an irreversible Bruton's tyrosine kinase (Btk) inhibitor having a Michael acceptor moiety wherein a covalent bond is formed between a portion of the Michael acceptor moiety and a portion of a cysteine residue of a Bruton's tyrosine kinase. ,Before,No,https://patents.google.com/patent/US8691546B2/en?oq=US8691546+
Imbruvica,US8697711 ,Pharmacyclics LLC,Cancer,Small Molecule,1,9/22/2006,5/23/2012,4/15/2014,12/28/2026,Active,Main Compound,The patent claims cover the compound and process for making ibrutinib (Imbruvica) and a pharmaceutical composition.,Before,Yes,https://patents.google.com/patent/US8697711B2/en?oq=US8697711+
Imbruvica,US8703780 ,Pharmacyclics LLC,Cancer,Small Molecule,1,9/22/2006,6/18/2012,4/22/2014,12/28/2026,Active,Method of Treatment,"The patent claims cover method of treating a leukemia in a subject comprising administering to a subject in need thereof an irreversible inhibitor of Bruton's tyrosine kinase (Btk), including ibrutinib (Imbruvica).",Before,Yes,https://patents.google.com/patent/US8703780B2/en?oq=US8703780+
Imbruvica,US8735403 ,Pharmacyclics LLC,Cancer,Small Molecule,1,9/22/2006,9/29/2011,5/27/2014,12/28/2026,Active,Main Compound,"The patent claims cover a large Markush group including ibrutinib (Imbruvica), and the stereochemistry at the single chiral center of imbruvica",Before,Yes,https://patents.google.com/patent/US8735403B2/en?oq=US8735403+
Imbruvica,US8735404 ,Pharmacyclics LLC,Cancer,Small Molecule,1,9/22/2006,12/22/2011,5/27/2014,4/8/2027,Active,Method of Treatment,"The patent claims cover a method for treating a disease selected from asthma, arthritis, rheumatoid arthritis, or lupus comprising administering to a subject in need thereof an irreversible inhibitor of Bruton's tyrosine kinase (Btk), wherein the inhibitor is selected from various compounds including ibrutinib (Imbruvica).  ",Before,No,https://patents.google.com/patent/US8735404B2/en?oq=US8735404+
Imbruvica,US8741908 ,Pharmacyclics LLC,Cancer,Small Molecule,1,9/22/2006,12/29/2011,6/3/2014,1/18/2027,Active,Derivative,The patent claims cover derivative compounds of ibrutinib (Imbruvica).,Before,No,https://patents.google.com/patent/US8741908B2/en?oq=US8741908+
Imbruvica,US8748438 ,Pharmacyclics LLC,Cancer,Small Molecule,1,9/22/2006,12/29/2011,6/10/2014,3/16/2027,Active,Method of Treatment,"The patent claims cover a method for treating Sjogren's syndrome comprising administering to an individual in need thereof an irreversible inhibitor of Bruton's tyrosine kinase (Btk), wherein the irreversible inhibitor includes ibrutinib (Imbruvica). ",Before,No,https://patents.google.com/patent/US8748438B2/en?oq=US8748438+
Imbruvica,US8748439 ,Pharmacyclics LLC,Cancer,Small Molecule,1,9/22/2006,4/18/2012,6/10/2014,1/10/2027,Active,Method of Treatment,The patent claims cover derivative compounds and a pharmaceutical composition.,Before,No,https://patents.google.com/patent/US8748439B2/en?oq=US8748439+
Imbruvica,US8754090,Pharmacyclics LLC,Cancer,Small Molecule,3,6/3/2010,12/29/2011,6/17/2014,6/3/2031,Active,Method of Treatment,The patent claims cover a  method for treating mantle cell lymphoma in an individual who has already received at least one prior therapy for mantle cell lymphoma comprising administering to the individual once per day between about 420 mg to about 840 mg of an oral dose of an inhibitor  -ibrutinib (Imbruvica) - of Bruton's tyrosine kinase (Btk),Before,Yes,https://patents.google.com/patent/US8754090B2/en?oq=US8754090
Imbruvica,US8754091,Pharmacyclics LLC,Cancer,Small Molecule,1,9/22/2006,7/5/2012,6/17/2014,12/28/2026,Active,Formulation / Combination,"The patent claims cover a pharmaceutical formulation comprising an irreversible, Bruton's tyrosine kinase (Btk) inhibitor, including ibrutinib (Imbruvica)or other  related compounds.",Before,Yes,https://patents.google.com/patent/US8754091B2/en?oq=US8754091
Imbruvica,US8759516 ,Pharmacyclics LLC,Cancer,Small Molecule,1,9/22/2006,7/26/2013,6/24/2014,12/28/2026,Active,Method of Production / Process,The patent claims cover a process for synthesizing the compound ibrutinib (Imbruvica). ,Before,No,https://patents.google.com/patent/US8759516B2/en?oq=US8759516+
Imbruvica,US8809273 ,Pharmacyclics LLC,Cancer,Small Molecule,1,3/28/2007,12/29/2011,8/19/2014,3/28/2027,Active,Method of Treatment,"The patent claims cover a  method for treating a bone resorption disorder in an individual comprising administering to an individual having a bone resorption disorder an irreversible Bruton's tyrosine kinase (Btk) inhibitor, namely ibrutinib (Imbruvica).",Before,No,https://patents.google.com/patent/US8809273B2/en?oq=US8809273+
Imbruvica,US8883435 ,Pharmacyclics LLC,Cancer,Small Molecule,1,9/22/2006,3/27/2008,11/11/2014,12/24/2029,Active,Method of Diagnosis,The patent claims cover a method of identifying an irreversible inhibitor of a Bruton's tyrosine kinase (Btk). This patent would be useful for identifying inhibitors such as ibrutinib (Imbruvica),Before,No,https://patents.google.com/patent/US8883435B2/en?oq=US8883435+
Imbruvica,US8883803 ,Pharmacyclics LLC,Cancer,Small Molecule,2,7/16/2008,12/30/2011,11/11/2014,1/31/2030,Active,Method of Treatment,The patent claims cover a method for treating a carcinoma in an individual comprising administering to the individual having a carcinoma ibrutinib (Imbruvica).,Before,No,https://patents.google.com/patent/US8883803B2/en?oq=US8883803+
Imbruvica,US8940750 ,Pharmacyclics LLC,Cancer,Small Molecule,1,3/28/2007,9/7/2012,1/27/2015,3/28/2027,Active,Method of Treatment,"The patent claims cover a  method of treating a mast cell proliferative disorder, comprising administering to a patient in need thereof a therapeutically effective amount of a compound that irreversibly inhibits an interleukin-2 inducible tyrosine kinase (ITK), including ibrutinib (Imbruvica). ",Before,No,https://patents.google.com/patent/US8940750B2/en?oq=US8940750+
Imbruvica,US8952015 ,Pharmacyclics LLC,Cancer,Small Molecule,1,9/22/2006,10/19/2010,2/10/2015,12/28/2026,Active,Method of Treatment,The patent claims cover a method of treating a blood cell cancer comprising administering to a subject in need thereof a composition containing a therapeutically effective amount of an inhibitor of a tyrosine kinase using various compounds including ibrutinib (Imbruvica). ,Before,Yes,https://patents.google.com/patent/US8952015B2/en?oq=US8952015+
Imbruvica,US8957079 ,Pharmacyclics LLC,Cancer,Small Molecule,1,9/22/2006,10/17/2012,2/17/2015,12/28/2026,Active,Main Compound,The patent claims cover ibrutinb (Imbruvica) and derivative compounds.,Before,Yes,https://patents.google.com/patent/US8957079B2/en?oq=US8957079+
Imbruvica,US8975266 ,Pharmacyclics LLC,Cancer,Small Molecule,1,9/22/2006,3/22/2013,3/10/2015,12/28/2026,Active,Method of Treatment,The patent claims cover a method for treating Hairy cell leukemia (HCL) in an individual comprising administering to a subject in need thereof a therapeutically effective amount an irreversible covalent Btk inhibitor such as ibrutinib (Imbruvica).,Before,No,https://patents.google.com/patent/US8975266B2/en?oq=US8975266+
Imbruvica,US8999999 ,Pharmacyclics LLC,Cancer,Small Molecule,3,6/3/2010,1/22/2013,4/7/2015,6/3/2031,Active,Method of Treatment,"The patent claims cover a method for treating relapsed or refractory chronic lymphocytic leukemia or relapsed or refractory small lymphocytic leukemia in an individual comprising administering to the individual in need thereof once per day between about 280 mg to about 840 mg of an oral dose of an irreversible inhibitor of Bruton's tyrosine kinase (Btk) - ibrutinib (Imbruvica) along with an additional cancer treatment regimen comprising bendamustine, bortezomib, CAL-101, chlorambucil, cyclophosphamide, dexamethasone, docetaxel, doxorubicin, endostatineverolimus, etoposide, fludarabine, fostamatinib, hydroxydaunorubicin, ibritumomab, ifosphamide, lenalidomide, mesalazine, ofatumumab, paclitaxel, pentostatin, prednisone, rituximab, temsirolimus, thalidomide, tositumomab, vincristine.",Before,Yes,https://patents.google.com/patent/US8999999B2/en?oq=US8999999+
Imbruvica,US9079908 ,Pharmacyclics LLC,Cancer,Small Molecule,1,3/28/2007,7/6/2012,7/14/2015,6/10/2027,Active,Derivative,The application claimed derivative compounds of ibrutinib (Imbruvica).,Before,No,https://patents.google.com/patent/US9079908B2/en?oq=US9079908+
Imbruvica,US9107924 ,Pharmacyclics LLC,Cancer,Small Molecule,2,7/16/2008,8/12/2013,8/18/2015,7/16/2029,Active,Method of Treatment,The patent claims cover a  method for treating HER2 amplified breast cancer in an individual in need thereof comprising administering to an individual in need thereof a composition comprising a therapeutically-effective amount of ibrutinib (Imbruvica) ,Before,No,https://patents.google.com/patent/US9107924B2/en?oq=US9107924+
Imbruvica,US9125889 ,Pharmacyclics LLC,Cancer,Small Molecule,3,6/3/2010,7/31/2014,9/8/2015,6/3/2031,Active,Method of Treatment,The patent claims cover a method for treating Waldenström's macroglobulinemia in an individual who has already received at least one prior therapy for Waldenström's macroglobulinemia comprising administering to the individual once per day between about 420 mg to about 840 mg of an oral dose of ibrutinib (Imbruvica).,After,Yes,https://patents.google.com/patent/US9125889B2/en?oq=US9125889+
Imbruvica,US9127012 ,Pharmacyclics LLC,Cancer,Small Molecule,1,9/22/2006,9/20/2013,9/8/2015,12/28/2026,Active,Method of Treatment,"The patent claims cover a method of treating a B-cell malignancy, comprising administering to a patient in need thereof a therapeutically effective amount of a compound that irreversibly inhibits EGFR, wherein the irreversible inhibitor is ibrutinib (Imbruvica). ",Before,No,https://patents.google.com/patent/US9127012B2/en?oq=US9127012+
Imbruvica,US9133198 ,Pharmacyclics LLC,Cancer,Small Molecule,1,9/22/2006,5/9/2013,9/15/2015,12/28/2026,Active,Method of Treatment,The patent claims cover a method for treating acute lymphoblastic leukemia (ALL) in an individual comprising administering to a subject in need thereof a therapeutically effective amount an irreversible covalent Btk inhibitor (ibrutinib- Imbruvica).,Before,No,https://patents.google.com/patent/US9133198B2/en?oq=US9133198+
Imbruvica,US9133201 ,Pharmacyclics LLC,Cancer,Small Molecule,1,9/22/2006,11/6/2013,9/15/2015,12/28/2026,Active,Method of Treatment,The patent claims cover a  method of treating pancreatic cancer comprising administering to a subject in need thereof a therapeutically effective amount of a compound selected from a Markush group belonging to ibrutinib (Imbruvica).,Before,No,https://patents.google.com/patent/US9133201B2/en?oq=US9133201+
Imbruvica,US9133202 ,Pharmacyclics LLC,Cancer,Small Molecule,1,9/22/2006,11/13/2013,9/15/2015,12/28/2026,Active,Method of Treatment,The patent claims cover a method for treating acute myelogenous leukemia (AML) in an individual comprising administering to the individual in need thereof a therapeutically effective amount an irreversible covalent Btk inhibitor selected from a large Markush group of ibrutinib.,After,No,https://patents.google.com/patent/US9133202B2/en?oq=US9133202+
Imbruvica,US9139591 ,Pharmacyclics LLC,Cancer,Small Molecule,1,3/28/2007,7/6/2012,9/22/2015,8/22/2027,Active,Derivative,The application claimed derivative compounds of ibrutinib (Imbruvica).,Before,No,https://patents.google.com/patent/US9139591B2/en?oq=US9139591+
Imbruvica,US9181257 ,Pharmacyclics LLC,Cancer,Small Molecule,1,9/22/2006,11/14/2013,11/10/2015,12/28/2026,Active,Derivative,The patent claims cover a Markush group structurally similar to ibrutinib.,After,Yes,https://patents.google.com/patent/US9181257B2/en?oq=US9181257+
Imbruvica,US9181263 ,Pharmacyclics LLC,Cancer,Small Molecule,1,3/28/2007,1/26/2015,9/24/2015,3/28/2027,Active,Derivative,The patent claims cover derivative compounds of ibrutinib (Imbruvica).,After,No,https://patents.google.com/patent/US9181263B2/en?oq=US9181263+
Imbruvica,US9193735 ,Pharmacyclics LLC,Cancer,Small Molecule,1,9/22/2006,1/15/2014,11/24/2015,12/28/2026,Active,Formulation / Combination,The patent claims cover a solid oral formulation comprising a therapeutically effective amount of a compound from a broad Markush group encompassing ibrutinib (Imbruvica) formulated for release of the compound in the intestine.,After,No,https://patents.google.com/patent/US9193735B2/en?oq=US9193735+
Imbruvica,US9206189 ,Pharmacyclics LLC,Cancer,Small Molecule,1,9/22/2006,7/24/2013,12/8/2015,12/28/2026,Active,Method of Treatment,The patent claims cover a method for treating Hodgkin's lymphoma in an individual comprising administering to a subject in need thereof a therapeutically effective amount an irreversible covalent Btk inhibitor ibrutinib (Imbruvica). ,Before,No,https://patents.google.com/patent/US9206189B2/en?oq=US9206189+
Imbruvica,US9212185 ,Pharmacyclics LLC,Cancer,Small Molecule,1,9/22/2006,11/14/2013,12/15/2015,12/28/2026,Active,Derivative,The patent claims cover deuterated analogs of ibrutinib (Imbruvica). ,After,No,https://patents.google.com/patent/US9212185B2/en?oq=US9212185+
Imbruvica,US9266893 ,Pharmacyclics LLC,Cancer,Small Molecule,1,9/22/2006,1/10/2014,2/23/2016,12/28/2026,Active,Formulation / Combination,"The patent claims cover a solid oral dosage form of ibrutinib or a pharmaceutically acceptable salt, at least one coating chosen from enteric coatings and delayed release coatings and at least one pharmaceutically acceptable excipient.",After,No,https://patents.google.com/patent/US9266893B2/en?oq=US9266893+
Imbruvica,US9278100,Pharmacyclics LLC,Cancer,Small Molecule,2,7/16/2008,12/30/2011,3/8/2016,11/16/2029,Active,Method of Treatment,"The patent claims cover a method for treating a solid tumor in an individual comprising administering to the individual in need thereof: (a) an anti-cancer agent; and (b) an irreversible covalent inhibitor of Bruton's tyrosine kinase (Btk) , namely ibrutinib (Imbruvica). ",Before,No,https://patents.google.com/patent/US9278100B2/en?oq=US9278100
Imbruvica,US9296753,Pharmacyclics LLC,Cancer,Small Molecule,6,6/4/2012,6/3/2013,3/29/2016,10/30/2033,Active,Crystalline,The patent claims cover crystalline Form A of ibrutinib (Imbruvica),Before,Yes,https://patents.google.com/patent/US9296753B2/en?oq=US9296753
Imbruvica,US9409911 ,Pharmacyclics LLC,Cancer,Small Molecule,1,9/22/2006,11/6/2013,8/9/2016,12/28/2026,Active,Method of Treatment,"The patent claims cover a method of treating a TXK-mediated B-cell malignancy, comprising administering to a patient in need thereof a therapeutically effective amount of a compound from a Markush Group of ibrutinib.",Before,No,https://patents.google.com/patent/US9409911B2/en?oq=US9409911+
Imbruvica,US9415050,Pharmacyclics LLC,Cancer,Small Molecule,15,8/12/2013,8/12/2014,8/16/2016,8/12/2034,Active,Method of Treatment,The patent claims cover a  method for treating a refractory HER2-amplified breast cancer in an individual in need thereof comprising administering to an individual in need thereof a composition comprising ibrutinib (Imbruvica).,After,No,https://patents.google.com/patent/US9415050B2/en?oq=US9415050
Imbruvica,US9421208,Pharmacyclics LLC,Cancer,Small Molecule,16,8/2/2013,8/1/2014,8/23/2016,8/1/2034,Active,Method of Treatment,"The patent claims cover a method for treating a solid tumor (including a carcinoma such as breast cancer,  pancreatic cancer,  colorectal cancer, bladder cancer, lung cancer, prostate cancer, ovarian cancer, and bile duct cance) to an individual in need of  Ibrutinib and abexinostat, a pharmaceutical composition and a pharmaceutically acceptable excipient. ",After,No,https://patents.google.com/patent/US9421208B2/en?oq=US9421208
Imbruvica,US9540382 ,Pharmacyclics LLC,Cancer,Small Molecule,6,6/4/2012,6/3/2013,1/10/2017,8/18/2033,Active,Method of Treatment,"The patent claims cover a method of treating cancer in a mammal comprising administering to the mammal a pharmaceutical formulation comprising about 40 mgs to about 200 mgsibrutinib (Imbruvica), a diluent, disintegrating agent, a surfactant and a lubricant where the cancer is (i) a B cell malignancy,
(ii) lymphoma, leukemia, or a solid tumor, or (iii) diffuse large B cell lymphoma, follicular lymphoma, small lymphocytic lymphoma, chronic lymphocytic leukemia, B cell prolymphocytic leukemia, lymphoplasmacytic lymphoma/Waldenström macroglobulinemia, splenic marginal zone lymphoma, plasma cell myeloma, plasmacytoma, extranodal marginal zone B cell lymphoma, nodal marginal zone B cell lymphoma, mantle cell lymphoma, mediastinal (thymic) large B cell lymphoma, intravascular large B cell lymphoma, primary effusion lymphoma, burkitt lymphoma/leukemia, lymphomatoid granulomatosis, or multiple myeloma.",Before,Yes,https://patents.google.com/patent/US9540382B2/en?oq=US9540382+
Imbruvica,US9545407B2,Pharmacyclics LLC,Cancer,Small Molecule,22,8/7/2014,8/7/2015,1/17/2017,8/7/2035,Active,Formulation / Combination,"The patent claims cover a  solid dispersion formulation, wherein the formulation comprises
a) about 49 to about 51% w/w of 50% active spray-dried ibrutinib; b) about 16 to about 18% w/w of lactose,c) about 24 to about 26% w/w of microcrystalline cellulose,d) about 5 to about 7% w/w of croscarmellose sodium,e) about 0.8 to about 1.2% w/w of colloidal silicon dioxide, and f) about 0.2 to about 0.8% w/w of magnesium stearate;
and wherein the 50% active spray-dried ibrutinib is a spray-dried ibrutinib composition comprising about 50% w/w of ibrutinib dispersed into a polymer matrix; and the polymer in the polymer matrix is hydroxypropyl methyl cellulose acetate succinate (HPMCAS).",After,No,https://patents.google.com/patent/US9545407B2/en?oq=US9545407B2
Imbruvica,US9556182 ,Pharmacyclics LLC,Cancer,Small Molecule,1,3/28/2007,7/8/2015,1/31/2017,3/28/2027,Active,Method of Treatment,The patent claims cover a method for treating a B-cell proliferative disorder or a mast cell proliferative disorder comprising administering to a subject in need thereof a therapeutically effective amount of compound from a Markush group including ibrutinib with another anticancer agent. ,After,No,https://patents.google.com/patent/US9556182B2/en?oq=US9556182+
Imbruvica,US9655857,Pharmacyclics LLC,Cancer,Small Molecule,28,3/3/2015,3/3/2016,5/23/2017,3/3/2036,Active,Formulation / Combination,"The patent claims cover a high-load solid tablet formulation comprising ibrutinib and one or more pharmaceutically acceptable excipients and wherein the high-load solid tablet formulation comprises at least 50% w/w of ibrutinib, and the excipients comprise
one or more diluents selected from the group consisting of lactose, sucrose, dextrose, dextrates, maltodextrin, mannitol, xylitol, sorbitol, cyclodextrins, calcium phosphate, calcium sulfate, starches, modified starches, cellulose, microcrystalline cellulose, microcellulose, and talc;one or more disintegrating agents selected from the group consisting of natural starch, a pregelatinized starch, a sodium starch, methylcrystalline cellulose, methylcellulose, croscarmellose, croscarmellose sodium, cross-linked sodium carboxymethylcellulose, cross-linked carboxymethylcellulose, cross-linked croscarmellose, cross-linked starch, cross-linked polymer, cross-linked polyvinylpyrrolidone, sodium alginate, a clay, and a gum;one or more binders selected from the group consisting of hydroxypropyl cellulose and polyvinylpyrrolidone;sodium laurel sulfate;silica; andmagnesium stearate.",After,No,https://patents.google.com/patent/US9655857B2/en?oq=US9655857
Imbruvica,US9713617 ,Pharmacyclics LLC,Cancer,Small Molecule,6,6/4/2012,12/21/2016,7/25/2017,6/3/2033,Active,Formulation / Combination,"The patent claims cover a  pharmaceutical formulation for oral administration comprising:
(a) about 40 mgs to about 200 mgs of ibrutinib, (b) about 40 wt % to about 50 wt % of a diluent; (c) about 3 wt % to about 10 wt % of a disintegrating agent; (d) about 2 wt % to about 7 wt % of a surfactant; and (e) about 0.2 wt % to about 1.0 wt % of a lubricant.",After,Yes,https://patents.google.com/patent/US9713617B2/en?oq=US9713617+
Imbruvica,US9717731B2,Pharmacyclics LLC,Cancer,Small Molecule,8,11/2/2012,11/1/2013,8/1/2017,11/1/2033,Active,Method of Treatment,"The patent claims cover a method of treating a subject having adult T-cell leukemia/lymphoma (ATLL) following treatment with a first anticancer therapy, comprising
administering to the subject an effective amount of ibrutinib to treat the adult T-cell leukemia/lymphoma (ATLL), after the discontinuation of the first anticancer therapy, and wherein the first anticancer therapy does not comprise administration of ibrutinib.",Before,No,https://patents.google.com/patent/US9717731B2/en?oq=US9717731B2
Imbruvica,US9724349 ,Pharmacyclics LLC,Cancer,Small Molecule,15,8/12/2013,6/30/2016,8/8/2017,8/12/2034,Active,Method of Treatment,"The patent claims cover a method for treating HER2 amplified cancer in an individual in need thereof, wherein the cancer is selected from the group consisting of endometrial, cervical, urothelial, ovarian, gastric, gastroesophageal junction (GEJ), head and neck, biliary tract, and prostate cancers, and the method comprises administering to the individual in need thereof a composition comprising ibrutinib or a pharmaceutically acceptable solvate or pharmaceutically acceptable salt thereof.",After,No,https://patents.google.com/patent/US9724349B2/en?oq=US9724349+
Imbruvica,US9725455 ,Pharmacyclics LLC,Cancer,Small Molecule,6,6/4/2012,4/26/2017,8/8/2017,6/3/2033,Active,Crystalline,The patent claims cover crystalline Form A of ibrutinib. ,After,Yes,https://patents.google.com/patent/US9725455B1/en?oq=US9725455+
Imbruvica,US9730938,Pharmacyclics LLC & Janssen,Cancer,Small Molecule,21,8/8/2014,8/6/2015,8/15/2017,8/6/2035,Active,Method of Treatment,"The patent claims cover a  method of treating a B-cell malignancy in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination comprising ibrutinib and a PIM inhibitor selected from SGI-1776, AZD1208, AZD1897, LGH447, JP_11646, CX-6258, and K00135, wherein the B-cell malignancy is acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), high-risk small lymphocytic lymphoma (SLL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia, multiple myeloma, extranodal marginal zone B cell lymphoma, nodal marginal zone B cell lymphoma, Burkitt's lymphoma, non-Burkitt high grade B cell lymphoma, primary mediastinal B-cell lymphoma (PMBL), immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma, B cell prolymphocytic leukemia, lymphoplasmacytic lymphoma, splenic marginal zone lymphoma, plasma cell myeloma, plasmacytoma, mediastinal (thymic) large B cell lymphoma, intravascular large B cell lymphoma, primary effusion lymphoma, or lymphomatoid granulomatosis.",After,No,https://patents.google.com/patent/US9730938B2/en?oq=US9730938
Imbruvica,US9795604,Pharmacyclics LLC,Cancer,Small Molecule,13,10/25/2013,10/24/2014,10/24/2017,10/24/2034,Active,Method of Treatment,The patent claims cover a  method of treating chronic graft versus host disease (GVHD) comprising administering to a patient having chronic GVHD a therapeutically effective amount of  ibrutinib. ,After,Yes,https://patents.google.com/patent/US9795604B2/en?oq=US9795604
Imbruvica,US9795605 ,Pharmacyclics LLC,Cancer,Small Molecule,2,7/16/2008,7/7/2015,10/24/2017,7/16/2029,Active,Method of Treatment,The patent claims cover a method for treating HER2 amplified breast cancer in an individual in need thereof comprising administering to the individual in need thereof a composition comprising a therapeutically-effective amount of ibrutinib. ,After,No,https://patents.google.com/patent/US9795605B2/en?oq=US9795605+
Imbruvica,US9801881 ,Pharmacyclics LLC,Cancer,Small Molecule,3,6/3/2010,11/26/2013,10/31/2017,6/3/2031,Active,Method of Treatment,The patent claims cover a method for treating chronic lymphocytic leukemia in an individual who has failed at least one prior therapy for chronic lymphocytic leukemia comprising administering to the individual once per day about 420 mg of an oral dose of ibrutinib (Imbruvica) ,After,Yes,https://patents.google.com/patent/US9801881B2/en?oq=US9801881+
Imbruvica,US9801883 ,Pharmacyclics LLC,Cancer,Small Molecule,3,6/3/2010,2/26/2016,10/31/2017,6/3/2031,Active,Method of Treatment,"The patent claims cover a  method for treating chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in an individual in need thereof, wherein the individual is treatment-naïve for CLL/SLL, comprising: administering to the individual once per day about 420 mg of an oral dose of a ibrutinib.",After,No,https://patents.google.com/patent/US9801883B2/en?oq=US9801883+
Imbruvica,US9814721 ,Pharmacyclics LLC,Cancer,Small Molecule,3,6/3/2010,3/10/2016,11/14/2017,6/3/2031,Active,Method of Treatment,"The patent claims cover a method for treating marginal zone lymphoma (MZL) in an individual in need thereof, wherein the individual has received at least one prior anti-CD20-based therapy, comprising: administering to the individual once per day about 560 mg of an oral dose of ibrutinib",After,Yes,https://patents.google.com/patent/US9814721B2/en?oq=US9814721+
Imbruvica,US9828383 ,Pharmacyclics LLC,Cancer,Small Molecule,6,6/4/2012,8/7/2017,11/28/2017,6/3/2033,Active,Method of Production / Process,The patent claims cover a method of making a pharmaceutical formulation of crystalline Form A ibrutinib and mixing mixing one or more excipients,After,No,https://patents.google.com/patent/US9828383B1/en?oq=US9828383+
Imbruvica,US9844552,Pharmacyclics LLC,Cancer,Small Molecule,19,12/3/2014,12/2/2015,12/19/2017,12/2/2035,Active,Method of Treatment,"The patent claims cover a method of treating pancreatic cancer in a pancreatic cancer patient having pancreatic fibrosis, comprising administering to the patient a therapeutically effective amount of ibrutinib and in combination gemcitabine",After,No,https://patents.google.com/patent/US9844552B2/en?oq=US9844552
Imbruvica,US9885086B2,Pharmacyclics LLC,Cancer,Small Molecule,9,3/20/2014,3/20/2015,2/6/2018,6/4/2035,Active,Method of Treatment,"The patent claims cover a method of maintenance therapy in a subject having a hematologic cancer, wherein the subject does not have a modification in PLCγ2 polypeptide at an amino acid position corresponding to amino acid position 845 of the amino acid sequence set forth in SEQ ID NO: 2, comprising: a. administering to the subject a maintenance therapy regimen comprising administering a therapeutically effective dose of  ibrutinib; and
b. monitoring the subject at predetermined intervals of time over the course of the maintenance therapy regimen to determine whether the subject acquires a mutation in an endogenous gene encoding PLCγ2 that results in a modification at an amino acid position corresponding to amino acid position 845 of the amino acid sequence set forth in SEQ ID NO: 2; and c. discontinuing treatment with the BTK inhibitor if the subject acquires the mutation.",After,No,https://patents.google.com/patent/US9885086B2/en?oq=US9885086B2
Keytruda,US 20210347889,Merck,Cancer,Biologic,198,11/5/2018,11/4/2019,11/11/2021,,Pending,Method of Treatment,"The application claims a method for treating cancer in a patient comprising administering to the patient 700 or 800 mg of an anti-LAG3 antibody via intravenous infusion, wherein the anti-LAG3 antibody comprises: (a) a light chain comprising CDRs of SEQ ID NOs: 26, 27 and 28 and (b) a heavy chain comprising CDRs of SEQ ID NOs: 29, 30 and 31, wherein the anti-PD-1 antibody is pembrolizumab.",After,No,https://patents.google.com/patent/US20210347889A1/en?oq=US+20210347889
Keytruda,US 20210403557,Merck,Cancer,Biologic,199,11/5/2018,11/4/2019,12/30/2021,,Pending,Method of Treatment,"The application claims a method for treating cancer in a patient comprising administering to the patient 2.1 mg to 700 mg of an anti-TIGIT antibody comprising a heavy chain and a light chain, wherein the light chain comprises light chain CDRs of SEQ ID NOs: 26, 27 and 28 and the heavy chain comprises heavy chain CDRs of SEQ ID NOs: 29, 30 and 31.",After,No,https://patents.google.com/patent/US20210403557A1/en?oq=US+20210403557
Keytruda,US 20220002410,Merck,Cancer,Biologic,197,11/7/2018,11/6/2019,1/6/2022,,Pending,Formulation / Combination,"The application claims a ormulation comprising: 16-22 mg/mL of an anti-LAG3 antibody or antigen binding fragment thereof; 3-7 mg/mL of an anti-PD-1 antibody or antigen binding fragment thereof; about 30-120 mg/mL of a non-reducing disaccharide; about 0.02-2.0 mg/mL polysorbate 80 or polysorbate 20; a buffer at pH about 4.5-6.5; and about 40-150 mM L-arginine or a pharmaceutically acceptable salt thereof, wherein the anti-LAG3 antibody or antigen-binding fragment thereof comprises a variable light chain region comprising CDRL1 of SEQ ID NO: 39, CDRL2 of SEQ ID NO: 40, and CDRL3 of SEQ ID NO: 41, and a variable heavy chain region comprising CDRH1 of SEQ ID NO: 42, CDRH2 of SEQ ID NO: 59, and CDRH3 of SEQ ID NO: 44, and the anti-PD-1 antibody or antigen-binding fragment thereof comprises a variable light chain region comprising CDRL1 of SEQ ID NO: 1, CDRL2 of SEQ ID NO: 2, and CDRL3 of SEQ ID NO: 3, and a variable heavy chain region comprising CDRH1 of SEQ ID NO: 6, CDRH2 of SEQ ID NO: 7, and CDRH3 of SEQ ID NO: 8, wherein the anti-LAG3 antibody is Ab6 or Ab6 variant, and the anti-PD-1 antibody is pembrolizumab or pembrolizumab variant.",After,No,https://patents.google.com/patent/US20220002410A1/en?oq=US+20220002410
Keytruda,US10010608,GlaxoSmithKline / Merck,Cancer,Biologic,55,5/31/2013,5/28/2014,7/3/2018,5/28/2034,Active,Method of Treatment,"The patent claims cover a method of treating melanoma in a mammal comprising administering to said mammal a combination therapy, wherein the combination therapy comprises a therapeutically effective amount of an anti-human PD-1 antibody, a therapeutically effective amount of  trametinib and a  therapeutically effective amount of dabrafenib, wherein:
the anti-human PD-1 antibody comprises a heavy chain comprising the sequence of amino acids set forth in SEQ ID NO: 21 and a light chain comprising the sequence of amino acids set forth in SEQ ID NO: 22, wherein the mammal has been diagnosed with advanced melanoma that tests positive for a BRAF V600 mutation.",Before,No,https://patents.google.com/patent/US10010608B2/en?oq=US10010608
Keytruda,US10138477B2,Merck,Cancer,Biologic,79,1/3/2013,12/11/2013,11/27/2018,12/11/2033,Active,Method of Production / Process,"The patent claims cover a method for producing a selected population of antibodies, by expression, secretion, and presentation of a mixed population of antibodies on the surface of yeast cells.",Before,No,https://patents.google.com/patent/US10138477B2/en?oq=US10138477B2
Keytruda,US10166527B2,Merck,Cancer,Biologic,119,11/1/2012,10/2/2013,1/1/2019,5/22/2035,Active,Method of Production / Process,"The patent claims cover a separating material for affinity chromatography based on a hydroxyl-containing porous base support, to a surface of which porous base support grafted are polymer chains by covalent bonding via OH groups present on the surface of the base support.",Before,No,https://patents.google.com/patent/US10166527B2/en?oq=US10166527B2
Keytruda,US10183968B2,Merck,Cancer,Biologic,22,10/31/2011,10/26/2012,1/22/2019,11/30/2034,Active,Method of Production / Process,"The patent claims cover a method of preparing a lyophilized pellet of a biological material, comprising: providing a vessel which contains a liquid composition comprising the biological material; providing a metal plate which comprises a top surface that is solid and flat and does not contain a hydrophobic film and a bottom surface that is in physical contact with a heat sink adapted to maintain the top surface of the metal plate at a temperature of −90° C. or below; positioning a dispensing tip above the top surface of the metal plate, the dispensing tip having an open end configured to dispense liquid droplets and another end connected to the vessel, wherein there is a gap of at least 0.1 cm between the top surface of the metal plate and the open end of the dispensing tip;
dispensing an aliquot of the liquid composition through the open end of the dispensing tip as a single droplet onto the top surface of the metal plate in a manner that maintains the droplet as a single droplet having a substantially spherical shape as it contacts and freezes on the top surface; and lyophilizing the frozen droplet to produce a dried pellet of substantially spherical shape.",Before,No,https://patents.google.com/patent/US10183968B2/en?oq=US10183968B2
Keytruda,US10188729,Merck,Cancer,Biologic,53,8/20/2013,8/18/2014,1/29/2019,9/9/2034,Active,Method of Treatment,"The patent claims cover a  method of treating a tumor in a patient comprising administering to the patient a bispecific antibody comprising (i) a first arm having a light chain (LC) variable region that comprises the amino acid sequences of CDR-L1, CDR-L2 and CDR-L3 of an LC variable region having the amino acid sequence of the LC variable region of MK-3475 (pembrolizumab) and a heavy chain (HC) variable region that comprises the amino acid sequences of CDR-H1, CDR-H2 and CDR-H3 of an HC variable region having the amino acid sequence of the HC variable region of MK-3475; and (ii) a second arm having an LC variable region that comprises the amino acid sequences of CDR-L1, CDR-L2 and CDR-L3 of an LC variable region having the amino acid sequence set forth in SEQ ID NO: 82 wherein residue 31 is Q and residue 57 is Q; and an HC variable region that comprises the amino acid sequences of CDR-H1, CDR-H2 and CDR-H3 of an HC variable region having the amino acid sequence set forth in SEQ ID NO: 81. ",Before,No,https://patents.google.com/patent/US10188729B2/en?oq=US10188729
Keytruda,US10241115,Merck,Cancer,Biologic,51,12/10/2013,12/8/2014,3/26/2019,12/8/2034,Active,Method of Treatment,"The patent claims cover a method for treating a human patient having a tumor, which comprises: (1) obtaining a PD-1:PD-Ligand proximity score for a tumor sample from the patient; wherein the PD-1:PD-Ligand proximity score has been assigned to the tumor sample by a process which comprises: (a) obtaining an image of tissue that has been removed from the tumor sample and immunohistochemically stained for PD-1 and PD-Ligand expression in a manner that allows stained PD-1 cells to be distinguished from stained PD-Ligand cells; (b) defining in the image one or more regions of interest (ROIs) that comprises neoplastic cells and associated stroma, wherein substantially all of the neoplastic cells and associated stroma in the image are contained in the defined ROIs; (c) randomly creating across each defined ROI a plurality of subregions of substantially the same shape and size, wherein each of the subregions defines an area that is large enough to include a spatially proximal pair of a stained PD-1 cell and a stained PD-Ligand cell and small enough to exclude pairs of stained PD-1 and PD-Ligand cells that are not spatially proximal; and
(d) calculating the percent of all of the subregions that are positive for both stained PD-1 cells and stained PD-Ligand cells to generate the PD-1:PD-ligand proximity score for the tumor sample, (2) comparing the PD-1:PD-Ligand proximity score for the tumor sample with a threshold PD-1:PD-Ligand proximity score, (3) classifying the tumor as biomarker positive or biomarker negative, wherein if the proximity score for the tumor sample is equal to or greater than the threshold proximity score, then the tumor is classified as positive for the PD-1:PD-Ligand proximity biomarker, and if the obtained score is less than the threshold score, then the tumor is classified as negative for the PD-1:PD-Ligand proximity biomarker, and (4) administering to the patient a PD-1 antagonist if the tumor is positive for the PD-1:PD-Ligand proximity biomarker and administering to the subject a cancer treatment that does not include a PD-1 antagonist if the tumor is negative for the PD-1:PD-Ligand proximity biomarker.",After,No,https://patents.google.com/patent/US10241115B2/en?oq=US10241115
Keytruda,US10308679B2,Merck,Cancer,Biologic,104,11/3/2014,10/23/2015,6/4/2019,12/18/2035,Active,Method of Production / Process," The patent claims cover a fusion protein comprising an N-intein polypeptide and an N-intein solubilization partner polypeptide joined by a peptide bond, wherein the N-intein solubilization partner polypeptide has a molecular weight of less than about 15 kDa, an Aliphatic Index value less than about 60, and a Grand Average Hydropathy value less than −1, and enhances solubility of the N-intein polypeptide compared to the N-intein polypeptide expressed in the absence of the solubilization partner polypeptide; and maintains the catalytic activity of the N-intein polypeptide when complexed with a C-intein domain, the C-intein domain not being a part of the fusion protein.",After,No,https://patents.google.com/patent/US10308679B2/en?oq=US10308679B2
Keytruda,US10429129B2,Merck,Cancer,Biologic,3,10/16/2013,10/13/2014,10/1/2019,11/9/2034,Active,Method of Production / Process,"The patent claims cover a method of preparing a dried pellet of an enveloped live virus, comprising: a) dispensing an aliquot of a liquid composition comprising the enveloped live virus as a single droplet onto a solid surface, wherein the temperature of the solid surface is at −90° C. or below, in a manner that maintains the droplet as a single droplet as it contacts and freezes on the surface as a frozen pellet; b) applying microwave radiation in a traveling wave format at a power in a range of between 0.5 and 8 KW/hr/Kg to the frozen pellet under a pressure below atmospheric pressure to produce a dried pellet;
wherein the drying yield, as obtained by a plaque assay, is greater than or equal to 50%.",After,No,https://patents.google.com/patent/US10429129B2/en?oq=US10429129B2
Keytruda,US10457720B2,Merck,Cancer,Biologic,91,3/4/2014,2/18/2015,10/29/2019,11/15/2035,Active,Method of Production / Process,"The patent claims cover a method for the separation of host cell proteins, antibody fragments and low molecular weight substances from solutions containing antibodies, said method comprising: contacting a solution containing antibodies with a hydrophobic chromatography material for a period of time whereby the antibodies stay in solution and host cell proteins, antibody fragments and low molecular weight substances are adsorbed by the hydrophobic chromatography material, wherein said hydrophobic chromatography material is a particulate material consisting of polystyrene or poly(ethyl)styrene, which is cross-linked with copolymer of divinylbenzene and ethyleneglycol methacrylate in a ratio of 98:2 up to 10:90% by weight.",After,No,https://patents.google.com/patent/US10457720B2/en?oq=US10457720B2
Keytruda,US10519194B2,Merck,Cancer,Biologic,100,7/12/2013,4/4/2014,3/31/2019,5/31/2035,Active,Method of Production / Process,"The patent claims cover method of reducing the amount of antibody fragments in a sample comprising an antibody to be purified, the method comprising the steps of: (a) providing a sample comprising an antibody and antibody fragments, wherein the fragments are in an amount equal to or greater than at least 0.2% of the amount of the antibody, (b) contacting the sample with activated carbon, wherein the activated carbon binds the antibody fragments, (c) removing the activated carbon from the sample,
thereby resulting in reducing the amount of fragments in the sample.",Before,No,https://patents.google.com/patent/US10519194B2/en?oq=US10519194B2
Keytruda,US10570202B2,Merck / Pfizer,Cancer,Biologic,48,2/4/2014,2/3/2015,2/25/2020,2/3/2035,Active,Method of Treatment,"The patent claims cover a method for treating a cancer in an individual comprising administering to the individual a combination therapy which comprises an antagonist of a Programmed Death 1 protein (PD-1) and a vascular endothelial growth factor receptor (VEGFR) inhibitor, wherein the PD-1 antagonist is an anti-PD-1 monoclonal antibody which comprises a heavy chain and a light chain, wherein the heavy and light chains comprise SEQ ID NO:21 and SEQ ID NO:22, respectively, and further wherein the VEGFR inhibitor is axitinib.",After,No,https://patents.google.com/patent/US10570202B2/en?oq=US10570202B2
Keytruda,US10676733B2,Merck,Cancer,Biologic,103,10/28/2014,10/27/2015,6/9/2020,4/27/2036,Active,Method of Production / Process,"The patent claims cover a  method for protein display on the surface of a host cell, the method comprising: (a) Introducing into a host cell at least one or more polynucleotides which encode a protein of interest to be displayed on the surface of said host cell, wherein the protein of interest comprises at least one Fc-domain; (b) Contacting the surface of said host cell with a first label, wherein said first label is biotin, a biotin-derivative, or a biotin analogue and covalently bound to the surface of said host cell;
(c) Contacting the surface of said host cell of (b) with a second label, whereby the second label specifically and non-covalently binds to said first label and to said protein of interest encoded by said at least one or more polynucleotides, wherein the second label is a multimeric protein, wherein the multimeric protein is or comprises one of protein A, protein L, protein G, protein A-G fusion, domains E, D, A, B of protein A, fused to avidin, strepavidin, neutravidin, or sequence variants thereof;
(d) Expressing said at least one or more polynucleotides in said host cell under conditions sufficient for secretion of said protein of interest encoded by the at least one or more polynucleotides; and (e) Contacting said host cells of step (d) with means for specifically detecting said protein of interest bound non-covalently by said second label and detecting host cells which display the protein of interest on their surface, wherein the means for specifically detecting said protein of interest is one of polyclonal antibody, monoclonal antibody, scFv-Fc, scFv, (Fab′)2, Fab, minibody, diabody, or VHH antibody.",After,No,https://patents.google.com/patent/US10676733B2/en?oq=US10676733B2
Keytruda,US10695426B2,Merck / Pfizer,Cancer,Biologic,44,8/25/2014,8/24/2015,6/30/2020,10/25/2035,Active,Method of Treatment,"The patent claims cover amethod for treating a cancer in a human comprising administering to the human a combination therapy which comprises an antagonist of a Programmed Death 1 protein (PD-1) and an ALK inhibitor, wherein the PD-1 antagonist is an anti-PD-1 monoclonal antibody which comprises a heavy chain and a light chain, wherein the heavy and light chain variable regions comprise SEQ ID NO: 13 and SEQ ID NO: 15, respectively, and further wherein the ALK inhibitor is crizotinib.",After,No,https://patents.google.com/patent/US10695426B2/en?oq=US10695426B2
Keytruda,US10751412B2,Merck / Dynavax,Cancer,Biologic,70,5/29/2015,5/26/2016,8/25/2020,11/8/2036,Active,Method of Treatment,"The patent claims cover a  method for treating cancer in an individual comprising administering to the individual a PD-1 antagonist and a TLR9 agonist, wherein the TLR9 agonist is a CpG-C type oligonucleotide having a sequence consisting of 5′ TCGAACGTTCGAACGTTCGAACGTTCGAAT-3′ (SEQ ID NO: 45), and wherein the PD-1 antagonist is: (i) a monoclonal antibody, or antigen binding fragment thereof, which comprises light chain CDRs of SEQ ID NOs: 7, 8 and 9 and heavy chain CDRs of SEQ ID NOs: 10, 11 and 12, or (ii) an anti-PD-1 monoclonal antibody which comprises a heavy chain and a light chain, and wherein the heavy chain comprises SEQ ID NO: 21 and the light chain comprises SEQ ID NO: 22.",After,No,https://patents.google.com/patent/US10751412B2/en?oq=US10751412B2
Keytruda,US10800846B2,Merck / Pfizer,Cancer,Biologic,59,2/26/2015,2/23/2016,10/13/2020,8/24/2036,Active,Method of Treatment,"The patent claims cover a method of treating non-small cell lung cancer in a subject, comprising administering to the subject a therapeutically effective amount of an inhibitor of the interaction between the PD-1 receptor and its ligand PD-L1, wherein the inhibitor is an anti-PD-L1 antibody comprising in its heavy chain the three complementarity determining regions (CDRs) according to SEQ ID NOs: 1, 2 and 3, and in its light chain the three CDRs according to SEQ ID NOs: 4, 5 and 6, and wherein the subject has not previously received therapy for metastatic or recurrent disease.  ",After,No,https://patents.google.com/patent/US10800846B2/en?oq=US10800846B2
Keytruda,US10858686B2,Merck,Cancer,Biologic,108,5/27/2010,6/13/2018,12/8/2020,9/18/2031,Active,Method of Production / Process," The patent claims cover a method for producing an Fc containing recombinant antibody having a F243A and a V264A mutation in the Fc region in a host cell comprising: a. providing a genetically modified cell that has been genetically engineered to produce an antibody having sialylated N-glycans, wherein the host cell comprises a nucleic acid encoding the amino acid sequence of SEQ ID NO:18, and wherein the nucleic acid encodes mutations at amino acid positions 243 and 264 of the Fc region, wherein the mutations are F243A and V264A, wherein the numbering is according to the EU index as in Kabat; b. culturing the transformed host cell under conditions which induce expression of the antibody or antibody fragment; andc. isolating the antibody or antibody fragment from the transformed host cell to produce the recombinant antibody or antibody fragment having sialylated N-glycans.",After,No,https://patents.google.com/patent/US10858686B2/en?oq=US10858686B2
Keytruda,US10899840B2,Merck / Pfizer,Cancer,Biologic,46,2/4/2014,2/3/2015,1/26/2021,2/3/2035,Active,Method of Treatment," The patent claims cover amethod for treating cancer in a human patient comprising administering to said human patient a combination therapy which comprises an antagonist of a Programmed Death 1 protein (PD-1) and a 4-1BB agonist, wherein the PD-1 antagonist is an anti-PD-1 monoclonal antibody which comprises a heavy chain and a light chain, wherein the heavy and light chains comprise SEQ ID NO: 21 and SEQ ID NO: 22, respectively; wherein the 4-1BB agonist is a 4-1BB agonist monoclonal antibody which comprises a heavy chain and a light chain, wherein the heavy and light chains comprise SEQ ID NO: 35 and SEQ ID NO: 36, respectively; and wherein the PD-1 antagonist is administered at a dose from 1.0 mg/kg to about 10 mg/kg, said 4-1BB agonist is administered at a dose from 0.6 mg/kg to 10.0 mg/kg and said PD-1 antagonist and said 4-1BB agonist are administered simultaneously or sequentially within about 30 minutes. (4-IBB agonist). ",After,No,https://patents.google.com/patent/US10899840B2/en?oq=US10899840B2
Keytruda,US10945990B2,Merck / Eisai,Cancer,Biologic,7,3/4/2015,3/3/2016,3/16/2021,6/27/2036,Active,Method of Treatment,"The patent claims cover method for treating triple negative breast cancer in an individual comprising administering to the individual a combination therapy which comprises (i) an antagonist of a Programmed Death 1 protein (PD-1), wherein the PD-1 antagonist is pembrolizumab, and (ii) eribulin or a pharmaceutically acceptable salt thereof.",After,No,https://patents.google.com/patent/US10945990B2/en?oq=US10945990B2
Keytruda,US10994008B2,Merck,Cancer,Biologic,53,8/20/2013,3/20/2018,5/4/2021,1/28/2035,Active,Method of Treatment,"The patent claims cover a  method of treating a tumor in a patient comprising administering to the patient a PD-1 antagonist and a GITR agonist, wherein the PD-1 antagonist is MK-3475 or antigen binding fragment thereof; wherein the GITR agonist is an antibody or antigen binding fragment thereof that comprises a light chain variable region that comprises CDR-L1, CDR-L2 and CDR-L3 of a light chain variable region of SEQ ID NO: 82 and a heavy chain variable region that comprises CDR-H1, CDR-H2 and CDR-H3 of a heavy chain variable region of SEQ ID NO:81; wherein CDR-L1 comprises amino acids 24-38 of SEQ ID NO:82 and amino acid 31 is N or Q, CDR-L2 comprises amino acids 54-60 of SEQ ID NO:82 and amino acid 57 is N or Q, CDR-L3 comprises amino acids 93-101 of SEQ ID NO:82, CDR-H1 comprises amino acids 26-35 of SEQ ID NO:81, CDR-H2 comprises amino acids 50-65 of SEQ ID NO:81, and CDR-H3 comprises amino acids 98-107 of SEQ ID NO:81; and wherein the PD-1 antagonist and GITR agonist are administered simultaneously or sequentially.",After,No,https://patents.google.com/patent/US10994008B2/en?oq=US10994008B2
Keytruda,US11014986B2,Merck,Cancer,Biologic,5,2/27/2015,2/22/2016,5/25/2021,2/22/2036,Active,Crystalline,"The patent claims cover a crystal of an anti-PD-1 monoclonal antibody (mAb), wherein the anti-PD-1 mAb is pembrolizumab and the crystal is characterized by unit cell dimensions of a=63.5 to 78.9 Å, b=110.2 to 112.2 Å, c=262.5 to 306 Å, α=90, β=90, γ =90° and a space group of P212121.",After,No,https://patents.google.com/patent/US11014986B2/en?oq=US11014986B2
Keytruda,US11052065B2,Merck,Cancer,Biologic,33,9/27/2017,9/24/2018,7/6/2021,9/24/2038,Active,Method of Treatment,The patent claims cover a method of treating prostate cancer squaric amide PSMA inhibitors and an anti-human PD-1 antibody or antigen binding fragment thereof to a human patient in need thereof.,After,No,https://patents.google.com/patent/US11052065B2/en?oq=US11052065B2
Keytruda,US11053315B2,Merck / Agenus,Cancer,Biologic,39,4/7/2017,4/5/2018,7/6/2021,6/21/2038,Active,Product,"The patent claims cover an  ntibody or antigen-binding fragment thereof that binds human ILT4, comprising: a heavy chain variable domain comprising: a CDR-H1 having an amino acid sequence of GYYWS (SEQ ID NO: 16), a CDR-H2 having an amino acid sequence of EINHSGSTNYNPSLKS (SEQ ID NO: 47) or EINHAGSTNYNPSLKS (SEQ ID NO: 48), and a CDR-H3 having an amino acid sequence of LPTRWVTTRYFDL (SEQ ID NO: 18); and a light chain variable domain comprising: a CDR-L1 having an amino acid sequence of TGSSSNIGAGYDVH (SEQ ID NO: 19), a CDR-L2 having an amino acid sequence of GNSNRPS(SEQ ID NO: 49), GQSNRPS(SEQ ID NO: 50), GESNRPS(SEQ ID NO: 51), GDSNRPS(SEQ ID NO: 52), GNANRPS(SEQ ID NO: 53), GQANRPS(SEQ ID NO: 54), GEANRPS(SEQ ID NO: 55), or GDANRPS(SEQ ID NO: 56), and a CDR-L3 having an amino acid sequence of QSFDNSLSAYV (SEQ ID NO: 21).",After,No,https://patents.google.com/patent/US11053315B2/en?oq=US11053315B2
Keytruda,US11117961B2,Merck,Cancer,Biologic,1,6/18/2007,11/13/2017,9/14/2021,11/9/2029,Active,Method of Treatment,"The patent claims cover a method of increasing the activity of an immune cell, comprising contacting the immune cell with a monoclonal antibody which binds to human programmed death receptor 1 (hPD-1), wherein the antibody blocks the binding of human PD-L1 and human PD-L2 to hPD-1 and comprises: a. three light chain CDRs having the amino acid sequences set forth in SEQ ID NOs: 15, 16 and 17 and b. three heavy chain CDRs having the amino acid sequences set forth in SEQ ID NOs: 18, 19 and 20.",After,No,https://patents.google.com/patent/US11117961B2/en?oq=US11117961B2
Keytruda,US11193937B2,Merck,Cancer,Biologic,66,4/2/2013,9/22/2017,12/7/2021,6/23/2034,Active,Method of Treatment,"The patent claims cover a method for treating a human patient diagnosed with non small cell lung carcinoma (NSCLC), the method comprising: a. obtaining a diagnostic report that provides one or both of a modified H score (MHS) and a modified P score (MPS) for PD-L1 expression for a tumor sample removed from the patient, wherein a specified threshold is selected from the group consisting of: (i) MHS=190; (ii) MPS=90; and (iii) MHS=190 and MPS=90; wherein the MHS and the MPS were determined by a scoring process comprising: (i) staining a tissue section from the tumor sample in an immunohistochemical (IHC) assay with an antibody that specifically binds to human PD-L1 (anti-PD-L1 Ab), wherein the anti-PD-L1 antibody is a monoclonal antibody which comprises a light chain mature variable region of SEQ ID NO:6 and a heavy chain mature variable region of SEQ ID NO:14, or the anti-PD-L1 antibody is a monoclonal antibody which comprises a light chain mature variable region of SEQ ID NO:21 and a heavy chain mature variable region of SEQ ID NO:29; (ii) examining each tumor nest in the tissue section for staining; and
(iii) assigning one or both of the MHS and MPS to the tissue section, wherein assigning the MHS comprises estimating, across all of the viable tumor cells and stained mononuclear inflammatory cells in all of the examined tumor nests, four separate percentages for cells that have no staining, weak staining, moderate staining and strong staining, wherein a cell must have at least partial membrane staining to be included in the weak, moderate or strong staining percentages, and wherein the sum of all four percentages equals 100; inputting the estimated percentages into the formula of MHS=1x(percent of weak staining cells)+2x (percent of moderate staining cells)+3x(percent of strong staining cells); wherein assigning the MPS comprises estimating, across all of the viable tumor cells and mononuclear inflammatory cells in all of the examined tumor nests, the percentage of cells that have at least partial membrane staining of any intensity; and wherein if both the MHS and MPS are assigned, the assignments may be performed in either order or simultaneously; and b. administering a PD-1 antagonist to the patient if one or both of the MHS and the MPS is at or above the specified threshold.",After,No,https://patents.google.com/patent/US11193937B2/en?oq=US11193937B2
Keytruda,US11207412B2,Merck,Cancer,Biologic,17,4/16/2018,4/16/2019,12/28/2021,6/26/2039,Active,Method of Production / Process,"The application claims a method for reducing the viscosity of a liquid formulation comprising a pharmaceutically active protein in a concentration in the range of at least 50 mg/ml up to 300 mg/ml, comprising combining the liquid formulation comprising protein with a viscosity-reducing concentration of one of the following combinations of excipients: meglumine+benzenesulfonic acid; ornithine+benzenesulfonic acid; ornithine+gluconic acid; ornithine+glucuronic acid; or mixtures of such combinations; wherein the amount of each of the excipients is from 50 to 150 mM.",After,No,https://patents.google.com/patent/US11207412B2/en?oq=US11207412B2
Keytruda,US11220668B2,Merck,Cancer,Biologic,72,4/28/2016,4/25/2017,1/11/2022,6/9/2038,Active,Method of Production / Process,"The patent claims cover a method for reducing the formation of trisulfide bonds in proteins comprising:
culturing cells expressing said proteins in a cell culture, wherein during the cell culturing a feed medium is added to the cell culture one or more times and said feed medium does not contain significant amounts of cysteine or cystine but comprises S-sulfocysteine and/or salts thereof, wherein said proteins exhibit trisulfide bonds when expressed by cells cultured in a cell culture medium using a feed medium in which cysteine and/or cystine is not replaced by S-sulfocysteine and/or salts thereof,
detecting reduced trisulfide linkage formation in said proteins in cells cultured in said feed medium comprising S-sulfocysteine and/or salts thereof relative to protein expressed by cells cultured in a cell culture medium where cysteine and/or cysteine in the feed medium has not been replaced by S-sulfocysteine and/or salts thereof.",After,No,https://patents.google.com/patent/US11220668B2/en?oq=US11220668B2
Keytruda,US11312772B2,Merck,Cancer,Biologic,25,8/4/2017,7/30/2018,4/26/2022,8/22/2038,Active,Method of Treatment,"The patent claims cover a method of treating cancer, said method comprising administering to a subject in need thereof a combination therapy that comprises a) a PD-1 antagonist; and b) a benzo[b]thiophene STING agonist; wherein
the PD-1 antagonist is administered once every 21 days; and the benzo[b]thiophene STING agonist is administered once every 3 to 28 days; and the benzo[b]thiophene STING agonist.",After,No,https://patents.google.com/patent/US11312772B2/en?oq=US11312772B2
Keytruda,US11326154B2,Merck,Cancer,Biologic,104,11/3/2014,4/18/2019,5/10/2022,4/4/2036,Active,Method of Production / Process,"The patent claims cover a soluble fusion protein comprising an N-intein polypeptide capable of forming an active intein complex by associating with a second fusion protein comprising a C-intein polypeptide, and at least one cysteine of the N-intein is substituted with an amino acid selected from the group consisting of: threonine, lysine, asparagine, serine, methionine, and tyrosine, wherein the N-intein polypeptide is covalently attached to a solid support.",After,No,https://patents.google.com/patent/US11326154B2/en?oq=US11326154B2
Keytruda,US11326211B2,Merck,Cancer,Biologic,42,4/17/2015,4/12/2016,5/10/2022,1/20/2038,Active,Method of Diagnosis,"The patent claims cover a method of treating a patient diagnosed with a tumor which comprises: (a) collecting a baseline blood sample from the patient prior to administering a dose of a PD-1 antagonist to the patient,(b) administering at least one dose of a PD-1 antagonist to the patient for a treatment cycle, (c) collecting a post-dose blood sample from the patient after the treatment cycle of the at least one dose of the PD-1 antagonist, (d) obtaining a signature score for a gene signature biomarker in each of the baseline and post-dose blood samples, and (e) treating the patient with a therapeutic regimen that comprises administering a PD-1 antagonist if the post-dose signature score is greater than the baseline signature score or treating the subject with a therapeutic regimen that does not include administering a PD-1 antagonist if the post-dose score is equal to or less than the baseline score;
wherein the gene signature biomarker comprises PD-L1, PD-L2, LAG3, STAT1, and CXCL10.",After,No,https://patents.google.com/patent/US11326211B2/en?oq=US11326211B2
Keytruda,US11377693B2,Merck,Cancer,Biologic,43,12/9/2014,12/8/2015,7/5/2022,2/17/2039,Active,Biomarker,"The patent claims cover a method for treating a patient having a tumor which comprises determining if a sample of the tumor is positive or negative for a gene signature biomarker based on a gene signature score, wherein the gene signature score is calculated based on a combination of gene expression values for all of the genes in the gene signature biomarker, and administering to the patient a PD-1 antagonist if the tumor is positive for the biomarker or administering to the subject a cancer treatment that does not include a PD-1 antagonist if the tumor is negative for the biomarker, wherein the gene signature biomarker is for a gene signature that comprises the 18-Gene Up-Down Signature.",After,No,https://patents.google.com/patent/US11377693B2/en?oq=US11377693B2
Keytruda,US20040241745A1,Ono Pharmaceutical,Cancer,Biologic,132,7/31/2001,7/30/2002,12/2/2004,,Abandoned,Product,"The application claimed a substance comprising a substance that recognizes PD-1, a substance that recognizes a membrane protein co-existing with PD-1 on a cell membrane, and a linker.",Before,No,https://patents.google.com/patent/US20040241745A1/en?oq=US20040241745A1
Keytruda,US20080032300A1,Merck,Cancer,Biologic,125,12/2/2004,12/1/2005,2/7/2008,,Abandoned,Method of Production / Process,The application claimed a method of screening cells for expression of a protein of interest.,Before,No,https://patents.google.com/patent/US20080032300A1/en?oq=US20080032300A1
Keytruda,US20080286824A1,Merck,Cancer,Biologic,129,8/26/2005,8/25/2006,11/20/2008,,Abandoned,Method of Production / Process,"The application claimed a fusion protein comprising a peptide sequence conferring resistance to an antibiotic fused to at least one sequence comprising SEQ ID NO: 1, 2 or 3.",Before,No,https://patents.google.com/patent/US20080286824A1/en?oq=US20080286824A1
Keytruda,US20100181254A1,Merck,Cancer,Biologic,110,5/25/2007,5/19/2008,7/22/2010,,Abandoned,Method of Production / Process,"The application claimed separating materials for ion exchange chromatography based on hydroxyl-containing base supports, to the surfaces of which copolymers are covalently bonded.",Before,No,https://patents.google.com/patent/US20100181254A1/en?oq=US20100181254A1
Keytruda,US20100184090A1,Merck,Cancer,Biologic,116,7/17/2007,7/16/2008,7/22/2010,,Abandoned,Method of Production / Process,The application claimed a method of screening cells for expression of a protein of interest (POI) comprising the steps of: (a) transfecting a cell with: (a) a nucleic acid encoding said POI; and (ii) a nucleic acid encoding dihydrofolate reductase (DHFR); (b) measuring DHFR expression using a fluorescent compound binding to DHFR; and (c) selecting about 0.001% to about 25% of the cells tested in step (b) based on high relative DHFR expression;wherein said cells are not selected for resistance to a toxic compound between step (a) and (b).,Before,No,https://patents.google.com/patent/US20100184090A1/en?oq=US20100184090A1
Keytruda,US20100256337A1,Merck,Cancer,Biologic,90,10/22/2007,10/21/2008,10/7/2010,,Abandoned,Method of Production / Process,"The application claimed a method for purifying an Fc-containing protein from free Fc-moieties present in a fluid comprising said Fc-containing protein, the method comprising the steps of: (a) loading said fluid on a blue dye affinity chromatography resin;
(b) washing the resin with a buffer having a pH of about 4.0 to about 6.0 thereby eliminating the free Fc-moieties from the resin; and (c) eluting the Fc-containing protein from the resin.",Before,No,https://patents.google.com/patent/US20100256337A1/en?oq=US20100256337A1
Keytruda,US20110091901A1,Merck,Cancer,Biologic,129,8/26/2005,9/29/2010,4/21/2011,,Abandoned,Method of Production / Process,"The application claimed a vector comprising a nucleic acid sequence encoding a fusion protein, said fusion protein comprising a peptide sequence conferring resistance to an antibiotic fused to at least one sequence comprising SEQ ID NO: 1, 2 or 3. ",Before,No,https://patents.google.com/patent/US20110091901A1/en?oq=US20110091901A1
Keytruda,US20110117626A1,Merck / Natrix,Cancer,Biologic,106,11/13/2009,11/15/2010,5/19/2011,,Abandoned,Method of Production / Process,"The application claimed a composite material, comprising: a support member, comprising a plurality of pores extending through the support member; anda macroporous cross-linked gel, comprising a plurality of macropores, and a plurality of pendant hydrophobic moieties;wherein the macroporous cross-linked gel is located in the pores of the support member; and the average pore diameter of the macropores is less than the average pore diameter of the pores.",Before,No,https://patents.google.com/patent/US20110117626A1/en?oq=US20110117626A1
Keytruda,US20110144311A1,Merck,Cancer,Biologic,92,8/14/2008,8/10/2009,6/16/2011,,Abandoned,Method of Production / Process,"The application claimed a method for purifying a monomeric monoclonal antibody from a sample, wherein the sample comprises the monomeric monoclonal antibody, host cell impurities, dimers, and higher order aggregates comprising: a) contacting the sample with a Protein A affinity chromatography column; b) eluting the monomeric monoclonal antibody from the Protein A affinity chromatography column with an elution buffer; and c) collecting one or more fractions of the monomeric monoclonal antibody from step (b) to form a Protein A product pool, wherein the product pool i) comprises less than 5% higher order aggregate, and ii) has a pH from about 3.5 to about 4.5, thereby purifying the monomeric monoclonal antibody from the sample.",Before,No,https://patents.google.com/patent/US20110144311A1/en?oq=US20110144311A1
Keytruda,US20110229933A1,Merck,Cancer,Biologic,121,9/26/2008,9/24/2009,9/22/2011,,Abandoned,Method of Production / Process,The application claimed a method for producing a protein comprising inoculating an initial mammalian cell growth medium with host cells expressing the protein and adding supplements.,Before,No,https://patents.google.com/patent/US20110229933A1/en?oq=US20110229933A1
Keytruda,US20110250644A1,Merck,Cancer,Biologic,80,12/19/2008,12/17/2009,10/13/2011,,Abandoned,Method of Production / Process,The application claimed a cell feed supplement concentrate for culture of mammalian cells used to produce proteins,Before,No,https://patents.google.com/patent/US20110250644A1/en?oq=US20110250644A1
Keytruda,US20120208986A1,Merck,Cancer,Biologic,114,10/20/2009,10/13/2010,8/16/2012,,Abandoned,Method of Production / Process,"The application claimed a method of purifying an antibody having an isoelectric point of greater than 7.0 from a mixture containing the antibody comprising the steps of: (a) applying said mixture onto a solid phase comprising a mixed mode resin containing ligands which comprise a negatively charged part and a hydrophobic part; and (b) eluting said antibody with an elution buffer containing at least about 0.3 M sodium chloride or about 0.2 to about 0.4 M sodium sulfate, buffered at pH of about 7.8 to about 8.5; and (c) recovering said antibody from the mixed mode resin.",Before,No,https://patents.google.com/patent/US20120208986A1/en?oq=US20120208986A1
Keytruda,US20130245139A1,Merck,Cancer,Biologic,97,3/12/2012,3/4/2013,9/19/2013,,Abandoned,Method of Production / Process,"The application claimed a flow-through chromatography method of separating a monomeric protein of interest from protein aggregates in a sample, the method comprising contacting the sample with a solid support comprising one or more cation exchange binding groups attached thereto, at a density of about 1 to about 30 mM, wherein the solid support selectively binds protein aggregates, thereby to separate the monomeric protein of interest from protein aggregates.",Before,No,https://patents.google.com/patent/US20130245139A1/en?oq=US20130245139A1
Keytruda,US20140011236A1,Merck,Cancer,Biologic,76,3/22/2011,3/15/2012,1/9/2014,,Abandoned,Product,"The application claimed an isolated hybrid polynucleotide comprising a promoter and a method for making a polypeptide comprising introducing, into an isolated fungal host cell, an isolated hybrid polynucleotide comprising a promoter.",Before,No,https://patents.google.com/patent/US20140011236A1/en?oq=US20140011236A1
Keytruda,US20140183136A1,Merck,Cancer,Biologic,110,5/25/2007,12/30/2013,7/3/2014,,Abandoned,Method of Production / Process,"The application claimed separating materials for ion exchange chromatography based on hydroxyl-containing base supports, to the surfaces of which copolymers are covalently bonded.",After,No,https://patents.google.com/patent/US20140183136A1/en?oq=US20140183136A1
Keytruda,US20140238935A1,Merck / Natrix,Cancer,Biologic,89,2/26/2013,2/26/2014,8/28/2014,,Abandoned,Method of Production / Process,"The application claimed a composite material, comprising: a support member, comprising a plurality of pores extending through the support member; and a cross-linked gel, wherein the cross-linked gel comprises a first functionality and a second functionality; the first functionality and the second functionality are cationic, anionic, hydrophobic, hydrophilic, thiophilic, hydrogen bond donating, hydrogen bond accepting, pi-pi bond donating, pi-pi bond accepting, or metal chelating; and the first functionality is different from the second functionality;wherein the cross-linked gel is located in the pores of the support member.",Before,No,https://patents.google.com/patent/US20140238935A1/en?oq=US20140238935A1
Keytruda,US20140287463A1,Merck,Cancer,Biologic,74,10/31/2011,10/24/2012,9/25/2014,,Abandoned,Method of Production / Process,The application claimed a  isolated modified Pichia sp. host cell wherein the host cell has been modified to reduce or eliminate expression of a functional gene product of a nucleic acid sequence encoding a polypeptide having the amino acid sequence set forth in SEQ ID NO:76.,Before,No,https://patents.google.com/patent/US20140287463A1/en?oq=US20140287463A1
Keytruda,US20140288278A1,Merck,Cancer,Biologic,94,10/31/2011,10/25/2012,9/25/2014,,Abandoned,Method of Production / Process,The application claimed a method of purifying monomeric monoclonal antibody (mAb) from a conditioned mixture comprising one or more impurities and heterogenous aggregates.,Before,No,https://patents.google.com/patent/US20140288278A1/en?oq=US20140288278A1
Keytruda,US20140302556A1,Merck,Cancer,Biologic,77,10/27/2011,10/22/2012,10/9/2014,,Abandoned,Method of Production / Process,"The application claimed a lower eukaryote host cell comprising a disruption in the expression of the endogenous protein mannosyltransferases 2 (PMT2) gene and a nucleic acid molecule encoding a mutant Pmt2p comprising at least one amino acid substitution, deletion, or insertion in the region of the Pmt2p protein comprising a conserved region having at least 80%, 90%, or 95% identity to the amino acid sequence of SEQ ID NO:9.",Before,No,https://patents.google.com/patent/US20140302556A1/en?oq=US20140302556A1
Keytruda,US20150299648A1,Merck,Cancer,Biologic,85,11/29/2012,11/22/2013,10/22/2015,,Abandoned,Method of Production / Process,The application claimed a cell culture medium for the production of a protein of interest in yeast host cells using a fed-batch fermentation process wherein the cell culture medium comprises a basal medium supplemented with an osmoprotectant.,Before,No,https://patents.google.com/patent/US20150299648A1/en?oq=US20150299648A1
Keytruda,US20150299690A1,Merck,Cancer,Biologic,84,12/10/2012,12/5/2013,10/22/2015,,Abandoned,Method of Production / Process,The application claimed an engineered lower eukaryotic host cells for expressing heterologous proteins and to methods of generating such strains.,Before,No,https://patents.google.com/patent/US20150299690A1/en?oq=US20150299690A1
Keytruda,US20150307850A1,Merck,Cancer,Biologic,71,12/4/2012,12/4/2013,10/29/2015,,Abandoned,Method of Production / Process,"The application claimed a conditional replication defective cytomegalovirus (rdCMVhet) comprising: (a) a nucleic acid encoding a fusion protein, wherein the fusion protein comprises an essential CMV protein, or a derivative thereof, fused to a destabilizing protein, wherein the essential protein is selected from the group consisting of IE1/2, UL37x1, UL44, UL51, UL52, UL53, UL56, UL77, UL79, UL84, UL87, and UL105; and (b) a nucleic acid encoding a heterologous polypeptide, and (c) a promoter operably linked to the nucleic acid encoding the heterologous polypeptide.",Before,No,https://patents.google.com/patent/US20150307850A1/en?oq=US20150307850A1
Keytruda,US20160083765A1,Merck,Cancer,Biologic,108,5/27/2010,11/3/2015,3/24/2016,,Abandoned,Method of Production / Process,"The application claimed a method for producing a recombinant antibody in a host cell comprising: a. providing a genetically modified cell that has been genetically engineered to produce an antibody having sialylated N-glycans, wherein the host cell comprises a nucleic acid encoding the heavy chain of the antibody, and wherein the nucleic acid encodes mutations at amino acid positions 243 and 264 of the heavy chain, wherein the mutations at positions 243 are selected from the group consisting of: F243A, F243G, F243S, F243T, F243V, F243L, and F243I and the mutations at position 264 are selected from the group consisting of: V264A, V264G, V264S and V264T; b. culturing the transformed host cell under conditions which induce expression of the antibody; and
c. isolating the antibody from the transformed host cell to produce the recombinant antibody having sialylated N-glycans.",After,No,https://patents.google.com/patent/US20160083765A1/en?oq=US20160083765A1
Keytruda,US20160084839A1,Merck,Cancer,Biologic,66,4/2/2013,3/31/2014,3/24/2016,,Abandoned,Method of Diagnosis,"The application claimed a process for scoring the expression of a programmed death ligand 1 (PD-L1) protein in
a tumor sample removed from an animal.",Before,No,https://patents.google.com/patent/US20160084839A1/en?oq=US20160084839A1
Keytruda,US20160194660A1,Merck,Cancer,Biologic,112,12/21/2012,12/18/2013,7/7/2016,,Abandoned,Product," The application claimed an expression vector which comprises the following elements: (a) at least one expression cassette for a first target polypeptide which comprises a first promoter operably linked to an insertion site for a nucleotide sequence encoding the first target polypeptide and a first polyadenylation (pA) signal; (b) an expression cassette for a eukaryotic selection marker which comprises a second promoter operably linked to a nucleotide sequence encoding the eukaryotic selection marker and to a second pA signal, wherein the eukaryotic selection marker is a puromycin resistance protein or a glutamine synthetase (GS) protein; (c) an expression cassette for a bacterial selection marker, and (d) a bacterial plasmid origin of replication,
wherein the first and second pA signals are the same or different and are selected from the group consisting of a thymidine kinase pA (TKpA) sequence and a simian virus 40 (SV40) early pA sequence, wherein the first promoter is a cytomegalovirus (CMV) promoter construct that is at least 90% identical to nucleotides 69 to 1,716 of SEQ ID NO:1 or an Elongation factor 1-alpha (EF-1 alpha) promoter construct that is at least 90% identical to nucleotides 12-1,444 of SEQ ID NO:2;
wherein the second promoter is a 3-phosphoglycerate kinase (PGK) promoter if the eukaryotic selection marker is a puromycin resistance protein; wherein the second promoter is a simian virus 40 (SV40) late promoter if the eukaryotic selection marker is a GS protein; andwherein the eukaryotic selection marker is a puromycin resistance protein if the first promoter is the CMV promoter.",Before,No,https://patents.google.com/patent/US20160194660A1/en?oq=US20160194660A1
Keytruda,US20160303231,GlaxoSmithKline / Merck,Cancer,Biologic,52,12/11/2013,12/3/2014,10/20/2016,,Abandoned,Method of Treatment," The application claimed amethod for treating a cancer in an individual comprising administering to the individual an antagonist of a Programmed Death 1 protein (PD-1) and a VEGFR inhibitor, wherein the VEGFR inhibitor is pazopanib.",After,No,https://patents.google.com/patent/US20160303231A1/en?oq=US20160303231
Keytruda,US20160304969,Merck,Cancer,Biologic,49,12/17/2013,12/15/2014,10/27/2016,,Abandoned,Biomarker,"The application claimed a method for testing a tumor for the presence or absence of a biomarker that predicts response to treatment with a PD-1 antagonist, which comprises: obtaining a sample from the tumor, measuring the raw RNA expression level in the tumor sample for each gene in a gene signature; normalizing each of the measured raw RNA expression levels; and
calculating the arithmetic mean of the normalized RNA expression levels for each of the genes to generate a score for the gene signature.",After,No,https://patents.google.com/patent/US20160304969A1/en?oq=US20160304969
Keytruda,US20160312295,Merck,Cancer,Biologic,50,12/17/2013,12/15/2014,10/27/2016,,Abandoned,Biomarker,"The application claimed a method for testing a tumor for the presence or absence of a biomarker that predicts response to treatment with a PD-1 antagonist, which comprises: obtaining a sample from the tumor, measuring the raw RNA expression level in the tumor sample for each gene in a gene signature; normalizing each of the measured raw RNA expression levels; and
calculating the arithmetic mean of the normalized RNA expression levels for each of the genes to generate a score for the gene signature.",After,No,https://patents.google.com/patent/US20160312295A1/en?oq=US20160312295
Keytruda,US20160312297A1,Merck,Cancer,Biologic,62,12/17/2013,12/15/2014,10/27/2016,,Abandoned,Biomarker,"The application claimed a method for testing a tumor for the presence or absence of a biomarker that predicts response to treatment with a PD-1 antagonist, which comprises: obtaining a sample from the tumor, measuring the raw RNA expression level in the tumor sample for each gene in a PD-L1 gene signature; normalizing each of the measured raw RNA expression levels; and
calculating the arithmetic mean of the normalized RNA expression levels for each of the genes to generate a score for the PD-L1 gene signature; wherein the PD-L1 gene signature comprises PD-L1, PD-L2, STAT1, LAG3, CXCL10, and CLEC10a.",After,No,https://patents.google.com/patent/US20160312297A1/en?oq=US20160312297A1
Keytruda,US20170037125,Incyte / Merck,Cancer,Biologic,47,2/4/2014,2/3/2015,2/9/2017,,Abandoned,Method of Treatment,"The application claimed a method for treating a cancer or tumor in a subject in need thereof, comprising administering to the subject a combination therapy which comprises an antagonist of a Programmed Death 1 protein (PD-1) and an inhibitor of indoleamine.",After,No,https://patents.google.com/patent/US20170037125A1/en?oq=US20170037125
Keytruda,US20170226550A1,Merck,Cancer,Biologic,75,8/7/2014,8/4/2015,8/10/2017,,Abandoned,Method of Production / Process,"The application claimed a method of producing a polypeptide, which comprises (a) providing a recombinant mammalian host cell capable of expressing the polypeptide; (b) culturing the host cell under conditions suitable for (i) effecting expression of the polypeptide and (ii) inhibiting expression of at least one RNAi target gene, and (c) recovering the expressed polypeptide, wherein the RNAi target gene is a mouse gene selected from the group of mouse genes listed in the table immediately below or is an orthologue of the selected mouse gene.",After,No,https://patents.google.com/patent/US20170226550A1/en?oq=US20170226550A1
Keytruda,US2017051060 ,Ono Pharmaceutical,Cancer,Biologic,131,7/3/2002,8/2/2016,2/23/2017,,Abandoned,Method of Treatment,"The application claimed a method of treating a tumor in a subject in need thereof comprising administering to the subject an immunosuppressive signal inhibitor of PD-1, PD-L1, or PD-L2.",After,No,https://patents.google.com/patent/US20170051060A1/en?oq=US2017051060+
Keytruda,US20180044418,Merck,Cancer,Biologic,8,3/20/2015,3/15/2016,2/15/2018,,Abandoned,Method of Treatment,"The application claimed a method for treating cancer in a human patient comprising administering to the patient a combination therapy which comprises an antagonist of a human Programmed Death 1 protein (PD-1) and a histone deactylase (HDAC) inhibitor (vorinostat), wherein the HDAC inhibitor is suberoylanilide hydroxamic acid (SAHA) or a pharmaceutically acceptable salt thereof.",After,No,https://patents.google.com/patent/US20180044418A1/en?oq=US20180044418
Keytruda,US20180092901,Merck / Eisai,Cancer,Biologic,6,3/4/2015,3/3/2016,4/5/2018,,Pending,Method of Treatment,"The application claims a method for treating a cancer in an individual comprising administering to the individual a combination therapy which comprises an antagonist of a Programmed Death 1 protein (PD-1) and a multiple receptor tyrosine kinase (multi-RTK) inhibitor, wherein the antagonist is not MPDL3280A.",After,No,https://patents.google.com/patent/US20180092901A1/en?oq=US20180092901
Keytruda,US20180118832A1,Merck,Cancer,Biologic,68,8/12/2016,8/11/2017,5/3/2018,,Abandoned,Method of Treatment," The application claimed a method of treating cancer, the method comprising administering to a cancer patient:
(i) a protein comprising a human TGFβRII, or fragment thereof capable of binding TGFβ; and an antibody, or antigen-binding fragment thereof, that binds human protein Programmed Death Ligand 1 (PD-L1); and (ii) an effective amount of at least one additional anti-cancer agent,thereby providing a combination therapy having an enhanced therapeutic effect compared to the effect of the protein and the at least one additional anti-cancer agent each administered alone.",After,No,https://patents.google.com/patent/US20180118832A1/en?oq=US20180118832A1
Keytruda,US20180185483,Advaxis / Merck,Cancer,Biologic,45,7/18/2014,1/9/2018,7/5/2018,,Abandoned,Method of Treatment,"The application claimed a method for treating prostate cancer in a patient comprising administering to the patient a combination therapy which comprises an antagonist of a Programmed Death 1 protein (PD-1) and a bioengineered live-attenuated Listeria monocytogenes strain deficient in at least one gene selected from the group consisting of a virulence gene, a metabolic gene and combinations thereof, wherein the live-attenuated Listeria monocytogenes stimulates Antigen Presenting Cells (APCs) capable of driving a cellular immune response to PSA expressing cells,  wherein the PD-1 antagonist is pembrolizumab.",After,No,https://patents.google.com/patent/US20180185483A1/en?oq=US20180185483
Keytruda,US20180215786A1,Merck,Cancer,Biologic,97,3/12/2012,3/14/2018,8/2/2018,,Abandoned,Method of Production / Process,"The application claimed a flow-through process for purifying a target molecule from a Protein A eluate comprising the steps of: (a) contacting the eluate recovered from a Protein A chromatography column with activated carbon; (b) contacting a flow-through sample from step (a) with an anion exchange chromatography media; and (c) contacting a flow-through sample from step (b) with a solid support comprising one or more cation exchange binding groups attached thereto, at a density of about 1 to about 30 mM; and (d) obtaining a flow-through sample from step (c) comprising the target molecule, wherein the eluate flows continuously through steps(a)-(c) and wherein level of one or more impurities in the flow-through sample after step (c) is lower than the level in the eluate in step (a).",After,No,https://patents.google.com/patent/US20180215786A1/en?oq=US20180215786A1
Keytruda,US20180282415,Merck / Pfizer,Cancer,Biologic,10,9/30/2015,9/27/2016,10/4/2018,,Abandoned,Method of Treatment,The application claimed a method for treating or delaying progression of a cancer in an individual comprising administering to the individual an effective amount of a PD-1 axis binding antagonist and an ALK inhibitor.,After,No,https://patents.google.com/patent/US20180282415A1/en?oq=US20180282415
Keytruda,US20180327447A1,Merck,Cancer,Biologic,99,11/18/2015,10/28/2016,11/15/2018,,Abandoned,Method of Production / Process,The application claimed a method for separating and purifying a protein from a mixture of proteins.,After,No,https://patents.google.com/patent/US20180327447A1/en?oq=US20180327447A1
Keytruda,US20180333503,ImmunoGen / Merck,Cancer,Biologic,34,5/16/2017,5/15/2018,11/22/2018,,Abandoned,Method of Treatment,"The application claimed a method for treating a patient having ovarian cancer, peritoneal cancer, or fallopian tube cancer comprising administering to said patient in need thereof: an immunoconjugate that binds to FOLR1, wherein said immunoconjugate comprises a maytansinoid and an anti-FOLR1 antibody or antigen-binding fragment thereof comprising a heavy chain variable region (VH) complementary determining region (CDR)1 sequence of SEQ ID NO:9, a VH CDR2 sequence of SEQ ID NO:10, and a VH CDR3 sequence of SEQ ID NO:12, and a light chain variable region (VL) CDR1 sequence of SEQ ID NO:6, a VL CDR2 sequence of SEQ ID NO:7, and a VL CDR3 sequence of SEQ ID NO:8, and an anti-PD-1 antibody or antigen-binding fragment thereof comprising a VII CDR1 sequence of SEQ ID NO:20, a VH CDR2 sequence of SEQ ID NO:21, and a VH CDR3 sequence of SEQ ID NO:22, and a VL CDR1 sequence of SEQ ID NO:23, a VL CDR2 sequence of SEQ ID NO:24, and a VL CDR3 sequence of SEQ ID NO:25.",After,No,https://patents.google.com/patent/US20180333503A1/en?oq=US20180333503
Keytruda,US20180346510A1,Merck,Cancer,Biologic,93,11/18/2015,10/28/2016,12/6/2018,,Abandoned,Method of Production / Process,"The application claimed  a method for separating and purifying a protein from a mixture of proteins, by the steps:
a) providing a sample comprising at least two different proteins, b) applying this mixture to an ion exchange material with a total protein load ≥5 mg/ml, especially ≥30 mg/ml, in particular ≥60 mg/ml, c) separating the proteins by elution characterized by simultaneous change in pH and conductivity.",After,No,https://patents.google.com/patent/US20180346510A1/en?oq=US20180346510A1
Keytruda,US20180353939A1,Merck / Natrix,Cancer,Biologic,89,2/26/2013,8/6/2018,12/13/2018,,Pending,Method of Production / Process,"The application claims a method, comprising the step of: contacting at a first flow rate a first fluid comprising a substance with a composite material comprising: a support member, comprising a plurality of pores extending through the support member; and
a cross-linked gel, wherein the cross-linked gel comprises a first functionality and a second functionality; the first functionality and the second functionality are cationic, anionic, hydrophobic, hydrophilic, thiophilic, hydrogen bond donating, hydrogen bond accepting, pi-pi bond donating, pi-pi bond accepting, or metal chelating; and the first functionality is different from the second functionality;wherein the cross-linked gel is located in the pores of the support member,
thereby adsorbing or absorbing a portion of the substance onto the composite material.",After,No,https://patents.google.com/patent/US20180353939A1/en?oq=US20180353939A1
Keytruda,US20190023791,GlaxoSmithKline / Merck,Cancer,Biologic,9,8/4/2015,8/3/2016,1/24/2019,,Abandoned,Method of Treatment," The application claimed a method of treating cancer in a human in need thereof comprising administering to the human:
a therapeutically effective amount of a monoclonal antibody that binds to human OX40 comprising: (a) a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:1; (b) a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:2; (c) a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:3; (d) a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:7; (e) a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:8; and (f) a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:9; and a therapeutically effective amount of a monoclonal antibody that binds to human PD-1 comprising: (a) a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:54; (b) a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:55; (c) a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:56; (d) a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:57; (e) a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:58; and (f) a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:59.",After,No,https://patents.google.com/patent/US20190023791A1/en?oq=US20190023791
Keytruda,US20190119415A1,Merck,Cancer,Biologic,110,5/25/2007,11/13/2018,4/25/2019,,Abandoned,Method of Production / Process,"The application claimed a separating material for ion exchange chromatography based on an organic, hydroxyl-containing polymer base support to the surface of which copolymers are covalently bonded.",After,No,https://patents.google.com/patent/US20190119415A1/en?oq=US20190119415A1
Keytruda,US20190144545A1,Merck / Pfizer,Cancer,Biologic,60,5/26/2016,5/22/2017,5/16/2019,,Pending,Method of Treatment,"The application claims a method of treating cancer in a subject, comprising administering to the subject a therapeutically effective amount of an inhibitor of the interaction between the PD-1 receptor and its ligand PD-L1.",After,No,https://patents.google.com/patent/US20190144545A1/en?oq=US20190144545A1
Keytruda,US20190160148,Eli Lilly / Merck,Cancer,Biologic,11,5/23/2016,5/19/2017,5/30/2019,,Abandoned,Method of Treatment,"The application claimed a method of treating breast cancer, comprising administering to a patient 200 mg of an anti-PD-1 antibody or antigen binding fragment thereof comprising three light chain CDRs (CDRL1, CDRL2 and CDRL3) and three heavy chain CDRs (CDRH1, CDRH2, and CDRH3), wherein CDRL1 comprises the amino acid sequence set forth in SEQ ID NO:5, CDRL2 comprises the amino acid sequence set forth in SEQ ID NO:6, CDRL3 comprises the amino acid sequence set forth in SEQ ID NO:7, CDRH1 comprises the amino acid sequence set forth in SEQ ID NO:8, CDRH2 comprises the amino acid sequence set forth in SEQ ID NO:9, and CDRH3 comprises the amino acid sequence set forth in SEQ ID NO:10 on day 1 of a 21-day cycle and 150 mg of abemaciclib or a pharmaceutically acceptable salt thereof twice daily on days 1-21 of the 21-day cycle.",After,No,https://patents.google.com/patent/US20190160148A1/en?oq=US20190160148
Keytruda,US20190183972,ImClone / Merck,Cancer,Biologic,12,6/3/2016,5/26/2017,6/20/2019,,Abandoned,Method of Treatment,"The application claimed a  method of treating non-small cell lung cancer, locally advanced and unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma, urothelial cancer, or biliary tract cancer in a patient, comprising administering to the patient in need of such treatment an effective amount of an anti-VEGFR-2 antibody comprising two light chains, each having the amino acid sequence of SEQ ID NO: 3 and two heavy chains, each having the amino acid sequence of SEQ ID NO: 4, and an effective amount of an anti-PD-1 antibody comprising two light chains, each having the amino acid sequence of SEQ ID NO: 5 and two heavy chains, each having the amino acid sequence of SEQ ID NO: 6; wherein the anti-PD-1 antibody is administered at a dose of 200 mg, once every three weeks.",After,No,https://patents.google.com/patent/US20190183972A1/en?oq=US20190183972
Keytruda,US20190219585,Merck,Cancer,Biologic,51,12/10/2013,1/17/2019,7/18/2019,,Abandoned,Method of Diagnosis,"The application claimed a process for assigning a PD-1:PD-Ligand proximity score to a tumor sample, which comprises: (a) obtaining an image of tissue that has been removed from the tumor sample and immunohistochemically stained for PD-1 and PD-Ligand expression in a manner that allows stained PD-1 cells to be distinguished from stained PD-Ligand cells; (b) defining in the image one or more regions of interest (ROIs) that comprises neoplastic cells and associated stroma, wherein substantially all of the neoplastic cells and associated stroma in the image are contained in the defined ROIs; (c) randomly creating across each defined ROI a plurality of subregions of substantially the same shape and size, wherein each of the subregions defines an area that is large enough to include a spatially proximal pair of a stained PD-1 cell and a stained PD-Ligand cell and small enough to exclude pairs of stained PD-1 and PD-Ligand cells that are not spatially proximal; and (d) calculating the percent of all of the subregions that are positive for both stained PD-1 cells and stained PD-Ligand cells to generate the PD-1:PD-ligand proximity score for the tumor sample.",After,No,https://patents.google.com/patent/US20190219585A1/en?oq=US20190219585
Keytruda,US20190233523,ImClone / Merck,Cancer,Biologic,13,9/26/2016,9/7/2017,8/1/2019,,Abandoned,Kit,"The application claimed a kit comprising Antibody 1 and Antibody 2, wherein Antibody 1 comprises two heavy chains and two light chains, wherein the Antibody 1 heavy chains comprise a HCVR having the amino acid sequence of SEQ ID NO: 1, and wherein the Antibody 1 light chains comprise a LCVR having the amino acid sequence of SEQ ID NO: 2, and wherein Antibody 2 comprises two heavy chains and two light chains, wherein the Antibody 2 heavy chains comprise a HCVR having the amino acid sequence of SEQ ID NO: 5, and the Antibody 2 light chains comprise a LCVR having the amino acid sequence of SEQ ID NO: 6, and wherein the amount of Antibody 1 is 400 mg to 800 mg, and the amount of Antibody 2 is 200 mg.",After,No,https://patents.google.com/patent/US20190233523A1/en?oq=US20190233523
Keytruda,US20190263927,Merck / Eisai,Cancer,Biologic,14,10/14/2016,10/13/2017,8/29/2019,,Abandoned,Method of Treatment,The application claimed a method for treating an urothelial cancer in an individual comprising administering to the individual a combination therapy which comprises an antagonist of a Programmed Death 1 protein (PD-1) and eribulin or a pharmaceutically acceptable salt thereof.,After,No,https://patents.google.com/patent/US20190263927A1/en?oq=US20190263927
Keytruda,US20190270802,Merck,Cancer,Biologic,15,10/21/2016,10/19/2017,9/5/2019,,Pending,Method of Treatment, The application claims a method for treating a cancer in an individual comprising administering to the individual a combination therapy which comprises an antagonist of a Programmed Death 1 protein (PD-1) and an antagonist of IL-27.,After,No,https://patents.google.com/patent/US20190270802A1/en?oq=US20190270802
Keytruda,US20190270812,Incyte / Merck,Cancer,Biologic,47,2/4/2014,4/4/2019,9/5/2019,,Pending,Method of Treatment,"The application claims a method for treating a cancer in an individual comprising administering to the individual a combination therapy which comprises an antagonist of a Programmed Death 1 protein (PD-1) and an inhibitor of indoleamine 2, 3-dioxygenase.",After,No,https://patents.google.com/patent/US20190270812A1/en?oq=US20190270812
Keytruda,US20190298826,GlaxoSmithKline / Merck,Cancer,Biologic,55,5/31/2013,6/29/2018,10/3/2019,,Abandoned,Formulation / Combination,The application claimed a combination comprising a PD-1 antagonist and one or both of tagretinib and/or dabrafenib. ,After,No,https://patents.google.com/patent/US20190298826A1/en?oq=US20190298826
Keytruda,US20190314505A1,Merck,Cancer,Biologic,18,4/16/2018,4/16/2019,12/28/2021,,Pending,Method of Production / Process,"The application claims a method for reducing the viscosity of a liquid formulation comprising a pharmaceutically active protein in a concentration in the range of at least 50 mg/ml up to 300 mg/ml, comprising the step of combining the protein solution with a viscosity-reducing concentration of an excipient selected from the group consisting of the meglumine, ornithine, carnitine, benzenesulfonic acid and sodium p-toluene sulfonic acid, gluconic acid, glucuronic acid, aminocaproic acid and succinate or mixtures thereof.",After,No,https://patents.google.com/patent/US20190314505A1/en?oq=US20190314505A1
Keytruda,US20190328762,Merck,Cancer,Biologic,16,12/20/2016,12/15/2017,10/31/2019,,Abandoned,Method of Treatment,"The application claimed a method of treating a cell-proliferation disorder, said method comprising administering to a subject in need thereof a combination therapy.
",After,No,https://patents.google.com/patent/US20190328762A1/en?oq=US20190328762
Keytruda,US20190330375A1,Merck,Cancer,Biologic,67,1/7/2017,7/2/2019,10/31/2019,,Pending,Method of Treatment,"The application claims a method of treating cancer or inhibiting tumor growth in a subject in need thereof, the method comprising administering to the subject a dose of at least 500 mg of a protein comprising a first polypeptide and a second polypeptide,
wherein the first polypeptide comprises: (a) at least a variable region of a heavy chain of an antibody that binds to human protein Programmed Death Ligand 1 (PD-L1); and (b) human Transforming Growth Factor β Receptor II (TGFβRII), or a fragment thereof, capable of binding Transforming Growth Factor β (TGFβ), wherein the second polypeptide comprises at least a variable region of a light chain of an antibody that binds PD-L1, andwherein the heavy chain of the first polypeptide and the light chain of the second polypeptide, when combined, form an antigen binding site that binds PD-L1.",After,No,https://patents.google.com/patent/US20190330375A1/en?oq=US20190330375A1
Keytruda,US20190383556A1,Merck,Cancer,Biologic,3,10/16/2013,8/30/2019,12/19/2019,,Abandoned,Method of Production / Process,"The application claimed a method of preparing a dried pellet of a biological material, comprising: a) dispensing an aliquot of a liquid composition comprising the biological material as a single droplet onto a solid surface, wherein the temperature of the solid surface is at −90° C. or below, in a manner that maintains the droplet as a single droplet as it contacts and freezes on the surface as a frozen pellet; b) applying microwave radiation in a traveling wave format to the frozen pellet under a pressure below atmospheric pressure to produce a dried pellet; wherein the biological material is a purified antibody.",After,No,https://patents.google.com/patent/US20190383556A1/en?oq=US20190383556A1
Keytruda,US20200055938A1,Merck,Cancer,Biologic,65,5/2/2017,5/1/2018,2/20/2020,,Pending,Formulation / Combination,"The application claims a formulation comprising: about 5-300 mg/mL of an anti-LAG3 antibody or antigen-binding fragment thereof, one or more of an excipient selected from the group consisting of histidine, aspartate, glutamine, glycine, proline, methionine, arginine or pharmaceutically acceptable salt thereof, NaCl, KCl, LiCl, CaCl2), MgCl2, ZnCl2, and FeCl2, at a total concentration of 10-1000 mM, and a buffer at pH about 5-8.",After,No,https://patents.google.com/patent/US20200055938A1/en?oq=US20200055938A1
Keytruda,US20200061184A1,Icahn School Of Medicine At Mount Sinai / Memorial Sloan Kettering Cancer Center / Merck,Cancer,Biologic,35,5/12/2017,5/11/2018,2/27/2020,,Pending,Method of Treatment," The application claims a first composition for use in a method for treating cancer in a human subject, wherein the first composition comprises a chimeric Newcastle disease virus (NDV), wherein the chimeric NDV comprises a packaged genome comprising a transgene encoding human interleukin-12 (“IL-12”), wherein the transgene encodes a human IL-12 p40 subunit and a human IL-12 p35 subunit, and wherein the method further comprises administering a second composition, wherein said second composition comprises an antibody that binds to human PD-1 (pembrolizumab), and blocks the interaction between human PD-1 and its ligands, PD-L1 and PD-L2.",After,No,https://patents.google.com/patent/US20200061184A1/en?oq=US20200061184A1
Keytruda,US20200115451A1,Merck,Cancer,Biologic,63,3/31/2017,3/28/2018,4/16/2020,,Pending,Method of Treatment,"The application claims a method of treating cancer in a human patient comprising administering: (a) 200 mg of an anti-PD-1 antibody or antigen binding fragment thereof and an anti-CTLA4 antibody or antigen binding fragment thereof; or (b) 2 mg/kg of an anti-PD-1 antibody or antigen binding fragment thereof and an anti-CTLA4 antibody or antigen binding fragment thereof, wherein the amount of the anti-CTLA4 antibody or antigen binding fragment thereof is selected from 10-75 mg, and wherein the anti-PD-1 antibody or antigen binding fragment thereof is administered once every three weeks and the anti-CTLA4 antibody or antigen binding fragment thereof is administered once every three weeks or once every six weeks, and wherein the anti-PD-1 antibody or antigen binding fragment comprises: light chain complementarity determining regions (CDRs) comprising amino acid sequences as set forth in SEQ ID Nos: 7, 8, and 9 and heavy chain CDRs comprising amino acid sequences as set forth in SEQ ID Nos: 10, 11, and 12.",After,No,https://patents.google.com/patent/US20200115451A1/en?oq=US20200115451A1
Keytruda,US20200147213A1,Merck,Cancer,Biologic,4,5/2/2017,5/1/2018,5/14/2020,,Pending,Formulation / Combination,"The application claims an anti-human PD-1 antibody formulation, comprising: a) about 5 mg/mL to about 200 mg/mL of an anti-human PD-1 antibody, or antigen binding fragment thereof; b) about 5 mM to about 20 mM buffer;
c) a stabilizer selected from the group consisting of: i) about 6% to about 8% weight/volume (w/v) sucrose, trehalose or (2-hydroxypropyl)-β-cyclodextrin; ii) about 3% to about 5% w/v mannitol, sorbitol, L-arginine, a pharmaceutically acceptable salt of L-arginine, L-proline, or a pharmaceutically acceptable salt of L-proline; and iii) about 1.8 to about 2.2% w/v glycine, or a pharmaceutically acceptable salt thereof; d) about 0.01% to about 0.10% non-ionic surfactant; and e) about 1 mM to about 20 mM anti-oxidant.",After,No,https://patents.google.com/patent/US20200147213A1/en?oq=+US20200147213A1
Keytruda,US20200206350A1,Merck,Cancer,Biologic,19,9/5/2017,8/31/2018,7/2/2020,,Pending,Formulation / Combination,The application claims  amino acid derivatives especially pegylated for reducing viscosity in formulations and particularly for PD-1 antibody formulation.,After,No,https://patents.google.com/patent/US20200206350A1/en?oq=US20200206350A1
Keytruda,US20200254091A1,Merck / Pfizer,Cancer,Biologic,64,10/13/2017,10/10/2018,8/13/2020,,Pending,Method of Treatment,"The application claims a method for treating cancer comprising administering to a patient in need thereof an amount of a PARP inhibitor and an amount of a PD-1 axis binding antagonist, wherein the amounts together are effective in treating cancer.",After,No,https://patents.google.com/patent/US20200254091A1/en?oq=US20200254091A1
Keytruda,US20200262919A1,Merck / Amgen,Cancer,Biologic,32,10/13/2017,10/12/2018,8/20/2020,,Pending,Method of Treatment,"The application claims a method of treating diffuse large B cell lymphoma (DLBCL) in a subject comprising: administering blinatumomab or a blinatumomab variant to the subject; and administering pembrolizumab, a pembrolizumab variant or an antigen-binding fragment thereof to the subject, thereby treating DLBCL in the subject.",After,No,https://patents.google.com/patent/US20200262919A1/en?oq=US20200262919A1
Keytruda,US20200262922A1,Merck,Cancer,Biologic,37,5/2/2017,5/1/2018,8/20/2020,,Pending,Formulation / Combination,"The application claims a  formulation for pembrolizumab comprising: (i) about 1 mg/ml to about 100 mg/ml of an anti-CTLA4 antibody, or antigen binding fragment thereof; wherein the anti-CTLA4 antibody or antigen-binding fragment thereof comprises three light chain CDRs comprising CDRL1 of SEQ ID NO: 38, CDRL2 of SEQ ID NO: 39, and CDRL3 of SEQ ID NO: 40 and three heavy chain CDRs comprising CDRH1 of SEQ ID NO: 35, CDRH2 of SEQ ID NO: 36, and CDRH3 of SEQ ID NO: 37; (ii) about 5 mM to about 20 mM buffer;(iii) about 6% to about 8% weight/volume (w/v) non-reducing sugar; (iv) about 0.01% to about 0.10% w/v non-ionic surfactant; and(v) about 1 mM to about 20 mM anti-oxidant.",After,No,https://patents.google.com/patent/US20200262922A1/en?oq=US20200262922A1
Keytruda,US20200277399A1,Merck Patent / Universität Für Bodenkultur Wien,Cancer,Biologic,113,10/3/2017,10/3/2018,9/3/2020,,Pending,Method of Production / Process,"The application claims a specific antigen-binding member (ABM) comprising a specific antigen-binding moiety and an antibody Fc region comprising a CH2 domain, which is engineered for a cysteine substitution at position 108 and/or 113, wherein numbering is according to the IMGT, and wherein the antibody Fc region does not comprise an antigen-binding CH3 domain.",After,No,https://patents.google.com/patent/US20200277399A1/en?oq=US20200277399A1
Keytruda,US20200289493A1,Tesaro / Merck,Cancer,Biologic,58,5/9/2017,5/9/2018,9/17/2020,,Pending,Method of Treatment,"The application claims a method of treating cancer, the method comprising: administering a therapeutically effective amount of an agent that inhibits poly [ADP-ribose] polymerase (PARP) and an agent that inhibits programmed death-1 protein (PD-1) signaling to a subject,wherein: (a) the subject is BRCA negative and the cancer is PD-L1 negative; (b) the agents are administered to the subject independent of DNA repair status, optionally independent of BRCA status; (c) administration of the agents to the subject is commenced prior to determining the DNA repair status of the subject or the BRCA status of the subject; or
(d) administration of the agents to the subject is commenced in the absence of determining the DNA repair status of the subject or the BRCA status of the subject.",After,No,https://patents.google.com/patent/US20200289493A1/en?oq=US20200289493A1
Keytruda,US20200325228A1,Merck / Pfizer,Cancer,Biologic,48,2/4/2014,1/14/2020,10/15/2020,,Abandoned,Method of Treatment," The application claimed amethod for treating a cancer in an individual comprising administering to the individual a combination therapy which comprises an antagonist of a Programmed Death 1 protein (PD-1) and a vascular endothelial growth factor receptor (VEGFR) inhibitor, wherein the PD-1 antagonist is an anti-PD-1 monoclonal antibody which comprises a heavy chain and a light chain, wherein the heavy and light chains comprise SEQ ID NO:21 and SEQ ID NO:22, respectively, and further wherein the VEGFR inhibitor is axitinib.",After,No,https://patents.google.com/patent/US20200325228A1/en?oq=US20200325228A1
Keytruda,US20200353022A1,Merck / Amgen,Cancer,Biologic,31,10/27/2017,10/26/2018,11/12/2020,,Pending,Method of Treatment,"The application claims a method of treating a cancer in a subject, said method comprising administering to said subject:
talimogene laherparepvec; and pembrolizumab, a pembrolizumab variant or an antigen-binding fragment thereof,
wherein said cancer is selected from the group consisting of: hepatocellular carcinoma, breast adenocarcinoma, colorectal adenocarcinoma, gastroesophageal adenocarcinoma, gastroesophageal squamous cell carcinoma, melanoma, non-small cell lung cancer and clear cell renal cell carcinoma.",After,No,https://patents.google.com/patent/US20200353022A1/en?oq=US20200353022A1
Keytruda,US20200354453A1,Merck,Cancer,Biologic,36,5/2/2017,5/1/2018,11/12/2020,,Pending,Formulation / Combination,"The application claims a formulation for pembrolizumab comprising: (i) about 10 mg/ml to about 200 mg/ml of an anti-TIGIT antibody, or antigen binding fragment thereof, (ii) about 5 mM to about 20 mM buffer; (iii) about 6% to about 8% weight/volume (w/v) non-reducing sugar;(iv) about 0.01% to about 0.10% (w/v) non-ionic surfactant; and (v) about 1 mM to about 20 mM anti-oxidant.",After,No,https://patents.google.com/patent/US20200354453A1/en?oq=US20200354453A1
Keytruda,US20200362040A1,Merck / Pfizer,Cancer,Biologic,59,2/26/2015,8/5/2020,11/19/2020,,Pending,Method of Treatment,"The application claims a method of treating cancer in a subject, comprising administering to the subject a therapeutically effective amount of an inhibitor of the interaction between the PD-1 receptor and its ligand PD-L1.",After,No,https://patents.google.com/patent/US20200362040A1/en?oq=US20200362040A1
Keytruda,US20210008135A1,Merck / Amgen,Cancer,Biologic,38,4/28/2017,4/27/2018,1/14/2021,,Pending,Method of Treatment,"The application claims a method of treating a tumor in a subject comprising: selecting a subject having a tumor comprising a CD8+ T-cell infiltration density of fewer than about 1500, about 1400, about 1300, about 1200, about 1100, about 1000, about 900, about 800, about 700, about 600, or about 500 cells/mm2; administering talimogene laherparepvec to the subject; and
administering pembrolizumab, a pembrolizumab variant or an antigen-binding fragment thereof to the subject.",After,No,https://patents.google.com/patent/US20210008135A1/en?oq=US20210008135A1
Keytruda,US20210024573A1,Merck,Cancer,Biologic,96,4/3/2018,3/26/2019,1/28/2021,,Pending,Method of Production / Process,"The application claims a method of separating a monomeric protein of interest from a mixture comprising aggregates of the protein of interest in a sample, the method comprising contacting the sample with a solid support, the solid support comprising a polyvinyl ether resin functionalized with a 2-acrylamido-2-methylpropane sulfonic acid (AMPS) and N,N-dimethylacrylamide (DMMA), wherein the molar ratio of DMMA to AMPS is greater than 2.0, and eluting the monomeric protein of interest from the solid support with a buffer having a solution conductivity between about 10 mS/cm and 20 mS/cm.",After,No,https://patents.google.com/patent/US20210024573A1/en?oq=US20210024573A1
Keytruda,US20210047408A1,Merck,Cancer,Biologic,23,2/13/2018,2/8/2019,2/18/2021,,Pending,Method of Treatment,"The application claims a method of treating cancer in a human patient comprising administering about 400 mg of an anti-PD-1 antibody, or antigen binding fragment thereof, to the patient every approximately six weeks, wherein the anti-PD-1 antibody or antigen-binding fragment thereof comprises: (a) light chain complementarity determining regions (CDRs) comprising a sequence of amino acids as set forth in SEQ ID NOs: 1, 2 and 3 and heavy chain CDRs comprising a sequence of amino acids as set forth in SEQ ID NOs: 6, 7 and 8; or (b) light chain CDRs comprising a sequence of amino acids as set forth in SEQ ID NOs: 11, 12 and 13 and heavy chain CDRs comprising a sequence of amino acids as set forth in SEQ ID NOs: 14, 15 and 16.",After,No,https://patents.google.com/patent/US20210047408A1/en?oq=US20210047408A1
Keytruda,US20210047409A1,Merck,Cancer,Biologic,26,2/13/2018,2/8/2019,2/18/2021,,Pending,Method of Treatment,"The application claims a method of treating cancer in a human patient comprising administering about 400 mg of an anti-PD-1 antibody or antigen binding fragment thereof to the patient approximately every six weeks and about 25 mg, about 50 mg, about 75 mg, or about 100 mg of an anti-CTLA4 antibody or antigen binding fragment thereof to the patient approximately every six weeks.",After,No,https://patents.google.com/patent/US20210047409A1/en?oq=US20210047409A1
Keytruda,US20210047670A1,Merck,Cancer,Biologic,108,5/27/2010,10/20/2020,2/18/2021,,Pending,Method of Production / Process,"The application claims a method for increasing the bioavailability of an Fc-containing polypeptide when administered subcutaneously, comprising: introducing mutations at amino acid positions 243 and 264 of the Fc region of the Fc-containing polypeptide, wherein the mutation at position 243 is selected from the group consisting of: F243A, F243G, F243S, F243T, F243V, F243L, F243I, F243D, F243Y, F243E, F243R, F243W, and F243K and the mutation at position 264 is selected from the group consisting of: V264A, V264G, V264S, V264T, V264D, V264E, V264K, V264W, V264H, V264P, V264N, V264Q and V264L,
wherein the numbering is according to the EU index as in Kabat; and wherein the bioavailability of the Fc-containing polypeptide comprising the mutations is increased when the Fc-containing polypeptide is administered subcutaneously compared to subcutaneous administration of an Fc-containing polypeptide without said mutations.",After,No,https://patents.google.com/patent/US20210047670A1/en?oq=US20210047670A1
Keytruda,US20210048247A1,Merck,Cancer,Biologic,3,10/16/2013,10/27/2020,2/18/2021,,Pending,Method of Production / Process,"The application claims a method of preparing a dried pellet of a biological material, comprising: a) dispensing an aliquot of a liquid composition comprising the biological material as a single droplet onto a solid surface, wherein the temperature of the solid surface is at −90° C. or below, in a manner that maintains the droplet as a single droplet as it contacts and freezes on the surface as a frozen pellet; b) applying microwave radiation in a traveling wave format to the frozen pellet under a pressure below atmospheric pressure to produce a dried pellet wherein the biological material is a purified antibody.",After,No,https://patents.google.com/patent/US20210048247A1/en?oq=US20210048247A1
Keytruda,US20210077463A1,Pfizer / Merck / Array,Cancer,Biologic,30,12/18/2017,12/17/2018,3/18/2021,,Pending,Method of Treatment,"The application claims a method for treating cancer comprising administering to a patient in need thereof an amount of a PARP inhibitor, an amount of a PD-1 axis binding antagonist, and an amount of a MEK inhibitor, wherein the amounts together are effective in treating cancer.
",After,No,https://patents.google.com/patent/US20210077463A1/en?oq=US20210077463A1
Keytruda,US20210101929A1,Merck,Cancer,Biologic,21,4/16/2018,4/16/2019,4/8/2021,,Pending,Method of Production / Process,The application claims a method of stabilizing of a liquid protein or peptide formulation or for suppressing protein aggregation in said formulation by treatment of the peptide- or protein-containing solution with a combination of meglumine and a physiologically well-tolerated organic counterion in effective concentrations to stabilize the protein or peptide molecules contained therein.,After,No,https://patents.google.com/patent/US20210101929A1/en?oq=US20210101929A1
Keytruda,US20210123919A1,Merck / Eisai,Cancer,Biologic,28,5/14/2018,5/13/2019,4/29/2021,,Pending,Method of Diagnosis,The application claims a method of predicting the response of a human subject having or suspected of having at least one cancer to a combination therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof and a Programmed Cell Death 1 protein (PD-1) antagonist.,After,No,https://patents.google.com/patent/US20210123919A1/en?oq=US20210123919A1
Keytruda,US20210196819A1,Merck / Dynavax,Cancer,Biologic,70,5/29/2015,8/21/2020,7/1/2021,,Pending,Method of Treatment,"The application claims a method for treating cancer in an individual comprising administering to the individual a combination therapy which comprises a PD-1 antagonist and a TLR9 agonist, wherein: the PD-1 antagonist is a monoclonal antibody, or antigen binding fragment thereof, which comprises: (a) light chain CDRs of SEQ ID NOs: 1, 2 and 3 and heavy chain CDRs of SEQ ID NOs: 4, 5 and 6; or (b) light chain CDRs of SEQ ID NOs: 7, 8 and 9 and heavy chain CDRs of SEQ ID NOs: 10, 11 and 12 ; and
the TLR9 agonist is a CpG-C type oligonucleotide, wherein the CpG-C type oligonucleotide comprises 5′-TCG Nq TTCGA ACG TTC GAA CGT TCG AAT-3′, wherein N are nucleosides and q=4.",After,No,https://patents.google.com/patent/US20210196819A1/en?oq=US20210196819A1
Keytruda,US20210246208A1,Merck,Cancer,Biologic,56,5/4/2018,5/6/2019,8/12/2021,,Pending,Formulation / Combination,"The application claims a pharmaceutical composition comprising a PD-1 axis binding antagonist, a TGFβ inhibitor, a DNA-PK inhibitor and at least one pharmaceutically acceptable excipient or adjuvant.",After,No,https://patents.google.com/patent/US20210246208A1/en?oq=US20210246208A1
Keytruda,US20210317214,Merck,Cancer,Biologic,201,9/13/2018,9/9/2019,10/14/2021,,Pending,Method of Treatment,The application claims a method for treating non-microsatellite instability-high (non-MSI-H) or proficient mismatch repair (pMMR) colorectal cancer in an individual comprising administering to the individual a PD-1 antagonist and a LAG3 antagonist.,After,No,https://patents.google.com/patent/US20210317214A1/en?oq=US20210317214
Keytruda,US20210317215A1,Merck,Cancer,Biologic,173,10/31/2018,10/28/2019,10/14/2021,,Pending,Method of Production / Process,The application claims a method for producing crystalline anti PD-1 monoclonal antibody (mAb). ,After,No,https://patents.google.com/patent/US20210317215A1/en?oq=US20210317215A1
Keytruda,US20210353614A1,Merck / Pfizer,Cancer,Biologic,69,3/14/2018,3/13/2019,11/18/2021,,Pending,Method of Treatment,"The application claims a method of treating a tumor in a subject comprising simultaneously or subsequentially administrating a topoisomerase inhibitor, an ataxia-telangiectasia mutated (ATM) inhibitor and an immune checkpoint inhibitor to said subject.",After,No,https://patents.google.com/patent/US20210353614A1/en?oq=US20210353614A1
Keytruda,US20210363243A1,Merck,Cancer,Biologic,29,2/1/2018,1/31/2019,11/25/2021,,Pending,Method of Treatment,"The application claims a method of treating cancer, comprising administering to a human patient in need thereof:
(a) an anti-human PD-1 monoclonal antibody or antigen binding fragment thereof; (b) an anti-human LAG3 monoclonal antibody or antigen binding fragment thereof; and (c) an anti-human TIGIT monoclonal antibody or antigen binding fragment thereof;
wherein optionally the anti-human PD-1 monoclonal antibody is a human antibody or a humanized antibody; wherein optionally the anti-human LAG3 monoclonal antibody is a human antibody or a humanized antibody; and wherein optionally the anti-human TIGIT monoclonal antibody is a human antibody or a humanized antibody.",After,No,https://patents.google.com/patent/US20210363243A1/en?oq=US20210363243A1
Keytruda,US20210379186A1,Merck,Cancer,Biologic,20,4/16/2018,4/16/2019,12/9/2021,,Pending,Method of Production / Process,"The application claims a method for increasing the thermostability of a liquid protein or peptide formulation, comprising the step of combining a protein or peptide solution with at least one excipient.",After,No,https://patents.google.com/patent/US20210379186A1/en?oq=US20210379186A1
Keytruda,US20210380694A1,Merck,Cancer,Biologic,195,11/7/2018,11/6/2019,12/9/2021,,Pending,Formulation / Combination,"The application claims an  anti-human PD-1 antibody formulation, comprising: a) about 5 mg/mL to about 250 mg/mL of an anti-human PD-1 antibody, or antigen binding fragment thereof; b) about 5 mM to about 20 mM buffer; c) about 1.5 to about 8.0% weight/volume (w/v) stabilizer selected from the group consisting of: a non-reducing sugar, (2-hydroxypropyl)-β-cyclodextrin, mannitol, sorbitol, L-arginine, a pharmaceutically acceptable salt of L-arginine, L-proline, a pharmaceutically acceptable salt of L-proline, L-histidine, a pharmaceutically acceptable salt of L-histidine, glycine, and a pharmaceutically acceptable salt of glycine;
d) a surfactant selected from: i) about 0.005% w/v to about 0.60% w/v non-ionic surfactant, ii) about 0.23% w/v to about 1.15% w/v ionic surfactant, or iii) about 0.005% w/v to about 0.20% w/v dimethyl-dodecylamine oxide (DDAO); and e) about 1 mM to about 30 mM anti-oxidant.",After,No,https://patents.google.com/patent/US20210380694A1/en?oq=US20210380694A1
Keytruda,US20210403560A1,Merck,Cancer,Biologic,1,6/18/2007,9/8/2021,12/30/2021,,Pending,Product,"The application claims a method of increasing the activity of an immune cell, comprising contacting the immune cell with a monoclonal antibody which binds to human programmed death receptor 1 (hPD-1), wherein the antibody blocks the binding of human PD-L1 and human PD-L2 to hPD-1 and comprises: a. three light chain CDRs having the amino acid sequences set forth in SEQ ID NOs: 9, 10 and 11 and b. three heavy chain CDRs having the amino acid sequences set forth in SEQ ID NOs: 12, 13 and 14.",After,No,https://patents.google.com/patent/US20210403560A1/en?oq=US20210403560A1
Keytruda,US20220002403A1,Merck / Agenus,Cancer,Biologic,39,4/7/2017,6/3/2021,1/6/2022,,Pending,Product,"The application claims an antibody or antigen-binding fragment thereof that binds one or more amino acid residues in a human immunoglobulin-like transcript 4 (ILT4) epitope selected from the group consisting of LYREKKSASW (SEQ ID NO:59), TRIRPEL (SEQ ID NO:60), NGQF (SEQ ID NO:61), and HTGRYGCQ (SEQ ID NO:62) and protects the epitope from deuterium exchange in the presence of a deuterium source and a pharmaceutical composition comprising: (i) an antibody that consists of two heavy chains and two light chains, wherein each light chain consists of the amino acid sequence set forth in SEQ ID NO:7 and each heavy chain consists of the amino acid sequence set forth in SEQ ID NO:2, and (ii) pembrolizumab.",After,No,https://patents.google.com/patent/US20220002403A1/en?oq=US20220002403A1
Keytruda,US20220010016,Bioline / Merck,Cancer,Biologic,200,10/17/2018,10/17/2019,1/13/2022,,Pending,Method of Treatment,"The application claims a method of treating metastatic pancreatic adenocarcinoma in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of each of a peptide set forth in SEQ ID NO: 1, an anti PD-1 and a chemotherapy, thereby treating the metastatic pancreatic adenocarcinoma.",After,No,https://patents.google.com/patent/US20220010016A1/en?oq=US20220010016
Keytruda,US20220017621A1,Merck,Cancer,Biologic,68,8/12/2016,6/24/2021,1/20/2022,,Pending,Method of Treatment,"The application claimed a method of treating cancer, the method comprising administering to a cancer patient:
(i) a protein comprising a human TGFβRII, or fragment thereof capable of binding TGFβ; and an antibody, or antigen-binding fragment thereof, that binds human protein Programmed Death Ligand 1 (PD-L1); and (ii) an effective amount of at least one additional anti-cancer agent,thereby providing a combination therapy having an enhanced therapeutic effect compared to the effect of the protein and the at least one additional anti-cancer agent each administered alone.",After,No,https://patents.google.com/patent/US20220017621A1/en?oq=US20220017621A1
Keytruda,US20220033496A1,Merck / Agenus,Cancer,Biologic,39,4/7/2017,6/3/2021,2/3/2022,,Pending,Product,"The application claims a antibody or antigen-binding fragment thereof that binds one or more amino acid residues in a human immunoglobulin-like transcript 4 (ILT4) epitope selected from the group consisting of LYREKKSASW (SEQ ID NO:59), TRIRPEL (SEQ ID NO:60), NGQF (SEQ ID NO:61), and HTGRYGCQ (SEQ ID NO:62) and protects the epitope from deuterium exchange in the presence of a deuterium source.",After,No,https://patents.google.com/patent/US20220033496A1/en?oq=US20220033496A1
Keytruda,US20220088191A1,Genmab / Merck,Cancer,Biologic,27,5/7/2018,5/7/2019,3/24/2022,,Pending,Method of Treatment,"The application claims a method of treating cancer in a subject, the method comprising administering to the subject an antibody or an antigen-binding fragment thereof, wherein the antibody binds to Programmed Death-1 (PD-1) and inhibits PD-1 activity, and an antibody-drug conjugate that binds to tissue factor (TF), wherein the antibody-drug conjugate comprises an anti-TF antibody or an antigen-binding fragment thereof conjugated to monomethyl auristatin E, wherein the anti-PD-1 antibody or antigen-binding fragment thereof comprises a heavy chain variable region and a light chain variable region.",After,No,https://patents.google.com/patent/US20220088191A1/en?oq=US20220088191A1
Keytruda,US20220088200A1,Merck,Cancer,Biologic,17,4/16/2018,12/6/2021,3/24/2022,,Pending,Method of Production / Process,"The application claims a method for reducing the viscosity of a liquid formulation comprising a pharmaceutically active protein in a concentration in the range of at least 50 mg/ml up to 300 mg/ml, comprising the step of combining the protein solution with a viscosity-reducing concentration of an excipient selected from the group consisting of the meglumine, ornithine, carnitine, benzenesulfonic acid and sodium p-toluene sulfonic acid, gluconic acid, glucuronic acid, aminocaproic acid and succinate or mixtures thereof.",After,No,https://patents.google.com/patent/US20220088200A1/en?oq=US20220088200A1
Keytruda,US20220089738A1,Merck,Cancer,Biologic,186,9/24/2020,9/23/2021,3/24/2022,,Pending,Formulation / Combination,"The application claims a formulation comprising: a) about 20 mg/mL to about 200 mg/mL of an anti-human PD-1 antibody, or antigen binding fragment thereof; b) about 0.0009-0.050 mg/ml of a PH20 variant or fragment thereof; c) about 5 mM to about 20 mM buffer; d) about 3% to about 10% weight/volume (w/v) of a non-reducing dissacharide selected from the group consisting of sucrose and trehalose; e) about 0.005% to about 0.10% (w/v) non-ionic surfactant; and, optionally
f) about 1 mM to about 30 mM anti-oxidant.",After,No,https://patents.google.com/patent/US20220089738A1/en?oq=US20220089738A1
Keytruda,US20220096650A1,GlaxoSmithKline / Merck,Cancer,Biologic,174,2/1/2019,1/31/2020,3/31/2022,,Pending,Method of Treatment,The application claims a method of treating cancer in a patient in need thereof comprising administering to the patient about 0.03 mg/kg to about 4.6 mg/kg of belantamab mafodotin and about 200 mg of pembrolizumab.,After,No,https://patents.google.com/patent/US20220096650A1/en?oq=US20220096650A1
Keytruda,US20220112564A1,Merck,Cancer,Biologic,188,2/14/2019,2/10/2020,4/14/2022,,Pending,Method of Diagnosis,The application claims a method for testing a tumor for the presence or absence of a biomarker that predicts response to treatment with a PD-1 antagonist.,After,No,https://patents.google.com/patent/US20220112564A1/en?oq=US20220112564A1
Keytruda,US2022023285A1,Merck / Eisai,Cancer,Biologic,6,3/4/2015,10/15/2021,1/27/2022,,Pending,Method of Treatment,The application claims a method for treating a cancer in an individual comprising administering to the individual a combination therapy which comprises an antagonist of a Programmed Death 1 protein (PD-1) and a multiple receptor tyrosine kinase (multi-RTK) inhibitor.,After,No,https://patents.google.com/patent/US20220023285A1/en?oq=US2022023285A1
Keytruda,US7148321B2,Merck,Cancer,Biologic,118,3/7/2001,3/7/2002,12/12/2006,5/28/2022,Expired,Product,"The patent claims cover a fusion protein comprising an immunoglobulin moiety fused to a non-immunoglobulin moiety, wherein the immunoglobulin moiety comprises: an IgG1 hinge positioned at the N-terminus of the immunoglobulin moiety; and a CH2 domain of a second antibody isotype adjacent to the IgG1 hinge.",Before,No,https://patents.google.com/patent/US7148321B2/en?oq=US7148321B2
Keytruda,US7262283B2,Merck,Cancer,Biologic,117,9/2/2002,8/8/2003,8/28/2007,2/13/2024,Active,Method of Production / Process,"The patent claims cover a method for the sequential production of partial proteomes from a complete proteome of a cell preparation comprising: a) providing a sample containing a cell preparationb) extracting the cytosolic proteins and the membrane/organelle proteins from the sample provided in step a), leaving a cell nucleus preparation, and c) extracting the proteins from the cell nucleus interior from the preparation obtained in step b) by treating with an extraction buffer having a pH of between 6.5 and 8 which comprises: in total from 0.1 to 7 percent by weight of one or more nonionic detergents
in total from 0.05 to 3 percent by weight of one or more cholic acid derivatives, andone or more salts of alkali metal and/or ammonium in a total concentration of between 75 and 500 mmol/l,wherein detergent-resistant proteins of the cytoskeleton and of the nuclear matrix are not extracted to a significant extent together with the proteins from the cell nucleus interior, but instead remain in the extraction residue.",Before,No,https://patents.google.com/patent/US7262283B2/en?oq=US7262283B2
Keytruda,US7316919B2,Merck / Nysa,Cancer,Biologic,107,2/19/2003,2/2/2004,1/8/2008,3/20/2025,Active,Method of Production / Process,"The patent claims cover a composite material comprising:(a) a support member comprising a plurality of pores extending through the support member; and(b) a non-self supporting macroporous cross-linked gel comprising macropores having an average size of 10 nm to 3000 nm, said macroporous gel being located in the pores of the support member;
wherein said macroporous cross-linked gel is present in the pores of the support member in an amount sufficient such that, in use, liquid passing through the composite material passes through said macropores of said macroporous cross-linked gel; and wherein said macropores of said macroporous cross-linked gel are smaller than said pores of said support member.",Before,No,https://patents.google.com/patent/US7316919B2/en?oq=US7316919B2
Keytruda,US7470778B2,Merck,Cancer,Biologic,124,6/13/2005,6/12/2006,12/30/2008,8/18/2026,Active,Method of Production / Process,"The patent claims cover a method for extraction of proteins, protein fragments and/or peptides from a biological sample, comprising treating said biological sample with an extractant.",Before,No,https://patents.google.com/patent/US7470778B2/en?oq=US7470778B2
Keytruda,US7595048B2,Ono Pharmaceutical,Cancer,Biologic,131,7/3/2002,7/2/2003,9/29/2009,8/8/2024,Active,Method of Treatment,"The patent claims cover a method for treatment of cancer, wherein a pharmaceutically effective amount of completely human anti-PD-1 antibody is parenterally administered to a subject with cancer in which PD-L1 or PD-L2 is over-expressed, postoperatively.",Before,No,https://patents.google.com/patent/US7595048B2/en?oq=US7595048B2
Keytruda,US7858746 ,Ono Pharmaceutical,Cancer,Biologic,132,7/31/2001,3/28/2008,12/28/2010,8/26/2023,Active,Product,The patent claims cover an  isolated polypeptide consisting of the amino acid sequence of SEQ ID NO: 29.,Before,No,https://patents.google.com/patent/US7858746B2/en?oq=US7858746+
Keytruda,US8066994B2,Merck,Cancer,Biologic,118,3/7/2001,7/19/2006,11/29/2011,11/11/2022,Active,Product,"The patent claims cover an  antibody or Ig fusion protein comprising an IgG2 antibody moiety comprising an IgG2 hinge, wherein the IgG2 hinge has been mutated to contain two cysteines.",Before,No,https://patents.google.com/patent/US8066994B2/en?oq=US8066994B2
Keytruda,US8133840B2,Merck / Natrix,Cancer,Biologic,105,6/7/2004,6/6/2005,3/13/2012,2/15/2028,Active,Method of Production / Process,"The patent claims cover a  composite material comprising: a support member that has a plurality of pores extending therethrough, and a non-self supporting macroporous crosslinked gel that is located in, and fills, the pores of the support member, wherein the macroporous crosslinked gel has macropores of average size between about 10 and about 3000 nm;
wherein, in the macroporous crosslinked gel is entrapped a stabilising polymer selected from the group consisting of a cellulose derivative, a polyester, a polyamide, a polyacrylate, poly(ethylene-co-vinyl alcohol), polyhydroxystyrene (poly(4-vinylphenol), aromatic poly(ether sulfone), a partially charged polymer, and a copolymer of neutral and charged monomers.",Before,No,https://patents.google.com/patent/US8133840B2/en?oq=US8133840B2
Keytruda,US8137933B2,Merck,Cancer,Biologic,109,11/12/2008,11/12/2009,3/20/2012,11/12/2029,Active,Method of Production / Process,"The patent claims cover method for producing a recombinant polypeptide in an isolated host cell, comprising introducing a polynucleotide encoding the polypeptide into a multiple cloning site of a vector, wherein the vector comprises the nucleotide sequence set forth in SEQ ID NO: 1, and introducing said vector comprising the polynucleotide encoding the polypeptide into a host cell under conditions which allow for expression of the polypeptide in said cell.",Before,No,https://patents.google.com/patent/US8137933B2/en?oq=US8137933B2
Keytruda,US8168179 ,Ono Pharmaceutical,Cancer,Biologic,131,7/3/2002,8/10/2009,5/1/2012,1/3/2025,Active,Method of Treatment,"The patent claims cover a method of treating a PD-L1-expressing tumor, comprising administering a pharmaceutically effective amount of an anti-PD-L1 antibody to a patient in need thereof, in combination with a pharmaceutically effective amount of one or more chemotherapy drugs, wherein said one or more chemotherapy drugs are selected from the group consisting of an alkylating agent, a nitrosourea agent, an antimetabolite, an antitumor antibiotic, an alkaloid derived from a plant, a topoisomerase inhibitor, a hormone therapy medicine, a hormone antagonist, an aromatase inhibitor, a P-glycoprotein inhibitor and a platinum complex derivative.",Before,No,https://patents.google.com/patent/US8168179B2/en?oq=US8168179+
Keytruda,US8187880B2,Merck / Nysa,Cancer,Biologic,107,2/19/2003,4/23/2008,5/29/2012,8/12/2026,Active,Method of Production / Process,"The patent claims cover a composite material comprising: (a) a support member comprising a plurality of pores extending through the support member; and (b) a non-self supporting macroporous cross-linked gel comprising macropores having an average size of 10 nm to 3000 nm, said macroporous gel being located in the pores of the support member;
wherein said macroporous cross-linked gel is present in the pores of the support member in an amount sufficient such that, in use, liquid passing through the composite material passes through said macropores of said macroporous cross-linked gel; wherein said macropores of said macroporous cross-linked gel are smaller than said pores of said support member; wherein the macroporous cross-linked gel is a gel bearing functional groups; and
wherein said functional groups are metal-affinity ligands.",Before,No,https://patents.google.com/patent/US8187880B2/en?oq=US8187880B2
Keytruda,US8192971B2,Merck / Nysa,Cancer,Biologic,107,2/19/2003,9/16/2008,6/5/2012,4/25/2026,Active,Method of Production / Process,"The patent claims cover a method for separating a substance from a fluid, comprising the step of:
placing the fluid in contact with a composite material that displays a specific interaction for the substance, wherein the composite material comprises: (a) a support member comprising a plurality of pores extending through the support member; and (b) a non-self supporting macroporous cross-linked gel comprising macropores having an average size of 10 nm to 3000 nm, said macroporous gel being located in the pores of the support member; wherein said macroporous cross-linked gel is present in the pores of the support member in an amount sufficient such that, in use, liquid passing through the composite material passes through said macropores of said macroporous cross-linked gel; said macropores of said macroporous cross-linked gel are smaller than said pores of said support member; said macroporous cross-linked gel is a gel bearing a plurality of functional groups; said functional groups are metal affinity ligands; a plurality of metal ions are complexed to said metal-affinity ligands; and the substance is selected from the group consisting of an albumin, lysozyme, a γ-globulin, an immunoglobulin, a protein, a polypeptide, interleukin-2 and its receptor, an enzyme, a monoclonal antibody, trypsin and its inhibitor, cytochrome C, myoglobin, recombinant human interleukin, and a recombinant fusion protein;thereby adsorbing or absorbing the substance to the composite material.",Before,No,https://patents.google.com/patent/US8192971B2/en?oq=US8192971B2
Keytruda,US8206958B2,Merck / Nysa,Cancer,Biologic,107,2/19/2003,12/5/2007,6/26/2012,9/7/2026,Active,Method of Production / Process,"The patent claims cover a process for adsorbing a biological substance from a liquid, which comprises
passing a liquid containing the biological substance through a composite material, wherein the composite material comprises (a) a support member comprising a plurality of pores extending through the support member; and
(b) a macroporous cross-linked gel; wherein the macroporous cross-linked gel has macropores; the macropores have an average diameter of 10 nm to 3000 nm; the macropores of the macroporous cross-linked gel are smaller than the pores of the support member; and the macroporous cross-linked gel is located in the pores of the support member and filling the pores of the support member; wherein the macroporous cross-linked gel bears binding sites that display specific interactions for the biological substance; and the liquid passes through the macropores of the macroporous cross-linked gel such that the binding sites sufficiently interact with the biological substance, thereby adsorbing from the liquid onto the binding sites the biological substance.",Before,No,https://patents.google.com/patent/US8206958B2/en?oq=US8206958B2
Keytruda,US8206982B2,Merck / Nysa,Cancer,Biologic,107,2/19/2003,10/14/2008,6/26/2012,4/7/2026,Active,Method of Production / Process,"The patent claims cover a  composite material comprising: (a) a support member comprising a plurality of pores extending through the support member; and (b) a non-self supporting macroporous cross-linked gel comprising macropores having an average size of 10 nm to 3000 nm, said macroporous gel being located in the pores of the support member;
wherein said macroporous cross-linked gel is present in the pores of the support member in an amount sufficient such that, in use, liquid passing through the composite material passes through said macropores of said macroporous cross-linked gel; said macropores of said macroporous cross-linked gel are smaller than said pores of said support member; and
the macroporous cross-linked gel is a gel bearing a plurality of reactive functional groups.",Before,No,https://patents.google.com/patent/US8206982B2/en?oq=US8206982B2
Keytruda,US8211682B2,Merck / Nysa,Cancer,Biologic,107,2/19/2003,10/3/2008,7/3/2012,6/20/2026,Active,Method of Production / Process,"The patent claims cover a composite material comprising: (a) a support member comprising a plurality of pores extending through the support member; and (b) a non-self supporting macroporous cross-linked gel comprising macropores having an average size of 10 nm to 3000 nm, said macroporous gel being located in the pores of the support member;
wherein said macroporous cross-linked gel is present in the pores of the support member in an amount sufficient such that, in use, liquid passing through the composite material passes through said macropores of said macroporous cross-linked gel;said macropores of said macroporous cross-linked gel are smaller than said pores of said support member;
the macroporous cross-linked gel is a gel bearing a plurality of functional groups; and
the functional groups are biological molecules or biological ions.
",Before,No,https://patents.google.com/patent/US8211682B2/en?oq=US8211682B2
Keytruda,US8354509,Merck,Cancer,Biologic,1,6/18/2007,6/13/2008,1/15/2013,6/13/2028,Active,Product,"The patent claims cover an  isolated antibody or antibody fragment which binds to human PD-1 comprising:
a. three light chain CDRs of 15, 16 and 17; and/or b. three heavy chain CDRs of SEQ ID NOs: 18, 19 and 20.
",Before,No,https://patents.google.com/patent/US8354509B2/en?oq=US8354509
Keytruda,US8357535B2,Merck,Cancer,Biologic,87,6/7/2007,6/6/2008,1/22/2013,6/6/2028,Active,Method of Production / Process,"The patent claims cover a method of screening cells for expression of a protein of interest, said method comprising the steps of: a) transfecting cells by an expression vector encoding: (i) a Puro-DHFR chimeric protein comprising:
SEQ ID NO: 2; or a functional polypeptide fragment of dihydrofolate reductase (DHFR) fused to a functional polypeptide fragment conferring resistance to puromycin (Puro), wherein said functional polypeptide fragment of dihydrofolate reductase comprises SEQ ID NO: 6, and said functional polypeptide fragment of puromycin N-acetyl transferase comprises SEQ ID NO:4; and (ii) a protein of interest; b) selecting cells being resistant to puromycin; and c) assaying the fluorescence of the cells selected in step (b) with a fluorescent compound binding to DHFR.",Before,No,https://patents.google.com/patent/US8357535B2/en?oq=US8357535B2
Keytruda,US8367809B2,Merck / Nysa,Cancer,Biologic,107,2/19/2003,10/30/2009,2/5/2013,2/10/2025,Active,Method of Production / Process,"The patent claims cover a composite material, comprising: (a) a support member comprising a plurality of pores extending through the support member, wherein the average pore diameter is between 0.1 and 25 μm; and (b) a non-self-supporting gel comprising a plurality of reactive functional groups, wherein the gel comprises a plurality of macropores having an average macropore diameter between about 10 nm and about 3000 nm; wherein the gel is chemically grafted to the surface of the pores of the support member; the gel is located in the pores of the support member and essentially fills the pores of the support member; and the macropores of the gel are smaller than the pores of the support member.",Before,No,https://patents.google.com/patent/US8367809B2/en?oq=US8367809B2
Keytruda,US8383782B2,Merck / Nysa,Cancer,Biologic,107,2/19/2003,10/30/2009,2/26/2013,1/16/2025,Active,Method of Production / Process,"The patent claims cover a composite material, comprising: (a) a support member comprising a plurality of pores extending through the support member, wherein the average pore diameter of the pores is between 0.1 and 25 μm; and
(b) a non-self-supporting gel comprising a polymer derived from a macromonomer selected from the group consisting of poly(ethylene glycol)diacrylate and poly(ethylene glycol)dimethacrylate, wherein the gel comprises a plurality of macropores having an average macropore diameter from about 10 nm to about 3000 nm;
wherein the gel is located in the pores of the support member; and the macropores of the gel are smaller than the pores of the support member.",Before,No,https://patents.google.com/patent/US8383782B2/en?oq=US8383782B2
Keytruda,US8445219B2,Merck,Cancer,Biologic,88,7/25/2008,6/26/2009,5/21/2013,7/4/2030,Expired,Method of Diagnosis,"The patent claims cover a method for determining the degree of receptor binding saturation effected by a monoclonal antibody of interest (Ab1) by means of a first (Ab1A) and a second (Ab2) monoclonal antibody each provided with an individual detection system, wherein Ab1 specifically binds to an epitope (E1) of a receptor domain in a tissue sample, Ab1A recognizes and binds to the same epitope E1 of the receptor domain, and Ab2 binds to an epitope (E2) of the same receptor domain that is different from E1, and said binding of Ab2 does not interact with binding of Ab1 or Ab1A to E1, the method comprising the steps: (i) applying antibody Ab2 to a tissue sample of an individual in an amount which is sufficient to achieve receptor binding saturation towards E2 and determining the signal strength provided by the individual detection system associated with antibody Ab2, (ii) applying antibody Ab1A to a tissue sample of the same individual that was treated before with said antibody Ab1, in an amount which is sufficient to bind to receptor epitope E1 not already bound by antibody Ab1, and determining the signal strength provided by the individual detection system associated with antibody Ab1A, and (iii) calculating from the difference of the signal strength obtained by steps (i) and (ii), the amount of receptor domains which can still bind antibody Ab1, thus determining the degree of receptor binding saturation effected by antibody Ab1.",Before,No,https://patents.google.com/patent/US8445219B2/en?oq=US8445219B2
Keytruda,US8460886B2,Ono Pharmaceutical / ER Squibb,Cancer,Biologic,133,7/4/2008,7/3/2009,6/11/2013,7/3/2029,Expired,Method of Diagnosis,The patent claims cover a method for evaluating the therapeutic efficacy of an anti-human PD-1 antibody in treating a cancer.,Before,No,https://patents.google.com/patent/US8460886B2/en?oq=US8460886B2
Keytruda,US8652849B2,Merck / Nysa,Cancer,Biologic,107,2/19/2003,10/14/2008,2/18/2014,2/18/2027,Active,Method of Production / Process,"The patent claims cover a method for separating a substance from a fluid, comprising the step of: placing the fluid in contact with a composite material that displays a specific interaction for the substance, wherein the composite material comprises: (a) a support member comprising a plurality of pores extending through the support member; and
(b) a non-self supporting macroporous cross-linked gel comprising macropores having an average size of 10 nm to 3000 nm, said macroporous gel being located in the pores of the support member; wherein said macroporous cross-linked gel is present in the pores of the support member in an amount sufficient such that, in use, liquid passing through the composite material passes through said macropores of said macroporous cross-linked gel; said macropores of said macroporous cross-linked gel are smaller than said pores of said support member; said macroporous cross-linked gel is a gel bearing a plurality of functional groups; said functional groups are metal-affinity ligands; and the substance is a metal-containing ion, thereby adsorbing or absorbing the substance to the composite material.",Before,No,https://patents.google.com/patent/US8652849B2/en?oq=US8652849B2
Keytruda,US8673988B2,Merck,Cancer,Biologic,122,7/30/2008,7/8/2009,3/18/2014,4/3/2030,Active,Method of Production / Process,The patent claims cover separating materials for ion exchange chromatography.,Before,No,https://patents.google.com/patent/US8673988B2/en?oq=US8673988B2
Keytruda,US8728474 ,Ono Pharmaceutical,Cancer,Biologic,131,7/3/2002,12/2/2010,5/20/2014,10/2/2025,Active,Method of Treatment,"The patent claims cover a method for treatment of a tumor in a patient, comprising administering to the patient a pharmaceutically effective amount of an anti-PD-1 monoclonal antibody.",Before,No,https://patents.google.com/patent/US8728474B2/en?oq=US8728474+
Keytruda,US8841106B2,Merck,Cancer,Biologic,87,6/7/2007,1/16/2013,9/23/2014,6/6/2028,Active,Method of Production / Process,"The patent claims cover an isolated Puro-DHFR polypeptide comprising SEQ ID NO: 2, said polypeptide having: (i) puromycin N-acetyl transferase activity; and (ii) dihydrofolate reductase activity.",Before,No,https://patents.google.com/patent/US8841106B2/en?oq=US8841106B2
Keytruda,US8900587,Merck,Cancer,Biologic,1,6/18/2007,12/19/2012,12/2/2014,8/22/2028,Active,Formulation / Combination,"The patent claims cover a  composition comprising an antibody in combination with a pharmaceutically acceptable carrier or diluent, wherein said antibody binds to human PD-1 and comprises: a heavy chain comprising amino acid residues 20 to 466 of SEQ ID NO: 31; and a light chain comprising amino acid residues 20 to 237 of SEQ ID NO: 36.",Before,No,https://patents.google.com/patent/US8900587B2/en?oq=US8900587
Keytruda,US8936918B2,Merck,Cancer,Biologic,82,2/25/2011,2/20/2012,1/20/2015,2/20/2032,Active,Method of Production / Process,"The patent claims cover a method of producing a recombinant glycoprotein having O-Man-GlcNAc; O-Man-GlcNAc-Gal; or O-Man-GlcNAc-Gal-Sia as the predominant O-glycan thereof in Pichia pastoris host cell which comprises: (a) providing Pichia pastoris host cells which (i) do not express functional beta-mannosyltransferase enzymes Bmt 1, 2, 3 and 4, and phospho-mannose transferase enzymes Mnn4a, Mnn4b and Pno1; and (ii) do express functional protein O-linked mannose β-1,2-N-linked acetylglucosaminyltransferase 1 (“POMGnT1”), UDP-GlcNAc transporter and α-1,2-mannosidase enzymes; (b) transfecting or transforming the Pichia pastoris host cells with nucleic acid encoding the glycoprotein of interest; and
(c) culturing the Pichia pastoris host cells so that the recombinant glycoprotein is produced.",Before,No,https://patents.google.com/patent/US8936918B2/en?oq=US8936918B2
Keytruda,US8951790,Merck,Cancer,Biologic,109,11/12/2008,1/6/2012,2/10/2015,12/23/2030,Active,Product,The patent claims cover a isolated vector comprising a multiple cloning site comprising the nucleotide sequence set forth in SEQ ID NO: 2.,Before,No,https://patents.google.com/patent/US8951790B2/en?oq=US8951790
Keytruda,US8952136,Merck,Cancer,Biologic,1,6/18/2007,12/19/2012,2/10/2015,10/1/2028,Active,Product,"The patent claims cover an isolated antibody or antibody fragment which binds to human programmed death receptor-1 (PD-1), comprising a. light chain CDRs of SEQ ID NOs: 9, 10 and 11; and b. heavy chain CDRs of SEQ ID NOs: 12, 13 and 14;
wherein said antibody or antibody fragment blocks binding of human PD-L1 and human PD-L2 to human PD-1.",Before,No,https://patents.google.com/patent/US8952136B2/en?oq=US8952136
Keytruda,US9067999 ,Ono Pharmaceutical,Cancer,Biologic,131,7/3/2002,3/4/2014,6/30/2015,7/2/2023,Active,Method of Treatment,"The patent claims cover a method of treating a lung cancer comprising administering a composition comprising a human or humanized anti-PD-1 monoclonal antibody to a human with the lung cancer, wherein the administration of the composition treats the lung cancer in the human.",Before,No,https://patents.google.com/patent/US9067999B1/en?oq=US9067999+
Keytruda,US9073994 ,Ono Pharmaceutical,Cancer,Biologic,131,7/3/2002,11/21/2014,7/7/2015,7/2/2023,Active,Method of Treatment,"The patent claims cover a method of treating a metastatic melanoma comprising intravenously administering an effective amount of a composition comprising a human or humanized anti-PD-1 monoclonal antibody and a solubilizer in a solution to a human with the metastatic melanoma, wherein the administration of the composition treats the metastatic melanoma in the human.",After,No,https://patents.google.com/patent/US9073994B2/en?oq=US9073994+
Keytruda,US9149738B2,Merck,Cancer,Biologic,102,4/23/2012,4/19/2013,10/6/2015,10/5/2033,Active,Method of Production / Process,The patent claims cover a method of purifying target molecules from one or more impurities in a sample.,Before,No,https://patents.google.com/patent/US9149738B2/en?oq=US9149738B2
Keytruda,US9175284B2,Merck,Cancer,Biologic,87,6/7/2007,9/10/2014,11/3/2015,6/6/2028,Active,Method of Production / Process,"The patent claims cover an  isolated nucleic acid encoding a Puro-DHFR polypeptide, wherein said Puro-DHFR polypeptide comprises SEQ ID NO: 2 and has: (i) puromycin N-acetyl transferase activity; and (ii) dihydrofolate reductase activity.",After,No,https://patents.google.com/patent/US9175284B2/en?oq=US9175284B2
Keytruda,US9220776,Merck,Cancer,Biologic,2,3/31/2011,3/29/2012,12/29/2015,9/1/2032,Active,Formulation / Combination,"The patent claims cover a stable lyophilized pharmaceutical formulation of an anti-human PD-1 antibody, wherein the formulation made by lyophilizing an aqueous solution comprising: a) 25-100 mg/mL of the anti-human PD-1 antibody; b) about 70 mg/mL sucrose; c) about 0.2 mg/mL polysorbate 80; and d) about 10 mM Histidine buffer at about pH 5.0-pH 6.0, and
wherein the antibody, comprises: i) a light chain comprising amino acid residues 20 to 237 of SEQ ID NO: 36; and
ii) a heavy chain comprising amino acid residues 20 to 466 of SEQ ID NO: 31.",Before,No,https://patents.google.com/patent/US9220776B2/en?oq=US9220776
Keytruda,US9328367B2,Merck,Cancer,Biologic,128,10/28/2011,10/23/2012,5/3/2016,10/23/2032,Active,Product,"The patent claims cover an  engineered Pichia pastoris host cell that has been modified to reduce or eliminate the activity of an ATT1 gene, wherein the ATT1 gene encodes a polypeptide comprising the amino acid sequence set forth in SEQ ID NO:7, wherein the activity of the ATT1 gene is reduced or eliminated by: (i) reducing or eliminating the expression of an ATT1 gene or polypeptide, or (ii) expressing a mutated form of an ATT1 gene; and wherein the host cell further comprises a nucleic acid encoding a recombinant protein.",Before,No,https://patents.google.com/patent/US9328367B2/en?oq=US9328367B2
Keytruda,US9393301 ,Ono Pharmaceutical,Cancer,Biologic,131,7/3/2002,1/19/2016,7/19/2016,7/2/2023,Active,Method of Treatment,The patent claims cover a method of treating a tumor in a human in need thereof comprising administering to the human an effective amount of a human or humanized anti-PD-L1 monoclonal antibody that inhibits an interaction between PD-1 and PD-L1 in combination with an effective amount of an anti-CTLA-4 antibody.,After,No,https://patents.google.com/patent/US9393301B2/en?oq=US9393301+
Keytruda,US9402899 ,Ono Pharmaceutical,Cancer,Biologic,131,7/3/2002,4/4/2014,8/2/2016,2/5/2024,Active,Method of Treatment,"The patent claims cover a method of treating a tumor in a human patient in need thereof comprising
administering to the human an effective amount of an anti-PD-L1 monoclonal antibody that inhibits an interaction between PD-1 and PD-L1,wherein the anti-PD-L1 monoclonal antibody treats the tumor in the patient.",Before,No,https://patents.google.com/patent/US9402899B2/en?oq=US9402899+
Keytruda,US9439962 ,Ono Pharmaceutical,Cancer,Biologic,131,7/3/2002,1/19/2016,9/13/2016,7/2/2023,Active,Method of Treatment,The patent claims cover a  method of treating a tumor in a human in need thereof comprising administering to the human an effective amount of an anti-PD-L1 monoclonal antibody that inhibits an interaction between PD-1 and PD-L1 in combination with an effective amount of a chemotherapeutic drug.,After,No,https://patents.google.com/patent/US9439962B2/en?oq=US9439962+
Keytruda,US9493736B2,Merck,Cancer,Biologic,95,4/27/2011,3/28/2012,11/15/2016,3/28/2032,Active,Method of Production / Process,"The patent claims cover a  method for lysing cells comprising a) providing a sample comprising the cells
b) adding a lysis solution at least comprising a water-immiscible oil or a water-immiscible ionic liquid to the sample
c) heating the mixture obtained in step b) to a temperature above 80° C. d) in case the temperature in step c) was above 100° C., cooling the sample to a temperature below 100° C. e) adding water or an aqueous buffer solution to the mixture, thereby obtaining a water-immiscible liquid phase and an aqueous phase.",Before,No,https://patents.google.com/patent/US9493736B2/en?oq=US9493736B2
Keytruda,US9528125B2,Merck,Cancer,Biologic,109,11/12/2008,1/28/2015,12/27/2016,11/12/2029,Active,Product,The patent claims cover plasmid vector which is the product of a method comprising introducing a polynucleotide encoding a polypeptide into a multiple cloning site of a vector that comprises the nucleotide sequence set forth in SEQ ID NO: 1.,After,No,https://patents.google.com/patent/US9528125B2/en?oq=US9528125B2
Keytruda,US9574003B2,Merck,Cancer,Biologic,78,3/6/2011,3/5/2012,2/21/2017,3/5/2032,Active,Method of Production / Process,"The patent claims cover a  method of selecting a Chinese hamster ovary (CHO) cell having a zero fucose level useful as a host cell for expressing a recombinant protein, the method comprising: (a) introducing a genetic mutation into a coding region for a GDP-mannose 4,6-dehydratase (GMD) in a CHO cell of a population of CHO cells by contacting the cells with methotrexate (MTX), thereby generating a CHO cell with a mutated GMD protein, (b) contacting the population of CHO cells comprising at least one CHO cell with a mutated GMD protein with a non-toxic fucose binding agent for an amount of time that allows binding of the fucose binding agent to a fucose moiety on a cell membrane of one or more cells of the population of cells, wherein the amount of time does not allow killing of the cells; and(c) depleting from the population of cells comprising mutated cells, a subpopulation of one or more cells which bind the fucose binding agent, thereby selecting cells useful as host cells for expressing recombinant proteins, the selected cells having zero fucose content in the absence of external fucose, wherein the expressed mutated GMD protein lacks amino acids encoded by exons 3 and 4 or lacks amino acids encoded by exons 8 and 9, and further wherein the cells exhibit a stable fucose phenotype for more than 100 population doublings.",Before,No,https://patents.google.com/patent/US9574003B2/en?oq=US9574003B2
Keytruda,US9827309,Merck,Cancer,Biologic,54,8/20/2013,8/15/2014,11/28/2017,8/15/2034,Active,Method of Treatment,"The patent claims cover a method for treating a cancer in an individual comprising administering to the individual a combination therapy which comprises an isolated monoclonal antibody that binds to Programmed Death 1 protein (PD-1), wherein the isolated anti-PD-1 monoclonal antibody is MK-3475 (pembrolizumab), and a dinaciclib compound. Method of Use Comination 2. treating cancer with pembrolizumab + dinaciclib (small molecule). ",Before,No,https://patents.google.com/patent/US9827309B2/en?oq=US9827309
Keytruda,US9834605,Merck,Cancer,Biologic,1,6/18/2007,12/19/2014,12/5/2017,5/14/2029,Active,Product,"The patent claims cover an isolated polynucleotide encoding an antibody or antibody fragment which binds to human programmed death receptor 1 (PD-1), wherein the antibody or antibody fragment comprises a. three light chain CDRs having the amino acid sequences set forth in SEQ ID NOs:15, 16 and 17; and/or b. three heavy chain CDRs having the amino acid sequences set forth in SEQ ID NOs: 18, 19 and 20.",After,No,https://patents.google.com/patent/US9834605B2/en?oq=US9834605
Keytruda,US9907849,Advaxis / Merck,Cancer,Biologic,45,7/18/2014,7/17/2015,1/28/2016,7/17/2035,Expired,Method of Treatment,"The patent claims cover a method for treating prostate cancer in a patient comprising administering to the patient a combination therapy which comprises an antagonist of a Programmed Death 1 protein (PD-1) and a bioengineered live-attenuated Listeria monocytogenes strain transformed with an expression vector to express a PSA antigen fused to a truncated Listeriolysin O (tLLO), and wherein the live-attenuated Listeria monocytogenes strain stimulates Antigen Presenting Cells (APCs) capable of driving a cellular immune response to PSA expressing cells.",After,No,https://patents.google.com/patent/US9907849B2/en?oq=US9907849
Keytruda,US9926341B2,Merck,Cancer,Biologic,123,12/20/2012,11/25/2013,3/27/2018,6/7/2034,Expired,Method of Production / Process,"The patent claims cover a method for isolating a target molecule from a sample comprising: a) adjusting the pH of the sample to a pH below the isoelectric point of the target molecule, b) mixing one or more copolymers with the sample, wherein the copolymer is synthesized from monomer units whereby each monomer unit that is used for synthesizing the copolymer has at least one hydrophobic or one anionic group, wherein the copolymer is obtained from (i) monomers of 2-acrylamido-2-methylpropane sulfonic acid and 4-acrylamido benzoic acid, or (ii) monomers of 2-acrylamido-2-methylpropane sulfonic acid and benzylacrylamide, whereby a target molecule-copolymer precipitate is formed, andc) separating the precipitate from the mixture of b), wherein the target molecule is an antibody, an Fc fragment of an antibody, or an Fab fragment of an antibody.",Before,No,https://patents.google.com/patent/US9926341B2/en?oq=US9926341B2
Keytruda,US9931604B2,Merck,Cancer,Biologic,120,3/15/2013,2/20/2014,4/3/2018,6/29/2034,Active,Method of Production / Process,"The patent claims cover an  apparatus for performing sonication on liquid samples, comprising:
a rack (1) for holding an array of sample vials (2); an ultrasonic probe (3) with an arrangement of recesses (4) corresponding to the array of sample vials (2) and adapted to respectively receive and contact an outer surface of a bottom portion (2 a) of a respective one of the sample vials (2); and a counter-holder (5) with an arrangement of pushing members (6) corresponding to the array of sample vials (2) and adapted to respectively apply a force to a respective one of the sample vials (2) so as to push the bottom portion (2 a) of each vial (2) into contact with the associated recess (4) of the probe (3), and wherein the pushing members are in the form of pushrods (6) and are arranged to apply the force to a top portion of the respective associated vials (2) wherein the pushrods are elastically biased towards the vials.",Before,No,https://patents.google.com/patent/US9931604B2/en?oq=US9931604B2
Keytruda,"US9988600B2
",Merck,Cancer,Biologic,81,7/11/2013,6/16/2014,6/5/2018,6/16/2034,Active,Method of Treatment,"The patent claims cover dry powder cell culture medium comprising at least one polymer embedded component, wherein said polymer is a poloxamer or a mixture thereof and said component is L-glutamine, sodium hydrogen carbonate, calcium chloride×2 H2O, choline chloride, ferric nitrate×9 H2O, ferrous sulphate×7 H2O, sodium phosphate, or monosodium phosphate (NaH2PO4) monohydrate.",Before,No,https://patents.google.com/patent/US9988600B2/en?oq=US9988600B2
Keytruda,US9995753,Merck,Cancer,Biologic,41,9/25/2015,9/23/2016,6/12/2018,9/23/2036,Active,Method of Diagnosis,"The patent claims cover an antibody or antigen-binding fragment thereof that binds pembrolizumab, comprising: three light chain CDRs of CDR-L1, CDR-L2 and CDR-L3 and three heavy chain CDRs of CDR-H1, CDR-H2 and CDR-H3.",After,No,https://patents.google.com/patent/US9995753B2/en?oq=US9995753
Revlimid,"US 10034872B2
",Celgene,Multiple Myeloma,Small Molecule,57,8/22/2014,8/20/2015,7/31/2018,8/20/2035,Active,Method of Treatment,"The patent claims cover a method of treating multiple myeloma in a patient having multiple myeloma and having received stem cell transplantation with lenalidomide. 
",After,No,https://patents.google.com/patent/US10034872B2/en?oq=US+10034872B2
Revlimid,US 2007049618A1,Celgene,Multiple Myeloma,Small Molecule,52,8/31/2005,8/30/2006,3/1/2007,,Abandoned,Derivative,The patent claims cover derivative compounds of lenalidomide.,After,No,https://patents.google.com/patent/US20070049618A1/en?oq=US+2007049618A1
Revlimid,US 2008027113A1,Celgene,Multiple Myeloma,Small Molecule,10,9/23/2003,4/28/2004,1/31/2008,,Abandoned,Method of Treatment,"The application claimed a method of treating  preventing or managing macular degeneration, which comprises administering to a patient in need of such treatment, prevention or management a therapeutically or prophylactically effective amount of an immunomodulatory compound (lenalidomide in an enantiomerically pure form), or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. ",Before,No,https://patents.google.com/patent/US20080027113A1/en?oq=US+2008027113A1
Revlimid,US 2008096952A1,Celgene,Multiple Myeloma,Small Molecule,8,12/15/1999,12/7/2007,4/24/2008,,Abandoned,Method of Treatment,The application claimed a method of treating atherosclerosis in a mammal comprising administering to a mammal having atherosclerosis an effective amount of a derivative compound of lenalidomide/thalidomide.,After,No,https://patents.google.com/patent/US20080096952A1/en?oq=US+2008096952A1
Revlimid,US 2008132541,Celgene,Multiple Myeloma,Small Molecule,6,5/15/2003,5/5/2004,6/5/2008,,Abandoned,Method of Treatment,The application claimed a method of treating a cancer which comprises administering to a patient having a cancer a therapeutically effective amount of a crystalline form (5 different forms are claimed) of lenalidomide (Revlimid). ,Before,No,https://patents.google.com/patent/US20080132541A1/en?oq=US+2008132541
Revlimid,US 2008213219A1,Celgene,Multiple Myeloma,Small Molecule,10,10/31/2002,3/19/2008,9/4/2008,,Abandoned,Method of Treatment,"The application claimed a method of treating macular degeneration, which comprises administering to a patient having macular degeneration about 5 to about 50 mg per day of  lenalidomide (Revlimid) or a pharmaceutically acceptable salt, solvate or stereoisomer thereof.",After,No,https://patents.google.com/patent/US20080213219A1/en?oq=US+2008213219A1
Revlimid,US 2008227816A1,Celgene,Multiple Myeloma,Small Molecule,14,12/30/2003,5/23/2008,9/18/2008,,Abandoned,Method of Treatment,"The application claimed a method of treating treating amyotrophic lateral sclerosis, which comprises administering to a patient having amyotrophic lateral sclerosis about 5 to about 50 mg per day of a derivative of lenalidomide or a pharmaceutically acceptable salt, solvate or stereoisomer thereof.",After,No,https://patents.google.com/patent/US20080227816A1/en?oq=US+2008227816A1
Revlimid,US 20090148853,Celgene,Multiple Myeloma,Small Molecule,42,12/7/2007,12/5/2008,6/11/2009,,Abandoned,Biomarker,The application claimed a method of predicting tumor response to treatment in a Non-Hodgkin's Lymphoma (NHL) patient wherein the drug is an analog of lenalidomide.,After,No,https://patents.google.com/patent/US20090148853A1/en?oq=US+20090148853
Revlimid,US 20090155207,Celgene,Multiple Myeloma,Small Molecule,26,11/29/2007,11/26/2008,6/18/2009,,Abandoned,Method of Treatment,"The application claimed a method of treating managing or preventing transverse myelitis, which comprises administering to a patient a therapeutically or prophylactically effective amount of an immunomodulatory compound (lenalidomide) or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.",After,No,https://patents.google.com/patent/US20090155207A1/en?oq=US+20090155207
Revlimid,US 2009087407A1,Celgene,Multiple Myeloma,Small Molecule,15,3/22/2004,10/10/2008,4/2/2009,,Abandoned,Method of Treatment,The application claimed a method of treating scleroderma with a derivative of lenalidomide. ,After,No,https://patents.google.com/patent/US20090087407A1/en?oq=US+2009087407A1
Revlimid,US 2011064735A1,Celgene,Multiple Myeloma,Small Molecule,20,8/7/2007,11/9/2010,3/17/2011,,Abandoned,Method of Treatment,"The application claimed a method of treating a lymphoma in a patient, which comprises administering lenalidomide to a patient having one or more of the following:
a) a disease burden of less than 50 cm2; b) an absolute lymphocyte count greater than 0.6×109/L; or c) not less than 230 days since last rituximab therapy.",After,No,https://patents.google.com/patent/US20110064735A1/en?oq=US+2011064735A1
Revlimid,US 20140106390,Celgene,Multiple Myeloma,Small Molecule,41,4/18/2011,4/17/2012,4/17/2014,,Abandoned,Biomarker,"The application claimed a method of predicting a patient response to a treatment of multiple myeloma, comprising: obtaining tumor cells from the patient;
culturing the tumor cells in the presence or absence of an immunomodulatory compound; measuring the level of a biomarker in the tumor cells; and
comparing the levels of the biomarker in the tumor cells cultured in the presence of an immunomodulatory compound to the levels of the biomarker in the tumor cells cultured in the absence of the immunomodulatory compound; wherein a decreased level of the biomarker in the presence of the immunomodulatory compound indicates the likelihood of an effective patient response to the immunomodulatory compound.",After,No,https://patents.google.com/patent/US20140106390A1/en?oq=US+20140106390
Revlimid,US 2015064172A1,Celgene,Multiple Myeloma,Small Molecule,61,8/27/2013,11/19/2013,3/5/2015,,Abandoned,Method of Treatment,"The application claimed a method of treating , stabilizing or lessening the severity or progression of one or more diseases and conditions associated with BTK comprising administering to a patient in need thereof an irreversible BTK inhibitor and lenalidomide, wherein the irreversible BTK inhibitor has not more than about 50% inhibition of a kinase selected from c-Kit, PDGFRa, RIPK2, HCK, EPHA6, LYN, CSK, LCK, ZAK/MLTK, LYN B, FRK/PTK5, FYN, BRAF, RIPK3, ARAF and SRMS, or combinations thereof.",After,No,https://patents.google.com/patent/US20150064172A1/en?oq=US+2015064172A1
Revlimid,US 20160153998,Celgene,Multiple Myeloma,Small Molecule,42,12/7/2007,11/13/2015,6/2/2016,,Abandoned,Biomarker,The application claimed a method of predicting tumor response to treatment in a Non-Hodgkin's Lymphoma (NHL) patient wherein the drug is an analog of lenalidomide.,After,No,https://patents.google.com/patent/US20160153998A1/en?oq=US+20160153998
Revlimid,US 2017000779A1,Antrogenesis / Celgene,Multiple Myeloma,Small Molecule,44,4/12/2002,2/8/2016,1/5/2017,,Abandoned,Method of Treatment,The application claimed a method of treating an individual in need of granulocytes.,After,No,https://patents.google.com/patent/US20170000779A1/en?oq=US+2017000779A1
Revlimid,"US 2017232030A1
",Epizyme / Celgene,Multiple Myeloma,Small Molecule,59,8/13/2014,8/12/2015,8/17/2017,,Abandoned,Formulation / Combination,The application claimed a combination of therapeutic compounds with lenalidomide. ,After,No,https://patents.google.com/patent/US20170232030A1/en?oq=US+2017232030A1
Revlimid,"US 2017242014A1
",Celgene,Multiple Myeloma,Small Molecule,38,10/13/2014,12/5/2014,8/24/2017,,Abandoned,Method of Diagnosis,"The application claimed a method  of identifying a subject having a solid tumor who is likely to be responsive to a treatment compound, wherein the treatment compound is thalidomide, lenalidomide, pomalidomide, Compound A, or Compound B, or a stereoisomer thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or a polymorph thereof.",After,No,https://patents.google.com/patent/US20170242014A1/en?oq=US+2017242014A1
Revlimid,"US 2018231561A1
",Celgene,Multiple Myeloma,Small Molecule,34,8/12/2015,8/11/2016,8/16/2018,,Abandoned,Method of Diagnosis,"The application claimed a method of  identifying a subject having a solid tumor who is likely to be responsive to a treatment compound (lenalidomide), comprising:(a) administering the treatment compound to a subject having a solid tumor; (b) obtaining a sample from the subject; (c) determining the level of a biomarker in the sample from the subject, wherein the biomarker is selected from the group consisting of biomarkers identified in Tables 1 to 6, and combinations thereof; and (d) diagnosing the subject as being likely to be responsive to the treatment compound if the level of the biomarker in the sample of the subject changes as compared to a reference level of the biomarker.",After,No,https://patents.google.com/patent/US20180231561A1/en?oq=US+2018231561A1
Revlimid,US 2018263968A1,Celgene,Multiple Myeloma,Small Molecule,5,8/3/2006,5/18/2018,9/20/2018,,Abandoned,Method of Treatment,"The application claimed a method of treating mantle cell lymphoma in a human, which comprises administering to a human having mantle cell lymphoma from about 5 mg to about 50 mg of lenalidomide.",After,No,https://patents.google.com/patent/US20180263968A1/en?oq=US+2018263968A1
Revlimid,US 2018267043A1,Celgene,Multiple Myeloma,Small Molecule,40,10/7/2014,10/6/2015,9/20/2018,,Abandoned,Biomarker,The application claimed a method of identifying a subject having cancer who is likely to be responsive to a treatment compound.,After,No,https://patents.google.com/patent/US20180267043A1/en?oq=US+2018267043A1
Revlimid,US 7325355B2,Celgene,Multiple Myeloma,Small Molecule,8,12/15/1999,8/30/2005,2/5/2008,12/11/2020,Expired,Method of Treatment,The patent claims cover a method of treating atherosclerosis in a mammal comprising administering to a mammal having atherosclerosis an effective amount lenalidomide (Revlimid).,Before,No,https://patents.google.com/patent/US7325355B2/en?oq=US+7325355B2
Revlimid,US 7977357,Celgene,Multiple Myeloma,Small Molecule,6,9/4/2003,7/23/2008,7/12/2011,1/8/2025,Active,Crystalline,"The patent claims cover unsolvated (""anhydrous"") crystalline forms of lenalidomide (Revlimid)",After,No,https://patents.google.com/patent/US7977357B2/en?oq=US+7977357
Revlimid,"US 8034831B2
",Celgene,Multiple Myeloma,Small Molecule,9,11/6/2002,12/5/2008,10/11/2011,7/22/2023,Active,Method of Treatment,The patent claims cover a method of treating myelofibrosis with myeloid metaplasia with a anlog of thalidomide/lenalidomide.,After,No,https://patents.google.com/patent/US8034831B2/en?oq=US+8034831B2
Revlimid,US 8058443,Celgene,Multiple Myeloma,Small Molecule,6,9/4/2003,12/15/2008,11/15/2011,1/7/2026,Active,Method of Production / Process,The patent claims cover a process  to prepare crystalline hemihydrate and dihydrate forms of lenalidomide,After,No,https://patents.google.com/patent/US8058443B2/en?oq=US+8058443
Revlimid,US 8143286,Celgene,Multiple Myeloma,Small Molecule,6,9/4/2003,12/15/2008,3/27/2012,10/15/2025,Active,Crystalline,The patent claims cover  a crystaline dihydrate form of lenalidomide and their formulations. ,After,No,https://patents.google.com/patent/US8143286B2/en?oq=US+8143286
Revlimid,US 8188118,Celgene,Multiple Myeloma,Small Molecule,6,5/17/2002,2/19/2009,5/29/2012,5/15/2023,Active,Method of Treatment,"The patent claims cover a method of treating multiple myeloma, which comprises administering to a patient having multiple myeloma (a) about 5 to about 25 mg per day of  lenalidomide (Revlimid)or a pharmaceutically acceptable salt, or stereoisomer thereof, for 21 consecutive days followed by seven consecutive days of rest from administration of said compound in a 28 day cycle, (b) 40 mg of dexamethasone, and (c) administering a therapeutically effective mount of an antibody, wherein the multiple myeloma is relapsed, refractory, or resistant to previous therapy.
",After,No,https://patents.google.com/patent/US8188118B2/en?oq=US+8188118
Revlimid,US 8193219,Celgene,Multiple Myeloma,Small Molecule,6,9/4/2003,10/3/2011,6/5/2012,9/3/2024,Active,Formulation / Combination,"The patent claims cover a  pharmaceutical composition for oral administration comprising between 5 mg and 25 mg of an unsolvated crystalline lenalidomide  having an X-ray powder diffraction pattern comprising peaks at approximately 8, 14.5, 16, 17.5, 20.5, 24, and 26 degrees 2θ, and a pharmaceutically acceptable excipient, diluent, or carrier, wherein the composition is a solid dosage form.",After,No,https://patents.google.com/patent/US8193219B2/en?oq=US+8193219
Revlimid,US 8198262,Celgene,Multiple Myeloma,Small Molecule,6,5/17/2002,8/19/2008,6/12/2012,4/23/2025,Active,Method of Treatment,The patent claims cover a method of treating multiple myeloma with a close analog of thalidomide/lenalidomide,After,No,https://patents.google.com/patent/US8198262B2/en?oq=US+8198262
Revlimid,US 8198306,Celgene,Multiple Myeloma,Small Molecule,6,5/17/2002,12/17/2009,6/12/2012,6/2/2024,Active,Method of Treatment,"The patent claims cover a method of treating multiple myeloma, which comprises cyclically administering to a patient having multiple myeloma: (a) about 5 to about 25 mg per day of lenalidomide (Revlimid) or a pharmaceutically acceptable salt or stereoisomer thereof for 21 consecutive days followed by seven consecutive days of rest from administration of said compound in a 28 day cycle, (b) 40 mg of dexamethasone, and (c) a therapeutically effective amount of a proteasome inhibitor.
",After,No,https://patents.google.com/patent/US8198306B2/en?oq=US+8198306
Revlimid,US 8207200,Celgene,Multiple Myeloma,Small Molecule,6,5/17/2002,5/8/2008,6/26/2012,7/28/2023,Active,Method of Treatment,"The patent claims cover a method of treating multiple myeloma, which comprises: (1) administering to a patient having multiple myeloma (a) about 5 to about 5 mg per day of lenalidomide (Revlimid) or a pharmaceutically acceptable salt thereof for 21 consecutive days followed by seven consecutive days of rest from administration of said compound in a 28 day cycle, and (b) 40 mg of dexamethasone; and (2) followed by stem cell transplantation.",After,No,https://patents.google.com/patent/US8207200B2/en?oq=US+8207200
Revlimid,US 8431598B2,Celgene,Multiple Myeloma,Small Molecule,6,9/4/2003,5/26/2011,4/30/2013,9/3/2024,Active,Crystalline, The patent claims cover an anhydrous crystalline form of lenalidomide,After,No,https://patents.google.com/patent/US8431598B2/en?oq=US+8431598B2
Revlimid,US 8440194,Celgene,Multiple Myeloma,Small Molecule,6,5/17/2002,2/19/2008,5/14/2013,1/31/2027,Active,Method of Treatment,"The patent claims cover a method of treating leukemia in a human, which comprises administering to a human having leukemia escalating doses of lenalidomide (Revlimid)wherein a starting dose is between about 2.5 mg/day and about 10 mg/day, and a maximum dose is between about 5 mg/day and about 50 mg/day, wherein the leukemia is chronic lymphocytic leukemia.",After,No,https://patents.google.com/patent/US8440194B2/en?oq=US+8440194
Revlimid,US 8492406B2,Celgene,Multiple Myeloma,Small Molecule,6,5/17/2002,4/7/2010,7/23/2013,12/11/2024,Active,Method of Treatment,"The patent claims cover a method of treating follicular lymphoma, which comprises administering to a patient having follicular lymphoma about 5 to about 50 mg per day of lenalidomide (Revlimid) or a pharmaceutically acceptable salt, solvate or stereoisomer thereof.",After,Yes,https://patents.google.com/patent/US8492406B2/en?oq=US+8492406B2
Revlimid,US 8530498B1,Celgene,Multiple Myeloma,Small Molecule,6,5/17/2002,4/8/2013,9/10/2013,5/15/2023,Active,Method of Treatment,"The patent claims cover a method of treating multiple myeloma, which comprises administering, on a 28 day cycle, to a patient having multiple myeloma:
(a) about 25 mg per day of lenalidomide (Revlimid) or a pharmaceutically acceptable salt or solvate thereof, for 21 consecutive days followed by seven consecutive days of rest from administration of the compound, and; (b) 40 mg per day of dexamethasone on days 1 though 4 in the 28 day cycle, wherein the patient has received previous therapy for multiple myeloma.",After,Yes,https://patents.google.com/patent/US8530498B1/en?oq=US+8530498B1
Revlimid,"US 8614328B2
",Celgene,Multiple Myeloma,Small Molecule,51,3/20/2007,3/1/2012,12/24/2013,3/19/2028,Active,Derivative,The patent claims cover analogs of lenalidomide. ,After,No,https://patents.google.com/patent/US8614328B2/en?oq=US+8614328B2
Revlimid,"US 8618136B2
",Celgene,Multiple Myeloma,Small Molecule,9,11/6/2002,3/8/2006,12/31/2013,2/28/2026,Active,Method of Treatment,The patent claims cover a method of treating myelofibrosis with myeloid metaplasia with an analog of thalidomide/lenalidomide. ,After,No,https://patents.google.com/patent/US8618136B2/en?oq=US+8618136B2
Revlimid,US 8623384,Celgene,Multiple Myeloma,Small Molecule,6,5/17/2002,5/8/2013,1/7/2014,5/15/2023,Active,Method of Treatment,"The patent claims cover  a method of treating acute myelogenous leukemia in a human, which comprises administering for a period of time, followed by a rest for a period of time, and repeating this sequential administration, to a human having acute myelogenous leukemia escalating doses of  lenalidomide (Revlimid)wherein a starting dose is between about 2.5 mg/day and about 25 mg/day, and a maximum dose is between about 25 mg/day and about 75 mg/day.
",After,No,https://patents.google.com/patent/US8623384B2/en?oq=US+8623384
Revlimid,US 8632787,Celgene,Multiple Myeloma,Small Molecule,6,5/17/2002,12/2/2011,1/21/2014,5/15/2023,Active,Method of Treatment,"The patent claims cover a method of treating a patient having acute myeloid leukemia, which comprises (a) administering to said patient a therapeutically effective amount of cytarabine and from about 5 mg per day to about 25 mg per day of lenalidomide (Revlimid) or a pharmaceutically acceptable salt, or solvate thereof wherein lenalidomide (Revlimid) is administered for 21 days followed by a period of rest and (b) repeating step (a).",After,No,https://patents.google.com/patent/US8632787B2/en?oq=US+8632787
Revlimid,US 8648095B2,Celgene,Multiple Myeloma,Small Molecule,6,5/17/2002,6/5/2012,2/11/2014,5/15/2023,Active,Method of Treatment,"The patent claims cover a method of treating multiple myeloma, which comprises cyclically administering to a patient having multiple myeloma: (a) about 1 to about 50 mg per day of lenalidomide (Revlimid) or a pharmaceutically acceptable salt, solvate or stereoisomer thereof for 21 consecutive days followed by seven consecutive days of rest from administration of said compound in a 28 day cycle, and (b) a therapeutically effective amount of dexamethasone.",After,Yes,https://patents.google.com/patent/US8648095B2/en?oq=US+8648095B2
Revlimid,US 8673939B2,Celgene,Multiple Myeloma,Small Molecule,6,5/17/2002,3/1/2013,3/18/2014,5/15/2023,Active,Method of Treatment, The patent claims cover a method of treating multiple  myeloma with close analog of thalidomide/lenalidomide.,After,No,https://patents.google.com/patent/US8673939B2/en?oq=US+8673939B2
Revlimid,US 8722647B2,Celgene,Multiple Myeloma,Small Molecule,6,5/17/2002,5/30/2012,5/13/2014,5/15/2023,Active,Method of Treatment, The patent claims cover a method of treating amyloidosis with an analog of thalidomide/lenalidomide,After,No,https://patents.google.com/patent/US8722647B2/en?oq=US+8722647B2
Revlimid,US 8722705B2,Celgene,Multiple Myeloma,Small Molecule,6,5/17/2002,7/15/2013,5/13/2014,5/15/2023,Active,Method of Treatment,"The patent claims cover a method of treating diffuse large B-cell lymphoma, which comprises administering to a human having diffuse large B-cell lymphoma
(a) from about 5 to about 50 mg per day of  lenalidomide (Revlimid) or a pharmaceutically acceptable salt, solvate or stereoisomer thereof; (b) a therapeutically effective amount of rituximab; and (c) a therapeutically effective amount of one or more additional active agents.
",After,No,https://patents.google.com/patent/US8722705B2/en?oq=US+8722705B2
Revlimid,US 8735428B2,Celgene,Multiple Myeloma,Small Molecule,6,5/17/2002,3/1/2013,5/27/2014,5/15/2023,Active,Method of Treatment,The patent claims cover a method of treating multiple myeloma with a close analog of thalidomide/lenalidomide,After,No,https://patents.google.com/patent/US8735428B2/en?oq=US+8735428B2
Revlimid,US 8759375B2,Celgene,Multiple Myeloma,Small Molecule,6,5/17/2002,1/14/2013,6/24/2014,5/15/2023,Active,Method of Treatment,The patent claims cover a method of treating multiple myeloma with a close analog of thalidomide/lenalidomide,After,No,https://patents.google.com/patent/US8759375B2/en?oq=US+8759375B2
Revlimid,US 8822499B2,Celgene,Multiple Myeloma,Small Molecule,6,9/4/2003,9/22/2011,9/2/2014,9/3/2024,Active,Crystalline,The patent claims cover a solid polymorphic mixture that is primarily the dihydrate form of lenalidomide,After,No,https://patents.google.com/patent/US8822499B2/en?oq=US+8822499B2
Revlimid,US 9050324,Celgene,Multiple Myeloma,Small Molecule,6,5/17/2002,3/25/2014,6/9/2015,5/15/2023,Active,Method of Treatment,"The patent claims cover a method of treating amyloidosis, which comprises administering to a patient having amyloidosis: (a) from about 1 mg to about 50 mg per day of lenalidomide (Revlimid) or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, and (b) a therapeutically effective amount of dexamethasone.",After,No,https://patents.google.com/patent/US9050324B2/en?oq=US+9050324
Revlimid,US 9056103B2,Celgene,Multiple Myeloma,Small Molecule,6,5/17/2002,12/31/2013,6/16/2015,5/15/2023,Active,Method of Treatment,"The patent claims cover a method of treating method of treating leukemia, which comprises administering to a patient having leukemia escalating doses of lenalidomide (Revlimid) or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein a starting dose is between about 1 mg per day and about 10 mg per day, and a maximum dose is between about 10 mg per day wherein the lenalidomide (Revlimid) or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof is administered for 21 days followed by seven days rest in a 28 day cycle, and wherein the leukemia is chronic lymphocytic leukemia.",After,No,https://patents.google.com/patent/US9056103B2/en?oq=US+9056103B2
Revlimid,US 9101621B2,Celgene,Multiple Myeloma,Small Molecule,6,5/17/2002,4/17/2014,8/11/2015,5/15/2023,Active,Method of Treatment,"The patent claims cover a method of treating multiple myeloma, which comprises administering to a patient having multiple myeloma about 1 to about 50 mg per day oflenalidomide (Revlimid) or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein the patient has previously received stem cell transplantation.",After,Yes,https://patents.google.com/patent/US9101621B2/en?oq=US+9101621B2
Revlimid,US 9101622B2,Celgene,Multiple Myeloma,Small Molecule,6,5/17/2002,9/10/2014,8/11/2015,5/15/2023,Active,Method of Treatment,"The patent claims cover a method of treating multiple myeloma, which comprises administering in a 28 day cycle to a patient having multiple myeloma: (a) about 1 to about 50 mg per day of lenalidomide (Revlimid) or a pharmaceutically acceptable salt, solvate or stereoisomer thereof for 21 consecutive days followed by seven consecutive days of rest from administration of said compound, and (b) a therapeutically effective amount of dexamethasone during such 28 day cycle, wherein the patient has not received previous treatment for multiple myeloma.",After,Yes,https://patents.google.com/patent/US9101622B2/en?oq=US+9101622B2
Revlimid,US 9155730B2,Celgene,Multiple Myeloma,Small Molecule,6,5/17/2002,3/26/2014,10/13/2015,5/15/2023,Active,Method of Treatment,"The patent claims cover a method of treating non-Hodgkin's lymphoma, which comprises (a) administering to a patient having non-Hodgkin's lymphoma from about 1 to about 50 mg per day of lenalidomide (Revlimid) or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, and a therapeutically effective amount of a second active agent; followed by(b) administering to the patient about 1 to about 50 mg per day of the compound, wherein the non-Hodgkin's lymphoma is follicular lymphoma.",After,Yes,https://patents.google.com/patent/US9155730B2/en?oq=US+9155730B2
Revlimid,"US 9181216B2
",Celgene,Multiple Myeloma,Small Molecule,51,3/20/2007,11/18/2013,11/10/2015,3/19/2028,Active,Derivative,The patent claims cover analogs of lenalidomide. ,After,No,https://patents.google.com/patent/US9181216B2/en?oq=US+9181216B2
Revlimid,"US 9192662
",Celgene,Multiple Myeloma,Small Molecule,46,1/29/2008,1/29/2009,11/24/2015,10/13/2033,Active,Method of Treatment,"The patent claims cover a method of treating or managing a disease associated with CD59 deficiency comprising administering to a patient a therapeutically effective amount of an immunomodulatory compound, wherein the immunomodulatory compound is lenalidomide and wherein the disease or disorder is paroxysmal nocturnal hemoglobinuria.",After,No,https://patents.google.com/patent/US9192662B2/en?oq=US+9192662
Revlimid,US 9283215B2,Celgene,Multiple Myeloma,Small Molecule,6,5/17/2002,3/7/2014,3/15/2016,5/15/2023,Active,Method of Treatment,"The patent claims cover a method of treating multiple myeloma, which comprises administering to a patient having multiple myeloma (a) about 1 to about 5 mg per day of lenalidomide (Revlimid) or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, and (b) a therapeutically effective amount of an antibody, wherein the compound is administered in one or more cycles, each of which comprises administering the compound for a period of time followed by a period of rest, wherein the multiple myeloma is relapsed, refractory, or relapsed and refractory.",After,No,https://patents.google.com/patent/US9283215B2/en?oq=US+9283215B2
Revlimid,US 9353080B2,Celgene,Multiple Myeloma,Small Molecule,6,9/4/2003,9/22/2011,5/31/2016,9/3/2024,Active,Crystalline,The patent claims cover  a polymorphic mixture of lenalidomide that contains at least 80% dihydrate and less than 20% amorphous content. ,After,No,https://patents.google.com/patent/US9353080B2/en?oq=US+9353080B2
Revlimid,US 9365538,Celgene,Multiple Myeloma,Small Molecule,6,9/4/2003,1/14/2009,6/14/2016,1/1/2026,Active,Crystalline,The patent claims cover a polymorphic mixture containing less than 20% amorphous and more than 80% unsolvated (anhydrous) crystalline form. ,After,No,https://patents.google.com/patent/US9365538B2/en?oq=US+9365538
Revlimid,US 9371309B2,Celgene,Multiple Myeloma,Small Molecule,6,9/4/2003,9/22/2011,6/21/2016,9/3/2024,Active,Crystalline,The patent claims cover a polymorphic mixture containing less than 20% amorphous and more than 80% of a hemihydrate crystalline form. ,After,No,https://patents.google.com/patent/US9371309B2/en?oq=US+9371309B2
Revlimid,US 9393238B2,Celgene,Multiple Myeloma,Small Molecule,6,5/17/2002,12/8/2014,7/19/2016,5/15/2023,Active,Method of Treatment,"The patent claims cover a method of treating non-Hodgkin's lymphoma, which comprises administering to a patient having non-Hodgkin's lymphoma about 1 to about 50 mg per day of lenalidomide (Revlimid) or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, and a therapeutically effective amount of a second active agent wherein the non-Hodgkin's lymphoma is follicular lymphoma and the second active agent is an anticancer agent.",After,Yes,https://patents.google.com/patent/US9393238B2/en?oq=US+9393238B2
Revlimid,US 9498472B2,Celgene,Multiple Myeloma,Small Molecule,6,5/17/2002,6/3/2015,11/22/2016,5/15/2023,Active,Method of Treatment,"The patent claims cover a method of treating a acute myelogenous leukemia in a human, which comprises cyclically administering for 21 days followed by seven days rest in a 28 day cycle to a human having acute myelogenous leukemia a therapeutically effective amount of lenalidomide (Revlimid) or a pharmaceutically acceptable salt or solvate thereof at an amount of about 1 mg/day to about 50 mg/day.",After,No,https://patents.google.com/patent/US9498472B2/en?oq=US+9498472B2
Revlimid,US 9662321B2,Celgene,Multiple Myeloma,Small Molecule,6,5/17/2002,5/20/2016,5/30/2017,5/15/2023,Active,Method of Treatment,"The patent claims cover a method of treating multiple myeloma, which comprises administering in a 28 day cycle to a patient having multiple myeloma: (a) about 1 to about 50 mg per day of lenalidomide (Revlimid) or a pharmaceutically acceptable salt, solvate or stereoisomer thereof for 21 consecutive days followed by seven consecutive days of rest from administration of the compound, (b) a therapeutically effective amount of dexamethasone during the 28 day cycle, and (c) a therapeutically effective amount of a proteasome inhibitor during the 28 day cycle.",After,No,https://patents.google.com/patent/US9662321B2/en?oq=US+9662321B2
Revlimid,US 9808450B2,Celgene,Multiple Myeloma,Small Molecule,7,3/26/2013,3/25/2014,11/7/2017,3/25/2034,Active,Crystalline,"The patent claims cover a crystalline solid form comprising lenalidomideor a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, prodrug, or clathrate thereof; and (b) a coformer; wherein the coformer is benzoic acid, glycolic acid, hippuric acid, magnesium bromide, sodium lauryl sulfate, vanillic acid, or zinc chloride.
",After,No,https://patents.google.com/patent/US9808450B2/en?oq=US+9808450B2
Revlimid,"US 9920027B2
",Celgene,Multiple Myeloma,Small Molecule,51,3/20/2007,10/2/2015,3/20/2018,3/19/2028,Active,Derivative,The patent claims cover analogs of lenalidomide. ,After,No,https://patents.google.com/patent/US9920027B2/en?oq=US+9920027B2
Revlimid,US RE46639E,Celgene,Multiple Myeloma,Small Molecule,51,3/20/2007,7/16/2014,12/19/2017,3/19/2028,Active,Derivative,The patent claims cover analogs of lenalidomide. ,After,No,https://patents.google.com/patent/USRE46639E1/en?oq=US+RE46639E
Revlimid,US10159675B2,Celgene,Multiple Myeloma,Small Molecule,30,12/2/2015,12/1/2016,12/25/2018,12/1/2036,Active,Method of Treatment,"The patent claims cover a method for treating , managing, and/or ameliorating lymphoma, while reducing an adverse effect associated with such treating, managing, and/or ameliorating, said method comprising administering to a patient in need thereof an effective amount of of a derivative of lenalidomide and lenalidomide.",After,No,https://patents.google.com/patent/US10159675B2/en?oq=US10159675B2
Revlimid,US10206914,Celgene,Multiple Myeloma,Small Molecule,6,5/17/2002,1/3/2017,2/19/2019,5/15/2023,Active,Method of Treatment,"The patent claims cover a method of treating multiple myeloma, the method comprising administering to a patient having multiple myeloma about 1 to about 50 mg per day of lenalidomide (Revlimid) or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein the patient has previously received hematopoietic stem cell transplantation.",After,No,https://patents.google.com/patent/US10206914B2/en?oq=US10206914
Revlimid,US10338077B2,Celgene,Multiple Myeloma,Small Molecule,37,6/2/2015,6/1/2016,7/2/2019,7/21/2036,Active,Method of Treatment,"The patent claims cover a method of treating a cancer with lenalidomide in a subject, comprising: (a) obtaining a sample from the subject;
(b) measuring mRNA level of cereblon (CRBN); (c) measuring mRNA level of IKZF1; (d) determining the ratio of the mRNA level of CRBN to the mRNA level of IKZF1; and
(e) diagnosing the subject as being likely to be responsive to lenalidomide if the ratio of the mRNA level of CRBN to the mRNA level of IKZF1 is higher than 3;
(f) administering lenalidomide to the subject diagnosed as being likely to be responsive to lenalidomide, wherein the cancer is an Adult T-cell Leukemia (ATL).",After,No,https://patents.google.com/patent/US10338077B2/en?oq=US10338077B2
Revlimid,US10385037B2,Celgene,Multiple Myeloma,Small Molecule,51,3/20/2007,2/2/2018,8/20/2019,3/24/2028,Active,Derivative,The patent claims cover analogs of lenalidomide. ,After,No,https://patents.google.com/patent/US10385037B2/en?oq=US10385037B2
Revlimid,US10589915B2,Celgene,Multiple Myeloma,Small Molecule,71,2/24/2016,2/22/2017,3/17/2020,11/12/2037,Active,Packaging,"The patent claims cover ackaging for use in distributing a pharmaceutical product to respective patients in a plurality of jurisdictions, a first jurisdiction of the plurality of jurisdictions having a different labeling requirement for the pharmaceutical product than a second jurisdiction of the plurality of jurisdictions, wherein the pharmaceutical product includes pomalidomide, lenalidomide, or other commercial product.",After,No,https://patents.google.com/patent/US10589915B2/en?oq=US10589915B2
Revlimid,US10590104B2,Celgene,Multiple Myeloma,Small Molecule,6,9/4/2003,11/26/2018,3/17/2020,9/3/2024,Active,Crystalline,The patent claims cover a crystalline form of lenalidomide. ,After,No,https://patents.google.com/patent/US10590104B2/en?oq=US10590104B2
Revlimid,US10689708B2,Celgene,Multiple Myeloma,Small Molecule,33,9/25/2015,9/22/2016,6/23/2020,9/22/2036,Active,Method of Diagnosis,The patent claims cover a method for treating a human diffuse large B-cell lymphoma (DLBCL) with lenalidomide.,After,No,https://patents.google.com/patent/US10689708B2/en?oq=US10689708B2
Revlimid,US10969381B2,Celgene,Multiple Myeloma,Small Molecule,64,5/23/2018,5/22/2019,4/6/2021,5/22/2039,Active,Biomarker,"The patent claims cover a method of identifying a subject having cancer who is likely to be responsive to a treatment compound, predicting responsiveness of a subject having or suspected of having cancer to a treatment compound, or monitoring efficacy of a treatment compound in treating cancer in a subject.",After,No,https://patents.google.com/patent/US10969381B2/en?oq=US10969381B2
Revlimid,US10996215B2,Celgene,Multiple Myeloma,Small Molecule,40,12/6/2013,4/5/2018,5/4/2021,1/16/2035,Active,Biomarker,The patent claims cover a method of determining whether a compound is effective as an immunomodulatory compound (lenalidomide) or anti-tumor agent.,After,No,https://patents.google.com/patent/US10996215B2/en?oq=US10996215B2
Revlimid,US11116782B2,Celgene,Multiple Myeloma,Small Molecule,4,10/15/2002,5/22/2019,9/14/2021,4/11/2023,Active,Method of Treatment,"The patent claims cover a method of treating myelodysplastic syndromes (MDS), comprising administering to a patient in need of such treatment about 1 to about 50 mg per day of  lenalidomide (Revlimid) or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof and a therapeutically effective amount of cytidine analog.
 ",After,No,https://patents.google.com/patent/US11116782B2/en?oq=US11116782B2
Revlimid,US11136306B2,Celgene,Multiple Myeloma,Small Molecule,6,9/4/2003,3/2/2020,10/5/2021,9/3/2024,Active,Crystalline,The patent claims cover a crystalline form of tlenalidomide with 3 X-ray diffraction peaks and endotherms in the DSC as 122C and 270C.,After,No,https://patents.google.com/patent/US11136306B2/en?oq=US11136306B2
Revlimid,US2002173658,Celgene,Multiple Myeloma,Small Molecule,1,5/30/1997,5/10/2002,11/21/2002,,Abandoned,Derivative,The application claimed derivative compounds and prodrugs related to thalidomide/lenalidomide.,Before,No,https://patents.google.com/patent/US20020173658A1/en?oq=US2002173658
Revlimid,US20030045552,Celgene,Multiple Myeloma,Small Molecule,27,12/27/2000,10/5/2001,3/6/2003,,Abandoned,Derivative,The application claimed derivative compounds related to lenalidomide.,Before,No,https://patents.google.com/patent/US20030045552A1/en?oq=US20030045552
Revlimid,US20040091455,Celgene,Multiple Myeloma,Small Molecule,10,10/31/2002,10/30/2003,5/13/2004,,Abandoned,Method of Treatment,"The application claimed a method of treating  preventing or managing macular degeneration, which comprises administering to a patient in need of such treatment, prevention or management a therapeutically or prophylactically effective amount of an immunomodulatory compound (lenalidomide), or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.",Before,No,https://patents.google.com/patent/US20040091455A1/en?oq=US20040091455
Revlimid,US20050100529,Celgene,Multiple Myeloma,Small Molecule,11,11/6/2003,11/3/2004,5/12/2005,,Abandoned,Method of Treatment,"The application claimed a method of treating, preventing or managing an asbestos-related disease or disorder, which comprises administering to a patient in need of such treatment, prevention or management a therapeutically or prophylactically effective amount of an immunomodulatory compound (lenalidomide), or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.",Before,No,https://patents.google.com/patent/US20050100529A1/en?oq=US20050100529
Revlimid,US20050143344,Celgene,Multiple Myeloma,Small Molecule,14,12/30/2003,12/23/2004,6/30/2005,,Abandoned,Method of Treatment,"The application claimed a method of treating or preventing a central nervous system disorder, which comprises administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of an immunomodulatory compound (lenalidomide), or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof.",Before,No,https://patents.google.com/patent/US20050143344A1/en?oq=US20050143344
Revlimid,US20050143420,Celgene,Multiple Myeloma,Small Molecule,13,12/2/2003,12/2/2004,6/30/2005,,Abandoned,Method of Treatment,"The application claimed a method of treating an individual having a hemoglobinopathy or an anemia, said method comprising administering to said individual an immunomodulatory compound (close analogs of lenalidomide) in an amount and for a time sufficient to reduce one or more symptoms of said hemoglobinopathy.",Before,No,https://patents.google.com/patent/US20050143420A1/en?oq=US20050143420
Revlimid,US20050148034,Celgene,Multiple Myeloma,Small Molecule,43,4/12/2002,4/14/2003,7/7/2005,,Abandoned,Biomarker,"The application claimed a method of identifying a modulator of angiogensis comprising: (a) culturing a plurality of stem cells in the presence of a test compound, for a time and under conditions suitable for the growth endothelial cells; and (b) comparing the amount of microvessel outgrowth from said stem cells in the presence of said test compound as compared to a control amount of microvessel outgrowth, wherein if said microvessel outgrowth is greater or less than said control level of microvessel outgrowth, the test compound is identified as a modulator of angiogenesis.",Before,No,https://patents.google.com/patent/US20050148034A1/en?oq=US20050148034
Revlimid,US20050203142,Celgene,Multiple Myeloma,Small Molecule,12,10/24/2002,10/23/2004,9/15/2005,,Abandoned,Method of Treatment,"The application claimed a method of treating, preventing, modifying or managing pain, which comprises administering to a patient in need of such treatment, prevention, modification or management a therapeutically or prophylactically effective amount of an immunomodulatory compound (lenalidomide), or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.",Before,No,https://patents.google.com/patent/US20050203142A1/en?oq=US20050203142
Revlimid,US20050214328,Celgene,Multiple Myeloma,Small Molecule,15,3/22/2004,3/22/2005,9/29/2005,,Abandoned,Method of Treatment,"The application claimed a method of treating , preventing or managing a skin disease or disorder characterized by overgrowth of the epidermis, keratosis, acne that does not comprise acne rosacea, or a wrinkle, which comprises administering to a patient in need of such treatment, prevention or management a therapeutically or prophylactically effective amount of an immunomodulatory compound (lenalidomide), or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.",Before,No,https://patents.google.com/patent/US20050214328A1/en?oq=US20050214328
Revlimid,US20050222209,Celgene,Multiple Myeloma,Small Molecule,16,4/1/2004,3/30/2005,10/6/2005,,Abandoned,Method of Treatment,"The application claimed a method of treating or preventing dysfunctional sleep, which comprises administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of an immunomodulatory compound (lenalidomide) or a pharmaceutically acceptable salt, solvate or stereoisomer thereof.",Before,No,https://patents.google.com/patent/US20050222209A1/en?oq=US20050222209
Revlimid,US20050239842,Celgene,Multiple Myeloma,Small Molecule,17,4/23/2004,4/21/2005,10/27/2005,,Abandoned,Method of Treatment,"The application claimed a method of treating preventing or managing pulmonary hypertension, which comprises administering to a patient in need of such treatment, prevention or management a therapeutically or prophylactically effective amount of an immunomodulatory compound (lenalidomide), or a pharmaceutically acceptable salt, solvate or stereoisomer thereof.",Before,No,https://patents.google.com/patent/US20050239842A1/en?oq=US20050239842
Revlimid,US20060122228,Celgene,Multiple Myeloma,Small Molecule,18,11/23/2004,11/18/2005,6/8/2006,,Abandoned,Method of Treatment,"The application claimed a method of treating , preventing or managing a central nervous system injury and related syndrome, which comprises administering to a patient in need thereof a therapeutically or prophylactically effective amount of an immunomodulatory compound (lenalidomide), or a pharmaceutically acceptable salt, solvate or stereoisomer thereof.",Before,No,https://patents.google.com/patent/US20060122228A1/en?oq=US20060122228
Revlimid,US2006069065,Celgene,Multiple Myeloma,Small Molecule,6,5/17/2002,11/4/2004,3/30/2006,,Abandoned,Method of Treatment,The application claimed a method of treating scleroderma with a close analog of thalidomide/lenalidomide,Before,No,https://patents.google.com/patent/US20060069065A1/en?oq=US2006069065
Revlimid,US2006105993,Celgene,Multiple Myeloma,Small Molecule,6,5/17/2002,1/4/2006,5/18/2006,,Abandoned,Method of Treatment,"The application claimed a method of treating lung cancer, which comprises administering to a patient in need thereof a therapeutically effective amount of lenalidomide (Revlimid) or a pharmaceutically acceptable salt, solvate or stereoisomer thereof.
",After,No,https://patents.google.com/patent/US20060105993A1/en?oq=US2006105993
Revlimid,US2006172970,Celgene,Multiple Myeloma,Small Molecule,6,5/17/2002,3/7/2006,8/3/2006,,Abandoned,Method of Treatment,The application claimed a method of treating lung cancer with a close analog of thalidomide/lenalidomide.,After,No,https://patents.google.com/patent/US20060172970A1/en?oq=US2006172970
Revlimid,US20070066512,Celgene,Multiple Myeloma,Small Molecule,47,9/12/2005,9/11/2006,3/22/2007,,Abandoned,Method of Treatment,"The application claimed a method of treating, managing or preventing a disorder associated with a hypoleptinemic state, or symptoms thereof, which comprises administering to a patient in need of such treatment, management or prevention a therapeutically or prophylactically effective amount of an immunomodulatory compound (lenalidomide), or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
",After,No,https://patents.google.com/patent/US20070066512A1/en?oq=US20070066512
Revlimid,US2007299020,Celgene,Multiple Myeloma,Small Molecule,6,5/17/2002,7/27/2007,12/27/2007,,Abandoned,Method of Treatment,The application claimed a method of treating ovarian cancer with a close analog of thalidomide/lenalidomide.,After,No,https://patents.google.com/patent/US20070299020A1/en?oq=US2007299020
Revlimid,US20080038263,Celgene,Multiple Myeloma,Small Molecule,5,8/3/2006,8/1/2007,2/14/2008,,Abandoned,Method of Treatment,"The application claimed a method of treating mantle cell lymphoma in a human, which comprises administering to a human in need thereof a therapeutically effective amount of lenalidomide.",After,No,https://patents.google.com/patent/US20080038263A1/en?oq=US20080038263
Revlimid,US20080051431,Celgene,Multiple Myeloma,Small Molecule,62,5/26/2006,5/24/2007,2/28/2008,,Abandoned,Formulation / Combination,"The application claimed a composition comprising an effective amount of an immunomodulatory compound (lenalidomide), or a pharmaceutically acceptable salt thereof, and an effective amount of valproic acid, hydroxyurea or trichostatin A, or a pharmaceutically acceptable salt thereof.",After,No,https://patents.google.com/patent/US20080051431A1/en?oq=US20080051431
Revlimid,US20080201173,Celgene,Multiple Myeloma,Small Molecule,28,12/5/2006,12/4/2007,8/21/2008,,Abandoned,Method of Delivery,"The application claimed a method  for delivering a drug in patient in need thereof, while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug, wherein prescriptions for the drug are filled only after a computer readable storage medium has been consulted to assure that a prescriber is registered in the medium and qualified to prescribe the drug, a pharmacy is registered in the medium and qualified to fill the prescription for the drug, and the patient is registered in the medium, the method comprising the steps of: a. defining a plurality of patient risk groups based upon a predefined set of risk parameters for the drug;
b. defining a set of information to be obtained from the patient, which information is probative of the risk that such adverse side effect is likely to occur if the drug is taken by the patient; c. in response to the information set, assigning the patient to at least one of the risk groups; d. entering the risk group assignment in the medium before the patient is approved to receive the drug; and e. registering in the computer readable storage medium a spouse of the patient, designated family member, or guardian to assist the patient in (1) taking the drug consistent with prescription guidelines; (2) preventing diversion of the drug; (3) returning the drug if the drug is no longer suitable for the patient; and/or (4) returning the drug to if the patient expires prior to using all of the drug.  This patent relates to Celgene's RevAssist® program.
",After,No,https://patents.google.com/patent/US20080201173A1/en?oq=US20080201173
Revlimid,US2008138295,Celgene,Multiple Myeloma,Small Molecule,6,5/17/2002,2/11/2008,6/12/2008,,Abandoned,Method of Treatment,The application claimed a method of treating Bechet's disease with a derivative compound related to thalidomide/lenalidomide.,After,No,https://patents.google.com/patent/US20080138295A1/en?oq=US2008138295
Revlimid,US2008206193,Celgene,Multiple Myeloma,Small Molecule,6,5/17/2002,4/25/2008,8/8/2008,,Abandoned,Method of Treatment,"The application claimed a method of treating thyroid cancer which comprises administering to a patient in need thereof a therapeutically effective amount of 
lenalidomide (Revlimid) or a pharmaceutically acceptable salt, solvate or stereoisomer thereof.",After,No,https://patents.google.com/patent/US20080206193A1/en?oq=US2008206193
Revlimid,US2008219948,Celgene,Multiple Myeloma,Small Molecule,6,5/17/2002,5/8/2008,9/11/2008,,Abandoned,Method of Treatment,"The application claimed a method of treating a method of treating Behcet's disease, which comprises administering to a patient having Behcet's disease from about 5 to about 50 mg per day of lenalidomide (Revlimid) or a pharmaceutically acceptable salt, solvate or stereoisomer thereof.

",After,No,https://patents.google.com/patent/US20080219948A1/en?oq=US2008219948
Revlimid,US2008219949,Celgene,Multiple Myeloma,Small Molecule,6,5/17/2002,5/8/2008,9/11/2008,,Abandoned,Method of Treatment,"The application claimed a method of treating Behcet's disease, which comprises administering to a patient having Behcet's disease from about 5 to about 50 mg per day of lenalidomide (Revlimid) or a pharmaceutically acceptable salt, solvate or stereoisomer thereof.",After,No,https://patents.google.com/patent/US20080219949A1/en?oq=US2008219949
Revlimid,US2008286232,Celgene,Multiple Myeloma,Small Molecule,6,5/17/2002,5/8/2008,11/20/2008,,Abandoned,Method of Treatment,"The application claimed a method of treating sarcoma, which comprises administering to a patient having sarcoma a therapeutically effective amount of lenalidomide (Revlimid) or a pharmaceutically acceptable salt, solvate or stereoisomer thereof.",After,No,https://patents.google.com/patent/US20080286232A1/en?oq=US2008286232
Revlimid,US2008317709,Celgene,Multiple Myeloma,Small Molecule,6,5/17/2002,4/19/2008,8/19/2008,,Abandoned,Method of Treatment,The application claimed a method of treating head cancer with a close analog of thalidomide/lenalidomide.,After,No,https://patents.google.com/patent/US20080317709A1/en?oq=US2008317709
Revlimid,US20090068210,Celgene,Multiple Myeloma,Small Molecule,45,7/9/2007,7/8/2008,3/12/2009,,Abandoned,Method of Treatment,The application claimed a method of providing an iNKT cell responsive to multiple myeloma comprising: (i) isolating an iNKT cell from a patient having multiple myeloma; and (ii) incubating the isolated iNKT cell with an immunomodulatory compound (lenalidomide),After,No,https://patents.google.com/patent/US20090068210A1/en?oq=US20090068210
Revlimid,US2009010877,Celgene,Multiple Myeloma,Small Molecule,6,5/17/2002,4/22/2008,1/8/2009,,Abandoned,Method of Treatment,"The application claimed a method of treating prostate cancer, which comprises administering to a patient having prostate cancer about 5 to about 50 mg per day oflenalidomide (Revlimid) or a pharmaceutically acceptable salt, solvate or stereoisomer thereof.",After,No,https://patents.google.com/patent/US20090010877A1/en?oq=US2009010877
Revlimid,US20090232776,Celgene,Multiple Myeloma,Small Molecule,23,11/8/2007,11/7/2008,9/17/2009,,Abandoned,Method of Treatment,"The application claimed a method of treating managing or preventing a disorder associated with endothelial dysfunction, said method comprising: 1) contacting an effective amount of an immunomodulatory compound (analog of lenalidomide), or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, with an endothelial progenitor cell; and 2) administering said endothelial progenitor cell contacted with an immunomodulatory compound, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, to a patient.
",After,No,https://patents.google.com/patent/US20090232776A1/en?oq=US20090232776
Revlimid,US2009123416,Celgene,Multiple Myeloma,Small Molecule,6,5/17/2002,1/15/2009,5/14/2009,,Abandoned,Method of Treatment,"The application claimed a method of treating bladder cancer, which comprises administering to a patient having bladder cancer about 5 to about 50 mg per day oflenalidomide (Revlimid) or a pharmaceutically acceptable salt, solvate or stereoisomer thereof.",After,No,https://patents.google.com/patent/US20090123416A1/en?oq=US2009123416
Revlimid,US20100098657,Celgene,Multiple Myeloma,Small Molecule,21,12/27/2007,12/22/2008,4/22/2010,,Abandoned,Method of Treatment,"The application claimed a method of treating cancer in a patient, comprising administering an immunomodulatory compound (analog of lenalidomide) and immunoglobulin G (IgG).
",After,No,https://patents.google.com/patent/US20100098657A1/en?oq=US20100098657
Revlimid,US2010063094,Celgene,Multiple Myeloma,Small Molecule,6,5/17/2002,11/18/2009,3/11/2010,,Abandoned,Method of Treatment,"The application claimed a method of treating colorectal cancer, which comprises administering to a patient having colorectal cancer about 5 to about 50 mg per day of lenalidomide (Revlimid) or a pharmaceutically acceptable salt, solvate or stereoisomer thereof.",After,No,https://patents.google.com/patent/US20100063094A1/en?oq=US2010063094
Revlimid,US2010099711,Celgene,Multiple Myeloma,Small Molecule,6,5/17/2002,12/17/2009,4/22/2010,,Abandoned,Method of Treatment, The application claimed a method of treating cancer with a close analog of thalidomide/lenalidomide,After,No,https://patents.google.com/patent/US20100099711A1/en?oq=US2010099711
Revlimid,US2010129363,Celgene,Multiple Myeloma,Small Molecule,6,5/17/2002,11/18/2009,5/27/2010,,Abandoned,Method of Treatment,The application claimed a method of treating chronic lymphocytic leukemia with a derivative of thalidomide/lenalidomide.,After,No,https://patents.google.com/patent/US20100129363A1/en?oq=US2010129363
Revlimid,US2011015228,Celgene,Multiple Myeloma,Small Molecule,6,9/4/2003,9/27/2010,1/20/2011,,Abandoned,Formulation / Combination,The application claimed a composition comprising amorphouslenalidomide,After,No,https://patents.google.com/patent/US20110015228A1/en?oq=US2011015228
Revlimid,US2011275672,Celgene,Multiple Myeloma,Small Molecule,6,5/15/2003,3/28/2011,11/10/2011,,Abandoned,Method of Treatment,"The application claimed a method of treating  a blood-borne tumor, which comprises administering to a patient having the blood-borne tumor a therapeutically effective amount of a hydrated crystalline form of lenalidomide (Revlimid).  ",After,No,https://patents.google.com/patent/US20110275672A1/en?oq=US2011275672
Revlimid,US20120053159,Celgene,Multiple Myeloma,Small Molecule,50,2/11/2009,2/9/2010,3/1/2012,,Abandoned,Derivative,The application claimed  deuterated analogs of lenalidomide.,After,No,https://patents.google.com/patent/US20120053159A1/en?oq=US20120053159
Revlimid,US20120065999,Celgene,Multiple Myeloma,Small Molecule,29,3/9/2009,3/9/2010,3/15/2012,,Abandoned,Method of Delivery,"The application claimed a prescription filling assistance device in communication with a registration center for managing master information on (1) hospitals and/or physicians, (2) patients, (3) updates of pharmacies and/or pharmacists, and (4) histories of filling prescriptions for one or more drugs to the patients, wherein the master information is registered in association with filling prescriptions for the particular drugs.  This patent relates to Celgene's RevAssist® program.
",After,No,https://patents.google.com/patent/US20120065999A1/en?oq=US20120065999
Revlimid,US2012035145,Celgene,Multiple Myeloma,Small Molecule,6,5/17/2002,10/19/2011,2/9/2012,,Abandoned,Method of Treatment,The application claimed a method of treating multiple myeloma in a human patient which comprises:(1) induction therapy which comprises sequentially or simultaneously administering to a patient having multiple myeloma: (a) melphalan: (b) prednisone; and (c) about 5 to about 25 mg per day of lenalidomide (Revlimid) or a pharmaceutically acceptable salt thereof: (2) followed by maintenance therapy which comprises administering to the patient 5 to about 25 mg per day of the compound or the pharmaceutically acceptable salt thereof until disease progression or unacceptable toxicity.,After,No,https://patents.google.com/patent/US20120035145A1/en?oq=US2012035145
Revlimid,US2013030021,Celgene,Multiple Myeloma,Small Molecule,1,7/24/1996,9/18/2012,1/31/2013,,Abandoned,Derivative,The application claimed a Markush group of derivative compounds related to thalidomide/lenalidomide.,After,No,https://patents.google.com/patent/US20130030021A1/en?oq=US2013030021
Revlimid,US2013046554,Celgene,Multiple Myeloma,Small Molecule,3,10/23/2000,10/19/2012,2/21/2013,,Abandoned,Method of Delivery,"The application claimed a method of treating a male patient having a disease or condition responsive to a teratogenic drug comprising permitting prescriptions for the drug to be filled by a pharmacy only after the pharmacy has retrieved an approval code for the prescription, wherein the generation of the prescription approval code comprises the following steps: (a) via a computer readable storage medium, registering a prescriber and the pharmacy with a distributor of a teratogenic drug;
(b) determining whether the patient is able to understand and carry out instructions; (c) upon determination that the patient is able to carry out the instructions, providing verbal and written warnings of the hazard of taking the drug and exposing fetus to the drug; (d) further providing verbal and written warnings of the risk of possible contraception failure and of the need to use barrier contraception when having sexual intercourse with women of child bearing potential; (e) obtaining acknowledgement of said warnings from the patient; (f) via a computer readable storage medium, registering the patient with the distributor; and (g) upon obtaining the acknowledgement and registrations, generating via a computer readable storage medium the prescription approval code to be retrieved by the pharmacy before the prescription is filled; and (h) upon retrieving a prescription approval code, administering the drug to the patient. This patent relates to Celgene's RevAssist® program.
",After,Yes,https://patents.google.com/patent/US20130046554A1/en?oq=US2013046554
Revlimid,US20140031325,Celgene,Multiple Myeloma,Small Molecule,55,12/6/2010,12/5/2011,1/30/2014,,Abandoned,Method of Treatment,"The application claimed a method of treating or preventing multiple myeloma in a human, wherein the method comprises administering to a human in need thereof cyclin-dependent kinase (CDK) inhibitor and administering lenalidomide.",After,No,https://patents.google.com/patent/US20140031325A1/en?oq=US20140031325
Revlimid,US2014187584,Celgene,Multiple Myeloma,Small Molecule,1,7/24/1996,1/15/2014,7/3/2014,,Abandoned,Derivative,The application claimed a Markush group of derivative compounds related to thalidomide/lenalidomide.,After,No,https://patents.google.com/patent/US20140187584A1/en?oq=US2014187584
Revlimid,US2014271638,Celgene,Multiple Myeloma,Small Molecule,5,8/3/2006,5/30/2014,9/18/2014,,Abandoned,Method of Treatment,"The application claimed a method of treating mantle cell lymphoma in a human, which comprises administering to a human having mantle cell lymphoma from about 5 mg to about 50 mg of lenalidomide.",After,No,https://patents.google.com/patent/US20140271638A1/en?oq=US2014271638
Revlimid,US20150139979,Celgene,Multiple Myeloma,Small Molecule,60,11/19/2013,11/19/2013,5/21/2015,,Abandoned,Method of Treatment,"The application claimed a method of treating , stabilizing or lessening the severity or progression of a B-cell non-Hodgkin lymphoma comprising administering to a patient in need thereof an irreversible BTK inhibitor and lenalidomide, wherein the irreversible BTK inhibitor has not more than about 50% inhibition of a kinase selected from c-Kit, PDGFRa, RIPK2, HCK, EPHA6, LYN, CSK, LCK, ZAK/MLTK, LYN B, FRK/PTK5, FYN, BRAF, RIPK3, ARAF and SRMS, or combinations thereof.",After,No,https://patents.google.com/patent/US20150139979A1/en?oq=US20150139979
Revlimid,US2015094336,Celgene,Multiple Myeloma,Small Molecule,6,5/17/2002,12/9/2014,4/2/2015,,Abandoned,Method of Treatment,"The application claimed a method of treating  of managing or preventing a specific cancer, which comprises administering to a patient in need of such treatment, management or prevention a therapeutically or prophylactically effective amount of an immunomodulatory compound, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof.",After,No,https://patents.google.com/patent/US20150094336A1/en?oq=US2015094336
Revlimid,US2015190386,Celgene,Multiple Myeloma,Small Molecule,6,5/17/2002,3/19/2015,7/9/2015,,Abandoned,Method of Treatment,"The application claimed a method of treating  of managing or preventing a specific cancer, which comprises administering to a patient in need of such treatment, management or prevention a therapeutically or prophylactically effective amount of an immunomodulatory compound, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof.",After,No,https://patents.google.com/patent/US20150190386A1/en?oq=US2015190386
Revlimid,US2016008345,Celgene,Multiple Myeloma,Small Molecule,6,5/17/2002,9/24/2015,1/14/2016,,Abandoned,Method of Treatment,"The application claimed a method of treating  of managing or preventing a specific cancer, which comprises administering to a patient in need of such treatment, management or prevention a therapeutically or prophylactically effective amount of an immunomodulatory compound, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof.",After,No,https://patents.google.com/patent/US20160008345A1/en?oq=US2016008345
Revlimid,US2016009684,Celgene,Multiple Myeloma,Small Molecule,6,9/4/2003,8/14/2015,1/14/2016,,Abandoned,Method of Production / Process,The application claimed  a method for preparing crystalline Form A (anhydrous) of lenalidomide,After,No,https://patents.google.com/patent/US20160009684A1/en?oq=US2016009684
Revlimid,US20160312292,Celgene,Multiple Myeloma,Small Molecule,39,12/6/2013,12/5/2014,10/27/2016,,Abandoned,Method of Diagnosis,The application claimed a method for predicting the clinical sensitivity of a diffuse large B-cell lymphoma (DLBCL) to treatment with lenalidomide.,After,No,https://patents.google.com/patent/US20160312292A1/en?oq=US20160312292
Revlimid,US20160313300,Celgene,Multiple Myeloma,Small Molecule,40,12/6/2013,12/5/2014,10/27/2016,,Abandoned,Biomarker,"The application claimed a method of determining whether a compound is immunomodulatory (lenalidomide), comprising: (a) contacting a first cell with the compound;
wherein optionally the cell is a cancer cell, or wherein optionally the cell is an immune cell; (b) obtaining a first sample from the first cell from step (a);
(c) determining the level of a biomarker in the first sample, and (d) comparing the level of the biomarker from step (c) to the level of the same protein obtained from a reference sample, wherein a change in the biomarker level as compared to the reference sample is indicative of the efficacy of the compound as an immunomodulatory compound.",After,No,https://patents.google.com/patent/US20160313300A1/en?oq=US20160313300
Revlimid,US2016096818,Celgene,Multiple Myeloma,Small Molecule,1,7/24/1996,10/6/2015,4/7/2016,,Abandoned,Derivative,The application claimed a Markush group of derivative compounds related to thalidomide/lenalidomide.,After,No,https://patents.google.com/patent/US20160096818A1/en?oq=US2016096818
Revlimid,US20170038387,Celgene,Multiple Myeloma,Small Molecule,35,8/4/2015,8/3/2016,2/9/2017,,Abandoned,Method of Diagnosis,"The application claimed a method of identifying a subject having chronic lymphocytic leukemia (CLL) who is likely to be responsive to a treatment compound, predicting the responsiveness of a subject having or suspected of having CLL to a treatment compound, or treating CLL in a subject comprising: (a) obtaining a first sample and a second sample from the subject having or suspected of having CLL; (b) administering 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione (Compound A) to the first sample and administering lenalidomide to the second sample; (c) determining the level of a biomarker in the first sample and determining the level of the biomarker in the second sample, wherein the biomarker is selected from the group consisting of BCL2L1, GZMB, IGHM, IKZF1, IRF8, KLF13, LGALS9, MARCKS, NDE1, NFKBIE, PTK2B, SAMSN1, SELL, SLAMF1, SNX20, SOD2, TCF7, TRAF1, WIZ, ZBTB10, IKZF3, CD40, CR2, CTSS, GBP1, ISG20, SASH1, and SEMA7A;
(d) diagnosing the subject as being likely to be responsive to the treatment compound if the level of the biomarker in the first sample is different from the level of the biomarker in the second sample; and(e) administering a therapeutically effective amount of the treatment compound to the subject diagnosed to be likely to be responsive to the treatment compound; wherein the treatment compound is Compound A or lenalidomide.",After,No,https://patents.google.com/patent/US20170038387A1/en?oq=US20170038387
Revlimid,US20170157103,Celgene,Multiple Myeloma,Small Molecule,24,12/4/2015,11/30/2016,6/8/2017,,Abandoned,Method of Treatment,"The application claimed a method of treating or managing diffuse large B-cell lymphoma, comprising administering to a patient in need of such treatment or management a therapeutically effective amount of lenalidomide or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.",After,No,https://patents.google.com/patent/US20170157103A1/en?oq=US20170157103
Revlimid,US2017027923,Celgene,Multiple Myeloma,Small Molecule,5,8/3/2006,6/9/2016,2/2/2017,,Abandoned,Method of Treatment,"The application claimed a method of treating mantle cell lymphoma, which comprises administering to a patient having mantle cell lymphoma from about 5 mg to about 50 mg of lenalidomide and a therapeutically effective amount of a second active agent selected from a hematopoietic growth factor, a cytokine, an anticancer agent, an antibiotic, a cox-2 inhibitor, a corticosteroid, rituximab, or a combination thereof.",After,No,https://patents.google.com/patent/US20170027923A1/en?oq=US2017027923
Revlimid,US2017095464,Celgene,Multiple Myeloma,Small Molecule,6,5/17/2002,10/17/2016,4/6/2017,,Abandoned,Method of Treatment,"The application claimed a method of treating eukemia in a human, which comprises administering to a human in need thereof a therapeutically effective amount of lenalidomide (Revlimid).",After,No,https://patents.google.com/patent/US20170095464A1/en?oq=US2017095464
Revlimid,US2017121303,Celgene,Multiple Myeloma,Small Molecule,6,9/4/2003,10/20/2016,5/4/2017,,Abandoned,Formulation / Combination,The application claimed a  composition comprising both crystalline Form A (anhydrous) and amorphous lenalidomide,After,No,https://patents.google.com/patent/US20170121303A1/en?oq=US2017121303
Revlimid,US2017121304,Celgene,Multiple Myeloma,Small Molecule,6,9/4/2003,10/20/2016,5/4/2017,,Abandoned,Formulation / Combination,"The application claimed a composition comprising hemihydrate forms of lenalidomide, either amorphous or crystalline.",After,No,https://patents.google.com/patent/US20170121304A1/en?oq=US2017121304
Revlimid,US2017121305 ,Celgene,Multiple Myeloma,Small Molecule,6,9/4/2003,10/20/2016,5/4/2017,,Abandoned,Formulation / Combination,"The application claimed  a composition comprising dihydrate forms of lenalidomide, either amorphous or crystalline. ",After,No,https://patents.google.com/patent/US20170121305A1/en?oq=US2017121305+
Revlimid,US2018000808A1,Celgene,Multiple Myeloma,Small Molecule,7,3/26/2013,9/18/2017,1/4/2018,,Abandoned,Crystalline,"The application claimed a solid form comprising lenalidomide or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, prodrug, or clathrate thereof; and (b) a coformer.",After,No,https://patents.google.com/patent/US20180000808A1/en?oq=US2018000808A1
Revlimid,US2018072700,Celgene,Multiple Myeloma,Small Molecule,6,9/4/2003,11/3/2017,3/15/2018,,Abandoned,Method of Treatment,The application claimeda method of treating multiple myeloma with various crystalline forms and mixtures of crystalline and amorphous lenalidomide,After,No,https://patents.google.com/patent/US20180072700A1/en?oq=US2018072700
Revlimid,US2018207185A1,Celgene,Multiple Myeloma,Small Molecule,4,10/15/2002,3/20/2018,7/26/2018,,Abandoned,Method of Treatment,"The application claimed a method of treating a a myelodysplastic syndrome, which comprises administering to a patient having a myelodysplastic syndrome a therapeutically effective amount of 5-azacytidine, and a therapeutically effective amount of lenalidomide (Revlimid) or a pharmaceutically acceptable salt thereof.",After,No,https://patents.google.com/patent/US20180207185A1/en?oq=US2018207185A1
Revlimid,US20190219562,Celgene,Multiple Myeloma,Small Molecule,63,1/12/2018,1/10/2019,7/18/2019,,Pending,Method of Diagnosis,The application claims a method of screening a cereblon modifying compound (lenalidomide) for treating a disease or disorder.,After,No,https://patents.google.com/patent/US20190219562A1/en?oq=US20190219562
Revlimid,US2019374529A1,Celgene,Multiple Myeloma,Small Molecule,5,8/3/2006,8/21/2019,12/12/2019,,Abandoned,Method of Treatment,"The application claimed a method of treating mantle cell lymphoma in a human, which comprises administering to a human having mantle cell lymphoma from about 5 mg to about 50 mg of lenalidomide.",After,No,https://patents.google.com/patent/US20190374529A1/en?oq=US2019374529A1
Revlimid,US20200118646A1,Celgene,Multiple Myeloma,Small Molecule,70,10/10/2018,10/9/2019,4/16/2020,,Pending,Method of Treatment,"The application claims a method of predicting if a subject has an Activated B Cell-like (ABC) subtype of Diffuse Large B-Cell Lymphoma (DLBCL) comprising administering a therapeutically effective amount of lenalidomide or a stereoisomer or a mixture of stereoisomers, tautomer, pharmaceutically acceptable salt, solvate, isotopologue, prodrug, hydrate, co-crystal, clathrate, or a polymorph thereof to the subject predicted to have the ABC subtype of DLBCL.",After,No,https://patents.google.com/patent/US20200118646A1/en?oq=US20200118646A1
Revlimid,US20200276175A1,Celgene,Multiple Myeloma,Small Molecule,5,8/3/2006,5/13/2020,9/3/2020,,Abandoned,Method of Treatment,"The application claimed a method of treating mantic cell lymphoma in a human, which comprises administering to a human having mantle cell lymphoma from about 5 mg to about 50 mg of lenalidomide.",After,No,https://patents.google.com/patent/US20200276175A1/en?oq=US20200276175A1
Revlimid,US20210102257A1,Celgene,Multiple Myeloma,Small Molecule,33,9/25/2015,5/18/2020,4/8/2021,,Pending,Method of Diagnosis,The application claimed a method for predicting the responsiveness of a diffuse large B-cell lymphoma (DLBCL) patient to treatment with lenalidomide. ,After,No,https://patents.google.com/patent/US20210102257A1/en?oq=US20210102257A1
Revlimid,US20210128619A1,Celgene,Multiple Myeloma,Small Molecule,69,11/5/2019,11/4/2020,5/6/2021,,Pending,Method of Treatment,The application claims a method of treating a disease caused by B Cell Maturation Agent (BCMA) expressing cells in a subject in need thereof wherein before said administering said subject has received one or more lines of prior therapy comprising lenalidomide.,After,No,https://patents.google.com/patent/US20210128619A1/en?oq=US20210128619A1
Revlimid,US20210330788A1,Celgene,Multiple Myeloma,Small Molecule,65,7/11/2018,7/10/2019,10/28/2021,,Pending,Method of Treatment,"The application claims a method of depleting BCMA-expressing cells in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of immune cells expressing a chimeric antigen receptor (CAR) directed to B Cell Maturation Antigen (BCMA), wherein the immune cells are administered in a dosage of from 150×106 cells to 450×106 cells, and wherein before said administration said subject has received one or more lines of prior therapy comprising one or more of: a proteasome inhibitor, lenalidomide, pomalidomide, thalidomide, bortezomib, dexamethasone, cyclophosphamide, doxorubicin, carfilzomib, ixazomib, cisplatin, doxorubicin, etoposide, an anti-CD38 antibody, panobinostat, and elotuzumab.",After,No,https://patents.google.com/patent/US20210330788A1/en?oq=US20210330788A1
Revlimid,US20220003749A1,Celgene,Multiple Myeloma,Small Molecule,40,12/6/2013,4/1/2021,1/6/2022,,Pending,Biomarker,"The application claims a method of monitoring interferon (IFN) therapy treatment response to a compound treatment in a patient having a cancer, or treating a cancer in a patient, wherein the compound is lenalidomide.",After,No,https://patents.google.com/patent/US20220003749A1/en?oq=US20220003749A1
Revlimid,US5635517,Celgene,Multiple Myeloma,Small Molecule,1,7/24/1996,7/24/1996,6/29/1999,10/4/2019,Expired,Method of Treatment,The patent claims cover a method of reducing undesirable levels of TNFα in a mammal which comprises administering thereto an effective amount of lenalidomide (Revlimid),Before,No,https://patents.google.com/patent/US5635517A/en?oq=US5635517
Revlimid,US5798368,Celgene,Multiple Myeloma,Small Molecule,1,8/22/1996,8/22/1996,8/25/1998,8/22/2016,Expired,Derivative,The patent claims cover a Markush group of derivative compounds related to thalidomide/lenalidomide.,Before,No,https://patents.google.com/patent/US5798368A/en?oq=US5798368
Revlimid,US6045501,Celgene,Multiple Myeloma,Small Molecule,2,8/28/1998,8/28/1998,4/4/2000,8/28/2018,Expired,Method of Delivery,"The patent claims cover a method for delivering a teratogenic drug to patients in need of the drug while avoiding the delivery of said drug to a foetus, comprising:
a. registering in a computer readable storage medium prescribers who are qualified to prescribe said drug; b. registering in said medium pharmacies to fill prescriptions for said drug;c. registering said patients in said medium, including information concerning the ability of female patients to become pregnant and the ability of male patients to impregnate females;d. retrieving from said medium information identifying a subpopulation of said female patients who are capable of becoming pregnant and male patients who are capable of impregnating females; e. providing to the subpopulation, counseling information concerning the risks attendant to fetal exposure to said drug;
f. determining whether patients comprising said subpopulation are pregnant; and g. in response to a determination of non-pregnancy for said patients, authorizing said registered pharmacies to fill prescriptions from said registered prescribers for said non-pregnant registered patients, wherein the said drug is thalidomide. This patent relates to Celgene's RevAssist® program.",Before,No,https://patents.google.com/patent/US6045501A/en?oq=US6045501
Revlimid,US6281230,Celgene,Multiple Myeloma,Small Molecule,1,7/24/1996,4/6/2000,8/28/2001,7/24/2016,Expired,Method of Treatment,"The patent claims cover a method of treating inflammation, inflammatory disease or autoimmune disease in a mammal which comprises administering thereto an effective amount of lenalidomide (Revlimid)",Before,No,https://patents.google.com/patent/US6281230B1/en?oq=US6281230
Revlimid,US6315720,Celgene,Multiple Myeloma,Small Molecule,3,10/23/2000,10/23/2000,11/13/2001,10/23/2020,Expired,Method of Delivery,"The patent claims cover a method delivering a drug to a patient in need of the drug, while avoiding the occurrence of an adverse side effect known or suspected of being caused by said drug, wherein said method is of the type in which prescriptions for said drug are filled only after a computer readable storage medium has been consulted to assure that the prescriber is registered in said medium and qualified to prescribe said drug, that the pharmacy is registered in said medium and qualified to fill the prescription for said drug, and the patient is registered in said medium and approved to receive said drug, the improvement comprising: a. defining a plurality of patient risk groups based upon a predefined set of risk parameters for said drug; b. defining a set of information to be obtained from said patient, which information is probative of the risk that said adverse side effect is likely to occur if said drug is taken by said patient;c. in response to said information set, assigning said patient to at least one of said risk groups and entering said risk group assignment in said medium;d. based upon said information and said risk group assignment, determining whether the risk that said adverse side effect is likely to occur is acceptable; and e. upon a determination that said risk is acceptable, generating a prescription approval code to be retrieved by said pharmacy before said prescription is filled. This patent relates to Celgene's RevAssist® program.",Before,Yes,https://patents.google.com/patent/US6315720B1/en?oq=US6315720
Revlimid,US6316471,Celgene,Multiple Myeloma,Small Molecule,1,7/24/1996,10/17/2000,11/13/2001,7/24/2016,Expired,Method of Treatment,"The patent claims cover a method of treating inflammation, inflammatory disease or autoimmune disease in a mammal which comprises administering thereto an effective amount oflenalidomide (Revlimid)",Before,No,https://patents.google.com/patent/US6316471B1/en?oq=US6316471
Revlimid,US6335349,Celgene,Multiple Myeloma,Small Molecule,1,7/24/1996,11/20/2000,1/1/2002,8/8/2016,Expired,Main Compound,"The patent claims cover a Markush group of compounds and derivatives including lenalidomide (Revlimid) , a method of treating an oncogenic or cancerous condition and a pharmaceutical composition.",Before,No,https://patents.google.com/patent/US6335349B1/en?oq=US6335349
Revlimid,US6395754,Celgene,Multiple Myeloma,Small Molecule,1,5/30/1997,5/28/1998,5/28/2002,5/28/2018,Expired,Main Compound,The patent claims cover derivative compounds and prodrugs related to thalidomide/lenalidomide.,Before,No,https://patents.google.com/patent/US6395754B1/en?oq=US6395754
Revlimid,US6476052,Celgene,Multiple Myeloma,Small Molecule,1,7/24/1996,8/7/2000,11/5/2002,8/8/2016,Expired,Method of Treatment,"The patent claims cover a method of treating inflammation, inflammatory disease or autoimmune disease using derivatives compounds of thalidomide/lenalidomide.",Before,No,https://patents.google.com/patent/US6476052B1/en?oq=US6476052
Revlimid,US6555554,Celgene,Multiple Myeloma,Small Molecule,1,7/24/1996,2/12/2001,4/29/2003,7/24/2016,Expired,Formulation / Combination,"The patent claims cover a pharmaceutical composition in combination with a pharmaceutically and physiologically suitable carrier comprising lenalidomide (Revlimid) or a physiologically acceptable non-toxic acid addition salt thereof, in a quantity sufficient upon administration in a single or multiple dose regimen to a mammal to produce at least one of the effects of reducing the level of TNFα, improving an oncogenic or cancerous condition, reducing inflammation, or improving autoimmune disease..",Before,No,https://patents.google.com/patent/US6555554B2/en?oq=US6555554
Revlimid,US6561976,Celgene,Multiple Myeloma,Small Molecule,2,8/28/1998,9/26/2001,5/13/2003,8/28/2018,Expired,Method of Delivery,"The patent claims cover a method distributing a teratogenic drug to a patient in need of the drug while preventing foetal exposure to the drug, said method comprising: a. registering in a computer readable storage medium physicians permitted to prescribe said drug; b. providing said patient with counseling information concerning the teratogenic risks attendant to foetal exposure to said drug; c. obtaining the informed consent of said patient to receive said drug despite said risks; d. registering said patient in said medium, including information concerning the ability of said patient to become pregnant or to impregnate a female; e. upon a determination that said patient is capable of becoming pregnant, determining that said patient is not currently pregnant, and registering same in said medium; f. permitting said patient access to said drug only after consulting said medium to verify that said patient is either incapable of becoming pregnant or is not currently pregnant, wherein the teratogenic drug is thalidomide This patent relates to Celgene's RevAssist® program.",Before,No,https://patents.google.com/patent/US6561976B2/en?oq=US6561976
Revlimid,US6561977,Celgene,Multiple Myeloma,Small Molecule,3,10/23/2000,9/27/2001,5/13/2003,10/23/2020,Expired,Method of Delivery,"The patent claims cover a method for delivering a drug to patients in need of the drug while restricting access to the drug by patients for whom the drug may be contraindicated, said method comprising permitting prescriptions for the drug to be filled by a pharmacy only after the pharmacy has retrieved an approval code for the prescription from a computer readable storage medium, wherein generation of the prescription approval code comprises the following steps: a. defining a plurality of patient risk groups based upon a predefined set of risk parameters for the drug; b. defining a set of information to be obtained from a patient, which information is probative of the risk that an adverse side effect is likely to occur if the drug is taken by the patient; c. in response to the information set, assigning the patient to at least one of the risk groups and entering the patient, the information and the patient's risk group assignment in the medium; d. based upon the information and the risk group assignment, determining whether the risk that the adverse side effect is likely to occur is acceptable; ande. upon a determination that the risk is acceptable, generating the prescription approval code to be retrieved by the pharmacy before the prescription is filled. This patent relates to Celgene's RevAssist® program.",Before,Yes,https://patents.google.com/patent/US6561977B2/en?oq=US6561977
Revlimid,US6755784,Celgene,Multiple Myeloma,Small Molecule,3,10/23/2000,3/7/2003,6/29/2004,11/26/2020,Expired,Method of Delivery,"The patent claims cover a method for delivering a drug to patients in need of the drug while restricting access to the drug by patients for whom the drug may be contraindicated, said method comprising permitting prescriptions for the drug to be filled by a pharmacy only after the pharmacy has received an approval code for the prescription from a computer readable storage medium, wherein generation of the prescription approval code comprises the following steps:
a. defining a plurality of patient risk groups based upon a predefined set of risk parameters for the drug; b. defining a set of information to be obtained from the patient, which information is probative of the risk that an adverse side effect is likely to occur if the drug is taken by the patient; c. in response to the information set, assigning the patient to at least one of the risk groups and entering the patient, the information and the patient's risk group assignment into the medium; d. based upon the information and the risk group assignment, determining whether the risk that the adverse side effect is likely to occur is acceptable; and e. upon a determination that the risk is acceptable, generating the prescription approval code to be received by the pharmacy before the prescription is filled. This patent relates to Celgene's RevAssist® program.",Before,Yes,https://patents.google.com/patent/US6755784B2/en?oq=US6755784
Revlimid,US6767326,Celgene,Multiple Myeloma,Small Molecule,2,8/28/1998,3/7/2003,7/27/2004,8/28/2018,Expired,Method of Delivery,"The patent claims cover a method for distributing a teratogenic drug to a patient in need of the drug while preventing foetal exposure to the drug, said method comprising: a. registering in a computer readable storage medium physicians permitted to prescribe said drug; b. providing said patient with counseling information concerning the teratogenic risks attendant to foetal exposure to said drug;c. obtaining the informed consent of said patient to receive said drug despite said risks; d. registering said patient in said medium, including information concerning the ability of said patient to become pregnant or to impregnate a female; e. upon a determination that said patient is capable of becoming pregnant, determining that said patient is not currently pregnant, and registering same in said medium;f. permitting said patient access to said drug only after consulting said medium to verify that said patient is either incapable of becoming pregnant or is not currently pregnant, wherein the teratogenic drug is thalidomide This patent relates to Celgene's RevAssist® program.",Before,No,https://patents.google.com/patent/US6767326B2/en?oq=US6767326
Revlimid,US6869399,Celgene,Multiple Myeloma,Small Molecule,3,10/23/2000,1/22/2004,3/22/2005,10/23/2020,Expired,Method of Delivery,"The patent claims cover a method for treating erythema nodosum leprosum using thalidomide while restricting access to thalidomide for patients for whom thalidomide may be contraindicated, said method comprising permitting prescriptions for thalidomide to be filled by a pharmacy only after the pharmacy has received an approval code for the prescription from a computer readable storage medium, wherein generation of the prescription approval code comprises the following steps: a. defining a plurality of patient risk groups based upon a predefined set of risk parameters for thalidomide; b. defining a set of information to be obtained from the patient, which information is probative of the risk that an adverse side effect is likely to occur if thalidomide is taken by the patient; c. in response to the information set, assigning the patient to at least one of the risk groups and entering the patient, the information and the patient's risk group assignment into the medium; d. based upon the information and the risk group assignment, determining whether the risk that the adverse side effect is likely to occur is acceptable; and e. upon a determination that the risk is acceptable, generating the prescription approval code to be received by the pharmacy before the prescription is filled. This patent relates to Celgene's RevAssist® program.",Before,No,https://patents.google.com/patent/US6869399B2/en?oq=US6869399
Revlimid,US6908432,Celgene,Multiple Myeloma,Small Molecule,2,8/28/1998,1/22/2004,6/21/2005,8/28/2018,Expired,Method of Delivery,"The patent claims cover a method for distributing a teratogenic drug to a patient in need of the drug while preventing foetal exposure to the drug, said method comprising:
a. regstering in a computer readable storage medium physicians permitted to prescribe said drug; b. providing said patient with information concerning the teratogenic risks attendant to foetal exposure to said drug; c. obtaining the informed consent of said patient to receive said drug despite said risks;
d. registering said patient in said medium, including information concerning the ability of said patient to become pregnant or to impregnate a female;
e. upon a determination that said patient is capable of becoming pregnant or capable of impregnating a female, determining that said patient is not currently pregnant or counseling said patient capable of impregnating a female to use a contraceptive device or formulation when engaging in sexual intercourse with a female, and registering same in said medium; f. permitting said patient access to said drug only after consulting said medium to verify that said patient (1) is a female who is not pregnant or (2) is a female incapable of becoming pregnant or (3) is a male who has been counseled to use a contraceptive device or formulation when engaging in sexual intercourse with a female, wherein the teratogenic drug is thalidomide. This patent relates to Celgene's RevAssist® program.",Before,No,https://patents.google.com/patent/US6908432B2/en?oq=US6908432
Revlimid,US7041680,Celgene,Multiple Myeloma,Small Molecule,1,7/24/1996,4/10/2002,5/9/2006,5/7/2019,Expired,Formulation / Combination,"The patent claims cover a  pharmaceutical composition comprising a therapeutically effective amount of the (S)-isomer of lenalidomide (Revlimid) or an acid addition salt of said isomer, wherein the (S) isomer is substantially free of its (R) isomer, in combination with a pharmaceutically and physiologically suitable carrier.",Before,No,https://patents.google.com/patent/US7041680B2/en?oq=US7041680
Revlimid,"US7091353
",Celgene,Multiple Myeloma,Small Molecule,27,12/27/2000,12/21/2001,8/15/2006,10/5/2021,Expired,Derivative,The patent claims cover derivative compounds related to lenalidomide.,Before,No,https://patents.google.com/patent/US7091353B2/en?oq=US7091353
Revlimid,US7119106,Celgene,Multiple Myeloma,Small Molecule,1,7/24/1996,1/6/2003,10/10/2006,5/7/2019,Expired,Formulation / Combination,"The patent claims cover a pharmaceutical composition comprising an effective amount of  lenalidomide (Revlimid) or an acid addition salt thereof, and a pharmaceutically acceptable carrier, diluent or excipient.",Before,No,https://patents.google.com/patent/US7119106B2/en?oq=US7119106
Revlimid,US7141018,Celgene,Multiple Myeloma,Small Molecule,3,10/23/2000,1/3/2005,11/28/2006,10/23/2020,Expired,Method of Delivery,"The patent claims cover a method for treating a patient having a disease or condition which is responsive to thalidomide while restricting access to thalidomide for patients for whom thalidomide may be contraindicated, the method comprising permitting prescriptions for thalidomide to be filled by a pharmacy only after the pharmacy has become aware of the generation of a prescription approval code for thalidomide for the patient from a computer readable storage medium, the generation of said prescription approval code comprising the following steps: a. defining a plurality of patient risk groups based upon a predefined set of risk parameters for thalidomide;
b. defining a set of information to be obtained from the patient, said set of information comprising the result of a determination of the ability of the patient to become pregnant and optionally comprising a determination that the patient is either (1) not currently pregnant or (2) currently pregnant; c. in response to said information set, assigning the patient to at least one of said risk groups and entering the patient, the information and the patient's risk group assignment into the medium;
d. based upon the information and the risk group assignment, determining whether the risk that the adverse side effect is likely to occur is acceptable; and
e. upon a determination that the risk is acceptable, generating the prescription approval code before the prescription is filled. This patent relates to Celgene's RevAssist® program.",Before,No,https://patents.google.com/patent/US7141018B2/en?oq=US7141018
Revlimid,US7182953,Celgene,Multiple Myeloma,Small Molecule,8,12/15/1999,12/11/2000,2/27/2007,6/13/2021,Expired,Method of Treatment,The patent claims cover a method of treating atherosclerosis in a mammal comprising administering to a mammal in need thereof an effective amount of lenalidomide (Revlimid). ,Before,No,https://patents.google.com/patent/US7182953B2/en?oq=US7182953
Revlimid,US7189740 ,Celgene,Multiple Myeloma,Small Molecule,4,10/15/2002,4/11/2003,3/13/2007,4/11/2023,Active,Method of Treatment,"The patent claims cover a method of treating myelodysplastic syndrome, which comprises administering to a patient in need thereof about 5 to about 50 mg per day of lenalidomide (Revlimid) or a pharmaceutically acceptable salt, solvate or stereoisomer thereof.",Before,Yes,https://patents.google.com/patent/US7189740B2/en?oq=US7189740+
Revlimid,US7323479,Celgene,Multiple Myeloma,Small Molecule,6,5/17/2002,11/6/2003,1/29/2008,4/1/2024,Active,Method of Treatment,The patent claims cover a method of treating brain cancer which comprises administering to a patient having brain cancer about 0.1 to about 150 mg per day of a derivative compound of lenalidomide. ,Before,No,https://patents.google.com/patent/US7323479B2/en?oq=US7323479
Revlimid,US7354948,Celgene,Multiple Myeloma,Small Molecule,6,11/6/2002,11/6/2003,4/8/2008,11/6/2023,Active,Method of Treatment,"The patent claims cover a method of treating chronic uveitis, which comprises administering to a patient in need of such treatment a therapeutically effective amount of an analog of thalidomide/lenalidomide.
",Before,No,https://patents.google.com/patent/US7354948B2/en?oq=US7354948
Revlimid,US7393862,Celgene,Multiple Myeloma,Small Molecule,6,5/17/2002,10/4/2005,7/1/2008,7/1/2023,Active,Method of Treatment,"The patent claims cover a method of treating leukemia in a human, which comprises administering to a human having leukemia from about 1 to about 50 mg per day offlenalidomide (Revlimid)",Before,No,https://patents.google.com/patent/US7393862B2/en?oq=US7393862
Revlimid,US7393863,Celgene,Multiple Myeloma,Small Molecule,4,10/15/2002,1/16/2007,7/1/2008,4/11/2023,Active,Method of Treatment,The patent claims cover a method of treating myelodysplastic syndrome with a close analog of thalidomide/lenalidomide.,After,No,https://patents.google.com/patent/US7393863B2/en?oq=US7393863
Revlimid,US7459466 ,Celgene,Multiple Myeloma,Small Molecule,1,5/30/1997,1/14/2005,12/2/2008,12/10/2019,Expired,Derivative,The patent claims cover a Markush group of derivative compounds related to thalidomide/lenalidomide.,Before,No,https://patents.google.com/patent/US7459466B2/en?oq=US7459466+
Revlimid,US7465800,Celgene,Multiple Myeloma,Small Molecule,6,9/4/2003,9/3/2004,12/16/2008,4/27/2027,Active,Crystalline,The patent claims cover crystalline hemihydrate forms lenalidomide. ,Before,Yes,https://patents.google.com/patent/US7465800B2/en?oq=US7465800
Revlimid,US7468363,Celgene,Multiple Myeloma,Small Molecule,6,5/17/2002,4/8/2005,12/23/2008,10/23/2023,Active,Method of Treatment,"The patent claims cover a method of treating non-Hodgkin's lymphoma, which comprises administering to a patient having non-Hodgkin's lymphoma from about 5 to about 50 mg per day of lenalidomide (Revlimid) or a pharmaceutically acceptable salt thereof.",Before,Yes,https://patents.google.com/patent/US7468363B2/en?oq=US7468363
Revlimid,"US7498171
",Antrogenesis / Celgene,Multiple Myeloma,Small Molecule,44,4/12/2002,4/11/2003,3/3/2009,1/18/2024,Expired,Method of Treatment,The patent claims cover a method for promoting the differentiation of mammalian CD34+ or CD133+ hematopoietic stem cells to CFU-GM (colony-forming units−granulocyte/macrophage) while inhibiting their differentiation to BFU-E (blast-forming units−erythrocyte).,Before,No,https://patents.google.com/patent/US7498171B2/en?oq=US7498171
Revlimid,"US7563810
",Celgene,Multiple Myeloma,Small Molecule,9,11/6/2002,4/11/2003,7/21/2009,4/13/2024,Active,Method of Treatment,"The patent claims cover a method of treating a myeloproliferative disease, which comprises administering to a patient having a myeloproliferative disease a therapeutically effective amount of lenalidomide (Revlimid) or a pharmaceutically acceptable salt thereof, wherein the myeloproliferative disease is selected from the group consisting of polycythemia rubra vera, primary thrombocythemia, and agnogenic myeloid metaplasia, and wherein the therapeutically effective amount is from about 1 mg to about 50 mg per day.

",Before,No,https://patents.google.com/patent/US7563810B2/en?oq=US7563810
Revlimid,"US7576104
",Celgene,Multiple Myeloma,Small Molecule,27,12/27/2000,9/21/2005,8/18/2009,4/19/2023,Active,Derivative,The patent claims cover derivative compounds related to lenalidomide.,Before,No,https://patents.google.com/patent/US7576104B2/en?oq=US7576104
Revlimid,US7629360,Celgene,Multiple Myeloma,Small Molecule,1,5/7/1999,11/17/2005,12/8/2009,12/8/2019,Expired,Method of Treatment,The patent claims cover a  method of treating cachexia or graft v. Host disease comprising administering to a patient in need of such treatment an effective amount of a derivative compound closely related to thalidomide.,Before,No,https://patents.google.com/patent/US7629360B2/en?oq=US7629360
Revlimid,US7709502 ,Celgene,Multiple Myeloma,Small Molecule,1,5/7/1999,4/12/2006,5/4/2010,2/15/2020,Expired,Derivative,The patent claims cover a substantially chirally pure (R) or a substantially chirally pure (S) isomer of lenalidomide (Revlimid).,After,No,https://patents.google.com/patent/US7709502B2/en?oq=US7709502+
Revlimid,US7855217,Celgene,Multiple Myeloma,Small Molecule,6,9/4/2003,12/15/2008,12/21/2010,11/24/2024,Active,Crystalline,The patent claims cover hemihydrate crystalline forms of lenalidomide (Revlimid).,After,Yes,https://patents.google.com/patent/US7855217B2/en?oq=US7855217
Revlimid,US7863297,Celgene,Multiple Myeloma,Small Molecule,4,10/15/2002,11/12/2007,1/4/2011,4/11/2023,Active,Method of Treatment,The patent claims cover a method of treating myelodysplastic syndrome with close analog of thalidomide/lenalidomide.,After,No,https://patents.google.com/patent/US7863297B2/en?oq=US7863297
Revlimid,"US7863451
",Celgene,Multiple Myeloma,Small Molecule,53,9/3/2004,9/1/2005,1/4/2011,3/1/2028,Active,Method of Production / Process,The patent claims cover a process for preparing the active ingredient lenalidomide.,Before,No,https://patents.google.com/patent/US7863451B2/en?oq=US7863451
Revlimid,US7874984,Celgene,Multiple Myeloma,Small Molecule,2,8/28/1998,4/12/2005,1/25/2011,6/17/2021,Expired,Method of Delivery,"The patent claims cover a method of treating a male patient, suffering from erythema nodosum leprosum, with thalidomide, said method comprising (a) permitting thalidomide to be distributed by a pharmacy only after the pharmacy has received a prescription and (b) administering said thalidomide to the patient, wherein the generation of the prescription comprises the following steps: (1) via a computer readable storage medium, registering a prescriber and the pharmacy with a distributor of thalidomide;(2) determining whether the patient is able to understand and carry out instructions;(3) upon determination that the patient is able to carry out the instructions, providing verbal and written warnings of the hazard of taking thalidomide and exposing fetus to the drug;
(4) further providing verbal and written warnings of the risk of possible contraception failure and of the need to use barrier contraception when having sexual intercourse with women of child bearing potential;(5) obtaining acknowledgement of said warnings from the patient;(6) via a computer readable storage medium, registering the patient with the distributor; and (7) upon obtaining the acknowledgement and registrations, generating via a computer readable storage medium the prescription to be received by the pharmacy before thalidomide is distributed. This patent relates to Celgene's RevAssist® program.",Before,No,https://patents.google.com/patent/US7874984B2/en?oq=US7874984
Revlimid,"US7893045
",Celgene,Multiple Myeloma,Small Molecule,20,8/7/2007,8/5/2008,2/22/2011,12/14/2028,Active,Method of Treatment,"The patent claims cover a method of treating a lymphoma in a human, comprising: a) measuring a patient's disease burden, an absolute lymphocyte count or time since last rituximab therapy; b) selecting a patient who has a disease burden of less than 50 cm2, an absolute lymphocyte count greater than 0.6×109/L, or not less than 230 days since last rituximab therapy; and c) administering a therapeutically effective amount of lenalidomide.",After,No,https://patents.google.com/patent/US7893045B2/en?oq=US7893045
Revlimid,US7959566,Celgene,Multiple Myeloma,Small Molecule,3,10/23/2000,5/19/2006,6/14/2011,3/11/2021,Expired,Method of Delivery,"The patent claims cover a method of treating a male patient, suffering from erythema nodosum leprosum, with thalidomide, by permitting prescriptions for thalidomide to be filled by a pharmacy only after the pharmacy has retrieved a prescription approval code for the prescription, comprising the following steps: (a) via a non-transitory computer readable storage medium, registering a prescriber and the pharmacy with a distributor of thalidomide; (b) determining whether the patient is able to understand and carry out instructions; (c) upon determination that the patient is able to carry out the instructions, providing verbal and written warnings of the hazard of taking thalidomide and exposing fetus to the drug; (d) further providing verbal and written warnings of the risk of possible contraception failure and of the need to use barrier contraception when having sexual intercourse with women of child bearing potential; (e) obtaining acknowledgement of said warnings from the patient; (f) providing the prescription for thalidomide to the patient from the prescriber; (g) via a non-transitory computer readable storage medium, registering the patient with the distributor; (h) upon obtaining the acknowledgement and registrations, generating the prescription approval code, and via a non-transitory computer readable storage medium, retrieving the prescription approval code by the pharmacy before the prescription is filled; and(i) upon retrieving the prescription approval code, administering thalidomide to the patient. This patent relates to Celgene's RevAssist® program.",After,No,https://patents.google.com/patent/US7959566B2/en?oq=US7959566
Revlimid,"US7964354 
",Celgene,Multiple Myeloma,Small Molecule,48,12/20/2007,12/19/2008,6/21/2011,1/21/2029,Active,Biomarker,The patent claims cover a  method of assessing the activity of analogs of lenalidomide.,After,No,https://patents.google.com/patent/US7964354B2/en?oq=US7964354+
Revlimid,US7968569,Celgene,Multiple Myeloma,Small Molecule,6,5/17/2002,5/15/2003,6/28/2011,10/7/2023,Active,Method of Treatment,"The patent claims cover a method of treating multiple myeloma, which comprises cyclically administering to a patient having multiple myeloma about 5 to about 25 mg per day of lenalidomide (Revlimid) or a pharmaceutically acceptable salt thereof, for 21 consecutive days followed by seven in combination with 40 mg per day dexamethasone.",Before,Yes,https://patents.google.com/patent/US7968569B2/en?oq=US7968569
Revlimid,US8012997,Celgene,Multiple Myeloma,Small Molecule,27,12/27/2000,7/23/2009,9/6/2011,10/5/2021,Expired,Derivative,The patent claims cover derivative compounds related to lenalidomide.,After,No,https://patents.google.com/patent/US8012997B2/en?oq=US8012997
Revlimid,"US8153659
",Celgene,Multiple Myeloma,Small Molecule,51,3/20/2007,3/19/2008,4/10/2012,2/9/2031,Active,Derivative,The patent claims cover analogs of lenalidomide. ,After,No,https://patents.google.com/patent/US8153659B2/en?oq=US8153659
Revlimid,US8158653,Celgene,Multiple Myeloma,Small Molecule,1,5/7/1999,4/12/2006,4/17/2012,6/25/2021,Expired,Formulation / Combination,The patent claims cover an oral dosage form in the form of a capsule or a tablet comprising a therapeutically effective amount of a  derivative compound closely related to thalidomide,After,No,https://patents.google.com/patent/US8158653B2/en?oq=US8158653
Revlimid,US8204763,Celgene,Multiple Myeloma,Small Molecule,2,8/28/1998,12/13/2010,6/19/2012,8/28/2018,Expired,Method of Delivery,"The patent claims cover a method of treating a male patient having a disease or condition responsive to a teratogenic drug comprising (A) permitting the drug to be distributed by a pharmacy only after the pharmacy has received a prescription and (B) administering the drug to the patient, wherein the generation of the prescription comprises the following steps: (a) via a computer readable storage medium, registering a prescriber and the pharmacy with a distributor of thalidomide;
(b) determining whether the patient is able to understand and carry out instructions;(c) upon determination that the patient is able to carry out the instructions, providing verbal and written warnings of the hazard of taking the drug and exposing fetus to the drug; (d) further providing verbal and written warnings of the risk of possible contraception failure and of the need to use barrier contraception when having sexual intercourse with women of child bearing potential; (e) obtaining acknowledgement of said warnings from the patient; (f) via a computer readable storage medium, registering the patient with the distributor; and (g) upon obtaining the acknowledgement and registrations, generating via a computer readable storage medium the prescription to be retrieved by the pharmacy before the drug is distributed. This patent relates to Celgene's RevAssist® program.",After,No,https://patents.google.com/patent/US8204763B2/en?oq=US8204763
Revlimid,US8263637,Celgene,Multiple Myeloma,Small Molecule,6,5/17/2002,5/16/2003,9/11/2012,12/18/2026,Active,Method of Treatment,The patent claims cover a method of treating multiple myeloma with a derivative compound of thalidomide/lenalidomide,Before,No,https://patents.google.com/patent/US8263637B2/en?oq=US8263637
Revlimid,US8288415,Celgene,Multiple Myeloma,Small Molecule,1,5/7/1999,12/10/2009,10/16/2012,1/19/2020,Expired,Formulation / Combination,"The patent claims cover a unit dosage form comprising  lenalidomide (Revlimid) or an acid addition salt thereof, and a pharmaceutically acceptable carrier, diluent, or excipient, wherein the amount is from 1 mg to 100 mg.",After,No,https://patents.google.com/patent/US8288415B2/en?oq=US8288415
Revlimid,US8315886,Celgene,Multiple Myeloma,Small Molecule,3,10/23/2000,12/13/2010,11/20/2012,3/27/2021,Expired,Method of Delivery,"The patent claims cover a  method of treating a male patient having a disease or condition responsive to a teratogenic drug comprising permitting prescriptions for the drug to be filled by a pharmacy only after the pharmacy has retrieved an approval code for the prescription, wherein the generation of the prescription approval code comprises the following steps: (a) via a computer readable storage medium, registering a prescriber and the pharmacy with a distributor of a teratogenic drug;
(b) determining whether the patient is able to understand and carry out instructions; (c) upon determination that the patient is able to carry out the instructions, providing verbal and written warnings of the hazard of taking the drug and exposing fetus to the drug; (d) further providing verbal and written warnings of the risk of possible contraception failure and of the need to use barrier contraception when having sexual intercourse with women of child bearing potential; (e) obtaining acknowledgement of said warnings from the patient; (f) via a computer readable storage medium, registering the patient with the distributor; and (g) upon obtaining the acknowledgement and registrations, generating via a computer readable storage medium the prescription approval code to be retrieved by the pharmacy before the prescription is filled; and (h) upon retrieving a prescription approval code, administering the drug to the patient. This patent relates to Celgene's RevAssist® program.",After,Yes,https://patents.google.com/patent/US8315886B2/en?oq=US8315886
Revlimid,"US8394832
",Celgene,Multiple Myeloma,Small Molecule,19,12/1/2004,11/30/2005,3/12/2013,3/17/2028,Expired,Method of Treatment,"The patent claims cover a method of treating or managing an immunodeficiency disease or disorder, which comprises administering to a patient in need of such treatment or management a therapeutically effective amount of an immunomodulatory compound (lenalidomide).",Before,No,https://patents.google.com/patent/US8394832B2/en?oq=US8394832
Revlimid,US8404716,Celgene,Multiple Myeloma,Small Molecule,4,10/15/2002,5/11/2010,3/26/2013,10/28/2023,Active,Method of Treatment,"The patent claims cover a method of treating myelodysplastic syndrome, which comprises (a) administering to a patient in need thereof a therapeutically effective amount of 5-azacytidine for a period of time followed by a period of rest; (b) repeating step (a); (c) administering to the patient from about 5 mg per day to about 25 mg per day oflenalidomide (Revlimid) or a pharmaceutically acceptable salt thereof for a period of time followed by a period of rest; and (d) repeating step (c).",After,No,https://patents.google.com/patent/US8404716B2/en?oq=US8404716
Revlimid,US8404717,Celgene,Multiple Myeloma,Small Molecule,4,10/15/2002,3/24/2011,3/26/2013,4/11/2023,Active,Method of Treatment,"The patent claims cover a method of treating a patient having transfusion dependent anemia due to low to intermediate-1-risk myelodysplastic syndrome, which comprises administering to said patient in need thereof about 5 to about 25 mg per day of lenalidomide (Revlimid) or a pharmaceutically acceptable salt, solvate or stereoisomer thereof.",After,Yes,https://patents.google.com/patent/US8404717B2/en?oq=US8404717
Revlimid,US8410136,Celgene,Multiple Myeloma,Small Molecule,6,5/17/2002,4/7/2010,4/2/2013,10/12/2023,Active,Method of Treatment,"The patent claims cover a method of treating hepatocellular carcinoma, which comprises administering to a patient having hepatocellular carcinoma about 5 to about 25 mg per day of  lenalidomide (Revlimid) or a pharmaceutically acceptable salt, solvate or stereoisomer thereof.",After,No,https://patents.google.com/patent/US8410136B2/en?oq=US8410136
Revlimid,"US8481568
",Celgene,Multiple Myeloma,Small Molecule,52,8/31/2005,2/17/2011,7/9/2013,8/30/2026,Active,Derivative,The patent claims cover derivative compounds of lenalidomide.,After,No,https://patents.google.com/patent/US8481568B2/en?oq=US8481568
Revlimid,US8589188,Celgene,Multiple Myeloma,Small Molecule,2,8/28/1998,5/17/2012,11/19/2013,8/28/2018,Expired,Method of Delivery,"The patent claims cover a method of distributing a drug to a patient comprising identifying that the patient has disease or condition responsive to a drug that is contraindicated for fetal exposure andpermitting the drug to be distributed to the patient by a pharmacy only after the pharmacy has received a prescription wherein generation of the prescription comprises the following steps: (a) via a computer readable storage medium, registering a prescriber and the pharmacy with a distributor of a teratogenic drug; (b) determining whether the patient is able to understand and carry out instructions;
(c) upon determination that the patient is able to carry out the instructions, providing verbal and written warnings of the hazard of taking the drug and exposing fetus to the drug; (d) further providing verbal and written warnings of the risk of possible contraception failure and of the need to use barrier contraception when having sexual intercourse with women of child bearing potential; (e) obtaining acknowledgement of said warnings from the patient; (f) via a computer readable storage medium, registering the patient with the distributor; and (g) upon obtaining the acknowledgement and registrations, generating via a computer readable storage medium the prescription to be retrieved by the pharmacy before the drug is distributed. This patent relates to Celgene's RevAssist® program.",After,No,https://patents.google.com/patent/US8589188B2/en?oq=US8589188
Revlimid,US8626531,Celgene,Multiple Myeloma,Small Molecule,3,10/23/2000,8/22/2012,1/7/2014,10/23/2020,Expired,Method of Delivery,"The patent claims cover a system for communicating over a network with a pharmacist for authorizing delivery of a contraindicated drug to a patient, the patient pre-assigned to at least one risk group of a plurality of risk groups, the plurality of risk groups defined based on factors which indicate one or more risks of one or more adverse side effects if the patient receives the drug, the system comprising: a computer device including: a computer readable medium having stored therein the plurality of risk groups, the at least one risk group assignment, and registration information of the patient; the computer device configured to provide: an interface configured to receive an on-line transmission of a pharmacist prescription for the patient in order to dispense the contraindicated drug to the patient; a generator configured to generate a prescription approval code based on comparison of the on-line transmission of the pharmacist prescription for the patient with the registration information of the patient stored in the computer readable medium to confirm if the patient is registered, and based on comparison of the on-line transmission of the pharmacist prescription for the patient with the risk group assignment stored in the computer readable medium to determine if the patient is eligible to receive the contraindicated drug, such that the risk group assignment is based on a predefined set of risk parameters for the contraindicated drug; and an interface configured to send an on-line transmission to the pharmacist including the generated prescription approval code when the registered patient is eligible to receive the drug; wherein the pharmacist can proceed with dispensation of the drug to the patient on the basis of the generated prescription approval code once received. This patent relates to Celgene's RevAssist® program.",After,Yes,https://patents.google.com/patent/US8626531B2/en?oq=US8626531
Revlimid,US8741929,Celgene,Multiple Myeloma,Small Molecule,5,8/3/2006,11/19/2009,6/3/2014,8/3/2028,Active,Method of Treatment,"The patent claims cover a method of treating mantle cell lymphoma in a human, which comprises (a) administering to a human having mantle cell lymphoma from about 5 mg to about 25 mg per day of lenalidomide (Revlimid) or a pharmaceutically acceptable salt or hydrate thereof for 21 days followed by seven days rest in a 28 day cycle; and (b) repeating step (a), wherein the mantle cell lymphoma is relapsed, refractory, or relapsed and refractory to conventional therapy.",After,Yes,https://patents.google.com/patent/US8741929B2/en?oq=US8741929
Revlimid,"US8889411
",Antrogenesis / Celgene,Multiple Myeloma,Small Molecule,44,4/12/2002,3/2/2009,11/18/2014,7/25/2025,Active,Method of Treatment,The patent claims cover a method of treating an individual in need of granulocytes.,After,No,https://patents.google.com/patent/US8889411B2/en?oq=US8889411
Revlimid,US9056120,Celgene,Multiple Myeloma,Small Molecule,4,10/15/2002,3/13/2013,6/16/2015,4/11/2023,Active,Method of Treatment,"The patent claims cover a method of treating method of treating myelodysplastic syndrome, which comprises administering to a patient in need thereof about 1 mg to about 25 mg per day of lenalidomide (Revlimid) or a pharmaceutically acceptable salt, solvate or stereoisomer thereof.",After,Yes,https://patents.google.com/patent/US9056120B2/en?oq=US9056120
Revlimid,"US9226913
",Celgene,Multiple Myeloma,Small Molecule,56,1/5/2010,1/5/2011,1/5/2016,4/26/2032,Expired,Method of Treatment,"The patent claims cover a method of treating  cancer, wherein the method comprises administering lenalidomide and administering artemisinin or a derivative thereof, wherein the cancer is breast, colon or lung cancer, wherein the artemisinin derivative is artesunate or artemisone, and wherein the combination exhibits a synergistic effect.",After,No,https://patents.google.com/patent/US9226913B2/en?oq=US9226913
Revlimid,"US9492471
",Celgene,Multiple Myeloma,Small Molecule,61,8/27/2013,11/19/2013,11/15/2016,11/19/2033,Expired,Method of Treatment,"The patent claims cover a method of treating , stabilizing or lessening the severity or progression of a disease or disorder selected from the group consisting of chronic lymphocytic leukemia and small lymphocytic lymphoma in a patient, the method comprising administering to the patient in need thereof therapeutically effective amounts of each of Compound 1, or a pharmaceutically acceptable salt thereof, an anti-CD20 antibody and at least one additional therapeutic agent selected from fludarabine, cyclophosphamide and bendamustine, wherein the therapeutically effective amount of Compound 1 is about 750 mg to about 1000 mg per day, and wherein the patient has failed at least one prior therapy.",After,No,https://patents.google.com/patent/US9492471B2/en?oq=US9492471
Revlimid,"US9694015
",Celgene,Multiple Myeloma,Small Molecule,25,9/10/2012,9/9/2013,7/4/2017,9/9/2033,Active,Method of Treatment,"The patent claims cover a method of treating or managing locally advanced breast cancer comprising administering to a patient in need of such treatment or management a therapeutically effective amount of lenalidomide or an enantiomer or mixture of enantiomers thereof; or a pharmaceutically acceptable salt, co-crystal, or clathrate thereof.
",After,No,https://patents.google.com/patent/US9694015B2/en?oq=US9694015
Revlimid,US9925207,Celgene,Multiple Myeloma,Small Molecule,4,10/15/2002,10/17/2014,3/27/2018,5/14/2023,Active,Method of Treatment,"The patent claims cover a method of treating a method of treating acute myeloid leukemia (AML) associated with a myelodysplastic syndrome, the method comprising administering to a patient having AML a therapeutically effective amount of 5-azacytidine, and a therapeutically effective amount of lenalidomide (Revlimid) or a pharmaceutically acceptable salt thereof wherein lenalidomide (Revlimid) is administered in an amount of about 5 mg to about 25 mg per day.",After,No,https://patents.google.com/patent/US9925207B2/en?oq=US9925207
Stelara, US20210253690A1,Janssen Biotech,Psoriasis,Biologic,15,2/14/2020,2/12/2021,8/19/2021,,Pending,Method of Treatment,"The application claims a method of treating moderately to severely active ulcerative colitis (UC) in a subject in need thereof, comprising administering to the subject a pharmaceutical composition comprising an anti-IL-12/IL-23p40 antibody.",After,No,https://patents.google.com/patent/US20210253690A1/en?oq=+US20210253690A1
Stelara,US10259867B2,Janssen Biotech,Psoriasis,Biologic,1,8/7/2000,5/1/2017,4/16/2019,1/8/2021,Expired,Method of Treatment,"The patent claims cover a method for reducing symptoms of systemic lupus erythematosus in an animal, comprising administering a composition comprising an effective amount of an isolated anti-IL-12 antibody comprising a heavy chain variable region of the amino acid sequence of SEQ ID NO: 7 and a light chain variable region of the amino acid sequence of SEQ ID NO: 8, to said animal.",After,No,https://patents.google.com/patent/US10259867B2/en?oq=US10259867B2
Stelara,US10765724B2,Janssen Biotech,Psoriasis,Biologic,3,3/29/2016,3/28/2017,9/8/2020,3/28/2037,Active,Method of Treatment,"The patent claims cover a method of treating psoriasis in a a patient using an increasing dosing or maintenance interval, comprising administering a pharmaceutical composition comprising an antibody to both IL-12 and IL-23 to the patient, wherein the antibody comprises a heavy chain variable amino acid sequence of SEQ ID NO: 7 and a light chain variable amino acid sequence of SEQ ID NO: 8, in an initial dose, a dose 4 weeks after the initial dose and a dose once every 12 weeks for 24 weeks after administration of the initial dose and increasing the dosing interval 28 weeks after administration of the initial dose to a dosing interval of every 24 weeks after identifying the patient as a responder to the antibody 28 weeks after administration of the initial dose, wherein the dose is 45 mg or 90 mg.",After,No,https://patents.google.com/patent/US10765724B2/en?oq=US10765724B2
Stelara,US10961307B2,Janssen Biotech,Psoriasis,Biologic,23,9/24/2018,9/24/2019,3/30/2021,9/24/2039,Active,Method of Treatment,"The patent claims cover a method of treating moderately to severely active ulcerative colitis (UC) in a subject in need thereof, comprising administering to the subject a pharmaceutical composition comprising a clinically proven safe and clinically proven effective amount of an anti-IL-12/IL-23p40 antibody. ",After,No,https://patents.google.com/patent/US10961307B2/en?oq=US10961307B2
Stelara,US11079361B2,Janssen Biotech,Psoriasis,Biologic,22,4/20/2018,4/19/2019,8/3/2021,6/22/2039,Active,Method of Production / Process,"The patent claims cover a method of operating a chromatography column in methods of manufacture for producing anti-IL-12/IL-23p40 antibodies, specific pharmaceutical compositions of the antibodies, and antigen binding fragments thereof, wherein the anti-IL-12/IL-23p40 antibodies comprise amino acid sequences selected from the group consisting of: (i) a heavy chain (HC) comprising the amino acid sequence of SEQ ID NO:10 and a light chain (LC) comprising the amino acid sequence of SEQ ID NO:11; (ii) a heavy chain variable domain amino acid sequence of SEQ ID NO:7 and a light chain variable domain amino acid sequence of SEQ ID NO:8; and (iii) heavy chain CDR amino acid sequences of SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3, and light chain CDR amino acid sequences of SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6",After,No,https://patents.google.com/patent/US11079361B2/en?oq=US11079361B2
Stelara,US11197913B2,Janssen Biotech,Psoriasis,Biologic,3,3/29/2016,8/14/2020,12/14/2021,3/28/2037,Active,Method of Treatment,"The patent claims cover a method of treating psoriatic arthritis in a patient using an increasing dosing or maintenance interval, comprising administering a pharmaceutical composition comprising an antibody to both IL-12 and IL-23 to the patient, wherein the antibody comprises a heavy chain variable amino acid sequence of SEQ ID NO: 7 and a light chain variable amino acid sequence of SEQ ID NO: 8, in an initial dose, a dose 4 weeks after the initial dose and a dose once every 12 weeks for 24 weeks after administration of the initial dose and increasing the dosing interval 28 weeks after administration of the initial dose to a dosing interval of every 24 weeks after identifying the patient as a responder to the antibody 28 weeks after administration of the initial dose, wherein the dose is 45 mg or 90 mg.",After,No,https://patents.google.com/patent/US11197913B2/en?oq=US11197913B2
Stelara,US11208474B2,Janssen Biotech,Psoriasis,Biologic,7,11/16/2016,11/15/2017,12/28/2021,12/18/2037,Active,Method of Treatment,The patent claims cover a method of treating psoriasis in a patient treated with an antibody to IL-12/23p40 and determined to be an inadequate responder to the IL-12/23p40 antibody treatment.,After,No,https://patents.google.com/patent/US11208474B2/en?oq=US11208474B2
Stelara,US11225516B2,Janssen Biotech,Psoriasis,Biologic,22,4/20/2018,4/19/2019,1/18/2022,5/3/2039,Active,Method of Production / Process,The patent claims cover a method of operation of chromatography to purify antibodies.,After,No,https://patents.google.com/patent/US11225516B2/en?oq=US11225516B2
Stelara,US2005002937 ,Janssen Biotech,Psoriasis,Biologic,1,8/7/2000,8/6/2004,1/6/2005,,Abandoned,Product,"The application claimed an isolated human antibody, or an antigen-binding portion thereof, that binds to human IL-12, wherein said human antibody is a neutralizing antibody.",Before,No,https://patents.google.com/patent/US20050002937A1/en?oq=US2005002937+
Stelara,US2008305114 ,Abbott & AbbVie Deutschland,Psoriasis,Biologic,12,3/25/1999,5/15/2008,12/11/2008,,Abandoned,Product,"The application claimed a method for inhibiting the activity of the p40 subunit of interleukin-12 (IL-12)  in a human subject suffering from an autoimmune disorder, comprising administering to the human subject an effective amount of a human antibody, or antigen-binding portion thereof, which is capable of binding to an epitope of the p40 subunit of IL-12, thereby inhibiting the activity of the p40 subunit of IL-12 in said subject. ",Before,No,https://patents.google.com/patent/US20080305114A1/en?oq=US2008305114+
Stelara,US20090022727A1,Durect Corp,Psoriasis,Biologic,4,1/26/2007,1/25/2008,1/22/2009,,Abandoned,Formulation / Combination,"The application claimed an injectable, nonaqueous suspension comprising at least one therapeutic agent suspended in a single component vehicle having an amphiphilic material. The patent describes a therapeutic agent that can be used with the formulation is an anti-IL-12 mAb. 
",Before,No,https://patents.google.com/patent/US20090022727A1/en?oq=US20090022727A1
Stelara,US2009175857 ,Abbott & AbbVie Deutschland,Psoriasis,Biologic,12,3/25/1999,10/16/2008,7/9/2009,,Abandoned,Product,"The application claimed an isolated human antibody, or antigen-binding portion thereof, which is capable of binding to an epitope of the p40 subunit of IL-12.
",Before,No,https://patents.google.com/patent/US20090175857A1/en?oq=US2009175857+
Stelara,US2009269302 ,Abbott & AbbVie Deutschland,Psoriasis,Biologic,12,3/25/1999,2/25/2009,10/29/2009,,Abandoned,Formulation / Combination,"The application claimed a pharmaceutical composition comprising a human antibody, or antigen binding portion thereof, capable of binding to an epitope of the p40 subunit of IL-12, and at least one additional agent selected from the group consisting of a buffer, a polyalcohol and a surfactant.",Before,No,https://patents.google.com/patent/US20090269302A1/en?oq=US2009269302+
Stelara,US2011123544 ,Abbott & AbbVie Deutschland,Psoriasis,Biologic,12,3/25/1999,10/22/2010,5/26/2011,,Abandoned,Product,"The application claimed an isolated antibody, or antigen binding portion thereof, that is capable of binding to the p40 subunit of IL-12 and is capable of altering the conformational structure of said p40 subunit of IL-12.",After,No,https://patents.google.com/patent/US20110123544A1/en?oq=US2011123544+
Stelara,US2012201831 ,Abbott & AbbVie Deutschland,Psoriasis,Biologic,12,3/25/1999,3/9/2012,8/9/2012,,Abandoned,Product,"The application claimed an isolated antibody, or antigen binding portion thereof, that is capable of binding to the p40 subunit of IL-12 and is capable of altering the conformational structure of said p40 subunit of IL-12.
",After,No,https://patents.google.com/patent/US20120201831A1/en?oq=US2012201831+
Stelara,US2012288494 ,Abbott & AbbVie Deutschland,Psoriasis,Biologic,12,3/25/1999,1/6/2012,11/15/2012,,Abandoned,Product,"The application claimed an isolated antibody that binds to the p40 subunit of IL-12 and/or IL-23, or an antigen binding portion thereof, wherein said antibody binds to a portion of the p40 subunit comprising at least one amino acid residue selected from residues 1-197 of the amino acid sequence of SEQ ID NO: 3, or within 1-10 Å of said amino acid residue",After,No,https://patents.google.com/patent/US20120288494A1/en?oq=US2012288494+
Stelara,US20140011704A1,Janssen Biotech,Psoriasis,Biologic,2,5/22/2007,9/18/2013,1/9/2014,,Abandoned,Method of Treatment,The application claimed a method for evaluating the effectiveness of treatment with an IL-12 antibody therapy for Crohn's disease,After,No,https://patents.google.com/patent/US20140011704A1/en?oq=US20140011704A1
Stelara,US2015017177 (A1),Durect Corp,Psoriasis,Biologic,4,1/26/2007,7/25/2014,1/15/2015,,Abandoned,Formulation / Combination,"The application claimed an injectable, nonaqueous suspension comprising at least one therapeutic agent suspended in a single component vehicle having an amphiphilic material. The patent describes a therapeutic agent that can be used with the formulation is an anti-IL-12 mAb. 
",After,No,https://patents.google.com/patent/US20150017177A1/en?oq=US2015017177+(A1)
Stelara,US20150291946A1,Janssen Biotech,Psoriasis,Biologic,9,12/28/2006,2/10/2015,10/15/2015,,Abandoned,Product,"The application claimed an expression vector comprising a nucleotide sequence encoding a sialidase enzyme, wherein the vector is capable of expressing a polypeptide having sialidase enzymatic activity in a mammalian cell culture expressing an Fc-containing molecule.

",After,No,https://patents.google.com/patent/US20150291946A1/en?oq=US20150291946A1
Stelara,US2015037348 ,Abbott & AbbVie Deutschland,Psoriasis,Biologic,12,3/25/1999,7/10/2014,2/5/2015,,Abandoned,Method of Treatment,"The application claimed a method of treating a human subject suffering from an autoimmune disorder, comprising administering to the human subject an effective amount of a human antibody, or antigen-binding portion thereof, which binds to an epitope of the p40 subunit of IL-12, thereby treating said subject. ",After,No,https://patents.google.com/patent/US20150037348A1/en?oq=US2015037348+
Stelara,US2015071875 ,Abbott & AbbVie Deutschland,Psoriasis,Biologic,12,3/25/1999,5/21/2014,3/12/2015,,Abandoned,Formulation / Combination,"The application claimed a pharmaceutical composition comprising a human antibody, or antigen binding portion thereof, capable of binding to an epitope of the p40 subunit of IL-12, and at least one additional agent selected from the group consisting of a buffer, a polyalcohol and a surfactant. ",After,No,https://patents.google.com/patent/US20150071875A1/en?oq=US2015071875+
Stelara,US2016193346 (A1),Durect Corp,Psoriasis,Biologic,4,1/26/2007,12/4/2015,7/7/2016,,Abandoned,Formulation / Combination,"The application claimed an injectable, nonaqueous suspension comprising at least one therapeutic agent suspended in a single component vehicle having an amphiphilic material.The patent describes a therapeutic agent that can be used with the formulation is an anti-IL-12 mAb. 
",After,No,https://patentimages.storage.googleapis.com/37/60/c4/a4ffcc0a402d9f/US20160193346A1.pdf
Stelara,US2017319702 (A1),Durect Corp,Psoriasis,Biologic,4,1/26/2007,5/1/2017,11/9/2017,,Abandoned,Formulation / Combination,"The application claimed an injectable, nonaqueous suspension comprising at least one therapeutic agent suspended in a single component vehicle having an amphiphilic material.The patent describes a therapeutic agent that can be used with the formulation is an anti-IL-12 mAb. 
",After,No,https://patents.google.com/patent/US20170319702A1/en?oq=US2017319702+(A1)
Stelara,US2018079809 ,Janssen Biotech,Psoriasis,Biologic,1,8/7/2000,12/4/2017,3/22/2018,,Abandoned,Product,"The application claimed an  isolated human anti-IL-12 antibody fragment, wherein said antibody fragment binds to a conformational epitope of the IL-12 protein comprising residues 15, 17-21, 23, 40-43, 45-47, 54-56 and 58-62 of the amino acid sequence of SEQ ID NO:9.",After,No,https://patents.google.com/patent/US20180079809A1/en?oq=US2018079809+
Stelara,US20190092853A1,Janssen Biotech,Psoriasis,Biologic,18,9/25/2017,9/24/2018,3/28/2019,,Pending,Method of Treatment,"The application claims a  method of treating active Systemic Lupus Erythematosus (SLE) in a patient, comprising administering an anti-IL-12/IL-23p40 antibody to the patient in a clinically proven safe and clinically proven effective amount, wherein the antibody comprises a heavy chain variable region and a light chain variable region, said heavy chain variable region comprising: a complementarity determining region heavy chain 1 (CDRH1) amino acid sequence of SEQ ID NO:1; a CDRH2 amino acid sequence of SEQ ID NO:2; and a CDRH3 amino acid sequence of SEQ ID NO:3; and said light chain variable region comprising: a complementarity determining region light chain 1 (CDRL1) amino acid sequence of SEQ ID NO:4; a CDRL2 amino acid sequence of SEQ ID NO:5; and a CDRL3 amino acid sequence of SEQ ID NO:6.",After,No,https://patents.google.com/patent/US20190092853A1/en?oq=US20190092853A1
Stelara,US20190352388A1,Janssen Biotech,Psoriasis,Biologic,17,5/18/2018,5/17/2019,11/21/2019,,Pending,Method of Treatment,The application claims a method for selecting and treating patients with active Systemic Lupus Erythematosus (SLE) that are predicted to have an increased likelihood of having a positive response to a treatment with an anti-IL-12/IL-23p40 antibody. ,After,No,https://patents.google.com/patent/US20190352388A1/en?oq=US20190352388A1
Stelara,US20200197517A1,Janssen Biotech,Psoriasis,Biologic,19,12/18/2018,12/17/2019,6/25/2020,,Pending,Method of Treatment,"The application claims a method of treating active Systemic Lupus Erythematosus (SLE) in a patient, comprising administering an anti-IL-12/IL-23p40 antibody to the patient in a clinically proven safe and clinically proven effective amount, including in combination wih other drugs.",After,No,https://patents.google.com/patent/US20200197517A1/en?oq=US20200197517A1
Stelara,US20200197622A1,Janssen Pharmaceuticals,Psoriasis,Biologic,38,12/21/2018,12/17/2019,6/25/2020,,Pending,Device,The application claims an accessory for an injection device wherein the injection device contains ustekinumab (Stelara).,After,No,https://patents.google.com/patent/US20200197622A1/en?oq=US20200197622A1
Stelara,US20200197623A1,Janssen Pharmaceuticals,Psoriasis,Biologic,37,12/21/2018,12/17/2019,6/25/2020,,Pending,Device,The application claims an accessory for an injection device wherein the injection device contains ustekinumab (Stelara).,After,No,https://patents.google.com/patent/US20200197623A1/en?oq=US20200197623A1
Stelara,US20200197624A1,Janssen Pharmaceuticals,Psoriasis,Biologic,36,12/21/2018,12/17/2019,6/25/2020,,Pending,Device,The application claims an accessory for an injection device wherein the injection device contains ustekinumab (Stelara).,After,No,https://patents.google.com/patent/US20200197624A1/en?oq=US20200197624A1
Stelara,US20200197625A1,Janssen Pharmaceuticals,Psoriasis,Biologic,35,12/21/2018,12/17/2019,6/25/2020,,Pending,Device,The application claims an accessory for an injection device wherein the injection device contains ustekinumab (Stelara).,After,No,https://patents.google.com/patent/US20200197625A1/en?oq=US20200197625A1
Stelara,US20200291107A1,Janssen Biotech,Psoriasis,Biologic,16,3/14/2019,3/12/2020,9/17/2020,,Pending,Product,"The application claims an isolated anti-IL-12/IL-23p40 antibody comprising amino acid sequences selected from the group consisting of: (i) a heavy chain (HC) comprising the amino acid sequence of SEQ ID NO: 10 and a light chain (LC) comprising the amino acid sequence of SEQ ID NO:11; (ii) a heavy chain variable domain amino acid sequence of SEQ ID NO:7 and a light chain variable domain amino acid sequence of SEQ ID NO:8; and (iii) heavy chain CDR amino acid sequences of SEQ ID NO: 1, SEQ ID NO:2, and SEQ ID NO:3, and light chain CDR amino acid sequences of SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6, wherein the anti-IL-12/IL-23p40 antibody is expressed in a Chinese Hamster Ovary cell (CHO cell) and its method of manufacture. ",After,No,https://patents.google.com/patent/US20200291107A1/en?oq=US20200291107A1
Stelara,US20200331996A1,Janssen Biotech,Psoriasis,Biologic,21,3/18/2019,3/16/2020,10/22/2020,,Pending,Method of Treatment,"The application claims a method of treating psoriasis in a pediatric patient in need thereof, comprising administering to the pediatric patient a pharmaceutical composition comprising a safe and effective amount of an anti-IL-12/IL-23p40 antibody.",After,No,https://patents.google.com/patent/US20200331996A1/en?oq=US20200331996A1
Stelara,US20200385453A1,Janssen Biotech,Psoriasis,Biologic,29,6/4/2019,6/4/2020,12/10/2020,,Pending,Method of Treatment,"The application claims a method of treating psoriatic arthritis in a subject in need thereof, comprising subcutaneously administering to the subject about 50 mg to about 150 mg of an anti-IL-23 antibody.",After,No,https://patents.google.com/patent/US20200385453A1/en?oq=US20200385453A1
Stelara,US20210030967A1,Janssen Pharmaceuticals,Psoriasis,Biologic,43,7/31/2019,7/28/2020,2/4/2021,,Pending,Device,"The application claims an  injection device with a discharge nozzle, wherein the injection device contains ustekinumab (Stelara).",After,No,https://patents.google.com/patent/US20210030967A1/en?oq=US20210030967A1
Stelara,US20210115129A1,Janssen Biotech,Psoriasis,Biologic,25,10/18/2019,10/16/2020,4/22/2021,,Pending,Formulation / Combination,The application claims a pharmaceutical composition of an anti-IL-12/IL-23p40 antibody  and methods for treating severely active ulcerative colitis.,After,No,https://patents.google.com/patent/US20210115129A1/en?oq=US20210115129A1
Stelara,US20210171622A1,Janssen Biotech,Psoriasis,Biologic,23,9/24/2018,2/11/2021,6/10/2021,,Pending,Formulation / Combination,The application claims a  pharmaceutical composition of an anti-IL-12/IL-23p40 antibody for use in treating a subject with moderately to severely active ulcerative colitis. ,After,No,https://patents.google.com/patent/US20210171622A1/en?oq=US20210171622A1
Stelara,US20210318334A1,Janssen Biotech,Psoriasis,Biologic,26,4/14/2020,4/13/2021,10/14/2021,,Pending,Method of Diagnosis,The application claims method for predicting exposure of an immunoglobulin G (IgG) therapeutic protein in a human patient in need of treatment with the IgG therapeutic protein.,After,No,https://patents.google.com/patent/US20210318334A1/en?oq=US20210318334A1
Stelara,US20210332124A1,Janssen Biotech,Psoriasis,Biologic,22,4/20/2018,7/2/2021,10/28/2021,,Pending,Method of Production / Process,"The application claims a system for producing an anti-IL-12/IL-23p40 antibody, a specific pharmaceutical composition of the antibody, and an antigen binding fragment thereof.",After,No,https://patents.google.com/patent/US20210332124A1/en?oq=US20210332124A1
Stelara,US20220002805A1,Janssen Biotech,Psoriasis,Biologic,30,11/15/2018,11/14/2019,1/6/2022,,Pending,Method of Diagnosis,The application claims a method of predicting a response of a subject diagnosed with an inflammatory bowel disease (IBD) to an anti-interleukin (IL) treatment of the IBD.,After,No,https://patents.google.com/patent/US20220002805A1/en?oq=US20220002805A1
Stelara,US20220025035A1,Janssen Biotech,Psoriasis,Biologic,28,7/13/2020,7/13/2021,1/27/2022,,Pending,Method of Treatment,"The application claims a method of treating psoriatic arthritis in a subject in need thereof, comprising subcutaneously administering to the subject about 50 mg to about 150 mg of an anti-IL-23 antibody once every 4 weeks.",After,No,https://patents.google.com/patent/US20220025035A1/en?oq=US20220025035A1
Stelara,US20220073603A1,Janssen Biotech,Psoriasis,Biologic,24,7/30/2020,7/30/2021,3/10/2022,,Pending,Formulation / Combination,"The application claims a pharmaceutical composition of an anti-IL-12/IL-23p40 antibody and a method of method of selling a drug product comprising ustekinumab, comprising manufacturing ustekinumab; promoting that a therapy comprising ustekinumab is safe and effective for treatment of a pediatric patients from 6 years to less than 12 years old with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.",After,No,https://patents.google.com/patent/US20220073603A1/en?oq=US20220073603A1
Stelara,US20220089716A1,Janssen Biotech,Psoriasis,Biologic,22,4/20/2018,12/8/2021,3/24/2022,,Pending,Method of Production / Process,The application claims a method of operation of chromatography to purity antibodies.,After,No,https://patents.google.com/patent/US20220089716A1/en?oq=US20220089716A1
Stelara,US20220112282A1,Janssen Biotech,Psoriasis,Biologic,27,10/9/2020,10/7/2021,4/14/2022,,Pending,Method of Treatment,"The application claims a method of treating Crohn's disease in a subject in need thereof, comprising: performing endoscopy on the subject prior to treatment to measure baseline simple endoscopic score for Crohn's disease (SES-CD) and baseline CDAI; administering to the subject a pharmaceutical composition comprising a clinically proven safe and clinically proven effective amount of an anti-IL-12/IL-23p40 antibody.",After,No,https://patents.google.com/patent/US20220112282A1/en?oq=US20220112282A1
Stelara,US6902734B2,Janssen Biotech,Psoriasis,Biologic,1,8/7/2000,8/1/2001,6/7/2005,9/25/2023,Active,Product,"The patent claims cover an isolated anti-IL-12 antibody, comprising a heavy chain variable region (VH) of the amino acid sequence set forth in SEQ ID NO:7 and a light chain variable region (VL) of the amino acid sequence set forth in SEQ ID NO:8.",Before,No,https://patents.google.com/patent/US6902734B2/en?oq=US6902734B2
Stelara,US6914128 ,Abbott & AbbVie Deutschland,Psoriasis,Biologic,12,3/25/1999,3/24/2000,7/5/2005,3/24/2020,Expired,Product,"The patent claims cover an  isolated human antibody, or antigen-binding portion thereof that binds to human IL-12 and dissociates from human IL-12 with a K4 of 1×10−10M or less and a koff rate constant of 1×10−3 s−1 or less, as determined by surface plasmon resonance. ",Before,No,https://patents.google.com/patent/US6914128B1/en?oq=US6914128+
Stelara,US7063964 ,Janssen Biotech,Psoriasis,Biologic,1,8/7/2000,10/28/2004,6/20/2006,8/1/2021,Expired,Product,The patent claims cover an isolated nucleic acid molecule encoding an anti-IL-12 antibody comprising a heavy chain variable region (VH) of the amino acid sequence set forth in SEQ ID NO:7 and a light chain variable region (VL) of the amino acid sequence set forth in SEQ ID NO:8 and a method for producing an anti-IL-12 antibody.,Before,No,https://patents.google.com/patent/US7063964B2/en?oq=US7063964+
Stelara,US7166285 ,Janssen Biotech,Psoriasis,Biologic,1,8/7/2000,10/28/2004,1/23/2007,5/3/2022,Expired,Product,"The patent claims cover an isolated anti-IL-12 antibody, comprising a heavy chain complementarity determining region 1 (CDR1) of the amino acid sequence set forth in SEQ ID NO:1, a heavy chain complementarity determining region 2 (CDR2) of the amino acid sequence set forth in SEQ ID NO:2, a heavy chain complementarity determining region 3 (CDR3) of the amino acid sequence set forth in SEQ ID NO:3, a light chain complementarity determining region 1 (CDR1) of the amino acid sequence set forth in SEQ ID NO:4, a light chain complementarity determining region 2 (CDR2) of the amino acid sequence set forth in SEQ ID NO:5, and a light chain complementarity determining region 3 (CDR3) of the amino acid sequence set forth in SEQ ID NO:6.",Before,No,https://patents.google.com/patent/US7166285B2/en?oq=US7166285+
Stelara,US7279157 ,Janssen Biotech,Psoriasis,Biologic,1,8/7/2000,10/28/2004,10/9/2007,1/13/2022,Expired,Method of Treatment,"The patent claims cover a method for treating psoriasis in an animal, comprising: contacting or administering a composition comprising an effective amount of an isolated anti-IL-12 antibody comprising a heavy chain variable region (VH) of the amino acid sequence set forth in SEQ ID NO:7 and a light chain variable region (VL) of the amino acid sequence set forth in SEQ ID NO:8, with, or to, said animal.",Before,No,https://patents.google.com/patent/US7279157B2/en?oq=US7279157+
Stelara,US7504485 ,Abbott & AbbVie Deutschland,Psoriasis,Biologic,12,3/25/1999,7/1/2004,3/17/2009,11/19/2021,Expired,Formulation / Combination,"The patent claims cover a pharmaceutical composition comprising an isolated human antibody, or antigen-binding portion thereof, which is capable of binding to an epitope of the p40 subunit of IL-12, and further comprising an additional agent. ",Before,No,https://patents.google.com/patent/US7504485B2/en?oq=US7504485+
Stelara,US7560247 ,Janssen Biotech,Psoriasis,Biologic,1,8/7/2000,1/29/2007,7/14/2009,8/8/2021,Expired,Product,"The patent claims cover an isolated nucleic acid molecule encoding an anti-IL-12 antibody, comprising a nucleic acid sequence encoding a heavy chain complementarity determining region 1 (CDR1) amino acid sequence of SEQ ID NO:1, a heavy chain complementarity determining region 2 (CDR2) amino acid sequence of SEQ ID NO:2, a heavy chain complementarity determining region 3 (CDR3) amino acid sequence of SEQ ID NO:3, a light chain complementarity determining region 1 (CDR1) amino acid sequence of SEQ ID NO:4, a light chain complementarity determining region 2 (CDR2) amino acid sequence of SEQ ID NO:5, and a light chain complementarity determining region 3 (CDR3) amino acid sequence of SEQ ID NO:6. ",Before,No,https://patents.google.com/patent/US7560247B2/en?oq=US7560247+
Stelara,US7736650,Janssen Biotech,Psoriasis,Biologic,11,12/21/2004,12/21/2005,6/15/2010,10/2/2026,Active,Product,The patent claims cover an expression vector comprising the nucleic acid sequence of SEQ ID NO: 11. ,Before,No,https://patents.google.com/patent/US7736650B2/en?oq=US7736650
Stelara,US7883704 ,Abbott & AbbVie Deutschland,Psoriasis,Biologic,12,3/25/1999,12/22/2006,2/8/2011,5/1/2021,Expired,Method of Treatment,"The patent claims cover a method for inhibiting the activity of the p40 subunit of IL-12 in a human subject suffering from an autoimmune disorder, comprising administering to the human subject an effective amount of a human antibody, or antigen-binding portion thereof, which is capable of binding to an epitope of the p40 subunit of IL-12, wherein the antibody, or antigen binding portion thereof, dissociates from the p40 subunit of IL-12 with a Kd of 1×10−10 M or less or a koff rate constant of 1×10−3 s−1 or less, as determined by surface plasmon resonance, thereby inhibiting the activity of the p40 subunit of IL-12 in said subject. ",Before,No,https://patents.google.com/patent/US7883704B2/en?oq=US7883704+
Stelara,US7887807 ,Janssen Biotech,Psoriasis,Biologic,1,8/7/2000,7/9/2009,2/15/2011,8/1/2021,Expired,Product,"The patent claims cover an isolated anti-IL-12 antibody, comprising a heavy chain complementarity determining region 1 (CDR1) comprising an amino acid sequence with not more than one conservative substitution from the amino acid sequence of SEQ ID NO:1, a heavy chain complementarity determining region 2 (CDR2) comprising an amino acid sequence with not more than one conservative substitution from the amino acid sequence of SEQ ID NO:2, a heavy chain complementarity determining region 3 (CDR3) comprising an amino acid sequence with not more than one conservative substitution from the amino acid sequence of SEQ ID NO:3, a light chain complementarity determining region 1 (CDR1) comprising an amino acid sequence with not more than one conservative substitution from the amino acid sequence of SEQ ID NO:4, a light chain complementarity determining region 2 (CDR2) comprising an amino acid sequence with not more than one conservative substitution from the amino acid sequence of SEQ ID NO:5, and a light chain complementarity determining region 3 (CDR3) comprising an amino acid sequence with not more than one conservative substitution from the amino acid sequence of SEQ ID NO:6, wherein the antibody is a variant of the antibody comprising an heavy chain CDR1 amino acid sequence of SEQ ID NO:1, the heavy chain CDR2 amino acid sequence of SEQ ID NO:2, the heavy chain CDR3 amino acid sequence of SEQ ID NO:3, the light chain CDR1 amino acid sequence of SEQ ID NO:4, the light chain CDR2 amino acid sequence of SEQ ID NO:5, and the light chain CDR3 amino acid sequence of SEQ ID NO:6.",Before,No,https://patents.google.com/patent/US7887807B2/en?oq=US7887807+
Stelara,US8080247 ,Janssen Biotech,Psoriasis,Biologic,1,8/7/2000,12/20/2005,12/20/2011,8/8/2022,Expired,Product,"The patent claims cover an  isolated human anti-IL-12 antibody, wherein said antibody binds to a conformational epitope of the IL-12 protein comprising residues 15, 17-21, 23, 40-43, 45-47, 54-56 and 58-62 of the amino acid sequence of SEQ ID NO:9.",Before,No,https://patents.google.com/patent/US8080247B2/en?oq=US8080247+
Stelara,US8084233 ,Janssen Biotech,Psoriasis,Biologic,1,8/7/2000,12/17/2010,12/27/2011,8/1/2021,Expired,Product,"The patent claims cover anisolated nucleic acid molecule encoding an anti-IL-12 antibody, vectors, host cells and a method of production.",After,No,https://patents.google.com/patent/US8084233B2/en?oq=US8084233+
Stelara,US8329170 ,Janssen Biotech,Psoriasis,Biologic,1,8/7/2000,11/18/2011,12/11/2012,8/1/2021,Expired,Method of Treatment,"The patent claims cover a method for treating psoriasis in an animal, comprising administering a composition comprising an effective amount of an isolated anti-IL-12 antibody, wherein said antibody binds to a conformational epitope of IL-12 protein comprising residues 15, 17-21, 23, 40-43, 45-47, 54-56 and 58-62 of the amino acid sequence of SEQ ID NO:9, to said animal.. Method of Use 2. Treating psoriasis with anti IL-12 antibody that binds to specified epitope (set of amino acid residues) of IL-12 3. not strictly blocking but likely to be asserted as psoriasis is a major use of Stelara",After,No,https://patents.google.com/patent/US8329170B2/en?oq=US8329170+
Stelara,US8329171 ,Janssen Biotech,Psoriasis,Biologic,1,8/7/2000,11/18/2011,12/11/2012,8/1/2021,Expired,Method of Treatment,"The patent claims cover a method for reducing symptoms of psoriatic arthritis in an animal, comprising administering a composition comprising an effective amount of an isolated anti-IL-12 antibody comprising a heavy chain variable region of the amino acid sequence of SEQ ID NO: 7 and a light chain variable region of the amino acid sequence of SEQ ID NO: 8, to said animal.",After,No,https://patents.google.com/patent/US8329171B2/en?oq=US8329171+
Stelara,US8361474 ,Janssen Biotech,Psoriasis,Biologic,11,12/21/2004,4/13/2010,1/9/2013,1/5/2027,Active,Product,The patent claims cover an expression vector comprising the nucleic acid sequence of SEQ ID NO:12. ,After,No,https://patents.google.com/patent/US8361474B2/en?oq=US8361474+
Stelara,US8540992 ,Janssen Biotech,Psoriasis,Biologic,9,12/28/2006,12/26/2007,9/24/2013,2/11/2029,Active,Method of Production / Process," The patent claims cover method for providing a sialidase enzymatic activity in a culture comprising a mammalian cell engineered to express an antibody, comprising transfecting the mammalian engineered cell with a vector encoding a catalytic domain of Arthrobacter ureafaciens sialidase enzyme A, wherein the polypeptide is secreted into the culture along with the antibody, whereby the antibody glycans can be acted upon by the polypeptide sialidase enzymatic activity, and wherein one or more of the avidity for multiply localized target proteins, the macrophage or monocyte activation, and serum half-life of the antibody are altered.",Before,No,https://patents.google.com/patent/US8540992B2/en?oq=US8540992+
Stelara,US8557745 ,Janssen Biotech,Psoriasis,Biologic,2,5/22/2007,5/22/2008,10/15/2013,2/16/2032,Active,Method of Treatment,The patent claims cover a method for predicting the suitability of treatment with an anti-IL-12 antibody therapy for Crohn's disease.,Before,No,https://patents.google.com/patent/US8557745B2/en?oq=US8557745+
Stelara,US8663980B2,Janssen Biotech,Psoriasis,Biologic,10,10/26/2007,10/24/2008,3/4/2014,11/18/2030,Active,Product,"The patent claims cover a mammalian expression vector comprising the nucleotide sequence of SEQ ID NO: 1, SEQ ID NO: 5, or SEQ ID NO: 6 and a method for producing an antibody.",Before,No,https://patents.google.com/patent/US8663980B2/en?oq=US8663980B2
Stelara,US8703141 ,Janssen Biotech,Psoriasis,Biologic,1,8/7/2000,11/7/2012,4/22/2014,8/1/2021,Expired,Method of Treatment,"The patent claims cover a method for reducing symptoms of Crohn's disease in an animal, comprising administering a composition comprising an effective amount of an isolated anti-IL-12 antibody comprising a heavy chain variable region of the amino acid sequence of SEQ ID NO: 7 and a light chain variable region of the amino acid sequence of SEQ ID NO: 8, to said animal. ",After,No,https://patents.google.com/patent/US8703141B2/en?oq=US8703141+
Stelara,US8765918 ,Abbott & AbbVie Deutschland,Psoriasis,Biologic,12,3/25/1999,3/23/2012,7/1/2014,3/24/2020,Expired,Formulation / Combination,"The patent claims cover a pharmaceutical composition comprising a human antibody, or antigen binding portion thereof, that binds to and neutralizes the p40 subunit of human interleukin (IL-12) and dissociates from the human IL-12 with a koff rate constant of about 1×10−4 s−1 to 1×10−5 s−1, as determined by surface plasmon resonance; and at least one additional agent selected from the group consisting of a buffer, a polyalcohol and a surfactant; wherein the antibody, or antigen binding portion thereof, is capable of binding to a first heterodimer and is also capable of binding to a second heterodimer, wherein the first heterodimer comprises the p40 subunit of human IL-12 and the p35 subunit of human IL-12, and wherein the second heterodimer comprises the p40 subunit of human IL-12 and a p19 subunit. ",After,No,https://patents.google.com/patent/US8765918B2/en?oq=US8765918+
Stelara,US8802095 (B2),Durect Corp,Psoriasis,Biologic,4,1/26/2007,10/26/2011,8/12/2014,1/25/2028,Active,Formulation / Combination,"The patent claims cover an injectable, nonaqueous suspension comprising at least one therapeutic agent comprising solid particles suspended in a vehicle consisting of a single component vehicle consisting of an amphiphilic material. The patent describes a therapeutic agent that can be used with the formulation is an anti-IL-12 mAb. ",After,No,https://patents.google.com/patent/US8802095B2/en?oq=US8802095+(B2)
Stelara,US8865174 ,Abbott & AbbVie Deutschland,Psoriasis,Biologic,12,3/25/1999,3/12/2012,10/21/2014,3/24/2020,Expired,Method of Treatment," The patent claims cover a method of treating a human subject suffering from an autoimmune disorder, comprising administering to the human subject an effective amount of a human antibody, or antigen-binding portion thereof, which binds to the p40 subunit of human interleukin-12 (IL-12) and dissociates from human IL-12 with a koff rate constant of about 1×10−4 s−1 to 1×10−5 s−1, as determined by surface plasmon resonance, wherein the antibody is capable of binding to a first heterodimer and is also capable of binding to a second heterodimer, wherein the first heterodimer comprises the p40 subunit of human IL-12 and the p35 subunit of human IL-12, and wherein the second heterodimer comprises the p40 subunit of human IL-12 and a p19 subunit, thereby treating said subject.",After,No,https://patents.google.com/patent/US8865174B2/en?oq=US8865174+
Stelara,US8894990 ,Janssen Biotech,Psoriasis,Biologic,1,8/7/2000,11/6/2012,11/25/2014,8/16/2021,Expired,Method of Treatment,"The patent claims cover a method for treating psoriatic arthritis in an animal, comprising administering a composition comprising an effective amount of an isolated anti-IL-12 antibody, wherein said antibody binds to a conformational epitope of IL-12 protein comprising residues 15, 17-21, 23, 40-43, 45-47, 54-56 and 58-62 of the amino acid sequence of SEQ ID NO:9, to said animal. ",After,No,https://patents.google.com/patent/US8894990B2/en?oq=US8894990+
Stelara,US8975040 ,Janssen Biotech,Psoriasis,Biologic,9,12/28/2006,8/23/2013,3/10/2015,1/7/2028,Active,Method of Production / Process,"The patent claims cover a method for controlling the properties of an antibody expressed in a cell line, comprising reducing the sialylation of the oligosaccharides in the Fc region by transfecting the cell line with a vector encoding a catalytic domain of Arthrobacter ureafaciens sialidase enzyme, wherein the antibody expressed comprises a reduced amount of sialic acid residues. ",After,No,https://patents.google.com/patent/US8975040B2/en?oq=US8975040+
Stelara,US8980626 ,Janssen Biotech,Psoriasis,Biologic,10,10/26/2007,1/24/2014,3/17/2015,10/24/2028,Active,Product,"The patent claims cover a mammalian expression vector comprising: mammalian expression control polynucleotide sequences;
a polynucleotide sequence encoding a constant region of an antibody; and restriction sites downstream from the expression control sequences, wherein the vector comprises the nucleotide sequence of SEQ ID NO:5. ",After,No,https://patents.google.com/patent/US8980626B2/en?oq=US8980626+
Stelara,US9035030 ,Abbott & AbbVie Deutschland,Psoriasis,Biologic,12,3/25/1999,2/21/2012,5/19/2015,3/24/2020,Expired,Product,"The patent claims cover an  isolated human antibody, or antigen-binding portion thereof, which is capable of binding to the p40 subunit of human interleukin 12 (IL-12) and dissociates from human IL-12 with a koff rate constant of about 1×10−4 s−1 to 1×10−5 s−1, as determined by surface plasmon resonance, wherein the antibody is capable of binding to a first heterodimer and is also capable of binding to a second heterodimer, wherein the first heterodimer comprises the p40 subunit of human IL-12 and the p35 subunit of human IL-12, and wherein the second heterodimer comprises the p40 subunit of human IL-12 and a p19 subunit.",After,No,https://patents.google.com/patent/US9035030B2/en?oq=US9035030+
Stelara,US9206248 ,Janssen Biotech,Psoriasis,Biologic,10,10/26/2007,2/9/2015,12/8/2015,10/24/2028,Active,Product,"The patent claims cover a mammalian expression vector comprising: mammalian expression control polynucleotide sequences; and
restriction sites downstream from the expression control sequences, wherein the vector comprises the nucleotide sequence of SEQ ID NO:3",After,No,https://patents.google.com/patent/US9206248B2/en?oq=US9206248+
Stelara,US9409984 ,Janssen Biotech,Psoriasis,Biologic,1,8/7/2000,2/26/2014,8/9/2016,2/27/2022,Expired,Method of Treatment,"The patent claims cover a method for treating psoriasis in an animal, comprising administering a composition comprising an effective amount of an isolated anti-IL-12antibody within the defined 6 CDR regions of the Vh and Vl regions.",After,No,https://patents.google.com/patent/US9409984B2/en?oq=US9409984
Stelara,US9428579 ,Janssen Biotech,Psoriasis,Biologic,1,8/7/2000,10/13/2014,8/30/2016,12/17/2021,Expired,Method of Treatment,"The patent claims cover a method for reducing symptoms of Crohn's disease in an animal, comprising administering a composition comprising an effective amount of an isolated anti-IL-12 antibody, wherein said antibody binds to a conformational epitope of IL-12 protein comprising residues 15, 17-21, 23, 40-43, 45-47, 54-56 and 58-62 of the amino acid sequence of SEQ ID NO:9, to said animal. ",After,No,https://patents.google.com/patent/US9428579B2/en?oq=US9428579+
Stelara,US9605067 ,Janssen Biotech,Psoriasis,Biologic,1,8/7/2000,7/22/2016,3/28/2017,8/1/2021,Expired,Product,"The patent claims cover isolated nucleic acid molecule encoding a mammalian anti-IL-12 antibody, wherein said antibody binds to a conformational epitope of IL-12 protein comprising residues 15, 17-21, 23, 40-43, 45-47, 54-56 and 58-62 of the amino acid sequence of SEQ ID NO:9. and methods of production.",After,No,https://patents.google.com/patent/US9605067B2/en?oq=US9605067+
Stelara,US9676848 ,Janssen Biotech,Psoriasis,Biologic,1,8/7/2000,6/30/2016,6/13/2017,8/1/2021,Expired,Formulation / Combination,The patent claims cover a pen-injector containing a liquid pharmaceutical formulation comprising an effective amount of an isolated anti-IL-12 antibody having a heavy chain variable region and a light chain variable region ,After,No,https://patents.google.com/patent/US9676848B2/en?oq=US9676848+
Stelara,US9862766 ,Janssen Biotech,Psoriasis,Biologic,1,8/7/2000,2/14/2017,1/9/2018,8/1/2021,Expired,Method of Treatment,"The patent claims cover a method for reducing symptoms of lupus in an animal, comprising administering a composition comprising an effective amount of an isolated anti-IL-12 antibody, wherein said antibody binds to a conformational epitope of IL-12 protein comprising residues 15, 17-21, 23, 40-43, 45-47, 54-56 and 58-62 of the amino acid sequence of SEQ ID NO:9, to said animal. ",After,No,https://patents.google.com/patent/US9862766B2/en?oq=US9862766+
Trulicity, US20210290841A1,Eli Lilly,Diabetes,Biologic,27,8/17/2018,8/8/2019,9/23/2021,,Pending,Device,"The application claims a delivery device, comprising: a dose member rotatable during a dose dispensing event; a detection system including a position indicator, and a controller in communication with the first and second electrical circuits, and operable to determine a number of units of rotation of the dose member based on, directly or indirectly, at least one of the generated first and second signals.",After,No,https://patents.google.com/patent/US20210290841A1/en?oq=US20210290841A1
Trulicity, US9764004B2,Eli Lilly,Diabetes,Biologic,12,10/26/2015,10/14/2016,9/19/2017,10/14/2036,Active,Product," The patent claims cover GLP-1 compounds, a pharmaceutical composition  and a method of treating fatty liver in bovines.",After,No,https://patents.google.com/patent/US9764004B2/en?oq=+US9764004B2
Trulicity,US 11123488 B2,Eli Lilly,Diabetes,Biologic,17,10/3/2018,9/27/2019,9/21/2021,9/27/2039,Active,Device,"The patent claims cover an injection device assembly comprising: a device housing having a proximal end and a distal end; a user-graspable portion configured to be grasped by a hand of a user; an outwardly flared end portion at the proximal end of the housing adjacent to the proximal opening; a syringe assembly at least partially disposed within the interior volume; a drive mechanism configured to move the entire syringe assembly from a storage position to an injection position and one or more main printed circuit boards (PCBs) disposed within the outwardly flared end portion of the device housing. . The patent describes how the device can be used with (GLP-1) receptor agonists such as dulaglutide or liraglutide

",After,No,https://patents.google.com/patent/US11123488B2/en?oq=US+11123488+B2
Trulicity,US10627377B2,Eli Lilly,Diabetes,Biologic,45,10/18/2017,10/11/2018,4/21/2020,10/11/2038,Active,Method of Production / Process,"The patent claims cover a testing method for accelerating silicone drainage rate for a siliconized syringe, comprising:
(a) placing a syringe including a film of silicone in a predefined orientation into a centrifugation holder of a centrifuge system, the syringe including a needle end and an opposite, flange end, the predefined orientation of said syringe including the flange end being disposed farther away from a center axis of the centrifuge system than the needle end or the needle end being disposed farther away from said center axis of the centrifuge system than the flange end; (b) activating a centrifugation of the centrifugation holder of the centrifuge system with the syringe at a predetermined G-rate and for a predetermined period of a time; (c) ending the centrifugation of the centrifugation holder with the syringe after the predetermined period of time has elapsed; and (d) assessing one or more injection functionality parameters of the syringe after the elapsed predetermined period of time.",After,No,https://patents.google.com/patent/US10627377B2/en?oq=US10627377B2
Trulicity,US10709766B2,Eli Lilly,Diabetes,Biologic,67,5/7/2015,11/22/2017,7/14/2020,8/19/2036,Active,Product,"The patent claims cover an an insulin receptor agonist, peptide linkers and a  human IgG Fc region. ",After,No,https://patents.google.com/patent/US10709766B2/en?oq=US10709766B2
Trulicity,US10987472B2,Eli Lilly,Diabetes,Biologic,35,2/28/2017,12/11/2020,4/27/2021,2/22/2038,Active,Device,"The patent claims cover a dose delivery measurement module for use with a medication delivery device having an actuator, a dose setting member, a magnetic ring with one or more dipoles, the magnetic ring fixed rotationally with the dose setting member that rotates during dose setting and/or dose deliveryof treatment. The patent describes how the device can be used with (GLP-1) receptor agonists such as dulaglutide or liraglutide

",After,No,https://patents.google.com/patent/US10987472B2/en?oq=US10987472B2
Trulicity,US11071831B2,Eli Lilly,Diabetes,Biologic,18,2/22/2018,2/20/2019,7/27/2021,2/20/2039,Active,Device,"The patent claims cover a dose detection module for removable attachment to a dose button of a medication delivery device, the dose button having a button sidewall, the device comprising a sensed component ring rotatable during dose dispensing.  The patent describes how the device can be used with (GLP-1) receptor agonists such as dulaglutide or liraglutide",After,No,https://patents.google.com/patent/US11071831B2/en?oq=US11071831B2
Trulicity,US11179522B2,Eli Lilly,Diabetes,Biologic,31,3/29/2019,3/19/2020,11/23/2021,3/19/2040,Active,Device,"The patent claims cover a medication delivery device, comprising: a housing defined about a longitudinal axis, a plunger having an elongated body with an end to drive a piston disposed within a medication cartridge barrel, a plunger drive system configured to distally advance the plunger, wherein the at least one pinion drive includes a first pinion drive and a second pinion drive disposed along opposite sides of the output drive member, wherein, in response to movement of the actuator to the extended position from the retracted position, wherein, in response to movement of the actuator to the retracted position from the extended position rotation of the at least one pinion drive in a second direction along the drive teeth is configured to axially translate the output drive member, with the one or more pawled ends of the output drive member in engagement with the ratchet teeth of said plunger to prevent said output drive member from translating axially relative to said plunger, thereby advancing the plunger in a distal direction.. The patent  describes how the device can be used with (GLP-1) receptor agonists such as dulaglutide or liraglutide",After,No,https://patents.google.com/patent/US11179522B2/en?oq=US11179522B2
Trulicity,US11253574B2,Eli Lilly,Diabetes,Biologic,67,5/7/2015,6/5/2020,2/22/2022,4/28/2036,Active,Method of Treatment,"The patent claims cover a method of treating a patient with diabetes mellitus comprising administering to a patient in need thereof a therapeutically effective amount of a fusion protein comprising an insulin receptor, peptide linkers and a human IgG Fc region. ",After,No,https://patents.google.com/patent/US11253574B2/en?oq=US11253574B2
Trulicity,US11298462B2,Eli Lilly,Diabetes,Biologic,55,3/15/2019,3/6/2020,4/12/2022,3/6/2040,Active,Device,"The patent claims cover an automatic injection device, comprising: a housing comprising a proximal end and a distal end;
a syringe including a needle, a shuttle having a distal surface comprising a shuttle protrusion and a curvilinear surface, a follower having a follower body and a latch, wherein: the follower has a coupled configuration in which the latch is biasedly coupled over the shuttle protrusion and the straight leading surface of the latch protrusion is in contact with the shuttle protrusion, and the follower has a decoupled configuration in which the latch has cleared the shuttle protrusion and the curved trailing surface of the latch protrusion is in sliding engagement with the curvilinear surface, the follower is rotatable relative to the shuttle, and the shuttle is moveable toward the proximal end of the housing to retract the syringe. The patent  describes how the device can be used with (GLP-1) receptor agonists such as dulaglutide or liraglutide

",After,No,https://patents.google.com/patent/US11298462B2/en?oq=US11298462B2
Trulicity,US20090232807A1,Eli Lilly,Diabetes,Biologic,9,12/22/2004,12/15/2005,9/17/2009,,Abandoned,Formulation / Combination,"The application claimed  a  stable solution formulation comprising a therapeutically effective amount of of any of 6 GLP-1 protein sequences (30 amino acids each) joined to an Fc portion of an immunoglobulin (1 sequence), wherein the  GLP-1-Fc fusion is at a pH of between about pH 6 and about pH 8.5. ",Before,No,https://patents.google.com/patent/US20090232807A1/en?oq=US20090232807A1
Trulicity,US20100196405A1,Eli Lilly,Diabetes,Biologic,2,7/10/2007,7/9/2008,8/5/2010,,Abandoned,Formulation / Combination,"The application claimed a  stable solution formulation comprising a therapeutically effective amount of a GLP-1-Fc fusion protein in citrate buffer with polysorbate-80 in the range of about 0.01% to 0.05% (w/v), mannitol in the range of about 4.3 to 5.0% (w/v), and wherein the solution has a pH in the range of about pH 6 to 7. ",Before,No,https://patents.google.com/patent/US20100196405A1/en?oq=US20100196405A1
Trulicity,US20110034373A1,Eli Lilly,Diabetes,Biologic,10,8/3/2007,7/30/2008,2/10/2011,,Abandoned,Method of Treatment,"The application claimed a method of treating obesity comprising administering an FGF-21 compound in combination with a GLP-1 compound, wherein the FGF-21 compound is an FGF-21 analog selected from the group consisting of Cys118-Cys134-FGF-21 (SEQ ID NO: 9), Cys118-Cys134-Ala167-FGF-21 (SEQ ID NO: 10), Cys21-Cys33-Ala167-FGF-21 (SEQ ID NO: 11), Cys26-Cys122-Ala167-FGF-21 (SEQ ID NO: 12), and Cys118-Cys134-Ala121-Ala167-FGF-21 (SEQ ID NO: 13).",Before,No,https://patents.google.com/patent/US20110034373A1/en?oq=US20110034373A1
Trulicity,US20140024586A1,Eli Lilly,Diabetes,Biologic,10,8/3/2007,10/3/2013,1/23/2014,,Abandoned,Method of Treatment,"The application claimed a  method of treating diabetes comprising administering an FGF-21 compound in combination with a GLP-1 compound, wherein the GLP-1 compound comprises an amino acid sequence of SEQ ID NO: 20.",Before,No,https://patents.google.com/patent/US20140024586A1/en?oq=US20140024586A1
Trulicity,US20180104312A1,Eli Lilly,Diabetes,Biologic,12,10/26/2015,10/14/2016,4/19/2018,,Abandoned,Product,"The application claimed GLP-1 compounds, a pharmaceutical composition and a method of treating a disease selected from the group consisting of T2DM, obesity, fatty liver disease, NASH, dyslipidernia, metabolic syndrome, hyperinsulinemia and nighttime hypoglycemia",After,No,https://patents.google.com/patent/US20180104312A1/en?oq=US20180104312A1
Trulicity,US20200023137A1,Eli Lilly,Diabetes,Biologic,35,2/28/2017,2/22/2018,1/23/2020,,Pending,Device,"The application claims a  medication delivery device comprising: a device body; a dose setting member attached to said device body and rotatable relative to said device body during dose delivery; a ring-shaped sensed element rotationally fixed with said dose setting member; an actuator attached to said device body and movable relative to said device body during dose delivery; a dose delivery measurement module removably attached to the actuator, including a plurality of rotation sensors attached to said module, equi-radially spaced apart and axially over said ring-shaped sensed element and responsive to relative rotation of said ring-shaped sensed element relative to said actuator during dose delivery; and a controller responsive to said rotation sensor to detect the amount of rotation of said dose setting member relative to said actuator during dose delivery. treatment The patent application describes how the device can be used with (GLP-1) receptor agonists such as dulaglutide or liraglutide

",After,No,https://patents.google.com/patent/US20200023137A1/en?oq=US20200023137A1
Trulicity,US20200030537A1,Eli Lilly,Diabetes,Biologic,42,2/17/2017,2/9/2018,1/30/2020,,Pending,Device,"The application claims a device for delivering a therapeutic fluid by chemical reaction. The patent describes how the device can be used with (GLP-1) receptor agonists such as dulaglutide or liraglutide

",After,No,https://patents.google.com/patent/US20200030537A1/en?oq=US20200030537A1
Trulicity,US20200147318A1,Eli Lilly,Diabetes,Biologic,50,8/21/2017,2/22/2018,5/14/2020,,Pending,Device,"The application claims a medication delivery device comprising a device body; a dose setting member; a sensed element attached to and rotationally fixed with said dose setting member; an actuator attached to said device body; a rotation sensor attached to said actuator during dose delivery and a controller responsive to said rotation sensor to determine the amount of dose delivery based on the detected rotation of said dose setting member relative to said actuator during dose delivery. The patent application describes how the device can be used with (GLP-1) receptor agonists such as dulaglutide or liraglutide

",After,No,https://patents.google.com/patent/US20200147318A1/en?oq=US20200147318A1
Trulicity,US20200171129,Eli Lilly,Diabetes,Biologic,7,6/1/2017,5/24/2018,6/4/2020,,Pending,Method of Treatment,The application claims a method of treating chronic kidney disease  (CKD) and associated diagnoses in a patient with dulaglutide. ,After,No,https://patents.google.com/patent/US20200171129A1/en?oq=US20200171129
Trulicity,US20200171246A1,Eli Lilly,Diabetes,Biologic,40,8/18/2017,8/17/2018,6/4/2020,,Pending,Device,"The application claims a medication delivery device comprising a device body, a dose setting member, a sensed element attached to and rotationally fixed with said dose setting member,  an actuator, a rotation sensor and an electronics assembly responsive to the rotation sensor to determine the amount of dose delivery based on the detected rotation of said dose setting member relative to said actuator during dose delivery. The patent application describes how the device can be used with (GLP-1) receptor agonists such as dulaglutide or liraglutide",After,No,https://patents.google.com/patent/US20200171246A1/en?oq=US20200171246A1
Trulicity,US20200179607A1,Eli Lilly,Diabetes,Biologic,63,5/2/2017,4/25/2018,6/11/2020,,Abandoned,Device,"The application claimed an injection device for dispensing medication from a medicament cartridge having a needle assembly at one end and a piston disposed opposite the needle assembly wherein advancement of the piston within the cartridge discharges medication from the needle assembly. The patent  application describes how the device can be used with (GLP-1) receptor agonists such as dulaglutide or liraglutide

",After,No,https://patents.google.com/patent/US20200179607A1/en?oq=US20200179607A1
Trulicity,US20200188595A1,Eli Lilly,Diabetes,Biologic,66,5/2/2017,4/25/2018,6/18/2020,,Pending,Device,"The application claims an  injection device comprising a housing assembly, a driver, a plunger and a breaking mechanism.  The patent application describes how the device can be used with (GLP-1) receptor agonists such as dulaglutide or liraglutide",After,No,https://patents.google.com/patent/US20200188595A1/en?oq=US20200188595A1
Trulicity,US20200197605A1,Eli Lilly,Diabetes,Biologic,22,5/5/2017,5/3/2018,6/25/2020,,Pending,Device,"The application claims a medication delivery device to control glucose in a patient and a method of treatment. The patent application describes how the device can be used with (GLP-1) receptor agonists such as dulaglutide or liraglutide

",After,No,https://patents.google.com/patent/US20200197605A1/en?oq=US20200197605A1
Trulicity,US20200197611A1,Eli Lilly,Diabetes,Biologic,52,7/27/2017,7/20/2018,6/25/2020,,Pending,Device,"The application claims a device for delivering a therapeutic fluid by chemical reaction comprising a barrel, an acutator, a syringe, and a plunger and a method of use. The patent application describes how the device can be used with (GLP-1) receptor agonists such as dulaglutide or liraglutide",After,No,https://patents.google.com/patent/US20200197611A1/en?oq=US20200197611A1
Trulicity,US20200206431A1,Eli Lilly,Diabetes,Biologic,61,8/21/2017,2/22/2018,7/2/2020,,Pending,Device,"The application claims a  medication delivery device comprising a device body; a dose setting member attached to said device body; a sensed element attached to and rotationally fixed with said dose setting member; an actuator attached to said device body; a dose detection module attached to said actuator and located proximal to said actuator and a controller responsive to said rotation sensor to determine the amount of dose delivery based on the detected rotation of said dose setting member relative to said actuator during dose delivery. The patent application describes how the device can be used with (GLP-1) receptor agonists such as dulaglutide or liraglutide

",After,No,https://patents.google.com/patent/US20200206431A1/en?oq=US20200206431A1
Trulicity,US20200222638A1,Eli Lilly,Diabetes,Biologic,60,10/12/2017,10/5/2018,7/16/2020,,Pending,Device,"The application claims a device for removing a protective shield, the device comprising a cup shaped body defined about a longitudinal axis, said body having a sidewall circumscribing an interior space and a distal bottom wall, and a proximal opening in communication with the interior space, wherein the proximal opening is configured to receive the protective shield to be disposed within the interior space, wherein the sidewall includes a plurality of sidewall openings formed therein, a plurality of fingers each having a proximal end flexibly coupled with the sidewall and extending distally within the corresponding sidewall openings, each of the fingers further including at least one projection extending in a circumferential direction and projecting toward the interior space, wherein the at least one projection on each finger is engageable with the protective shield when the protective shield is disposed within the interior space. The patent application describes how the device can be used with (GLP-1) receptor agonists such as dulaglutide or liraglutide",After,No,https://patents.google.com/patent/US20200222638A1/en?oq=US20200222638A1
Trulicity,US20200225200A1,Eli Lilly,Diabetes,Biologic,45,10/18/2017,3/26/2020,7/16/2020,,Pending,Method of Production / Process,The application claims a method of testing syringes for preparation to be pre-loaded with medication,After,No,https://patents.google.com/patent/US20200225200A1/en?oq=US20200225200A1
Trulicity,US20200238068A1,Eli Lilly,Diabetes,Biologic,25,10/4/2017,9/27/2018,7/30/2020,,Pending,Device,"The application claims a transparent tubing, the transparent tubing comprising: a longitudinal axis having a center; an inner circumferential surface defining a fluid pathway therethrough for delivering a first medium having a first index of refraction n1;
an outer circumferential surface; at least one visual marker; and, at least one integrated lens disposed opposite from the at least one visual marker, the at least one integrated lens configured to direct light from the at least one visual marker for detecting a presence or an absence in the fluid pathway of a second medium having a second index of refraction n2, where the second index of refraction n2 is different from the first index of refraction n1. The patent application describes how the device can be used with (GLP-1) receptor agonists such as dulaglutide or liraglutide

",After,No,https://patents.google.com/patent/US20200238068A1/en?oq=US20200238068A1
Trulicity,US20200276383A1,Eli Lilly,Diabetes,Biologic,43,9/13/2017,9/10/2018,9/3/2020,,Pending,Device,"The application claims a tube management device for an infusion set having a flexible tube for conveying a medication between a reservoir and an infusion site on a patient, the device comprising: a central spindle defining an axis; a base member projecting radially outwardly from the central spindle; an upper member projecting radially outwardly from the central spindle wherein the base member and the upper member are axially spaced apart; a plurality of retainer members disposed on at least one of the base member and the upper member, wherein the central spindle, the base member, the upper member, and the plurality of retainer members define a toroidal space sized to receive a variable length of the flexible tube; and wherein the plurality of retainer members restrict radially outward movement of a length of the flexible tube wound about the central spindle. The patent application describes how the device can be used with (GLP-1) receptor agonists such as dulaglutide or liraglutide

",After,No,https://patents.google.com/patent/US20200276383A1/en?oq=US20200276383A1
Trulicity,US20200330558A1,Eli Lilly,Diabetes,Biologic,3,11/21/2017,11/13/2018,10/22/2020,,Pending,Method of Treatment,"The application claims a method of improving glycemic control in a subject having type 2 diabetes (T2D) and in need of additional glycemic control, comprising: a) identifying a subject having T2D and in need of further glycemic control; b) administering to said subject a first dose of dulaglutide once weekly for a minimum of four weeks; and c) increasing the dose to a second dose administered once weekly, wherein the first dose is selected from the group consisting of 1.5 and 3.0 mg, and the second dose is selected from the group consisting of 3.0 and 4.5 mg.",After,No,https://patents.google.com/patent/US20200330558A1/en?oq=US20200330558A1
Trulicity,US20200397996A1,Eli Lilly,Diabetes,Biologic,18,2/22/2018,2/20/2019,12/24/2020,,Pending,Device,"The application claims a medication delivery device comprising: a device body; a dose setting component coupled to said device body and rotatable relative to said device body in relation to an amount of a set or delivered dose, said dose setting component having a proximal surface; an annular sensed element positioned on the proximal surface of said dose setting component; and
a carrier including a proximal overlapping support contactable against said annular sensed element opposite the proximal surface of said dose setting component, said carrier being axially and rotationally fixed to said dose setting component.  The patent application describes how the device can be used with (GLP-1) receptor agonists such as dulaglutide or liraglutide",After,No,https://patents.google.com/patent/US20200397996A1/en?oq=US20200397996A1
Trulicity,US20210038816A1,Eli Lilly,Diabetes,Biologic,64,9/8/2017,8/31/2018,2/11/2021,,Pending,Device,"The application claims a device for delivering a therapeutic fluid by a chemical reaction, the device comprising: a housing having a first chamber, a second chamber, and a third chamber; wherein the device has: a loaded configuration in which the first chamber contains a liquid base, the second chamber contains a polymeric acid, and the third chamber contains the therapeutic fluid; and a delivery configuration in which the liquid base reacts with the polymeric acid to generate a propellant gas that delivers the therapeutic fluid from the third chamber. The patent application  describes how the device can be used with (GLP-1) receptor agonists such as dulaglutide or liraglutide

",After,No,https://patents.google.com/patent/US20210038816A1/en?oq=US20210038816A1
Trulicity,US20210146052A1,Eli Lilly,Diabetes,Biologic,34,4/19/2018,4/12/2019,5/20/2021,,Pending,Device,The application claims an injection device assembly comprising: a device housing defining an interior volume extending about a longitudinal axis; a syringe assembly at least partially disposed within the interior volume; a drive mechanism coupled with the syringe assembly and including a plunger engageable with the piston; a status sensing system including a light emitter configured to emit electromagnetic radiation; i) an injection ready state wherein the syringe assembly is in the storage position and the piston is in the initial piston distal position;ii) a needle insertion state wherein the syringe assembly is in the injection position and the piston is in the initial piston distal position; and iii) a drug delivered state wherein the syringe assembly is in the injection position and the piston is in the final piston proximal position.,After,No,https://patents.google.com/patent/US20210146052A1/en?oq=US20210146052A1
Trulicity,US20210146061A1,Eli Lilly,Diabetes,Biologic,28,8/21/2017,8/14/2018,5/20/2021,,Pending,Device,"The application claims a medication delivery device comprising: a device body; a sensed element attached to and rotationally fixed with said dose setting member; an actuator attached to said device body; a rotational sensor attached to said actuator and a a controller operatively coupled to the rotational sensor, wherein, in response to receiving the generated signal from said rotational sensor, the controller is configured to determine a number of the axially extending surface features passing the movable element of the rotational sensor during dose delivery. The patent application describes how the device can be used with (GLP-1) receptor agonists such as dulaglutide or liraglutide

",After,No,https://patents.google.com/patent/US20210146061A1/en?oq=US20210146061A1
Trulicity,US20210215625A1,Eli Lilly,Diabetes,Biologic,8,8/21/2018,1/22/2021,7/15/2021,,Pending,Method of Production / Process,"The application claims a  method of determining absolute protein concentration of a protein in solution, comprising the steps of:
a. denaturing the protien; b. performing qNMR spectroscopy on the denatured protein, wherein said step of performing qNMR spectroscopy includes use of a diffusion filter; and c. calculating the absolute protein concentration of the protein using a reference standard and a referencing technique.",After,No,https://patents.google.com/patent/US20210215625A1/en?oq=US20210215625A1
Trulicity,US20210236739A1,Eli Lilly,Diabetes,Biologic,35,2/28/2017,4/23/2021,8/5/2021,,Pending,Device,"The application claims a  method of administering medicationincluding  insulin analogs and GLP-1 receptor agonists to a patient with a medication delivery device, wherein the medication delivery device comprises a housing, a reservoir containing a medication, a needle in fluid communication with the reservoir, an actuator, a dose setting member, and a magnetic ring with one or more dipoles, the magnetic ring fixed rotationally with the dose setting member that rotates during dose setting and/or dose delivery, the actuator comprising a rotatable dose skirt and a push dose button positioned proximal to said rotatable dose skirt, and a dose delivery measurement module having a module body engageable with at least one of the push dose button and the rotatable dose skirt, a plurality of magnetic sensing elements coupled to said module body, the magnetic sensing elements spaced equi-radially apart to define a ring pattern, positioned axially over said magnetic ring, and are arranged in an overlapping position relative to an outer circumference of the magnetic ring, and a controller operably connected to the magnetic sensing elements, wherein the magnetic sensing elements are configured to detect an angular position and/or a rotational movement of the magnetic ring relative to the magnetic sensing elements in order to generate a signal representative of the detected angular position and/or rotational movement, wherein the controller is configured to receive the signal.",After,No,https://patents.google.com/patent/US20210236739A1/en?oq=US20210236739A1
Trulicity,US20210268188A1,Eli Lilly,Diabetes,Biologic,17,10/3/2018,5/14/2021,9/2/2021,,Pending,Device,"The application claims an injection device assembly comprising:a housing;a syringe assembly at least partially disposed within the housing;a drive mechanism configured to drive the syringe assembly from a storage position to an injection position;one or more skin-contact sensors, each sensor being configured to detect contact with skin tissue;an accelerometer disposed within the housing and configured to output a signal representative of sensed acceleration; anda processing circuit operably coupled with the one or more skin-contact sensors and the accelerometer configured to analyze the signal output by the accelerometer to detect acceleration spikes, and
determine that a first acceleration spike detected in the signal output by the accelerometer is caused by initiation of a dispensing event in which the syringe assembly is driven by the drive mechanism from the storage position to the injection position when at least one of the one or more skin-contact sensors detect contact with skin tissue at the time the first acceleration spike was detected. The patent application describes how the device can be used with (GLP-1) receptor agonists such as dulaglutide or liraglutide",After,No,https://patents.google.com/patent/US20210268188A1/en?oq=US20210268188A1
Trulicity,US20210330888A1,Eli Lilly,Diabetes,Biologic,18,2/22/2018,7/2/2021,10/28/2021,,Pending,Device,"The application claims a dose detection module to attach to a dose actuator of a medication delivery device, the dose actuator having a cylindrical button sidewall, the device comprising a sensed component rotatable during dose dispensing, said module comprising:
a housing; a plurality of attachment arms configured for coupling to the actuator; and an electronics assembly contained in the housing, comprising a processor, and at least one measurement sensor operably coupled to the processor, wherein the at least one measurement sensor is configured to detect angular position and/or rotational movement of the sensed component to generate position signals, wherein the electronics assembly includes an identification sensor operably coupled to the processor, wherein, when the dose detection module is attached to the dose actuator, a light guide member is disposed between the identification sensor and an axial surface of the dose actuator, the light guide member is configured to provide an optical path for the identification sensor. The patent application describes how the device can be used with (GLP-1) receptor agonists such as dulaglutide or liraglutide",After,No,https://patents.google.com/patent/US20210330888A1/en?oq=US20210330888A1
Trulicity,US20210353853A1,Eli Lilly,Diabetes,Biologic,24,8/26/2019,8/21/2020,5/31/2022,,Pending,Device,The application claims a rotary sub-assembly for pumping of drug fluid in a drug-delivery device. The patent application describes how the device can be used with (GLP-1) receptor agonists such as dulaglutide or liraglutide,After,No,https://patents.google.com/patent/US20210353853A1/en?oq=US20210353853A1
Trulicity,US20210361880A1,Eli Lilly,Diabetes,Biologic,49,12/19/2018,12/12/2019,11/25/2021,,Pending,Device,"The application claims a herapeutic agent delivery system, comprising  a housing; a drive wheel carried by the housing, the drive wheel being rotatable relative to the housing; a plunger rod being rotatable with the drive wheel relative to the housing from a first rotational configuration to a second rotational configuration,  a plunger restraint maintaining the plunger rod in the first translational configuration when the plunger rod is disposed in the first rotational configuration, a needle being movable relative to the housing from a stowed configuration to a deployed configuration and a therapeutic agent delivery assembly carrying a therapeutic agent and in communication with the needle. The patent application describes how the device can be used with (GLP-1) receptor agonists such as dulaglutide or liraglutide",After,No,https://patents.google.com/patent/US20210361880A1/en?oq=US20210361880A1
Trulicity,US20210369971A1,Eli Lilly,Diabetes,Biologic,39,8/31/2017,8/22/2018,12/2/2021,,Pending,Device,"The application claims a medication delivery device comprising: a device body having a longitudinal axis; an actuator that is movable relative to the device body during a dose setting operation and movable relative to the device body along the longitudinal axis during a dose dispensing operation to deliver a medication, the actuator including a contactable surface defining a plurality of teeth;
a dose setting member that rotates relative to the device body during the dose dispensing operation, the dose setting member including a finger extending at least one of radially or axially and configured to apply a mechanical force to the contactable surface as the finger contacts the teeth of the contactable surface during relative rotation; and a dose detection system configured to detect rotation of the dose setting member relative to the actuator during the dose dispensing operation, the dose detection system including a piezoelectric sensor. The patent application describes how the device can be used with (GLP-1) receptor agonists such as dulaglutide or liraglutide

",After,No,https://patents.google.com/patent/US20210369971A1/en?oq=US20210369971A1
Trulicity,US20210369973A1,Eli Lilly,Diabetes,Biologic,35,2/28/2017,8/12/2021,12/2/2021,,Pending,Device,"The application claims a dose detection system adapted for a medication delivery device, the medication delivery device comprising a substantially elongate housing, an injectable medication held by the housing, the housing having a proximal end portion and a distal end portionof treatment. The patent application describes how the device can be used with (GLP-1) receptor agonists such as dulaglutide or liraglutide

",After,No,https://patents.google.com/patent/US20210369973A1/en?oq=US20210369973A1
Trulicity,US20220031936A1,Eli Lilly,Diabetes,Biologic,33,10/10/2018,10/8/2019,2/3/2022,,Pending,Device,"The application claims a drug-delivery device assembly comprising: a manifold configured to detachably couple with an infusion hub configured to subcutaneously deliver a primary drug into a patient's body, the manifold defining a fluid channel that connects a proximal surface of the manifold with a distal surface of the manifold; a screw cap having an internal surface that, when the screw cap is coupled to the manifold, opposes the distal surface of the manifold; and a flexible drug reservoir disposed between the distal surface of the manifold and the internal surface of the screw cap, the flexible drug reservoir configured to store a secondary drug,
wherein the screw cap is configured to couple to the manifold using screw threads such that rotation of the screw cap relative to the manifold causes a distance between the internal surface of the screw cap and the distal surface of the manifold to decrease, thereby compressing the flexible drug reservoir such that the secondary drug is expelled from the reservoir, through the fluid channel in the manifold, and through the infusion hub. The application claims a device for delivering a therapeutic fluid by chemical reaction. The patent application describes how the device can be used with (GLP-1) receptor agonists such as dulaglutide or liraglutide",After,No,https://patents.google.com/patent/US20220031936A1/en?oq=US20220031936A1
Trulicity,US20220031957A1,Eli Lilly,Diabetes,Biologic,20,7/28/2020,7/23/2021,2/3/2022,,Pending,Device,"The application claims a dose detection system, the system comprising: one or more light emitting diodes (LEDs); one or more batteries; and a processing circuit configured to: determine a use case type from a plurality of use case types for the dose detection system; determine a battery life status of said one or more batteries from a plurality of battery life status; and provide a light indication pattern via the one or more LEDs comprising: (i) a first light indication segment based on the determined use case type, and (ii) a second light indication segment based on the determined battery life status after a period of delay after completion of the first light indication segment.",After,No,https://patents.google.com/patent/US20220031957A1/en?oq=US20220031957A1
Trulicity,US20220040415A1,Eli Lilly,Diabetes,Biologic,31,3/29/2019,10/22/2021,2/10/2022,,Pending,Device,"The application claims a medication delivery device, comprising: a housing defined about a longitudinal axis; a medication cartridge comprising a piston disposed therein; a plunger having an elongated body with an end to drive the piston within the medication cartridge, a plunger drive system configured to distally advance the plunger, a dose selector configured to allow the actuator to move to a lesser dose set position that is less than the extended position that defines a full dose setting, wherein, in response to movement of the actuator to the extended position or the lesser dose set position from the retracted position, wherein, in response to movement of the actuator to the retracted position from the extended position, rotation of the at least one pinion drive is in a second direction to axially translate the output drive member, with the one or more pawled ends of the output drive member in engagement with the ratchet teeth of said plunger, thereby advancing the plunger in a distal direction. The patent application describes how the device can be used with (GLP-1) receptor agonists such as dulaglutide or liraglutide

",After,No,https://patents.google.com/patent/US20220040415A1/en?oq=US20220040415A1
Trulicity,US20220088308A1,Eli Lilly,Diabetes,Biologic,62,2/12/2019,2/5/2020,3/24/2022,,Pending,Device,"The application claims an apparatus for delivering multiple injections of a pharmaceutical liquid to a patient, comprising: a needle magazine including a body defining a plurality of injection needle compartments that are each sealed in an air-tight manner from each other and from external atmosphere, a drug container containing the pharmaceutical liquid, a drug container septum that separates the drug fluid pathway from an intermediate pathway that leads to the needle magazine; a drive assembly configured to, when actuated, drive a needle assembly of one of the injection needle compartments such that the injection needle of the driven needle assembly extends from the needle magazine and into a patien. The claims include the apparatus, wherein pharmaceutical liquid comprises at least one of insulin, an insulin analog, a GLP-1 receptor agonist, glucagon, a glucagon analog, a glucagon derivative, a gastric inhibitory polypeptide (GIP), a GIP analog, a GIP derivative, an oxyntomodulin analog, an oxyntomodulin derivative, a therapeutic antibody, and a therapeutic agent for pain-related treatments.",After,No,https://patents.google.com/patent/US20220088308A1/en?oq=US20220088308A1
Trulicity,US20220111147A1,Eli Lilly,Diabetes,Biologic,48,12/19/2018,12/12/2019,4/14/2022,,Pending,Device,"The application claims a therapeutic agent delivery system, comprising:a housing having a distal end portion; a therapeutic agent delivery assembly carried by the housing, the therapeutic agent delivery assembly comprising: a chamber comprising a passageway; a therapeutic agent carried in the passageway; a needle in communication with the passageway; the therapeutic agent delivery assembly being translatable relative to the housing from a stowed configuration to a deployed configuration, a user input configured to be actuated by a user, an input restraint being rotatable relative to the housing from a first rotational configuration to a second rotational configuration, a sleeve being translatable relative to the housing from an exposed configuration to a retracted configuration. The patent application describes how the device can be used with (GLP-1) receptor agonists such as dulaglutide or liraglutide",After,No,https://patents.google.com/patent/US20220111147A1/en?oq=US20220111147A1
Trulicity,US20220118194A1,Eli Lilly,Diabetes,Biologic,41,2/27/2019,2/20/2020,4/21/2022,,Pending,Device," The application claims a medication delivery device comprising: a housing; an outlet; a dose button that is axially translatable relative to the housing to activate a dose dispensing mode in which medication is dispensed out of the outlet, the dose button comprising a support and a cap coupled to the support; a compartment defined between the support and the cap; a tubular body that rotates relative to the housing during the dose dispensing mode; and an electronics assembly, the electronics assembly including a sensor configured to sense in an axial direction rotation of the tubular body and a controller configured to receive a signal from the sensor, and wherein at least a portion of the electronic assembly is positioned within the compartment. The patent application describes how the device can be used with (GLP-1) receptor agonists such as dulaglutide or liraglutide

",After,No,https://patents.google.com/patent/US20220118194A1/en?oq=US20220118194A1
Trulicity,US20220134013A1,Eli Lilly,Diabetes,Biologic,32,2/27/2019,2/20/2020,5/5/2022,,Pending,Device,"The application claims a medication delivery device comprising: a housing; an outlet; a dose button to activate a dose dispensing mode in which medication is dispensed out of the outlet;a  printed circuit board; a protruded dose element that is rotatable relative to the printed circuit board during a dose dispensing event; a switch mounted to the printed circuit board, the switch comprising a conductive pad coupled to the printed circuit board and a cantilevered arm, the cantilevered arm having a first curved portion extending from the printed circuit board and a second curved portion that, in the dose dispensing event, is configured to move toward and contact the conductive pad to change the switch to a first state when an arm portion of the cantilevered arm is in slidable contact with the protruded dose element, and configured to move away and be spaced from the conductive pad to change the switch to a second state; and
a controller configured to receive a signal from the switch. The patent application describes how the device can be used with (GLP-1) receptor agonists such as dulaglutide or liraglutide",After,No,https://patents.google.com/patent/US20220134013A1/en?oq=US20220134013A1
Trulicity,US20220143187A1,Eli Lilly,Diabetes,Biologic,6,3/15/2019,3/11/2020,5/12/2022,,Pending,Formulation / Combination,"A composition comprising: a) dulaglutide; b) polysorbate 80 (PS80); c) a phenolic preservative selected from the group consisting of phenol, m-cresol and mixtures thereof; and d) a solvent modifier selected from the group consisting of N-methyl-2-pyrrolidone (NMP), polyethylene glycol (PEG) 400, propylene glycol (PPG) and glycerol.",After,No,https://patents.google.com/patent/US20220143187A1/en?oq=US20220143187A1
Trulicity,US20220160954A1,Eli Lilly,Diabetes,Biologic,16,4/16/2019,4/15/2020,5/26/2022,,Pending,Device,"The application claims an infusion head of a drug infusion system, the drug infusion system including a drug delivery device configured to deliver a primary drug to the infusion head. The patent application describes how the device can be used with (GLP-1) receptor agonists such as dulaglutide or liraglutide",After,No,https://patents.google.com/patent/US20220160954A1/en?oq=US20220160954A1
Trulicity,US7452966B2,Eli Lilly,Diabetes,Biologic,1,6/12/2003,6/10/2004,11/18/2008,12/7/2027,Active,Product,The patent claims cover heterologous fusion proteins comprising a GLP-1 analog of 30 amino acids and an Fc portion of an immunoglobulin (IgG) and a peptide linker.,Before,No,https://patents.google.com/patent/US7452966B2/en?oq=US7452966B2
Trulicity,US8273854B2,Eli Lilly,Diabetes,Biologic,1,6/12/2003,10/31/2008,9/25/2012,5/15/2026,Active,Method of Treatment,The patent claims cover a method of treating a patient with non-insulin dependent diabetes mellitus comprising administering to the patient a therapeutically effective amount of a heterologous fusion protein comprising: a GLP-1 analog comprising SEQ ID NO: 1.,Before,No,https://patents.google.com/patent/US8273854B2/en?oq=US8273854B2
Trulicity,US8557769B2,Eli Lilly,Diabetes,Biologic,10,8/3/2007,6/27/2012,10/15/2013,7/30/2028,Expired,Method of Treatment,"The patent claims cover a method of treating diabetes comprising administering an FGF-21 compound in combination with a GLP-1 compound, wherein the FGF-21 compound has the amino acid sequence of SEQ ID NO: 2, and wherein the GLP-1 compound has the amino acid sequence of SEQ ID NO: 19.",Before,No,https://patents.google.com/patent/US8557769B2/en?oq=US8557769B2
Trulicity,US9161953B2,Eli Lilly,Diabetes,Biologic,14,12/22/2010,12/20/2011,10/20/2015,12/20/2031,Active,Method of Treatment,"The application claims a method for treating diabetes in a patient in need thereof, the method comprising: (i) administering a therapeutically effective amount of a GLP-1 receptor agonist compound to the patient for a period of time of 1 day to 1 month prior to allogeneic islet transplant; and (ii) transplanting allogeneic islets into the patient; thereby treating the diabetes in the patient, wherein the patient is not administered an immunosuppressive drug or an immunosuppressive treatment regimen before, during, or after any step in the method.",Before,No,https://patents.google.com/patent/US9161953B2/en?oq=US9161953B2
Trulicity,US9855318,Eli Lilly,Diabetes,Biologic,67,5/7/2015,4/28/2016,1/2/2018,4/28/2036,Active,Product,The patent claims cover a  homodimer of two fusion proteins of having the amino acid sequence of SEQ ID NO: 12. and pharmaceutical compositions. ,After,No,https://patents.google.com/patent/US9855318B2/en?oq=US9855318
Trulicity,US9884093B2,Eli Lilly,Diabetes,Biologic,12,10/26/2015,10/14/2016,2/6/2018,10/14/2036,Active,Product,"The patent claims cover GLP-1 compounds, a method of treating a disease selected from the group consisting of T2DM, obesity, fatty liver disease, NASH, dyslipidemia, metabolic syndrome, hyperinsulinemia and nighttime hypoglycemia and a pharmaceutical composition.",After,No,https://patents.google.com/patent/US9884093B2/en?oq=US9884093B2